The	O
isolation	O
of	O
fMHV	O
allowed	O
the	O
localization	O
of	O
the	O
region	O
responsible	O
for	O
S	O
protein	O
incorporation	O
into	O
virions	B-COMP
to	O
the	O
carboxy	O
-	O
terminal	O
64	O
of	O
the	O
1	O
,	O
324	O
residues	O
of	O
this	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
is	O
the	O
major	O
virion	B-COMP
structural	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
results	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
n	O
-	O
PCR	O
)	O
assays	O
for	O
the	O
diagnosis	O
of	O
canine	O
coronavirus	O
(	O
CCV	O
)	O
infection	O
,	O
and	O
the	O
comparison	O
with	O
other	O
diagnostic	O
techniques	O
,	O
such	O
as	O
electron	O
microscopy	O
(	O
EM	O
)	O
and	O
virus	O
isolation	O
using	O
A	O
-	O
72	O
cell	B-COMP
line	O
are	O
reported	O
.	O

Both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
cleavage	O
products	O
were	O
detected	O
in	O
virus	O
-	O
infected	O
cells	B-COMP
and	O
were	O
found	O
to	O
be	O
physically	O
associated	O
.	O

This	O
anti	O
-	O
body	O
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	O
is	O
dependent	O
on	O
mouse	O
MAb	O
subclass	O
,	O
and	O
MAb	O
of	O
IgG2a	B-COMP
subclass	O
has	O
a	O
strong	O
ADE	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
MAb	O
FK50	O
-	O
4	O
that	O
showed	O
a	O
strong	O
neutralizing	O
activity	O
in	O
feline	O
macrophages	O
,	O
despite	O
the	O
fact	O
that	O
the	O
MAb	O
belonged	O
to	O
the	O
IgG2a	B-COMP
subclass	O
.	O

Since	O
little	O
is	O
known	O
about	O
this	O
generally	O
low	O
-	O
abundance	O
virion	B-COMP
component	O
,	O
we	O
have	O
characterized	O
the	O
E	O
protein	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
),	O
an	O
83	O
-	O
residue	O
polypeptide	O
.	O

Using	O
an	O
antiserum	O
to	O
the	O
hydrophilic	O
carboxy	O
terminus	O
of	O
this	O
otherwise	O
hydrophobic	O
protein	O
,	O
we	O
found	O
that	O
the	O
E	O
protein	O
was	O
synthesized	O
in	O
infected	O
cells	B-COMP
with	O
similar	O
kinetics	O
as	O
the	O
other	O
viral	O
structural	O
proteins	O
.	O

A	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
secretion	O
of	O
IFN	O
by	O
both	O
Mphi	O
and	O
L929	O
cells	B-COMP
incubated	O
with	O
cocaine	O
,	O
with	O
a	O
concomitant	O
decrease	O
in	O
virus	O
replication	O
,	O
is	O
also	O
reported	O
.	O

TITLE	O
:	O
Development	O
,	O
characterization	O
,	O
and	O
diagnostic	O
applications	O
of	O
monoclonal	O
antibodies	B-COMP
against	O
bovine	O
rotavirus	O
.	O

However	O
,	O
in	O
perinuclear	O
regions	O
the	O
gene	O
1	O
proteins	O
and	O
nucleocapsid	B-COMP
were	O
intercalated	O
with	O
sites	O
of	O
M	O
protein	O
localization	O
.	O

Quantification	O
of	O
PMNs	O
by	O
morphometry	O
showed	O
that	O
there	O
were	O
constantly	O
less	O
granulocytes	O
in	O
the	O
lungs	O
of	O
the	O
animals	O
treated	O
with	O
the	O
anti	O
-	O
CD18	O
antibody	B-COMP
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
kinetics	O
of	O
viral	O
load	O
observed	O
in	O
the	O
lungs	O
and	O
kidneys	O
correlated	O
with	O
the	O
level	O
of	O
IBV	O
-	O
specific	O
CTL	O
activity	O
of	O
effector	O
cells	B-COMP
prepared	O
from	O
spleens	O
of	O
infected	O
chicks	O
.	O

The	O
carboxyl	O
terminus	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
houses	O
an	O
epitope	O
(	O
s	O
)	O
responsible	O
for	O
induction	O
of	O
CTL	O
responses	O
to	O
IBV	O
N	O
protein	O
.	O

Elevated	O
numbers	O
of	O
splenic	O
CD4	O
(+)	O
cells	B-COMP
during	O
the	O
acute	O
phase	O
of	O
infection	O
may	O
be	O
associated	O
with	O
viral	O
clearance	O
.	O

At	O
1	O
d	O
.	O
p	O
.	O
i	O
.,	O
almost	O
all	O
epithelial	O
cells	B-COMP
were	O
involved	O
in	O
the	O
degeneration	O
.	O

At	O
2	O
and	O
3	O
d	O
.	O
p	O
.	O
i	O
.,	O
a	O
great	O
number	O
of	O
basal	O
cells	B-COMP
were	O
recognized	O
,	O
but	O
the	O
BrdU	O
labelling	O
index	O
tended	O
to	O
decrease	O
.	O

At	O
4	O
and	O
5	O
d	O
.	O
p	O
.	O
i	O
.,	O
the	O
BrdU	O
labelling	O
index	O
of	O
basal	O
cells	B-COMP
significantly	O
decreased	O
than	O
1	O
d	O
.	O
p	O
.	O
i	O
.,	O
and	O
a	O
few	O
number	O
of	O
regenerated	O
immature	O
ciliated	O
epithelia	O
appeared	O
.	O

ABSTRACT	O
:	O
Gene	O
3b	O
(	O
ORF	O
3b	O
)	O
in	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
encodes	O
a	O
putative	O
nonstructural	O
polypeptide	O
of	O
27	O
.	O
7	O
kDa	O
with	O
unknown	O
function	O
that	O
during	O
translation	O
in	O
vitro	O
is	O
capable	O
of	O
becoming	O
a	O
glycosylated	O
integral	O
membrane	B-COMP
protein	O
of	O
31	O
kDa	O
.	O

In	O
the	O
virulent	O
Miller	O
strain	O
of	O
TGEV	O
,	O
ORF	O
3b	O
is	O
5	O
'-	O
terminal	O
on	O
mRNA	O
3	O
-	O
1	O
and	O
is	O
presumably	O
translated	O
following	O
5	O
'	O
cap	O
-	O
dependent	O
ribosomal	B-COMP
entry	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
membrane	B-COMP
fusion	O
requires	O
the	O
cysteine	O
-	O
rich	O
domain	O
in	O
the	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
mediates	O
the	O
early	O
events	O
leading	O
to	O
infection	O
of	O
cells	B-COMP
,	O
including	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	B-COMP
membranes	O
.	O

There	O
was	O
no	O
variation	O
in	O
the	O
isotype	O
-	O
specific	O
BCV	O
antibody	B-COMP
titres	O
between	O
healthy	O
quarters	O
of	O
the	O
same	O
udder	O
,	O
but	O
subclinical	O
mastitis	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
IgA	O
antibodies	B-COMP
and	O
weak	O
false	O
IgM	O
positive	O
reactions	O
in	O
undiluted	O
milk	O
.	O

In	O
addition	O
,	O
a	O
two	O
-	O
way	O
cross	O
-	O
neutralization	O
test	O
was	O
performed	O
in	O
embryonated	O
eggs	O
with	O
the	O
beta	O
method	O
(	O
constant	O
-	O
virus	O
,	O
diluted	O
-	O
serum	B-COMP
)	O
and	O
the	O
reciprocal	O
neutralization	O
titers	O
were	O
calculated	O
to	O
give	O
the	O
relatedness	O
(	O
r	O
)	O
values	O
.	O

2	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
cells	B-COMP
/	O
L	O
within	O
6	O
to	O
8	O
hours	O
in	O
the	O
early	O
neutropenia	O
group	O
and	O
from	O
4	O
.	O
6	O
+/-	O

Surprisingly	O
,	O
the	O
TGEV	O
nucleoprotein	O
(	O
N	O
)	O
underwent	O
proteolysis	O
in	O
parallel	O
with	O
the	O
activation	O
of	O
caspases	O
within	O
the	O
host	B-COMP
cell	I-COMP
.	O

Indirect	O
immunofluorescence	O
microscopy	O
showed	O
that	O
E	O
is	O
localized	O
to	O
the	O
Golgi	B-COMP
complex	I-COMP
in	O
cells	B-COMP
transiently	O
expressing	O
IBV	O
E	O
.	O
When	O
coexpressed	O
with	O
IBV	O
M	O
,	O
both	O
from	O
cDNA	O
and	O
in	O
IBV	O
infection	O
,	O
the	O
two	O
proteins	O
are	O
colocalized	O
in	O
Golgi	B-COMP
membranes	O
,	O
near	O
the	O
coronavirus	O
budding	O
site	O
.	O

Electron	O
microscopy	O
revealed	O
corona	O
-	O
like	O
virus	B-COMP
particles	I-COMP
in	O
these	O
necrotic	O
cells	B-COMP
.	O

The	O
putative	O
virus	O
was	O
isolated	O
and	O
cultured	O
in	O
epithelioma	O
papillosum	O
cyprini	O
(	O
EPC	O
)	O
cells	B-COMP
.	O

TITLE	O
:	O
The	O
amino	O
and	O
carboxyl	O
domains	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	B-COMP
protein	O
interact	O
with	O
3	O
'	O
genomic	O
RNA	O
.	O

ABSTRACT	O
:	O
Our	O
prior	O
studies	O
showed	O
that	O
polyhydroxylated	O
styrylquinolines	O
are	O
potent	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
inhibitors	O
that	O
block	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
cell	B-COMP
culture	O
at	O
nontoxic	O
concentrations	O
.	O

The	O
results	O
indicate	O
that	O
M	O
protein	O
molecules	O
interact	O
with	O
each	O
other	O
through	O
multiple	O
contact	O
sites	O
,	O
particularly	O
at	O
the	O
transmembrane	B-COMP
level	O
.	O

TITLE	O
:	O
Host	B-COMP
protein	O
interactions	O
with	O
the	O
3	O
'	O
end	O
of	O
bovine	O
coronavirus	O
RNA	O
and	O
the	O
requirement	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
for	O
coronavirus	O
defective	O
genome	O
replication	O
.	O

TITLE	O
:	O
Protection	O
studies	O
on	O
winter	O
dysentery	O
caused	O
by	O
bovine	O
coronavirus	O
in	O
cattle	O
using	O
antigens	O
prepared	O
from	O
infected	O
cell	B-COMP
lysates	O
.	O

For	O
this	O
,	O
the	O
vaccine	O
strain	O
was	O
genetically	O
engineered	O
to	O
express	O
chimeric	O
fimbriae	B-COMP
carrying	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
C	O
(	O
379	O
-	O
388	O
)	O
and	O
A	O
(	O
521	O
-	O
531	O
)	O
epitopes	O
of	O
the	O
spike	O
protein	O
inserted	O
into	O
the	O
987P	O
major	O
fimbrial	O
subunit	O
FasA	O
.	O
BALB	O
/	O
c	O
mice	O
administered	O
orally	O
serovar	O
Typhimurium	O
chi4550	O
expressing	O
the	O
chimeric	O
fimbriae	B-COMP
from	O
the	O
tet	O
promoter	O
in	O
pCS154	O
(	O
fas	O
(+)	O
asd	O
(+))	O
produced	O
systemic	O
antibodies	B-COMP
against	O
both	O
fimbria	B-COMP
and	O
the	O
TGEV	O
C	O
epitope	O
but	O
not	O
against	O
the	O
TGEV	O
A	O
epitope	O
.	O

These	O
B	O
cells	B-COMP
mainly	O
existed	O
in	O
the	O
lamina	O
propria	O
,	O
and	O
some	O
cells	B-COMP
were	O
recognized	O
in	O
the	O
interepithelial	O
space	O
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
membrane	B-COMP
fractions	O
containing	O
helicase	O
,	O
p28	B-COMP
,	O
and	O
N	O
but	O
not	O
in	O
the	O
fractions	O
containing	O
p65	O
and	O
p1a	O
-	O
22	O
.	O

In	O
contrast	O
,	O
both	O
experimental	O
groups	O
presented	O
greater	O
values	O
of	O
PMN	O
cells	B-COMP
on	O
day	O
8	O
compared	O
with	O
the	O
SHAM	O
group	O
(	O
p	O
<	O
.	O
001	O
).	O

In	O
this	O
patient	O
,	O
fludrocortisone	O
resulted	O
in	O
a	O
significant	O
and	O
rapid	O
decrease	O
in	O
serum	B-COMP
potassium	O
even	O
with	O
continued	O
heparin	O
administration	O
and	O
acute	O
renal	O
failure	O
.	O

D	O
-	O
RNAs	O
expressing	O
the	O
CAT	O
gene	O
were	O
demonstrated	O
to	O
be	O
capable	O
of	O
producing	O
CAT	O
protein	O
in	O
a	O
helper	O
-	O
dependent	O
expression	O
system	O
to	O
about	O
1	O
.	O
6	O
microgram	O
per	O
10	O
(	O
6	O
)	O
cells	B-COMP
.	O

Samples	O
of	O
blood	O
and	O
respiratory	O
tract	O
secretions	O
were	O
sent	O
to	O
central	O
laboratories	O
for	O
antibody	B-COMP
testing	O
,	O
culture	O
,	O
DNA	O
testing	O
,	O
and	O
histopathological	O
analyses	O
.	O

TITLE	O
:	O
Localization	O
of	O
linear	O
B	O
-	O
cell	B-COMP
epitopes	O
on	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	B-COMP
protein	O
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
3	O
'	O
terminal	O
9	O
.	O
8	O
kb	O
of	O
the	O
genomic	O
RNA	O
and	O
analyzed	O
the	O
structure	O
of	O
the	O
viral	B-COMP
genome	I-COMP
.	O

Lupus	O
anticoagulant	O
,	O
IgG	O
anticardiolipin	O
and	O
anti	O
-	O
beta2	O
-	O
glycoprotein	O
I	O
antibodies	B-COMP
were	O
positive	O
.	O

BHK	O
cells	B-COMP
expressing	O
both	O
MHVR1	O
and	O
MHVR2	O
supported	O
srr	O
replication	O
to	O
the	O
same	O
extent	O
as	O
did	O
BHK	O
-	O
R1	O
cells	B-COMP
,	O
suggesting	O
that	O
inefficient	O
infection	O
by	O
srr	O
mutants	O
in	O
BHK	O
-	O
R2	O
cells	B-COMP
resulted	O
from	O
the	O
absence	O
of	O
the	O
effective	O
receptor	O
MHVR1	O
.	O

Thus	O
,	O
a	O
coronaviral	O
infection	O
of	O
glial	O
cells	B-COMP
could	O
lead	O
to	O
the	O
production	O
of	O
inflammatory	O
molecules	O
that	O
have	O
been	O
associated	O
with	O
central	O
nervous	O
system	O
pathologies	O
such	O
as	O
MS	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
induces	O
apoptosis	O
in	O
swine	O
testicular	O
cell	B-COMP
lines	O
but	O
not	O
in	O
intestinal	O
enterocytes	O
.	O

Macrophage	O
infiltration	O
into	O
the	O
gray	O
matter	O
of	O
CD4	O
T	O
cell	B-COMP
-	O
enriched	O
recipients	O
was	O
greater	O
than	O
that	O
observed	O
in	O
mice	O
receiving	O
undepleted	O
splenocytes	O
.	O

MHV	O
-	O
JHM	O
-	O
infected	O
RAG1	O
-/-	O
mice	O
receiving	O
donors	O
depleted	O
of	O
both	O
CD4	O
and	O
CD8	O
T	O
cells	B-COMP
did	O
not	O
develop	O
demyelination	O
.	O

Two	O
pharmacological	O
approaches	O
exist	O
to	O
reduce	O
the	O
vascular	O
resistance	O
:	O
Reduction	O
of	O
the	O
increased	O
vascular	O
tone	O
by	O
relaxation	O
of	O
vascular	O
smooth	B-COMP
muscle	I-COMP
cells	I-COMP
(	O
effect	O
of	O
vasodilators	O
).	O

Pre	O
-	O
existing	O
antibody	B-COMP
titres	O
(	O
as	O
a	O
result	O
of	O
natural	O
infection	O
)	O
in	O
the	O
serum	B-COMP
of	O
these	O
animals	O
were	O
found	O
to	O
be	O
significantly	O
increased	O
as	O
a	O
result	O
of	O
a	O
single	O
shot	O
vaccination	O
carried	O
out	O
between	O
2	O
and	O
12	O
weeks	O
before	O
calving	O
.	O

Decreasing	O
viral	O
RNA	O
levels	O
in	O
both	O
brains	O
and	O
spinal	O
cords	O
following	O
initial	O
virus	O
clearance	O
coincided	O
with	O
an	O
overall	O
progressive	O
loss	O
of	O
both	O
total	O
and	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
.	O

By	O
9	O
weeks	O
p	O
.	O
i	O
.,	O
T	O
cells	B-COMP
had	O
largely	O
disappeared	O
from	O
brains	O
of	O
both	O
infected	O
groups	O
,	O
consistent	O
with	O
the	O
decline	O
of	O
viral	O
RNA	O
.	O

By	O
contrast	O
,	O
a	O
significant	O
number	O
of	O
CD8	O
(+)	O
T	O
cells	B-COMP
which	O
contained	O
detectable	O
viral	O
RNA	O
were	O
recovered	O
from	O
spinal	O
cords	O
of	O
V	O
-	O
1	O
-	O
infected	O
mice	O
.	O

Pulse	O
-	O
labeling	O
experiments	O
showed	O
that	O
newly	O
synthesized	O
,	O
unglycosylated	O
M	O
protein	O
interacted	O
with	O
N	O
protein	O
in	O
a	O
pre	O
-	O
Golgi	B-COMP
compartment	O
,	O
which	O
is	O
part	O
of	O
the	O
MHV	O
budding	O
site	O
.	O

These	O
data	O
indicated	O
that	O
M	O
protein	O
interacted	O
with	O
the	O
nucleocapsid	B-COMP
,	O
consisting	O
of	O
N	O
protein	O
and	O
mRNA	O
1	O
,	O
in	O
infected	O
cells	B-COMP
.	O

Intracellular	B-COMP
M	O
protein	O
-	O
N	O
protein	O
interaction	O
was	O
maintained	O
after	O
removal	O
of	O
viral	O
RNAs	O
by	O
RNase	O
treatment	O
.	O

The	O
assay	O
is	O
used	O
to	O
monitor	O
the	O
response	O
to	O
vaccination	O
,	O
but	O
field	O
challenge	O
can	O
only	O
be	O
detected	O
if	O
flock	O
antibody	B-COMP
status	O
is	O
monitored	O
continually	O
.	O

Our	O
findings	O
establish	O
the	O
importance	O
of	O
cellular	B-COMP
factors	O
in	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
synthesis	O
.	O

Correction	O
of	O
the	O
metabolic	O
acidosis	O
by	O
insulin	O
therapy	O
resulted	O
in	O
intracellular	B-COMP
penetration	O
of	O
phosphate	O
and	O
potassium	O
,	O
causing	O
severe	O
hypophosphataemia	O
and	O
hypokaliaemia	O
responsible	O
for	O
ARD	O
.	O

Serum	B-COMP
samples	O
were	O
obtained	O
at	O
time	O
of	O
arrival	O
and	O
again	O
28	O
days	O
after	O
arrival	O
;	O
sera	B-COMP
were	O
analyzed	O
for	O
antibodies	B-COMP
to	O
BCV	O
,	O
using	O
an	O
antibody	B-COMP
-	O
detection	O
ELISA	O
.	O

Cattle	O
shedding	O
BCV	O
from	O
the	O
nasal	O
cavity	O
and	O
developing	O
an	O
antibody	B-COMP
response	O
against	O
BCV	O
were	O
1	O
.	O
6	O
times	O
more	O
likely	O
to	O
require	O
treatment	O
for	O
respiratory	O
tract	O
disease	O
than	O
cattle	O
that	O
did	O
not	O
shed	O
the	O
virus	O
or	O
develop	O
an	O
immune	O
response	O
against	O
BCV	O
.	O

The	O
28S	O
rRNA	O
cleavage	O
occurred	O
as	O
early	O
as	O
4	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	B-COMP
,	O
with	O
the	O
appearance	O
of	O
subsequent	O
cleavage	O
products	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
intact	O
28S	O
rRNA	O
with	O
increasing	O
times	O
of	O
infection	O
;	O
almost	O
all	O
of	O
the	O
intact	O
28S	O
rRNA	O
disappeared	O
by	O
24	O
h	O
p	O
.	O
i	O
.	O

To	O
identify	O
new	O
receptor	O
-	O
ligand	O
interactions	O
that	O
might	O
be	O
used	O
to	O
redirect	O
vectors	O
to	O
the	O
apical	O
surface	O
,	O
we	O
investigated	O
the	O
process	O
of	O
infection	O
of	O
airway	O
epithelial	O
cells	B-COMP
by	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
a	O
common	O
cause	O
of	O
respiratory	O
tract	O
infections	O
.	O

Three	O
cases	O
has	O
a	O
deficit	O
of	O
the	O
complex	O
IV	O
,	O
e	O
of	O
the	O
complex	B-COMP
I	I-COMP
-	O
IV	O
,	O
2	O
of	O
the	O
complex	B-COMP
I	I-COMP
and	O
one	O
the	O
complex	B-COMP
I	I-COMP
-	O
III	O
-	O
IV	O
.	O

Only	O
one	O
patient	O
had	O
multiple	O
deletions	O
in	O
the	O
mtDNA	B-COMP
.	O

We	O
found	O
that	O
92	O
%	O
of	O
the	O
patients	O
developing	O
ARDS	O
had	O
low	O
or	O
borderline	O
serum	B-COMP
total	O
protein	O
levels	O
(<	O
6	O
g	O
/	O
dL	O
).	O

Logistic	O
and	O
multiple	O
regression	O
analyses	O
confirmed	O
that	O
of	O
18	O
clinical	O
variables	O
,	O
initial	O
serum	B-COMP
total	O
protein	O
level	O
and	O
protein	O
change	O
over	O
time	O
were	O
the	O
most	O
statistically	O
significant	O
predictors	O
of	O
weight	O
gain	O
,	O
prolonged	O
mechanical	O
ventilation	O
,	O
ARDS	O
development	O
,	O
and	O
mortality	O
in	O
the	O
study	O
population	O
.	O

Prospective	O
,	O
randomized	O
trials	O
of	O
serum	B-COMP
protein	O
manipulation	O
are	O
needed	O
to	O
establish	O
whether	O
there	O
is	O
a	O
cause	O
-	O
effect	O
relationship	O
to	O
this	O
association	O
.	O

IHD	O
patients	O
had	O
disseminated	O
intravascular	O
red	O
cell	B-COMP
aggregation	O
,	O
slowing	O
of	O
the	O
microflow	O
,	O
hypercoagulation	O
.	O

In	O
this	O
study	O
,	O
the	O
immunoprophylactic	O
effects	O
of	O
chicken	O
egg	O
yolk	B-COMP
immunoglobulin	O
(	O
Ig	O
Y	O
)	O
against	O
PEDV	O
were	O
investigated	O
in	O
neonatal	O
pigs	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
a	O
ten	O
-	O
year	O
experience	O
.	O

Rescue	O
of	O
rFPV	O
-	O
derived	O
CD	O
-	O
61	O
occurred	O
earlier	O
and	O
with	O
higher	O
efficiency	O
than	O
demonstrated	O
previously	O
for	O
electroporation	O
of	O
in	O
vitro	O
T7	O
-	O
generated	O
RNA	O
transcripts	O
in	O
avian	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
technique	O
for	O
providing	O
life	O
support	O
,	O
in	O
case	O
the	O
natural	O
lungs	O
are	O
failing	O
and	O
are	O
not	O
able	O
to	O
maintain	O
a	O
sufficient	O
oxygenation	O
of	O
the	O
body	O
'	O
s	O
organ	O
systems	O
.	O

The	O
CPE	O
was	O
induced	O
most	O
rapidly	O
in	O
IC	O
-	O
21	O
cells	B-COMP
and	O
was	O
visible	O
microscopically	O
in	O
all	O
cell	B-COMP
lines	O
tested	O
.	O

We	O
examined	O
by	O
confocal	O
microscopy	O
the	O
subcellular	O
localization	O
of	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
N	O
protein	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
context	O
of	O
an	O
infected	O
cell	B-COMP
and	O
found	O
that	O
N	O
protein	O
localizes	O
both	O
to	O
the	O
cytoplasmic	B-COMP
and	O
nucleolar	O
compartments	O
.	O

Neuraminidase	O
treatment	O
of	O
purified	O
virions	B-COMP
resulted	O
in	O
a	O
shift	O
of	O
the	O
sedimentation	O
value	O
from	O
the	O
higher	O
to	O
the	O
lower	O
density	O
.	O

These	O
results	O
suggest	O
that	O
binding	O
of	O
sialoglycoproteins	O
to	O
the	O
virion	B-COMP
surface	O
is	O
responsible	O
for	O
the	O
sedimentation	O
behavior	O
of	O
TGEV	O
.	O

ABSTRACT	O
:	O
The	O
architecture	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
includes	O
three	O
different	O
structural	O
levels	O
,	O
the	O
envelope	B-COMP
,	O
an	O
internal	O
core	O
,	O
and	O
the	O
nucleocapsid	B-COMP
that	O
is	O
released	O
when	O
the	O
core	O
is	O
disrupted	O
.	O

At	O
high	O
salt	O
concentrations	O
(	O
200	O
to	O
300	O
mM	O
),	O
the	O
M	O
protein	O
was	O
no	O
longer	O
associated	O
with	O
the	O
nucleocapsid	B-COMP
,	O
which	O
resulted	O
in	O
destruction	O
of	O
the	O
core	O
structure	O
.	O

It	O
is	O
proposed	O
that	O
the	O
M	O
protein	O
is	O
embedded	O
within	O
the	O
virus	O
membrane	B-COMP
and	O
that	O
the	O
C	O
region	O
,	O
exposed	O
to	O
the	O
interior	O
face	O
of	O
the	O
virion	B-COMP
in	O
a	O
population	O
of	O
these	O
molecules	O
,	O
interacts	O
with	O
the	O
nucleocapsid	B-COMP
to	O
which	O
it	O
is	O
anchored	O
,	O
forming	O
the	O
core	O
.	O

Anti	O
-	O
Mig	O
-	O
treated	O
mice	O
displayed	O
a	O
significant	O
decrease	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
in	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cell	B-COMP
recruitment	O
into	O
the	O
CNS	O
as	O
compared	O
with	O
normal	O
rabbit	O
serum	B-COMP
-	O
treated	O
mice	O
.	O

As	O
a	O
result	O
,	O
antibodies	B-COMP
to	O
eight	O
or	O
ten	O
kinds	O
of	O
pathogens	O
were	O
detected	O
in	O
SPF	O
chickens	O
on	O
each	O
farm	O
.	O

In	O
considering	O
the	O
possible	O
role	O
of	O
this	O
hyperactive	O
membrane	B-COMP
fusion	O
activity	O
in	O
neurovirulence	O
,	O
we	O
discovered	O
that	O
the	O
growth	O
of	O
JHM	O
in	O
tissue	O
culture	O
selected	O
for	O
variants	O
that	O
had	O
lost	O
murine	O
CEACAM	O
-	O
independent	O
fusion	O
activity	O
.	O

Previous	O
results	O
indicated	O
that	O
CD8	O
T	O
cells	B-COMP
infiltrating	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
were	O
largely	O
antigen	O
specific	O
in	O
both	O
diseases	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
role	O
of	O
heterogeneous	O
nuclear	O
ribonucleoprotein	B-COMP
A1	O
as	O
a	O
host	B-COMP
factor	O
in	O
murine	O
coronavirus	O
discontinuous	O
transcription	O
and	O
genome	O
replication	O
.	O

ABSTRACT	O
:	O
Serial	O
passage	O
of	O
virulent	O
transmissible	O
gastroenteritis	O
virus	O
through	O
cell	B-COMP
culture	O
reduced	O
its	O
virulence	O
in	O
3	O
-	O
day	O
-	O
old	O
piglets	O
.	O

ABSTRACT	O
:	O
Archived	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
25	O
pigs	O
naturally	O
infected	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
examined	O
by	O
in	O
situ	O
hybridization	O
for	O
TGEV	O
nucleic	B-COMP
acid	O
using	O
a	O
nonradioactive	O
digoxigenin	O
-	O
labeled	O
cDNA	O
probe	O
that	O
targeted	O
the	O
nucleocapsid	B-COMP
sequence	O
of	O
TGEV	O
strains	O
.	O

The	O
simple	O
and	O
rapid	O
procedure	O
described	O
here	O
makes	O
this	O
assay	O
an	O
ideal	O
alternative	O
technique	O
to	O
electron	O
microscopy	O
and	O
viral	O
isolation	O
in	O
cell	B-COMP
culture	O
for	O
detection	O
of	O
CCV	O
shedding	O
in	O
feces	O
.	O

Infectivity	O
-	O
neutralizing	O
(	O
IN	O
)	O
and	O
hemagglutinin	O
-	O
inhibiting	O
(	O
HAI	O
)	O
antibodies	B-COMP
induced	O
by	O
RBCV	O
infections	O
were	O
monitored	O
in	O
sequential	O
serum	B-COMP
samples	O
collected	O
from	O
cattle	O
during	O
a	O
naturally	O
evolving	O
and	O
experimentally	O
monitored	O
epizootic	O
of	O
shipping	O
fever	O
pneumonia	O
(	O
SFP	O
).	O

Cattle	O
nasally	O
shedding	O
RBCV	O
at	O
the	O
beginning	O
of	O
the	O
epizootic	O
started	O
with	O
low	O
levels	O
of	O
serum	B-COMP
IN	O
and	O
HAI	O
antibodies	B-COMP
.	O

Furthermore	O
,	O
UV	O
cross	O
-	O
linking	O
studies	O
indicate	O
that	O
highly	O
purified	O
mitochondrial	B-COMP
aconitase	O
binds	O
specifically	O
to	O
the	O
MHV	O
3	O
'	O
protein	O
-	O
binding	O
element	O
.	O

TITLE	O
:	O
Interferon	O
-	O
alpha	O
-	O
producing	O
cells	B-COMP
are	O
localized	O
in	O
gut	O
-	O
associated	O
lymphoid	O
tissues	O
in	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infected	O
piglets	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infection	O
of	O
piglets	O
results	O
in	O
a	O
very	O
rapid	O
and	O
massive	O
release	O
of	O
IFN	O
-	O
alpha	O
in	O
serum	B-COMP
and	O
secretions	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
characterize	O
the	O
IFN	O
-	O
alpha	O
-	O
producing	O
cells	B-COMP
(	O
IPC	O
)	O
in	O
tissues	O
of	O
TGEV	O
-	O
infected	O
piglets	O
.	O

However	O
,	O
similar	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
responses	O
to	O
demyelinating	O
and	O
non	O
demyelinating	O
JHMV	O
variants	O
support	O
the	O
notion	O
that	O
CD8	O
+	O
T	O
cells	B-COMP
do	O
not	O
contribute	O
to	O
the	O
demyelinating	O
process	O
.	O

Although	O
acute	O
JHMV	O
infection	O
is	O
thus	O
primarily	O
controlled	O
by	O
CD8	O
+	O
T	O
cells	B-COMP
,	O
both	O
CD4	O
+	O
T	O
cells	B-COMP
and	O
B	O
cells	B-COMP
make	O
significant	O
contributions	O
in	O
maintaining	O
the	O
balance	O
between	O
viral	O
replication	O
and	O
immune	O
control	O
,	O
thus	O
allowing	O
host	B-COMP
and	O
pathogen	O
survival	O
.	O

Its	O
C	O
-	O
terminal	O
region	O
extends	O
cytoplasmically	O
in	O
the	O
infected	O
cell	B-COMP
and	O
in	O
the	O
virion	B-COMP
toward	O
the	O
interior	O
.	O

The	O
N	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
E	O
protein	O
is	O
hydrophobic	O
and	O
lies	O
buried	O
within	O
the	O
membrane	B-COMP
,	O
but	O
its	O
orientation	O
in	O
the	O
lipid	O
membrane	B-COMP
is	O
not	O
known	O
.	O

ABSTRACT	O
:	O
One	O
missing	O
link	O
in	O
the	O
coronavirus	O
assembly	O
is	O
the	O
physical	O
interaction	O
between	O
two	O
crucial	O
structural	O
proteins	O
,	O
the	O
membrane	B-COMP
(	O
M	O
)	O
and	O
envelope	B-COMP
(	O
E	O
)	O
proteins	O
.	O

The	O
constitutive	O
tetA	O
promoter	O
and	O
the	O
in	O
vivo	O
activated	O
nirB	O
and	O
pagC	O
promoters	O
were	O
evaluated	O
for	O
their	O
use	O
to	O
express	O
two	O
epitopes	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
protein	O
carried	O
by	O
fimbriae	B-COMP
which	O
were	O
displayed	O
on	O
a	O
Salmonella	O
vaccine	O
strain	O
.	O

Constructs	O
with	O
the	O
pagC	O
promoter	O
were	O
shown	O
to	O
drive	O
increased	O
expression	O
of	O
chimeric	O
987P	O
fimbriae	B-COMP
in	O
macrophages	O
as	O
well	O
as	O
in	O
Mg	O
(	O
2	O
+)-	O
poor	O
media	O
,	O
mimicking	O
a	O
major	O
environmental	O
signal	O
found	O
in	O
Salmonella	O
-	O
containing	O
endocytic	O
vacuoles	B-COMP
of	O
macrophages	O
.	O

The	O
ELISA	O
detected	O
antibodies	B-COMP
specific	O
for	O
TCV	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
a	O
closely	O
related	O
avian	O
coronavirus	O
,	O
but	O
did	O
not	O
detect	O
antibodies	B-COMP
specific	O
for	O
other	O
avian	O
viruses	O
(	O
avian	O
influenza	O
,	O
avian	O
reovirus	O
,	O
avian	O
paramyxovirus	O
3	O
,	O
avian	O
adenovirus	O
1	O
,	O
or	O
Newcastle	O
disease	O
virus	O
).	O

Coronavirus	O
particles	O
were	O
detected	O
by	O
immune	O
electron	O
microscopy	O
with	O
BCV	O
antibodies	B-COMP
from	O
the	O
intestinal	O
contents	O
of	O
birds	O
killed	O
at	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
12	O
DPI	O
.	O

These	O
results	O
indicate	O
that	O
although	O
IBDV	O
alone	O
has	O
the	O
potential	O
to	O
markedly	O
reduce	O
opsonizing	O
ability	O
of	O
antibody	B-COMP
,	O
this	O
effect	O
is	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
exacerbated	O
by	O
IBV	O
infection	O
.	O

Furthermore	O
,	O
hnRNP	O
A1	O
and	O
PTB	O
,	O
both	O
of	O
which	O
also	O
bind	O
to	O
the	O
complementary	O
strands	O
at	O
the	O
5	O
'	O
end	O
of	O
MHV	O
RNA	O
,	O
together	O
mediate	O
the	O
formation	O
of	O
an	O
RNP	B-COMP
complex	O
involving	O
the	O
5	O
'-	O
and	O
3	O
'-	O
end	O
fragments	O
of	O
MHV	O
RNA	O
in	O
vitro	O
.	O

TITLE	O
:	O
Maternal	O
antibody	B-COMP
to	O
infectious	O
bronchitis	O
virus	O
:	O
its	O
role	O
in	O
protection	O
against	O
infection	O
and	O
development	O
of	O
active	O
immunity	O
to	O
vaccine	O
.	O

TITLE	O
:	O
Bovine	O
coronaviruses	O
associated	O
with	O
enteric	O
and	O
respiratory	O
diseases	O
in	O
Canadian	O
dairy	O
cattle	O
display	O
different	O
reactivities	O
to	O
anti	O
-	O
HE	O
monoclonal	O
antibodies	B-COMP
and	O
distinct	O
amino	O
acid	O
changes	O
in	O
their	O
HE	O
,	O
S	O
and	O
ns4	O
.	O
9	O
protein	O
.	O

Herein	O
we	O
show	O
that	O
axonal	O
damage	O
occurred	O
in	O
areas	O
of	O
demyelination	O
and	O
also	O
in	O
adjacent	O
areas	O
devoid	O
of	O
myelin	B-COMP
damage	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
the	O
treatment	O
of	O
acute	O
respiratory	O
failure	O
in	O
full	O
-	O
term	O
neonates	O
].	O

ABSTRACT	O
:	O
Antibodies	B-COMP
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
cross	O
-	O
react	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
in	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
indicating	O
that	O
IBV	O
and	O
TCV	O
may	O
share	O
an	O
amino	O
acid	O
sequence	O
similarity	O
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
faeces	O
by	O
reverse	O
-	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
plasma	O
antiviral	O
antibodies	B-COMP
by	O
immunofluorescence	O
.	O

TITLE	O
:	O
Feline	O
and	O
canine	O
coronaviruses	O
are	O
released	O
from	O
the	O
basolateral	O
side	O
of	O
polarized	O
epithelial	O
LLC	B-COMP
-	O
PK1	O
cells	B-COMP
expressing	O
the	O
recombinant	O
feline	O
aminopeptidase	O
-	O
N	O
cDNA	O
.	O

TITLE	O
:	O
Induction	O
of	O
caspase	O
-	O
dependent	O
apoptosis	O
in	O
cultured	O
cells	B-COMP
by	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
replicase	O
protein	O
complexes	O
are	O
translocated	O
to	O
sites	O
of	O
M	O
protein	O
accumulation	O
in	O
the	O
ERGIC	B-COMP
at	O
late	O
times	O
of	O
infection	O
.	O

In	O
this	O
study	O
,	O
immunofluorescence	O
confocal	O
microscopy	O
was	O
used	O
to	O
define	O
the	O
relationship	O
of	O
the	O
membrane	B-COMP
populations	O
comprising	O
the	O
putative	O
replication	O
complexes	O
at	O
different	O
times	O
of	O
infection	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
delayed	O
brain	O
tumor	O
cells	B-COMP
.	O

TITLE	O
:	O
Study	O
of	O
protection	O
by	O
recombinant	O
fowl	O
poxvirus	O
expressing	O
C	O
-	O
terminal	O
nucleocapsid	B-COMP
protein	O
of	O
infectious	O
bronchitis	O
virus	O
against	O
challenge	O
.	O

The	O
IP	O
test	O
did	O
not	O
react	O
with	O
sera	B-COMP
from	O
either	O
15	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
dogs	O
or	O
7	O
SPF	O
dogs	O
immunized	O
with	O
a	O
multivalent	O
vaccine	O
,	O
including	O
canine	O
parvovirus	O
type	O
2	O
,	O
canine	O
distemper	O
virus	O
,	O
canine	O
adenovirus	O
type	O
2	O
,	O
and	O
canine	O
parainfluenza	O
virus	O
.	O

These	O
anti	O
-	O
MCMV	O
effects	O
were	O
attributed	O
to	O
prototypical	O
NK1	O
.	O
1	O
(+)	O
CD3	O
(-)	O
NK	O
cells	B-COMP
and	O
not	O
to	O
NK1	O
.	O
1	O
(+)	O
CD3	O
(+)	O
""""	O
NK	O
/	O
T	O
""""	O
cells	B-COMP
.	O

By	O
immunohistochemical	O
analysis	O
,	O
virus	O
-	O
specific	O
antigen	O
was	O
found	O
first	O
in	O
the	O
pyramidal	O
cells	B-COMP
of	O
the	O
hippocampus	O
and	O
cerebral	O
cortex	O
,	O
and	O
later	O
in	O
the	O
large	O
-	O
sized	O
neurons	O
of	O
the	O
pons	O
and	O
spinal	O
cord	O
.	O

S	O
glycoprotein	O
binds	O
to	O
specific	O
receptors	O
on	O
the	O
apical	O
membranes	O
of	O
enterocytes	O
,	O
and	O
can	O
undergo	O
a	O
temperature	O
-	O
dependent	O
,	O
receptor	O
-	O
mediated	O
conformational	O
change	O
that	O
leads	O
to	O
fusion	O
of	O
the	O
viral	B-COMP
envelope	I-COMP
with	O
host	B-COMP
membranes	O
to	O
initiate	O
infection	O
.	O

These	O
data	O
suggest	O
that	O
B	O
cells	B-COMP
may	O
function	O
as	O
antibody	B-COMP
-	O
independent	O
innate	O
immune	O
response	O
during	O
JHMV	O
infection	O
in	O
vivo	O
.	O

Reactive	O
immunoglobulins	O
pertained	O
to	O
the	O
IgG1	B-COMP
,	O
IgG2a	B-COMP
and	O
IgG2b	B-COMP
subclasses	O
,	O
recognized	O
cryptic	O
epitopes	O
and	O
were	O
detected	O
from	O
10	O
days	O
up	O
to	O
8	O
weeks	O
after	O
MHV	O
-	O
infection	O
.	O

TITLE	O
:	O
Impaired	O
T	O
cell	B-COMP
immunity	O
in	O
B	O
cell	B-COMP
-	O
deficient	O
mice	O
following	O
viral	O
central	O
nervous	O
system	O
infection	O
.	O

ABSTRACT	O
:	O
CD8	O
(+)	O
T	O
cells	B-COMP
are	O
required	O
to	O
control	O
acute	O
viral	O
replication	O
in	O
the	O
CNS	O
following	O
infection	O
with	O
neurotropic	O
coronavirus	O
.	O

Following	O
viral	O
recrudescence	O
in	O
muMT	O
mice	O
,	O
total	O
CD8	O
(+)	O
T	O
cell	B-COMP
numbers	O
were	O
similar	O
to	O
those	O
of	O
wild	O
-	O
type	O
mice	O
that	O
had	O
cleared	O
infectious	O
virus	O
;	O
however	O
,	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
were	O
reduced	O
at	O
least	O
3	O
-	O
fold	O
by	O
class	O
I	O
tetramer	O
and	O
IFN	O
-	O
gamma	O
ELISPOT	O
analysis	O
.	O

Using	O
a	O
model	O
of	O
virus	O
infection	O
restricted	O
to	O
the	O
CNS	O
,	O
the	O
results	O
provide	O
novel	O
evidence	O
for	O
a	O
role	O
of	O
B	O
cells	B-COMP
in	O
regulating	O
T	O
cell	B-COMP
expansion	O
and	O
differentiation	O
into	O
effector	O
cells	B-COMP
.	O

One	O
monoclonal	O
antibody	B-COMP
,	O
5G1	O
,	O
had	O
a	O
high	O
neutralizing	O
titer	O
,	O
and	O
the	O
other	O
,	O
6C4	O
,	O
was	O
more	O
effective	O
in	O
neutralizing	O
and	O
binding	O
to	O
virulent	O
TGEV	O
than	O
to	O
attenuated	O
TGEVs	O
.	O

CEACAM1	O
has	O
cell	B-COMP
adhesion	O
activity	O
and	O
acts	O
as	O
a	O
signaling	O
molecule	O
,	O
and	O
long	O
-	O
tail	O
isoforms	O
inhibit	O
the	O
growth	O
of	O
colon	O
and	O
prostate	O
tumor	O
cells	B-COMP
in	O
rodents	O
.	O

ABSTRACT	O
:	O
The	O
Fas	O
/	O
Fas	O
ligand	O
(	O
FasL	O
)	O
system	O
has	O
been	O
implicated	O
in	O
alveolar	O
epithelial	O
cell	B-COMP
apoptosis	O
during	O
pulmonary	O
fibrosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Variation	O
of	O
the	O
sequence	O
in	O
the	O
gene	O
encoding	O
for	O
transmembrane	B-COMP
protein	O
M	O
of	O
canine	O
coronavirus	O
(	O
CCV	O
).	O

Negative	O
-	O
strand	O
DI	O
RNA	O
transcripts	O
that	O
were	O
coexpressed	O
with	O
the	O
partial	O
-	O
length	O
positive	O
-	O
strand	O
RNA	O
transcripts	O
were	O
no	O
more	O
stable	O
than	O
those	O
expressed	O
alone	O
,	O
suggesting	O
that	O
a	O
higher	O
stability	O
of	O
the	O
expressed	O
negative	O
-	O
strand	O
RNA	O
transcripts	O
was	O
an	O
unlikely	O
reason	O
for	O
the	O
higher	O
DI	O
RNA	O
accumulation	O
in	O
cells	B-COMP
coexpressing	O
two	O
complementary	O
DI	O
RNA	O
transcripts	O
.	O

Regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
the	O
packaging	O
signal	O
,	O
N	O
protein	O
bound	O
to	O
MHV	O
defective	O
interfering	O
RNAs	O
and	O
intracellularly	O
expressed	O
non	O
-	O
MHV	O
RNA	O
transcripts	O
to	O
form	O
ribonucleoprotein	B-COMP
complexes	O
;	O
M	O
protein	O
,	O
however	O
,	O
interacted	O
selectively	O
with	O
RNAs	O
containing	O
the	O
packaging	O
signal	O
.	O

This	O
is	O
the	O
first	O
example	O
for	O
any	O
RNA	O
virus	O
in	O
which	O
a	O
viral	B-COMP
envelope	I-COMP
protein	O
and	O
a	O
known	O
viral	O
RNA	O
packaging	O
signal	O
have	O
been	O
shown	O
to	O
determine	O
the	O
specificity	O
and	O
selectivity	O
of	O
RNA	O
packaging	O
into	O
virions	B-COMP
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
possible	O
inhibition	O
of	O
cytokinesis	O
in	O
these	O
cells	B-COMP
.	O

These	O
studies	O
have	O
indicated	O
that	O
adhesion	O
molecules	O
such	O
as	O
intracellular	B-COMP
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
neutrophils	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
),	O
substance	O
P	O
,	O
and	O
chemokines	O
acting	O
via	O
the	O
CCR	O
-	O
1	O
chemokine	O
receptor	O
play	O
a	O
pro	O
-	O
inflammatory	O
role	O
while	O
complement	O
factor	O
C5a	O
plays	O
an	O
anti	O
-	O
inflammatory	O
role	O
in	O
pancreatitis	O
and	O
lung	O
injury	O
.	O

Comparison	O
of	O
the	O
TGEV	O
polymerase	O
sequence	O
with	O
that	O
of	O
other	O
RNA	O
viruses	O
revealed	O
high	O
sequence	O
homology	O
with	O
the	O
A	O
-	O
E	O
domains	O
of	O
the	O
palm	O
subdomain	O
of	O
nucleic	B-COMP
acid	O
polymerases	O
.	O

Selenoenzymes	O
play	O
a	O
major	O
role	O
in	O
protecting	O
cells	B-COMP
against	O
peroxidation	O
,	O
especially	O
lipid	O
peroxidation	O
and	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
inflammatory	O
processes	O
.	O

The	O
antibody	B-COMP
patterns	O
in	O
the	O
broiler	O
breeders	O
indicated	O
frequent	O
field	O
infections	O
breaking	O
through	O
vaccinal	O
immunity	O
.	O

We	O
concluded	O
that	O
IBV	O
vaccination	O
strategies	O
should	O
aim	O
at	O
high	O
and	O
uniform	O
antibody	B-COMP
titers	O
in	O
the	O
broiler	O
breeders	O
.	O

Increased	O
numbers	O
of	O
T	O
cells	B-COMP
,	O
monocytes	O
,	O
macrophages	O
,	O
NK	O
cells	B-COMP
,	O
eosinophils	O
,	O
and	O
RANTES	O
-	O
and	O
eotaxin	O
-	O
positive	O
cells	B-COMP
,	O
but	O
not	O
neutrophils	O
,	O
were	O
observed	O
during	O
common	O
cold	O
in	O
allergic	O
and	O
nonallergic	O
patients	O
,	O
and	O
increased	O
numbers	O
of	O
mast	O
cells	B-COMP
in	O
allergic	O
patients	O
.	O

In	O
some	O
cases	O
,	O
the	O
number	O
of	O
apoptotic	O
lymphocytes	O
was	O
increased	O
in	O
lymphoid	O
follicles	O
as	O
well	O
as	O
in	O
T	O
-	O
cell	B-COMP
zones	O
.	O

These	O
data	O
indicate	O
that	O
oligodendrocytes	O
and	O
neurons	O
have	O
the	O
potential	O
to	O
present	O
antigen	O
to	O
T	O
cells	B-COMP
and	O
thus	O
be	O
damaged	O
by	O
direct	O
antigen	O
-	O
specific	O
interactions	O
with	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

Mitochondrial	B-COMP
neurogastrointestinal	O
encephalomyopathy	O
is	O
characterized	O
by	O
gastrointestinal	O
dysmotility	O
,	O
cachexia	O
,	O
ptosis	O
with	O
external	O
ophthalmoparesis	O
,	O
neuropathy	O
,	O
leukoencephalopathy	O
and	O
laboratory	O
evidence	O
of	O
mitochondrial	B-COMP
alteration	O
.	O

Five	O
of	O
the	O
six	O
inoculated	O
mice	O
showed	O
massive	O
disruption	O
of	O
the	O
olfactory	O
bulb	O
,	O
including	O
death	O
of	O
mitral	O
cells	B-COMP
;	O
the	O
other	O
was	O
more	O
modestly	O
affected	O
.	O

TITLE	O
:	O
Humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
in	O
turkey	O
poults	O
infected	O
with	O
turkey	O
coronavirus	O
.	O

In	O
addition	O
,	O
Ig	O
gradually	O
increased	O
from	O
7	O
to	O
21	O
d	O
PI	O
and	O
remained	O
at	O
80	O
immunofluroescent	O
antibody	B-COMP
assay	O
(	O
IFA	O
)	O
titers	O
or	O
more	O
thereafter	O
.	O

TITLE	O
:	O
Antibody	B-COMP
is	O
required	O
for	O
clearance	O
of	O
infectious	O
murine	O
hepatitis	O
virus	O
A59	O
from	O
the	O
central	O
nervous	O
system	O
,	O
but	O
not	O
the	O
liver	O
.	O

Hyaline	O
membrane	B-COMP
formation	O
,	O
intra	O
-	O
alveolar	O
neutrophil	O
(	O
PMN	O
)	O
accumulation	O
and	O
intra	O
-	O
alveolar	O
/	O
perivascular	O
haemorrhage	O
were	O
graded	O
semiquantitatively	O
(	O
0	O
-	O
4	O
).	O

ABSTRACT	O
:	O
The	O
difference	O
in	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
compositions	O
between	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
virion	B-COMP
and	O
the	O
core	O
has	O
been	O
studied	O
.	O

DF	O
24	O
/	O
00	O
replicated	O
well	O
in	O
various	O
fish	O
cell	B-COMP
lines	O
.	O

Coronaviral	O
particles	O
from	O
intestinal	O
contents	O
or	O
the	O
sucrose	O
density	O
gradient	O
preparation	O
were	O
mainly	O
spherical	O
in	O
shape	O
and	O
had	O
envelope	B-COMP
and	O
central	O
depression	O
.	O

Antibody	B-COMP
production	O
in	O
response	O
to	O
BA	O
antigens	O
was	O
not	O
influenced	O
by	O
VE	O
.	O

Ron	O
tk	O
-/-	O
mice	O
succumb	O
to	O
nickel	O
-	O
induced	O
ALI	O
earlier	O
,	O
express	O
larger	O
,	O
early	O
increases	O
in	O
interleukin	O
-	O
6	O
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
display	O
greater	O
serum	B-COMP
nitrite	O
levels	O
,	O
and	O
exhibit	O
earlier	O
onset	O
of	O
pulmonary	O
pathology	O
and	O
augmented	O
pulmonary	O
tyrosine	O
nitrosylation	O
.	O

ABSTRACT	O
:	O
A	O
serodiagnostic	O
ELISA	O
utilizing	O
the	O
recombinant	O
nucleoprotein	O
(	O
rN	O
protein	O
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
developed	O
,	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
141	O
virus	O
neutralization	O
(	O
VN	O
)	O
positive	O
and	O
101	O
negative	O
sera	B-COMP
.	O

Plasma	O
vWF	O
:	O
Ag	O
concentration	O
seems	O
to	O
be	O
an	O
important	O
,	O
early	O
marker	O
of	O
trauma	O
severity	O
,	O
while	O
serum	B-COMP
sE	O
-	O
selectin	O
level	O
may	O
serve	O
as	O
prognostic	O
factor	O
in	O
immediate	O
postinjury	O
period	O
course	O
.	O

Thus	O
,	O
in	O
the	O
presence	O
of	O
soMHVR	O
,	O
JHMV	O
srr7	O
-	O
infected	O
DBT	O
cells	B-COMP
overlaid	O
onto	O
BHK	O
cells	B-COMP
induce	O
BHK	O
cell	B-COMP
syncytia	O
and	O
the	O
spread	O
of	O
JHMV	O
srr7	O
infection	O
.	O

The	O
IBV	O
E	O
protein	O
is	O
palmitoylated	O
on	O
one	O
or	O
two	O
cysteine	O
residues	O
adjacent	O
to	O
its	O
transmembrane	B-COMP
domain	O
,	O
but	O
palmitoylation	O
was	O
not	O
required	O
for	O
proper	O
Golgi	B-COMP
targeting	O
.	O

The	O
expression	O
of	O
a	O
reporter	O
gene	O
(	O
beta	O
-	O
glucuronidase	O
)	O
by	O
using	O
the	O
selected	O
TRS	O
led	O
to	O
the	O
production	O
of	O
2	O
to	O
8	O
microg	O
of	O
protein	O
per	O
10	O
(	O
6	O
)	O
cells	B-COMP
.	O

As	O
the	O
E	O
and	O
M	O
proteins	O
are	O
essential	O
for	O
TGEV	O
virion	B-COMP
budding	O
,	O
these	O
replicon	O
RNAs	O
should	O
replicate	O
but	O
not	O
result	O
in	O
the	O
production	O
of	O
infectious	O
virus	O
.	O

Following	O
cotransfection	O
of	O
BHK	O
cells	B-COMP
with	O
the	O
replicon	O
RNAs	O
carrying	O
gfp	O
,	O
GFP	O
expression	O
was	O
evident	O
by	O
fluorescent	O
microscopy	O
and	O
leader	O
-	O
containing	O
transcripts	O
carrying	O
gfp	O
were	O
detected	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
).	O

This	O
study	O
describes	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
anti	O
-	O
IBV	O
activity	O
of	O
natural	O
spleen	O
cell	B-COMP
-	O
derived	O
and	O
recombinant	O
chicken	O
interferon	O
type	O
I	O
(	O
rChIFN	O
-	O
alpha	O
).	O

Both	O
natural	O
and	O
rChIFN	O
-	O
alpha	O
inhibited	O
replication	O
of	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
in	O
chicken	O
kidney	O
cells	B-COMP
(	O
CKC	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
the	O
antiviral	O
activity	O
of	O
the	O
former	O
accounted	O
for	O
entirely	O
by	O
its	O
content	O
of	O
type	O
I	O
IFN	O
.	O

Both	O
1	O
-	O
step	O
RT	O
-	O
PCR	O
and	O
nested	O
PCR	O
recognized	O
cell	B-COMP
culture	O
passaged	O
isolates	O
of	O
10	O
bovine	O
respiratory	O
coronavirus	O
(	O
BRCV	O
),	O
5	O
calf	O
diarrhea	O
(	O
CD	O
)	O
and	O
8	O
winter	O
dysentery	O
(	O
WD	O
)	O
strains	O
of	O
BCV	O
,	O
but	O
not	O
transmissible	O
gastroenteritis	O
coronavirus	O
or	O
bovine	O
rotavirus	O
.	O

TITLE	O
:	O
Isotype	O
-	O
specific	O
antibody	B-COMP
-	O
secreting	O
cells	B-COMP
in	O
systemic	O
and	O
mucosal	O
associated	O
lymphoid	O
tissues	O
and	O
antibody	B-COMP
responses	O
in	O
serum	B-COMP
of	O
conventional	O
pigs	O
inoculated	O
with	O
PEDV	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
)	O
has	O
been	O
developed	O
to	O
detect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)-	O
specific	O
antibody	B-COMP
secreting	O
cells	B-COMP
(	O
ASC	O
)	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
(	O
duodenum	O
and	O
ileum	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
)	O
and	O
systemic	O
locations	O
(	O
spleen	O
and	O
blood	O
)	O
of	O
conventional	O
pigs	O
so	O
as	O
to	O
characterise	O
the	O
mucosal	O
and	O
systemic	O
antibody	B-COMP
response	O
generated	O
by	O
the	O
infection	O
with	O
PEDV	O
.	O

High	O
serum	B-COMP
levels	O
of	O
soluble	O
interleukin	O
-	O
2	O
receptor	O
,	O
interleukin	O
-	O
6	O
,	O
human	O
interleukin	O
-	O
10	O
and	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
were	O
observed	O
.	O

MHV	O
-	O
infected	O
NOS2	O
(-/-)	O
mice	O
displayed	O
a	O
marked	O
decrease	O
in	O
mortality	O
as	O
compared	O
to	O
infected	O
NOS2	O
(+/+)	O
mice	O
that	O
correlated	O
with	O
a	O
significant	O
decrease	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
the	O
number	O
of	O
apoptotic	O
cells	B-COMP
(	O
determined	O
by	O
TUNEL	O
staining	O
)	O
present	O
in	O
the	O
brain	O
.	O

Furthermore	O
,	O
the	O
whole	O
viral	O
antigen	O
detects	O
all	O
antibodies	B-COMP
against	O
the	O
viral	O
structural	O
proteins	O
,	O
including	O
spike	O
(	O
S	O
),	O
nucleocapsid	B-COMP
,	O
matrix	O
,	O
and	O
other	O
proteins	O
.	O

ABSTRACT	O
:	O
Eleven	O
-	O
day	O
-	O
old	O
conventionally	O
reared	O
piglets	O
were	O
inoculated	O
orally	O
with	O
two	O
different	O
doses	O
of	O
the	O
cell	B-COMP
-	O
culture	O
adapted	O
strain	O
CV	O
-	O
777	O
of	O
the	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
or	O
the	O
virulent	O
isolate	O
of	O
the	O
same	O
strain	O
and	O
challenged	O
with	O
the	O
same	O
virulent	O
PEDV	O
3	O
weeks	O
later	O
.	O

At	O
different	O
postinoculation	O
day	O
(	O
PID	O
)	O
and	O
postchallenge	O
day	O
(	O
PCD	O
)	O
virus	O
-	O
specific	O
antibody	B-COMP
-	O
secreting	O
cells	B-COMP
(	O
ASC	O
)	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
(	O
duodenum	O
and	O
ileum	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
)	O
and	O
systemic	O
locations	O
(	O
blood	O
and	O
spleen	O
)	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
).	O

The	O
ASC	O
and	O
serum	B-COMP
antibody	B-COMP
responses	O
after	O
the	O
challenge	O
corresponded	O
to	O
a	O
secondary	O
immune	O
response	O
in	O
the	O
groups	O
inoculated	O
with	O
attenuated	O
virus	O
,	O
whereas	O
a	O
primary	O
response	O
was	O
evident	O
in	O
the	O
control	O
group	O
.	O

However	O
,	O
limited	O
information	O
is	O
available	O
concerning	O
the	O
direct	O
effects	O
of	O
lead	O
on	O
the	O
host	B-COMP
immune	O
response	O
to	O
an	O
infectious	O
agent	O
after	O
developmental	O
exposure	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
Elisa	O
),	O
using	O
as	O
antigen	O
canine	O
coronavirus	O
-	O
infected	O
CrFK	O
cell	B-COMP
supernatant	O
,	O
was	O
developed	O
to	O
detect	O
antibodies	B-COMP
against	O
canine	O
coronavirus	O
(	O
CCoV	O
).	O

Early	O
during	O
clearance	O
of	O
the	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
,	O
only	O
few	O
virus	O
-	O
specific	O
Ab	O
-	O
secreting	O
cells	B-COMP
(	O
ASC	B-COMP
)	O
were	O
detected	O
in	O
the	O
periphery	O
or	O
CNS	O
,	O
although	O
mature	O
B	O
cells	B-COMP
and	O
ASC	B-COMP
without	O
viral	O
specificity	O
were	O
recruited	O
into	O
the	O
CNS	O
concomitant	O
with	O
T	O
cells	B-COMP
.	O

Virus	O
-	O
specific	O
ASC	O
peaked	O
in	O
lymphoid	O
organs	O
before	O
the	O
CNS	O
,	O
suggesting	O
peripheral	O
B	O
cell	B-COMP
priming	O
and	O
maturation	O
.	O

Using	O
this	O
approach	O
,	O
we	O
found	O
that	O
the	O
chimeric	O
virus	O
containing	O
the	O
BCV	O
S	O
protein	O
on	O
the	O
virion	B-COMP
surface	O
entered	O
and	O
replicated	O
in	O
HRT	O
-	O
18	O
cells	B-COMP
;	O
this	O
was	O
specifically	O
blocked	O
by	O
prior	O
treatment	O
of	O
the	O
virus	O
with	O
a	O
neutralizing	O
antibody	B-COMP
specific	O
to	O
the	O
BCV	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
BCV	O
S	O
protein	O
is	O
responsible	O
for	O
initiating	O
chimeric	O
virus	O
infection	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
S	O
protein	O
but	O
not	O
the	O
HE	O
protein	O
of	O
BCV	O
is	O
necessary	O
and	O
sufficient	O
for	O
infection	O
of	O
the	O
chimeric	O
viruses	O
in	O
HRT	O
-	O
18	O
cells	B-COMP
,	O
suggesting	O
that	O
BCV	O
likely	O
uses	O
the	O
S	O
protein	O
as	O
a	O
primary	O
vehicle	O
to	O
infect	O
permissive	O
cells	B-COMP
.	O

1	O
.	O
9	O
x	O
10	O
(	O
6	O
)	O
cells	B-COMP
/	O
mL	O
,	O
p	O
<.	O
05	O
)	O
and	O
improved	O
bacterial	O
clearance	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
8	O
.	O
1	O
+/-	O
4	O
.	O
2	O
x	O
10	O
(	O
2	O
)	O
vs	O
.	O
1	O
.	O
6	O
+/-	O

In	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
induced	O
by	O
endotoxins	O
,	O
a	O
high	O
production	O
of	O
inflammatory	O
mediators	O
by	O
microvascular	O
lung	O
endothelial	O
cells	B-COMP
(	O
LMVEC	O
)	O
can	O
be	O
observed	O
.	O

Activation	O
of	O
cells	B-COMP
by	O
endotoxins	O
may	O
result	O
in	O
elevated	O
secretion	O
of	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
sPLA	O
(	O
2	O
))	O
which	O
is	O
thought	O
to	O
contribute	O
to	O
tissue	O
damage	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
role	O
of	O
sPLA	O
(	O
2	O
)	O
in	O
chemokine	O
production	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	B-COMP
(	O
LMVEC	O
)	O
stimulated	O
with	O
the	O
endotoxins	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
lipoteichoic	O
acid	O
(	O
LTA	O
).	O

Results	O
of	O
mutagenesis	O
and	O
in	O
vitro	O
cleavage	O
assays	O
show	O
that	O
PLP	O
-	O
1	O
was	O
able	O
to	O
cleave	O
in	O
trans	O
when	O
the	O
proposed	O
p50	O
cleavage	O
sequence	O
replaced	O
the	O
p28	B-COMP
cleavage	O
sequence	O
.	O

Mutagenesis	O
was	O
also	O
used	O
to	O
investigate	O
cleavage	O
between	O
Gly	O
-	O
904	O
and	O
Val	O
-	O
905	O
,	O
a	O
cleavage	O
site	O
predicted	O
to	O
produce	O
a	O
precursor	O
of	O
p65	O
,	O
p72	O
,	O
that	O
was	O
detected	O
in	O
cells	B-COMP
infected	O
with	O
MHV	O
strain	O
JHM	O
,	O
but	O
not	O
with	O
MHV	O
-	O
A59	O
.	O

ABSTRACT	O
:	O
A	O
commercially	O
available	O
blocking	O
ELISA	O
was	O
analyzed	O
for	O
its	O
ability	O
to	O
identify	O
antibodies	B-COMP
to	O
porcine	O
coronaviruses	O
(	O
transmissible	O
gastroenteritis	O
virus	O
[	O
TGEV	O
]	O
or	O
porcine	O
respiratory	O
coronavirus	O
[	O
PRCV	O
]),	O
to	O
differentiate	O
antibodies	B-COMP
to	O
TGEV	O
and	O
PRCV	O
,	O
and	O
to	O
identify	O
TGEV	O
-	O
infected	O
herds	O
.	O

TITLE	O
:	O
Genetic	O
evidence	O
for	O
a	O
structural	O
interaction	O
between	O
the	O
carboxy	O
termini	O
of	O
the	O
membrane	B-COMP
and	O
nucleocapsid	B-COMP
proteins	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
nucleoproteins	O
(	O
N	O
proteins	O
)	O
localize	O
to	O
the	O
cytoplasm	B-COMP
and	O
the	O
nucleolus	B-COMP
,	O
a	O
subnuclear	O
structure	O
,	O
in	O
both	O
virus	O
-	O
infected	O
primary	O
cells	B-COMP
and	O
in	O
cells	B-COMP
transfected	O
with	O
plasmids	O
that	O
express	O
N	O
protein	O
.	O

Pull	O
-	O
down	O
assays	O
demonstrated	O
that	O
IBV	O
N	O
protein	O
interacted	O
with	O
nucleolin	O
and	O
therefore	O
provided	O
a	O
possible	O
explanation	O
as	O
to	O
how	O
coronavirus	O
N	O
proteins	O
localize	O
to	O
the	O
nucleolus	B-COMP
.	O

In	O
severe	O
cases	O
,	O
injury	O
to	O
distal	O
motor	O
axons	B-COMP
probably	O
occurs	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
experimental	O
virus	O
infection	O
may	O
induce	O
host	B-COMP
responses	O
that	O
provoke	O
enhanced	O
immunoglobulin	O
E	O
(	O
IgE	O
)	O
synthesis	O
.	O

The	O
reduced	O
MHV	O
production	O
in	O
SB	O
203580	O
-	O
treated	O
cells	B-COMP
was	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
a	O
decrease	O
in	O
virus	O
-	O
specific	O
protein	O
synthesis	O
and	O
virus	O
-	O
specific	O
mRNA	O
accumulation	O
.	O

In	O
virus	O
overlay	O
binding	O
assays	O
with	O
immobilized	O
cell	B-COMP
surface	I-COMP
proteins	O
,	O
the	O
mutant	O
virus	O
only	O
recognized	O
pAPN	O
.	O

On	O
the	O
other	O
hand	O
,	O
binding	O
to	O
the	O
sialic	O
acid	O
residues	O
of	O
the	O
high	O
-	O
molecular	O
-	O
mass	O
glycoprotein	O
was	O
observed	O
regardless	O
of	O
whether	O
the	O
cellular	B-COMP
proteins	O
had	O
been	O
separated	O
under	O
reducing	O
or	O
nonreducing	O
conditions	O
.	O

The	O
prevalence	O
of	O
antibodies	B-COMP
to	O
FIV	O
was	O
10	O
.	O
4	O
per	O
cent	O
in	O
all	O
the	O
cats	O
,	O
4	O
.	O
9	O
per	O
cent	O
in	O
healthy	O
cats	O
and	O
16	O
.	O
7	O
per	O
cent	O
in	O
sick	O
cats	O
.	O

Sex	O
,	O
age	O
and	O
health	O
status	O
were	O
each	O
independently	O
highly	O
associated	O
with	O
FIV	O
antibodies	B-COMP
.	O

Therefore	O
,	O
one	O
recombination	O
pathway	O
in	O
human	O
cells	B-COMP
involves	O
mutant	O
integrases	O
bound	O
solely	O
at	O
core	O
sites	O
,	O
which	O
is	O
reminiscent	O
of	O
the	O
Flp	O
/	O
FRT	O
and	O
Cre	O
/	O
loxP	O
pathways	O
.	O

ABSTRACT	O
:	O
A	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
cELISA	O
)	O
was	O
developed	O
for	O
detection	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
antibodies	B-COMP
.	O

Sera	B-COMP
with	O
discordant	O
cELISA	O
and	O
IFAT	O
results	O
were	O
further	O
evaluated	O
by	O
western	O
immunoblot	O
analyses	O
.	O

The	O
cELISA	O
detected	O
antibodies	B-COMP
specific	O
for	O
TCV	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
a	O
closely	O
related	O
coronavirus	O
,	O
but	O
did	O
not	O
detect	O
antibodies	B-COMP
specific	O
for	O
other	O
avian	O
viruses	O
.	O

Positive	O
reactivity	O
was	O
seen	O
with	O
polyclonal	O
antibodies	B-COMP
to	O
the	O
TCV	O
Indiana	O
isolate	O
,	O
the	O
TCV	O
Virginia	O
isolate	O
,	O
TCV	O
-	O
ATCC	O
,	O
and	O
the	O
IBV	O
Massachusetts	O
strain	O
as	O
well	O
as	O
monoclonal	O
antibodies	B-COMP
to	O
the	O
TCV	O
North	O
Carolina	O
isolate	O
or	O
the	O
membrane	B-COMP
protein	O
of	O
IBV	O
.	O

Reactivity	O
of	O
antibodies	B-COMP
to	O
unrelated	O
virus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
adenovirus	O
,	O
or	O
enterovirus	O
with	O
different	O
TCV	O
isolates	O
was	O
all	O
negative	O
,	O
except	O
positive	O
response	O
was	O
seen	O
between	O
enterovirus	O
antibody	B-COMP
and	O
a	O
TCV	O
western	O
North	O
Carolina	O
isolate	O
,	O
suggesting	O
coinfection	O
of	O
turkeys	O
with	O
TCV	O
and	O
enterovirus	O
in	O
that	O
particular	O
case	O
.	O

MHV	O
infection	O
triggers	O
a	O
robust	O
cell	B-COMP
-	O
mediated	O
response	O
in	O
which	O
both	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	B-COMP
are	O
essential	O
in	O
controlling	O
viral	O
replication	O
and	O
spread	O
.	O

The	O
virus	O
-	O
specific	O
IgA	B-COMP
antibody	I-COMP
responses	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
showed	O
negative	O
correlation	O
with	O
duration	O
of	O
TCV	O
antigen	O
in	O
the	O
corresponding	O
locations	O
of	O
intestine	O
with	O
Spearman	O
'	O
s	O
correlation	O
coefficient	O
of	O
-	O
0	O
.	O
85	O
(	O
p	O
=	O
0	O
.	O
034	O
),	O
-	O
0	O
.	O
74	O
(	O
p	O
=	O
0	O
.	O
096	O
),	O
and	O
-	O
0	O
.	O
75	O
(	O
p	O
=	O
0	O
.	O
084	O
),	O
respectively	O
.	O

RESULTS	O
The	O
serum	B-COMP
level	O
of	O
MIF	O
increased	O
significantly	O
in	O
ARDS	O
patients	O
as	O
compared	O
with	O
normal	O
persons	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

These	O
findings	O
demonstrate	O
a	O
novel	O
mechanism	O
for	O
immune	O
-	O
mediated	O
neuropathology	O
and	O
show	O
that	O
activated	O
CD8	O
T	O
cells	B-COMP
may	O
serve	O
as	O
important	O
mediators	O
of	O
bystander	O
demyelination	O
during	O
times	O
of	O
infection	O
,	O
including	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
.	O

A	O
pool	O
of	O
Elisa	O
positive	O
sera	B-COMP
were	O
also	O
tested	O
to	O
clearly	O
identify	O
the	O
binding	O
profiles	O
of	O
CCoV	O
proteins	O
.	O

The	O
patient	O
had	O
a	O
markedly	O
elevated	O
serum	B-COMP
ferritin	O
concentration	O
of	O
7880	O
micrograms	O
/	O
L	O
,	O
a	O
specific	O
finding	O
for	O
the	O
adult	O
onset	O
Still	O
'	O
s	O
disease	O
(	O
AOSD	O
).	O

TITLE	O
:	O
Antibody	B-COMP
responses	O
of	O
cattle	O
with	O
respiratory	O
coronavirus	O
infections	O
during	O
pathogenesis	O
of	O
shipping	O
fever	O
pneumonia	O
are	O
lower	O
with	O
antigens	O
of	O
enteric	O
strains	O
than	O
with	O
those	O
of	O
a	O
respiratory	O
strain	O
.	O

These	O
isolates	O
were	O
identified	O
by	O
immunofluorescence	O
using	O
monoclonal	O
antibodies	B-COMP
produced	O
against	O
reference	O
serotypes	O
:	O
Mass	O
,	O
Conn	O
,	O
and	O
Ark	O
.	O
RT	O
-	O
PCRs	O
were	O
performed	O
on	O
viral	O
RNAs	O
to	O
amplify	O
S1	O
gene	O
using	O
a	O
specific	O
set	O
of	O
primers	O
S1OLIGO3	O
'	O
and	O
S1OLIGO5	O
'.	O

Diagnosing	O
TRALI	O
has	O
implications	O
not	O
only	O
for	O
the	O
plasma	O
exchange	O
recipient	O
,	O
but	O
also	O
for	O
the	O
management	O
of	O
donors	O
found	O
to	O
have	O
leukocyte	O
antibodies	B-COMP
.	O

In	O
conclusion	O
,	O
sialodacryoadenitis	O
virus	O
infection	O
in	O
rats	O
was	O
associated	O
with	O
increased	O
frequency	O
of	O
hepatic	O
mtDNA	B-COMP
deletions	O
.	O

Although	O
the	O
naive	O
T	O
-	O
cell	B-COMP
fraction	O
and	O
the	O
helper	O
T	O
-	O
cell	B-COMP
subtype	O
1	O
fraction	O
were	O
increased	O
,	O
the	O
mitogenic	O
responses	O
of	O
T	O
-	O
cells	B-COMP
and	O
the	O
allogeneic	O
mixed	O
leukocyte	O
reaction	O
were	O
severely	O
suppressed	O
.	O

The	O
underlying	O
pathological	O
events	O
were	O
respectively	O
pulmonary	O
tuberculosis	O
and	O
upper	O
respiratory	O
infection	O
in	O
the	O
two	O
monophasic	O
cases	O
;	O
in	O
the	O
22	O
recurrent	O
ONM	O
patients	O
:	O
pulmonary	O
tuberculosis	O
(	O
3	O
),	O
neurocysticercosis	O
(	O
1	O
),	O
polyarteritis	O
nodosa	O
(	O
1	O
),	O
antinuclear	O
antibody	B-COMP
and	O
rheumatoid	O
factor	O
(	O
1	O
),	O
antiphospholipid	O
antibody	B-COMP
primary	O
syndrome	O
(	O
1	O
),	O
diabetes	O
mellitus	O
(	O
1	O
),	O
hypothyroidism	O
(	O
1	O
),	O
and	O
amenorrhea	O
-	O
galactorrhea	O
(	O
4	O
).	O

This	O
conserved	O
multifunctional	O
protein	O
is	O
also	O
efficient	O
in	O
inducing	O
NDV	O
-	O
specific	O
antibody	B-COMP
in	O
chickens	O
.	O

In	O
addition	O
,	O
a	O
B	O
-	O
cell	B-COMP
epitope	O
of	O
the	O
S2	O
glycoprotein	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
inserted	O
in	O
-	O
frame	O
to	O
replace	O
the	O
NP	O
-	O
IDE	O
.	O

To	O
directly	O
analyze	O
progenitor	O
differentiation	O
,	O
glial	O
cultures	O
from	O
spinal	O
cords	O
of	O
wild	O
-	O
type	O
mice	O
undergoing	O
remyelination	O
after	O
MHV	O
-	O
A59	O
demyelination	O
were	O
treated	O
for	O
3	O
d	O
with	O
either	O
exogenous	O
FGF2	O
or	O
an	O
FGF2	O
neutralizing	O
antibody	B-COMP
.	O

RNA	O
transcripts	O
derived	O
from	O
the	O
full	O
-	O
length	O
MHV	O
-	O
A59	O
construct	O
were	O
infectious	O
,	O
although	O
transfection	O
frequencies	O
were	O
enhanced	O
10	O
-	O
to	O
15	O
-	O
fold	O
in	O
the	O
presence	O
of	O
transcripts	O
encoding	O
the	O
nucleocapsid	B-COMP
protein	O
N	O
.	O
Plaque	O
-	O
purified	O
virus	O
derived	O
from	O
the	O
infectious	O
construct	O
replicated	O
efficiently	O
and	O
displayed	O
similar	O
growth	O
kinetics	O
,	O
plaque	O
morphology	O
,	O
and	O
cytopathology	O
in	O
murine	O
cells	B-COMP
as	O
did	O
wild	O
-	O
type	O
MHV	O
-	O
A59	O
.	O

The	O
pathognomonic	O
ELS	O
presented	O
as	O
ordered	O
molecular	O
aggregates	O
when	O
stained	O
using	O
the	O
Verhoeff	O
-	O
van	O
Gieson	O
technique	O
for	O
elastic	B-COMP
fibers	I-COMP
.	O

RESULTS	O
:	O
The	O
pathognomonic	O
ELS	O
presented	O
as	O
ordered	O
molecular	O
aggregates	O
when	O
stained	O
using	O
the	O
Verhoeff	O
-	O
van	O
Gieson	O
technique	O
for	O
elastic	B-COMP
fibers	I-COMP
.	O

In	O
this	O
study	O
,	O
antibody	B-COMP
-	O
coated	O
viruses	O
and	O
free	O
virions	B-COMP
were	O
subjected	O
to	O
nanofiltration	O
to	O
determine	O
whether	O
the	O
antibody	B-COMP
-	O
mediated	O
increase	O
in	O
size	O
contributes	O
to	O
the	O
elimination	O
of	O
viruses	O
which	O
are	O
otherwise	O
too	O
small	O
to	O
be	O
retained	O
by	O
filters	O
of	O
a	O
given	O
nominal	O
pore	B-COMP
diameter	O
.	O

TITLE	O
:	O
Reversible	O
posterior	O
leukoencephalopathy	O
syndrome	O
and	O
silent	O
cerebral	O
infarcts	O
are	O
associated	O
with	O
severe	O
acute	O
chest	O
syndrome	O
in	O
children	O
with	O
sickle	O
cell	B-COMP
disease	O
.	O

This	O
study	O
examines	O
patients	O
with	O
sickle	O
cell	B-COMP
disease	O
who	O
developed	O
severe	O
episodes	O
of	O
ACS	O
,	O
leading	O
to	O
endotracheal	O
intubation	O
,	O
ventilatory	O
support	O
for	O
respiratory	O
failure	O
,	O
and	O
erythrocytapheresis	O
.	O

TITLE	O
:	O
The	O
virulence	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
is	O
not	O
dependent	O
on	O
efficient	O
spike	O
protein	O
cleavage	O
and	O
cell	B-COMP
-	O
to	O
-	O
cell	B-COMP
fusion	O
.	O

TITLE	O
:	O
[	O
Variation	O
in	O
manifestations	O
of	O
heteroplasmic	O
mtDNA	B-COMP
mutation	O
8993	O
T	O
>	O
G	O
in	O
two	O
families	O
].	O

A	O
broad	O
spectrum	O
of	O
clinical	O
symptoms	O
may	O
be	O
observed	O
in	O
families	O
with	O
heteroplasmic	O
mtDNA	B-COMP
mutations	O
8993	O
T	O
>	O
G	O
.	O
Affected	O
children	O
with	O
a	O
mutation	O
load	O
higher	O
than	O
90	O
%	O
usually	O
do	O
not	O
survive	O
after	O
infancy	O
.	O

In	O
both	O
investigated	O
families	O
,	O
a	O
profound	O
increase	O
in	O
the	O
levels	O
of	O
heteroplasmy	O
of	O
mtDNA	B-COMP
mutation	O
8993	O
T	O
>	O
G	O
was	O
observed	O
in	O
two	O
subsequent	O
generations	O
.	O

Because	O
the	O
changes	O
in	O
neurotransmitter	O
systems	O
found	O
in	O
the	O
arcuate	O
nucleus	B-COMP
in	O
SIDS	O
victims	O
were	O
also	O
found	O
in	O
the	O
chronic	O
controls	O
with	O
known	O
hypoxia	O
,	O
specificity	O
of	O
these	O
markers	O
for	O
SIDS	O
has	O
not	O
been	O
established	O
.	O

The	O
results	O
showed	O
that	O
the	O
feline	O
cells	B-COMP
were	O
permissive	O
to	O
IBV	O
but	O
the	O
hamster	O
cells	B-COMP
were	O
not	O
.	O

A	O
high	O
antibody	B-COMP
titer	O
persisted	O
at	O
396	O
.	O
0	O
;	O
241	O
.	O
0	O
;	O
and	O
201	O
.	O
5	O
,	O
at	O
3	O
,	O
6	O
,	O
and	O
9	O
months	O
after	O
the	O
2nd	O
injection	O
,	O
respectively	O
.	O

Serum	B-COMP
and	O
various	O
tissues	O
were	O
collected	O
from	O
all	O
animals	O
and	O
assayed	O
for	O
PCV	O
,	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
porcine	O
parvovirus	O
,	O
porcine	O
enterovirus	O
types	O
1	O
-	O
3	O
,	O
swine	O
influenza	O
virus	O
,	O
porcine	O
respiratory	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
,	O
porcine	O
endogenous	O
retrovirus	O
,	O
porcine	O
lymphotropic	O
herpesvirus	O
type	O
1	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
.	O

In	O
acute	O
infections	O
,	O
we	O
need	O
two	O
sera	B-COMP
samples	O
given	O
in	O
2	O
weeks	O
period	O
with	O
4	O
-	O
fold	O
rise	O
or	O
fall	O
in	O
titers	O
.	O

The	O
recombinant	O
virus	O
with	O
the	O
gene	O
order	O
5	O
'-	O
pol	O
-	O
E	O
-	O
M	O
-	O
S	O
-	O
N	O
-	O
3	O
'	O
was	O
also	O
tested	O
for	O
the	O
ability	O
to	O
replicate	O
in	O
the	O
natural	O
host	B-COMP
,	O
the	O
mouse	O
.	O

Upon	O
infection	O
of	O
cells	B-COMP
with	O
Albany	O
4	O
followed	O
by	O
transfection	O
with	O
synthetic	O
RNA	O
transcribed	O
from	O
the	O
DI	O
-	O
like	O
cDNA	O
construct	O
,	O
recombinant	O
mouse	O
hepatitis	O
viruses	O
as	O
the	O
large	O
plaque	O
forming	O
phenotype	O
were	O
isolated	O
by	O
plaque	O
assays	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
of	O
391	O
degrees	O
C	O
.	O
By	O
RT	O
-	O
PCR	O
and	O
sequencing	O
,	O
those	O
large	O
plaque	O
phenotypes	O
were	O
confirmed	O
to	O
have	O
contained	O
the	O
thermostable	O
phenotype	O
marker	O
derived	O
from	O
the	O
transfected	O
RNA	O
,	O
demonstrating	O
that	O
recombination	O
occurred	O
between	O
the	O
Albany	O
4	O
genomic	O
RNA	O
and	O
the	O
in	O
vitro	O
RNA	O
transcripts	O
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
epitope	O
region	O
capable	O
of	O
inducing	O
neutralizing	O
antibodies	B-COMP
against	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

CD4	O
(+)	O
T	O
cells	B-COMP
are	O
important	O
in	O
amplifying	O
demyelination	O
by	O
attracting	O
macrophages	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
viral	O
infection	O
;	O
however	O
,	O
the	O
mechanisms	O
governing	O
the	O
entry	O
of	O
these	O
cells	B-COMP
into	O
the	O
CNS	O
are	O
poorly	O
understood	O
.	O

Reactivation	O
in	O
antibody	B-COMP
-	O
deficient	O
mice	O
is	O
not	O
associated	O
with	O
increased	O
T	O
-	O
cell	B-COMP
infiltration	O
,	O
but	O
is	O
prevented	O
via	O
transfer	O
of	O
neutralizing	O
antibody	B-COMP
.	O

The	O
low	O
turnover	O
of	O
virus	O
,	O
T	O
cells	B-COMP
,	O
and	O
B	O
cells	B-COMP
constitute	O
a	O
unifying	O
feature	O
of	O
persistent	O
infection	O
,	O
illustrating	O
the	O
dichotomy	O
between	O
distinct	O
immune	O
effectors	O
in	O
regulating	O
acute	O
and	O
persistent	O
central	O
nervous	O
system	O
infection	O
.	O

TITLE	O
:	O
Efficient	O
induction	O
of	O
primary	O
and	O
secondary	O
T	O
cell	B-COMP
-	O
dependent	O
immune	O
responses	O
in	O
vivo	O
in	O
the	O
absence	O
of	O
functional	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
receptors	O
.	O

In	O
the	O
present	O
study	O
,	O
these	O
mice	O
were	O
used	O
to	O
investigate	O
the	O
extent	O
by	O
which	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
are	O
essential	O
for	O
T	O
cell	B-COMP
immunity	O
in	O
vivo	O
.	O

Tg	O
-/-	O
mice	O
generated	O
near	O
normal	O
primary	O
and	O
secondary	O
Ab	O
responses	O
to	O
OVA	O
,	O
readily	O
mounted	O
first	O
and	O
second	O
set	O
allogeneic	O
skin	O
graft	O
rejection	O
responses	O
,	O
and	O
developed	O
primary	O
and	O
recall	O
CD8	O
T	O
cell	B-COMP
responses	O
to	O
vaccinia	O
virus	O
.	O

However	O
,	O
Tg	O
-/-	O
mice	O
generated	O
a	O
slightly	O
lower	O
level	O
of	O
IgG2a	B-COMP
Abs	O
to	O
OVA	O
,	O
exhibited	O
a	O
somewhat	O
delayed	O
first	O
set	O
skin	O
graft	O
rejection	O
response	O
with	O
lower	O
allo	O
-	O
specific	O
CTL	O
,	O
and	O
developed	O
a	O
significantly	O
lower	O
number	O
of	O
IFN	O
-	O
gamma	O
-	O
producing	O
vaccinia	O
-	O
specific	O
CD8	O
+	O
T	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
binds	O
to	O
viral	O
murine	O
CEACAM	O
receptor	O
glycoproteins	O
and	O
causes	O
membrane	B-COMP
fusion	O
.	O

After	O
incubation	O
with	O
soluble	O
receptor	O
at	O
37	O
degrees	O
C	O
and	O
pH	O
6	O
.	O
5	O
,	O
virions	B-COMP
became	O
hydrophobic	O
and	O
bound	O
to	O
liposomes	O
.	O

Although	O
axonal	O
injury	O
occurs	O
in	O
MS	O
,	O
it	O
is	O
regarded	O
as	O
a	O
secondary	O
event	O
to	O
the	O
myelin	B-COMP
damage	O
.	O

ABSTRACT	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
activated	O
neutrophil	O
-	O
endothelial	O
cell	B-COMP
interaction	O
in	O
DIC	O
can	O
cause	O
endothelial	O
injury	O
contributing	O
to	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
and	O
a	O
poor	O
outcome	O
after	O
trauma	O
.	O

Binding	O
of	O
S	O
(	O
547	O
)	O
to	O
hAPN	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
hAPN	O
monoclonal	O
antibody	B-COMP
that	O
inhibits	O
binding	O
of	O
virus	O
to	O
hAPN	O
and	O
blocks	O
virus	O
infection	O
of	O
human	O
cells	B-COMP
and	O
was	O
also	O
blocked	O
by	O
polyclonal	O
anti	O
-	O
HCoV	O
-	O
229E	O
antibody	B-COMP
.	O

To	O
determine	O
the	O
lag	O
between	O
T	O
-	O
cell	B-COMP
priming	O
and	O
optimal	O
activity	O
within	O
the	O
CNS	O
,	O
the	O
accumulation	O
of	O
virus	O
-	O
specific	O
CD8	O
+	O
T	O
cells	B-COMP
in	O
the	O
CNS	O
relative	O
to	O
that	O
in	O
peripheral	O
lymphoid	O
organs	O
was	O
assessed	O
by	O
using	O
gamma	O
interferon	O
-	O
specific	O
ELISPOT	O
assays	O
and	O
class	O
I	O
tetramer	O
staining	O
.	O

The	O
specific	O
antibody	B-COMP
titer	O
against	O
IBV	O
was	O
also	O
tested	O
,	O
and	O
a	O
difference	O
(	O
P	O
<	O
0	O
.	O
0091	O
)	O
between	O
the	O
two	O
experimental	O
groups	O
was	O
found	O
with	O
peak	O
titer	O
values	O
of	O
6	O
,	O
816	O
and	O
4	O
,	O
349	O
.	O

Annexin	O
-	O
V	O
staining	O
of	O
the	O
spleen	O
cells	B-COMP
demonstrated	O
that	O
the	O
cells	B-COMP
collected	O
at	O
2	O
weeks	O
p	O
.	O
i	O
.	O
were	O
undergoing	O
significantly	O
more	O
apoptosis	O
than	O
cells	B-COMP
collected	O
at	O
10	O
days	O
p	O
.	O
i	O
.	O

These	O
results	O
demonstrated	O
that	O
IBV	O
specific	O
CD8	O
(+)	O
memory	O
T	O
cells	B-COMP
generated	O
at	O
3	O
to	O
6	O
weeks	O
p	O
.	O
i	O
.	O

Expression	O
of	O
the	O
E	O
protein	O
alone	O
results	O
in	O
its	O
incorporation	O
into	O
vesicles	B-COMP
that	O
are	O
released	O
from	O
cells	B-COMP
,	O
and	O
the	O
coexpression	O
of	O
the	O
E	O
protein	O
with	O
the	O
membrane	B-COMP
protein	O
M	O
leads	O
to	O
the	O
assembly	O
of	O
coronavirus	O
-	O
like	O
particles	O
.	O

Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	O
elastase	O
in	O
the	O
pathogenesis	O
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	O
elastase	O
,	O
and	O
how	O
these	O
actions	O
affect	O
host	B-COMP
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

Coagulation	O
and	O
fibrinolytic	O
proteins	O
may	O
have	O
an	O
additional	O
role	O
beyond	O
fibrin	O
turnover	O
and	O
inflammation	O
,	O
e	O
.	O
g	O
.,	O
in	O
mechanisms	O
mediating	O
cell	B-COMP
recruitment	O
and	O
migration	O
.	O

MHV	O
-	O
2	O
was	O
injected	O
intraperitoneally	O
into	O
4	O
-	O
week	O
-	O
old	O
ICR	O
mice	O
,	O
IFN	O
or	O
the	O
vehicle	O
was	O
administered	O
intramuscularly	O
for	O
5	O
days	O
,	O
and	O
the	O
antiviral	O
effect	O
was	O
evaluated	O
based	O
on	O
survival	O
periods	O
,	O
liver	O
histology	O
,	O
serum	B-COMP
alanine	O
transaminase	O
(	O
ALT	O
)	O
levels	O
,	O
and	O
MHV	O
-	O
2	O
virus	O
titers	O
in	O
the	O
liver	O
tissues	O
.	O

Infected	O
patients	O
showed	O
seroconversion	O
on	O
the	O
Vero	O
cells	B-COMP
in	O
which	O
the	O
virus	O
was	O
isolated	O
.	O

Infected	O
patients	O
showed	O
seroconversion	O
on	O
the	O
Vero	O
cells	B-COMP
in	O
which	O
the	O
virus	O
was	O
isolated	O
.	O

Immunohistochemical	O
and	O
immunofluorescence	O
staining	O
revealed	O
reactivity	O
with	O
group	O
I	O
coronavirus	O
polyclonal	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Human	O
papillomavirus	O
type	O
16	O
E7	O
peptide	O
-	O
directed	O
CD8	O
+	O
T	O
cells	B-COMP
from	O
patients	O
with	O
cervical	O
cancer	O
are	O
cross	O
-	O
reactive	O
with	O
the	O
coronavirus	O
NS2	O
protein	O
.	O

Recent	O
evidence	O
suggests	O
that	O
cross	O
-	O
reactivity	O
represents	O
the	O
inherent	O
nature	O
of	O
the	O
T	O
-	O
cell	B-COMP
repertoire	O
.	O

In	O
contrast	O
,	O
we	O
could	O
not	O
detect	O
E6	O
-	O
reactive	O
T	O
cells	B-COMP
in	O
healthy	O
individuals	O
.	O

We	O
defined	O
the	O
clinical	O
presentation	O
and	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
and	O
investigated	O
the	O
causal	O
agents	O
by	O
chest	O
radiography	O
and	O
laboratory	O
testing	O
of	O
nasopharyngeal	O
aspirates	O
and	O
sera	B-COMP
samples	O
.	O

TITLE	O
:	O
Rhinovirus	O
infections	O
in	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
recipients	O
with	O
pneumonia	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
impact	O
of	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
and	O
coronavirus	O
infections	O
in	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
(	O
HSCT	O
)	O
recipients	O
.	O

ABSTRACT	O
:	O
Transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
)	O
is	O
a	O
severe	O
reaction	O
between	O
leukocyte	O
antigen	O
and	O
antibody	B-COMP
during	O
transfusion	O
of	O
plasma	O
-	O
containing	O
components	O
.	O

CONCLUSIONS	O
:	O
The	O
ER	O
lakes	O
are	O
involved	O
in	O
the	O
maturation	O
of	O
the	O
viruses	O
,	O
and	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
of	O
the	O
virus	O
entering	O
the	O
cells	B-COMP
from	O
extracellular	B-COMP
space	I-COMP
are	O
removed	O
and	O
degraded	O
in	O
the	O
endosome	B-COMP
/	O
lysosome	B-COMP
.	O

The	O
Result	O
of	O
Blast	O
shows	O
only	O
the	O
difference	O
in	O
one	O
nucleic	B-COMP
acid	O
from	O
the	O
TOR2	O
strain	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

We	O
have	O
used	O
convalescent	O
sera	B-COMP
from	O
several	O
SARS	O
patients	O
to	O
detect	O
proteins	O
in	O
the	O
culture	O
supernatants	O
from	O
cells	B-COMP
exposed	O
to	O
lavage	O
another	O
SARS	O
patient	O
.	O

This	O
was	O
found	O
to	O
be	O
a	O
novel	O
nucleocapsid	B-COMP
protein	O
that	O
matched	O
almost	O
exactly	O
one	O
predicted	O
by	O
an	O
open	O
reading	O
frame	O
in	O
the	O
recently	O
published	O
nucleotide	O
sequence	O
of	O
the	O
same	O
virus	O
isolate	O
(>	O
96	O
%	O
coverage	O
).	O

These	O
results	O
suggest	O
that	O
the	O
nucleocapsid	B-COMP
protein	O
is	O
a	O
major	O
immunogen	O
that	O
may	O
be	O
useful	O
for	O
early	O
diagnostics	O
,	O
and	O
that	O
the	O
spike	O
glycoprotein	O
may	O
present	O
a	O
particularly	O
attractive	O
target	O
for	O
prophylactic	O
intervention	O
in	O
combating	O
SARS	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
genetic	O
elements	O
were	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
from	O
blood	O
,	O
fecal	O
samples	O
,	O
and	O
effusive	O
fluid	O
collected	O
from	O
33	O
cheetahs	O
in	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
Feline	O
coronavirus	O
-	O
specific	O
serum	B-COMP
antibodies	B-COMP
were	O
also	O
measured	O
by	O
indirect	O
immunofluorescence	O
.	O

The	O
SARS	O
E	O
protein	O
may	O
fold	O
in	O
water	O
solution	O
in	O
a	O
similar	O
way	O
as	O
it	O
in	O
membrane	B-COMP
-	O
water	O
mixed	O
environment	O
.	O

TITLE	O
:	O
Cloning	O
and	O
sequence	O
analysis	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
Chinju99	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
is	O
the	O
predominant	O
inducer	O
of	O
neutralizing	O
antibodies	B-COMP
and	O
has	O
been	O
implicated	O
in	O
virulence	O
and	O
host	B-COMP
cell	I-COMP
tropism	O
.	O

The	O
presence	O
of	O
this	O
packaging	O
signal	O
was	O
further	O
confirmed	O
by	O
showing	O
the	O
expression	O
and	O
rescue	O
of	O
the	O
mRNA	O
including	O
the	O
first	O
649	O
nt	O
of	O
the	O
TGEV	O
genome	O
under	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
in	O
TGEV	O
-	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Chemical	O
modification	O
of	O
the	O
proteins	O
bovine	O
serum	B-COMP
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
chicken	O
lysozyme	O
by	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
(	O
3	O
-	O
HP	O
)	O
yielded	O
compounds	O
which	O
exerted	O
antiviral	O
activity	O
in	O
vitro	O
as	O
compared	O
with	O
the	O
native	O
unmodified	O
proteins	O
.	O

Systemic	O
toxic	O
changes	O
included	O
degeneration	O
and	O
necrosis	O
of	O
the	O
parenchyma	O
cells	B-COMP
in	O
the	O
lung	O
,	O
liver	O
,	O
kidney	O
,	O
heart	O
,	O
and	O
adrenal	O
gland	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
temporal	O
profile	O
of	O
serum	B-COMP
antibody	B-COMP
against	O
coronavirus	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
to	O
evaluate	O
the	O
reliability	O
of	O
indirect	O
immuno	O
-	O
fluorescence	O
assay	O
(	O
IFA	O
)	O
in	O
the	O
diagnosis	O
of	O
SARS	O
.	O

In	O
addition	O
to	O
the	O
polyprotein	O
chain	O
ORFs	O
1a	O
and	O
1b	O
and	O
the	O
four	O
genes	O
coding	O
for	O
the	O
major	O
structural	O
proteins	O
,	O
spike	O
(	O
S	O
),	O
small	O
envelop	O
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
nuleocaspid	O
(	O
N	O
),	O
respectively	O
,	O
ZCURVE_CoV	O
also	O
predicts	O
5	O
-	O
6	O
putative	O
proteins	O
in	O
length	O
between	O
39	O
and	O
274	O
amino	O
acids	O
with	O
unknown	O
functions	O
.	O

TITLE	O
:	O
Prospective	O
observational	O
study	O
of	O
antiphospholipid	O
antibodies	B-COMP
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
comparison	O
with	O
catastrophic	O
antiphospholipid	O
syndrome	O
.	O

The	O
high	O
aPL	O
antibody	B-COMP
levels	O
in	O
serum	B-COMP
possibly	O
triggered	O
by	O
sepsis	O
were	O
associated	O
with	O
high	O
aPL	O
antibody	B-COMP
levels	O
in	O
BALF	O
,	O
which	O
can	O
be	O
explained	O
by	O
high	O
capillary	O
-	O
alveolar	O
permeability	O
.	O

The	O
macrophage	O
-	O
inducible	O
Salmonella	O
ssaH	O
and	O
spiC	O
/	O
ssaB	O
promoters	O
were	O
compared	O
for	O
their	O
ability	O
to	O
express	O
the	O
TGEV	O
C	O
and	O
A	O
epitopes	O
in	O
the	O
context	O
of	O
the	O
heterologous	O
987P	O
fimbriae	B-COMP
on	O
Salmonella	O
vaccines	O
.	O

CONCLUSIONS	O
:	O
The	O
damage	O
of	O
cellular	B-COMP
immunity	O
is	O
probably	O
an	O
important	O
mechanism	O
of	O
pathogenesis	O
of	O
SARS	O
.	O

SARS	O
is	O
pathologically	O
characterized	O
by	O
interstitial	O
exudative	O
inflammation	O
of	O
lung	O
with	O
the	O
formation	O
of	O
hyaline	O
membrane	B-COMP
in	O
acute	O
phase	O
.	O

The	O
antibodies	B-COMP
used	O
included	O
CD20	O
,	O
CD45RO	O
(	O
UCHL	O
-	O
1	O
),	O
CD4	O
,	O
CD8	O
,	O
CD68	O
and	O
CD34	O
.	O

Examination	O
of	O
CPE	O
cells	B-COMP
on	O
thin	O
-	O
section	O
revealed	O
characteristic	O
coronavirus	O
particles	O
within	O
the	O
cisternae	O
of	O
endoplasmic	B-COMP
reticulum	I-COMP
,	O
Golgi	B-COMP
apparatus	I-COMP
,	O
vesicles	B-COMP
and	O
extracellular	B-COMP
space	I-COMP
.	O

Infectious	O
virons	O
entered	O
cells	B-COMP
by	O
endocytosis	O
or	O
membrane	B-COMP
fusion	O
and	O
released	O
through	O
a	O
budding	O
process	O
.	O

Mice	O
and	O
chickens	O
vaccinated	O
with	O
the	O
expressed	O
IBV	O
S1	O
glycoprotein	O
produced	O
antibodies	B-COMP
that	O
neutralized	O
IBV	O
infectivity	O
.	O

Inclusion	B-COMP
bodies	I-COMP
containing	O
elementary	O
bodies	O
,	O
reticulate	O
antibodies	B-COMP
and	O
intermediate	O
bodies	O
of	O
Chlamydia	O
-	O
like	O
agent	O
were	O
visualized	O
in	O
multiple	O
organs	O
from	O
the	O
7	O
dead	O
cases	O
,	O
including	O
lungs	O
(	O
7	O
cases	O
),	O
spleens	O
(	O
2	O
cases	O
),	O
livers	O
(	O
2	O
cases	O
),	O
kidneys	O
(	O
3	O
cases	O
)	O
and	O
lymph	O
nodes	O
(	O
1	O
cases	O
),	O
by	O
ultrathin	O
section	O
electron	O
microscopy	O
(	O
EM	O
).	O

Since	O
the	O
Chlamydia	O
-	O
like	O
agents	O
visualized	O
in	O
both	O
organs	O
and	O
cell	B-COMP
cultures	O
could	O
not	O
react	O
with	O
the	O
genus	O
specific	O
antibodies	B-COMP
against	O
Chlamydia	O
and	O
monoclonal	O
antibodies	B-COMP
against	O
C	O
.	O
pneumoniae	O
and	O
C	O
.	O
psittaci	O
,	O
the	O
results	O
might	O
well	O
be	O
suggestive	O
of	O
a	O
novel	O
Chlamydia	O
-	O
like	O
agent	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
serum	B-COMP
interleukins	O
and	O
T	O
-	O
lymphocyte	O
subsets	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Interferon	O
beta	O
was	O
five	O
to	O
ten	O
times	O
more	O
effective	O
in	O
Caco2	O
cells	B-COMP
.	O

Interferon	O
gamma	O
was	O
slightly	O
better	O
than	O
interferon	O
alpha	O
in	O
Vero	O
cell	B-COMP
cultures	O
,	O
but	O
was	O
completely	O
ineffective	O
in	O
Caco2	O
cell	B-COMP
cultures	O
.	O

Other	O
common	O
findings	O
included	O
elevated	O
levels	O
of	O
serum	B-COMP
alanine	O
aminotransferase	O
,	O
lactate	O
dehydrogenase	O
and	O
erythrocyte	O
sedimentation	O
(	O
76	O
.	O
2	O
%,	O
28	O
.	O
6	O
%	O
and	O
47	O
.	O
8	O
%,	O
respectively	O
),	O
and	O
decreased	O
levels	O
of	O
serum	B-COMP
iron	O
and	O
albumin	O
(	O
63	O
.	O
2	O
%	O
and	O
47	O
.	O
8	O
%,	O
respectively	O
).	O

Fever	O
,	O
lymphopenia	O
,	O
low	O
serum	B-COMP
iron	O
and	O
chest	O
radiograph	O
are	O
helpful	O
to	O
diagnose	O
SARS	O
early	O
;	O
age	O
is	O
the	O
independent	O
predictor	O
of	O
an	O
outcome	O
.	O

A	O
large	O
dose	O
of	O
glucocorticoid	O
may	O
aggravate	O
the	O
suppression	O
and	O
make	O
the	O
body	O
in	O
an	O
active	O
metabolic	O
state	O
(	O
the	O
increase	O
of	O
blood	O
glucose	O
and	O
the	O
decrease	O
of	O
sera	B-COMP
albumin	O
).	O

The	O
soluble	O
parts	O
of	O
the	O
cell	B-COMP
crude	O
extract	O
were	O
then	O
partially	O
purified	O
by	O
GST	O
affinity	O
chromatography	O
.	O

Specific	O
antibodies	B-COMP
of	O
IgM	O
and	O
IgG	O
against	O
SARS	O
virus	O
in	O
267	O
serum	B-COMP
specimens	O
from	O
patients	O
with	O
SARS	O
and	O
132	O
from	O
non	O
-	O
SARS	O
patients	O
or	O
healthy	O
persons	O
were	O
assayed	O
with	O
IFA	O
or	O
ELISA	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
(	O
ppv	O
),	O
negative	O
predictive	O
value	O
(	O
NPV	O
),	O
and	O
accuracy	O
were	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
the	O
antibodies	B-COMP
in	O
diagnosis	O
of	O
SARS	O
.	O

The	O
antibodies	B-COMP
against	O
SARS	O
virus	O
can	O
be	O
detected	O
in	O
the	O
mid	O
-	O
and	O
late	O
stage	O
of	O
SARS	O
.	O

One	O
outstanding	O
question	O
in	O
understanding	O
CTL	O
escape	O
is	O
whether	O
a	O
CD8	O
T	O
cell	B-COMP
response	O
to	O
two	O
or	O
more	O
immunodominant	O
CTL	O
epitopes	O
would	O
prevent	O
CTL	O
escape	O
.	O

Although	O
CTL	O
escape	O
at	O
multiple	O
epitopes	O
seems	O
intuitively	O
unlikely	O
,	O
CTL	O
escape	O
at	O
multiple	O
CD8	O
T	O
cell	B-COMP
epitopes	O
has	O
been	O
documented	O
in	O
some	O
chronically	O
infected	O
individual	O
animals	O
.	O

The	O
laboratory	O
test	O
show	O
that	O
33	O
%	O
patients	O
with	O
leukopenia	O
and	O
thrombocytopenia	O
,	O
53	O
.	O
3	O
%	O
with	O
elevated	O
serum	B-COMP
aminotransferase	O
and	O
26	O
.	O
6	O
%	O
with	O
increased	O
creatinine	O
kinase	O
levels	O
.	O

The	O
IgG	B-COMP
antibody	I-COMP
was	O
detected	O
in	O
22	O
out	O
of	O
34	O
(	O
64	O
.	O
7	O
%)	O
patients	O
and	O
the	O
average	O
time	O
for	O
the	O
occurrence	O
of	O
antibody	B-COMP
was	O
(	O
18	O
.	O
2	O
+/-	O

TITLE	O
:	O
[	O
Primary	O
investigation	O
on	O
the	O
changing	O
mode	O
of	O
plasma	O
specific	O
IgG	B-COMP
antibody	I-COMP
in	O
SARS	O
patients	O
and	O
their	O
physicians	O
and	O
nurses	O
].	O

ABSTRACT	O
:	O
To	O
primarily	O
investigate	O
the	O
changing	O
mode	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
in	O
clinically	O
diagnosed	O
SARS	O
patients	O
and	O
the	O
possibility	O
of	O
subclinical	O
infection	O
in	O
physicians	O
and	O
nurses	O
through	O
close	O
association	O
with	O
SARS	O
patients	O
.	O

The	O
CD	O
+	O
4	O
and	O
CD	O
+	O
8	O
in	O
T	O
cell	B-COMP
in	O
peripheral	O
blood	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

The	O
CD	O
+	O
4	O
and	O
CD	O
+	O
8	O
in	O
T	O
cell	B-COMP
in	O
13	O
patients	O
with	O
SARS	O
significantly	O
decreased	O
[	O
CD	O
+	O
4	O
:	O
(	O
16	O
.	O
10	O
+/-	O
4	O
.	O
31	O
)	O
percent	O
vs	O
.	O
(	O
38	O
.	O
30	O
+/-	O
8	O
.	O
52	O
)	O
percent	O
,	O
t	O
=	O
8	O
.	O
174	O
,	O
P	O
<	O
0	O
.	O
01	O
;	O
CD	O
+	O
8	O
:	O
(	O
19	O
.	O
90	O
+/-	O
5	O
.	O
40	O
)	O
percent	O
vs	O
.	O
(	O
28	O
.	O
38	O
+/-	O
4	O
.	O
33	O
)	O
percent	O
,	O
t	O
=	O
4	O
.	O
055	O
,	O
P	O
<	O
0	O
.	O
01	O
].	O

The	O
present	O
study	O
evaluated	O
the	O
contributions	O
of	O
CCR5	O
to	O
the	O
activation	O
and	O
trafficking	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
into	O
the	O
MHV	O
-	O
infected	O
CNS	O
mice	O
.	O

Histological	O
analysis	O
of	O
RAG1	O
(-/-)	O
recipients	O
of	O
either	O
CCR5	O
(+/+)	O
or	O
CCR5	O
(-/-)-	O
derived	O
CD8	O
(+)	O
T	O
cells	B-COMP
revealed	O
only	O
focal	O
areas	O
of	O
demyelination	O
with	O
no	O
significant	O
differences	O
in	O
white	O
matter	O
destruction	O
.	O

Klenow	O
-	O
FragELTM	O
DNA	O
Fragmentation	O
Detection	O
Kit	O
and	O
immunohistochemical	O
alkaline	O
phosphatase	O
detection	O
reagent	O
kit	O
were	O
used	O
to	O
detect	O
cell	B-COMP
apoptosis	O
and	O
expressions	O
of	O
CD68	O
,	O
CD20	O
,	O
CD4	O
,	O
CD8	O
and	O
CD45RA	O
in	O
the	O
pathological	O
tissues	O
of	O
SARS	O
patients	O
.	O

Apoptotic	O
cells	B-COMP
increased	O
significantly	O
in	O
the	O
spleen	O
,	O
lung	O
and	O
lymph	O
nodes	O
of	O
SARS	O
patients	O
as	O
compared	O
with	O
normal	O
tissues	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
expression	O
of	O
the	O
immune	O
cell	B-COMP
markers	O
and	O
their	O
active	O
antigens	O
in	O
the	O
involved	O
tissues	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

In	O
the	O
lymph	O
nodes	O
,	O
scattered	O
T	O
lymphocytes	O
positive	O
for	O
Ki67	O
and	O
CD45RO	O
markers	O
(	O
active	O
T	O
lymphocytes	O
)	O
were	O
seen	O
,	O
but	O
the	O
T	O
lymphocytes	O
subpopulations	O
were	O
obviously	O
decreased	O
,	O
which	O
was	O
especially	O
so	O
with	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
and	O
NK	O
cells	B-COMP
.	O

Significantly	O
enhanced	O
activity	O
of	O
the	O
macrophages	O
occurs	O
in	O
SARS	O
as	O
the	O
major	O
reactive	O
cells	B-COMP
,	O
but	O
T	O
lymphocyte	O
subsets	O
are	O
obviously	O
decreased	O
,	O
indicating	O
the	O
important	O
roles	O
of	O
the	O
macrophages	O
and	O
T	O
lymphocytes	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
.	O

CONCLUSIONS	O
:	O
Significantly	O
enhanced	O
activity	O
of	O
the	O
macrophages	O
occurs	O
in	O
SARS	O
as	O
the	O
major	O
reactive	O
cells	B-COMP
,	O
but	O
T	O
lymphocyte	O
subsets	O
are	O
obviously	O
decreased	O
,	O
indicating	O
the	O
important	O
roles	O
of	O
the	O
macrophages	O
and	O
T	O
lymphocytes	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
.	O

At	O
the	O
first	O
week	O
,	O
the	O
counts	O
of	O
white	O
blood	O
cells	B-COMP
(	O
WBCs	O
),	O
lymphocyte	O
and	O
platelets	O
were	O
(	O
4	O
.	O
4	O
+/-	O
1	O
.	O
5	O
)	O
x	O
10	O
(	O
9	O
)/	O
L	O
,	O
0	O
.	O
22	O
+/-	O
0	O
.	O
12	O
and	O
(	O
143	O
+/-	O
37	O
)	O
x	O
10	O
(	O
9	O
)/	O
L	O
,	O
which	O
were	O
significantly	O
lower	O
when	O
compared	O
with	O
those	O
at	O
the	O
2nd	O
to	O
4th	O
week	O
.	O

ABSTRACT	O
:	O
Porcine	O
organs	O
,	O
cells	B-COMP
and	O
tissues	O
provide	O
a	O
viable	O
source	O
of	O
transplants	O
in	O
humans	O
,	O
though	O
there	O
is	O
some	O
concern	O
of	O
public	O
health	O
risk	O
from	O
adaptation	O
of	O
swine	O
infectious	O
agents	O
in	O
humans	O
.	O

As	O
previously	O
shown	O
,	O
a	O
lower	O
pre	O
-	O
existing	O
anti	O
-	O
MHV	O
antibody	B-COMP
level	O
was	O
found	O
in	O
susceptible	O
HIII	O
mice	O
as	O
compared	O
to	O
resistant	O
LIII	O
mice	O
.	O

Although	O
mounting	O
a	O
Th2	O
response	O
as	O
indicated	O
by	O
IgG1	B-COMP
responses	O
,	O
they	O
were	O
also	O
able	O
to	O
readily	O
synthesize	O
large	O
amounts	O
of	O
IgG2a	B-COMP
antibodies	B-COMP
after	O
immunization	O
or	O
during	O
infection	O
,	O
reflecting	O
a	O
Th1	O
response	O
.	O

The	O
transfer	O
of	O
anti	O
-	O
MHV	O
antibodies	B-COMP
to	O
susceptible	O
HIII	O
mice	O
was	O
capable	O
of	O
conferring	O
resistance	O
to	O
MHV3	O
,	O
providing	O
the	O
antibodies	B-COMP
were	O
present	O
before	O
virus	O
infection	O
and	O
in	O
large	O
amounts	O
.	O

They	O
were	O
no	O
longer	O
in	O
large	O
vacuoles	B-COMP
but	O
packaged	O
into	O
smaller	O
vacuoles	B-COMP
in	O
the	O
cytoplasm	B-COMP
,	O
and	O
occasionally	O
in	O
small	O
groups	O
.	O

Gradient	O
fractionation	O
and	O
biochemical	O
extraction	O
experiments	O
demonstrated	O
that	O
Pol	O
was	O
not	O
an	O
integral	O
membrane	B-COMP
protein	O
but	O
was	O
tightly	O
associated	O
with	O
membranes	O
and	O
coimmunoprecipitated	O
with	O
the	O
replicase	O
proteins	O
3CLpro	O
,	O
p22	O
,	O
and	O
p12	O
.	O

UV	O
cross	O
-	O
linking	O
experiments	O
revealed	O
that	O
several	O
CB3	O
cellular	B-COMP
proteins	O
similar	O
in	O
size	O
to	O
hnRNP	O
A1	O
interacted	O
with	O
the	O
MHV	O
RNA	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
functions	O
of	O
hnRNP	O
A1	O
in	O
MHV	O
RNA	O
synthesis	O
can	O
be	O
replaced	O
by	O
other	O
closely	O
related	O
hnRNPs	O
,	O
further	O
supporting	O
the	O
roles	O
of	O
cellular	B-COMP
proteins	O
in	O
MHV	O
RNA	O
synthesis	O
.	O

The	O
CD	O
4	O
and	O
CD	O
8	O
T	O
lymphocytes	O
in	O
peripheral	O
blood	O
were	O
(	O
416	O
.	O
6	O
+/-	O
235	O
.	O
0	O
)	O
cells	B-COMP
/	O
microl	O
and	O
(	O
296	O
.	O
1	O
+/-	O
181	O
.	O
5	O
)	O
cells	B-COMP
/	O
microl	O
in	O
survival	O
patients	O
and	O
(	O
143	O
.	O
8	O
+/-	O
78	O
.	O
1	O
)	O
cells	B-COMP
/	O
microl	O
,	O
(	O
103	O
.	O
6	O
+/-	O
63	O
.	O
2	O
)	O
cells	B-COMP
/	O
microl	O
in	O
dead	O
patients	O
,	O
they	O
often	O
decreased	O
compared	O
to	O
the	O
normal	O
values	O
,	O
especially	O
in	O
dead	O
cases	O
.	O

Since	O
it	O
is	O
a	O
member	O
of	O
the	O
Coronaviridae	O
,	O
its	O
spike	O
protein	O
(	O
S2	O
)	O
is	O
believed	O
to	O
play	O
a	O
central	O
role	O
in	O
viral	O
entry	O
by	O
facilitating	O
fusion	O
between	O
the	O
viral	O
and	O
host	O
cell	B-COMP
membranes	I-COMP
.	O

The	O
protein	O
responsible	O
for	O
viral	O
-	O
induced	O
membrane	B-COMP
fusion	O
of	O
HIV	O
-	O
1	O
(	O
gp41	O
)	O
differs	O
in	O
length	O
,	O
and	O
has	O
no	O
sequence	O
homology	O
with	O
S2	O
.	O

Serum	B-COMP
coronavirus	O
nucleic	B-COMP
acid	O
was	O
positive	O
in	O
3	O
patients	O
,	O
coronavirus	O
antibody	B-COMP
positive	O
in	O
two	O
and	O
both	O
were	O
positive	O
in	O
one	O
.	O

Serum	B-COMP
coronavirus	O
nucleic	B-COMP
acid	O
was	O
positive	O
in	O
3	O
patients	O
,	O
coronavirus	O
antibody	B-COMP
positive	O
in	O
two	O
and	O
both	O
were	O
positive	O
in	O
one	O
.	O

Cases	O
of	O
more	O
than	O
10	O
days	O
'	O
duration	O
exhibited	O
organizing	O
-	O
phase	O
DAD	O
,	O
type	O
II	O
pneumocyte	O
hyperplasia	O
,	O
squamous	O
metaplasia	O
,	O
multinucleated	O
giant	O
cells	B-COMP
,	O
and	O
acute	O
bronchopneumonia	O
.	O

However	O
,	O
in	O
none	O
of	O
the	O
examined	O
flocks	O
was	O
the	O
presence	O
of	O
antibodies	B-COMP
against	O
reticuloendoteliosis	O
virus	O
found	O
.	O

The	O
disease	O
appears	O
to	O
have	O
originated	O
in	O
Guangdong	O
Province	O
,	O
and	O
the	O
causative	O
agent	O
,	O
SARS	O
coronavirus	O
,	O
is	O
likely	O
to	O
have	O
originated	O
from	O
an	O
animal	O
host	B-COMP
,	O
perhaps	O
sold	O
in	O
public	O
markets	O
.	O

Comparison	O
of	O
phylogenetic	O
trees	O
for	O
11	O
known	O
host	B-COMP
-	O
species	O
and	O
36	O
coronaviruses	O
,	O
representing	O
coronavirus	O
groups	O
1	O
-	O
3	O
and	O
SARS	O
-	O
CoV	O
,	O
based	O
on	O
N	O
showed	O
statistical	O
incongruence	O
indicating	O
multiple	O
host	B-COMP
-	O
species	O
shifts	O
for	O
coronaviruses	O
.	O

However	O
,	O
current	O
sampling	O
suggests	O
host	B-COMP
-	O
species	O
shifts	O
between	O
mouse	O
and	O
rat	O
,	O
chicken	O
and	O
turkey	O
,	O
mammals	O
and	O
manx	O
shearwater	O
,	O
and	O
humans	O
and	O
other	O
mammals	O
.	O

In	O
this	O
report	O
,	O
recombinant	O
N	O
protein	O
from	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
was	O
produced	O
and	O
purified	O
from	O
Escherichia	O
coli	O
as	O
well	O
as	O
Sf9	O
(	O
insect	O
)	O
cells	B-COMP
,	O
and	O
used	O
for	O
the	O
coating	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
plates	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
observed	O
in	O
serum	B-COMP
levels	O
of	O
interleukins	O
(	O
ILs	O
),	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
mean	O
concentration	O
of	O
serum	B-COMP
TGF	O
-	O
beta1	O
in	O
SARS	O
patients	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
clinical	O
courses	O
.	O

CONCLUSIONS	O
:	O
Attention	O
should	O
be	O
paid	O
to	O
whether	O
these	O
genotype	O
and	O
mutation	O
patterns	O
are	O
related	O
to	O
the	O
virus	O
'	O
s	O
biological	O
activities	O
,	O
epidemic	O
characteristics	O
and	O
host	B-COMP
clinical	O
symptoms	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
underlying	O
cellular	B-COMP
mechanisms	O
in	O
the	O
pancreas	O
after	O
acute	O
pancreatitis	O
and	O
to	O
study	O
the	O
pathogenesis	O
of	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
.	O

Although	O
initial	O
clinical	O
trials	O
in	O
cystic	O
fibrosis	O
and	O
non	O
-	O
small	O
cell	B-COMP
lung	O
cancer	O
have	O
shown	O
promise	O
the	O
results	O
have	O
not	O
been	O
as	O
good	O
as	O
might	O
have	O
been	O
anticipated	O
.	O

ABSTRACT	O
:	O
To	O
observe	O
IgG	O
and	O
IgM	O
antibodies	B-COMP
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
explore	O
their	O
significance	O
.	O

During	O
the	O
recovery	O
,	O
follow	O
-	O
up	O
stages	O
and	O
in	O
the	O
front	O
healthy	O
crowd	O
,	O
the	O
positive	O
ratios	O
of	O
IgG	O
were	O
all	O
higher	O
than	O
those	O
of	O
IgM	O
.	O
The	O
changeable	O
tendency	O
SARS	O
antibody	B-COMP
is	O
more	O
different	O
than	O
that	O
of	O
other	O
infectious	O
diseases	O
.	O

Because	O
its	O
sequence	O
data	O
differ	O
from	O
that	O
of	O
known	O
human	O
coronaviruses	O
,	O
SARS	O
-	O
CoV	O
is	O
suspected	O
to	O
have	O
crossed	O
the	O
species	O
barrier	O
between	O
an	O
animal	O
host	B-COMP
and	O
humans	O
.	O

The	O
risk	O
of	O
transfusion	O
-	O
transmitted	O
human	O
T	O
-	O
cell	B-COMP
leukemia	O
virus	O
I	O
/	O
II	O
is	O
1	O
:	O
2	O
,	O
993	O
,	O
000	O
,	O
based	O
on	O
Red	O
Cross	O
estimates	O
.	O

In	O
addition	O
,	O
subgenomic	O
transcripts	O
were	O
initiated	O
from	O
the	O
consensus	O
sequence	O
ACGAAC	O
in	O
both	O
the	O
WT	O
and	O
infectious	O
clone	O
SARS	O
-	O
CoV	O
.	O
Availability	O
of	O
a	O
SARS	O
-	O
CoV	O
full	O
-	O
length	O
cDNA	O
provides	O
a	O
template	O
for	O
manipulation	O
of	O
the	O
viral	B-COMP
genome	I-COMP
,	O
allowing	O
for	O
the	O
rapid	O
and	O
rational	O
development	O
and	O
testing	O
of	O
candidate	O
vaccines	O
and	O
therapeutics	O
against	O
this	O
important	O
human	O
pathogen	O
.	O

The	O
result	O
showed	O
2	O
/	O
66	O
cases	O
(	O
3	O
.	O
0	O
%)	O
were	O
positive	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	B-COMP
antibody	I-COMP
and	O
66	O
cases	O
were	O
negative	O
of	O
SARS	O
-	O
CoV	O
-	O
IgM	B-COMP
antibody	I-COMP
in	O
the	O
66	O
cases	O
healthy	O
controls	O
;	O
in	O
31	O
cases	O
with	O
SLE	O
,	O
positive	O
rates	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	B-COMP
antibody	I-COMP
were	O
58	O
.	O
1	O
%	O
(	O
18	O
/	O
31	O
)	O
and	O
29	O
%	O
(	O
9	O
/	O
31	O
),	O
respectively	O
,	O
in	O
which	O
7	O
cases	O
(	O
22	O
.	O
6	O
%)	O
were	O
positive	O
of	O
both	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	B-COMP
antibody	I-COMP
.	O

The	O
average	O
titers	O
of	O
IgG	O
and	O
IgM	B-COMP
antibody	I-COMP
in	O
positive	O
samples	O
were	O
18	O
.	O
23	O
+/-	O

It	O
was	O
concluded	O
that	O
not	O
all	O
SARS	O
patients	O
could	O
produce	O
the	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-COMP
.	O

BALB	O
/	O
b	O
mice	O
had	O
25	O
-	O
fold	O
more	O
MHV	O
-	O
specific	O
antibody	B-COMP
-	O
secreting	O
cells	B-COMP
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
site	O
of	O
infection	O
,	O
than	O
B6	O
mice	O
,	O
suggesting	O
that	O
local	O
production	O
of	O
anti	O
-	O
MHV	O
antibody	B-COMP
contributed	O
to	O
this	O
absence	O
of	O
CTL	O
escape	O
.	O

Treatment	O
with	O
the	O
pan	B-COMP
-	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
blocked	O
MHV	O
-	O
induced	O
apoptosis	O
,	O
suggesting	O
an	O
involvement	O
of	O
the	O
caspase	O
-	O
dependent	O
pathway	O
.	O

We	O
analysed	O
epidemiological	O
information	O
and	O
collected	O
serum	B-COMP
and	O
nasopharyngeal	O
aspirates	O
from	O
patients	O
with	O
SARS	O
in	O
Guangdong	O
in	O
mid	O
-	O
February	O
,	O
2003	O
.	O

A	O
further	O
73	O
BAL	O
samples	O
were	O
obtained	O
from	O
20	O
infants	O
(	O
median	O
age	O
2	O
days	O
,	O
range	O
1	O
to	O
402	O
)	O
receiving	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
The	O
specificities	O
and	O
sensitivities	O
of	O
five	O
recombinant	O
proteins	O
of	O
the	O
surface	O
protective	O
antigen	O
(	O
SpaA	O
)	O
of	O
Erysipelothrix	O
rhusiopathiae	O
were	O
examined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
the	O
aim	O
of	O
developing	O
a	O
reliable	O
serological	O
test	O
for	O
the	O
detection	O
of	O
protective	O
antibody	B-COMP
against	O
E	O
.	O
rhusiopathiae	O
.	O

The	O
mechanism	O
of	O
SARS	O
pathogenesis	O
may	O
involve	O
both	O
direct	O
viral	O
cytocidal	O
effects	O
on	O
the	O
target	O
cells	B-COMP
and	O
immune	O
-	O
mediated	O
mechanisms	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
SARS	O
coronavirus	O
in	O
the	O
testing	O
condition	O
could	O
survive	O
in	O
serum	B-COMP
,	O
1	O
:	O
20	O
diluted	O
sputum	O
and	O
feces	O
for	O
at	O
least	O
96	O
h	O
,	O
whereas	O
it	O
could	O
remain	O
alive	O
in	O
urine	O
for	O
at	O
least	O
72	O
h	O
with	O
a	O
low	O
level	O
of	O
infectivity	O
.	O

TITLE	O
:	O
[	O
The	O
quantitative	O
detection	O
of	O
anti	O
-	O
coronavirus	O
antibody	B-COMP
titer	O
in	O
medical	O
personnel	O
closely	O
contacted	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
].	O

The	O
number	O
of	O
total	O
B	O
cells	B-COMP
of	O
clinically	O
diagnosed	O
SARS	O
was	O
(	O
292	O
+/-	O
181	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
,	O
significantly	O
greater	O
than	O
that	O
of	O
healthy	O
adults	O
which	O
was	O
(	O
200	O
+/-	O
65	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
(	O
F	O
=	O
6	O
.	O
17	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
smaller	O
than	O
that	O
of	O
patients	O
infected	O
with	O
mycoplasma	O
pneumonia	O
which	O
was	O
(	O
359	O
+/-	O
168	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
(	O
F	O
=	O
6	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

Serum	B-COMP
samples	O
were	O
also	O
obtained	O
from	O
23	O
confirmed	O
SARS	O
patients	O
on	O
the	O
day	O
of	O
hospital	O
admission	O
,	O
11	O
of	O
whom	O
subsequently	O
required	O
intensive	O
care	O
.	O

These	O
data	O
were	O
confirmed	O
by	O
the	O
RT	O
-	O
PCR	O
system	O
for	O
the	O
nucleocapsid	B-COMP
region	O
,	O
which	O
showed	O
an	O
even	O
higher	O
detection	O
rate	O
of	O
87	O
%.	O

When	O
these	O
vaccinated	O
cats	O
were	O
challenged	O
with	O
a	O
high	O
dose	O
of	O
heterologous	O
FIPV	O
,	O
the	O
survival	O
rate	O
was	O
75	O
%	O
(	O
6	O
/	O
8	O
),	O
while	O
the	O
survival	O
rate	O
in	O
the	O
control	O
group	O
immunized	O
with	O
SF	O
-	O
9	O
cell	B-COMP
-	O
derived	O
antigen	O
was	O
12	O
.	O
5	O
%	O
(	O
1	O
/	O
8	O
).	O

Here	O
we	O
identify	O
a	O
metallopeptidase	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
isolated	O
from	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
permissive	O
Vero	O
E6	O
cells	B-COMP
,	O
that	O
efficiently	O
binds	O
the	O
S1	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

The	O
monoclonal	O
antibodies	B-COMP
of	O
CD8	O
,	O
CD20	O
,	O
CD34	O
,	O
LCA	O
,	O
CD56	O
,	O
CD68	O
,	O
and	O
AE1	O
/	O
AE3	O
are	O
used	O
to	O
demonstrate	O
the	O
different	O
cells	B-COMP
in	O
the	O
lung	O
specimens	O
of	O
SARS	O
patients	O
in	O
order	O
to	O
study	O
the	O
patterns	O
of	O
cell	B-COMP
responses	O
in	O
this	O
new	O
disease	O
.	O

Acute	O
and	O
convalescent	O
phase	O
serum	B-COMP
specimens	O
collected	O
from	O
SARS	O
patients	O
were	O
found	O
with	O
seroconversions	O
and	O
/	O
or	O
a	O
fourfold	O
or	O
greater	O
rises	O
in	O
indirect	O
fluorescence	O
antibodies	B-COMP
(	O
IgG	O
and	O
IgM	O
)	O
titers	O
when	O
the	O
3	O
isolates	O
(	O
infected	O
Vero	O
cells	B-COMP
)	O
were	O
used	O
as	O
antigen	O
.	O

During	O
the	O
8th	O
-	O
12th	O
week	O
,	O
the	O
cell	B-COMP
counts	O
of	O
CD4	O
+	O
cell	B-COMP
[(	O
578	O
+/-	O

With	O
depressing	O
cellular	B-COMP
immunity	O
,	O
the	O
activation	O
of	O
T	O
lymphocytes	O
were	O
suppressed	O
obviously	O
in	O
SARS	O
patients	O
,	O
especially	O
for	O
critical	O
patients	O
.	O

Fragments	O
containing	O
the	O
N	O
-	O
terminal	O
amino	O
acid	O
residues	O
17	O
-	O
537	O
and	O
272	O
-	O
537	O
but	O
not	O
17	O
-	O
276	O
bound	O
specifically	O
to	O
Vero	O
E6	O
cells	B-COMP
and	O
purified	O
soluble	O
receptor	O
,	O
ACE2	O
,	O
recently	O
identified	O
by	O
M	O
.	O
Farzan	O
and	O
co	O
-	O
workers	O
[	O
Nature	O
426	O
(	O
2003	O
)	O
450	O
-	O
454	O
].	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
nucleic	B-COMP
acid	O
-	O
based	O
molecular	O
techniques	O
has	O
significantly	O
enhanced	O
laboratory	O
diagnosis	O
and	O
monitoring	O
of	O
atypical	O
pneumonia	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
presence	O
of	O
anti	O
-	O
coronavirus	O
antibodies	B-COMP
were	O
0	O
.	O
44	O
and	O
0	O
.	O
90	O
,	O
respectively	O
,	O
antibody	B-COMP
concentrations	O
(	O
1	O
:	O
1	O
,	O
600	O
)	O
were	O
0	O
.	O
94	O
and	O
0	O
.	O
88	O
.	O

In	O
contrast	O
,	O
N	O
protein	O
association	O
in	O
the	O
majority	O
of	O
the	O
intracellular	B-COMP
RNP	B-COMP
complexes	O
was	O
susceptible	O
to	O
RNase	O
A	O
-	O
treatment	O
.	O

The	O
pulmonary	O
alveoli	O
were	O
thickened	O
with	O
interstitial	O
mononuclear	O
inflammatory	O
infiltrates	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
desquamation	O
of	O
pneumocytes	O
and	O
hyaline	O
-	O
membrane	B-COMP
formation	O
;	O
fibrinoid	O
material	O
and	O
erythrocytes	O
were	O
present	O
in	O
alveolar	O
spaces	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
ability	O
of	O
adenoviral	O
delivery	O
of	O
codon	O
-	O
optimised	O
SARS	O
-	O
CoV	O
strain	O
Urbani	O
structural	O
antigens	O
spike	O
protein	O
S1	O
fragment	O
,	O
membrane	B-COMP
protein	O
,	O
and	O
nucleocapsid	B-COMP
protein	O
to	O
induce	O
virus	O
-	O
specific	O
broad	O
immunity	O
in	O
rhesus	O
macaques	O
.	O

ABSTRACT	O
:	O
The	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
receptor	O
(	O
MHVR	O
),	O
CEACAM1	O
,	O
has	O
two	O
different	O
functions	O
for	O
MHV	O
entry	O
into	O
cells	B-COMP
:	O
binding	O
to	O
MHV	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
and	O
activation	O
of	O
the	O
S	O
protein	O
to	O
execute	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
,	O
the	O
latter	O
of	O
which	O
is	O
accompanied	O
by	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
maintaining	O
the	O
GenBank	O
(	O
R	O
)	O
nucleic	B-COMP
acid	O
sequence	O
database	O
,	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
provides	O
data	O
analysis	O
and	O
retrieval	O
resources	O
for	O
the	O
data	O
in	O
GenBank	O
and	O
other	O
biological	O
data	O
made	O
available	O
through	O
NCBI	O
'	O
s	O
website	O
.	O

VOPBA	O
identified	O
a	O
150	O
kDa	O
protein	O
,	O
as	O
a	O
putative	O
PEDV	O
receptor	O
in	O
enterocytes	O
and	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	B-COMP
.	O

TITLE	O
:	O
Mitochondrial	B-COMP
HSP70	O
,	O
HSP40	O
,	O
and	O
HSP60	O
bind	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
Murine	O
hepatitis	O
virus	O
genome	O
.	O

Intracerebral	O
infection	O
of	O
RAG1	O
(-/-)	O
mice	O
with	O
a	O
recombinant	O
CXCL10	O
-	O
expressing	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
)	O
resulted	O
in	O
protection	O
from	O
disease	O
and	O
increased	O
survival	O
that	O
correlated	O
with	O
a	O
significant	O
increase	O
in	O
recruitment	O
and	O
activation	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	B-COMP
within	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
Historically	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
beta	O
-	O
lactam	O
antibiotics	O
play	O
an	O
essential	O
role	O
in	O
treating	O
bacterial	O
infections	O
while	O
demonstrating	O
selectivity	O
for	O
prokaryotic	O
cells	B-COMP
.	O

However	O
,	O
whether	O
these	O
compounds	O
affect	O
human	O
normal	O
or	O
nontransformed	O
cells	B-COMP
was	O
unknown	O
.	O

T	O
lymphocytes	O
play	O
an	O
important	O
role	O
in	O
MHV	O
infection	O
,	O
and	O
costimulatory	O
signals	O
are	O
an	O
important	O
component	O
of	O
T	O
cell	B-COMP
function	O
.	O

MHV	O
replication	O
is	O
impaired	O
in	O
autophagy	O
knockout	O
,	O
APG5	O
-/-,	O
embryonic	O
stem	O
cell	B-COMP
lines	O
,	O
but	O
wild	O
-	O
type	O
levels	O
of	O
MHV	O
replication	O
are	O
restored	O
by	O
expression	O
of	O
Apg5	O
in	O
the	O
APG5	O
-/-	O
cells	B-COMP
.	O

The	O
current	O
evidence	O
does	O
not	O
support	O
the	O
use	O
of	O
TNF	O
-	O
alpha	O
monoclonal	O
antibody	B-COMP
in	O
this	O
group	O
of	O
children	O
.	O

In	O
SNP	O
,	O
infliximab	O
treatment	O
was	O
found	O
to	O
decrease	O
pathologic	O
score	O
(	O
9	O
.	O
4	O
+/-	O
1	O
.	O
2	O
versus	O
3	O
.	O
6	O
+/-	O
0	O
.	O
8	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
serum	B-COMP
amylase	O
activity	O
(	O
20442	O
+/-	O

Final	O
diagnosis	O
of	O
SARS	O
was	O
determined	O
by	O
the	O
results	O
of	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
paired	O
serum	B-COMP
.	O

Concentrations	O
of	O
surfactant	O
protein	O
(	O
SP	O
)-	O
A	O
and	O
SP	O
-	O
D	O
in	O
sera	B-COMP
reflected	O
the	O
clinical	O
features	O
.	O

None	O
of	O
these	O
healthcare	O
workers	O
had	O
antibody	B-COMP
to	O
SARS	O
CoV	O
,	O
indicating	O
that	O
subclinical	O
or	O
mild	O
infection	O
attributable	O
to	O
SARS	O
-	O
CoV	O
in	O
adults	O
is	O
rare	O
.	O

Virus	O
entered	O
cells	B-COMP
by	O
endocytosis	O
or	O
membrane	B-COMP
fusion	O
and	O
was	O
released	O
through	O
a	O
budding	O
process	O
.	O

TITLE	O
:	O
Early	O
detection	O
of	O
antibodies	B-COMP
against	O
various	O
structural	O
proteins	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
SARS	O
patients	O
.	O

The	O
results	O
mentioned	O
above	O
suggest	O
that	O
SARS	O
-	O
CoV	O
is	O
responding	O
to	O
host	B-COMP
immunological	O
pressures	O
and	O
experiencing	O
variation	O
which	O
provide	O
clues	O
,	O
information	O
and	O
evidence	O
of	O
molecular	O
biology	O
for	O
the	O
clinical	O
pathology	O
,	O
vaccine	O
developing	O
and	O
epidemic	O
investigation	O
.	O

Paired	O
serum	B-COMP
samples	O
were	O
taken	O
in	O
herds	O
during	O
outbreaks	O
of	O
severe	O
respiratory	O
diseases	O
(	O
acute	O
sera	B-COMP
)	O
and	O
3	O
weeks	O
after	O
(	O
convalescent	O
sera	B-COMP
).	O

Herein	O
we	O
show	O
that	O
this	O
process	O
of	O
bystander	O
T	O
-	O
cell	B-COMP
-	O
mediated	O
demyelination	O
is	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)-	O
dependent	O
.	O

Moreover	O
,	O
the	O
viral	B-COMP
genome	I-COMP
of	O
SARS	O
-	O
CoV	O
has	O
been	O
fully	O
sequenced	O
.	O

However	O
,	O
much	O
of	O
the	O
biological	O
behaviour	O
of	O
the	O
virus	O
is	O
not	O
known	O
and	O
data	O
on	O
the	O
tissue	O
and	O
cellular	B-COMP
tropism	O
of	O
SARS	O
-	O
CoV	O
are	O
limited	O
.	O

Antibodies	B-COMP
that	O
specifically	O
recognize	O
the	O
SARS	O
-	O
CoV	O
spike	O
and	O
nucleocapsid	B-COMP
proteins	O
may	O
provide	O
a	O
rapid	O
screening	O
method	O
to	O
allow	O
accurate	O
identification	O
and	O
isolation	O
of	O
patients	O
with	O
the	O
virus	O
early	O
in	O
their	O
infection	O
.	O

To	O
gain	O
further	O
insights	O
into	O
this	O
enzyme	O
,	O
the	O
first	O
crystal	O
structures	O
of	O
the	O
native	O
and	O
inhibitor	O
-	O
bound	O
forms	O
of	O
the	O
ACE2	O
extracellular	B-COMP
domains	O
were	O
solved	O
to	O
2	O
.	O
2	O
-	O
and	O
3	O
.	O
0	O
-	O
A	O
resolution	O
,	O
respectively	O
.	O

The	O
alveolar	O
spaces	O
are	O
filled	O
with	O
fibrinous	O
exudates	O
and	O
lined	O
with	O
hyaline	O
membrane	B-COMP
.	O

When	O
human	O
ACE2	O
cDNA	O
was	O
transduced	O
into	O
NIH3T3	O
cells	B-COMP
,	O
the	O
ACE2	O
expressing	O
NIH3T3	O
cells	B-COMP
could	O
be	O
infected	O
with	O
HIV	O
/	O
SARS	O
pseudovirus	O
.	O

Marked	O
accumulation	O
of	O
cells	B-COMP
in	O
mitosis	O
was	O
observed	O
in	O
two	O
patients	O
and	O
apoptosis	O
was	O
observed	O
in	O
all	O
three	O
patients	O
.	O

Concentrations	O
of	O
G	O
-	O
CSF	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
sTNFRI	O
and	O
sTNFRII	O
,	O
IL	O
-	O
1RA	O
and	O
IL	O
-	O
10	O
in	O
BALF	O
as	O
well	O
as	O
in	O
serum	B-COMP
were	O
determined	O
by	O
ELISA	O
.	O

Results	O
in	O
patients	O
with	O
ARDS	O
and	O
ALI	O
exhibited	O
significant	O
positive	O
correlations	O
in	O
BALF	O
of	O
G	O
-	O
CSF	O
levels	O
with	O
that	O
of	O
IL	O
-	O
6	O
,	O
sTNFRII	O
,	O
and	O
IL	O
-	O
1RA	O
and	O
of	O
G	O
-	O
CSF	O
levels	O
in	O
serum	B-COMP
with	O
that	O
of	O
serum	B-COMP
IL	O
-	O
6	O
,	O
IL	O
-	O
1RA	O
,	O
and	O
IL	O
-	O
10	O
.	O

The	O
sera	B-COMP
from	O
health	O
donors	O
,	O
which	O
were	O
collected	O
before	O
the	O
out	O
-	O
break	O
of	O
SARS	O
,	O
were	O
used	O
as	O
negative	O
control	O
in	O
the	O
study	O
.	O

The	O
recombinant	O
S1	O
protein	O
could	O
react	O
with	O
three	O
antibody	B-COMP
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

The	O
recombinant	O
N	O
-	O
terminal	O
protein	O
of	O
SARS	O
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	O
antibody	B-COMP
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	O
response	O
to	O
SARS	O
virus	O
.	O

Increased	O
apoptosis	O
appeared	O
to	O
contribute	O
to	O
the	O
diminished	O
presence	O
of	O
CD8	O
T	O
cells	B-COMP
in	O
MHV	O
-	O
JHM	O
-	O
infected	O
brain	O
with	O
the	O
consequence	O
of	O
a	O
lower	O
potential	O
for	O
IFNgamma	O
production	O
and	O
antiviral	O
activity	O
.	O

When	O
transmitted	O
to	O
host	B-COMP
organisms	O
that	O
are	O
not	O
under	O
the	O
influence	O
of	O
the	O
pro	O
-	O
apoptotic	O
drug	O
,	O
the	O
new	O
""""	O
anti	O
-	O
apoptotic	O
""""	O
strains	O
may	O
cause	O
unexpected	O
diseases	O
.	O

Hence	O
,	O
drugs	O
that	O
suppresses	O
Bcl	O
-	O
2	O
or	O
restore	O
p53	O
function	O
might	O
be	O
effective	O
in	O
restoring	O
the	O
parity	O
of	O
resistance	O
to	O
apoptosis	O
between	O
infected	O
and	O
uninfected	O
cells	B-COMP
.	O

TITLE	O
:	O
Role	O
of	O
specific	O
CD8	O
+	O
T	O
cells	B-COMP
in	O
the	O
severity	O
of	O
a	O
fulminant	O
zoonotic	O
viral	O
hemorrhagic	O
fever	O
,	O
hantavirus	O
pulmonary	O
syndrome	O
.	O

The	O
antiviral	O
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	O
inactivation	O
and	O
cell	B-COMP
cycle	O
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

To	O
investigate	O
the	O
origin	O
and	O
transmission	O
route	O
of	O
SARS	O
-	O
CoV	O
in	O
Taiwan	O
'	O
s	O
epidemic	O
,	O
we	O
conducted	O
a	O
systematic	O
viral	O
lineage	O
study	O
by	O
sequencing	O
the	O
entire	O
viral	B-COMP
genome	I-COMP
from	O
ten	O
SARS	O
patients	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
showed	O
SARS	O
patients	O
had	O
a	O
significant	O
decrease	O
of	O
circulating	O
DC	O
cell	B-COMP
subset	O
frequency	O
,	O
which	O
maybe	O
lead	O
to	O
the	O
host	B-COMP
immunodeficiency	O
response	O
to	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Viral	B-COMP
particles	I-COMP
,	O
consistent	O
with	O
coronavirus	O
,	O
could	O
be	O
detected	O
in	O
lung	O
pneumocytes	O
in	O
most	O
of	O
the	O
patients	O
.	O

We	O
considered	O
whether	O
cholesterol	O
was	O
indirectly	O
involved	O
in	O
membrane	B-COMP
fusion	O
by	O
condensing	O
CEACAMs	O
into	O
""""	O
lipid	B-COMP
raft	I-COMP
""""	O
membrane	B-COMP
microdomains	O
,	O
thereby	O
creating	O
opportunities	O
for	O
simultaneous	O
binding	O
of	O
multiple	O
S	O
proteins	O
that	O
subsequently	O
cooperate	O
in	O
the	O
receptor	O
-	O
triggered	O
membrane	B-COMP
fusion	O
process	O
.	O

TITLE	O
:	O
Presence	O
of	O
an	O
encephalomyocarditis	O
virus	O
internal	O
ribosome	B-COMP
entry	O
site	O
sequence	O
in	O
avian	O
infectious	O
bronchitis	O
virus	O
defective	O
RNAs	O
abolishes	O
rescue	O
by	O
helper	O
virus	O
.	O

Using	O
this	O
platform	O
,	O
we	O
sequenced	O
SARS	O
-	O
CoV	O
genomes	O
from	O
Vero	O
cell	B-COMP
culture	O
isolates	O
of	O
12	O
patients	O
and	O
directly	O
from	O
four	O
patient	O
tissues	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
coronaviruses	O
mediates	O
viral	O
entry	O
into	O
host	B-COMP
cells	B-COMP
.	O

Numbers	O
of	O
unstimulated	O
and	O
mitogen	O
-	O
stimulated	O
cytokine	O
-	O
secreting	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
were	O
measured	O
repeatedly	O
during	O
and	O
after	O
hospitalization	O
in	O
13	O
patients	O
with	O
SARS	O
using	O
enzyme	O
-	O
linked	O
immunospot	O
technology	O
.	O

Here	O
we	O
describe	O
conditions	O
that	O
result	O
not	O
only	O
in	O
the	O
efficient	O
expression	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
on	O
the	O
surface	O
of	O
cells	B-COMP
,	O
but	O
in	O
its	O
incorporation	O
into	O
lentiviral	O
particles	O
that	O
can	O
be	O
used	O
to	O
transduce	O
cells	B-COMP
in	O
an	O
S	O
glycoprotein	O
-	O
dependent	O
manner	O
.	O

Together	O
,	O
these	O
studies	O
describe	O
important	O
tools	O
that	O
can	O
be	O
used	O
to	O
study	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
structure	O
and	O
function	O
,	O
including	O
approaches	O
that	O
can	O
be	O
used	O
to	O
identify	O
inhibitors	O
of	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
target	O
cells	B-COMP
.	O

TITLE	O
:	O
Recombinant	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
immunochromatographic	O
tests	O
for	O
detection	O
of	O
immunoglobulin	O
G	O
antibodies	B-COMP
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
SARS	O
patients	O
.	O

A	O
total	O
of	O
81	O
sera	B-COMP
,	O
including	O
67	O
from	O
convalescent	O
patients	O
and	O
seven	O
pairs	O
from	O
two	O
time	O
points	O
of	O
infection	O
,	O
were	O
analyzed	O
,	O
and	O
all	O
showed	O
immunoreactivity	O
towards	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
).	O

ABSTRACT	O
:	O
To	O
identify	O
a	O
major	O
antigenic	O
determinant	O
for	O
use	O
in	O
the	O
development	O
of	O
a	O
rapid	O
serological	O
diagnostic	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
infection	O
and	O
to	O
study	O
the	O
immune	O
response	O
during	O
SARS	O
coronavirus	O
infection	O
in	O
humans	O
,	O
we	O
cloned	O
the	O
full	O
length	O
and	O
six	O
truncated	O
fragments	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
,	O
expressed	O
them	O
,	O
and	O
purified	O
them	O
as	O
glutathione	O
S	O
-	O
transferase	O
-	O
tagged	O
recombinant	O
proteins	O
.	O

TITLE	O
:	O
Prior	O
infection	O
and	O
passive	O
transfer	O
of	O
neutralizing	O
antibody	B-COMP
prevent	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
.	O

It	O
is	O
noted	O
,	O
however	O
,	O
that	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
CoV	O
N	O
)	O
shares	O
little	O
homology	O
with	O
nucleocapsid	B-COMP
proteins	O
of	O
other	O
members	O
of	O
the	O
coronavirus	O
family	O
[	O
Science	O
300	O
(	O
2003	O
)	O
1399	O
;	O
Science	O
300	O
(	O
2003	O
)	O
1394	O
].	O

The	O
common	O
laboratory	O
findings	O
include	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
elevated	O
serum	B-COMP
alanine	O
and	O
aspartate	O
aminotransferase	O
,	O
lactate	O
dehydrogenase	O
,	O
creatine	O
phosphokinase	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

Viral	O
replication	O
was	O
reduced	O
by	O
more	O
than	O
six	O
orders	O
of	O
magnitude	O
in	O
the	O
lungs	O
of	O
mice	O
vaccinated	O
with	O
these	O
S	O
plasmid	O
DNA	O
expression	O
vectors	O
,	O
and	O
protection	O
was	O
mediated	O
by	O
a	O
humoral	O
but	O
not	O
a	O
T	O
-	O
cell	B-COMP
-	O
dependent	O
immune	O
mechanism	O
.	O

The	O
B	O
cell	B-COMP
-	O
deficient	O
mice	O
developed	O
subclinical	O
intestinal	O
infection	O
and	O
transmitted	O
virus	O
for	O
longer	O
than	O
three	O
months	O
,	O
although	O
virus	O
RNA	O
was	O
not	O
detected	O
in	O
feces	O
late	O
in	O
the	O
infection	O
.	O

Based	O
on	O
6	O
strains	O
with	O
accurate	O
dates	O
of	O
host	B-COMP
death	O
,	O
we	O
estimated	O
the	O
time	O
of	O
the	O
last	O
common	O
ancestor	O
to	O
be	O
about	O
August	O
or	O
September	O
2002	O
,	O
and	O
the	O
evolution	O
rate	O
to	O
be	O
about	O
0	O
.	O
16	O
base	O
/	O
day	O
,	O
that	O
is	O
,	O
the	O
SARS	O
coronavirus	O
would	O
on	O
average	O
change	O
a	O
base	O
every	O
seven	O
days	O
.	O

Virus	O
-	O
neutralizing	O
antibodies	B-COMP
developed	O
in	O
the	O
pigs	O
.	O

Eight	O
(	O
2	O
%)	O
were	O
laboratory	O
-	O
confirmed	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infections	O
,	O
206	O
(	O
52	O
%)	O
were	O
SARS	O
-	O
CoV	O
negative	O
,	O
and	O
184	O
(	O
46	O
%)	O
had	O
undetermined	O
SARS	O
-	O
CoV	O
status	O
because	O
of	O
missing	O
convalescent	O
-	O
phase	O
serum	B-COMP
specimens	O
.	O

We	O
show	O
that	O
infection	O
with	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
resulted	O
in	O
distinct	O
ultrastructural	O
features	O
:	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
,	O
nucleocapsid	B-COMP
inclusions	O
,	O
and	O
large	O
granular	O
areas	O
of	O
cytoplasm	B-COMP
.	O

An	O
ELISA	O
based	O
on	O
recombinant	O
nucleocapsid	B-COMP
protein	O
for	O
IgG	O
detection	O
was	O
tested	O
with	O
serum	B-COMP
from	O
149	O
healthy	O
blood	O
donors	O
who	O
donated	O
3	O
years	O
previously	O
and	O
with	O
serum	B-COMP
positive	O
for	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
(	O
by	O
indirect	O
immunofluorescence	O
assay	O
)	O
from	O
106	O
patients	O
with	O
SARS	O
-	O
CoV	O
pneumonia	O
.	O

All	O
positive	O
samples	O
were	O
confirmed	O
by	O
two	O
separate	O
western	O
-	O
blot	O
assays	O
(	O
with	O
recombinant	O
nucleocapsid	B-COMP
protein	O
and	O
recombinant	O
spike	O
polypeptide	O
).	O

IgG	B-COMP
antibody	I-COMP
to	O
SARS	O
CoV	O
was	O
first	O
detected	O
between	O
day	O
5	O
and	O
day	O
47	O
after	O
onset	O
of	O
illness	O
(	O
mean	O
+/-	O

The	O
greatest	O
risk	O
of	O
new	O
diseases	O
comes	O
from	O
zoonoses	O
--	O
pathogens	O
that	O
circulate	O
among	O
wild	O
animals	O
and	O
are	O
occasionally	O
transferred	O
to	O
humans	O
by	O
intermediate	O
invertebrate	O
hosts	B-COMP
or	O
vectors	O
that	O
are	O
sensitive	O
to	O
climatic	O
conditions	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
preischemic	O
treatment	O
with	O
pioglitazone	O
,	O
a	O
peroxisome	B-COMP
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
ligand	O
,	O
on	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
the	O
intrinsic	O
ability	O
of	O
non	O
-	O
replicating	O
virions	B-COMP
to	O
induce	O
comparable	O
immune	O
responses	O
in	O
the	O
notable	O
absence	O
of	O
any	O
adjuvant	O
.	O

Also	O
inactivated	O
preparations	O
of	O
viruses	O
from	O
the	O
paramyxo	O
-	O
(	O
Newcastle	O
disease	O
virus	O
),	O
rhabdo	O
-	O
(	O
rabies	O
virus	O
),	O
corona	O
-	O
(	O
infectious	O
bronchitis	O
virus	O
)	O
and	O
reovirus	O
(	O
avian	O
reovirus	O
)	O
families	O
led	O
to	O
IgG2a	B-COMP
antibody	I-COMP
responses	O
;	O
however	O
,	O
the	O
genetic	O
background	O
of	O
the	O
host	B-COMP
did	O
result	O
in	O
considerable	O
variation	O
.	O

Gamma	O
-	O
irradiated	O
cell	B-COMP
culture	O
supernatants	O
of	O
Vero	O
E6	O
cells	B-COMP
,	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
were	O
used	O
as	O
positive	O
controls	O
.	O

With	O
this	O
objective	O
,	O
we	O
deleted	O
the	O
group	O
-	O
specific	O
gene	O
cluster	O
open	O
reading	O
frame	O
3abc	O
or	O
7ab	O
and	O
obtained	O
deletion	O
mutant	O
viruses	O
that	O
not	O
only	O
multiplied	O
well	O
in	O
cell	B-COMP
culture	O
but	O
also	O
showed	O
an	O
attenuated	O
phenotype	O
in	O
the	O
cat	O
.	O

To	O
investigate	O
serum	B-COMP
total	O
LD	O
,	O
LD	O
isoenzymes	O
,	O
and	O
other	O
parameters	O
including	O
blood	O
lymphocyte	O
subsets	O
as	O
prognostic	O
indicators	O
in	O
SARS	O
patients	O
for	O
adverse	O
clinical	O
outcomes	O
in	O
terms	O
of	O
admission	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
death	O
.	O

Apart	O
from	O
age	O
,	O
serum	B-COMP
LD1	O
activity	O
was	O
the	O
best	O
prognostic	O
indicator	O
for	O
predicting	O
death	O
in	O
patients	O
with	O
SARS	O
compared	O
with	O
serum	B-COMP
total	O
LD	O
activity	O
,	O
haemoglobin	O
concentration	O
,	O
leucocyte	O
and	O
lymphocyte	O
counts	O
.	O

The	O
suppressed	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+,	O
and	O
natural	O
killer	O
cell	B-COMP
counts	O
were	O
also	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
SARS	O
.	O

EP3	O
and	O
EP4	O
also	O
formed	O
conformational	O
epitopes	O
,	O
and	O
antibodies	B-COMP
against	O
these	O
epitopes	O
existed	O
in	O
all	O
52	O
of	O
the	O
sera	B-COMP
tested	O
.	O

Serum	B-COMP
concentrations	O
of	O
C3	O
,	O
C4	O
,	O
CRP	O
and	O
PA	O
were	O
(	O
1	O
.	O
18	O
+/-	O

There	O
was	O
no	O
significant	O
difference	O
in	O
serum	B-COMP
level	O
of	O
C3	O
between	O
the	O
three	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TRALI	O
is	O
associated	O
with	O
antibodies	B-COMP
to	O
white	O
blood	O
cells	B-COMP
and	O
biologically	O
active	O
lipids	O
in	O
trans	O
-	O
fused	O
blood	O
components	O
.	O

The	O
degree	O
of	O
malnutrition	O
,	O
control	O
of	O
ascites	O
,	O
level	O
of	O
encephalopathy	O
,	O
prothrombin	O
time	O
,	O
concentration	O
of	O
serum	B-COMP
albumin	O
,	O
and	O
concentration	O
of	O
serum	B-COMP
bilirubin	O
predict	O
the	O
risk	O
of	O
complications	O
and	O
death	O
following	O
surgery	O
.	O

There	O
were	O
no	O
significant	O
differences	O
for	O
the	O
3	O
values	O
among	O
patients	O
with	O
SARS	O
without	O
anti	O
-	O
SARS	O
coronavirus	O
antibody	B-COMP
,	O
patients	O
with	O
M	O
.	O
pneumoniae	O
infection	O
,	O
and	O
healthy	O
subjects	O
.	O

The	O
number	O
of	O
NK	O
cells	B-COMP
and	O
the	O
expression	O
of	O
CD158b	O
on	O
the	O
surface	O
of	O
NK	O
cells	B-COMP
changed	O
in	O
patients	O
with	O
SARS	O
and	O
correlated	O
with	O
disease	O
severity	O
and	O
the	O
presence	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
-	O
specific	O
antibodies	B-COMP
;	O
SARS	O
differed	O
from	O
M	O
.	O
pneumoniae	O
infection	O
in	O
pathogenesis	O
involving	O
NK	O
cells	B-COMP
.	O

When	O
C3H	O
/	O
He	O
mice	O
were	O
immunized	O
by	O
three	O
separate	O
injections	O
,	O
high	O
antibody	B-COMP
titre	O
(	O
1	O
:	O
3200	O
-	O
1	O
:	O
6400	O
,	O
average	O
titre	O
is	O
1	O
:	O
4580	O
)	O
and	O
high	O
CTL	O
activity	O
(	O
67	O
.	O
4	O
+/-	O
8	O
.	O
4	O
%	O
(	O
E	O
:	O
T	O
=	O
25	O
:	O
1	O
),	O
69	O
.	O
6	O
+/-	O
6	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
50	O
:	O
1	O
)	O
and	O
71	O
.	O
8	O
+/-	O
6	O
.	O
2	O
%	O
(	O
E	O
:	O
T	O
=	O
100	O
:	O
1	O
))	O
were	O
observed	O
.	O

RESULTS	O
:	O
Key	O
recommendations	O
,	O
listed	O
by	O
category	O
and	O
not	O
by	O
hierarchy	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
;	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	O
;	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
;	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
equivalence	O
of	O
crystalloid	B-COMP
and	O
colloid	O
resuscitation	O
;	O
aggressive	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
vasopressor	O
preference	O
for	O
norepinephrine	O
and	O
dopamine	O
;	O
cautious	O
use	O
of	O
vasopressin	O
pending	O
further	O
studies	O
;	O
avoiding	O
low	O
-	O
dose	O
dopamine	O
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	O
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
avoidance	O
of	O
supranormal	O
oxygen	O
delivery	O
as	O
a	O
goal	O
of	O
therapy	O
;	O
stress	O
-	O
dose	O
steroid	O
therapy	O
for	O
septic	O
shock	O
;	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
high	O
risk	O
for	O
death	O
;	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	O
artery	O
disease	O
or	O
acute	O
hemorrhage	O
,	O
targeting	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
appropriate	O
use	O
of	O
fresh	O
frozen	O
plasma	O
and	O
platelets	O
;	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
a	O
semirecumbent	O
bed	O
position	O
unless	O
contraindicated	O
;	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
maintenance	O
of	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
;	O
equivalence	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
and	O
intermittent	O
hemodialysis	O
;	O
lack	O
of	O
utility	O
of	O
bicarbonate	O
use	O
for	O
pH	O
>	O
or	O
=	O
7	O
.	O
15	O
;	O
use	O
of	O
deep	O
vein	O
thrombosis	O
/	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
.	O

The	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
a	O
423	O
amino	O
-	O
acid	O
,	O
predicted	O
phospho	O
-	O
protein	O
of	O
46	O
kDa	O
that	O
shares	O
little	O
homology	O
with	O
other	O
members	O
of	O
the	O
coronavirus	O
family	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
time	O
-	O
course	O
of	O
viraemia	O
and	O
antibody	B-COMP
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
RT	O
-	O
PCR	O
and	O
ELISA	O
were	O
used	O
to	O
assay	O
376	O
blood	O
samples	O
from	O
135	O
SARS	O
patients	O
at	O
various	O
stages	O
of	O
the	O
illness	O
,	O
including	O
samples	O
from	O
patients	O
who	O
were	O
in	O
their	O
early	O
convalescent	O
phase	O
.	O

Ultrastructural	O
analysis	O
of	O
infected	O
Vero	O
cells	B-COMP
showed	O
the	O
virions	B-COMP
within	O
cell	B-COMP
vesicles	B-COMP
and	O
around	O
the	O
cell	B-COMP
membrane	I-COMP
.	O

In	O
this	O
study	O
,	O
12	O
sets	O
of	O
nested	O
primers	O
covering	O
the	O
SARS	O
-	O
CoV	O
genome	O
have	O
been	O
screened	O
and	O
showed	O
sufficient	O
sensitivity	O
to	O
detect	O
SARS	O
-	O
CoV	O
in	O
RNA	O
isolated	O
from	O
virus	O
cultured	O
in	O
Vero	O
6	O
cells	B-COMP
.	O

Some	O
cats	O
were	O
also	O
tested	O
for	O
feline	O
leukaemia	O
virus	O
antigen	O
,	O
feline	O
immunodeficiency	O
virus	O
,	O
and	O
Toxoplasma	O
gondii	O
antibodies	B-COMP
.	O

It	O
would	O
also	O
be	O
useful	O
in	O
the	O
investigation	O
of	O
suspected	O
FIP	O
as	O
most	O
cats	O
with	O
this	O
condition	O
have	O
high	O
IFA	O
titres	O
of	O
antibodies	B-COMP
.	O

The	O
positive	O
rate	O
of	O
specific	O
antibodies	B-COMP
was	O
higher	O
in	O
ICU	O
where	O
the	O
work	O
intensity	O
was	O
higher	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
During	O
inhalation	O
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	O
,	O
blood	O
arterial	O
oxygen	O
partial	O
pressure	O
fell	O
gradually	O
,	O
and	O
eventually	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	O
-	O
8	O
in	O
serum	B-COMP
rises	O
significantly	O
after	O
inhalation	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	O
-	O
6	O
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	O
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	O
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	O
,	O
edema	O
and	O
atelectasis	O
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	O
in	O
other	O
organs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
two	O
second	O
-	O
generation	O
,	O
replicase	O
(	O
R	O
)	O
gene	O
-	O
based	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
kits	O
--	O
the	O
RealArt	O
HPA	O
coronavirus	O
LC	O
kit	O
(	O
Artus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
the	O
LightCycler	O
SARS	O
-	O
CoV	O
quantification	O
kit	O
(	O
Roche	O
,	O
Penzberg	O
,	O
Germany	O
)--	O
and	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
.	O

Interferons	O
are	O
cytokines	O
which	O
induce	O
the	O
synthesis	O
of	O
several	O
antivirally	O
active	O
proteins	O
in	O
the	O
cell	B-COMP
.	O

TITLE	O
:	O
Fatal	O
immune	O
-	O
mediated	O
pancytopenia	O
and	O
a	O
TRALI	O
-	O
like	O
syndrome	O
associated	O
with	O
high	O
titers	O
of	O
recipient	O
-	O
type	O
antibodies	B-COMP
against	O
donor	O
-	O
derived	O
peripheral	O
blood	O
cells	B-COMP
after	O
allogeneic	O
bone	O
marrow	O
transplantation	O
following	O
dose	O
reduced	O
conditioning	O
.	O

Antibodies	B-COMP
to	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
panleukopenia	O
virus	O
/	O
canine	O
parvovirus	O
(	O
FPLV	O
/	O
CPV	O
),	O
feline	O
coronavirus	O
/	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FECV	O
/	O
IPV	O
),	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
and	O
feline	O
herpesvirus	O
1	O
(	O
FHV1	O
)	O
have	O
been	O
detected	O
in	O
other	O
Serengeti	O
predators	O
,	O
indicating	O
that	O
these	O
viruses	O
are	O
present	O
in	O
the	O
ecosystem	O
.	O

Antibodies	B-COMP
to	O
CDV	O
,	O
FIV	O
,	O
FPLV	O
/	O
CPV	O
,	O
FECV	O
/	O
FIPV	O
,	O
FCV	O
,	O
and	O
FHV1	O
were	O
present	O
in	O
47	O
%,	O
3	O
.	O
5	O
%,	O
81	O
%,	O
36	O
%,	O
72	O
%,	O
and	O
0	O
.	O
5	O
%	O
of	O
study	O
hyenas	O
,	O
respectively	O
.	O

Online	O
database	O
analysis	O
and	O
the	O
T2	O
cell	B-COMP
binding	O
test	O
disclosed	O
that	O
the	O
number	O
of	O
HLA	O
-	O
A2	O
-	O
restricted	O
immunogenic	O
epitopes	O
of	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
decreased	O
or	O
even	O
lost	O
in	O
comparison	O
with	O
the	O
homologous	O
sequences	O
of	O
the	O
S	O
protein	O
of	O
HCoV	O
-	O
229e	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
synthesizes	O
several	O
putative	O
viral	B-COMP
envelope	I-COMP
proteins	O
,	O
including	O
the	O
spike	O
(	O
S	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
small	O
envelope	B-COMP
(	O
E	O
)	O
glycoproteins	O
.	O

TITLE	O
:	O
Intracellular	B-COMP
targeting	O
signals	O
contribute	O
to	O
localization	O
of	O
coronavirus	O
spike	O
proteins	O
near	O
the	O
virus	O
assembly	O
site	O
.	O

This	O
signal	O
can	O
retain	O
a	O
chimeric	O
reporter	O
protein	O
in	O
the	O
ERGIC	B-COMP
and	O
when	O
mutated	O
allows	O
transport	O
of	O
the	O
full	O
-	O
length	O
S	O
protein	O
as	O
well	O
as	O
the	O
chimera	O
to	O
the	O
plasma	B-COMP
membrane	I-COMP
.	O

ABSTRACT	O
:	O
The	O
p28	B-COMP
and	O
p65	O
proteins	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
are	O
the	O
most	O
amino	O
-	O
terminal	O
protein	O
domains	O
of	O
the	O
replicase	O
polyprotein	O
.	O

Furthermore	O
,	O
ACE2	O
was	O
present	O
in	O
arterial	O
and	O
venous	O
endothelial	O
cells	B-COMP
and	O
arterial	O
smooth	B-COMP
muscle	I-COMP
cells	I-COMP
in	O
all	O
organs	O
studied	O
.	O

The	O
treatment	O
was	O
lasted	O
for	O
13	O
days	O
to	O
investigate	O
the	O
changes	O
of	O
the	O
clinical	O
indexes	O
such	O
as	O
creatine	O
kinase	O
(	O
CK	O
),	O
lactate	O
dehydogenase	O
(	O
LDH	O
)	O
and	O
serum	B-COMP
sodium	O
levels	O
.	O

Expression	O
of	O
viral	O
antigens	O
was	O
much	O
lower	O
in	O
infected	O
cells	B-COMP
treated	O
with	O
nelfinavir	O
than	O
in	O
untreated	O
infected	O
cells	B-COMP
.	O

Its	O
virion	B-COMP
encodes	O
several	O
proteins	O
including	O
a	O
replicase	O
and	O
four	O
structural	O
proteins	O
.	O

ABSTRACT	O
:	O
Viral	B-COMP
particles	I-COMP
of	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
consist	O
of	O
three	O
virion	B-COMP
structural	O
proteins	O
,	O
including	O
spike	O
protein	O
,	O
membrane	B-COMP
protein	O
,	O
and	O
envelope	B-COMP
protein	O
.	O

TITLE	O
:	O
[	O
Determination	O
and	O
comparison	O
of	O
anti	O
-	O
SARS	O
antibody	B-COMP
in	O
children	O
and	O
adults	O
].	O

Both	O
cell	B-COMP
tropism	O
and	O
respiratory	O
lesions	O
were	O
distinct	O
from	O
those	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
infection	O
,	O
excluding	O
hMPV	O
as	O
the	O
primary	O
cause	O
of	O
SARS	O
.	O

TITLE	O
:	O
Glycan	O
arrays	O
lead	O
to	O
the	O
discovery	O
of	O
autoimmunogenic	O
activity	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Using	O
carbohydrate	O
microarrays	O
,	O
we	O
characterized	O
the	O
carbohydrate	O
binding	O
activity	O
of	O
SARS	O
-	O
CoV	O
neutralizing	O
antibodies	B-COMP
elicited	O
by	O
an	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

Purified	O
N	O
protein	O
was	O
used	O
to	O
measure	O
the	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibodies	B-COMP
from	O
16	O
SARS	O
-	O
CoV	O
infected	O
patients	O
'	O
sera	B-COMP
and	O
from	O
131	O
control	O
subjects	O
using	O
ELISA	O
assay	O
.	O

None	O
of	O
131	O
control	O
sera	B-COMP
gave	O
positive	O
reaction	O
in	O
either	O
assay	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
protein	O
was	O
found	O
to	O
be	O
expressed	O
at	O
the	O
cell	B-COMP
surface	I-COMP
upon	O
transient	O
transfection	O
.	O

Coexpression	O
of	O
SARS	O
-	O
CoV	O
S	O
with	O
human	O
immunodeficiency	O
virus	O
-	O
based	O
reporter	O
constructs	O
yielded	O
viruses	O
that	O
were	O
infectious	O
for	O
a	O
range	O
of	O
cell	B-COMP
lines	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
induces	O
apoptosis	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

Noticeably	O
,	O
the	O
time	O
to	O
pan	B-COMP
-	O
consolidation	O
of	O
the	O
lung	O
were	O
less	O
than	O
7	O
days	O
in	O
7	O
fatal	O
cases	O
.	O

Moreover	O
,	O
this	O
construct	O
significantly	O
reduced	O
the	O
plaque	O
formation	O
of	O
SARS	O
coronaviruses	O
in	O
Vero	O
-	O
E6	O
cells	B-COMP
.	O

The	O
fusion	O
protein	O
could	O
react	O
with	O
all	O
the	O
sera	B-COMP
from	O
convalescent	O
SARS	O
patients	O
but	O
not	O
with	O
the	O
sera	B-COMP
from	O
healthy	O
donors	O
.	O

In	O
two	O
follow	O
-	O
up	O
surveys	O
of	O
the	O
SARS	O
patients	O
discharged	O
from	O
our	O
hospital	O
,	O
the	O
changes	O
of	O
CD3	O
(+),	O
CD4	O
(+),	O
CD8	O
(+),	O
CD8	O
(+)	O
CD28	O
(+),	O
CD8	O
(+)	O
CD28	O
(-),	O
CD3	O
(+)	O
CD25	O
(+),	O
CD3	O
(+)	O
CD69	O
(+),	O
CD3	O
(+)	O
HLA	O
-	O
DR	O
(+)	O
T	O
cells	B-COMP
and	O
the	O
ratio	O
of	O
CD4	O
(+)/	O
CD8	O
(+)	O
T	O
cells	B-COMP
in	O
peripheral	O
blood	O
of	O
SARS	O
patients	O
treated	O
unitedly	O
with	O
Chinese	O
and	O
Western	O
medicines	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

As	O
for	O
the	O
percentages	O
of	O
CD3	O
(+),	O
CD8	O
(+),	O
CD4	O
(+)/	O
CD8	O
(+),	O
CD3	O
(+)	O
CD25	O
(+),	O
CD3	O
(+)	O
CD69	O
(+)	O
and	O
CD3	O
(+)	O
HLA	O
-	O
DR	O
(+)	O
T	O
cells	B-COMP
,	O
there	O
was	O
marked	O
difference	O
between	O
1st	O
and	O
2nd	O
follow	O
-	O
up	O
results	O
,	O
but	O
for	O
other	O
molecules	O
there	O
was	O
no	O
notable	O
difference	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
SARS	O
-	O
induced	O
cytopathic	O
effects	O
(	O
CPEs	O
)	O
is	O
a	O
rational	O
approach	O
for	O
the	O
prevention	O
of	O
SARS	O
,	O
and	O
an	O
understanding	O
of	O
the	O
cellular	B-COMP
stress	O
responses	O
induced	O
by	O
viral	O
infection	O
is	O
important	O
for	O
understanding	O
the	O
CPEs	O
.	O

Polyclonal	O
antibodies	B-COMP
,	O
which	O
recognized	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
membrane	B-COMP
(	O
M	O
)	O
proteins	O
,	O
detected	O
viral	O
N	O
and	O
M	O
proteins	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
at	O
least	O
6	O
and	O
12	O
h	O
post	O
-	O
infection	O
(	O
h	O
.	O
p	O
.	O
i	O
.),	O
respectively	O
.	O

Deletion	O
of	O
a	O
cytoplasmic	B-COMP
domain	O
of	O
U274	O
,	O
which	O
contains	O
Yxxphi	O
and	O
diacidic	O
motifs	O
,	O
abolished	O
its	O
transport	O
to	O
the	O
cell	B-COMP
surface	I-COMP
.	O

In	O
addition	O
,	O
U274	O
expressed	O
on	O
the	O
cell	B-COMP
surface	I-COMP
can	O
internalize	O
antibodies	B-COMP
from	O
the	O
culture	O
medium	O
into	O
the	O
cells	B-COMP
.	O

Thus	O
,	O
this	O
region	O
of	O
the	O
spike	O
protein	O
might	O
be	O
a	O
target	O
for	O
generation	O
of	O
therapeutic	O
neutralizing	O
antibodies	B-COMP
against	O
SARS	O
CoV	O
and	O
for	O
vaccine	O
development	O
to	O
elicit	O
protective	O
humoral	O
immunity	O
.	O

TITLE	O
:	O
Cleavage	O
and	O
serum	B-COMP
reactivity	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
major	O
surface	O
antigen	O
of	O
the	O
virus	O
and	O
is	O
responsible	O
for	O
receptor	O
binding	O
and	O
the	O
generation	O
of	O
neutralizing	O
antibody	B-COMP
.	O

TITLE	O
:	O
Murine	O
viral	O
hepatitis	O
involves	O
NK	O
cell	B-COMP
depletion	O
associated	O
with	O
virus	O
-	O
induced	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
NK	O
cell	B-COMP
production	O
is	O
impaired	O
by	O
viral	O
infection	O
favouring	O
fulminant	O
hepatitis	O
.	O

The	O
expression	O
of	O
S	O
with	O
the	O
two	O
other	O
putative	O
virion	B-COMP
envelope	B-COMP
proteins	O
,	O
the	O
matrix	O
M	O
and	O
small	O
envelope	B-COMP
E	O
proteins	O
,	O
did	O
not	O
augment	O
the	O
neutralizing	O
antibody	B-COMP
response	O
.	O

The	O
deduced	O
sequence	O
contains	O
a	O
probable	O
cleaved	O
signal	O
sequence	O
and	O
a	O
C	O
-	O
terminal	O
transmembrane	B-COMP
helix	O
,	O
indicating	O
that	O
U122	O
is	O
likely	O
to	O
be	O
a	O
type	O
I	O
membrane	B-COMP
protein	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
virus	O
replication	O
by	O
small	O
interfering	O
RNAs	O
in	O
mammalian	O
cells	B-COMP
.	O

In	O
30	O
patients	O
with	O
ARDS	O
due	O
to	O
multitrauma	O
,	O
pneumonia	O
or	O
after	O
surgery	O
(	O
p	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)-	O
ratio	O
67	O
+/-	O
23	O
mmHg	O
)	O
pECLA	O
was	O
established	O
by	O
insertion	O
of	O
cannulae	O
to	O
the	O
femoral	O
artery	O
and	O
vein	O
followed	O
by	O
connection	O
with	O
a	O
membrane	B-COMP
gas	O
exchanger	O
.	O

ABSTRACT	O
:	O
An	O
immunocomb	O
-	O
based	O
dot	O
-	O
ELISA	O
,	O
employing	O
specially	O
designed	O
apparatus	O
,	O
was	O
used	O
to	O
measure	O
the	O
antibody	B-COMP
status	O
for	O
the	O
three	O
major	O
poultry	O
diseases	O
--	O
Newcastle	O
disease	O
,	O
infectious	O
bursal	O
disease	O
and	O
infectious	O
bronchitis	O
--	O
in	O
single	O
test	O
sera	B-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
a	O
highly	O
effective	O
method	O
to	O
reverse	O
hypoxia	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
but	O
has	O
only	O
once	O
been	O
described	O
in	O
a	O
patient	O
with	O
postpneumonectomy	O
pulmonary	O
edema	O
.	O

A	O
cell	B-COMP
-	O
based	O
assay	O
,	O
with	O
SARS	O
virus	O
and	O
Vero	O
E6	O
cells	B-COMP
,	O
was	O
developed	O
to	O
screen	O
existing	O
drugs	O
,	O
natural	O
products	O
,	O
and	O
synthetic	O
compounds	O
to	O
identify	O
effective	O
anti	O
-	O
SARS	O
agents	O
.	O

ABSTRACT	O
:	O
The	O
seroprevalence	O
of	O
antibody	B-COMP
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
cohorts	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
with	O
subclinical	O
infection	O
in	O
SARS	O
and	O
non	O
-	O
SARS	O
medical	O
wards	O
was	O
2	O
.	O
3	O
%	O
(	O
3	O
of	O
131	O
HCWs	O
)	O
and	O
0	O
%	O
(	O
0	O
of	O
192	O
HCWs	O
),	O
respectively	O
.	O

An	O
assay	O
for	O
determining	O
neutralizing	O
antibody	B-COMP
titers	O
was	O
developed	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
sensitivity	O
and	O
specificity	O
of	O
four	O
kits	O
for	O
detection	O
of	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
IgG	O
in	O
sera	B-COMP
of	O
SARS	O
patients	O
.	O

RESULTS	O
:	O
Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
not	O
detected	O
in	O
sera	B-COMP
collected	O
from	O
SARS	O
patients	O
at	O
the	O
first	O
week	O
after	O
onset	O
by	O
any	O
of	O
the	O
four	O
kits	O
,	O
however	O
,	O
it	O
was	O
detectable	O
in	O
sera	B-COMP
obtained	O
at	O
the	O
second	O
week	O
of	O
illness	O
by	O
EIA	O
No	O
.	O
B	O
,	O
and	O
two	O
IFA	O
,	O
but	O
not	O
by	O
EIA	O
No	O
.	O
A	O
,	O
with	O
the	O
positive	O
rates	O
of	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
),	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
42	O
.	O
9	O
%	O
(	O
3	O
/	O
7	O
),	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
survival	O
rate	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	B-COMP
was	O
greatly	O
increased	O
by	O
the	O
treatment	O
with	O
SNAP	O
,	O
and	O
the	O
concentration	O
of	O
this	O
compound	O
needed	O
to	O
inhibit	O
the	O
viral	O
cytopathic	O
effect	O
to	O
50	O
%	O
was	O
222	O
microM	O
,	O
with	O
a	O
selectivity	O
index	O
of	O
3	O
.	O

Monoclonal	O
antibody	B-COMP
reagents	O
that	O
recognise	O
specific	O
antigens	O
on	O
SARS	O
-	O
CoV	O
are	O
needed	O
urgently	O
.	O

SARS	O
-	O
CoV	O
IgG	B-COMP
antibody	I-COMP
could	O
inhibit	O
SARS	O
-	O
CoV	O
-	O
mediated	O
cytopathic	O
response	O
,	O
indicating	O
it	O
might	O
be	O
one	O
of	O
protective	O
antibodies	B-COMP
.	O

CONCLUSIONS	O
:	O
The	O
A	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	B-COMP
antibody	I-COMP
in	O
serum	B-COMP
of	O
convalescent	O
patients	O
tended	O
to	O
elevate	O
in	O
half	O
an	O
year	O
after	O
SARS	O
onset	O
.	O

By	O
use	O
of	O
an	O
immunofluorescent	O
(	O
IF	O
)	O
test	O
as	O
the	O
""""	O
gold	O
standard	O
""","	O
both	O
the	O
ELISA	O
and	O
the	O
immunochromatographic	O
test	O
were	O
able	O
to	O
detect	O
immunoglobulin	O
G	O
antibodies	B-COMP
to	O
SARS	O
not	O
only	O
from	O
late	O
-	O
convalescent	O
-	O
stage	O
samples	O
(>	O
21	O
days	O
from	O
the	O
onset	O
of	O
clinical	O
symptoms	O
),	O
as	O
previously	O
established	O
,	O
but	O
also	O
from	O
early	O
-	O
acute	O
-	O
phase	O
samples	O
(	O
1	O
to	O
10	O
days	O
from	O
onset	O
).	O

ABSTRACT	O
:	O
The	O
sensitivities	O
and	O
specificities	O
of	O
an	O
immunofluorescence	O
assay	O
and	O
an	O
enzyme	O
immunoassay	O
for	O
detection	O
of	O
antibodies	B-COMP
specific	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
compared	O
for	O
148	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
in	O
sars	O
patients	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
nucleocapsid	B-COMP
protein	O
.	O

Nucleocapsid	B-COMP
protein	O
could	O
be	O
detected	O
from	O
days	O
6	O
to	O
24	O
in	O
nasopharyngeal	O
aspirate	O
specimens	O
,	O
from	O
days	O
11	O
to	O
31	O
in	O
urine	O
specimens	O
,	O
and	O
from	O
days	O
8	O
to	O
32	O
in	O
fecal	O
specimens	O
after	O
the	O
onset	O
of	O
illness	O
.	O

TITLE	O
:	O
An	O
efficient	O
method	O
to	O
make	O
human	O
monoclonal	O
antibodies	B-COMP
from	O
memory	O
B	O
cells	B-COMP
:	O
potent	O
neutralization	O
of	O
SARS	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
aurintricarboxylic	O
acid	O
(	O
ATA	O
)	O
on	O
SARS	O
-	O
CoV	O
replication	O
in	O
cell	B-COMP
culture	O
,	O
and	O
found	O
that	O
ATA	O
could	O
drastically	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
,	O
with	O
viral	O
production	O
being	O
1000	O
-	O
fold	O
less	O
than	O
that	O
in	O
the	O
untreated	O
control	O
.	O

The	O
cytosol	B-COMP
and	O
nucleus	B-COMP
fractions	O
of	O
virus	O
-	O
infected	O
cells	B-COMP
as	O
well	O
as	O
the	O
crude	O
virions	B-COMP
were	O
analyzed	O
either	O
by	O
one	O
-	O
dimensional	O
electrophoresis	O
followed	O
by	O
ESI	O
-	O
MS	O
/	O
MS	O
identification	O
or	O
by	O
shotgun	O
strategy	O
with	O
two	O
-	O
dimensional	O
liquid	O
chromatography	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
.	O

For	O
the	O
first	O
time	O
,	O
all	O
of	O
the	O
four	O
predicted	O
structural	O
proteins	O
of	O
SARS	O
-	O
CoV	O
were	O
identified	O
,	O
including	O
S	O
(	O
Spike	O
),	O
M	O
(	O
Membrane	B-COMP
),	O
N	O
(	O
Nucleocapsid	B-COMP
),	O
and	O
E	O
(	O
Envolope	O
)	O
proteins	O
.	O

The	O
peptides	O
from	O
S1	O
domain	O
of	O
SARS	O
-	O
Cov	O
S	O
-	O
protein	O
were	O
synthesized	O
by	O
peptide	O
synthesizer	O
,	O
and	O
the	O
immunological	O
reaction	O
of	O
the	O
peptides	O
with	O
the	O
serum	B-COMP
of	O
SARS	O
patients	O
were	O
examined	O
by	O
means	O
of	O
ELISA	O
.	O

The	O
high	O
-	O
throughput	O
capacity	O
of	O
this	O
procedure	O
and	O
the	O
safety	O
of	O
using	O
SARS	O
pseudoviruses	O
should	O
make	O
possible	O
large	O
-	O
scale	O
analyses	O
of	O
neutralizing	O
antibody	B-COMP
responses	O
against	O
SARS	O
-	O
CoV	O
.	O

Totally	O
531	O
samples	O
(	O
including	O
urine	O
,	O
stool	O
,	O
and	O
OWF	O
)	O
were	O
collected	O
from	O
177	O
convalescence	O
patients	O
with	O
positive	O
SARS	O
antibody	B-COMP
which	O
were	O
confirmed	O
by	O
ELISA	O
method	O
.	O

Synthetic	O
peptide	O
binding	O
and	O
competitive	O
-	O
inhibition	O
assays	O
further	O
confirmed	O
that	O
patients	O
with	O
SARS	O
generated	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
.	O
Immunopositive	O
phage	O
clones	O
and	O
epitope	O
-	O
based	O
peptide	O
antigens	O
demonstrated	O
clinical	O
diagnostic	O
potential	O
by	O
reacting	O
with	O
serum	B-COMP
from	O
patients	O
with	O
SARS	O
.	O

Other	O
variable	O
features	O
include	O
multinucleated	O
giant	O
cells	B-COMP
,	O
pneumocytes	O
with	O
cytomegaly	O
and	O
variable	O
amounts	O
of	O
inflammatory	O
cells	B-COMP
and	O
foamy	O
macrophages	O
.	O

The	O
results	O
indicate	O
that	O
HCoV	O
-	O
229E	O
first	O
binds	O
to	O
CD13	O
in	O
the	O
Triton	O
X	O
-	O
100	O
-	O
resistant	O
microdomain	O
,	O
then	O
clusters	O
CD13	O
by	O
cross	O
-	O
linking	O
,	O
and	O
thereby	O
reaches	O
the	O
caveolar	O
region	O
before	O
entering	O
cells	B-COMP
.	O

Antiviral	O
activity	O
varied	O
with	O
the	O
use	O
of	O
different	O
cell	B-COMP
lines	O
.	O

We	O
conclusively	O
show	O
that	O
SCoV	O
E	O
protein	O
contains	O
an	O
unusually	O
short	O
,	O
palindromic	O
transmembrane	B-COMP
helical	O
hairpin	O
around	O
a	O
previously	O
unidentified	O
pseudo	O
-	O
center	O
of	O
symmetry	O
,	O
a	O
structural	O
feature	O
which	O
seems	O
to	O
be	O
unique	O
to	O
SCoV	O
.	O
The	O
hairpin	O
deforms	O
lipid	O
bilayers	O
by	O
way	O
of	O
increasing	O
their	O
curvature	O
,	O
providing	O
for	O
the	O
first	O
time	O
a	O
molecular	O
explanation	O
of	O
E	O
protein	O
'	O
s	O
pivotal	O
role	O
in	O
viral	O
budding	O
.	O

However	O
,	O
viral	O
nucleic	B-COMP
acid	O
and	O
antigen	O
were	O
detected	O
only	O
with	O
Wolgemuth	O
-	O
infected	O
kidneys	O
by	O
ISH	O
and	O
IHC	O
.	O

The	O
acute	O
phase	O
is	O
marked	O
by	O
an	O
abrupt	O
rise	O
in	O
the	O
secretion	O
of	O
so	O
-	O
called	O
stress	O
hormones	O
with	O
an	O
associated	O
increase	O
in	O
mitochondrial	B-COMP
and	O
metabolic	O
activity	O
.	O

The	O
combination	O
of	O
severe	O
inflammation	O
and	O
secondary	O
changes	O
in	O
endocrine	O
profile	O
diminish	O
energy	O
production	O
,	O
metabolic	O
rate	O
,	O
and	O
normal	O
cellular	B-COMP
processes	O
,	O
leading	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
A	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
spike	O
protein	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
hampers	O
its	O
maturation	O
and	O
incorporation	O
into	O
virions	B-COMP
at	O
the	O
nonpermissive	O
temperature	O
.	O

Intracellularly	O
retained	O
S	O
proteins	O
only	O
contained	O
endoglycosidase	O
H	O
-	O
sensitive	O
N	O
-	O
glycans	O
,	O
whereas	O
mutant	O
proteins	O
that	O
migrated	O
to	O
the	O
plasma	B-COMP
membrane	I-COMP
acquired	O
N	O
-	O
linked	O
oligosaccharides	O
of	O
the	O
complex	O
type	O
.	O

However	O
,	O
the	O
central	O
processes	O
in	O
the	O
evolution	O
of	O
emerging	O
viruses	O
are	O
unclear	O
,	O
particularly	O
the	O
selection	O
pressures	O
faced	O
by	O
viruses	O
in	O
new	O
host	B-COMP
species	O
.	O

All	O
of	O
the	O
recombinants	O
retained	O
21	O
amino	O
acid	O
substitutions	O
and	O
a	O
7	O
-	O
amino	O
-	O
acid	O
insert	O
found	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
S	O
of	O
MHV	O
/	O
BHK	O
,	O
suggesting	O
that	O
these	O
residues	O
were	O
responsible	O
for	O
the	O
extended	O
host	B-COMP
range	O
of	O
MHV	O
/	O
BHK	O
.	O

Flow	O
cytometry	O
showed	O
that	O
MHV	O
-	O
A59	O
bound	O
only	O
to	O
cells	B-COMP
that	O
expressed	O
the	O
murine	O
glycoprotein	O
receptor	O
CEACAM1a	O
.	O

Typically	O
the	O
transmembrane	B-COMP
glycoproteins	O
of	O
class	O
I	O
fusion	O
proteins	O
contain	O
the	O
oligomerization	O
domains	O
and	O
the	O
surface	O
glycoproteins	O
(	O
SU	O
)	O
are	O
monomeric	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
85	O
.	O
9	O
%	O
of	O
serum	B-COMP
samples	O
contained	O
NAbs	O
against	O
SARS	O
-	O
CoV	O
and	O
that	O
most	O
of	O
the	O
NAb	O
activities	O
could	O
be	O
attributed	O
to	O
immunoglobulin	O
G	O
.	O
The	O
NAbs	O
became	O
detectable	O
first	O
at	O
5	O
-	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
their	O
levels	O
peaked	O
at	O
20	O
-	O
30	O
days	O
and	O
then	O
were	O
sustained	O
for	O
>	O
150	O
days	O
.	O

Such	O
differences	O
were	O
detected	O
in	O
individual	O
sera	B-COMP
from	O
various	O
mouse	O
strains	O
,	O
and	O
were	O
ascribed	O
to	O
the	O
fact	O
that	O
proteins	O
insolubilized	O
on	O
solid	O
supports	O
expose	O
a	O
variety	O
of	O
conformational	O
and	O
cryptic	O
antigenic	O
determinants	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	O
(	O
S	O
)	O
forms	O
the	O
distinctive	O
virion	B-COMP
surface	O
structures	O
that	O
are	O
characteristic	O
of	O
this	O
viral	O
family	O
,	O
appearing	O
in	O
negatively	O
stained	O
electron	O
microscopy	O
as	O
stems	O
capped	O
with	O
spherical	O
bulbs	O
.	O

In	O
this	O
report	O
,	O
we	O
generated	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
predicted	O
replicase	O
protein	O
and	O
used	O
the	O
antibodies	B-COMP
to	O
identify	O
and	O
characterize	O
12	O
of	O
the	O
16	O
predicted	O
mature	O
replicase	O
proteins	O
(	O
nsp1	O
,	O
nsp2	O
,	O
nsp3	O
,	O
nsp4	O
,	O
nsp5	O
,	O
nsp8	O
,	O
nsp9	O
,	O
nsp12	O
,	O
nsp13	O
,	O
nsp14	O
,	O
nsp15	O
,	O
and	O
nsp16	O
)	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	B-COMP
.	O

CEACAM1a	O
functions	O
as	O
an	O
intercellular	O
adhesion	O
molecule	O
,	O
an	O
angiogenic	O
factor	O
,	O
and	O
a	O
tumor	O
cell	B-COMP
growth	O
inhibitor	O
.	O

TITLE	O
:	O
[	O
Distribution	O
and	O
timing	O
of	O
antibody	B-COMP
to	O
SARS	O
-	O
CoV	O
in	O
SARS	O
cases	O
of	O
transmission	O
chain	O
or	O
non	O
-	O
transmission	O
chain	O
].	O

TITLE	O
:	O
[	O
Studies	O
on	O
IgG	O
antibodies	B-COMP
of	O
SARS	O
patients	O
].	O

Enzyme	O
-	O
linked	O
immunoassay	O
kit	O
for	O
SARS	O
coronavirus	O
antibodies	B-COMP
developed	O
by	O
HuaDa	O
Biological	O
Company	O
was	O
applied	O
to	O
detect	O
specific	O
serum	B-COMP
IgG	O
from	O
SARS	O
patients	O
and	O
the	O
production	O
of	O
SARS	O
specific	O
antibodies	B-COMP
among	O
patients	O
of	O
different	O
age	O
groups	O
,	O
sex	O
and	O
with	O
or	O
without	O
steroid	O
treatment	O
were	O
statistically	O
compared	O
.	O

The	O
close	O
monitoring	O
of	O
the	O
blood	O
cell	B-COMP
counts	O
,	O
the	O
blood	O
gas	O
analysis	O
and	O
chest	O
radiography	O
might	O
be	O
crucial	O
to	O
the	O
early	O
diagnosis	O
.	O

TITLE	O
:	O
[	O
Anti	O
-	O
SARS	O
virus	O
activities	O
of	O
different	O
recombinant	O
human	O
interferons	O
in	O
cell	B-COMP
culture	O
system	O
].	O

RESULTS	O
:	O
Close	O
examination	O
of	O
whole	O
genome	O
sequence	O
of	O
54	O
SARS	O
-	O
CoV	O
isolates	O
identified	O
before	O
14th	O
October	O
2003	O
,	O
including	O
22	O
from	O
patients	O
in	O
Singapore	O
,	O
revealed	O
the	O
mutations	O
engendered	O
during	O
human	O
-	O
to	O
-	O
Vero	O
and	O
Vero	O
-	O
to	O
-	O
human	O
transmission	O
as	O
well	O
as	O
in	O
multiple	O
Vero	O
cell	B-COMP
passages	O
in	O
order	O
to	O
refine	O
our	O
analysis	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

The	O
SARS	O
incidence	O
among	O
EMTs	O
was	O
assessed	O
by	O
investigating	O
probable	O
SARS	O
(	O
P	O
-	O
SARS	O
)	O
and	O
by	O
surveying	O
the	O
seroprevalence	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-COMP
.	O

Clinical	O
samples	O
tested	O
negative	O
for	O
IgM	O
antibodies	B-COMP
to	O
Japanese	O
encephalitis	O
,	O
West	O
Nile	O
,	O
dengue	O
,	O
and	O
measles	O
viruses	O
,	O
and	O
for	O
RNA	O
of	O
coronavirus	O
,	O
paramyxovirus	O
,	O
enterovirus	O
,	O
and	O
influenza	O
viruses	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
activation	O
of	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
and	O
the	O
p38	O
MAPK	O
inhibitor	O
partially	O
inhibited	O
its	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

Thus	O
,	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
pathway	O
is	O
activated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

We	O
tested	O
chloroquine	O
phosphate	O
for	O
its	O
antiviral	O
potential	O
against	O
SARS	O
-	O
CoV	O
-	O
induced	O
cytopathicity	O
in	O
Vero	O
E6	O
cell	B-COMP
culture	O
.	O

With	O
these	O
highly	O
infectious	O
SARS	O
-	O
CoV	O
pseudotypes	O
,	O
several	O
cell	B-COMP
lines	O
derived	O
from	O
various	O
tissues	O
were	O
revealed	O
as	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
,	O
which	O
were	O
highly	O
corresponding	O
to	O
the	O
expression	O
pattern	O
of	O
virus	O
'	O
s	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Histochemical	O
study	O
for	O
VG	O
,	O
Masson	O
,	O
reticulin	O
,	O
orcein	O
,	O
PAS	B-COMP
,	O
sirius	O
red	O
stains	O
and	O
immunohistochemical	O
study	O
for	O
vimentin	B-COMP
,	O
desmin	B-COMP
,	O
smooth	O
muscle	O
actin	O
,	O
HHF	O
-	O
35	O
,	O
CD34	O
,	O
F8	O
,	O
collagen	B-COMP
types	O
I	O
and	O
III	O
were	O
also	O
performed	O
.	O

The	O
principal	O
lesions	O
consisted	O
of	O
acute	O
alveolar	O
exudative	O
inflammation	O
,	O
hyperplasia	O
of	O
alveolar	O
epithelium	O
,	O
necrosis	O
,	O
alveolar	O
hyaline	O
membrane	B-COMP
formation	O
,	O
alveolar	O
desquamation	O
and	O
focal	O
fibroplasia	O
.	O

Nine	O
significantly	O
increased	O
and	O
three	O
significantly	O
decreased	O
serum	B-COMP
biomarkers	O
were	O
discovered	O
in	O
the	O
SARS	O
patients	O
compared	O
with	O
the	O
controls	O
.	O

RESULTS	O
:	O
Nine	O
significantly	O
increased	O
and	O
three	O
significantly	O
decreased	O
serum	B-COMP
biomarkers	O
were	O
discovered	O
in	O
the	O
SARS	O
patients	O
compared	O
with	O
the	O
controls	O
.	O

CONCLUSIONS	O
:	O
Phage	O
antibody	B-COMP
library	O
for	O
human	O
Fab	O
fragment	O
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
nonstructural	O
protein	O
p28	B-COMP
arrests	O
cell	B-COMP
cycle	O
in	O
G0	O
/	O
G1	O
phase	O
.	O

Expression	O
of	O
p28	B-COMP
did	O
not	O
alter	O
the	O
amount	O
of	O
p53	O
transcripts	O
yet	O
increased	O
the	O
amount	O
of	O
p21	O
(	O
Cip1	O
)	O
transcripts	O
,	O
suggesting	O
that	O
p28	B-COMP
expression	O
increased	O
p53	O
stability	O
and	O
that	O
p21	O
(	O
Cip1	O
)	O
was	O
transcriptionally	O
activated	O
in	O
a	O
p53	O
-	O
dependent	O
manner	O
.	O

Infection	O
mediated	O
by	O
an	O
S	O
-	O
protein	O
variant	O
whose	O
cytoplasmic	B-COMP
domain	O
had	O
been	O
truncated	O
and	O
altered	O
to	O
include	O
a	O
fragment	O
of	O
the	O
cytoplasmic	B-COMP
tail	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
envelope	B-COMP
glycoprotein	O
was	O
,	O
in	O
both	O
cases	O
,	O
substantially	O
more	O
efficient	O
than	O
that	O
mediated	O
by	O
wild	O
-	O
type	O
S	O
protein	O
.	O

The	O
neutralizing	O
ability	O
of	O
antisera	O
directed	O
against	O
the	O
expressed	O
structural	O
proteins	O
was	O
greater	O
than	O
that	O
of	O
convalescent	O
patient	O
antisera	O
,	O
confirming	O
that	O
,	O
as	O
immunogens	O
,	O
the	O
former	O
induce	O
strong	O
,	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibody	B-COMP
responses	O
.	O

The	O
higher	O
concentration	O
of	O
about	O
20	O
ASC	O
/	O
10	O
(	O
6	O
)	O
cells	B-COMP
in	O
spleens	O
may	O
,	O
at	O
least	O
partially	O
,	O
account	O
for	O
the	O
presence	O
of	O
antibody	B-COMP
in	O
the	O
serum	B-COMP
although	O
bone	O
marrow	O
ASC	O
were	O
not	O
determined	O
.	O

TITLE	O
:	O
Detection	O
of	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
in	O
serum	B-COMP
from	O
SARS	O
-	O
infected	O
donors	O
with	O
ELISA	O
and	O
Western	O
blot	O
.	O

Evaluation	O
of	O
sera	B-COMP
from	O
healthy	O
controls	O
(	O
n	O
=	O
60	O
)	O
resulted	O
in	O
two	O
weakly	O
positive	O
ELISA	O
results	O
with	O
the	O
remainder	O
being	O
negative	O
while	O
the	O
S2	O
protein	O
WB	O
demonstrated	O
three	O
positive	O
results	O
from	O
the	O
20	O
controls	O
with	O
a	O
history	O
of	O
SARS	O
contact	O
and	O
no	O
positive	O
results	O
in	O
40	O
noncontact	O
controls	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
against	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
,	O
a	O
modified	O
DimerX	O
flow	O
cytometry	O
assay	O
was	O
performed	O
with	O
peripheral	O
blood	O
mononuclear	O
cell	B-COMP
(	O
PBMC	O
)	O
from	O
HLA	O
-	O
A2	O
+	O
SARS	O
-	O
recovered	O
donors	O
at	O
different	O
time	O
points	O
post	O
disease	O
.	O

The	O
percentages	O
of	O
CD8	O
+	O
DimerX	O
-	O
S1203	O
+	O
cells	B-COMP
paralleled	O
the	O
numbers	O
of	O
interferon	O
-	O
gamma	O
-	O
positive	O
spots	O
in	O
an	O
ELISPOT	O
assay	O
using	O
the	O
same	O
antigenic	O
peptide	O
.	O

The	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
utilizes	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
to	O
infect	O
cells	B-COMP
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
induces	O
highly	O
potent	O
neutralizing	O
antibodies	B-COMP
:	O
implication	O
for	O
developing	O
subunit	O
vaccine	O
.	O

This	O
suggests	O
that	O
RBD	O
can	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-COMP
responses	O
and	O
has	O
potential	O
to	O
be	O
developed	O
as	O
an	O
effective	O
and	O
safe	O
subunit	O
vaccine	O
for	O
prevention	O
of	O
SARS	O
.	O

Replicase	O
protein	O
precursors	O
and	O
mature	O
products	O
are	O
thought	O
to	O
mediate	O
the	O
formation	O
and	O
function	O
of	O
viral	O
replication	O
complexes	O
on	O
the	O
surfaces	O
of	O
intracellular	B-COMP
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
.	O

We	O
used	O
immunofluorescence	O
confocal	O
microscopy	O
to	O
show	O
that	O
p28	B-COMP
localizes	O
to	O
viral	O
replication	O
complexes	O
in	O
the	O
cytoplasm	B-COMP
during	O
early	O
times	O
postinfection	O
.	O

Mucosal	O
antibodies	B-COMP
to	O
coronaviruses	O
in	O
the	O
secretions	O
of	O
the	O
nasal	O
cavity	O
proved	O
to	O
be	O
more	O
important	O
than	O
serum	B-COMP
antibodies	B-COMP
not	O
only	O
in	O
protection	O
from	O
infection	O
,	O
but	O
also	O
in	O
the	O
pattern	O
of	O
clinical	O
manifestations	O
of	O
the	O
disease	O
.	O

Most	O
of	O
these	O
are	O
zoonoses	O
,	O
which	O
have	O
the	O
capacity	O
to	O
infect	O
humans	O
directly	O
or	O
via	O
an	O
intermediate	O
host	B-COMP
.	O

When	O
the	O
host	B-COMP
produces	O
antibodies	B-COMP
against	O
these	O
viral	O
antigens	O
,	O
the	O
antibodies	B-COMP
also	O
bind	O
to	O
the	O
host	B-COMP
'	O
s	O
own	O
ACTH	O
,	O
which	O
limits	O
the	O
host	B-COMP
'	O
s	O
stress	O
response	O
by	O
interfering	O
with	O
ACTH	O
'	O
s	O
ability	O
to	O
stimulate	O
the	O
secretion	O
of	O
corticosteroids	O
.	O

The	O
lowest	O
serum	B-COMP
potassium	O
during	O
the	O
treatment	O
and	O
the	O
duration	O
of	O
hypokalemia	O
in	O
GCS	O
group	O
were	O
significantly	O
different	O
from	O
that	O
in	O
non	O
-	O
GCS	O
group	O
[(	O
3	O
.	O
66	O
+/-	O
0	O
.	O
50	O
)	O
mmol	O
/	O
L	O
vs	O
(	O
4	O
.	O
01	O
+/-	O
0	O
.	O
51	O
)	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
1	O
(	O
1	O
,	O
75	O
)	O
days	O
vs	O
1	O
(	O
1	O
,	O
9	O
)	O
days	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
].	O

SARS	O
-	O
CoV	O
RNA	O
was	O
quantified	O
using	O
a	O
one	O
-	O
step	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
targeting	O
the	O
nucleocapsid	B-COMP
gene	O
.	O

In	O
the	O
first	O
event	O
,	O
polymorphonuclear	O
cells	B-COMP
become	O
primed	O
and	O
pulmonary	O
vascular	O
endothelium	O
becomes	O
activated	O
secondary	O
to	O
the	O
production	O
of	O
biologically	O
active	O
mediators	O
,	O
as	O
a	O
result	O
of	O
physiologic	O
stress	O
.	O

The	O
second	O
event	O
is	O
the	O
infusion	O
of	O
biologically	O
active	O
mediators	O
in	O
a	O
stored	O
cellular	B-COMP
blood	O
product	O
.	O

The	O
catalytic	O
dyad	O
His	O
-	O
41	O
and	O
Cys	O
-	O
145	O
in	O
the	O
active	O
pocket	O
between	O
domain	O
I	O
and	O
II	O
seem	O
to	O
polarize	O
the	O
pi	O
-	O
electron	O
density	O
of	O
the	O
peptide	O
bond	O
between	O
Gln	O
and	O
Ser	B-COMP
in	O
the	O
octapeptide	O
,	O
leading	O
to	O
an	O
increase	O
of	O
positive	O
charge	O
on	O
C	O
(	O
CO	O
)	O
of	O
Gln	O
and	O
negative	O
charge	O
on	O
N	O
(	O
NH	O
)	O
of	O
Ser	B-COMP
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
RNA	O
and	O
antibody	B-COMP
from	O
convalescent	O
-	O
phase	O
SARS	O
patients	O
discharged	O
from	O
hospital	O
.	O

Conjunctival	O
,	O
throat	O
,	O
stool	O
,	O
and	O
urine	O
specimens	O
were	O
collected	O
weekly	O
from	O
64	O
patients	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
RNA	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
;	O
serum	B-COMP
samples	O
were	O
collected	O
weekly	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
antibody	B-COMP
with	O
indirect	O
enzyme	O
immunoassay	O
and	O
immunofluorescence	O
assay	O
.	O

Although	O
SARS	O
-	O
CoV	O
was	O
not	O
isolated	O
from	O
any	O
patient	O
,	O
specimens	O
from	O
three	O
patients	O
were	O
positive	O
for	O
viral	O
RNA	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
and	O
all	O
patients	O
had	O
detectable	O
rises	O
in	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Silencing	O
of	O
SARS	O
-	O
CoV	O
spike	O
gene	O
by	O
small	O
interfering	O
RNA	O
in	O
HEK	O
293T	O
cells	B-COMP
.	O

The	O
results	O
showed	O
that	O
the	O
cells	B-COMP
transfected	O
with	O
pEGFP	O
-	O
optS	O
expressed	O
S	O
-	O
EGFP	O
fusion	O
protein	O
at	O
a	O
higher	O
level	O
compared	O
with	O
those	O
transfected	O
with	O
pEGFP	O
-	O
S	O
,	O
which	O
contains	O
wildtype	O
SARS	O
-	O
CoV	O
spike	O
gene	O
sequence	O
.	O

The	O
green	O
fluorescence	O
,	O
mean	O
fluorescence	O
intensity	O
,	O
and	O
SARS	O
-	O
CoV	O
S	O
RNA	O
transcripts	O
were	O
found	O
significantly	O
reduced	O
,	O
and	O
the	O
expression	O
of	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
was	O
strongly	O
inhibited	O
in	O
those	O
cells	B-COMP
co	O
-	O
transfected	O
with	O
either	O
EGFP	O
-	O
or	O
S	O
-	O
specific	O
siRNAs	O
.	O

In	O
addition	O
,	O
we	O
examined	O
the	O
subcellular	O
localization	O
of	O
the	O
N	O
protein	O
by	O
confocal	O
microscopy	O
in	O
Trichoplusia	O
ni	O
BT1	O
Tn	O
5B1	O
-	O
4	O
cells	B-COMP
infected	O
with	O
recombinant	O
baculovirus	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
CCR2	O
,	O
but	O
not	O
CCL2	O
,	O
is	O
important	O
in	O
host	B-COMP
defense	O
following	O
viral	O
infection	O
of	O
the	O
CNS	O
,	O
and	O
CCR2	O
ligand	O
(	O
s	O
),	O
other	O
than	O
CCL2	O
,	O
participates	O
in	O
generating	O
a	O
protective	O
response	O
.	O

Surfactant	O
secretion	O
in	O
epithelial	O
type	O
II	O
cells	B-COMP
is	O
inhibited	O
by	O
calcium	O
channel	O
blockers	O
and	O
it	O
predisposes	O
to	O
develop	O
ARDS	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
can	O
induce	O
membrane	B-COMP
permeability	O
changes	O
when	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Sequencing	O
and	O
subsequent	O
analysis	O
revealed	O
9	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
representing	O
the	O
entire	O
S	O
protein	O
gene	O
,	O
tricistronic	O
gene	O
3	O
,	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
gene	O
,	O
bicistronic	O
gene	O
5	O
,	O
and	O
N	O
protein	O
gene	O
in	O
the	O
order	O
of	O
5	O
'-	O
3	O
'.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
alone	O
can	O
mediate	O
the	O
membrane	B-COMP
fusion	O
required	O
for	O
virus	O
entry	O
and	O
cell	B-COMP
fusion	O
.	O

Here	O
,	O
we	O
try	O
to	O
provide	O
a	O
relational	O
insight	O
on	O
those	O
UC	O
-	O
ORFs	O
,	O
suggesting	O
that	O
a	O
number	O
of	O
them	O
are	O
remotely	O
related	O
to	O
structural	O
proteins	O
of	O
coronaviruses	O
and	O
other	O
viruses	O
infecting	O
mammalian	O
hosts	B-COMP
.	O

ABSTRACT	O
:	O
T	O
cell	B-COMP
accumulation	O
and	O
effector	O
function	O
following	O
CNS	O
infection	O
is	O
limited	O
by	O
a	O
paucity	O
of	O
Ag	O
presentation	O
and	O
inhibitory	O
factors	O
characteristic	O
of	O
the	O
CNS	O
environment	O
.	O

These	O
data	O
suggest	O
that	O
an	O
instructional	O
program	O
intrinsic	O
to	O
T	O
cell	B-COMP
differentiation	O
,	O
rather	O
than	O
Ag	O
load	O
or	O
factors	O
in	O
the	O
inflamed	O
CNS	O
,	O
prominently	O
regulate	O
CD8	O
+	O
T	O
cell	B-COMP
function	O
.	O

PCR	O
primers	O
were	O
designed	O
to	O
conserved	O
regions	O
within	O
the	O
nucleocapsid	B-COMP
gene	O
of	O
TCV	O
and	O
to	O
the	O
polymerase	O
gene	O
of	O
TAstV	O
-	O
2	O
.	O

The	O
rSCoVN	O
protein	O
expressed	O
in	O
recombinant	O
strains	O
was	O
about	O
8	O
%	O
of	O
the	O
total	O
cell	B-COMP
protein	O
,	O
520	O
mg	O
/	O
L	O
of	O
rSCoVN	O
protein	O
was	O
achieved	O
,	O
and	O
a	O
maximum	O
cell	B-COMP
A	O
at	O
600	O
nm	O
of	O
62	O
was	O
achieved	O
in	O
shake	O
flask	O
culture	O
.	O

The	O
rSCoVN	O
protein	O
had	O
a	O
high	O
specificity	O
against	O
mouse	O
-	O
anti	O
-	O
SARS	O
-	O
CoVN	O
-	O
mAb	O
and	O
SARS	O
positive	O
sera	B-COMP
,	O
but	O
had	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	B-COMP
.	O

But	O
serum	B-COMP
total	O
protein	O
remained	O
normal	O
during	O
the	O
whole	O
clinical	O
course	O
.	O

But	O
serum	B-COMP
total	O
protein	O
remained	O
normal	O
during	O
the	O
whole	O
clinical	O
course	O
.	O

TITLE	O
:	O
[	O
Comparison	O
of	O
serum	B-COMP
biochemical	O
features	O
between	O
SARS	O
and	O
other	O
viral	O
pneumonias	O
].	O

Serum	B-COMP
total	O
protein	O
(	O
TP	O
),	O
albumin	O
(	O
Alb	O
),	O
total	O
cholesterol	O
(	O
TC	O
),	O
triglyceride	O
(	O
TG	O
),	O
calcium	O
(	O
Ca	O
),	O
ferrum	O
(	O
Fe	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
creatine	O
kinase	O
(	O
CK	O
),	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
between	O
SARS	O
and	O
other	O
viral	O
pneumonias	O
were	O
examined	O
by	O
Roche	O
Diagnostics	O
assay	O
,	O
HITACHI7600	O
automatic	O
analyzer	O
.	O

Serum	B-COMP
of	O
60	O
SARS	O
patients	O
,	O
20	O
samples	O
of	O
serum	B-COMP
and	O
20	O
samples	O
of	O
gargling	O
fluid	O
of	O
medical	O
staff	O
of	O
the	O
""""	O
Fever	O
Clinic	O
""","	O
and	O
one	O
cDNA	O
specimen	O
obtained	O
from	O
one	O
SARS	O
suspect	O
patient	O
were	O
examined	O
with	O
F	O
-	O
PCR	O
diagnosis	O
kit	O
and	O
gene	O
-	O
chip	O
technique	O
for	O
SARS	O
coronavirus	O
.	O

The	O
findings	O
indicate	O
that	O
antisense	O
knockdown	O
of	O
SARS	O
could	O
be	O
a	O
useful	O
strategy	O
for	O
treatment	O
of	O
SARS	O
,	O
and	O
could	O
also	O
be	O
suitable	O
for	O
studies	O
of	O
the	O
pathological	O
function	O
of	O
SARS	O
genes	O
in	O
a	O
cellular	B-COMP
model	O
system	O
.	O

The	O
cytoskeletal	B-COMP
network	O
along	O
the	O
edge	O
of	O
the	O
infected	O
cells	B-COMP
was	O
enhanced	O
and	O
could	O
be	O
involved	O
in	O
transporting	O
and	O
expelling	O
the	O
progeny	O
virus	B-COMP
particles	I-COMP
.	O

The	O
absolute	O
numbers	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
and	O
NK	O
cells	B-COMP
were	O
associated	O
with	O
the	O
severity	O
of	O
the	O
disease	O
,	O
and	O
detection	O
of	O
these	O
two	O
kinds	O
of	O
cells	B-COMP
was	O
useful	O
for	O
predicting	O
the	O
prognosis	O
of	O
SARS	O
.	O

Serum	B-COMP
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	O
coronavirus	O
antibody	B-COMP
.	O

We	O
showed	O
that	O
the	O
overexpression	O
of	O
7a	O
,	O
but	O
not	O
of	O
3a	O
or	O
the	O
viral	O
structural	O
proteins	O
,	O
nucleocapsid	B-COMP
,	O
membrane	B-COMP
,	O
and	O
envelope	B-COMP
,	O
induces	O
apoptosis	O
.	O

Unlike	O
229E	O
-	O
infected	O
cells	B-COMP
,	O
which	O
produced	O
viral	O
titers	O
of	O
10	O
(	O
3	O
.	O
5	O
)	O
to	O
10	O
(	O
6	O
)	O
TCID50	O
/	O
ml	O
,	O
SARS	O
-	O
CoV	O
replicated	O
poorly	O
in	O
PM	O
,	O
producing	O
titers	O
of	O
10	O
(	O
1	O
.	O
75	O
)	O
to	O
10	O
(	O
2	O
)	O
TCID50	O
/	O
ml	O
.	O

Long	O
-	O
term	O
surveillance	O
of	O
the	O
change	O
of	O
antibody	B-COMP
is	O
necessary	O
.	O

Increasingly	O
we	O
have	O
found	O
that	O
proteomic	O
approaches	O
allow	O
the	O
rapid	O
analysis	O
of	O
a	O
whole	O
plethora	O
of	O
cell	B-COMP
cycle	O
proteins	O
that	O
may	O
be	O
affected	O
by	O
virus	O
infection	O
.	O

Expression	O
profiling	O
in	O
animal	O
models	O
of	O
ALI	O
(	O
canine	O
and	O
murine	O
)	O
and	O
human	O
ALI	O
detected	O
significant	O
expression	O
of	O
pre	O
-	O
B	O
-	O
cell	B-COMP
colony	O
-	O
enhancing	O
factor	O
(	O
PBEF	O
),	O
a	O
gene	O
not	O
previously	O
associated	O
with	O
lung	O
pathophysiology	O
.	O

Serum	B-COMP
anti	O
-	O
N	O
immunoglobulins	O
and	O
splenocytes	O
proliferative	O
responses	O
against	O
N	O
protein	O
were	O
observed	O
in	O
immunized	O
BALB	O
/	O
c	O
mice	O
.	O

Three	O
of	O
the	O
21	O
and	O
1	O
of	O
the	O
7	O
convalescent	O
-	O
phase	O
serum	B-COMP
samples	O
from	O
persons	O
with	O
increases	O
in	O
antibodies	B-COMP
against	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
229E	O
,	O
respectively	O
,	O
tested	O
positive	O
by	O
the	O
recombinant	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
-	O
based	O
ELISA	O
.	O

None	O
of	O
these	O
samples	O
were	O
found	O
to	O
contain	O
a	O
specific	O
antibody	B-COMP
in	O
the	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
polypeptide	O
-	O
based	O
Western	O
blot	O
assay	O
.	O

The	O
loss	O
of	O
control	O
in	O
trafficking	O
these	O
cells	B-COMP
contributes	O
to	O
inflammatory	O
diseases	O
.	O

Analysis	O
of	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
(	O
S	O
)	O
using	O
recombinant	O
plasmid	O
and	O
virus	O
infections	O
demonstrated	O
that	O
the	O
S	O
-	O
precursor	O
(	O
proS	O
)	O
exists	O
as	O
a	O
approximately	O
190	O
kDa	O
endoplasmic	B-COMP
reticulum	I-COMP
form	O
and	O
a	O
approximately	O
210	O
kDa	O
Golgi	B-COMP
-	O
modified	O
form	O
.	O

In	O
agreement	O
,	O
proS	O
processing	O
,	O
cytopathic	O
effects	O
,	O
and	O
viral	O
titers	O
were	O
enhanced	O
in	O
recombinant	O
Vero	O
E6	O
cells	B-COMP
overexpressing	O
furin	O
,	O
PC7	O
or	O
PC5B	O
.	O

TITLE	O
:	O
Expression	O
of	O
cellular	B-COMP
oncogene	O
Bcl	O
-	O
xL	O
prevents	O
coronavirus	O
-	O
induced	O
cell	B-COMP
death	O
and	O
converts	O
acute	O
infection	O
to	O
persistent	O
infection	O
in	O
progenitor	O
rat	O
oligodendrocytes	O
.	O

Here	O
we	O
show	O
that	O
the	O
progenitor	O
oligodendrocytes	O
(	O
central	O
glial	O
4	O
[	O
CG	O
-	O
4	O
]	O
cells	B-COMP
)	O
derived	O
from	O
newborn	O
rat	O
brain	O
were	O
permissive	O
to	O
MHV	O
infection	O
,	O
which	O
resulted	O
in	O
cell	B-COMP
death	O
,	O
although	O
viral	O
replication	O
was	O
restricted	O
.	O

Although	O
viral	O
genomic	O
RNAs	O
continuously	O
persisted	O
in	O
Bcl	O
-	O
xL	O
-	O
expressing	O
CG	O
-	O
4	O
cells	B-COMP
over	O
10	O
passages	O
,	O
infectious	O
virus	O
could	O
no	O
longer	O
be	O
isolated	O
beyond	O
2	O
passages	O
of	O
the	O
cell	B-COMP
.	O

The	O
data	O
also	O
suggest	O
that	O
direct	O
virus	O
-	O
host	B-COMP
cell	I-COMP
interaction	O
is	O
one	O
of	O
the	O
underlying	O
mechanisms	O
that	O
regulate	O
viral	O
persistence	O
in	O
CNS	O
cells	B-COMP
.	O

We	O
have	O
also	O
determined	O
the	O
structure	O
of	O
an	O
HR1	O
-	O
HR2	O
S	O
core	O
fragment	O
,	O
containing	O
a	O
shorter	O
HR1	O
peptide	O
and	O
a	O
C	O
-	O
terminally	O
longer	O
HR2	O
peptide	O
that	O
extends	O
up	O
to	O
the	O
transmembrane	B-COMP
region	O
.	O

TITLE	O
:	O
Chronological	O
evolution	O
of	O
IgM	O
,	O
IgA	O
,	O
IgG	O
and	O
neutralisation	O
antibodies	B-COMP
after	O
infection	O
with	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Abstract	O
Serum	B-COMP
levels	O
of	O
IgG	O
,	O
IgM	O
and	O
IgA	O
against	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
detected	O
serially	O
with	O
the	O
use	O
of	O
immunofluorescent	O
antibody	B-COMP
assays	O
in	O
30	O
patients	O
with	O
SARS	O
.	O

The	O
kinetics	O
of	O
neutralisation	O
antibodies	B-COMP
obtained	O
with	O
100x	O
the	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
TW1	O
strain	O
in	O
five	O
patients	O
with	O
SARS	O
nearly	O
paralleled	O
those	O
for	O
IgG	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
kinetics	O
of	O
the	O
IgG	O
,	O
IgM	O
and	O
IgA	O
responses	O
between	O
patients	O
with	O
or	O
without	O
underlying	O
medical	O
disease	O
,	O
steroid	O
or	O
intravenous	O
immunoglobulin	O
therapy	O
,	O
or	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Viral	O
and	O
cellular	B-COMP
proteins	O
involved	O
in	O
coronavirus	O
replication	O
.	O

Consistently	O
,	O
no	O
viral	O
RNA	O
synthesis	O
was	O
detected	O
after	O
transfection	O
of	O
EAV	O
full	O
-	O
length	O
RNAs	O
encoding	O
ATPase	O
/	O
helicase	O
-	O
deficient	O
nsp10	O
into	O
susceptible	O
cells	B-COMP
.	O

TITLE	O
:	O
Natural	O
history	O
of	O
a	O
recurrent	O
feline	O
coronavirus	O
infection	O
and	O
the	O
role	O
of	O
cellular	B-COMP
immunity	O
in	O
survival	O
and	O
disease	O
.	O

Cellular	B-COMP
receptors	O
play	O
an	O
important	O
role	O
in	O
virus	O
attachment	O
and	O
entry	O
.	O

Convalescent	O
serology	O
results	O
were	O
positive	O
for	O
antibodies	B-COMP
to	O
coronavirus	O
.	O

It	O
has	O
become	O
clear	O
that	O
the	O
knowledge	O
of	O
the	O
changes	O
occurring	O
within	O
a	O
viral	B-COMP
genome	I-COMP
is	O
indispensable	O
for	O
effective	O
fighting	O
of	O
the	O
pathogen	O
.	O

We	O
conducted	O
genome	O
sequencing	O
and	O
phylogenetic	O
analyses	O
of	O
SARS	O
-	O
CoV	O
.	O
Based	O
on	O
genome	O
sequencing	O
,	O
we	O
predicted	O
the	O
E	O
protein	O
is	O
a	O
transmembrane	B-COMP
(	O
TM	B-COMP
)	O
protein	O
characterized	O
by	O
a	O
TM	B-COMP
region	O
with	O
strong	O
hydrophobicity	O
and	O
alpha	O
-	O
helix	O
conformation	O
.	O

TITLE	O
:	O
The	O
epitope	O
study	O
on	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
.	O

All	O
patient	O
sera	B-COMP
in	O
this	O
study	O
displayed	O
strong	O
positive	O
immunoreactivities	O
against	O
the	O
recombinant	O
N	O
proteins	O
,	O
whereas	O
normal	O
sera	B-COMP
gave	O
negative	O
immunoresponses	O
to	O
these	O
proteins	O
,	O
indicating	O
that	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
an	O
antigenic	O
protein	O
.	O

The	O
binding	O
specificity	O
of	O
phage	O
antibody	B-COMP
to	O
SARS	O
virus	O
was	O
detected	O
by	O
ELISA	O
.	O

ABSTRACT	O
:	O
To	O
express	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
and	O
produce	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
)	O
to	O
N	O
protein	O
.	O

TITLE	O
:	O
[	O
Analyses	O
of	O
subset	O
,	O
activated	O
state	O
and	O
expression	O
pattern	O
of	O
24	O
repertoire	O
TCR	B-COMP
Vbeta	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
in	O
convalescence	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)].	O

The	O
percentages	O
of	O
CD3	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cells	B-COMP
were	O
lower	O
than	O
normal	O
reference	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
).	O

Expression	O
of	O
TCR	B-COMP
Vbeta	O
on	O
T	O
cells	B-COMP
from	O
convalescent	O
SARS	O
patients	O
were	O
different	O
from	O
normal	O
controls	O
.	O

However	O
,	O
pcDNAM	O
stimulated	O
the	O
highest	O
cellular	B-COMP
immune	O
response	O
than	O
other	O
plasmids	O
,	O
and	O
pcDNASa	O
-	O
pcDNASb	O
stimulated	O
the	O
highest	O
humoral	O
immune	O
response	O
in	O
week	O
12	O
.	O

Based	O
on	O
tertiary	O
structural	O
comparisons	O
,	O
we	O
propose	O
the	O
s2m	O
RNA	O
binds	O
one	O
or	O
more	O
proteins	O
possessing	O
an	O
oligomer	O
-	O
binding	O
-	O
like	O
fold	O
,	O
and	O
we	O
suggest	O
a	O
possible	O
mechanism	O
for	O
SARS	O
viral	O
RNA	O
hijacking	O
of	O
host	B-COMP
protein	O
synthesis	O
,	O
both	O
based	O
upon	O
observed	O
s2m	O
RNA	O
macromolecular	O
mimicry	O
of	O
a	O
relevant	O
ribosomal	B-COMP
RNA	I-COMP
fold	O
.	O

(	O
3	O
)	O
The	O
IgG	B-COMP
antibody	I-COMP
emerged	O
in	O
one	O
of	O
24	O
children	O
,	O
whose	O
mother	O
,	O
a	O
nurse	O
,	O
had	O
suffered	O
from	O
SARS	O
(	O
4	O
%).	O

RESULTS	O
:	O
(	O
1	O
)	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
mixed	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
were	O
38	O
%	O
(	O
8	O
/	O
21	O
)	O
and	O
33	O
%	O
(	O
7	O
/	O
21	O
)	O
in	O
pediatric	O
cases	O
;	O
whereas	O
the	O
rates	O
were	O
75	O
%	O
(	O
27	O
/	O
36	O
)	O
and	O
69	O
%	O
(	O
25	O
/	O
36	O
)	O
in	O
adult	O
patients	O
.	O

Serum	B-COMP
from	O
one	O
medical	O
worker	O
who	O
had	O
been	O
close	O
contact	O
to	O
SARS	O
patients	O
was	O
positive	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
and	O
total	O
antibodies	B-COMP
.	O

The	O
neutralized	O
antibody	B-COMP
levels	O
were	O
from	O
1	O
:	O
16	O
to	O
1	O
:	O
203	O
,	O
with	O
medium	O
level	O
of	O
1	O
:	O
43	O
.	O

The	O
residual	O
solutions	O
were	O
inoculated	O
into	O
prepared	O
cell	B-COMP
cultures	O
to	O
isolate	O
live	O
virus	O
.	O

The	O
isolate	O
could	O
cause	O
typical	O
cytopathic	O
effects	O
,	O
similar	O
to	O
those	O
SARS	O
-	O
CoV	O
on	O
Vero	O
-	O
E6	O
cells	B-COMP
and	O
the	O
effects	O
could	O
be	O
stably	O
passed	O
.	O

The	O
hybridoma	O
cell	B-COMP
strains	O
were	O
screened	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
fluorescent	O
-	O
antibody	B-COMP
assay	O
(	O
IFA	O
)	O
and	O
Western	O
blotting	O
.	O

Monoclonal	O
antibodies	B-COMP
we	O
made	O
were	O
specific	O
to	O
the	O
SARS	O
-	O
CoV	O
,	O
and	O
they	O
had	O
been	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
in	O
autopsy	O
lung	O
tissues	O
specimens	O
with	O
positive	O
results	O
.	O

CONCLUSIONS	O
:	O
Monoclonal	O
antibodies	B-COMP
we	O
made	O
were	O
specific	O
to	O
the	O
SARS	O
-	O
CoV	O
,	O
and	O
they	O
had	O
been	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
in	O
autopsy	O
lung	O
tissues	O
specimens	O
with	O
positive	O
results	O
.	O

Nucleic	B-COMP
acid	O
amplification	O
tests	O
(	O
NAATs	O
)	O
have	O
been	O
evaluated	O
for	O
detecting	O
most	O
respiratory	O
pathogens	O
,	O
and	O
commercial	O
assays	O
are	O
available	O
for	O
some	O
pathogens	O
.	O

Of	O
all	O
the	O
subjects	O
,	O
81	O
.	O
2	O
%	O
(	O
311	O
of	O
383	O
patients	O
)	O
tested	O
positive	O
for	O
serum	B-COMP
SARS	O
-	O
CoV	O
IgG	O
.	O
Of	O
those	O
testing	O
positive	O
,	O
27	O
.	O
3	O
%	O
(	O
85	O
of	O
311	O
patients	O
)	O
were	O
suffering	O
from	O
lung	O
diffusion	O
abnormities	O
(	O
DLCO	O
<	O
80	O
%	O
pred	O
)	O
and	O
21	O
.	O
5	O
%	O
(	O
67	O
of	O
311	O
patients	O
)	O
exhibited	O
lung	O
fibrotic	O
changes	O
.	O

In	O
this	O
study	O
,	O
HMGB1	O
was	O
detected	O
in	O
pulmonary	O
endothelial	O
cells	B-COMP
and	O
macrophages	O
under	O
baseline	O
conditions	O
.	O

The	O
ELISA	O
for	O
detection	O
of	O
SARS	O
virus	O
antigen	O
was	O
developed	O
by	O
using	O
antibody	B-COMP
with	O
the	O
highest	O
affinity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
provide	O
a	O
structural	O
and	O
cellular	B-COMP
framework	O
in	O
which	O
to	O
explore	O
the	O
role	O
of	O
orf7a	O
in	O
SARS	O
-	O
CoV	O
pathogenesis	O
.	O

S450	O
-	O
650	O
-	O
based	O
ELISA	O
system	O
was	O
able	O
to	O
detect	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
Abs	O
in	O
patient	O
sera	B-COMP
.	O

From	O
27	O
SARS	O
patients	O
who	O
tested	O
positive	O
with	O
the	O
neutralization	O
test	O
,	O
100	O
%	O
of	O
the	O
24	O
sera	B-COMP
collected	O
from	O
1	O
to	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
were	O
positive	O
for	O
the	O
N	O
protein	O
.	O

CONCLUSIONS	O
:	O
The	O
positive	O
rate	O
of	O
SARS	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
of	O
patients	O
was	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
.	O

We	O
demonstrate	O
that	O
siRNAs	O
directed	O
against	O
Spike	O
sequences	O
and	O
the	O
3	O
'-	O
UTR	O
can	O
inhibit	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
Vero	O
-	O
E6	O
cells	B-COMP
,	O
and	O
holds	O
out	O
promise	O
for	O
the	O
development	O
of	O
an	O
effective	O
antiviral	O
agent	O
against	O
SARS	O
-	O
CoV	O
.	O

These	O
peptides	O
strongly	O
partitioned	O
into	O
lipid	O
membranes	O
and	O
induced	O
lipid	O
vesicle	B-COMP
permeabilization	O
at	O
peptide	O
/	O
lipid	O
ratios	O
of	O
1	O
:	O
100	O
in	O
two	O
independent	O
leakage	O
assays	O
.	O

A	O
few	O
mucosal	O
epithelial	O
cells	B-COMP
and	O
lymphocytes	O
in	O
the	O
intestine	O
were	O
positively	O
stained	O
for	O
coronavirus	O
with	O
ISH	O
.	O

Immunoprecipitation	O
analysis	O
revealed	O
2	O
antibody	B-COMP
-	O
binding	O
epitopes	O
:	O
one	O
MAb	O
(	O
201	O
)	O
bound	O
within	O
the	O
receptor	O
-	O
binding	O
domain	O
at	O
aa	O
490	O
-	O
510	O
,	O
and	O
the	O
other	O
MAb	O
(	O
68	O
)	O
bound	O
externally	O
to	O
the	O
domain	O
at	O
aa	O
130	O
-	O
150	O
.	O

RESULTS	O
:	O
Both	O
MAbs	O
bound	O
to	O
S	O
glycoprotein	O
expressed	O
on	O
transfected	O
cells	B-COMP
but	O
differed	O
in	O
their	O
ability	O
to	O
block	O
binding	O
of	O
S	O
glycoprotein	O
to	O
Vero	O
E6	O
cells	B-COMP
.	O

Using	O
beads	O
of	O
different	O
sizes	O
and	O
molecular	O
beacons	O
in	O
two	O
fluorophore	O
colours	O
,	O
synthetic	O
nucleic	B-COMP
acid	O
control	O
sequences	O
were	O
specifically	O
detected	O
for	O
three	O
respiratory	O
pathogens	O
,	O
including	O
the	O
SARS	O
coronavirus	O
in	O
proof	O
-	O
of	O
-	O
concept	O
experiments	O
.	O

Direct	O
sequencing	O
of	O
RT	O
-	O
PCR	O
products	O
derived	O
from	O
cells	B-COMP
infected	O
with	O
the	O
plaque	O
-	O
purified	O
virus	O
,	O
which	O
had	O
lost	O
expression	O
of	O
EGFP	O
,	O
confirmed	O
loss	O
of	O
the	O
EGFP	O
ORF	O
.	O

Serum	B-COMP
testosterone	O
concentrations	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
reduced	O
in	O
vaccinated	O
roosters	O
with	O
epididymal	O
stones	O
(	O
3	O
.	O
6	O
+/-	O
0	O
.	O
30	O
ng	O
/	O
ml	O
)	O
when	O
compared	O
with	O
nonvaccinated	O
roosters	O
that	O
did	O
not	O
have	O
epididymal	O
stones	O
(	O
7	O
.	O
0	O
+/-	O

ABSTRACT	O
:	O
Findings	O
coming	O
from	O
autopsies	O
and	O
serum	B-COMP
of	O
SARS	O
patients	O
suggest	O
an	O
important	O
immune	O
-	O
inflammatory	O
implication	O
in	O
the	O
evolution	O
to	O
respiratory	O
distress	O
.	O

In	O
total	O
she	O
received	O
over	O
20	O
units	O
of	O
red	O
blood	O
cells	B-COMP
and	O
large	O
quantities	O
of	O
fresh	O
frozen	O
plasma	O
and	O
platelets	O
.	O

Experiments	O
were	O
done	O
to	O
compare	O
the	O
pathogenesis	O
of	O
enterotropic	O
strain	O
MHV	O
-	O
Y	O
in	O
immunocompetent	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	O
with	O
that	O
in	O
B	O
and	O
T	O
cell	B-COMP
-	O
deficient	O
mice	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
safe	O
and	O
sensitive	O
Spike	O
protein	O
-	O
based	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
antibody	B-COMP
responses	O
to	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
identified	O
a	O
truncated	O
antigenic	O
fragment	O
named	O
protein	O
C	O
[	O
441	O
to	O
700	O
amino	O
acids	O
(	O
a	O
.	O
a	O
.)]	O
as	O
the	O
immunodominant	O
fragment	O
of	O
Spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

These	O
results	O
demonstrate	O
key	O
sequences	O
required	O
for	O
efficient	O
frameshifting	O
,	O
and	O
the	O
utility	O
of	O
mass	O
spectrometry	O
to	O
study	O
ribosomal	B-COMP
frameshifting	O
.	O

The	O
recombinant	O
protein	O
could	O
be	O
used	O
as	O
an	O
antigen	O
for	O
detecting	O
the	O
serum	B-COMP
of	O
SARS	O
CoV	O
-	O
infected	O
patients	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
gene	O
vaccine	O
could	O
induce	O
the	O
production	O
of	O
specific	O
antibody	B-COMP
,	O
which	O
offers	O
clues	O
for	O
the	O
research	O
of	O
SARS	O
DNA	O
vaccine	O
.	O

TITLE	O
:	O
Function	O
of	O
HAb18G	O
/	O
CD147	O
in	O
invasion	O
of	O
host	B-COMP
cells	B-COMP
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Although	O
none	O
of	O
the	O
SARS	O
-	O
CoV	O
proteins	O
was	O
found	O
to	O
be	O
directly	O
bound	O
to	O
HAb18G	O
/	O
CD147	O
,	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
bound	O
to	O
CyPA	O
,	O
which	O
interacted	O
with	O
HAb18G	O
/	O
CD147	O
.	O

Further	O
research	O
showed	O
that	O
HAb18G	O
/	O
CD147	O
,	O
a	O
transmembrane	B-COMP
molecule	O
,	O
was	O
highly	O
expressed	O
on	O
293	O
cells	B-COMP
and	O
that	O
CyPA	O
was	O
integrated	O
with	O
SARS	O
-	O
CoV	O
.	O
HAb18G	O
/	O
CD147	O
-	O
antagonistic	O
peptide	O
(	O
AP	O
)-	O
9	O
,	O
an	O
AP	O
of	O
HAb18G	O
/	O
CD147	O
,	O
had	O
a	O
high	O
rate	O
of	O
binding	O
to	O
293	O
cells	B-COMP
and	O
an	O
inhibitory	O
effect	O
on	O
SARS	O
-	O
CoV	O
.	O
These	O
results	O
show	O
that	O
HAb18G	O
/	O
CD147	O
,	O
mediated	O
by	O
CyPA	O
bound	O
to	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
plays	O
a	O
functional	O
role	O
in	O
facilitating	O
invasion	O
of	O
host	B-COMP
cells	B-COMP
by	O
SARS	O
-	O
CoV	O
.	O
Our	O
findings	O
provide	O
some	O
evidence	O
for	O
the	O
cytologic	O
mechanism	O
of	O
invasion	O
by	O
SARS	O
-	O
CoV	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
screening	O
anti	O
-	O
SARS	O
drugs	O
.	O

In	O
contrast	O
to	O
the	O
catalytic	O
dyad	O
observed	O
in	O
X	O
-	O
ray	O
structures	O
of	O
CCP	O
and	O
other	O
coronavirus	O
cysteine	O
proteinases	O
,	O
a	O
catalytic	O
triad	B-COMP
comprising	O
Asp187	O
,	O
His41	O
,	O
and	O
Cys145	O
is	O
found	O
in	O
the	O
theoretical	O
model	O
of	O
the	O
substrate	O
-	O
bound	O
CCP	O
.	O

It	O
has	O
been	O
observed	O
that	O
the	O
catalytic	O
dyad	O
(	O
His	O
-	O
41	O
/	O
Cys	O
-	O
145	O
)	O
site	O
between	O
domains	O
I	O
and	O
II	O
attracts	O
the	O
pi	O
electron	O
density	O
from	O
the	O
peptide	O
bond	O
Gln	O
-	O
Ser	B-COMP
,	O
increasing	O
the	O
positive	O
charge	O
on	O
C	O
(	O
CO	O
)	O
of	O
Gln	O
and	O
the	O
negative	O
charge	O
on	O
N	O
(	O
NH	O
)	O
of	O
Ser	B-COMP
,	O
so	O
as	O
to	O
weaken	O
the	O
Gln	O
-	O
Ser	B-COMP
peptide	O
bond	O
.	O

By	O
transforming	O
the	O
symbolic	O
sequence	O
codes	O
into	O
the	O
digital	O
codes	O
,	O
and	O
using	O
some	O
optimal	O
space	O
-	O
time	O
evolvement	O
rules	O
of	O
cellular	B-COMP
automata	O
,	O
a	O
biological	O
sequence	O
can	O
be	O
represented	O
by	O
a	O
unique	O
image	O
,	O
the	O
so	O
-	O
called	O
cellular	B-COMP
automata	O
image	O
.	O

With	O
biological	O
sequences	O
entering	O
into	O
databanks	O
rapidly	O
increasing	O
in	O
the	O
post	O
-	O
genomic	O
era	O
,	O
it	O
is	O
anticipated	O
that	O
the	O
cellular	B-COMP
automata	O
image	O
will	O
become	O
a	O
very	O
useful	O
vehicle	O
for	O
investigation	O
into	O
their	O
key	O
features	O
,	O
identification	O
of	O
their	O
function	O
,	O
as	O
well	O
as	O
revelation	O
of	O
their	O
""""	O
fingerprint	O
"""."	O

These	O
include	O
ecological	O
,	O
environmental	O
or	O
demographic	O
factors	O
that	O
place	O
people	O
in	O
increased	O
contact	O
with	O
the	O
natural	O
host	B-COMP
for	O
a	O
previously	O
unfamiliar	O
zoonotic	O
agent	O
or	O
that	O
promote	O
the	O
spread	O
of	O
the	O
pathogen	O
.	O

In	O
both	O
scenarios	O
,	O
environmental	O
factors	O
relating	O
to	O
demography	O
,	O
land	B-COMP
pressure	O
and	O
imbalances	O
in	O
production	O
intensification	O
have	O
led	O
to	O
an	O
unstable	O
epidemiological	O
situation	O
,	O
as	O
evidenced	O
by	O
the	O
highly	O
pathogenic	O
avian	O
influenza	O
upsurge	O
early	O
in	O
2004	O
,	O
when	O
the	O
main	O
outbreaks	O
were	O
located	O
in	O
areas	O
which	O
had	O
both	O
large	O
scale	O
,	O
peri	O
-	O
urban	O
commercial	O
holdings	O
and	O
a	O
high	O
density	O
of	O
smallholder	O
poultry	O
units	O
.	O

ABSTRACT	O
:	O
A	O
recent	O
publication	O
reported	O
that	O
a	O
tyrosine	O
-	O
dependent	O
sorting	O
signal	O
,	O
present	O
in	O
cytoplasmic	B-COMP
tail	O
of	O
the	O
spike	O
protein	O
of	O
most	O
coronaviruses	O
,	O
mediates	O
the	O
intracellular	B-COMP
retention	O
of	O
the	O
spike	O
protein	O
.	O

Human	O
cell	B-COMP
lines	O
were	O
infected	O
with	O
Cytomegalovirus	O
,	O
Human	O
Herpesvirus	O
-	O
6	O
,	O
Camelpox	O
virus	O
,	O
SARS	O
coronavirus	O
or	O
Yellow	O
fever	O
virus	O
.	O

A	O
novel	O
coronavirus	O
was	O
identified	O
as	O
the	O
aetiological	O
agent	O
of	O
SARS	O
and	O
the	O
30kb	O
viral	B-COMP
genome	I-COMP
was	O
deciphered	O
with	O
unprecedented	O
speed	O
in	O
a	O
coordinated	O
manner	O
by	O
the	O
global	O
community	O
.	O

The	O
newly	O
generated	O
recombinant	O
MVA	O
,	O
ADS	O
-	O
MVA	O
,	O
is	O
replication	O
incompetent	O
in	O
mammalian	O
cells	B-COMP
and	O
highly	O
immunogenic	O
in	O
terms	O
of	O
inducing	O
potent	O
neutralizing	O
antibodies	B-COMP
in	O
mice	O
,	O
rabbits	O
,	O
and	O
monkeys	O
.	O

3a	O
protein	O
appeared	O
to	O
undergo	O
posttranslational	O
modifications	O
in	O
infected	O
cells	B-COMP
and	O
was	O
incorporated	O
into	O
SCoV	O
particles	O
,	O
establishing	O
that	O
3a	O
protein	O
was	O
a	O
SCoV	O
structural	O
protein	O
.	O

TITLE	O
:	O
The	O
transmembrane	B-COMP
oligomers	O
of	O
coronavirus	O
protein	O
E	O
.	O
ABSTRACT	O
:	O
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
protein	O
E	O
(	O
SCoVE	O
)	O
and	O
its	O
homologs	O
in	O
other	O
coronaviruses	O
associate	O
through	O
their	O
putative	O
transmembrane	B-COMP
domain	O
to	O
form	O
homooligomeric	O
alpha	O
-	O
helical	O
bundles	O
in	O
vivo	O
.	O

The	O
numbers	O
of	O
peripheral	O
white	O
blood	O
cells	B-COMP
and	O
lymphocytes	O
were	O
in	O
the	O
normal	O
range	O
without	O
any	O
specific	O
changes	O
typical	O
of	O
SARS	O
.	O

RESULTS	O
:	O
The	O
abnormalities	O
of	O
serum	B-COMP
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

C57BL	O
/	O
6	O
mice	O
were	O
infected	O
with	O
a	O
recombinant	O
A59	O
virus	O
expressing	O
the	O
gp33	O
epitope	O
,	O
an	O
H	O
-	O
2Db	O
-	O
restricted	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
epitope	O
encoded	O
in	O
the	O
glycoprotein	O
of	O
lymphocytic	O
choriomeningitis	O
virus	O
,	O
as	O
a	O
fusion	O
with	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
RA59	O
-	O
gfp	O
/	O
gp33	O
).	O

TITLE	O
:	O
Exogenous	O
ACE2	O
expression	O
allows	O
refractory	O
cell	B-COMP
lines	O
to	O
support	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
.	O

ABSTRACT	O
:	O
Of	O
30	O
cell	B-COMP
lines	O
and	O
primary	O
cells	B-COMP
examined	O
,	O
productive	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
Urbani	O
strain	O
)	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
after	O
low	O
-	O
multiplicity	O
inoculation	O
was	O
detected	O
in	O
only	O
six	O
:	O
three	O
African	O
green	O
monkey	O
kidney	O
epithelial	O
cell	B-COMP
lines	O
(	O
Vero	O
,	O
Vero	O
E6	O
,	O
and	O
MA104	O
),	O
a	O
human	O
colon	O
epithelial	O
line	O
(	O
CaCo	O
-	O
2	O
),	O
a	O
porcine	O
kidney	O
epithelial	O
line	O
[	O
PK	O
(	O
15	O
)],	O
and	O
mink	O
lung	O
epithelial	O
cells	B-COMP
(	O
Mv	O
1	O
Lu	O
).	O

SARS	O
-	O
CoV	O
produced	O
a	O
lytic	O
infection	O
in	O
Vero	O
,	O
Vero	O
E6	O
,	O
and	O
MA104	O
cells	B-COMP
,	O
but	O
there	O
was	O
no	O
visible	O
cytopathic	O
effect	O
in	O
Caco	O
-	O
2	O
,	O
Mv	O
1	O
Lu	O
,	O
or	O
PK	O
(	O
15	O
)	O
cells	B-COMP
.	O

CONCLUSIONS	O
:	O
Autologous	O
stem	O
cell	B-COMP
transplantation	O
might	O
be	O
effective	O
in	O
the	O
treatment	O
advanced	O
solid	O
tumors	O
in	O
children	O
.	O

In	O
this	O
review	O
,	O
several	O
antiviral	O
substances	O
shown	O
to	O
be	O
active	O
in	O
vitro	O
will	O
be	O
introduced	O
and	O
summarized	O
in	O
the	O
order	O
of	O
the	O
virus	O
'	O
replication	O
steps	O
;	O
that	O
is	O
,	O
binding	O
to	O
cellular	B-COMP
receptor	O
,	O
fusion	O
and	O
entry	O
to	O
the	O
cells	B-COMP
,	O
viral	O
RNA	O
replication	O
and	O
transcription	O
,	O
protein	O
processing	O
and	O
so	O
on	O
.	O

Monoclonal	O
antibodies	B-COMP
(	O
Mabs	O
)	O
and	O
established	O
drugs	O
,	O
such	O
as	O
interferons	O
and	O
HIV	O
proteinase	O
inhibitors	O
,	O
are	O
also	O
discussed	O
in	O
relation	O
to	O
anti	O
-	O
SARS	O
clinical	O
use	O
.	O

We	O
expressed	O
and	O
purified	O
soluble	O
recombinant	O
protein	O
X4	O
from	O
E	O
.	O
coli	O
,	O
and	O
generated	O
specific	O
antibodies	B-COMP
against	O
protein	O
X4	O
.	O

Treatment	O
with	O
and	O
overexpression	O
of	O
protein	O
X4	O
inhibited	O
the	O
growth	O
of	O
Balb	O
/	O
c	O
3T3	O
cells	B-COMP
as	O
determined	O
by	O
cell	B-COMP
counting	O
and	O
MTT	O
assays	O
.	O

These	O
data	O
demonstrate	O
that	O
JHM	O
-	O
specific	O
antibodies	B-COMP
are	O
sufficient	O
to	O
cause	O
demyelination	O
and	O
that	O
myelin	B-COMP
destruction	O
in	O
the	O
presence	O
of	O
anti	O
-	O
virus	O
antibodies	B-COMP
results	O
from	O
a	O
combination	O
of	O
complement	O
-	O
and	O
Fc	O
receptor	O
-	O
dependent	O
mechanisms	O
.	O

This	O
viral	B-COMP
genome	I-COMP
consists	O
of	O
29	O
,	O
728	O
nucleotides	O
with	O
overall	O
organization	O
in	O
agreement	O
with	O
that	O
of	O
published	O
isolates	O
.	O

We	O
further	O
demonstrated	O
that	O
2C5	O
,	O
but	O
not	O
1A5	O
,	O
was	O
able	O
to	O
block	O
binding	O
of	O
the	O
RBD	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
on	O
targeted	O
cells	B-COMP
.	O

TITLE	O
:	O
Epitope	O
mapping	O
and	O
biological	O
function	O
analysis	O
of	O
antibodies	B-COMP
produced	O
by	O
immunization	O
of	O
mice	O
with	O
an	O
inactivated	O
Chinese	O
isolate	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Some	O
of	O
these	O
S	O
-	O
specific	O
mAbs	O
were	O
able	O
to	O
recognize	O
cleaved	O
products	O
of	O
S	O
protein	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Antibody	B-COMP
detection	O
with	O
a	O
recombinant	O
COOH	O
portion	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
N13	O
(	O
amino	O
acids	O
221	O
to	O
422	O
),	O
was	O
demonstrated	O
to	O
be	O
more	O
specific	O
and	O
sensitive	O
than	O
that	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
,	O
and	O
an	O
N13	O
-	O
based	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
providing	O
a	O
convenient	O
and	O
specific	O
test	O
for	O
serodiagnosis	O
and	O
epidemiological	O
study	O
of	O
SARS	O
was	O
developed	O
.	O

ABSTRACT	O
:	O
We	O
have	O
investigated	O
to	O
develop	O
novel	O
vaccines	O
against	O
SARS	O
CoV	O
using	O
cDNA	O
constructs	O
encoding	O
the	O
structural	O
antigen	O
;	O
spike	O
protein	O
(	O
S	O
),	O
membrane	B-COMP
protein	O
(	O
M	O
),	O
envelope	B-COMP
protein	O
(	O
E	O
),	O
or	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
derived	O
from	O
SARS	O
CoV	O
.	O
Mice	O
vaccinated	O
with	O
SARS	O
-	O
N	O
or	O
-	O
M	O
DNA	O
using	O
pcDNA	O
3	O
.	O
1	O
(+)	O
plasmid	O
vector	O
showed	O
T	O
cell	B-COMP
immune	O
responses	O
(	O
CTL	O
induction	O
and	O
proliferation	O
)	O
against	O
N	O
or	O
M	O
protein	O
,	O
respectively	O
.	O

In	O
this	O
communication	O
,	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
SARS	O
vaccine	O
candidates	O
based	O
on	O
the	O
recombinant	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
)	O
expressing	O
SARS	O
-	O
CoV	O
spike	O
or	O
nucleocapsid	B-COMP
proteins	O
in	O
ferrets	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
)	O
is	O
a	O
major	O
target	O
for	O
neutralizing	O
antibodies	B-COMP
.	O

Polyclonal	O
antibodies	B-COMP
against	O
the	O
SARS	O
N	O
protein	O
have	O
been	O
produced	O
and	O
the	O
strong	O
binding	O
sites	O
of	O
the	O
anti	O
-	O
nucleocapsid	B-COMP
protein	O
(	O
NP	O
)	O
antibodies	B-COMP
produced	O
were	O
mapped	O
to	O
aa	O
1	O
-	O
20	O
,	O
aa	O
150	O
-	O
170	O
and	O
aa	O
390	O
-	O
410	O
.	O

TITLE	O
:	O
Subcellular	O
localization	O
and	O
membrane	B-COMP
association	O
of	O
SARS	O
-	O
CoV	O
3a	O
protein	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
shown	O
that	O
3a	O
protein	O
was	O
mainly	O
located	O
in	O
Golgi	B-COMP
apparatus	I-COMP
with	O
different	O
tags	O
at	O
N	O
-	O
or	O
C	O
-	O
terminus	O
.	O

Immunostaining	O
indicated	O
that	O
viral	O
infection	O
had	O
a	O
limited	O
effect	O
on	O
culture	O
characteristics	O
,	O
overall	O
cell	B-COMP
survival	O
,	O
or	O
cell	B-COMP
morphology	O
at	O
the	O
early	O
postinfection	O
times	O
studied	O
.	O

An	O
inflammatory	O
CSF	O
was	O
defined	O
as	O
one	O
in	O
which	O
a	O
total	O
nucleated	O
cell	B-COMP
count	O
was	O
greater	O
than	O
5	O
cells	B-COMP
/	O
microl	O
or	O
one	O
in	O
which	O
the	O
total	O
nucleated	O
cell	B-COMP
count	O
was	O
normal	O
but	O
the	O
nucleated	O
cell	B-COMP
differential	O
count	O
was	O
abnormal	O
.	O

Reported	O
data	O
showed	O
that	O
this	O
was	O
a	O
relatively	O
high	O
degree	O
of	O
sensitivity	O
and	O
specificity	O
for	O
SARS	O
-	O
CoV	O
antibody	B-COMP
testing	O
.	O

Elevated	O
Mx1	O
expression	O
signified	O
a	O
strong	O
host	B-COMP
response	O
to	O
mediate	O
antiviral	O
resistance	O
.	O

TITLE	O
:	O
Mixed	O
infections	O
in	O
vitro	O
with	O
different	O
Chlamydiaceae	O
strains	O
and	O
a	O
cell	B-COMP
culture	O
adapted	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Vero	O
cells	B-COMP
were	O
dually	O
infected	O
with	O
ca	O
-	O
PEDV	O
and	O
one	O
of	O
the	O
three	O
chlamydial	O
strains	O
Chlamydia	O
trachomatis	O
S45	O
,	O
Chlamydophila	O
abortus	O
S26	O
/	O
3	O
or	O
Chlamydophila	O
pecorum	O
1710S	O
.	O

Immunofluorescence	O
techniques	O
,	O
immunohistochemical	O
(	O
IH	O
)	O
staining	O
and	O
electron	O
microscopy	O
were	O
subsequently	O
employed	O
to	O
investigate	O
the	O
cell	B-COMP
layers	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-COMP
and	O
protective	O
immunity	O
to	O
SARS	O
coronavirus	O
infection	O
of	O
mice	O
induced	O
by	O
a	O
soluble	O
recombinant	O
polypeptide	O
containing	O
an	O
N	O
-	O
terminal	O
segment	O
of	O
the	O
spike	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
,	O
required	O
for	O
receptor	O
binding	O
and	O
membrane	B-COMP
fusion	O
,	O
is	O
incorporated	O
into	O
the	O
assembling	O
virion	B-COMP
by	O
interactions	O
with	O
the	O
viral	B-COMP
membrane	I-COMP
(	O
M	O
)	O
protein	O
.	O

The	O
essential	O
sequence	O
was	O
mapped	O
to	O
the	O
membrane	B-COMP
-	O
proximal	O
region	O
of	O
the	O
cytoplasmic	B-COMP
domain	O
,	O
which	O
is	O
also	O
known	O
to	O
be	O
of	O
critical	O
importance	O
for	O
the	O
fusion	O
function	O
of	O
the	O
S	O
protein	O
.	O

During	O
the	O
1970th	O
and	O
80th	O
,	O
many	O
new	O
agents	O
were	O
characterized	O
from	O
diagnostic	O
cell	B-COMP
cultures	O
and	O
clinical	O
specimens	O
.	O

Moreover	O
isotope	O
-	O
coded	O
affinity	O
tag	O
technology	O
coupled	O
with	O
two	O
-	O
dimensional	O
LC	O
-	O
MS	O
/	O
MS	O
were	O
also	O
applied	O
to	O
the	O
differential	O
proteins	O
of	O
infected	O
cells	B-COMP
.	O

TITLE	O
:	O
Evaluation	O
by	O
indirect	O
immunofluorescent	O
assay	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
of	O
the	O
dynamic	O
changes	O
of	O
serum	B-COMP
antibody	B-COMP
responses	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Electron	O
microscopy	O
confirmed	O
the	O
presence	O
of	O
viral	B-COMP
particles	I-COMP
in	O
passage	O
11	O
cells	B-COMP
.	O

The	O
purified	O
SARS	O
-	O
CoV	O
rNP	B-COMP
was	O
used	O
as	O
an	O
antigen	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
antibodies	B-COMP
in	O
IgG	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
ELISA	O
was	O
evaluated	O
in	O
comparison	O
with	O
neutralizing	O
antibody	B-COMP
assay	O
and	O
the	O
authentic	O
SARS	O
-	O
CoV	O
antigen	O
-	O
based	O
IgG	O
ELISA	O
.	O

The	O
results	O
suggest	O
that	O
the	O
newly	O
developed	O
SARS	O
-	O
CoV	O
rNP	B-COMP
-	O
based	O
IgG	O
ELISA	O
is	O
a	O
valuable	O
tool	O
for	O
the	O
diagnosis	O
and	O
seroepidemiological	O
study	O
of	O
SARS	O
.	O

These	O
data	O
suggest	O
that	O
in	O
contrast	O
to	O
the	O
results	O
seen	O
with	O
MMPs	O
,	O
inhibition	O
of	O
protease	O
activity	O
via	O
TIMP	O
-	O
1	O
expression	O
correlates	O
with	O
the	O
differential	O
tissue	O
distribution	O
of	O
T	O
-	O
cell	B-COMP
subsets	O
during	O
acute	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
coronavirus	O
.	O

To	O
evaluate	O
an	O
automatic	O
nucleic	B-COMP
acid	O
extraction	O
system	O
and	O
two	O
standardized	O
real	O
-	O
time	O
PCR	O
assays	O
for	O
rapid	O
diagnosis	O
of	O
SARS	O
CoV	O
during	O
outbreak	O
and	O
post	O
-	O
epidemic	O
periods	O
in	O
Hong	O
Kong	O
.	O

These	O
data	O
suggest	O
that	O
the	O
cellular	B-COMP
immune	O
response	O
to	O
acute	O
neurotropic	O
JHMV	O
infection	O
requires	O
a	O
distinct	O
CD4	O
(+)	O
T	O
cell	B-COMP
component	I-COMP
,	O
but	O
is	O
independent	O
of	O
a	O
requirement	O
for	O
IL	O
-	O
2	O
for	O
induction	O
,	O
activation	O
,	O
recruitment	O
,	O
and	O
/	O
or	O
maintenance	O
of	O
CD8	O
(+)	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
during	O
acute	O
infection	O
.	O

In	O
26	O
(	O
81	O
.	O
2	O
%)	O
symptomatic	O
cases	O
,	O
hypoxic	O
-	O
ischemic	O
encephalopathy	O
(	O
69	O
.	O
2	O
%)	O
was	O
the	O
most	O
common	O
etiologic	O
factor	O
,	O
followed	O
by	O
central	O
nervous	O
system	O
anomaly	O
including	O
malformation	O
of	O
cortical	O
development	O
(	O
11	O
.	O
5	O
%),	O
and	O
Sturge	O
Weber	O
syndrome	O
(	O
3	O
.	O
8	O
%),	O
and	O
chromosomal	B-COMP
translocation	O
with	O
Down	O
syndrome	O
(	O
11	O
.	O
5	O
%).	O

SARS	O
has	O
been	O
defined	O
using	O
clinical	O
and	O
epidemiological	O
criteria	O
and	O
cases	O
are	O
considered	O
laboratory	O
-	O
confirmed	O
if	O
SARS	O
coronavirus	O
is	O
isolated	O
,	O
if	O
antibody	B-COMP
to	O
SARS	O
coronavirus	O
is	O
detected	O
,	O
or	O
a	O
polymerase	O
chain	O
reaction	O
test	O
by	O
appropriate	O
criteria	O
is	O
positive	O
.	O

Recently	O
,	O
a	O
small	O
fragment	O
on	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
residues	O
318	O
-	O
510	O
)	O
was	O
characterized	O
as	O
a	O
minimal	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
mediates	O
virus	O
binding	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
the	O
functional	O
receptor	O
on	O
susceptible	O
cells	B-COMP
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
a	O
Saccharomyces	O
cerevisiae	O
-	O
expressed	O
nucleocapsid	B-COMP
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
infectious	O
bronchitis	O
virus	O
.	O

Using	O
non	O
-	O
ribosomal	B-COMP
primers	O
,	O
the	O
cDNA	O
fragments	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
bovine	O
parainfluenza	O
virus	O
3	O
were	O
efficiently	O
amplified	O
by	O
subtracting	O
the	O
cDNA	O
amplicons	O
derived	O
from	O
uninfected	O
cells	B-COMP
from	O
those	O
that	O
were	O
derived	O
from	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

In	O
SARS	O
CoV	O
-	O
infected	O
cells	B-COMP
,	O
10	O
sgRNAs	O
,	O
including	O
2	O
novel	O
ones	O
,	O
were	O
identified	O
,	O
which	O
were	O
predicted	O
to	O
be	O
functional	O
in	O
the	O
expression	O
of	O
12	O
open	O
reading	O
frames	O
located	O
in	O
the	O
3	O
'	O
one	O
-	O
third	O
of	O
the	O
genome	O
.	O

In	O
conclusion	O
,	O
SARS	O
-	O
CoV	O
surface	O
proteins	O
S	O
,	O
M	O
and	O
E	O
show	O
differential	O
subcellular	O
localizations	O
when	O
expressed	O
alone	O
suggesting	O
that	O
additional	O
cellular	B-COMP
or	O
viral	O
factors	O
might	O
be	O
required	O
for	O
coordinated	O
trafficking	O
to	O
the	O
virus	O
assembly	O
site	O
in	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
-	I-COMP
Golgi	I-COMP
intermediate	I-COMP
compartment	I-COMP
.	O

The	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
),	O
three	O
N	O
fragments	O
(	O
N1	O
,	O
N2	O
,	O
and	O
N3	O
)	O
and	O
the	O
intraviral	O
domain	O
of	O
the	O
membrane	B-COMP
protein	O
(	O
M2	O
)	O
were	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
histidine	O
-	O
tagged	O
proteins	O
.	O

Six	O
reference	O
sera	B-COMP
from	O
SARS	O
patients	O
were	O
used	O
to	O
detect	O
virus	O
-	O
specific	O
IgG	O
in	O
an	O
ELISA	O
using	O
each	O
recombinant	O
protein	O
as	O
coating	O
antigen	O
.	O

The	O
strong	O
neutralizing	O
capacity	O
exhibited	O
in	O
micro	O
-	O
cytopathic	O
effect	O
neutralization	O
tests	O
indicated	O
the	O
specific	O
antibodies	B-COMP
are	O
protective	O
.	O

Serum	B-COMP
levels	O
of	O
MBL	O
were	O
also	O
significantly	O
lower	O
in	O
patients	O
with	O
SARS	O
than	O
in	O
control	O
subjects	O
.	O

These	O
results	O
suggest	O
that	O
MBL	O
contributes	O
to	O
the	O
first	O
-	O
line	O
host	B-COMP
defense	O
against	O
SARS	O
-	O
CoV	O
and	O
that	O
MBL	O
deficiency	O
is	O
a	O
susceptibility	O
factor	O
for	O
acquisition	O
of	O
SARS	O
.	O

Herein	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
in	O
vitro	O
analysis	O
of	O
a	O
hammerhead	O
ribozyme	O
targeted	O
to	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	B-COMP
mRNA	O
.	O

Although	O
stability	O
and	O
delivery	O
problems	O
must	O
be	O
overcome	O
,	O
a	O
hammerhead	O
ribozyme	O
targeted	O
to	O
the	O
IBV	O
nucleocapsid	B-COMP
mRNA	O
most	O
likely	O
has	O
antiviral	O
activity	O
and	O
may	O
be	O
an	O
effective	O
therapeutic	O
/	O
prophylactic	O
reagent	O
in	O
the	O
future	O
.	O

hAPN	O
protein	O
was	O
specifically	O
expressed	O
on	O
epithelial	O
cells	B-COMP
of	O
the	O
proximal	O
convoluted	O
renal	O
tubules	O
,	O
bronchi	O
,	O
alveolar	O
sacs	O
,	O
and	O
intestinal	O
villi	O
.	O

In	O
that	O
kennel	O
antibody	B-COMP
responses	O
to	O
CRCoV	O
indicated	O
a	O
seasonal	O
occurrence	O
of	O
the	O
virus	O
,	O
which	O
coincided	O
with	O
two	O
outbreaks	O
of	O
respiratory	O
disease	O
.	O

CHV	O
antibody	B-COMP
responses	O
were	O
detected	O
throughout	O
the	O
year	O
.	O

In	O
the	O
other	O
kennel	O
,	O
which	O
reported	O
few	O
cases	O
of	O
CIRD	O
a	O
high	O
prevalence	O
of	O
antibodies	B-COMP
to	O
CRCoV	O
was	O
detected	O
on	O
entry	O
but	O
only	O
sporadic	O
seroconversions	O
to	O
CRCoV	O
or	O
CHV	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibodies	B-COMP
to	O
the	O
S	O
glycoprotein	O
and	O
related	O
proteins	O
as	O
potential	O
therapeutics	O
for	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
viral	B-COMP
nucleocapsid	I-COMP
(	O
N	O
)	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
viral	O
RNA	O
packaging	O
.	O

These	O
results	O
suggest	O
that	O
the	O
N	O
protein	O
oligomerization	O
involves	O
the	O
C	O
-	O
terminal	O
residues	O
285	O
-	O
422	O
,	O
and	O
this	O
region	O
is	O
a	O
good	O
target	O
for	O
mutagenic	O
studies	O
to	O
disrupt	O
N	O
protein	O
self	O
-	O
association	O
and	O
virion	B-COMP
assembly	O
.	O

To	O
determine	O
whether	O
RANTES	O
play	O
an	O
role	O
in	O
the	O
process	O
of	O
SARS	O
,	O
THP	O
-	O
1	O
cells	B-COMP
were	O
incubated	O
with	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
and	O
ELISA	O
was	O
used	O
to	O
test	O
RANTES	O
levels	O
in	O
the	O
supernatants	O
;	O
Then	O
the	O
effect	O
of	O
dexamethasone	O
on	O
the	O
induced	O
secretion	O
was	O
evaluated	O
.	O

TITLE	O
:	O
Multiorgan	O
dysfunction	O
syndrome	O
in	O
sickle	O
cell	B-COMP
disease	O
.	O

Ten	O
episodes	O
of	O
multiorgan	O
failure	O
were	O
identified	O
with	O
sickle	O
cell	B-COMP
disease	O
and	O
defining	O
criteria	O
of	O
organ	O
failure	O
of	O
two	O
or	O
more	O
organs	O
that	O
is	O
lung	O
,	O
liver	O
,	O
or	O
renal	O
were	O
established	O
according	O
to	O
Acute	O
Physiological	O
and	O
Chronic	O
Health	O
Evaluation	O
-	O
II	O
(	O
APACHE	O
-	O
II	O
)	O
criteria	O
.	O

In	O
mixed	O
neural	O
cell	B-COMP
cultures	O
,	O
srr7	O
infected	O
a	O
limited	O
number	O
of	O
cells	B-COMP
and	O
infection	O
did	O
not	O
spread	O
,	O
although	O
wt	O
JHMV	O
induced	O
syncytia	O
in	O
most	O
of	O
the	O
cells	B-COMP
.	O

srr7	O
-	O
infected	O
cells	B-COMP
were	O
positive	O
for	O
GS	O
-	O
lectin	O
,	O
a	O
microglia	O
marker	O
.	O

Using	O
cytopathic	O
assays	O
,	O
no	O
increase	O
in	O
virus	O
titer	O
was	O
detected	O
in	O
infected	O
DCs	O
and	O
cell	B-COMP
-	O
culture	O
supernatant	O
,	O
confirming	O
that	O
virus	O
replication	O
was	O
incomplete	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	B-COMP
protein	O
of	O
SARS	O
coronavirus	O
has	O
a	O
high	O
binding	O
affinity	O
to	O
the	O
human	O
cellular	B-COMP
heterogeneous	O
nuclear	O
ribonucleoprotein	B-COMP
A1	O
.	O

To	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ELISA	O
,	O
56	O
positive	O
sera	B-COMP
and	O
204	O
negative	O
sera	B-COMP
were	O
tested	O
.	O

The	O
results	O
suggest	O
that	O
the	O
IgG	O
ELISA	O
using	O
whole	O
virus	O
antigen	O
of	O
SARS	O
-	O
CoV	O
has	O
a	O
high	O
sensitivity	O
and	O
specificity	O
in	O
detecting	O
SARS	O
IgG	O
antibodies	B-COMP
.	O

Vasculitic	O
processes	O
ranged	O
from	O
attachment	O
and	O
emigration	O
of	O
FCoV	O
-	O
infected	O
monocytes	O
to	O
vascular	O
/	O
perivascular	O
granulomatous	O
infiltrates	O
with	O
destruction	O
of	O
the	O
vascular	O
basal	B-COMP
lamina	I-COMP
.	O

TITLE	O
:	O
Antibody	B-COMP
responses	O
to	O
individual	O
proteins	O
of	O
SARS	O
coronavirus	O
and	O
their	O
neutralization	O
activities	O
.	O

The	O
profile	O
of	O
specific	O
antibodies	B-COMP
to	O
individual	O
proteins	O
of	O
the	O
virus	O
is	O
critical	O
to	O
the	O
development	O
of	O
vaccine	O
and	O
diagnostic	O
tools	O
.	O

ABSTRACT	O
:	O
A	O
wide	O
range	O
of	O
RNA	O
viruses	O
use	O
programmed	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
for	O
the	O
production	O
of	O
viral	O
fusion	O
proteins	O
.	O

While	O
two	O
of	O
the	O
three	O
non	O
-	O
neutralizing	O
antibodies	B-COMP
recognized	O
at	O
second	O
epitope	O
within	O
amino	O
acids	O
270	O
-	O
350	O
.	O

HRCT	O
scores	O
were	O
increased	O
and	O
correlated	O
with	O
T	O
-	O
cell	B-COMP
numbers	O
and	O
their	O
subpopulations	O
,	O
and	O
inversely	O
with	O
CD4	O
/	O
CD8	O
ratio	O
.	O

TITLE	O
:	O
Selective	O
replication	O
of	O
coronavirus	O
genomes	O
that	O
express	O
nucleocapsid	B-COMP
protein	O
.	O

Demyelination	O
does	O
not	O
develop	O
in	O
infected	O
RAG1	O
-/-	O
(	O
recombination	O
activation	O
gene	O
-	O
deficient	O
)	O
mice	O
but	O
can	O
be	O
induced	O
by	O
several	O
experimental	O
interventions	O
,	O
including	O
adoptive	O
transfer	O
of	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
or	O
antibodies	B-COMP
.	O

A	O
fusion	O
peptide	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
of	O
class	O
I	O
viral	O
fusion	O
proteins	O
is	O
believed	O
to	O
initiate	O
viral	O
and	O
cell	B-COMP
membrane	I-COMP
interactions	O
and	O
subsequent	O
fusion	O
.	O

Single	O
intrasplenic	O
immunization	O
of	O
plasmid	O
DNA	O
encoding	O
S1	O
-(	O
3	O
)	O
induced	O
anti	O
-	O
spike	O
protein	O
antibodies	B-COMP
.	O

The	O
mAb	O
could	O
recognize	O
the	O
spike	O
protein	O
on	O
the	O
MLV	O
/	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
albeit	O
with	O
no	O
neutralizing	O
effect	O
on	O
the	O
infectivity	O
of	O
the	O
pseudotype	O
virus	O
.	O

Then	O
the	O
recombinant	O
eukaryotic	O
expression	O
vector	O
pCI	O
-	O
neo	O
/	O
nsp2	O
was	O
transfected	O
into	O
COS	O
-	O
7	O
cells	B-COMP
using	O
lipofectin	O
reagent	O
to	O
express	O
the	O
nsp2	O
protein	O
.	O

The	O
eukaryotic	O
expression	O
vector	O
(	O
pCI	O
-	O
neo	O
/	O
nsp2	O
)	O
was	O
constructed	O
and	O
expressed	O
the	O
protein	O
in	O
COS	O
-	O
7	O
cells	B-COMP
successfully	O
.	O

It	O
also	O
inhibited	O
giant	O
cell	B-COMP
formation	O
in	O
co	O
-	O
cultures	O
of	O
HIV	O
-	O
infected	O
cells	B-COMP
and	O
uninfected	O
Molt	O
-	O
4	O
cells	B-COMP
.	O

It	O
also	O
suppressed	O
replication	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
in	O
Vero	O
cells	B-COMP
with	O
an	O
EC	O
50	O
of	O
11	O
.	O
56	O
microg	O
/	O
ml	O
.	O

Serum	B-COMP
epidermal	O
growth	O
factor	O
levels	O
also	O
were	O
not	O
significantly	O
different	O
between	O
the	O
furosemide	O
treatment	O
group	O
and	O
the	O
control	O
group	O
(	O
P	O
>	O
.	O
05	O
).	O

Phylogenetic	O
analyses	O
performed	O
on	O
the	O
replicase	O
gene	O
and	O
nucleocapsid	B-COMP
protein	O
sequences	O
,	O
indicated	O
that	O
the	O
novel	O
coronaviruses	O
described	O
in	O
the	O
present	O
study	O
all	O
branch	O
off	O
from	O
group	O
III	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Persistence	O
was	O
established	O
after	O
most	O
of	O
the	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
died	O
.	O

Hsp60	O
levels	O
were	O
measured	O
in	O
the	O
serum	B-COMP
of	O
trauma	O
patients	O
.	O

Immunohistochemistry	O
was	O
used	O
,	O
with	O
monoclonal	O
antibodies	B-COMP
,	O
to	O
detect	O
the	O
thyroglobulin	O
(	O
TG	O
),	O
calcitonin	O
and	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
the	O
thyroid	O
glands	O
.	O

PTH	O
positive	O
cells	B-COMP
were	O
seen	O
in	O
the	O
normal	O
thyroid	O
glands	O
and	O
those	O
of	O
the	O
SARS	O
patients	O
with	O
a	O
slightly	O
weaker	O
intensity	O
of	O
reaction	O
,	O
however	O
,	O
with	O
significant	O
difference	O
in	O
IOD	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
without	O
significant	O
difference	O
in	O
mean	O
slight	O
absorption	O
MOD	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Deformation	O
,	O
enlargement	O
,	O
and	O
dystrophy	O
of	O
follicular	O
cells	B-COMP
in	O
thyroid	O
glands	O
were	O
found	O
in	O
the	O
SARS	O
patients	O
.	O

A	O
case	O
control	O
study	O
involving	O
44	O
SARS	O
cases	O
,	O
16	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-COMP
-	O
positive	O
contacts	O
,	O
87	O
antibody	B-COMP
-	O
negative	O
contacts	O
,	O
and	O
50	O
non	O
-	O
contacts	O
in	O
Vietnam	O
,	O
failed	O
to	O
obtain	O
any	O
evidence	O
that	O
the	O
ACE2	O
gene	O
polymorphisms	O
are	O
involved	O
in	O
the	O
disease	O
process	O
in	O
the	O
population	O
.	O

To	O
prevent	O
further	O
antibody	B-COMP
-	O
mediated	O
cases	O
,	O
the	O
evaluation	O
of	O
TRALI	O
should	O
include	O
leucocyte	O
antibody	B-COMP
testing	O
of	O
implicated	O
donors	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
level	O
and	O
dynamic	O
change	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
-	O
specific	O
IgG	B-COMP
antibody	I-COMP
in	O
conavalescent	O
SARS	O
patients	O
,	O
and	O
to	O
provide	O
information	O
for	O
prevention	O
and	O
vaccine	O
development	O
.	O

IgG	B-COMP
antibody	I-COMP
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

CONCLUSIONS	O
:	O
Data	O
showed	O
that	O
all	O
the	O
SARS	O
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	B-COMP
antibody	I-COMP
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	B-COMP
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	B-COMP
antibody	I-COMP
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
purified	O
recombinant	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
for	O
producing	O
mAbs	O
,	O
and	O
New	O
Zealand	O
white	O
rabbits	O
were	O
immunized	O
for	O
producing	O
polyclonal	O
antibodies	B-COMP
.	O

However	O
,	O
immunologic	O
alterations	O
of	O
circulating	O
and	O
resident	O
immune	O
cell	B-COMP
populations	O
contributing	O
to	O
the	O
posttraumatic	O
immunosuppression	O
are	O
poorly	O
understood	O
.	O

We	O
therefore	O
characterized	O
the	O
influence	O
of	O
pulmonary	O
contusion	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
,	O
peritoneal	O
macrophages	O
,	O
splenocytes	O
,	O
and	O
splenic	O
macrophages	O
.	O

Measurement	O
of	O
antibody	B-COMP
avidity	O
can	O
be	O
used	O
to	O
differentiate	O
primary	O
infection	O
from	O
reexposure	O
and	O
to	O
assess	O
humoral	O
responses	O
to	O
candidate	O
vaccines	O
.	O

Cytokine	O
production	O
was	O
also	O
observed	O
for	O
Mphi	O
,	O
which	O
were	O
refractory	O
to	O
cell	B-COMP
surface	I-COMP
phenotypic	O
changes	O
.	O

Nucleocapsid	B-COMP
gene	O
was	O
obtained	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
a	O
SARS	O
patient	O
and	O
inserted	O
into	O
the	O
vector	O
pFastBacHTa	O
expressing	O
baculovirus	O
.	O

7	O
samples	O
of	O
sera	B-COMP
from	O
4	O
SARS	O
patients	O
in	O
acute	O
progressive	O
stage	O
in	O
Guangdong	O
province	O
were	O
all	O
IFA	O
positive	O
.	O

In	O
view	O
of	O
studying	O
the	O
MHV3	O
binding	O
to	O
cells	B-COMP
or	O
cell	B-COMP
extracts	O
,	O
we	O
performed	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
like	O
virus	O
-	O
binding	O
assay	O
,	O
preparing	O
microplates	O
with	O
L929	O
cells	B-COMP
,	O
A	O
/	O
J	O
or	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
and	O
also	O
with	O
proteins	O
extracted	O
from	O
these	O
cells	B-COMP
.	O

High	O
levels	O
of	O
expression	O
of	O
recombinant	O
S1	O
protein	O
were	O
observed	O
in	O
several	O
transgenic	O
lines	O
by	O
Western	O
blot	O
analysis	O
using	O
specific	O
antibodies	B-COMP
.	O

The	O
detailed	O
pathology	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
the	O
host	B-COMP
response	O
to	O
the	O
viral	O
infection	O
are	O
still	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
shown	O
that	O
the	O
3a	O
protein	O
was	O
expressed	O
in	O
the	O
lungs	O
and	O
intestinal	O
tissues	O
of	O
SARS	O
patients	O
and	O
that	O
the	O
protein	O
localized	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
in	O
3a	O
-	O
transfected	O
monkey	O
kidney	O
Vero	O
E6	O
cells	B-COMP
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	B-COMP
condensation	O
and	O
DNA	O
fragmentation	O
suggested	O
that	O
the	O
3a	O
protein	O
may	O
trigger	O
apoptosis	O
.	O

Viroporins	O
are	O
a	O
growing	O
family	O
of	O
viral	O
proteins	O
able	O
to	O
enhance	O
membrane	B-COMP
permeability	O
,	O
promoting	O
virus	O
budding	O
.	O

No	O
infectious	O
SARS	O
-	O
CoV	O
contamination	O
was	O
found	O
in	O
any	O
of	O
the	O
samples	O
collected	O
,	O
but	O
the	O
nucleic	B-COMP
acid	O
of	O
SARS	O
-	O
CoV	O
could	O
be	O
detected	O
in	O
the	O
sewage	O
from	O
the	O
two	O
hospitals	O
before	O
disinfection	O
.	O

On	O
admission	O
the	O
patient	O
presented	O
with	O
pyrexia	O
associated	O
with	O
lymphopenia	O
and	O
liver	O
cell	B-COMP
necrosis	O
but	O
no	O
respiratory	O
symptoms	O
.	O

RESULTS	O
:	O
The	O
SARS	O
-	O
antibodies	B-COMP
could	O
be	O
used	O
as	O
the	O
diagnostic	O
evidence	O
.	O

TITLE	O
:	O
Comprehensive	O
antibody	B-COMP
epitope	O
mapping	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
:	O
insight	O
into	O
the	O
humoral	O
immunity	O
of	O
SARS	O
.	O

The	O
antibody	B-COMP
responses	O
to	O
the	O
N	O
protein	O
fragments	O
in	O
mammalian	O
sera	B-COMP
revealed	O
that	O
3	O
regions	O
of	O
the	O
N	O
protein	O
are	O
strong	O
antigenic	O
domains	O
.	O

A	O
mutation	O
in	O
the	O
spike	O
gene	O
(	O
residue	O
24079	O
)	O
appeared	O
to	O
be	O
unique	O
to	O
adaptation	O
in	O
FRhK4	O
cells	B-COMP
.	O

Normal	O
lamellar	B-COMP
body	I-COMP
formation	O
requires	O
SP	O
-	O
B	O
and	O
a	O
member	O
of	O
the	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
family	O
of	O
ATP	O
-	O
dependent	O
membrane	B-COMP
-	O
associated	O
transport	O
proteins	O
,	O
ABCA3	O
.	O

In	O
general	O
,	O
viruses	O
tend	O
to	O
be	O
restricted	O
to	O
the	O
natural	O
host	B-COMP
species	O
which	O
they	O
infect	O
.	O

RESULTS	O
:	O
The	O
purified	O
hyperimmune	O
globulins	O
were	O
formulated	O
as	O
a	O
5	O
percent	O
solution	O
,	O
with	O
an	O
antibody	B-COMP
titer	O
specifically	O
against	O
the	O
SARS	O
virus	O
of	O
1	O
:	O
83	O
,	O
1	O
:	O
1600	O
,	O
and	O
1	O
:	O
200	O
,	O
as	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
immunofluorescence	O
assay	O
,	O
and	O
neutralizing	O
antibody	B-COMP
test	O
,	O
respectively	O
.	O

Both	O
of	O
the	O
neural	O
cell	B-COMP
lines	O
showed	O
no	O
apparent	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
by	O
infection	O
but	O
produced	O
virus	O
with	O
infectivity	O
of	O
10	O
(	O
2	O
-	O
5	O
)	O
per	O
ml	O
,	O
in	O
sharp	O
contrast	O
to	O
the	O
production	O
by	O
infected	O
Vero	O
E6	O
cells	B-COMP
of	O
>	O
10	O
(	O
9	O
)	O
per	O
ml	O
that	O
showed	O
a	O
lytic	O
infection	O
with	O
characteristic	O
rounding	O
CPE	O
.	O

Notably	O
,	O
the	O
cellular	B-COMP
receptor	O
for	O
the	O
virus	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
was	O
expressed	O
at	O
similar	O
levels	O
on	O
Vero	O
E6	O
and	O
CaCo	O
-	O
2	O
cells	B-COMP
,	O
but	O
at	O
undetectable	O
levels	O
on	O
OL	O
and	O
C6	O
cells	B-COMP
.	O

The	O
C	O
-	O
terminus	O
of	O
the	O
N	O
,	O
which	O
contains	O
both	O
NLS2	O
(	O
aa257	O
-	O
265	O
)	O
and	O
NLS3	O
(	O
aa369	O
-	O
390	O
)	O
was	O
localized	O
to	O
the	O
cytoplasm	B-COMP
and	O
the	O
nucleolus	B-COMP
.	O

The	O
deletion	O
of	O
two	O
hydrophobic	O
regions	O
that	O
flanked	O
the	O
NLS3	O
recovered	O
its	O
activity	O
and	O
localized	O
to	O
the	O
nucleus	B-COMP
.	O

Furthermore	O
,	O
deletion	O
of	O
leucine	O
rich	O
region	O
(	O
220	O
-	O
LALLLLDRLNRL	O
)	O
resulted	O
in	O
the	O
accumulation	O
of	O
N	O
to	O
the	O
cytoplasm	B-COMP
and	O
nucleolus	B-COMP
,	O
and	O
when	O
fusing	O
this	O
peptide	O
to	O
EGFP	O
localization	O
was	O
cytoplasmic	B-COMP
,	O
suggesting	O
that	O
the	O
N	O
may	O
act	O
as	O
a	O
shuttle	O
protein	O
.	O

ABSTRACT	O
:	O
Different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
neutralizing	O
antibody	B-COMP
response	O
against	O
SARS	O
-	O
CoV	O
were	O
compared	O
using	O
a	O
mouse	O
model	O
.	O

Sera	B-COMP
of	O
all	O
the	O
mice	O
immunized	O
with	O
i	O
.	O
m	O
.	O

The	O
sensitivity	O
of	O
all	O
primers	O
was	O
between	O
0	O
.	O
0004	O
and	O
0	O
.	O
04	O
PFU	O
with	O
viral	O
cell	B-COMP
lysate	O
and	O
between	O
0	O
.	O
004	O
and	O
0	O
.	O
4	O
PFU	O
in	O
spiked	O
stool	O
specimen	O
per	O
PCR	O
assay	O
.	O

To	O
develop	O
a	O
safe	O
,	O
simple	O
,	O
and	O
reliable	O
screening	O
method	O
for	O
SARS	O
diagnosis	O
and	O
epidemiological	O
study	O
,	O
two	O
recombinant	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
proteins	O
(	O
N	O
'	O
protein	O
and	O
(	O
N	O
)	O
Delta	O
(	O
121	O
)	O
protein	O
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
purified	O
by	O
affinity	O
chromatography	O
,	O
and	O
used	O
as	O
antigens	O
for	O
indirect	O
,	O
immunoglobulin	O
G	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
).	O

Mice	O
immunized	O
twice	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
elicited	O
higher	O
antibody	B-COMP
responses	O
than	O
mice	O
immunized	O
three	O
times	O
with	O
the	O
DNA	O
vaccine	O
or	O
once	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
.	O

In	O
cell	B-COMP
lines	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
a	O
potential	O
SARS	O
-	O
CoV	O
receptor	O
.	O

The	O
viral	O
culture	O
yielded	O
no	O
organisms	O
and	O
there	O
were	O
no	O
viral	B-COMP
particles	I-COMP
seen	O
on	O
electron	O
microscopic	O
examination	O
.	O

In	O
donors	O
,	O
the	O
presence	O
of	O
infectious	O
micro	O
-	O
organisms	O
,	O
like	O
human	O
immunodeficiency	O
virus	O
,	O
hepatitis	O
B	O
virus	O
,	O
hepatitis	O
C	O
virus	O
and	O
human	O
T	O
cell	B-COMP
lymphotrophic	O
virus	O
,	O
should	O
be	O
evaluated	O
in	O
addition	O
to	O
the	O
possibility	O
of	O
other	O
new	O
infectious	O
agents	O
(	O
e	O
.	O
g	O
.	O
transmissible	O
spongiform	O
encephalopathies	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
).	O

TITLE	O
:	O
[	O
Development	O
of	O
monoclonal	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
and	O
identification	O
of	O
antigenic	O
epitopes	O
].	O

Now	O
,	O
we	O
show	O
that	O
these	O
cells	B-COMP
also	O
mediate	O
the	O
same	O
process	O
in	O
mice	O
lacking	O
alphabeta	O
T	O
cells	B-COMP
(	O
T	O
-	O
cell	B-COMP
receptor	O
beta	O
-	O
deficient	O
[	O
TCRbeta	O
(-/-)]	O
mice	O
)	O
and	O
demyelination	O
is	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
dependent	O
.	O

TITLE	O
:	O
Apical	O
entry	O
and	O
release	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
in	O
polarized	O
Calu	O
-	O
3	O
lung	O
epithelial	O
cells	B-COMP
.	O

Importantly	O
,	O
both	O
ACE	O
-	O
2	O
and	O
viral	O
antigen	O
appeared	O
to	O
preferentially	O
colocalize	O
at	O
the	O
apical	O
domain	O
of	O
infected	O
cells	B-COMP
.	O

In	O
highly	O
polarized	O
Calu	O
-	O
3	O
cells	B-COMP
grown	O
on	O
the	O
membrane	B-COMP
inserts	O
,	O
we	O
found	O
that	O
cells	B-COMP
exposed	O
to	O
virus	O
through	O
the	O
apical	O
rather	O
than	O
the	O
basolateral	O
surface	O
showed	O
high	O
levels	O
of	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Thorp	O
and	O
Gallagher	O
first	O
reported	O
that	O
depletion	O
of	O
cholesterol	O
inhibited	O
virus	O
entry	O
and	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
suggesting	O
the	O
importance	O
of	O
lipid	B-COMP
rafts	I-COMP
in	O
MHV	O
replication	O
(	O
E	O
.	O
B	O
.	O
Thorp	O
and	O
T	O
.	O
M	O
.	O
Gallagher	O
,	O
J	O
.	O
Virol	O
.	O

However	O
,	O
the	O
MHV	O
receptor	O
is	O
not	O
present	O
in	O
lipid	B-COMP
rafts	I-COMP
,	O
and	O
anchoring	O
of	O
the	O
MHV	O
receptor	O
to	O
lipid	B-COMP
rafts	I-COMP
did	O
not	O
enhance	O
MHV	O
infection	O
;	O
thus	O
,	O
the	O
mechanism	O
of	O
lipid	B-COMP
rafts	I-COMP
involvement	O
is	O
not	O
clear	O
.	O

Thus	O
,	O
the	O
lipid	B-COMP
raft	I-COMP
involvement	O
in	O
MHV	O
entry	O
occurs	O
at	O
a	O
step	O
following	O
virus	O
binding	O
.	O

The	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
and	O
the	O
viral	O
RNA	O
were	O
also	O
detected	O
in	O
the	O
sera	B-COMP
by	O
ELISA	O
and	O
RT	O
-	O
PCR	O
,	O
respectively	O
.	O

RICT	O
with	O
several	O
pairs	O
of	O
MoAbs	O
showed	O
a	O
high	O
sensitivity	O
for	O
the	O
detection	O
of	O
recombinant	O
N	O
-	O
Ag	O
as	O
well	O
as	O
viral	O
N	O
-	O
Ag	O
of	O
SARS	O
-	O
CoV	O
.	O
rSN122	O
and	O
rSN21	O
-	O
2	O
were	O
the	O
best	O
MoAbs	O
for	O
immobilized	O
antibody	B-COMP
and	O
enzyme	O
labeling	O
,	O
respectively	O
.	O

Autoantibodies	O
against	O
cell	B-COMP
nuclei	I-COMP
(	O
ANA	O
),	O
autoantibodies	O
against	O
smooth	O
muscles	O
(	O
SMA	O
),	O
autoantibodies	O
against	O
parietal	O
cells	B-COMP
(	O
PCA	O
),	O
autoantibodies	O
against	O
heart	O
cells	B-COMP
(	O
HRA	O
)	O
were	O
detected	O
by	O
using	O
immunofluorescence	O
,	O
and	O
autoantibodies	O
against	O
live	O
-	O
kidney	O
microsomes	O
(	O
LKM	O
)	O
and	O
anti	O
-	O
M2	O
antibodies	B-COMP
were	O
detected	O
by	O
ELISA	O
in	O
sera	B-COMP
taken	O
from	O
27	O
SARS	O
patients	O
and	O
18	O
healthy	O
controls	O
.	O

ANA	O
,	O
AMA	O
,	O
LKM	O
and	O
SMA	O
were	O
found	O
positive	O
in	O
3	O
,	O
1	O
,	O
1	O
,	O
and	O
1	O
of	O
the	O
27	O
SARS	O
sera	B-COMP
.	O

The	O
positive	O
rate	O
of	O
patient	O
serum	B-COMP
and	O
mouthwash	O
was	O
33	O
.	O
6	O
%,	O
(	O
12	O
/	O
36	O
)	O
and	O
67	O
.	O
5	O
%,	O
(	O
27	O
/	O
40	O
),	O
respectively	O
,	O
while	O
the	O
positive	O
rate	O
of	O
healthy	O
people	O
was	O
zero	O
(	O
0	O
/	O
160	O
).	O

RESULTS	O
:	O
The	O
positive	O
rate	O
of	O
patient	O
serum	B-COMP
and	O
mouthwash	O
was	O
33	O
.	O
6	O
%,	O
(	O
12	O
/	O
36	O
)	O
and	O
67	O
.	O
5	O
%,	O
(	O
27	O
/	O
40	O
),	O
respectively	O
,	O
while	O
the	O
positive	O
rate	O
of	O
healthy	O
people	O
was	O
zero	O
(	O
0	O
/	O
160	O
).	O

TITLE	O
:	O
Autoantibodies	O
against	O
human	O
epithelial	O
cells	B-COMP
and	O
endothelial	O
cells	B-COMP
after	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
infection	O
.	O

In	O
this	O
study	O
,	O
the	O
development	O
of	O
autoantibodies	O
against	O
human	O
epithelial	O
cells	B-COMP
and	O
endothelial	O
cells	B-COMP
in	O
patients	O
with	O
SARS	O
at	O
different	O
time	O
periods	O
(	O
the	O
first	O
week	O
:	O
phase	O
I	O
,	O
1	O
month	O
after	O
the	O
disease	O
onset	O
:	O
phase	O
II	O
/	O
phase	O
III	O
)	O
were	O
investigated	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
the	O
predicted	O
FCoV	O
proteins	O
identified	O
16	O
replicase	O
proteins	O
(	O
nsp1	O
-	O
nsp16	O
)	O
and	O
four	O
structural	O
proteins	O
(	O
spike	O
,	O
membrane	B-COMP
,	O
envelope	B-COMP
and	O
nucleocapsid	B-COMP
).	O

VSV	O
-	O
SARS	O
-	O
St19	O
was	O
neutralized	O
by	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-COMP
and	O
soluble	O
ACE2	O
,	O
and	O
its	O
infection	O
was	O
blocked	O
by	O
treatment	O
of	O
Vero	O
E6	O
cells	B-COMP
with	O
anti	O
-	O
ACE2	O
antibody	B-COMP
.	O

TITLE	O
:	O
Excretion	O
and	O
detection	O
of	O
SARS	O
coronavirus	O
and	O
its	O
nucleic	B-COMP
acid	O
from	O
digestive	O
system	O
.	O

Results	O
showed	O
that	O
the	O
plasmid	O
-	O
derived	O
siRNAs	O
targeting	O
the	O
non	O
-	O
structural	O
protein	O
1	O
(	O
NSP1	O
)	O
sequence	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
could	O
specifically	O
inhibit	O
the	O
expression	O
of	O
the	O
NSP1	O
sequence	O
and	O
effectively	O
suppress	O
the	O
replication	O
and	O
propagation	O
of	O
SARS	O
-	O
CoV	O
in	O
cultured	O
Vero	O
E6	O
cell	B-COMP
lines	O
.	O

We	O
also	O
demonstrated	O
,	O
by	O
passive	O
antibody	B-COMP
transfer	O
,	O
that	O
the	O
antibody	B-COMP
response	O
induced	O
by	O
the	O
vaccine	O
was	O
sufficient	O
for	O
controlling	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
shown	O
that	O
3b	O
protein	O
was	O
predominately	O
localized	O
to	O
nucleus	B-COMP
with	O
EGFP	O
tag	O
at	O
its	O
N	O
-	O
or	O
C	O
-	O
terminus	O
.	O

The	O
localization	O
patterns	O
were	O
similar	O
in	O
different	O
transfected	O
cells	B-COMP
.	O

C23	O
,	O
B23	O
and	O
fibrillarin	O
all	O
are	O
important	O
nucleolar	O
proteins	O
,	O
which	O
localize	O
in	O
the	O
region	O
of	O
the	O
nucleolus	B-COMP
.	O

During	O
the	O
two	O
weeks	O
,	O
symptoms	O
and	O
adverse	O
effects	O
were	O
close	O
monitored	O
;	O
37	O
of	O
them	O
had	O
their	O
serum	B-COMP
checked	O
for	O
immunological	O
responses	O
.	O

We	O
hypothesized	O
that	O
SARS	O
-	O
CoV	O
encodes	O
a	O
small	O
envelope	B-COMP
E	O
protein	O
that	O
is	O
homologous	O
with	O
MHV	O
E	O
protein	O
,	O
thus	O
inducing	O
T	O
-	O
cell	B-COMP
apoptosis	O
.	O

In	O
this	O
study	O
,	O
infection	O
kinetics	O
(	O
titres	O
and	O
antigen	O
expression	O
)	O
of	O
FIPV	O
79	O
-	O
1146	O
,	O
and	O
FECV	O
79	O
-	O
1683	O
,	O
were	O
determined	O
in	O
peripheral	O
blood	O
monocytes	O
from	O
3	O
donor	O
cats	O
and	O
compared	O
to	O
those	O
in	O
Crandell	O
feline	O
kidney	O
(	O
CrFK	O
)	O
cells	B-COMP
.	O

The	O
infection	O
kinetics	O
in	O
monocytes	O
were	O
host	B-COMP
dependent	O
.	O

In	O
CrFK	O
cells	B-COMP
,	O
FIPV	O
and	O
FECV	O
infection	O
kinetics	O
did	O
not	O
differ	O
.	O

In	O
acute	O
lung	O
lesion	O
syndrome	O
(	O
ALLS	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
the	O
oxygenation	O
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
reflects	O
the	O
degree	O
of	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
damage	O
.	O

TITLE	O
:	O
Identification	O
of	O
immunodominant	O
epitopes	O
on	O
the	O
membrane	B-COMP
protein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Similar	O
to	O
other	O
coronaviruses	O
,	O
the	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
transmembrane	B-COMP
glycoprotein	O
with	O
multiple	O
biological	O
functions	O
.	O

TITLE	O
:	O
First	O
external	O
quality	O
assurance	O
of	O
antibody	B-COMP
diagnostic	O
for	O
SARS	O
-	O
new	O
coronavirus	O
.	O

This	O
review	O
therefore	O
summarizes	O
the	O
current	O
pathophysiological	O
concepts	O
underlying	O
the	O
evolution	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
and	O
focuses	O
on	O
:	O
(	O
1	O
)	O
possible	O
reasons	O
for	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	O
;	O
(	O
2	O
)	O
cellular	B-COMP
and	O
humoral	O
mediator	O
responses	O
leading	O
to	O
a	O
sustained	O
and	O
self	O
-	O
perpetuating	O
inflammation	O
of	O
the	O
lung	O
;	O
(	O
3	O
)	O
consequences	O
with	O
regard	O
to	O
fluid	O
balance	O
,	O
pulmonary	O
perfusion	O
,	O
ventilation	O
,	O
and	O
efficiency	O
of	O
gas	O
exchange	O
;	O
and	O
(	O
4	O
)	O
mechanisms	O
underlying	O
the	O
aggravating	O
complications	O
commonly	O
seen	O
in	O
ARDS	O
,	O
especially	O
ventilator	O
-	O
associated	O
lung	O
injury	O
,	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
and	O
lung	O
fibrosis	O
.	O

Cocultivation	O
of	O
PBMC	O
with	O
fixed	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	B-COMP
was	O
even	O
more	O
efficient	O
than	O
exposure	O
to	O
live	O
virus	O
in	O
eliciting	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
induction	O
.	O

A	O
combination	O
of	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
strongly	O
inhibited	O
SARS	O
-	O
CoV	O
replication	O
in	O
Vero	O
cells	B-COMP
,	O
while	O
the	O
single	O
cytokines	O
were	O
much	O
less	O
effective	O
.	O

Virus	O
replication	O
is	O
not	O
necessary	O
for	O
IFN	O
induction	O
since	O
efficient	O
IFN	O
expression	O
could	O
be	O
obtained	O
also	O
by	O
the	O
cocultivation	O
of	O
normal	O
PBMC	O
with	O
fixed	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
CD45	O
+,	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+,	O
CD19	O
+	O
and	O
CD16	O
+/	O
56	O
+	O
cell	B-COMP
counts	O
over	O
the	O
five	O
weeks	O
of	O
the	O
SARS	O
illness	O
although	O
CD4	O
+/	O
CD8	O
+	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O

Neutrophil	O
elastase	O
activities	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
serum	B-COMP
,	O
and	O
lung	O
tissue	O
were	O
all	O
significantly	O
lower	O
in	O
the	O
sivelestat	O
group	O
than	O
in	O
the	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
.	O
05	O
).	O

In	O
contrast	O
,	O
truncation	O
of	O
26	O
or	O
39	O
amino	O
acids	O
eliminating	O
either	O
one	O
or	O
both	O
of	O
the	O
two	O
endodomain	O
cysteine	O
-	O
rich	O
motifs	O
,	O
respectively	O
,	O
inhibited	O
cell	B-COMP
fusion	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
S	O
.	O
The	O
17	O
and	O
26	O
amino	O
-	O
acid	O
deletions	O
did	O
not	O
adversely	O
affect	O
S	O
cell	B-COMP
-	O
surface	O
expression	O
,	O
while	O
the	O
39	O
amino	O
-	O
acid	O
truncation	O
inhibited	O
S	O
cell	B-COMP
-	O
surface	O
expression	O
suggesting	O
that	O
the	O
membrane	B-COMP
proximal	O
cysteine	O
-	O
rich	O
motif	O
plays	O
an	O
essential	O
role	O
in	O
S	O
cell	B-COMP
-	O
surface	O
expression	O
.	O

This	O
genetic	O
analysis	O
reveals	O
that	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
contains	O
extracellular	B-COMP
domains	O
that	O
regulate	O
cell	B-COMP
fusion	O
as	O
well	O
as	O
distinct	O
endodomains	O
that	O
function	O
in	O
intracellular	B-COMP
transport	O
,	O
cell	B-COMP
-	O
surface	O
expression	O
,	O
and	O
cell	B-COMP
fusion	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
a	O
major	O
virion	B-COMP
structural	O
protein	O
.	O

These	O
findings	O
suggest	O
that	O
measurement	O
of	O
tissue	O
and	O
/	O
or	O
serum	B-COMP
levels	O
of	O
chemokines	O
during	O
reperfusion	O
may	O
be	O
an	O
important	O
adjunct	O
to	O
predicting	O
tissue	O
injury	O
along	O
with	O
ongoing	O
inflammation	O
during	O
the	O
clinical	O
course	O
of	O
reperfusion	O
injury	O
.	O

The	O
phosphoprotein	O
is	O
stable	O
and	O
localizes	O
in	O
the	O
cytoplasm	B-COMP
and	O
coprecipitates	O
with	O
the	O
membrane	B-COMP
fraction	O
.	O

Further	O
,	O
we	O
show	O
that	O
the	O
phosphorylated	O
protein	O
is	O
translocated	O
to	O
the	O
cytoplasm	B-COMP
by	O
binding	O
to	O
14	O
-	O
3	O
-	O
3	O
(	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
).	O

Coincidentally	O
,	O
the	O
N	O
protein	O
was	O
also	O
found	O
to	O
downregulate	O
the	O
expression	O
of	O
the	O
theta	O
isoform	O
of	O
14	O
-	O
3	O
-	O
3	O
(	O
14	O
-	O
3	O
-	O
3theta	O
),	O
leading	O
to	O
the	O
accumulation	O
of	O
phosphorylated	O
N	O
protein	O
in	O
the	O
nucleus	B-COMP
,	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

ABSTRACT	O
:	O
The	O
association	O
between	O
a	O
robust	O
or	O
depressed	O
antibody	B-COMP
response	O
and	O
clinical	O
severity	O
of	O
SARS	O
remains	O
unknown	O
.	O

The	O
kit	O
was	O
able	O
to	O
specifically	O
detect	O
SARS	O
-	O
CoV	O
N	O
proteins	O
in	O
serum	B-COMP
samples	O
.	O

Sinigrin	O
(	O
IC50	O
:	O
217	O
microM	O
)	O
was	O
more	O
efficient	O
in	O
blocking	O
the	O
cleavage	O
processing	O
of	O
the	O
3CLpro	O
than	O
indigo	O
(	O
IC50	O
:	O
752	O
microM	O
)	O
and	O
beta	O
-	O
sitosterol	O
(	O
IC50	O
:	O
1210	O
microM	O
)	O
in	O
the	O
cell	B-COMP
-	O
based	O
assay	O
.	O

Likewise	O
,	O
elastase	O
,	O
a	O
major	O
protease	O
produced	O
in	O
the	O
lungs	O
during	O
inflammation	O
,	O
also	O
enhanced	O
SARS	O
-	O
CoV	O
infection	O
in	O
cultured	O
cells	B-COMP
.	O

The	O
denatured	O
inclusion	B-COMP
bodies	I-COMP
were	O
purified	O
with	O
Ni	O
-	O
NTA	O
chelate	O
agarose	O
and	O
its	O
purity	O
can	O
reach	O
90	O
%.	O

ABSTRACT	O
:	O
A	O
seroepidemiologic	O
study	O
was	O
conducted	O
in	O
North	O
China	O
in	O
2003	O
to	O
determine	O
the	O
neutralizing	O
antibody	B-COMP
titer	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
convalescent	O
sera	B-COMP
.	O

To	O
detect	O
early	O
SARS	O
-	O
CoV	O
infection	O
,	O
a	O
one	O
-	O
step	O
,	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
that	O
could	O
simultaneously	O
detect	O
nucleocapsid	B-COMP
(	O
N	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
spike	O
(	O
S	O
)	O
genes	O
of	O
SARS	O
-	O
CoV	O
with	O
the	O
same	O
PCR	O
condition	O
using	O
either	O
Applied	O
Biosystems	O
(	O
ABI	O
)	O
Prism	O
7700	O
Sequence	O
Detection	O
System	O
or	O
Roche	O
LightCycler	O
.	O

TITLE	O
:	O
Replication	O
of	O
respiratory	O
viruses	O
,	O
particularly	O
influenza	O
virus	O
,	O
rhinovirus	O
,	O
and	O
coronavirus	O
in	O
HuH7	O
hepatocarcinoma	O
cell	B-COMP
line	O
.	O

The	O
objective	O
was	O
to	O
determine	O
the	O
ability	O
of	O
HuH7	O
cells	B-COMP
to	O
support	O
the	O
replication	O
of	O
prototype	O
and	O
wild	O
strains	O
of	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
The	O
entry	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SCV	O
)	O
into	O
cells	B-COMP
is	O
initiated	O
by	O
binding	O
of	O
its	O
spike	O
envelope	B-COMP
glycoprotein	O
(	O
S	O
)	O
to	O
a	O
receptor	O
,	O
ACE2	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
current	O
status	O
of	O
the	O
main	O
technologies	O
used	O
to	O
produce	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
from	O
the	O
B	O
cells	B-COMP
of	O
antigen	O
-	O
sensitized	O
animals	O
.	O

The	O
expression	O
of	O
haPrP	O
protein	O
reduced	O
to	O
21	O
.	O
8	O
%	O
in	O
the	O
preparation	O
of	O
Sf9	O
cells	B-COMP
infected	O
with	O
recombinant	O
baculovirus	O
exposed	O
for	O
5	O
min	O
and	O
was	O
undetectable	O
exposed	O
for	O
20	O
min	O
.	O

TITLE	O
:	O
Characterization	O
of	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
recognizing	O
a	O
15	O
-	O
residues	O
epitope	O
on	O
the	O
spike	O
protein	O
HR2	O
region	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Adaptation	O
of	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
from	O
chicken	O
embryo	O
to	O
Vero	O
cells	B-COMP
showed	O
the	O
accumulation	O
of	O
49	O
amino	O
acid	O
mutations	O
.	O

The	O
genus	O
Torovirus	O
,	O
within	O
the	O
family	O
Coronaviridae	O
,	O
is	O
less	O
well	O
characterized	O
,	O
in	O
part	O
because	O
toroviruses	O
cannot	O
yet	O
be	O
grown	O
in	O
cell	B-COMP
culture	O
(	O
except	O
for	O
the	O
Berne	O
virus	O
).	O

Within	O
the	O
pp1b	O
sequence	O
the	O
polymerase	O
and	O
helicase	O
domains	O
were	O
identified	O
,	O
as	O
well	O
as	O
sequences	O
predicted	O
to	O
be	O
involved	O
in	O
ribosomal	B-COMP
frameshifting	O
,	O
including	O
the	O
conserved	O
slippery	O
sequence	O
UUUAAAC	O
and	O
two	O
potential	O
pseudoknot	O
structures	O
.	O

Our	O
results	O
showed	O
that	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
can	O
significantly	O
activate	O
NF	O
-	O
kappaB	O
only	O
in	O
Vero	O
E6	O
cells	B-COMP
,	O
which	O
are	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
but	O
not	O
in	O
Vero	O
or	O
HeLa	O
cells	B-COMP
.	O

Our	O
objective	O
was	O
to	O
study	O
the	O
outcome	O
of	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
HSCT	O
)	O
for	O
Shwachman	O
-	O
Diamond	O
Syndrome	O
(	O
SDS	O
).	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
linear	O
B	O
-	O
cell	B-COMP
epitopes	O
and	O
entry	O
-	O
blocking	O
peptide	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
using	O
synthetic	O
overlapping	O
peptide	O
library	O
.	O

Further	O
study	O
revealed	O
that	O
the	O
activity	O
of	O
the	O
NADH	O
-	O
cytochrome	O
was	O
altered	O
and	O
the	O
inner	B-COMP
mitochondrial	I-COMP
membrane	I-COMP
was	O
depolarized	O
in	O
the	O
transfected	O
human	O
embryo	O
lung	O
fibroblast	O
by	O
the	O
nsp10	O
protein	O
gene	O
.	O

The	O
cytopathic	O
effect	O
of	O
the	O
Coronavirus	O
229E	O
strain	O
appeared	O
more	O
extensive	O
in	O
these	O
cells	B-COMP
than	O
in	O
the	O
control	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Beginning	O
in	O
the	O
1950s	O
respiratory	O
viruses	O
have	O
been	O
gradually	O
discovered	O
by	O
isolation	O
in	O
cell	B-COMP
cultures	O
The	O
last	O
were	O
the	O
coronaviruses	O
in	O
the	O
1960s	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
later	O
health	O
status	O
of	O
newborn	O
infants	O
who	O
received	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
acute	O
respiratory	O
failure	O
in	O
the	O
era	O
after	O
the	O
UK	O
ECMO	O
trial	O
.	O

ABSTRACT	O
:	O
More	O
often	O
we	O
are	O
faced	O
with	O
the	O
cases	O
of	O
young	O
people	O
(	O
who	O
are	O
in	O
a	O
serious	O
condition	O
)	O
who	O
land	B-COMP
in	O
ICU	O
,	O
because	O
of	O
severe	O
narcotics	O
intoxication	O
,	O
which	O
they	O
took	O
occasionally	O
on	O
the	O
concerts	O
,	O
discotheques	O
and	O
social	O
events	O
.	O

TITLE	O
:	O
T	O
-	O
Cell	B-COMP
response	O
profiling	O
to	O
biological	O
threat	O
agents	O
including	O
the	O
SARS	O
coronavirus	O
.	O

The	O
T	O
cell	B-COMP
array	O
is	O
an	O
early	O
and	O
sensitive	O
multiplex	O
measure	O
of	O
active	O
infection	O
,	O
exposure	O
to	O
a	O
pathogen	O
,	O
or	O
effective	O
,	O
recent	O
vaccination	O
.	O

TITLE	O
:	O
False	O
positive	O
antibody	B-COMP
results	O
against	O
human	O
T	O
-	O
cell	B-COMP
lymphotropic	O
virus	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ELISA	O
and	O
a	O
neutralization	O
test	O
were	O
used	O
to	O
measure	O
anti	O
-	O
SARS	O
antibodies	B-COMP
.	O

Surprisingly	O
,	O
with	O
the	O
use	O
of	O
ELISA	O
for	O
HTLV	O
,	O
sera	B-COMP
for	O
13	O
patients	O
were	O
positive	O
for	O
HTLV	O
(	O
50	O
%),	O
and	O
seroconversion	O
for	O
HTLV	O
was	O
also	O
observed	O
in	O
10	O
patients	O
(	O
38	O
.	O
5	O
%).	O

TITLE	O
:	O
[	O
Expression	O
of	O
the	O
recombinant	O
SARS	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
in	O
Pichia	O
pastoris	O
and	O
identification	O
of	O
its	O
bioactivity	O
].	O

TITLE	O
:	O
Role	O
of	O
vascular	O
cell	B-COMP
adhesion	O
molecules	O
and	O
leukocyte	O
apoptosis	O
in	O
the	O
lymphopenia	O
and	O
thrombocytopenia	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

However	O
,	O
lymphopenia	O
may	O
be	O
due	O
to	O
enhanced	O
cell	B-COMP
death	O
.	O

Donors	O
were	O
blood	O
type	O
O	O
and	O
seronegative	O
for	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
syphilis	O
and	O
human	O
T	O
-	O
cell	B-COMP
lymphotropic	O
virus	O
types	O
I	O
and	O
II	O
(	O
HTLV	O
-	O
I	O
and	O
-	O
II	O
).	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-COMP
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
produced	O
in	O
vitro	O
using	O
specific	O
pathogen	O
free	O
chicken	O
embryos	O
,	O
primary	O
chicken	O
kidney	O
cells	B-COMP
(	O
CKC	O
)	O
and	O
/	O
or	O
tracheal	O
organ	O
culture	O
(	O
TOC	O
).	O

In	O
this	O
paper	O
,	O
a	O
stable	O
chicken	O
embryo	O
-	O
related	O
(	O
CER	O
)	O
cell	B-COMP
line	O
was	O
adapted	O
and	O
maintained	O
in	O
serum	B-COMP
free	O
(	O
SF	O
)	O
or	O
animal	O
protein	O
free	O
(	O
APF	O
)	O
medium	O
after	O
a	O
direct	O
switch	O
of	O
the	O
medium	O
.	O

Using	O
the	O
exon	O
splicing	O
enhancers	O
,	O
including	O
a	O
bidirectional	O
splicing	O
enhancer	O
(	O
BSE	O
)	O
or	O
an	O
exon	O
splicing	O
enhancer	O
derived	O
from	O
the	O
EDA	O
alternative	O
exon	O
of	O
the	O
fibronectin	O
gene	O
(	O
EDA	O
ESE	O
),	O
were	O
also	O
found	O
to	O
increase	O
STR2	O
protein	O
expression	O
in	O
CHO	O
/	O
dhFr	O
-	O
cells	B-COMP
by	O
1	O
.	O
7	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
.	O

However	O
,	O
only	O
a	O
minor	O
form	O
of	O
the	O
Endo	O
H	O
-	O
resistant	O
glycoproteins	O
(	O
approximately	O
130	O
kDa	O
)	O
was	O
detected	O
in	O
CHO	O
/	O
dhFr	O
-	O
cells	B-COMP
.	O

Serological	O
examination	O
of	O
the	O
mice	O
transplanted	O
with	O
tumours	O
as	O
well	O
as	O
their	O
cage	O
mates	O
in	O
the	O
quarantine	O
colony	O
did	O
not	O
detect	O
any	O
antibodies	B-COMP
against	O
MHV	O
.	O

ABSTRACT	O
:	O
To	O
clone	O
and	O
express	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
,	O
and	O
to	O
evaluate	O
its	O
antigenicity	O
and	O
application	O
value	O
in	O
the	O
development	O
of	O
serological	O
diagnostic	O
test	O
for	O
SARS	O
.	O

TITLE	O
:	O
Enhanced	O
expression	O
and	O
purification	O
of	O
membrane	B-COMP
proteins	O
by	O
SUMO	O
fusion	O
in	O
Escherichia	O
coli	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
FLAP	O
and	O
SARS	O
-	O
CoV	O
membrane	B-COMP
proteins	O
are	O
greatly	O
enhanced	O
by	O
SUMO	O
fusions	O
in	O
E	O
.	O
coli	O
.	O

ABSTRACT	O
:	O
Concanavalin	O
A	O
-	O
Sandwich	O
ELISA	O
(	O
Con	O
A	O
-	O
S	O
-	O
ELISA	O
)	O
was	O
developed	O
for	O
the	O
detection	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
or	O
chicken	O
specific	O
anti	O
-	O
viral	O
antibodies	B-COMP
.	O

Thus	O
,	O
the	O
Con	O
A	O
-	O
S	O
-	O
ELISA	O
proved	O
to	O
be	O
able	O
to	O
detect	O
alternatively	O
homologous	O
and	O
heterologous	O
IBV	O
strains	O
or	O
specific	O
chicken	O
anti	O
-	O
IBV	O
antibodies	B-COMP
,	O
using	O
the	O
Con	O
A	O
as	O
capture	O
reagent	O
of	O
this	O
assay	O
.	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	O
to	O
protein	O
X4	O
expressed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

These	O
studies	O
showed	O
that	O
SARS	O
-	O
CoV	O
Vero	O
E6	O
cell	B-COMP
lysates	O
for	O
the	O
ELISA	O
to	O
detect	O
SARS	O
-	O
CoV	O
antibodies	B-COMP
could	O
lead	O
to	O
the	O
false	O
-	O
positive	O
reactions	O
or	O
cross	O
-	O
reactions	O
of	O
SARS	O
-	O
CoV	O
antibodies	B-COMP
in	O
non	O
-	O
SARS	O
diseases	O
and	O
healthy	O
controls	O
,	O
and	O
the	O
false	O
-	O
positive	O
reactions	O
or	O
cross	O
-	O
reactions	O
were	O
related	O
to	O
Vero	O
E6	O
cell	B-COMP
lysates	O
and	O
autoantibodies	O
in	O
non	O
-	O
SARS	O
population	O
.	O

TITLE	O
:	O
Binding	O
interaction	O
of	O
SARS	O
coronavirus	O
3CL	O
(	O
pro	O
)	O
protease	O
with	O
vacuolar	B-COMP
-	O
H	O
+	O
ATPase	O
G1	O
subunit	O
.	O

TITLE	O
:	O
A	O
major	O
determinant	O
for	O
membrane	B-COMP
protein	O
interaction	O
localizes	O
to	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
mouse	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

The	O
M	O
protein	O
is	O
anchored	O
in	O
the	O
viral	B-COMP
envelope	I-COMP
by	O
three	O
transmembrane	B-COMP
segments	O
flanked	O
by	O
a	O
short	O
amino	O
-	O
terminal	O
ectodomain	O
and	O
a	O
large	O
carboxy	O
-	O
terminal	O
endodomain	O
.	O

These	O
results	O
demonstrate	O
that	O
while	O
nsp2	O
of	O
MHV	O
and	O
SARS	O
-	O
CoV	O
is	O
dispensable	O
for	O
viral	O
replication	O
in	O
cell	B-COMP
culture	O
,	O
deletion	O
of	O
the	O
nsp2	O
coding	O
sequence	O
attenuates	O
viral	O
growth	O
and	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
fails	O
to	O
activate	O
cytokine	O
-	O
mediated	O
innate	O
immune	O
responses	O
in	O
cultured	O
human	O
monocyte	O
-	O
derived	O
dendritic	B-COMP
cells	B-COMP
.	O

Our	O
data	O
strongly	O
suggest	O
that	O
SCV	O
fails	O
to	O
activate	O
host	B-COMP
cell	I-COMP
cytokine	O
gene	O
expression	O
in	O
human	O
macrophages	O
and	O
DCs	O
.	O

368	O
clinical	O
specimens	O
such	O
as	O
the	O
throat	O
swab	O
,	O
serum	B-COMP
,	O
feces	O
,	O
and	O
urine	O
from	O
different	O
cases	O
,	O
52	O
cell	B-COMP
cultures	O
and	O
50	O
animal	O
specimens	O
were	O
detected	O
by	O
the	O
molecular	O
beacon	O
-	O
based	O
PCR	O
.	O

All	O
SARS	O
testes	O
displayed	O
widespread	O
germ	O
cell	B-COMP
destruction	O
,	O
few	O
or	O
no	O
spermatozoon	O
in	O
the	O
seminiferous	O
tubule	O
,	O
thickened	O
basement	B-COMP
membrane	I-COMP
,	O
and	O
leukocyte	O
infiltration	O
.	O

Identification	O
of	O
patients	O
with	O
cellular	B-COMP
phenotypes	O
characterized	O
by	O
increased	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
Akt	O
,	O
and	O
protein	O
38	O
,	O
as	O
well	O
as	O
discrete	O
patterns	O
of	O
gene	O
activation	O
,	O
may	O
permit	O
identification	O
of	O
patients	O
with	O
sepsis	O
who	O
are	O
likely	O
to	O
have	O
a	O
worse	O
clinical	O
outcome	O
,	O
thereby	O
permitting	O
early	O
institution	O
of	O
therapies	O
that	O
modulate	O
deleterious	O
signaling	O
pathways	O
before	O
organ	O
system	O
dysfunction	O
develops	O
,	O
reducing	O
morbidity	O
and	O
improving	O
survival	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
of	O
severe	O
complications	O
,	O
such	O
as	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
in	O
malignant	O
lymphoma	O
,	O
differs	O
between	O
clinical	O
stages	O
and	O
histological	O
types	O
of	O
the	O
disease	O
,	O
but	O
they	O
occur	O
frequently	O
in	O
stage	O
IV	O
or	O
natural	O
killer	O
(	O
NK	O
)	O
cell	B-COMP
lymphoma	O
.	O

The	O
expressed	O
S1	O
protein	O
of	O
CCV	O
,	O
which	O
was	O
identified	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
can	O
be	O
specifically	O
recognized	O
by	O
polyclonal	O
antibody	B-COMP
against	O
CCV	O
.	O

The	O
SARS	O
-	O
CoV	O
VLPs	O
thus	O
produced	O
were	O
designated	O
VLP	B-COMP
(	O
GFP	O
-	O
PS580	O
).	O

Nevertheless	O
,	O
when	O
Vero	O
E6	O
cells	B-COMP
were	O
infected	O
with	O
VLPs	O
produced	O
in	O
the	O
absence	O
of	O
the	O
viral	O
N	O
protein	O
,	O
no	O
green	O
fluorescence	O
was	O
visualized	O
.	O

Whereas	O
the	O
low	O
-	O
virulence	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
isolates	O
primarily	O
replicate	O
in	O
the	O
epithelial	O
cells	B-COMP
of	O
the	O
enteric	O
tract	O
,	O
highly	O
virulent	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
isolates	O
have	O
acquired	O
the	O
ability	O
to	O
replicate	O
efficiently	O
in	O
macrophages	O
,	O
which	O
allows	O
rapid	O
dissemination	O
of	O
the	O
virulent	O
virus	O
throughout	O
the	O
body	O
.	O

Similarly	O
,	O
the	O
sera	B-COMP
of	O
immunized	O
mice	O
could	O
also	O
react	O
specifically	O
with	O
SARS	O
-	O
CoV	O
particles	O
.	O

Among	O
which	O
,	O
one	O
monkey	O
showed	O
part	O
of	O
thickened	O
septum	B-COMP
fused	O
with	O
each	O
other	O
.	O

RESULTS	O
:	O
No	O
statistically	O
significant	O
difference	O
in	O
serum	B-COMP
SARS	O
IgG	B-COMP
antibody	I-COMP
positive	O
rate	O
was	O
found	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
among	O
2	O
,	O
757	O
serum	B-COMP
samples	O
.	O

TITLE	O
:	O
[	O
Cloning	O
of	O
ACE	O
-	O
2	O
gene	O
encoding	O
the	O
functional	O
receptor	O
for	O
the	O
SARS	O
coronavirus	O
and	O
its	O
expression	O
in	O
eukaryotic	O
cells	B-COMP
].	O

This	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-COMP
.	O

Fusion	O
proteins	O
with	O
relative	O
molecular	O
mass	O
of	O
26	O
,	O
700	O
,	O
22	O
,	O
500	O
and	O
46	O
,	O
000	O
dalton	O
were	O
successfully	O
expressed	O
with	O
amounts	O
of	O
35	O
%,	O
35	O
%	O
and	O
30	O
%	O
of	O
total	O
cell	B-COMP
protein	O
and	O
purified	O
by	O
Ni	O
affinity	O
chromatography	O
,	O
respectively	O
.	O

Western	O
Blot	O
and	O
ELISA	O
analysis	O
showed	O
that	O
the	O
S1c	O
protein	O
could	O
be	O
specifically	O
recognized	O
by	O
the	O
sera	B-COMP
from	O
SARS	O
patients	O
.	O

However	O
,	O
the	O
pathophysiological	O
significance	O
of	O
the	O
anti	O
-	O
N	O
antibodies	B-COMP
in	O
SARS	O
pathogenesis	O
is	O
largely	O
unknown	O
.	O

Specific	O
anti	O
-	O
N	O
scFvs	O
were	O
isolated	O
by	O
panning	O
against	O
a	O
recombinant	O
nucleocapsid	B-COMP
protein	O
and	O
reactivity	O
was	O
confirmed	O
with	O
phage	O
-	O
ELISA	O
.	O

The	O
SARS	O
-	O
CoV	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
was	O
almost	O
completely	O
down	O
regulated	O
from	O
the	O
cell	B-COMP
surface	I-COMP
of	O
persistently	O
infected	O
cells	B-COMP
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
develop	O
a	O
rapid	O
immunoturbidimetric	O
assay	O
for	O
measurement	O
of	O
AGP	O
in	O
feline	O
serum	B-COMP
and	O
peritoneal	O
fluid	O
and	O
to	O
compare	O
the	O
results	O
with	O
those	O
obtained	O
by	O
RID	O
.	O

AGP	O
was	O
purified	O
by	O
perchloric	O
acid	O
precipitation	O
and	O
ion	O
-	O
exchange	O
chromatography	O
from	O
a	O
pool	O
of	O
peritoneal	O
fluid	O
obtained	O
from	O
cats	O
with	O
FIP	O
,	O
as	O
determined	O
by	O
a	O
panel	O
of	O
laboratory	O
tests	O
,	O
including	O
serum	B-COMP
AGP	O
concentration	O
,	O
albumin	O
:	O
globulin	O
ratio	O
,	O
and	O
total	O
protein	O
concentration	O
,	O
anti	O
-	O
coronavirus	O
antibody	B-COMP
titers	O
,	O
and	O
effusion	O
analysis	O
.	O

Significant	O
correlation	O
(	O
P	O
<	O
.	O
001	O
)	O
was	O
obtained	O
between	O
methods	O
for	O
both	O
peritoneal	O
fluid	O
(	O
R2	O
=.	O
9259	O
)	O
and	O
serum	B-COMP
(	O
R2	O
=.	O
9448	O
)	O
samples	O
.	O

This	O
rapid	O
immunoturbidimetric	O
assay	O
for	O
measurement	O
of	O
feline	O
AGP	O
in	O
serum	B-COMP
and	O
peritoneal	O
fluid	O
may	O
be	O
of	O
value	O
in	O
the	O
diagnosis	O
of	O
FIP	O
and	O
possibly	O
other	O
inflammatory	O
diseases	O
in	O
cats	O
.	O

ABSTRACT	O
:	O
We	O
critically	O
reviewed	O
published	O
English	O
language	O
literature	O
and	O
concluded	O
that	O
from	O
1998	O
onward	O
the	O
survival	O
of	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
(	O
SCT	O
)	O
patients	O
who	O
experienced	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
transfer	O
has	O
improved	O
.	O

This	O
encouraging	O
outcome	O
trend	O
reflects	O
evolving	O
advances	O
such	O
as	O
use	O
of	O
recombinant	O
hematopoietic	O
growth	O
factors	O
,	O
use	O
of	O
mobilized	O
blood	O
cells	B-COMP
rather	O
than	O
marrow	O
,	O
protective	O
strategies	O
for	O
acute	O
lung	O
injury	O
and	O
early	O
goal	O
-	O
directed	O
therapy	O
for	O
sepsis	O
syndrome	O
.	O

RBD	O
of	O
SARS	O
-	O
Cov	O
spike	O
protein	O
was	O
expressed	O
as	O
inclusion	B-COMP
body	I-COMP
when	O
fused	O
as	O
TrxA	O
tag	O
form	O
in	O
both	O
BL21	O
(	O
DE3	O
)	O
and	O
Rosetta	O
-	O
gamiB	O
(	O
DE3	O
)	O
under	O
many	O
different	O
cultures	O
and	O
induction	O
conditions	O
.	O

The	O
geometrical	O
mean	O
of	O
GST	O
and	O
GST	O
/	O
RBD	O
binding	O
to	O
Vero	O
E6	O
cells	B-COMP
were	O
77	O
.	O
08	O
and	O
352	O
.	O
73	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
serological	O
response	O
profile	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
infection	O
was	O
defined	O
by	O
neutralization	O
tests	O
and	O
subclass	O
-	O
specific	O
immunofluorescent	O
(	O
IF	O
)	O
tests	O
using	O
serial	O
sera	B-COMP
from	O
20	O
patients	O
.	O

In	O
contrast	O
,	O
neutralizing	O
antibody	B-COMP
and	O
SARS	O
CoV	O
IgGAM	O
and	O
IgG	B-COMP
antibody	I-COMP
titers	O
remained	O
stable	O
over	O
this	O
period	O
.	O

Two	O
HLA	O
-	O
A2	O
hot	O
-	O
spots	O
in	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	B-COMP
protein	O
were	O
predicted	O
by	O
using	O
MULTIPRED	O
.	O

Deletion	O
of	O
the	O
group	O
-	O
specific	O
ORFs	O
of	O
SARS	O
-	O
CoV	O
,	O
either	O
alone	O
or	O
in	O
various	O
combinations	O
,	O
did	O
not	O
dramatically	O
influence	O
replication	O
efficiency	O
in	O
cell	B-COMP
culture	O
or	O
in	O
the	O
levels	O
of	O
viral	O
RNA	O
synthesis	O
.	O

Deletion	O
of	O
ORF3a	O
did	O
not	O
alter	O
subcellular	O
localization	O
of	O
the	O
S	O
glycoprotein	O
from	O
distinct	O
punctuate	O
localization	O
in	O
the	O
rER	B-COMP
/	O
Golgi	B-COMP
apparatus	I-COMP
.	O

TITLE	O
:	O
SR	O
-	O
rich	O
motif	O
plays	O
a	O
pivotal	O
role	O
in	O
recombinant	O
SARS	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
multimerization	O
.	O

TITLE	O
:	O
Comparison	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
with	O
serum	B-COMP
neutralization	O
test	O
for	O
serodiagnosis	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
.	O

The	O
presence	O
of	O
antibodies	B-COMP
in	O
these	O
experimental	O
samples	O
was	O
confirmed	O
by	O
SN	O
and	O
ELISA	O
in	O
which	O
the	O
sensitivity	O
of	O
the	O
ELISA	O
was	O
89	O
.	O
1	O
%,	O
and	O
the	O
corresponding	O
specificity	O
was	O
94	O
.	O
5	O
%.	O

Six	O
health	O
horses	O
were	O
immunized	O
4	O
times	O
and	O
serum	B-COMP
was	O
collected	O
periodically	O
to	O
measure	O
the	O
profile	O
of	O
specific	O
IgG	O
and	O
neutralizing	O
antibodies	B-COMP
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
a	O
microneutralization	O
test	O
.	O

Treatment	O
did	O
not	O
alter	O
accumulation	O
of	O
T	O
cells	B-COMP
or	O
macrophages	O
within	O
the	O
CNS	O
as	O
compared	O
to	O
control	O
mice	O
.	O

TITLE	O
:	O
Differential	O
localization	O
and	O
turnover	O
of	O
infectious	O
bronchitis	O
virus	O
3b	O
protein	O
in	O
mammalian	O
versus	O
avian	O
cells	B-COMP
.	O

A	O
proteasome	O
inhibitor	O
stabilized	O
IBV	O
3b	O
in	O
mammalian	O
cells	B-COMP
,	O
but	O
had	O
little	O
effect	O
on	O
IBV	O
3b	O
in	O
avian	O
cells	B-COMP
,	O
suggesting	O
that	O
rapid	O
turnover	O
of	O
IBV	O
3b	O
in	O
mammalian	O
cells	B-COMP
is	O
proteasome	O
-	O
dependent	O
while	O
turnover	O
in	O
avian	O
cells	B-COMP
may	O
be	O
proteasome	O
-	O
independent	O
.	O

ABSTRACT	O
:	O
Rituximab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	B-COMP
approved	O
for	O
malignant	O
lymphoma	O
,	O
is	O
being	O
increasingly	O
,	O
effectively	O
,	O
and	O
safely	O
used	O
for	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
and	O
other	O
humoral	O
autoimmune	O
disorders	O
.	O

In	O
infected	O
cells	B-COMP
,	O
SARS	O
-	O
CoV	O
N	O
protein	O
localized	O
exclusively	O
to	O
the	O
cytoplasm	B-COMP
.	O

In	O
contrast	O
to	O
the	O
avian	O
coronavirus	O
N	O
protein	O
,	O
overexpressed	O
SARS	O
-	O
CoV	O
N	O
protein	O
remained	O
principally	O
localized	O
to	O
the	O
cytoplasm	B-COMP
,	O
with	O
very	O
few	O
cells	B-COMP
exhibiting	O
nucleolar	O
localization	O
.	O

Previously	O
,	O
the	O
differences	O
between	O
virulent	O
field	O
PEDV	O
strains	O
and	O
a	O
Vero	O
cell	B-COMP
culture	O
adapted	O
PEDV	O
DR13	O
strain	O
were	O
determined	O
using	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
(	O
RFLP	O
),	O
and	O
PEDV	O
shedding	O
patterns	O
in	O
pigs	O
were	O
reported	O
.	O

Here	O
,	O
we	O
observed	O
that	O
transient	O
expression	O
of	O
ORF7a	O
protein	O
fused	O
with	O
myc	O
or	O
GFP	O
tags	O
at	O
its	O
N	O
or	O
C	O
terminus	O
inhibited	O
cell	B-COMP
growth	O
and	O
prevented	O
BrdU	O
incorporation	O
in	O
different	O
cultural	O
cells	B-COMP
,	O
suggesting	O
that	O
ORF7a	O
expression	O
may	O
regulate	O
cell	B-COMP
cycle	O
progression	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
properties	O
of	O
S	O
receptor	O
utilization	O
and	O
/	O
or	O
fusogenicity	O
mainly	O
determine	O
organ	O
and	O
host	B-COMP
cell	I-COMP
tropism	O
but	O
that	O
HE	O
enhances	O
the	O
efficiency	O
of	O
infection	O
and	O
promotes	O
viral	O
dissemination	O
,	O
at	O
least	O
in	O
some	O
tissues	O
,	O
presumably	O
by	O
serving	O
as	O
a	O
second	O
receptor	O
-	O
binding	O
protein	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
this	O
cellular	B-COMP
receptor	O
(	O
soR	O
)	O
is	O
sufficient	O
for	O
S	O
binding	O
and	O
for	O
subsequent	O
induction	O
of	O
the	O
conformational	O
changes	O
required	O
for	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
.	O

To	O
this	O
end	O
,	O
the	O
soR	O
domain	O
was	O
coupled	O
to	O
single	O
-	O
chain	O
monoclonal	O
antibody	B-COMP
425	O
,	O
which	O
is	O
directed	O
against	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
),	O
resulting	O
in	O
a	O
bispecific	O
adapter	O
protein	O
(	O
soR	O
-	O
425	O
).	O

SARS	O
-	O
CoV	O
GFP	O
replicated	O
to	O
titers	O
similar	O
to	O
those	O
of	O
wild	O
-	O
type	O
viruses	O
in	O
cell	B-COMP
lines	O
.	O

Infection	O
was	O
highly	O
cytolytic	O
,	O
as	O
infected	O
ciliated	O
cells	B-COMP
were	O
necrotic	O
and	O
shed	O
over	O
time	O
onto	O
the	O
luminal	O
surface	O
of	O
the	O
epithelium	O
.	O

However	O
,	O
a	O
real	O
-	O
time	O
-	O
imaging	O
analysis	O
of	O
Simian	O
virus	O
40	O
(	O
SV40	O
)	O
'	O
s	O
entry	O
in	O
cells	B-COMP
has	O
indicated	O
the	O
existence	O
of	O
caveolar	O
endocytosis	O
during	O
virus	O
entry	O
.	O

SV40	O
enclosed	O
in	O
caveolae	B-COMP
vesicles	B-COMP
move	O
to	O
the	O
caveosome	O
,	O
then	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
.	O

Single	O
crown	B-COMP
-	O
like	O
virion	B-COMP
was	O
directly	O
visualized	O
and	O
quantitative	O
measurements	O
of	O
the	O
dimensions	O
for	O
the	O
structural	O
proteins	O
were	O
provided	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
devastating	O
disease	O
process	O
characterized	O
by	O
severe	O
acute	O
lung	O
injury	O
,	O
inflammatory	O
cell	B-COMP
recruitment	O
to	O
the	O
lung	O
,	O
upregulation	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
increased	O
oxidative	O
stress	O
.	O

Expression	O
of	O
SARS	O
6	O
protein	O
in	O
mammalian	O
cells	B-COMP
elicits	O
biological	O
activity	O
of	O
stimulating	O
cellular	B-COMP
DNA	O
synthesis	O
.	O

Elevated	O
levels	O
of	O
lactate	O
in	O
brain	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
,	O
abnormal	O
urine	O
organic	O
acids	O
,	O
and	O
changes	O
in	O
muscle	O
respiratory	B-COMP
chain	I-COMP
enzymes	O
are	O
present	O
but	O
inconsistent	O
,	O
without	O
identifiable	O
mitochondrial	B-COMP
DNA	I-COMP
mutations	O
or	O
deletions	O
.	O

With	O
a	O
linear	O
mixed	O
model	O
,	O
neutralizing	O
antibody	B-COMP
titer	O
was	O
shown	O
to	O
peak	O
between	O
week	O
5	O
and	O
week	O
8	O
after	O
onset	O
and	O
to	O
decline	O
thereafter	O
,	O
with	O
a	O
half	O
-	O
life	O
of	O
6	O
.	O
4	O
weeks	O
.	O

Yolk	B-COMP
immunoglobulin	O
(	O
IgY	O
)	O
was	O
extracted	O
using	O
the	O
water	O
dilution	O
method	O
,	O
followed	O
by	O
further	O
purification	O
on	O
a	O
Sephadex	O
G	O
-	O
75	O
column	O
.	O

We	O
set	O
out	O
to	O
determine	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
soluble	O
ectodomain	O
of	O
this	O
type	O
-	O
I	O
transmembrane	B-COMP
protein	O
by	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	B-COMP
protein	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
:	O
crystal	O
structure	O
of	O
its	O
N	O
-	O
terminal	O
domain	O
and	O
multimerization	O
properties	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
packages	O
viral	O
genomic	O
RNA	O
into	O
a	O
ribonucleoprotein	B-COMP
complex	I-COMP
.	O

The	O
IgG	B-COMP
antibody	I-COMP
of	O
all	O
17	O
patients	O
,	O
whose	O
serum	B-COMP
was	O
checked	O
1	O
year	O
after	O
disease	O
onset	O
,	O
remained	O
positive	O
.	O

While	O
there	O
was	O
no	O
change	O
in	O
the	O
extent	O
of	O
phosphorylated	O
eNOS	O
at	O
ser	B-COMP
,	O
chronic	O
EtOH	O
stimulation	O
caused	O
dose	O
-	O
dependent	O
increases	O
in	O
NO	O
production	O
and	O
increased	O
eNOS	O
expression	O
,	O
effects	O
that	O
were	O
attenuated	O
by	O
the	O
transcriptional	O
inhibitor	O
,	O
alpha	O
-	O
amanitin	O
(	O
AA	O
),	O
and	O
wortmannin	O
,	O
a	O
specific	O
phosphatidylinositol	O
3	O
kinase	O
(	O
PI3	O
K	O
)	O
inhibitor	O
.	O

In	O
this	O
work	O
,	O
by	O
using	O
yeast	O
two	O
-	O
hybrid	O
and	O
surface	O
plasmon	O
resonance	O
techniques	O
,	O
the	O
residues	O
197	O
-	O
221	O
of	O
the	O
membrane	B-COMP
protein	O
and	O
the	O
residues	O
351	O
-	O
422	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
were	O
determined	O
to	O
be	O
involved	O
in	O
their	O
interaction	O
.	O

Here	O
,	O
we	O
show	O
that	O
electrostatic	O
interactions	O
between	O
the	O
carboxyl	O
termini	O
of	O
SARS	O
-	O
CoV	O
membrane	B-COMP
protein	O
and	O
nucleocapsid	B-COMP
protein	O
largely	O
mediate	O
the	O
interaction	O
of	O
these	O
two	O
proteins	O
.	O

Several	O
recent	O
studies	O
investigating	O
the	O
presence	O
of	O
parvovirus	O
B19	O
and	O
herpesviruses	O
in	O
temporal	O
arteries	O
with	O
giant	O
cell	B-COMP
arteritis	O
have	O
yielded	O
contradictory	O
results	O
.	O

We	O
also	O
provide	O
an	O
example	O
to	O
illustrate	O
that	O
the	O
carbohydrate	O
microarray	O
is	O
also	O
a	O
discovery	O
tool	O
;	O
this	O
is	O
particularly	O
useful	O
for	O
identifying	O
immunologic	O
sugar	O
moieties	O
,	O
including	O
complex	O
carbohydrates	O
of	O
cancer	O
cells	B-COMP
and	O
sugar	O
signatures	O
of	O
previously	O
unrecognized	O
microbial	O
pathogens	O
.	O

in	O
cells	B-COMP
infected	O
with	O
both	O
live	O
and	O
UV	O
-	O
inactivated	O
viruses	O
and	O
that	O
Bax	O
activation	O
was	O
partially	O
blocked	O
by	O
treatment	O
with	O
the	O
caspase	O
-	O
8	O
inhibitor	O
.	O

Dietary	O
supplement	O
containing	O
bovine	O
serum	B-COMP
had	O
no	O
effect	O
on	O
any	O
parameter	O
measured	O
.	O

Electron	O
microscopy	O
has	O
been	O
used	O
,	O
however	O
,	O
to	O
elucidate	O
the	O
structure	O
and	O
function	O
of	O
many	O
bacterial	O
features	O
,	O
such	O
as	O
flagellae	O
,	O
fimbriae	B-COMP
and	O
spores	O
and	O
in	O
the	O
study	O
of	O
bacteriophages	O
.	O

It	O
is	O
clear	O
that	O
cell	B-COMP
and	O
tissue	O
pathology	O
approaches	O
are	O
of	O
value	O
in	O
all	O
of	O
these	O
spheres	O
,	O
providing	O
cell	B-COMP
and	O
tissue	O
relevance	O
to	O
microbiological	O
and	O
immunological	O
observations	O
.	O

It	O
covers	O
the	O
taxonomy	O
,	O
structure	O
of	O
virion	B-COMP
,	O
viral	B-COMP
genome	I-COMP
and	O
proteins	O
,	O
unique	O
replication	O
strategy	O
,	O
receptors	O
and	O
viral	O
pathogenesis	O
.	O

The	O
control	O
and	O
simvastatin	O
groups	O
had	O
similar	O
serum	B-COMP
levels	O
and	O
similar	O
bronchoalveolar	O
lavage	O
fluid	O
levels	O
of	O
cytokines	O
(	O
interleukin	O
-	O
1	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
)	O
and	O
P	O
-	O
selectin	O
at	O
all	O
measurements	O
,	O
except	O
for	O
a	O
significantly	O
higher	O
level	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
P	O
-	O
selectin	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
006	O
).	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
an	O
Escherichia	O
coli	O
-	O
expressed	O
,	O
denatured	O
spike	O
(	O
S	O
)	O
protein	O
fragment	O
of	O
the	O
severe	O
acute	O
respiratory	O
coronavirus	O
,	O
containing	O
residues	O
1029	O
to	O
1192	O
which	O
include	O
the	O
heptad	O
repeat	O
2	O
(	O
HR2	O
)	O
domain	O
,	O
was	O
able	O
to	O
induce	O
neutralizing	O
polyclonal	O
antibodies	B-COMP
(	O
C	O
.	O
T	O
.	O
Keng	O
,	O
A	O
.	O
Zhang	O
,	O
S	O
.	O
Shen	O
,	O
K	O
.	O
M	O
.	O
Lip	O
,	O
B	O
.	O
C	O
.	O
Fielding	O
,	O
T	O
.	O
H	O
.	O
Tan	O
,	O
C	O
.	O
F	O
.	O
Chou	O
,	O
C	O
.	O
B	O
.	O
Loh	O
,	O
S	O
.	O
Wang	O
,	O
J	O
.	O
Fu	O
,	O
X	O
.	O
Yang	O
,	O
S	O
.	O
G	O
.	O
Lim	O
,	O
W	O
.	O
Hong	O
,	O
and	O
Y	O
.	O
J	O
.	O
Tan	O
,	O
J	O
.	O
Virol	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
have	O
been	O
no	O
comprehensive	O
studies	O
investigating	O
viral	O
infection	O
at	O
the	O
cellular	B-COMP
level	O
in	O
humans	O
.	O

TITLE	O
:	O
[	O
Prospective	O
2	O
-	O
year	O
clinical	O
study	O
of	O
patients	O
with	O
positive	O
IgG	O
-	O
antibodies	B-COMP
after	O
recovering	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

In	O
contrast	O
,	O
N	O
-	O
GST	O
elicited	O
strong	O
T	O
cell	B-COMP
IL	O
-	O
4	O
but	O
minimal	O
IFN	O
-	O
gamma	O
responses	O
and	O
a	O
much	O
greater	O
antibody	B-COMP
response	O
.	O

ABSTRACT	O
:	O
Late	O
infantile	O
neuronal	O
ceroid	O
lipofuscinosis	O
(	O
LINCL	O
),	O
a	O
pediatric	O
autosomal	B-COMP
recessive	O
neurodegenerative	O
lysosomal	O
storage	O
disorder	O
,	O
results	O
from	O
mutations	O
in	O
the	O
CLN2	O
gene	O
and	O
consequent	O
deficiency	O
in	O
tripeptidyl	O
-	O
peptidase	O
I	O
(	O
TPP	O
-	O
I	O
)	O
and	O
progressive	O
destruction	O
of	O
neurons	O
.	O

The	O
lung	O
tissue	O
is	O
very	O
rich	O
in	O
this	O
protein	O
;	O
many	O
different	O
lung	O
cells	B-COMP
produce	O
VEGF	O
and	O
also	O
respond	O
to	O
VEGF	O
.	O

These	O
data	O
suggest	O
that	O
some	O
coronaviruses	O
,	O
including	O
HCoV	O
-	O
OC43	O
and	O
SARS	O
-	O
CoV	O
,	O
readily	O
adapt	O
to	O
growth	O
in	O
cells	B-COMP
from	O
heterologous	O
species	O
.	O

Human	O
cells	B-COMP
lack	O
this	O
receptor	O
and	O
are	O
therefore	O
not	O
susceptible	O
to	O
MHV	O
.	O

To	O
demonstrate	O
that	O
MHV	O
can	O
be	O
retargeted	O
to	O
a	O
nonnative	O
receptor	O
on	O
human	O
cells	B-COMP
,	O
we	O
produced	O
bispecific	O
adapter	O
proteins	O
composed	O
of	O
the	O
N	O
-	O
terminal	O
D1	O
domain	O
of	O
mCEACAM1a	O
linked	O
to	O
a	O
short	O
targeting	O
peptide	O
,	O
the	O
six	O
-	O
amino	O
-	O
acid	O
His	O
tag	O
.	O

2	O
-	O
BP	O
effected	O
only	O
two	O
-	O
to	O
fivefold	O
reductions	O
in	O
S	O
palmitoylation	O
,	O
yet	O
this	O
correlated	O
with	O
reduced	O
S	O
complexing	O
with	O
virion	B-COMP
membrane	I-COMP
(	O
M	O
)	O
proteins	O
and	O
consequent	O
exclusion	O
of	O
S	O
from	O
virions	B-COMP
.	O

It	O
contains	O
a	O
highly	O
conserved	O
transmembrane	B-COMP
domain	O
that	O
consists	O
of	O
three	O
parts	O
:	O
an	O
N	O
-	O
terminal	O
tryptophan	O
-	O
rich	O
domain	O
,	O
a	O
central	O
domain	O
,	O
and	O
a	O
cysteine	O
-	O
rich	O
C	O
-	O
terminal	O
domain	O
.	O

In	O
addition	O
,	O
the	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
activity	O
of	O
S	O
was	O
monitored	O
by	O
a	O
Renilla	O
luciferase	O
-	O
based	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
assay	O
.	O

S	O
(	O
VSV	O
-	O
TMDCyt	O
),	O
a	O
chimera	O
with	O
the	O
cytoplasmic	B-COMP
and	O
transmembrane	B-COMP
domains	O
of	O
VSV	O
-	O
G	O
,	O
was	O
impaired	O
in	O
the	O
SARSpp	O
and	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
assays	O
,	O
showing	O
3	O
to	O
25	O
%	O
activity	O
compared	O
to	O
the	O
wild	O
type	O
,	O
depending	O
on	O
the	O
assay	O
and	O
the	O
cells	B-COMP
used	O
.	O

The	O
NIH	O
3T3	O
cell	B-COMP
,	O
a	O
non	O
-	O
permissive	O
cell	B-COMP
line	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
was	O
used	O
as	O
controls	O
.	O

In	O
addition	O
,	O
virus	O
/	O
cell	B-COMP
membrane	I-COMP
fusion	O
occurred	O
in	O
the	O
presence	O
of	O
sulfhydryl	O
-	O
blocking	O
reagents	O
and	O
oxidoreductase	O
inhibitors	O
.	O

If	O
the	O
virus	O
cannot	O
bind	O
to	O
the	O
molecule	O
,	O
or	O
if	O
the	O
molecule	O
is	O
absent	O
,	O
epithelial	O
cells	B-COMP
of	O
the	O
intestine	O
and	O
liver	O
are	O
not	O
infected	O
and	O
mice	O
are	O
resistant	O
.	O

The	O
persistence	O
of	O
detectable	O
IgG	O
antibodies	B-COMP
and	O
neutralizing	O
viral	O
antibodies	B-COMP
for	O
up	O
to	O
720	O
days	O
suggest	O
that	O
SARS	O
patients	O
may	O
be	O
protected	O
from	O
recurrent	O
SARS	O
-	O
CoV	O
infection	O
for	O
up	O
to	O
2	O
years	O
.	O

TITLE	O
:	O
The	O
expression	O
of	O
membrane	B-COMP
protein	O
augments	O
the	O
specific	O
responses	O
induced	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
DNA	O
immunization	O
.	O

Further	O
experiments	O
in	O
field	O
mouse	O
also	O
support	O
the	O
claim	O
that	O
membrane	B-COMP
protein	O
can	O
augment	O
the	O
N	O
-	O
specific	O
immune	O
responses	O
.	O

Maintenance	O
of	O
serum	B-COMP
Ab	O
was	O
correlated	O
with	O
tissue	O
distribution	O
of	O
virus	O
-	O
specific	O
Ab	O
-	O
secreting	O
cells	B-COMP
(	O
ASC	O
).	O

PCA	O
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
CONCLUSIONS	O
:	O
The	O
molecular	O
and	O
cellular	B-COMP
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	O
/	O
fibroleukin	O
expression	O
and	O
the	O
coagulation	O
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

The	O
fibrotic	O
changes	O
and	O
intra	O
-	O
alveolar	O
inflammatory	O
cells	B-COMP
had	O
decreased	O
but	O
were	O
still	O
observed	O
sporadically	O
28	O
and	O
84	O
days	O
after	O
exposure	O
.	O

TITLE	O
:	O
Functional	O
peptide	O
microarrays	O
for	O
specific	O
and	O
sensitive	O
antibody	B-COMP
diagnostics	O
.	O

By	O
using	O
spacer	O
molecules	O
of	O
different	O
type	O
and	O
length	O
for	O
NA	O
-	O
mediated	O
peptide	O
presentation	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
a	O
minimum	O
spacer	O
length	O
is	O
imperative	O
for	O
antibody	B-COMP
binding	O
,	O
whereas	O
the	O
peptide	O
immobilization	O
direction	O
has	O
only	O
secondary	O
importance	O
for	O
antibody	B-COMP
affinity	O
and	O
binding	O
.	O

In	O
contrast	O
,	O
of	O
the	O
898	O
canine	O
serum	B-COMP
samples	O
,	O
160	O
(	O
17	O
.	O
8	O
%)	O
were	O
positive	O
for	O
anti	O
-	O
BCoV	O
antibodies	B-COMP
,	O
and	O
the	O
antibody	B-COMP
titers	O
ranged	O
from	O
1	O
:	O
5	O
to	O
more	O
than	O
1	O
:	O
640	O
,	O
with	O
1	O
:	O
160	O
being	O
the	O
most	O
frequent	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
titers	O
of	O
the	O
anti	O
-	O
BCoV	O
and	O
anti	O
-	O
CCoV	O
antibodies	B-COMP
in	O
the	O
198	O
serum	B-COMP
samples	O
of	O
dogs	O
with	O
a	O
known	O
history	O
of	O
CCoV	O
vaccination	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
developed	O
a	O
test	O
for	O
the	O
diagnosis	O
and	O
prognostic	O
assessment	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
based	O
on	O
the	O
detection	O
of	O
the	O
SARS	O
-	O
coronavirus	O
RNA	O
in	O
serum	B-COMP
by	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
feasibility	O
of	O
automating	O
the	O
serum	B-COMP
RNA	O
extraction	O
procedure	O
in	O
order	O
to	O
increase	O
the	O
throughput	O
of	O
the	O
assay	O
.	O

We	O
developed	O
a	O
modified	O
protocol	O
in	O
compliance	O
with	O
the	O
recommended	O
biosafety	O
guidelines	O
from	O
the	O
World	O
Health	O
Organization	O
based	O
on	O
the	O
use	O
of	O
the	O
MagNA	O
Pure	O
total	O
nucleic	B-COMP
acid	O
large	O
volume	O
isolation	O
kit	O
for	O
the	O
extraction	O
of	O
SARS	O
-	O
coronavirus	O
RNA	O
.	O

TITLE	O
:	O
Promoter	O
activity	O
of	O
SARS	O
coronavirus	O
5	O
'	O
UTR	O
sequence	O
in	O
eukaryotic	O
cells	B-COMP
.	O

B	O
:	O
The	O
cDNA	O
sequence	O
corresponding	O
to	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
possessed	O
a	O
promoter	O
activity	O
in	O
eukaryotic	O
cells	B-COMP
.	O

casei	O
at	O
1	O
-	O
3	O
d	O
of	O
age	O
significantly	O
enhanced	O
the	O
production	O
of	O
anti	O
-	O
BSA	O
antibody	B-COMP
in	O
DSD	O
-	O
fed	O
chickens	O
(	O
60	O
d	O
of	O
age	O
)	O
administered	O
orally	O
with	O
1	O
mg	O
BSA	O
at	O
32	O
and	O
33	O
d	O
of	O
age	O
and	O
subcutaneously	O
with	O
5	O
microg	O
BSA	O
at	O
33	O
d	O
of	O
age	O
.	O

It	O
does	O
,	O
however	O
,	O
have	O
several	O
similarities	O
to	O
the	O
coronavirus	O
M	O
proteins	O
;	O
(	O
i	O
)	O
they	O
are	O
triple	O
membrane	B-COMP
spanning	O
with	O
the	O
same	O
topology	O
,	O
(	O
ii	O
)	O
they	O
have	O
similar	O
intracellular	B-COMP
localizations	O
(	O
predominantly	O
Golgi	B-COMP
),	O
(	O
iii	O
)	O
both	O
are	O
viral	O
structural	O
proteins	O
,	O
and	O
(	O
iv	O
)	O
they	O
appear	O
to	O
interact	O
with	O
the	O
E	O
and	O
S	O
proteins	O
,	O
as	O
well	O
as	O
with	O
each	O
other	O
.	O

ABSTRACT	O
:	O
Interferon	O
(	O
IFN	O
)-	O
alphas	O
bind	O
to	O
and	O
activate	O
their	O
cognate	O
cell	B-COMP
surface	I-COMP
receptor	O
to	O
invoke	O
an	O
antiviral	O
response	O
in	O
target	O
cells	B-COMP
.	O

For	O
Cp	O
felis	O
,	O
the	O
majority	O
of	O
seropositive	O
animals	O
had	O
relatively	O
low	O
antibody	B-COMP
titres	O
,	O
and	O
the	O
risk	O
of	O
these	O
animals	O
infecting	O
others	O
is	O
not	O
known	O
.	O

By	O
using	O
an	O
antiserum	O
raised	O
against	O
the	O
pp1a	O
/	O
pp1ab	O
residues	O
526	O
-	O
713	O
,	O
the	O
upstream	O
processing	O
product	O
,	O
nsp2	O
,	O
was	O
identified	O
as	O
an	O
85	O
kDa	O
protein	O
in	O
TGEV	O
-	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
In	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
relationships	O
between	O
changes	O
in	O
the	O
elastic	O
behavior	O
of	O
the	O
respiratory	O
system	O
and	O
biological	O
markers	O
of	O
extra	O
-	O
cellular	B-COMP
matrix	I-COMP
or	O
surfactant	O
turn	O
-	O
over	O
could	O
give	O
some	O
insights	O
into	O
its	O
pathophysiological	O
determinants	O
.	O

In	O
17	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
we	O
assessed	O
the	O
relationship	O
between	O
chord	O
compliance	O
measured	O
on	O
pressure	O
-	O
volume	O
curves	O
obtained	O
at	O
two	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
0	O
and	O
10	O
[	O
Symbol	O
:	O
see	O
text	O
]	O
cm	O
[	O
Symbol	O
:	O
see	O
text	O
]	O
H	O
(	O
2	O
)	O
O	O
)	O
and	O
biological	O
markers	O
of	O
collagen	B-COMP
turn	O
-	O
over	O
or	O
surfactant	O
degradation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
obtained	O
simultaneously	O
in	O
the	O
early	O
phase	O
of	O
the	O
disease	O
(	O
first	O
4	O
days	O
).	O

ABSTRACT	O
:	O
In	O
a	O
cohort	O
study	O
of	O
56	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
titers	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibodies	B-COMP
and	O
neutralizing	O
antibodies	B-COMP
(	O
NAbs	O
)	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
were	O
assessed	O
at	O
regular	O
intervals	O
(	O
at	O
1	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
16	O
,	O
and	O
24	O
months	O
after	O
the	O
onset	O
of	O
disease	O
)	O
by	O
use	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
neutralization	O
assay	O
.	O

The	O
CXC	O
chemokine	O
ligand	O
10	O
(	O
CXCL10	O
)	O
is	O
expressed	O
following	O
MHV	O
infection	O
and	O
signals	O
T	O
cells	B-COMP
to	O
migrate	O
into	O
the	O
CNS	O
.	O

They	O
were	O
interviewed	O
and	O
asked	O
to	O
provide	O
a	O
blood	O
sample	O
for	O
SARS	O
coronavirus	O
immunoglobulin	O
G	O
antibody	B-COMP
testing	O
.	O

However	O
,	O
treatment	O
with	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
small	O
interfering	O
RNA	O
indicated	O
that	O
the	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
signaling	O
pathway	O
was	O
not	O
related	O
to	O
inhibition	O
of	O
cell	B-COMP
proliferation	O
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
nucleocapsid	B-COMP
(	O
rN	O
)	O
protein	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
extracted	O
from	O
cell	B-COMP
lysates	O
containing	O
6M	O
urea	O
,	O
then	O
purified	O
by	O
Ni	O
(	O
2	O
+)-	O
affinity	O
chromatography	O
.	O

In	O
animal	O
immunogenicity	O
studies	O
,	O
we	O
found	O
that	O
most	O
anti	O
-	O
rN	O
protein	O
antibodies	B-COMP
were	O
IgG2a	B-COMP
in	O
BALB	O
/	O
c	O
mice	O
vaccinated	O
with	O
rN	O
emulsified	O
in	O
Montanide	O
ISA	O
-	O
51	O
containing	O
the	O
synthetic	O
oligodeoxynucleotide	O
,	O
CpG	O
.	O
In	O
contrast	O
,	O
anti	O
-	O
rN	O
protein	O
antibodies	B-COMP
of	O
mice	O
immunized	O
with	O
rN	O
protein	O
in	O
PBS	O
were	O
found	O
to	O
mainly	O
be	O
IgG1	B-COMP
.	O

To	O
identify	O
functional	O
CTL	O
epitopes	O
of	O
the	O
N	O
protein	O
,	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
peptides	O
containing	O
the	O
H	O
-	O
2K	O
(	O
d	O
)	O
CTL	O
motif	O
emulsified	O
in	O
adjuvant	O
ISA	O
-	O
51	O
/	O
CpG	O
.	O
Using	O
an	O
IFN	O
-	O
gamma	O
secretion	O
cell	B-COMP
assay	O
and	O
analysis	O
by	O
flow	O
cytometry	O
,	O
peptides	O
containing	O
residues	O
81	O
-	O
95	O
were	O
found	O
to	O
be	O
capable	O
of	O
stimulating	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
cell	B-COMP
proliferation	O
in	O
vitro	O
.	O

Our	O
current	O
results	O
together	O
with	O
those	O
of	O
others	O
suggest	O
that	O
some	O
immunodominant	O
B	O
-	O
cell	B-COMP
and	O
T	O
-	O
cell	B-COMP
epitopes	O
are	O
conserved	O
in	O
the	O
mouse	O
,	O
monkey	O
,	O
and	O
human	O
.	O

ABSTRACT	O
:	O
A	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
vaccine	O
produced	O
in	O
insect	O
cells	B-COMP
in	O
a	O
pre	O
-	O
clinical	O
development	O
stage	O
is	O
described	O
.	O

Screening	O
station	O
scores	O
(	O
the	O
sum	O
of	O
10	O
items	O
)	O
consisted	O
of	O
triage	O
scores	O
,	O
white	O
blood	O
cell	B-COMP
count	O
,	O
and	O
CXR	O
.	O

Results	O
from	O
each	O
antibody	B-COMP
test	O
were	O
related	O
to	O
four	O
explanatory	O
variables	O
(	O
breed	O
,	O
age	O
,	O
gender	O
and	O
health	O
status	O
at	O
the	O
time	O
of	O
blood	O
collection	O
)	O
using	O
univariate	O
ordinal	O
logistic	O
regression	O
analyses	O
,	O
Mann	O
Whitney	O
U	O
tests	O
,	O
one	O
-	O
sample	O
sign	O
tests	O
or	O
Kruskal	O
-	O
Wallis	O
analyses	O
,	O
as	O
appropriate	O
.	O

The	O
distribution	O
of	O
median	O
Coronase	O
antibody	B-COMP
titres	O
by	O
breed	O
was	O
very	O
similar	O
to	O
the	O
pattern	O
of	O
breed	O
predisposition	O
to	O
FIP	O
recently	O
reported	O
in	O
Sydney	O
.	O

There	O
was	O
no	O
statistical	O
relationship	O
between	O
the	O
Coronase	O
or	O
7B	O
FIP	O
antibody	B-COMP
titres	O
and	O
age	O
,	O
gender	O
or	O
overall	O
health	O
status	O
,	O
even	O
when	O
considering	O
only	O
those	O
cats	O
in	O
which	O
clinical	O
signs	O
suggestive	O
of	O
FIP	O
were	O
present	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
predicted	O
partial	O
amino	O
acid	O
sequences	O
of	O
the	O
polymerase	O
,	O
spike	O
,	O
and	O
membrane	B-COMP
proteins	O
,	O
and	O
full	O
sequence	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
showed	O
that	O
FECV	O
is	O
genetically	O
most	O
closely	O
related	O
to	O
group	O
1	O
coronaviruses	O
.	O

TITLE	O
:	O
Identification	O
of	O
Hepta	O
-	O
and	O
Octo	O
-	O
Uridine	O
stretches	O
as	O
sole	O
signals	O
for	O
programmed	O
+	O
1	O
and	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
during	O
translation	O
of	O
SARS	O
-	O
CoV	O
ORF	O
3a	O
variants	O
.	O

To	O
study	O
the	O
cellular	B-COMP
response	O
in	O
the	O
acute	O
phase	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
host	B-COMP
cell	I-COMP
interaction	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
chemokines	O
,	O
adhesion	O
molecules	O
,	O
and	O
DC	O
-	O
SIGN	O
(	O
dendritic	B-COMP
cell	B-COMP
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
nonintegrin	O
)	O
by	O
SARS	O
-	O
CoV	O
.	O
Immunohistochemistry	O
revealed	O
neutrophil	O
,	O
macrophage	O
,	O
and	O
CD8	O
T	O
-	O
cell	B-COMP
infiltration	O
in	O
the	O
lung	O
autopsy	O
of	O
a	O
SARS	O
patient	O
who	O
died	O
during	O
the	O
acute	O
phase	O
of	O
illness	O
.	O

In	O
in	O
vitro	O
study	O
,	O
we	O
showed	O
that	O
the	O
A549	O
and	O
THP	O
-	O
1	O
cell	B-COMP
lines	O
were	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
.	O
A549	O
cells	B-COMP
produced	O
CCL2	O
/	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
CXCL8	O
/	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
after	O
interaction	O
with	O
SARS	O
-	O
CoV	O
and	O
expressed	O
P	O
-	O
selectin	O
and	O
VCAM	O
-	O
1	O
.	O

Serum	B-COMP
IgG	B-COMP
antibody	I-COMP
against	O
SARS	O
coronavirus	O
is	O
positive	O
in	O
a	O
small	O
proportion	O
(	O
around	O
10	O
%)	O
of	O
the	O
medical	O
staff	O
members	O
exposed	O
to	O
the	O
virus	O
in	O
our	O
hospital	O
,	O
but	O
may	O
not	O
cause	O
obvious	O
symptoms	O
,	O
suggesting	O
SARS	O
coronavirus	O
infection	O
might	O
in	O
some	O
cases	O
have	O
mild	O
or	O
even	O
no	O
clinical	O
manifestations	O
.	O

RESULTS	O
:	O
Serum	B-COMP
IgG	B-COMP
antibody	I-COMP
against	O
SARS	O
coronavirus	O
was	O
detected	O
in	O
all	O
the	O
19	O
SARS	O
patients	O
,	O
and	O
among	O
the	O
200	O
staff	O
members	O
,	O
20	O
(	O
10	O
%)	O
were	O
found	O
positive	O
for	O
the	O
antibody	B-COMP
but	O
with	O
no	O
obvious	O
or	O
only	O
mild	O
symptoms	O
.	O

It	O
is	O
mainly	O
localized	O
to	O
the	O
ER	O
and	O
the	O
Golgi	B-COMP
apparatus	I-COMP
.	O

T	O
cells	B-COMP
are	O
critical	O
in	O
controlling	O
viral	O
replication	O
,	O
but	O
also	O
contribute	O
to	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
Valinomycin	O
was	O
recently	O
reported	O
to	O
be	O
the	O
most	O
potent	O
agent	O
against	O
severe	O
acute	O
respiratory	O
-	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

Although	O
the	O
coronavirus	O
(	O
CoV	O
)	O
S	O
glycoproteins	O
share	O
membership	O
in	O
this	O
class	O
of	O
envelope	B-COMP
glycoproteins	O
,	O
cleavage	O
to	O
generate	O
the	O
respective	O
S1	O
and	O
S2	O
subunits	O
appears	O
absent	O
in	O
a	O
subset	O
of	O
CoV	O
species	O
,	O
including	O
that	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

This	O
effect	O
on	O
the	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
activity	O
by	O
the	O
S	O
glycoprotein	O
is	O
not	O
,	O
however	O
,	O
reflected	O
in	O
the	O
infectivity	O
of	O
pseudotyped	O
lentiviruses	O
bearing	O
the	O
cleaved	O
glycoprotein	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
entry	O
into	O
host	B-COMP
cells	B-COMP
:	O
Opportunities	O
for	O
therapeutic	O
intervention	O
.	O

In	O
case	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
inflammation	O
spill	O
over	O
from	O
the	O
lungs	O
,	O
particularly	O
there	O
is	O
a	O
persistent	O
increase	O
of	O
IL	O
-	O
6	O
and	O
CRP	O
in	O
serum	B-COMP
,	O
and	O
this	O
is	O
associated	O
with	O
a	O
worst	O
prognosis	O
and	O
possible	O
development	O
of	O
sepsis	O
-	O
related	O
complications	O
.	O

SARS	O
-	O
coronavirus	O
has	O
a	O
wide	O
host	B-COMP
range	O
.	O

We	O
carried	O
out	O
fluorescence	O
-	O
dequenching	O
fusion	O
assays	O
of	O
R18	O
-	O
labeled	O
virions	B-COMP
and	O
show	O
that	O
for	O
IBV	O
,	O
coronavirus	O
-	O
cell	B-COMP
fusion	O
occurs	O
in	O
a	O
low	O
-	O
pH	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
half	O
-	O
maximal	O
rate	O
of	O
fusion	O
occurring	O
at	O
pH	O
5	O
.	O
5	O
.	O

In	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
/	O
SARS	O
S	O
coexpression	O
study	O
,	O
all	O
mutants	O
except	O
the	O
913P	O
mutant	O
incorporated	O
the	O
S	O
(	O
H	O
)	O
form	O
into	O
the	O
virions	B-COMP
as	O
effectively	O
as	O
did	O
the	O
wild	O
-	O
type	O
S	O
(	O
H	O
)	O
form	O
.	O

The	O
first	O
step	O
consisted	O
in	O
the	O
introduction	O
of	O
each	O
end	O
of	O
the	O
viral	B-COMP
genome	I-COMP
into	O
the	O
BAC	O
with	O
accessory	O
sequences	O
allowing	O
proper	O
transcription	O
.	O

For	O
each	O
measurement	O
,	O
a	O
dosage	O
of	O
0	O
.	O
3	O
mg	O
/	O
kg	O
ICG	B-COMP
was	O
injected	O
central	O
-	O
venously	O
.	O

ICG	B-COMP
-	O
PDR	O
does	O
reflect	O
ICG	B-COMP
blood	O
clearance	O
with	O
sufficient	O
accuracy	O
in	O
critically	O
ill	O
patients	O
and	O
may	O
be	O
used	O
as	O
a	O
surrogate	O
.	O

TITLE	O
:	O
SARS	O
patients	O
-	O
derived	O
human	O
recombinant	O
antibodies	B-COMP
to	O
S	O
and	O
M	O
proteins	O
efficiently	O
neutralize	O
SARS	O
-	O
coronavirus	O
infectivity	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
specific	O
SARS	O
virus	O
-	O
targeted	O
antibody	B-COMP
preparation	O
for	O
emergent	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
virus	O
infection	O
.	O

By	O
using	O
phage	O
display	O
technology	O
,	O
we	O
constructed	O
a	O
naive	O
antibody	B-COMP
library	O
from	O
convalescent	O
SARS	O
patient	O
lymphocytes	O
.	O

The	O
selected	O
Fab	O
antibodies	B-COMP
expressed	O
in	O
the	O
periplasma	O
of	O
E	O
.	O
coli	O
were	O
soluble	O
and	O
further	O
purified	O
and	O
tested	O
for	O
their	O
binding	O
properties	O
and	O
antiviral	O
function	O
to	O
SARS	O
virus	O
.	O

The	O
functional	O
Fab	O
antibodies	B-COMP
were	O
converted	O
to	O
full	O
human	O
IgG	O
antibodies	B-COMP
with	O
recombinant	O
baculovirus	O
/	O
insect	O
cell	B-COMP
systems	O
and	O
their	O
neutralizing	O
activities	O
were	O
further	O
determined	O
.	O

In	O
addition	O
,	O
the	O
SARS	O
N	O
protein	O
-	O
targeted	O
human	O
Fab	O
antibody	B-COMP
reacted	O
with	O
the	O
denatured	O
N	O
proteins	O
,	O
whereas	O
none	O
of	O
the	O
S	O
and	O
M	O
protein	O
specific	O
neutralizing	O
antibodies	B-COMP
did	O
.	O

TITLE	O
:	O
Nucleocapsid	B-COMP
protein	O
of	O
SARS	O
-	O
CoV	O
activates	O
the	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
by	O
binding	O
directly	O
to	O
regulatory	O
elements	O
for	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
.	O

Western	O
blot	O
analysis	O
indicated	O
that	O
N	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
the	O
production	O
of	O
COX	O
-	O
2	O
protein	O
in	O
mammalian	O
cells	B-COMP
.	O

The	O
cross	O
-	O
reactivity	O
demonstrated	O
between	O
CRCoV	O
antibodies	B-COMP
from	O
different	O
countries	O
and	O
a	O
UK	O
viral	O
isolate	O
suggests	O
immunological	O
similarity	O
.	O

The	O
human	O
adenovirus	O
vector	O
was	O
used	O
to	O
express	O
the	O
soluble	O
S	O
-	O
protein	O
(	O
corresponding	O
to	O
1	O
approximately	O
1190	O
amino	O
acids	O
)	O
fused	O
with	O
Myc	O
/	O
His	O
tag	O
using	O
codon	O
-	O
optimized	O
gene	O
construct	O
in	O
HEK239	O
cells	B-COMP
.	O

Purified	O
soluble	O
S	O
-	O
protein	O
was	O
readily	O
detected	O
by	O
Western	O
blot	O
with	O
anti	O
-	O
Myc	O
antibody	B-COMP
and	O
showed	O
the	O
ability	O
to	O
bind	O
to	O
surface	O
of	O
Vero	O
cells	B-COMP
,	O
demonstrating	O
that	O
the	O
soluble	O
S	O
-	O
protein	O
could	O
remain	O
the	O
biologic	O
activity	O
in	O
the	O
native	O
molecule	O
.	O

TITLE	O
:	O
Enhanced	O
identification	O
of	O
viral	O
and	O
atypical	O
bacterial	O
pathogens	O
in	O
lower	O
respiratory	O
tract	O
samples	O
with	O
nucleic	B-COMP
acid	O
amplification	O
tests	O
.	O

Acute	O
pancreatitis	O
is	O
an	O
acute	O
inflammatory	O
disorder	O
of	O
the	O
pancreas	O
caused	O
by	O
an	O
intracellular	B-COMP
activation	O
of	O
pancreatic	O
digestive	O
enzymes	O
.	O

LXA	O
(	O
4	O
)	O
is	O
generated	O
in	O
vivo	O
during	O
acute	O
lung	O
injury	O
,	O
and	O
we	O
observed	O
that	O
nanomolar	O
quantities	O
increased	O
basal	O
epithelial	O
cell	B-COMP
proliferation	O
and	O
potently	O
blocked	O
acid	O
-	O
triggered	O
interleukin	O
-	O
6	O
release	O
and	O
neutrophil	O
transmigration	O
across	O
well	O
-	O
differentiated	O
normal	O
human	O
bronchial	O
epithelial	O
cells	B-COMP
.	O

Expression	O
of	O
recombinant	O
human	O
ALX	O
in	O
A549	O
airway	O
epithelial	O
cells	B-COMP
uncovered	O
ALX	O
-	O
dependent	O
inhibition	O
of	O
cytokine	O
release	O
by	O
LXA	O
(	O
4	O
).	O

To	O
examine	O
the	O
mechanism	O
of	O
inhibition	O
of	O
dengue	O
virus	O
,	O
we	O
developed	O
two	O
replicon	O
systems	O
for	O
dengue	O
type	O
1	O
virus	O
:	O
(	O
i	O
)	O
a	O
stable	O
cell	B-COMP
line	O
that	O
harbored	O
replicons	O
containing	O
a	O
luciferase	O
reporter	O
and	O
a	O
neomycin	O
phosphotransferase	O
selection	O
marker	O
and	O
(	O
ii	O
)	O
a	O
luciferase	O
-	O
expressing	O
replicon	O
that	O
could	O
differentiate	O
between	O
viral	O
translation	O
and	O
RNA	O
replication	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
cytokine	O
gene	O
expression	O
and	O
induction	O
of	O
chemokine	O
genes	O
in	O
non	O
-	O
lymphatic	O
cells	B-COMP
infected	O
with	O
SARS	O
coronavirus	O
.	O

TITLE	O
:	O
Cell	B-COMP
cycle	O
perturbations	O
induced	O
by	O
infection	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
and	O
their	O
effect	O
on	O
virus	O
replication	O
.	O

The	O
relationship	O
between	O
positive	O
-	O
strand	O
RNA	O
viruses	O
and	O
the	O
cell	B-COMP
cycle	O
and	O
the	O
concomitant	O
effects	O
on	O
virus	O
replication	O
are	O
not	O
clearly	O
understood	O
.	O

Analysis	O
of	O
various	O
cell	B-COMP
cycle	O
-	O
regulatory	O
proteins	O
and	O
cellular	B-COMP
morphology	O
indicated	O
that	O
there	O
was	O
a	O
down	O
-	O
regulation	O
of	O
cyclins	O
D1	O
and	O
D2	O
(	O
G1	O
regulatory	O
cyclins	O
)	O
and	O
that	O
a	O
proportion	O
of	O
virus	O
-	O
infected	O
cells	B-COMP
underwent	O
aberrant	O
cytokinesis	O
,	O
in	O
which	O
the	O
cells	B-COMP
underwent	O
nuclear	O
,	O
but	O
not	O
cytoplasmic	B-COMP
,	O
division	O
.	O

ABSTRACT	O
:	O
Virus	O
attachment	O
to	O
host	B-COMP
cells	B-COMP
is	O
mediated	O
by	O
dedicated	O
virion	B-COMP
proteins	O
,	O
which	O
specifically	O
recognize	O
one	O
or	O
,	O
at	O
most	O
,	O
a	O
limited	O
number	O
of	O
cell	B-COMP
surface	I-COMP
molecules	O
.	O

Recently	O
,	O
biochemical	O
and	O
structural	O
studies	O
of	O
cellular	B-COMP
macro	O
domains	O
have	O
been	O
performed	O
,	O
showing	O
that	O
they	O
are	O
active	O
as	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphatases	O
.	O

TITLE	O
:	O
Anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
immune	O
responses	O
:	O
the	O
role	O
played	O
by	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cells	B-COMP
.	O

The	O
expansion	O
of	O
the	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cell	B-COMP
population	O
was	O
associated	O
with	O
higher	O
anti	O
-	O
SARS	O
-	O
CoV	O
immunoglobulin	O
G	O
titers	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
that	O
stimulated	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cells	B-COMP
display	O
an	O
interferon	O
-	O
gamma	O
-	O
dependent	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
and	O
are	O
able	O
to	O
directly	O
kill	O
SARS	O
-	O
CoV	O
-	O
infected	O
target	O
cells	B-COMP
.	O

TITLE	O
:	O
Sialic	O
acid	O
is	O
a	O
receptor	O
determinant	O
for	O
infection	O
of	O
cells	B-COMP
by	O
avian	O
Infectious	O
bronchitis	O
virus	O
.	O

Neuraminidase	O
treatment	O
rendered	O
Vero	O
,	O
baby	O
hamster	O
kidney	O
and	O
primary	O
chicken	O
kidney	O
cells	B-COMP
resistant	O
to	O
infection	O
by	O
the	O
IBV	O
-	O
Beaudette	O
strain	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
pumpless	O
arteriovenous	O
extracorporeal	O
membrane	B-COMP
oxygenator	O
(	O
interventional	O
lung	O
assist	O
(	O
ILA	O
))	O
does	O
not	O
significantly	O
improve	O
oxygenation	O
in	O
a	O
lavage	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Identification	O
of	O
functionally	O
important	O
negatively	O
charged	O
residues	O
in	O
the	O
carboxy	O
end	O
of	O
mouse	O
hepatitis	O
coronavirus	O
A59	O
nucleocapsid	B-COMP
protein	O
.	O

Peptides	O
analogous	O
to	O
regions	O
of	O
the	O
N	O
-	O
terminus	O
or	O
the	O
pre	O
-	O
transmembrane	B-COMP
domain	O
of	O
the	O
S2	O
subunit	O
inhibited	O
SARS	O
-	O
CoV	O
plaque	O
formation	O
by	O
40	O
-	O
70	O
%	O
at	O
concentrations	O
of	O
15	O
-	O
30	O
microM	O
.	O
Interestingly	O
,	O
peptides	O
analogous	O
to	O
the	O
SARS	O
-	O
CoV	O
or	O
MHV	O
loop	O
region	O
inhibited	O
viral	O
plaque	O
formation	O
by	O
>	O
80	O
%	O
at	O
similar	O
concentrations	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
in	O
BALB	O
/	O
c	O
mice	O
by	O
IMP	B-COMP
dehydrogenase	O
inhibitors	O
,	O
including	O
ribavirin	O
.	O

Our	O
data	O
do	O
not	O
support	O
the	O
use	O
of	O
ribavirin	O
or	O
other	O
IMP	B-COMP
dehydrogenase	O
inhibitors	O
for	O
treating	O
SARS	O
infections	O
in	O
humans	O
.	O

The	O
results	O
show	O
that	O
prime	O
-	O
immunization	O
with	O
SARS	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
can	O
induce	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cell	B-COMP
responses	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
-	O
specific	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	B-COMP
were	O
CD62L	O
(-),	O
a	O
marker	O
for	O
memory	O
cells	B-COMP
,	O
and	O
-	O
30	O
to	O
50	O
%	O
of	O
the	O
cells	B-COMP
expressed	O
IL	O
-	O
7Ralpha	O
(	O
CD127	O
),	O
a	O
marker	O
for	O
the	O
capacity	O
of	O
effector	O
cells	B-COMP
to	O
develop	O
into	O
memory	O
cells	B-COMP
.	O

Immunohistochemical	O
stains	O
showed	O
a	O
strong	O
positivity	O
of	O
X4	O
protein	O
in	O
denudation	O
cells	B-COMP
,	O
vascular	O
endothelial	O
cells	B-COMP
and	O
also	O
erythrocytes	O
and	O
neutrophils	O
in	O
the	O
alveoli	O
of	O
the	O
lung	O
tissues	O
from	O
the	O
4	O
cases	O
.	O

T	O
cell	B-COMP
antigen	O
epitopes	O
of	O
S2	O
protein	O
were	O
predicted	O
on	O
the	O
basis	O
of	O
Internet	O
database	O
.	O

ABSTRACT	O
:	O
Maturation	O
of	O
dendritic	B-COMP
cells	B-COMP
(	O
DC	O
)	O
is	O
a	O
key	O
immunological	O
process	O
regulating	O
immune	O
responses	O
to	O
pathogens	O
and	O
vaccines	O
,	O
as	O
well	O
as	O
tolerance	O
and	O
autoimmune	O
processes	O
.	O

ABSTRACT	O
:	O
Various	O
semisynthetic	O
derivatives	O
of	O
glycopeptide	O
antibiotics	O
including	O
vancomycin	O
,	O
eremomycin	O
,	O
teicoplanin	O
,	O
ristocetin	O
A	O
and	O
DA	O
-	O
40926	O
have	O
been	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
and	O
human	O
(	O
SARS	O
-	O
CoV	O
,	O
Frankfurt	O
-	O
1	O
strain	O
)	O
coronavirus	O
in	O
cell	B-COMP
culture	O
in	O
comparison	O
with	O
their	O
activity	O
against	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
).	O

We	O
addressed	O
the	O
relationship	O
between	O
emulsion	O
structure	O
and	O
levels	O
of	O
in	O
vivo	O
antibody	B-COMP
formation	O
to	O
inactivated	O
New	O
Castle	O
Disease	O
virus	O
(	O
NDV	O
)	O
and	O
Infectious	O
Bronchitis	O
virus	O
(	O
IBV	O
)	O
as	O
antigens	O
in	O
3	O
-	O
week	O
-	O
old	O
chickens	O
.	O

2	O
positive	O
clones	O
that	O
having	O
specific	O
affinity	O
to	O
SARS	O
sera	B-COMP
were	O
obtained	O
.	O

The	O
dissociation	O
constant	O
of	O
AS3	O
-	O
3	O
was	O
1	O
.	O
98	O
x	O
10	O
(-	O
8	O
)	O
M	O
.	O
Immunofluorescent	O
microscopy	O
revealed	O
that	O
it	O
reacted	O
with	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

Two	O
(	O
0	O
.	O
57	O
%)	O
of	O
353	O
asymptomatic	O
children	O
from	O
the	O
high	O
-	O
risk	O
area	O
were	O
tested	O
positive	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
antibody	B-COMP
compared	O
with	O
0	O
of	O
361	O
in	O
the	O
low	O
-	O
risk	O
region	O
.	O

Different	O
coronavirus	O
E	O
proteins	O
share	O
striking	O
similarities	O
in	O
biochemical	O
properties	O
and	O
biological	O
functions	O
,	O
but	O
seem	O
to	O
adopt	O
distinct	O
membrane	B-COMP
topology	O
.	O

It	O
was	O
revealed	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
termini	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
are	O
exposed	O
to	O
the	O
cytoplasmic	B-COMP
side	O
of	O
the	O
membranes	O
(	O
N	O
(	O
cyto	O
)	O
C	O
(	O
cyto	O
)).	O

At	O
the	O
same	O
time	O
,	O
arterial	O
oxygen	O
tension	O
(	O
PaO	O
2	O
),	O
cytokines	O
and	O
activated	O
NF	O
-	O
	O
B	O
levels	O
of	O
peripheral	O
blood	O
mononuclear	O
cell	B-COMP
were	O
measured	O
.	O

Here	O
we	O
describe	O
the	O
observation	O
of	O
a	O
ribosome	B-COMP
-	O
mRNA	O
pseudoknot	O
complex	O
that	O
is	O
stalled	O
in	O
the	O
process	O
of	O
-	O
1	O
frameshifting	O
.	O

Dismal	O
overall	O
survival	O
reflects	O
the	O
poor	O
outcome	O
in	O
this	O
patient	O
group	O
and	O
highlights	O
the	O
acute	O
need	O
for	O
new	O
agents	O
with	O
activity	O
in	O
refractory	O
germ	O
cell	B-COMP
neoplasms	O
.	O

TITLE	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
-	O
infected	O
monocytes	O
internalize	O
viral	B-COMP
membrane	I-COMP
-	O
bound	O
proteins	O
upon	O
antibody	B-COMP
addition	O
.	O

TITLE	O
:	O
Analysis	O
of	O
ACE2	O
in	O
polarized	O
epithelial	O
cells	B-COMP
:	O
surface	O
expression	O
and	O
function	O
as	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

The	O
cellular	B-COMP
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
has	O
been	O
shown	O
to	O
be	O
localized	O
on	O
the	O
apical	B-COMP
plasma	I-COMP
membrane	I-COMP
of	O
polarized	O
respiratory	O
epithelial	O
cells	B-COMP
and	O
to	O
mediate	O
infection	O
from	O
the	O
apical	O
side	O
of	O
these	O
cells	B-COMP
.	O

Here	O
,	O
these	O
results	O
were	O
confirmed	O
and	O
extended	O
by	O
including	O
a	O
colon	O
carcinoma	O
cell	B-COMP
line	O
(	O
Caco	O
-	O
2	O
),	O
a	O
lung	O
carcinoma	O
cell	B-COMP
line	O
(	O
Calu	O
-	O
3	O
)	O
and	O
Vero	O
E6	O
cells	B-COMP
in	O
our	O
analysis	O
.	O

Indeed	O
,	O
in	O
a	O
recent	O
study	O
we	O
reported	O
that	O
the	O
alpha	O
-	O
helical	O
putative	O
transmembrane	B-COMP
domain	O
of	O
E	O
protein	O
(	O
ETM	O
)	O
forms	O
several	O
SDS	O
-	O
resistant	O
TM	O
interactions	O
:	O
a	O
dimer	O
,	O
a	O
trimer	O
,	O
and	O
two	O
pentameric	O
forms	O
.	O

The	O
phages	O
specifically	O
inhibited	O
IBV	O
infectivity	O
in	O
HeLa	O
cells	B-COMP
and	O
blocked	O
IBV	O
haemagglutination	O
.	O

The	O
results	O
may	O
contribute	O
to	O
development	O
of	O
antiviral	O
therapeutics	O
for	O
IBV	O
and	O
studying	O
the	O
determinants	O
for	O
viral	O
and	O
cell	B-COMP
interaction	O
.	O

ABSTRACT	O
:	O
Infection	O
by	O
different	O
coronaviruses	O
(	O
CoVs	O
)	O
causes	O
alterations	O
in	O
the	O
transcriptional	O
and	O
translational	O
patterns	O
,	O
cell	B-COMP
cycle	O
,	O
cytoskeleton	B-COMP
,	O
and	O
apoptosis	O
pathways	O
of	O
the	O
host	B-COMP
cells	B-COMP
.	O

Both	O
viral	O
and	O
cellular	B-COMP
proteins	O
are	O
required	O
for	O
replication	O
and	O
transcription	O
,	O
and	O
the	O
role	O
of	O
selected	O
proteins	O
is	O
addressed	O
.	O

ABSTRACT	O
:	O
A	O
Vero	O
cell	B-COMP
attenuated	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
strain	O
,	O
DR13	O
,	O
was	O
distinguished	O
from	O
wild	O
-	O
type	O
PEDV	O
using	O
restriction	O
enzyme	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
).	O

Similar	O
morphological	O
studies	O
and	O
labeling	O
experiments	O
argued	O
against	O
the	O
previously	O
proposed	O
involvement	O
of	O
the	O
autophagic	O
pathway	O
as	O
the	O
source	O
for	O
the	O
vesicles	B-COMP
with	O
which	O
the	O
replicase	O
is	O
associated	O
and	O
instead	O
suggested	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
to	O
be	O
the	O
most	O
likely	O
donor	O
of	O
the	O
membranes	O
that	O
carry	O
the	O
SARS	O
-	O
CoV	O
replication	O
complex	O
.	O

Total	O
lymphocytes	O
,	O
T	O
lymphocyte	O
,	O
CD4	O
+	O
T	O
and	O
naive	O
CD4	O
+	O
T	O
cell	B-COMP
were	O
still	O
significantly	O
lower	O
than	O
the	O
normal	O
levels	O
even	O
one	O
year	O
after	O
disease	O
onset	O
.	O

The	O
lentogenic	O
viral	O
infection	O
resulted	O
in	O
an	O
immediate	O
stimulation	O
of	O
complement	O
activity	O
,	O
followed	O
by	O
a	O
decrease	O
to	O
initial	O
complement	O
levels	O
within	O
2	O
weeks	O
post	O
vaccination	O
,	O
when	O
the	O
antibody	B-COMP
response	O
took	O
over	O
immune	O
defence	O
.	O

These	O
two	O
genes	O
encode	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	O
)	O
and	O
envelope	B-COMP
E	O
protein	O
.	O

The	O
RDRP	O
and	O
envelope	B-COMP
E	O
genes	O
,	O
based	O
on	O
published	O
sequences	O
,	O
have	O
been	O
synthesized	O
and	O
cloned	O
into	O
mammalian	O
expression	O
vectors	O
.	O

Two	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
RDRP	O
successfully	O
inhibited	O
the	O
expression	O
of	O
the	O
gene	O
,	O
whereas	O
both	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
envelope	B-COMP
E	O
decreased	O
approx	O
90	O
%	O
of	O
the	O
envelope	B-COMP
E	O
gene	O
expression	O
.	O

No	O
cytotoxicity	O
was	O
seen	O
in	O
host	B-COMP
HepG2	O
and	O
Vero	O
cells	B-COMP
,	O
up	O
to	O
the	O
highest	O
concentration	O
tested	O
.	O

In	O
this	O
study	O
,	O
the	O
interaction	O
of	O
SARS	O
-	O
CoV	O
with	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
),	O
the	O
key	O
regulators	O
of	O
immune	O
responses	O
,	O
was	O
analysed	O
.	O

Microarray	O
analysis	O
was	O
applied	O
to	O
assess	O
changes	O
in	O
cellular	B-COMP
expression	O
profiles	O
during	O
different	O
stages	O
of	O
two	O
independent	O
,	O
highly	O
controlled	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infections	O
in	O
vitro	O
.	O

Total	O
RNA	O
was	O
harvested	O
from	O
MHV	O
-	O
or	O
mock	O
-	O
infected	O
L	O
cells	B-COMP
at	O
3	O
,	O
5	O
and	O
6	O
h	O
post	O
-	O
infection	O
and	O
hybridized	O
to	O
Affymetrix	O
microarrays	O
representing	O
approximately	O
12	O
,	O
500	O
murine	O
genes	O
and	O
expressed	O
sequences	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
in	O
patients	O
with	O
ARDS	O
shows	O
neutrophil	O
predominance	O
with	O
increased	O
edema	O
fluid	O
to	O
serum	B-COMP
protein	O
ratio	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
report	O
a	O
serum	B-COMP
-	O
free	O
culture	O
system	O
for	O
primary	O
neonatal	O
pulmonary	O
cells	B-COMP
that	O
can	O
support	O
the	O
growth	O
of	O
octamer	O
-	O
binding	O
transcription	O
factor	O
4	O
+	O
(	O
Oct	O
-	O
4	O
+)	O
epithelial	O
colonies	O
with	O
a	O
surrounding	O
mesenchymal	O
stroma	O
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
the	O
presence	O
of	O
Oct	O
-	O
4	O
+	O
long	O
-	O
term	O
BrdU	O
label	O
-	O
retaining	O
cells	B-COMP
at	O
the	O
bronchoalveolar	O
junction	O
of	O
neonatal	O
lung	O
,	O
providing	O
a	O
link	O
between	O
the	O
Oct	O
-	O
4	O
+	O
cells	B-COMP
in	O
vivo	O
and	O
in	O
vitro	O
and	O
strengthening	O
their	O
identity	O
as	O
putative	O
neonatal	O
lung	O
stem	O
/	O
progenitor	O
cells	B-COMP
.	O

The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
in	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	O
were	O
around	O
40	O
%,	O
which	O
is	O
much	O
lower	O
than	O
the	O
positive	O
rate	O
in	O
clinically	O
diagnosed	O
adult	O
SARS	O
patients	O
,	O
indicating	O
that	O
a	O
large	O
proportion	O
of	O
those	O
""""	O
SARS	O
""""	O
children	O
were	O
infected	O
with	O
respiratory	O
viruses	O
other	O
than	O
SARS	O
-	O
CoV	O
during	O
SARS	O
epidemic	O
in	O
Beijing	O
.	O

RESULTS	O
:	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
ranged	O
from	O
39	O
.	O
1	O
%	O
to	O
43	O
.	O
5	O
%	O
in	O
the	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	O
,	O
zero	O
in	O
children	O
and	O
6	O
.	O
0	O
%	O
to	O
9	O
.	O
0	O
%	O
in	O
adults	O
who	O
had	O
closely	O
contacted	O
with	O
the	O
clinically	O
diagnosed	O
SARS	O
children	O
.	O

CONCLUSIONS	O
:	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
in	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	O
were	O
around	O
40	O
%,	O
which	O
is	O
much	O
lower	O
than	O
the	O
positive	O
rate	O
in	O
clinically	O
diagnosed	O
adult	O
SARS	O
patients	O
,	O
indicating	O
that	O
a	O
large	O
proportion	O
of	O
those	O
""""	O
SARS	O
""""	O
children	O
were	O
infected	O
with	O
respiratory	O
viruses	O
other	O
than	O
SARS	O
-	O
CoV	O
during	O
SARS	O
epidemic	O
in	O
Beijing	O
.	O

TITLE	O
:	O
Amino	O
acids	O
15	O
-	O
28	O
in	O
the	O
ectodomain	O
of	O
SARS	O
coronavirus	O
3a	O
protein	O
induces	O
neutralizing	O
antibodies	B-COMP
.	O

The	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-COMP
could	O
detect	O
intracellular	B-COMP
3a	O
as	O
well	O
as	O
3a	O
expressed	O
on	O
the	O
cell	B-COMP
surface	I-COMP
.	O

Interestingly	O
,	O
only	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-COMP
can	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
although	O
the	O
binding	O
affinity	O
of	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-COMP
was	O
lower	O
than	O
the	O
anti	O
-	O
3a	O
C	O
-	O
terminal	O
antibody	B-COMP
.	O

TITLE	O
:	O
Long	O
-	O
lived	O
effector	O
/	O
central	O
memory	O
T	O
-	O
cell	B-COMP
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
antigen	O
in	O
recovered	O
SARS	O
patients	O
.	O

However	O
,	O
karyotypic	O
examination	O
of	O
bone	O
marrow	O
cells	B-COMP
revealed	O
that	O
chromosomal	B-COMP
translocation	O
with	O
t	O
(	O
4	O
;	O
10	O
)(	O
q12	O
;	O
p11	O
)	O
had	O
occurred	O
in	O
2000	O
,	O
and	O
chronic	O
eosinophilic	O
leukemia	O
was	O
diagnosed	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
observed	O
by	O
conducting	O
an	O
extensive	O
analysis	O
of	O
the	O
two	O
-	O
dimensional	O
cellular	B-COMP
automata	O
images	O
of	O
known	O
SARS	O
-	O
CoV	O
genome	O
sequences	O
that	O
the	O
V	O
-	O
shaped	O
cross	O
-	O
lines	O
only	O
exist	O
in	O
some	O
special	O
locations	O
,	O
and	O
hence	O
can	O
be	O
used	O
as	O
a	O
fingerprint	O
to	O
identify	O
the	O
SARS	O
sequences	O
.	O

The	O
results	O
demonstrated	O
that	O
(	O
1	O
)	O
a	O
single	O
dose	O
of	O
RBD	O
-	O
rAAV	O
vaccination	O
could	O
induce	O
sufficient	O
neutralizing	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
infection	O
;	O
(	O
2	O
)	O
two	O
more	O
repeated	O
doses	O
of	O
the	O
vaccination	O
boosted	O
the	O
neutralizing	O
antibody	B-COMP
to	O
about	O
5	O
times	O
of	O
the	O
level	O
achieved	O
by	O
a	O
single	O
dose	O
of	O
the	O
immunization	O
and	O
(	O
3	O
)	O
the	O
level	O
of	O
the	O
antibody	B-COMP
continued	O
to	O
increase	O
for	O
the	O
entire	O
duration	O
of	O
the	O
experiment	O
of	O
5	O
.	O
5	O
months	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibody	B-COMP
combination	O
against	O
SARS	O
coronavirus	O
:	O
synergy	O
and	O
coverage	O
of	O
escape	O
mutants	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
induction	O
of	O
apoptosis	O
by	O
SARS	O
-	O
CoV	O
M	O
protein	O
in	O
animal	O
cells	B-COMP
and	O
possible	O
implications	O
are	O
discussed	O
.	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	O
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	B-COMP
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	B-COMP
aspartate	O
aminotransferase	O
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	O
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	B-COMP
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	B-COMP
aspartate	O
aminotransferase	O
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

ABSTRACT	O
:	O
As	O
with	O
all	O
viruses	O
,	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
utilizes	O
specific	O
host	B-COMP
cell	I-COMP
factors	O
during	O
its	O
infection	O
cycle	O
.	O

While	O
many	O
different	O
viruses	O
target	O
proteins	O
to	O
the	O
nucleolus	B-COMP
and	O
recruit	O
nucleolar	O
proteins	O
to	O
facilitate	O
virus	O
replication	O
,	O
the	O
effect	O
of	O
infection	O
on	O
the	O
nucleolus	B-COMP
in	O
terms	O
of	O
morphology	O
and	O
protein	O
content	O
is	O
unknown	O
.	O

Some	O
of	O
these	O
ORFs	O
encode	O
for	O
genes	O
that	O
are	O
homologous	O
to	O
proteins	O
found	O
in	O
all	O
known	O
coronaviruses	O
,	O
namely	O
the	O
replicase	O
genes	O
(	O
ORFs	O
1a	O
and	O
1b	O
)	O
and	O
the	O
four	O
structural	O
proteins	O
:	O
nucleocapsid	B-COMP
,	O
spike	O
,	O
membrane	B-COMP
and	O
envelope	B-COMP
,	O
and	O
these	O
proteins	O
are	O
expected	O
to	O
be	O
essential	O
for	O
the	O
replication	O
of	O
the	O
virus	O
.	O

CONCLUSIONS	O
:	O
SNPs	O
in	O
the	O
OAS1	O
3	O
'-	O
UTR	O
and	O
MxA	O
promoter	O
region	O
appear	O
associated	O
with	O
host	B-COMP
susceptibility	O
to	O
SARS	O
in	O
Chinese	O
Han	O
population	O
.	O

However	O
,	O
the	O
cellular	B-COMP
immune	O
responses	O
to	O
E	O
protein	O
remain	O
unclear	O
in	O
humans	O
.	O

TITLE	O
:	O
M	O
and	O
N	O
proteins	O
of	O
SARS	O
coronavirus	O
induce	O
apoptosis	O
in	O
HPF	O
cells	B-COMP
.	O

TITLE	O
:	O
Infection	O
with	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
stimulates	O
an	O
early	O
gamma	O
interferon	O
response	O
in	O
the	O
serum	B-COMP
of	O
pigs	O
.	O

BeauR	O
-	O
M41	O
(	O
S	O
)	O
EP10	O
was	O
more	O
efficacious	O
than	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
protecting	O
more	O
birds	O
against	O
virulent	O
challenge	O
and	O
providing	O
a	O
better	O
serological	O
antibody	B-COMP
response	O
.	O

Indeed	O
,	O
binding	O
of	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
protein	O
to	O
Vero	O
E6	O
cells	B-COMP
was	O
diminished	O
on	O
cells	B-COMP
treated	O
with	O
IL	O
-	O
4	O
,	O
but	O
also	O
on	O
cells	B-COMP
exposed	O
to	O
IFN	O
-	O
gamma	O
.	O

By	O
in	O
situ	O
hybridization	O
,	O
the	O
Mass	O
and	O
Ark	O
nucleocapsid	B-COMP
(	O
Nc	O
)	O
genes	O
were	O
detected	O
only	O
at	O
7	O
days	O
in	O
the	O
tracheas	O
.	O

TITLE	O
:	O
The	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	O
is	O
distinct	O
from	O
its	O
counterpart	O
in	O
animal	O
SARS	O
-	O
CoV	O
and	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
the	O
envelope	B-COMP
protein	O
in	O
infected	O
cells	B-COMP
.	O

Coronavirus	O
replication	O
entails	O
ribosome	B-COMP
frameshifting	O
during	O
genome	O
translation	O
,	O
the	O
synthesis	O
of	O
both	O
genomic	O
and	O
multiple	O
subgenomic	O
RNA	O
species	O
,	O
and	O
the	O
assembly	O
of	O
progeny	O
virions	B-COMP
by	O
a	O
pathway	O
that	O
is	O
unique	O
among	O
enveloped	O
RNA	O
viruses	O
.	O

Forty	O
-	O
seven	O
recipients	O
of	O
living	O
donor	O
renal	O
transplants	O
prior	O
to	O
the	O
induction	O
era	O
who	O
received	O
conventional	O
triple	O
drug	O
immunosuppression	O
without	O
antibody	B-COMP
induction	O
served	O
as	O
historic	O
controls	O
.	O

Med	O
Hypotheses	O
2004	O
;	O
62	O
(	O
3	O
):	O
354	O
-	O
7	O
]	O
in	O
which	O
it	O
is	O
presumed	O
that	O
in	O
hyper	O
-	O
endemic	O
areas	O
of	O
malaria	O
(	O
central	O
Africa	O
),	O
all	O
primates	O
(	O
humans	O
and	O
non	O
-	O
human	O
primates	O
)	O
have	O
shared	O
a	O
retrovirus	O
that	O
augments	O
their	O
T	O
-	O
cell	B-COMP
response	O
to	O
the	O
malaria	O
parasite	O
.	O

The	O
virus	O
can	O
be	O
called	O
""""	O
primate	O
T	O
-	O
cell	B-COMP
retrovirus	O
""""	O
(	O
PTRV	O
).	O

TITLE	O
:	O
Induction	O
of	O
transcription	O
factor	O
Egr	O
-	O
1	O
gene	O
expression	O
in	O
astrocytoma	O
cells	B-COMP
by	O
Murine	O
coronavirus	O
infection	O
.	O

Here	O
we	O
characterized	O
the	O
activation	O
of	O
an	O
immediate	O
-	O
early	O
transcription	O
factor	O
Egr	O
-	O
1	O
by	O
MHV	O
infection	O
in	O
an	O
astrocytoma	O
cell	B-COMP
line	O
.	O

Experiments	O
with	O
ultraviolet	O
light	O
-	O
inactivated	O
virus	O
revealed	O
that	O
the	O
induction	O
of	O
Egr	O
-	O
1	O
did	O
not	O
require	O
virus	O
replication	O
and	O
was	O
likely	O
mediated	O
during	O
cell	B-COMP
entry	O
.	O

These	O
data	O
suggested	O
that	O
,	O
in	O
infected	O
cells	B-COMP
,	O
nsp1	O
promotes	O
host	B-COMP
mRNA	O
degradation	O
and	O
thereby	O
suppresses	O
host	B-COMP
gene	O
expression	O
,	O
including	O
proteins	O
involved	O
in	O
host	B-COMP
innate	O
immune	O
functions	O
.	O

SCoV	O
nsp1	O
-	O
mediated	O
promotion	O
of	O
host	B-COMP
mRNA	O
degradation	O
may	O
play	O
an	O
important	O
role	O
in	O
SCoV	O
pathogenesis	O
.	O

NL63	O
-	O
S	O
does	O
not	O
exhibit	O
significant	O
homology	O
to	O
SARS	O
-	O
S	O
but	O
is	O
highly	O
related	O
to	O
the	O
S	O
-	O
protein	O
of	O
hCoV	O
-	O
229E	O
,	O
which	O
enters	O
target	O
cells	B-COMP
by	O
engaging	O
CD13	O
.	O

ABSTRACT	O
:	O
Protein	O
ubiquitination	O
has	O
been	O
identified	O
as	O
a	O
regulatory	O
mechanism	O
in	O
key	O
cellular	B-COMP
activities	O
,	O
and	O
deubiquitination	O
is	O
recognized	O
as	O
an	O
important	O
step	O
in	O
processes	O
governed	O
by	O
ubiquitin	O
and	O
ubiquitin	O
-	O
like	O
modifiers	O
.	O

This	O
review	O
centers	O
on	O
structural	O
-	O
functional	O
aspects	O
that	O
characterize	O
the	O
confirmed	O
viral	O
deubiquitinating	O
enzymes	O
,	O
and	O
their	O
relationships	O
to	O
established	O
families	O
of	O
cellular	B-COMP
deubiquitinating	O
enzymes	O
.	O

Although	O
most	O
of	O
the	O
assays	O
have	O
initially	O
been	O
focused	O
on	O
RNA	O
extracted	O
from	O
nasopharyngeal	O
aspirates	O
,	O
urine	O
,	O
and	O
stools	O
,	O
several	O
of	O
the	O
more	O
recently	O
developed	O
assays	O
have	O
been	O
based	O
on	O
the	O
analysis	O
of	O
RNA	O
extracted	O
from	O
plasma	O
and	O
serum	B-COMP
.	O

When	O
SR	O
-	O
COS7	O
cells	B-COMP
or	O
R	O
-	O
COS7	O
cells	B-COMP
were	O
cocultured	O
with	O
AG	O
-	O
COS7	O
cells	B-COMP
,	O
syncytia	O
with	O
yellow	O
fluorescence	O
were	O
conveniently	O
observed	O
after	O
12	O
h	O
in	O
SR	O
-	O
COS7	O
cells	B-COMP
plus	O
AG	O
-	O
COS7	O
cells	B-COMP
,	O
but	O
not	O
in	O
R	O
-	O
COS7	O
cells	B-COMP
plus	O
AG	O
-	O
COS7	O
cells	B-COMP
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
H5N1	O
viral	O
infection	O
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	B-COMP
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

Antibody	B-COMP
binding	O
to	O
discontinuous	O
peptides	O
provides	O
evidence	O
that	O
amino	O
acids	O
274	O
-	O
283	O
and	O
373	O
-	O
382	O
assemble	O
to	O
a	O
structural	O
unit	O
particularly	O
rich	O
in	O
basic	O
amino	O
acids	O
.	O

This	O
report	O
summarizes	O
the	O
recommendations	O
from	O
a	O
WHO	O
Technical	O
Meeting	O
on	O
Animal	O
Models	O
and	O
Antibody	B-COMP
Assays	O
for	O
Evaluating	O
Candidate	O
SARS	O
Vaccines	O
held	O
on	O
25	O
-	O
26	O
August	O
2005	O
in	O
South	O
Mimms	O
,	O
UK	O
,	O
provides	O
guidance	O
on	O
the	O
use	O
of	O
animal	O
models	O
,	O
and	O
outlines	O
the	O
steps	O
to	O
develop	O
standard	O
reagents	O
and	O
assays	O
for	O
immunological	O
evaluation	O
of	O
candidate	O
SARS	O
vaccines	O
.	O

Herein	O
,	O
we	O
screened	O
12	O
,	O
000	O
people	O
in	O
a	O
community	O
stricken	O
by	O
SARS	O
10	O
months	O
previously	O
and	O
found	O
53	O
individuals	O
(	O
0	O
.	O
44	O
%)	O
who	O
had	O
immunoglobulin	O
G	O
antibodies	B-COMP
to	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	B-COMP
(	O
N	O
)	O
produced	O
in	O
bacteria	O
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
a	O
novel	O
monoclonal	O
antibody	B-COMP
specific	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
Seven	O
-	O
mer	O
phage	O
random	O
peptide	O
libraries	O
were	O
panned	O
against	O
2C10	O
,	O
a	O
monoclonal	O
antibody	B-COMP
that	O
showed	O
neutralizing	O
activities	O
against	O
PEDV	O
.	O

In	O
neutralization	O
inhibition	O
assays	O
,	O
the	O
two	O
peptide	O
motifs	O
and	O
a	O
24	O
-	O
mer	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
endodomain	O
of	O
PEDV	O
S	O
protein	O
were	O
observed	O
to	O
compete	O
for	O
the	O
antigen	O
binding	O
site	O
of	O
2C10	O
,	O
as	O
demonstrated	O
by	O
the	O
loss	O
or	O
reduction	O
of	O
neutralizing	O
activity	O
of	O
the	O
monoclonal	O
antibody	B-COMP
.	O

We	O
show	O
that	O
the	O
80R	O
-	O
binding	O
epitope	O
on	O
the	O
S1	O
RBD	O
overlaps	O
very	O
closely	O
with	O
the	O
ACE2	O
-	O
binding	O
site	O
,	O
providing	O
a	O
rationale	O
for	O
the	O
strong	O
binding	O
and	O
broad	O
neutralizing	O
ability	O
of	O
the	O
antibody	B-COMP
.	O

This	O
study	O
thus	O
identifies	O
residues	O
critical	O
for	O
RNA	O
binding	O
on	O
the	O
nucleocapsid	B-COMP
surface	O
,	O
and	O
presents	O
biochemical	O
and	O
genetic	O
evidence	O
that	O
directly	O
links	O
the	O
RNA	O
binding	O
capacity	O
of	O
the	O
coronavirus	O
N	O
protein	O
to	O
the	O
viral	O
infectivity	O
in	O
cultured	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
potential	O
B	O
-	O
cell	B-COMP
antigenic	O
epitopes	O
within	O
the	O
N	O
-	O
terminus	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
)	O
M	O
protein	O
and	O
characterize	O
monoclonal	O
antibody	B-COMP
(	O
MAb	O
)	O
against	O
the	O
protein	O
as	O
well	O
as	O
its	O
recognizing	O
region	O
,	O
we	O
expressed	O
and	O
purified	O
a	O
portion	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
(	O
amino	O
acid	O
1	O
-	O
43	O
)	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
).	O

TITLE	O
:	O
Coronavirus	O
nucleocapsid	B-COMP
protein	O
is	O
an	O
RNA	O
chaperone	O
.	O

TITLE	O
:	O
An	O
arginine	O
-	O
to	O
-	O
proline	O
mutation	O
in	O
a	O
domain	O
with	O
undefined	O
functions	O
within	O
the	O
helicase	O
protein	O
(	O
Nsp13	O
)	O
is	O
lethal	O
to	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
cultured	O
cells	B-COMP
.	O

We	O
also	O
found	O
that	O
the	O
GxxxG	O
motif	O
contributes	O
toward	O
the	O
trimerization	O
of	O
the	O
entire	O
spike	O
protein	O
;	O
in	O
that	O
,	O
mutations	O
in	O
the	O
GxxxG	O
motif	O
decrease	O
trimerization	O
of	O
the	O
full	O
-	O
length	O
protein	O
expressed	O
in	O
mammalian	O
cells	B-COMP
.	O

Studies	O
of	O
the	O
pathogenesis	O
of	O
anthrax	O
and	O
of	O
the	O
immune	O
responses	O
following	O
infection	O
and	O
immunization	O
underscore	O
the	O
pivotal	O
role	O
that	O
antibodies	B-COMP
to	O
the	O
protective	O
antigen	O
play	O
in	O
protection	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
functional	O
roles	O
of	O
the	O
previously	O
reported	O
neutralizing	O
epitopes	O
within	O
S2	O
subunit	O
were	O
investigated	O
using	O
an	O
antigen	O
specific	O
antibody	B-COMP
depletion	O
assay	O
.	O

Depletion	O
of	O
antibodies	B-COMP
against	O
these	O
regions	O
significantly	O
diminished	O
,	O
though	O
not	O
completely	O
abolished	O
,	O
the	O
neutralizing	O
effects	O
of	O
anti	O
-	O
S2	O
IgG	O
.	O
It	O
suggests	O
the	O
absence	O
of	O
a	O
major	O
neutralizing	O
domain	O
on	O
S2	O
protein	O
.	O

Femoral	O
head	O
necrosis	O
and	O
low	O
serum	B-COMP
triiodothyronine	O
and	O
thyroxine	O
levels	O
,	O
commonly	O
found	O
in	O
patients	O
with	O
SARS	O
,	O
raise	O
the	O
possibility	O
of	O
thyroid	O
dysfunction	O
.	O

The	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUPT	O
nick	O
end	O
-	O
labeling	O
assay	O
was	O
performed	O
to	O
identify	O
apoptotic	O
cells	B-COMP
.	O

No	O
distinct	O
calcitonin	O
-	O
positive	O
cells	B-COMP
were	O
detectable	O
in	O
the	O
SARS	O
thyroids	O
.	O

In	O
conclusion	O
,	O
both	O
parafollicular	O
and	O
follicular	O
cells	B-COMP
were	O
injured	O
.	O

TITLE	O
:	O
Carboxyl	O
terminus	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
:	O
self	O
-	O
association	O
analysis	O
and	O
nucleic	B-COMP
acid	O
binding	O
characterization	O
.	O

ABSTRACT	O
:	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
the	O
transmembrane	B-COMP
domain	O
of	O
three	O
viral	O
ion	O
channel	O
proteins	O
on	O
the	O
lipid	O
bilayer	O
structure	O
by	O
X	O
-	O
ray	O
reflectivity	O
and	O
scattering	O
from	O
oriented	O
planar	O
bilayers	O
.	O

Since	O
certain	O
residues	O
at	O
these	O
positively	O
selected	O
sites	O
are	O
associated	O
with	O
receptor	O
recognition	O
and	O
/	O
or	O
membrane	B-COMP
fusion	O
,	O
they	O
are	O
likely	O
to	O
be	O
the	O
crucial	O
residues	O
for	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
of	O
SARS	O
-	O
CoVs	O
,	O
and	O
subsequent	O
adaptation	O
to	O
human	O
hosts	B-COMP
.	O

ABSTRACT	O
:	O
In	O
(+)	O
RNA	O
coronaviruses	O
,	O
replication	O
and	O
transcription	O
of	O
the	O
giant	O
approximately	O
30	O
kb	O
genome	O
to	O
produce	O
genome	O
-	O
and	O
subgenome	O
-	O
size	O
RNAs	O
of	O
both	O
polarities	O
are	O
mediated	O
by	O
a	O
cognate	O
membrane	B-COMP
-	O
bound	O
enzymatic	O
complex	O
.	O

A	O
parallel	O
between	O
the	O
nsp8	O
RdRp	O
and	O
cellular	B-COMP
DNA	O
-	O
dependent	O
RNA	O
primases	O
is	O
drawn	O
to	O
propose	O
that	O
the	O
nsp8	O
RdRp	O
produces	O
primers	O
utilized	O
by	O
the	O
primer	O
-	O
dependent	O
nsp12	O
RdRp	O
.	O

These	O
results	O
provide	O
important	O
intracellular	B-COMP
clue	O
for	O
tracing	O
host	B-COMP
response	O
to	O
SARS	O
-	O
CoV	O
infection	O
and	O
suggest	O
a	O
role	O
of	O
mitochondria	B-COMP
in	O
that	O
process	O
.	O

Using	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	B-COMP
protein	O
(	O
SCVme	O
),	O
and	O
core	O
streptavidin	O
(	O
cSA	O
)	O
of	O
Streptomyces	O
avidinii	O
as	O
model	O
proteins	O
,	O
specific	O
immobilization	O
of	O
the	O
GBP	O
-	O
fusion	O
proteins	O
onto	O
the	O
gold	O
nanoparticles	O
and	O
generation	O
of	O
protein	O
nanopatterns	O
on	O
the	O
bare	O
gold	O
surface	O
were	O
demonstrated	O
.	O

The	O
poly	O
(	O
dimethylsiloxane	O
)	O
microfluidic	O
channels	O
were	O
created	O
on	O
the	O
gold	O
surface	O
and	O
were	O
used	O
for	O
antigen	O
-	O
antibody	B-COMP
and	O
DNA	O
-	O
DNA	O
interaction	O
studies	O
.	O

Serum	B-COMP
IgG	O
blocked	O
binding	O
of	O
the	O
S	O
-	O
protein	O
to	O
the	O
ACE2	O
receptor	O
and	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

Entry	O
into	O
human	O
B	O
cell	B-COMP
lines	O
occurred	O
in	O
a	O
FcgammaRII	O
-	O
dependent	O
and	O
ACE2	O
-	O
independent	O
fashion	O
indicating	O
that	O
ADE	O
of	O
virus	O
entry	O
is	O
a	O
novel	O
cell	B-COMP
entry	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
.	O
Vaccinated	O
animals	O
showed	O
no	O
signs	O
of	O
enhanced	O
lung	O
pathology	O
or	O
hepatitis	O
and	O
viral	O
load	O
was	O
undetectable	O
or	O
greatly	O
reduced	O
in	O
lungs	O
following	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Altogether	O
our	O
results	O
indicate	O
that	O
a	O
recombinant	O
trimeric	O
S	O
protein	O
was	O
able	O
to	O
elicit	O
an	O
efficacious	O
protective	O
immune	O
response	O
in	O
vivo	O
and	O
warrant	O
concern	O
in	O
the	O
safety	O
evaluation	O
of	O
a	O
human	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O

Serum	B-COMP
levels	O
of	O
11	O
cytokines	O
and	O
chemokines	O
,	O
in	O
14	O
patients	O
with	O
SARS	O
and	O
24	O
patients	O
with	O
CAP	O
,	O
were	O
serially	O
checked	O
using	O
a	O
bead	O
-	O
based	O
multiassay	O
system	O
.	O

RESULTS	O
:	O
The	O
serum	B-COMP
levels	O
of	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	O
-	O
2	O
and	O
IL	O
-	O
6	O
were	O
significantly	O
elevated	O
during	O
SARS	O
infection	O
.	O

Using	O
the	O
phage	O
-	O
displayed	O
peptide	O
library	O
screening	O
method	O
and	O
purified	O
Fab	O
fragments	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
Fab	O
)	O
from	O
normal	O
human	O
sera	B-COMP
and	O
convalescent	O
sera	B-COMP
from	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
as	O
targets	O
,	O
11	O
B	O
cell	B-COMP
epitopes	O
of	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
(	O
S	O
protein	O
)	O
and	O
membrane	B-COMP
protein	O
(	O
M	O
protein	O
)	O
were	O
screened	O
.	O

Fusion	O
protein	O
between	O
green	O
fluorescence	O
protein	O
(	O
GFP	O
)	O
and	O
S450	O
-	O
650	O
(	O
S450	O
-	O
650	O
-	O
GFP	O
)	O
was	O
able	O
to	O
stain	O
Vero	O
E6	O
cells	B-COMP
and	O
deletion	O
of	O
the	O
beta6	O
fragment	O
rendered	O
the	O
fusion	O
product	O
(	O
S511	O
-	O
650	O
-	O
GFP	O
)	O
unable	O
to	O
do	O
so	O
.	O

A	O
total	O
of	O
56	O
serum	B-COMP
samples	O
collected	O
from	O
22	O
healthcare	O
workers	O
in	O
the	O
Hanoi	O
French	O
Hospital	O
during	O
the	O
SARS	O
epidemic	O
in	O
2003	O
were	O
evaluated	O
and	O
compared	O
to	O
the	O
conventional	O
neutralizing	O
assay	O
using	O
infectious	O
SARS	O
-	O
CoV	O
.	O
The	O
results	O
of	O
the	O
neutralization	O
assay	O
using	O
VSV	O
-	O
SARS	O
-	O
St19	O
pseudotype	O
showed	O
good	O
correlations	O
with	O
those	O
using	O
infectious	O
SARS	O
-	O
CoV	O
.	O
The	O
newly	O
developed	O
neutralization	O
assay	O
was	O
more	O
sensitive	O
to	O
low	O
antibody	B-COMP
titers	O
in	O
serum	B-COMP
samples	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
double	O
-	O
stranded	O
RNA	O
,	O
produced	O
during	O
MHV	O
infection	O
,	O
is	O
not	O
accessible	O
to	O
cellular	B-COMP
PRRs	O
.	O

TITLE	O
:	O
The	O
ORF7b	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
expressed	O
in	O
virus	O
-	O
infected	O
cells	B-COMP
and	O
incorporated	O
into	O
SARS	O
-	O
CoV	O
particles	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
infection	O
of	O
cultured	O
cells	B-COMP
with	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
Raf	O
/	O
MEK	O
/	O
ERK	O
)	O
signal	O
transduction	O
pathway	O
(	O
Y	O
.	O
Cai	O
et	O
al	O
.,	O
Virology	O
355	O
:	O
152	O
-	O
163	O
,	O
2006	O
).	O

Herein	O
,	O
we	O
show	O
that	O
this	O
response	O
is	O
similarly	O
public	O
when	O
the	O
NP366	O
+	O
Vbeta4	O
+	O
CD8	O
T	O
cell	B-COMP
response	O
is	O
analyzed	O
.	O

Therefore	O
,	O
even	O
in	O
CD8	O
T	O
cell	B-COMP
responses	O
that	O
appear	O
to	O
be	O
oligoclonotypic	O
,	O
the	O
total	O
response	O
is	O
highly	O
diverse	O
.	O

Humoral	O
immune	O
responses	O
of	O
vaccinated	O
mice	O
were	O
investigated	O
for	O
up	O
to	O
12	O
months	O
at	O
a	O
1	O
-	O
month	O
interval	O
and	O
the	O
neutralizing	O
titers	O
of	O
produced	O
antibodies	B-COMP
were	O
reported	O
at	O
months	O
0	O
,	O
3	O
,	O
6	O
and	O
12	O
post	O
-	O
vaccination	O
.	O

Sera	B-COMP
were	O
analyzed	O
for	O
antibodies	B-COMP
against	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
feline	O
herpesvirus	O
1	O
(	O
feline	O
rhinotracheitis	O
:	O
FHV1	O
),	O
feline	O
/	O
canine	O
parvovirus	O
(	O
FPV	O
/	O
CPV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
feline	O
coronavirus	O
:	O
FIPV	O
),	O
and	O
canine	O
distemper	O
virus	O
(	O
CDV	O
)	O
or	O
for	O
the	O
presence	O
of	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigens	O
.	O

Ten	O
lions	O
(	O
71	O
%)	O
had	O
antibodies	B-COMP
against	O
FIV	O
,	O
11	O
(	O
79	O
%)	O
had	O
antibodies	B-COMP
against	O
CDV	O
,	O
11	O
(	O
79	O
%)	O
had	O
antibodies	B-COMP
against	O
FCV	O
,	O
nine	O
(	O
64	O
%)	O
had	O
antibodies	B-COMP
against	O
FHV1	O
,	O
and	O
five	O
(	O
36	O
%)	O
had	O
antibodies	B-COMP
against	O
FPV	O
.	O

The	O
suitability	O
of	O
this	O
replicon	O
cell	B-COMP
line	O
in	O
drug	O
screening	O
was	O
demonstrated	O
by	O
testing	O
the	O
inhibitory	O
effect	O
of	O
several	O
existing	O
drugs	O
and	O
the	O
results	O
demonstrate	O
that	O
the	O
SARS	O
-	O
CoV	O
replicon	O
cell	B-COMP
lines	O
provide	O
a	O
safe	O
tool	O
for	O
the	O
identification	O
of	O
SARS	O
-	O
CoV	O
replicase	O
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
deletion	O
mutant	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
been	O
engineered	O
by	O
deleting	O
the	O
structural	O
E	O
gene	O
in	O
an	O
infectious	O
cDNA	O
clone	O
that	O
was	O
constructed	O
as	O
a	O
bacterial	O
artificial	O
chromosome	B-COMP
(	O
BAC	O
).	O

ABSTRACT	O
:	O
Respiratory	O
distress	O
syndrome	O
(	O
RDS	O
)	O
is	O
a	O
multifactorial	O
developmental	O
disease	O
caused	O
by	O
lung	O
immaturity	O
and	O
presenting	O
as	O
high	O
-	O
permeability	O
lung	O
edema	O
"("""	O
hyaline	O
membrane	B-COMP
disease	O
""")."	O

Individual	O
cysteine	O
clusters	O
were	O
altered	O
via	O
cysteine	O
-	O
to	O
-	O
alanine	O
amino	O
acid	O
replacement	O
and	O
the	O
modified	O
S	O
glycoproteins	O
were	O
tested	O
for	O
their	O
transport	O
to	O
cell	B-COMP
-	O
surfaces	O
and	O
ability	O
to	O
cause	O
cell	B-COMP
fusion	O
in	O
transient	O
transfection	O
assays	O
.	O

Mutagenesis	O
of	O
the	O
cysteine	O
cluster	O
I	O
,	O
located	O
immediately	O
proximal	O
to	O
the	O
predicted	O
transmembrane	B-COMP
,	O
domain	O
did	O
not	O
appreciably	O
reduce	O
cell	B-COMP
-	O
surface	O
expression	O
,	O
although	O
S	O
-	O
mediated	O
cell	B-COMP
fusion	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
S	O
.	O
Similarly	O
,	O
mutagenesis	O
of	O
the	O
cysteine	O
cluster	O
II	O
located	O
adjacent	O
to	O
cluster	O
I	O
reduced	O
S	O
-	O
mediated	O
cell	B-COMP
fusion	O
by	O
more	O
than	O
60	O
%	O
compared	O
to	O
the	O
wild	O
-	O
type	O
S	O
,	O
while	O
cell	B-COMP
-	O
surface	O
expression	O
was	O
reduced	O
by	O
less	O
than	O
20	O
%.	O

Mutagenesis	O
of	O
cysteine	O
clusters	O
III	O
and	O
IV	O
did	O
not	O
appreciably	O
affect	O
S	O
cell	B-COMP
-	O
surface	O
expression	O
or	O
S	O
-	O
mediated	O
cell	B-COMP
fusion	O
.	O

Although	O
the	O
chickens	O
were	O
not	O
vaccinated	O
against	O
any	O
poultry	O
diseases	O
,	O
serum	B-COMP
antibodies	B-COMP
to	O
Newcastle	O
disease	O
,	O
infectious	O
bursal	O
disease	O
and	O
infectious	O
bronchitis	O
were	O
detected	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
viral	O
mRNAs	O
and	O
viral	O
proteins	O
of	O
the	O
targets	O
were	O
significantly	O
decreased	O
or	O
completely	O
inhibited	O
in	O
cell	B-COMP
lines	O
after	O
being	O
infected	O
with	O
the	O
recombinant	O
adenoviruses	O
that	O
expressed	O
specific	O
shRNA	O
molecules	O
.	O

Subsequent	O
analysis	O
revealed	O
no	O
differences	O
in	O
T	O
cell	B-COMP
proliferation	O
,	O
IFN	O
-	O
gamma	O
secretion	O
by	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
,	O
or	O
CD8	O
+	O
T	O
cell	B-COMP
cytolytic	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
oligodendrocyte	O
apoptosis	O
is	O
triggered	O
by	O
MHV	O
infection	O
during	O
cell	B-COMP
entry	O
through	O
the	O
activation	O
of	O
the	O
Fas	O
signaling	O
pathway	O
.	O

First	O
,	O
the	O
receptor	O
of	O
HCoV	O
229E	O
,	O
human	O
aminopeptidase	O
N	O
(	O
hAPN	O
or	O
CD13	O
)	O
is	O
expressed	O
mainly	O
on	O
human	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
and	O
macrophages	O
indicating	O
that	O
targeting	O
of	O
HCoV	O
229E	O
-	O
based	O
vectors	O
to	O
professional	O
antigen	O
presenting	O
cells	B-COMP
can	O
be	O
achieved	O
by	O
receptor	O
-	O
mediated	O
transduction	O
.	O

These	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
containing	O
HCoV	O
229E	O
-	O
based	O
vector	O
RNA	O
have	O
the	O
ability	O
to	O
transduce	O
human	O
DCs	O
and	O
to	O
mediate	O
heterologous	O
gene	O
expression	O
in	O
these	O
cells	B-COMP
.	O

In	O
support	O
of	O
this	O
,	O
we	O
found	O
that	O
the	O
dibasic	O
motif	O
on	O
the	O
SARS	O
S	O
protein	O
was	O
required	O
for	O
its	O
localization	O
to	O
the	O
ERGIC	B-COMP
/	O
Golgi	B-COMP
region	O
when	O
coexpressed	O
with	O
SARS	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
.	O

Expression	O
of	O
collectrin	O
in	O
Xenopus	O
oocytes	O
and	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	B-COMP
enhances	O
amino	O
acid	O
transport	O
by	O
the	O
transporter	O
B	O
(	O
0	O
)	O
AT1	O
.	O

Transfected	O
cells	B-COMP
secreted	O
these	O
recombinant	O
mini	O
-	O
antibodies	B-COMP
efficiently	O
,	O
mainly	O
as	O
dimers	O
stabilized	O
covalently	O
by	O
inter	O
-	O
chain	O
disulphide	O
bridges	O
.	O

HCoV	O
-	O
NL63	O
S	O
is	O
expressed	O
as	O
a	O
single	O
-	O
chain	O
glycoprotein	O
and	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	O
domain	O
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
transmembrane	B-COMP
fusion	O
domain	O
(	O
S2	O
).	O

Our	O
results	O
provide	O
an	O
initial	O
basis	O
for	O
understanding	O
an	O
intriguing	O
interplay	O
between	O
the	O
presence	O
or	O
absence	O
of	O
proteolytic	O
maturation	O
among	O
the	O
coronavirus	O
groups	O
and	O
the	O
membrane	B-COMP
fusion	O
activity	O
of	O
their	O
S	O
glycoproteins	O
.	O

ABSTRACT	O
:	O
We	O
have	O
combined	O
molecular	O
beacon	O
(	O
MB	O
)	O
probes	O
with	O
barcoded	O
metal	O
nanowires	O
to	O
enable	O
no	O
-	O
wash	O
,	O
sealed	O
chamber	O
,	O
multiplexed	O
detection	O
of	O
nucleic	B-COMP
acids	O
.	O

N	O
gene	O
expression	O
prevents	O
cellular	B-COMP
RNA	O
degradation	O
and	O
partially	O
rescues	O
the	O
dramatic	O
translation	O
shutoff	O
characteristic	O
of	O
the	O
VVDeltaE3L	O
virus	O
.	O

The	O
entire	O
ectodomain	O
of	O
S	O
protein	O
was	O
fused	O
between	O
the	O
gp64	O
signal	O
peptide	O
and	O
the	O
VSV	O
-	O
G	O
membrane	B-COMP
anchor	O
and	O
successfully	O
displayed	O
on	O
the	O
baculovirus	O
surface	O
.	O

Subcutaneous	O
injection	O
with	O
purified	O
S	O
-	O
displayed	O
baculoviruses	O
without	O
adjuvant	O
elicited	O
highly	O
effective	O
production	O
of	O
specific	O
and	O
neutralizing	O
antibodies	B-COMP
against	O
S	O
protein	O
in	O
mice	O
.	O

Blunt	O
and	O
penetrating	O
trauma	O
patients	O
were	O
randomly	O
assigned	O
to	O
rFVIIa	O
(	O
200	O
+	O
100	O
+	O
100	O
microg	O
/	O
kg	O
)	O
at	O
0	O
,	O
1	O
,	O
and	O
3	O
hours	O
after	O
transfusion	O
of	O
8	O
units	O
of	O
red	O
blood	O
cells	B-COMP
(	O
RBCs	O
)	O
or	O
to	O
placebo	O
.	O

TITLE	O
:	O
Absence	O
of	O
surface	O
expression	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
antigens	O
on	O
infected	O
cells	B-COMP
isolated	O
from	O
cats	O
with	O
FIP	O
.	O

How	O
these	O
cells	B-COMP
survive	O
in	O
immune	O
cats	O
is	O
not	O
known	O
.	O

No	O
surface	O
expression	O
of	O
viral	O
antigens	O
was	O
detected	O
on	O
FIPV	O
positive	O
cells	B-COMP
.	O

In	O
conclusion	O
,	O
it	O
can	O
be	O
stated	O
that	O
in	O
FIP	O
cats	O
,	O
FIPV	O
replicates	O
in	O
cells	B-COMP
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
without	O
carrying	O
viral	O
antigens	O
in	O
their	O
plasma	B-COMP
membrane	I-COMP
,	O
which	O
could	O
allow	O
them	O
to	O
escape	O
from	O
antibody	B-COMP
-	O
dependent	O
cell	B-COMP
lysis	O
.	O

This	O
study	O
characterizes	O
the	O
inhibitory	O
effect	O
of	O
ATA	O
on	O
vaccinia	O
virus	O
replication	O
in	O
HeLa	O
,	O
Huh7	O
,	O
and	O
AD293	O
cells	B-COMP
.	O

Thus	O
,	O
ATA	O
inhibits	O
vaccinia	O
virus	O
replication	O
by	O
targeting	O
both	O
cellular	B-COMP
and	O
viral	O
factors	O
essential	O
for	O
the	O
early	O
stage	O
of	O
replication	O
.	O

VRP	O
-	O
N	O
-	O
induced	O
pathology	O
presented	O
at	O
day	O
4	O
,	O
peaked	O
around	O
day	O
7	O
,	O
and	O
persisted	O
through	O
day	O
14	O
,	O
and	O
was	O
likely	O
mediated	O
by	O
cellular	B-COMP
immune	O
responses	O
.	O

This	O
may	O
indicate	O
that	O
the	O
protein	O
is	O
not	O
essential	O
in	O
cell	B-COMP
culture	O
,	O
but	O
the	O
highly	O
conserved	O
amino	O
acid	O
sequence	O
of	O
the	O
ORF4	O
protein	O
among	O
clinical	O
isolates	O
suggests	O
that	O
the	O
protein	O
plays	O
an	O
important	O
role	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
lipid	B-COMP
rafts	I-COMP
also	O
play	O
an	O
important	O
role	O
in	O
the	O
life	O
cycle	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
).	O

This	O
inhibition	O
was	O
prevented	O
by	O
addition	O
of	O
cholesterol	O
to	O
the	O
culture	O
medium	O
,	O
indicating	O
that	O
the	O
reduction	O
of	O
virus	B-COMP
particle	I-COMP
release	O
was	O
caused	O
by	O
the	O
loss	O
of	O
cholesterol	O
in	O
the	O
cell	B-COMP
membrane	I-COMP
.	O

We	O
show	O
that	O
nsp3	O
-	O
TM	O
is	O
sufficient	O
in	O
mediating	O
ER	B-COMP
membrane	I-COMP
association	O
of	O
a	O
cytosolic	B-COMP
protein	O
.	O

The	O
extent	O
of	O
disease	O
depends	O
on	O
the	O
number	O
of	O
conidia	O
inhaled	O
and	O
the	O
function	O
of	O
the	O
host	B-COMP
'	O
s	O
cellular	B-COMP
immune	O
system	O
.	O

Blood	O
contamination	O
of	O
CSF	O
resulted	O
in	O
<	O
or	O
=	O
333	O
erythrocytes	O
/	O
microL	O
in	O
cats	O
with	O
CSF	O
IgG	O
.	O
The	O
correlation	O
between	O
serum	B-COMP
and	O
CSF	O
IgG	O
and	O
the	O
fact	O
that	O
CSF	O
IgG	O
was	O
detected	O
only	O
in	O
strongly	O
seropositive	O
cats	O
suggested	O
that	O
CSF	O
anti	O
-	O
coronavirus	O
IgG	O
was	O
derived	O
from	O
blood	O
.	O

Light	O
and	O
electron	O
microscopic	O
studies	O
of	O
the	O
antigen	O
in	O
acute	O
Kawasaki	O
disease	O
ciliated	O
bronchial	O
epithelium	O
indicate	O
that	O
the	O
Kawasaki	O
disease	O
-	O
associated	O
antigen	O
localizes	O
to	O
cytoplasmic	B-COMP
inclusion	I-COMP
bodies	O
that	O
are	O
consistent	O
with	O
aggregates	O
of	O
viral	O
protein	O
and	O
associated	O
nucleic	B-COMP
acid	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
coronavirus	O
E	O
viroporin	O
protein	O
transmembrane	B-COMP
domain	O
in	O
virus	O
assembly	O
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
nucleocapsid	B-COMP
and	O
spike	O
protein	O
-	O
based	O
immunoglobulin	O
G	O
immunoassays	O
were	O
developed	O
and	O
evaluated	O
.	O

Virus	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
that	O
develop	O
during	O
convalescence	O
prevent	O
reinfection	O
in	O
animal	O
models	O
.	O

In	O
addition	O
,	O
our	O
present	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
infection	O
of	O
endothelial	O
cells	B-COMP
and	O
fibroblasts	O
in	O
SARS	O
.	O

Human	O
metapneumovirus	O
was	O
identified	O
in	O
nasopharyngeal	O
aspirate	O
amplification	O
of	O
the	O
viral	O
fusion	O
and	O
nucleocapsid	B-COMP
genes	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
and	O
phylogenetic	O
analysis	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
investigate	O
immunogenicity	O
in	O
the	O
induction	O
of	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
N	O
gene	O
recombinant	O
replication	O
-	O
defective	O
adenoviral	O
vector	O
,	O
rAd	O
-	O
N	O
,	O
was	O
generated	O
and	O
immunized	O
BALB	O
/	O
c	O
mice	O
in	O
a	O
pcDNA3	O
.	O
1	O
-	O
N	O
prime	O
-	O
rAd	O
-	O
N	O
boost	O
regimen	O
.	O

We	O
therefore	O
explored	O
exosome	O
-	O
based	O
vaccines	O
containing	O
the	O
spike	O
S	O
proteins	O
of	O
SARS	O
-	O
CoV	O
.	O
S	O
-	O
containing	O
exosomes	O
were	O
obtained	O
by	O
replacing	O
the	O
transmembrane	B-COMP
and	O
cytoplasmic	B-COMP
domains	O
of	O
the	O
S	O
protein	O
by	O
those	O
of	O
VSV	O
-	O
G	O
.	O
The	O
immunogenicity	O
and	O
efficacy	O
of	O
the	O
S	O
-	O
containing	O
exosomes	O
were	O
tested	O
in	O
mice	O
and	O
compared	O
to	O
an	O
adenoviral	O
vector	O
vaccine	O
expressing	O
the	O
S	O
protein	O
.	O

Both	O
,	O
S	O
-	O
containing	O
exosomes	O
and	O
the	O
adenoviral	O
vector	O
vaccine	O
induced	O
neutralizing	O
antibody	B-COMP
titers	O
.	O

The	O
samples	O
from	O
normal	O
blood	O
donors	O
were	O
also	O
tested	O
for	O
antibodies	B-COMP
against	O
other	O
respiratory	O
virus	O
.	O

Because	O
of	O
this	O
,	O
it	O
is	O
speculated	O
that	O
children	O
vaccinated	O
with	O
various	O
childhood	O
vaccines	O
might	O
develop	O
cross	O
immunity	O
against	O
SARS	O
-	O
CoV	O
.	O
Antisera	O
and	O
T	O
cells	B-COMP
from	O
mice	O
immunised	O
with	O
various	O
vaccines	O
were	O
used	O
to	O
determine	O
whether	O
they	O
developed	O
cross	O
reactivity	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
results	O
showed	O
no	O
marked	O
cross	O
reactivity	O
against	O
SARS	O
-	O
CoV	O
,	O
which	O
implies	O
that	O
the	O
reduced	O
symptoms	O
among	O
children	O
infected	O
by	O
SARS	O
-	O
CoV	O
may	O
be	O
caused	O
by	O
other	O
factors	O
.	O

Furthermore	O
,	O
the	O
most	O
closely	O
related	O
bat	O
and	O
SARS	O
coronaviruses	O
diverged	O
in	O
1986	O
,	O
an	O
estimated	O
divergence	O
time	O
of	O
17	O
years	O
prior	O
to	O
the	O
outbreak	O
,	O
suggesting	O
that	O
there	O
may	O
have	O
been	O
transmission	O
via	O
an	O
unknown	O
intermediate	O
host	B-COMP
.	O

A	O
similar	O
differential	O
effect	O
is	O
observed	O
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	B-COMP
and	O
in	O
type	O
2	O
pneumocytes	O
although	O
TNFalpha	O
is	O
not	O
induced	O
in	O
respiratory	O
epithelial	O
cells	B-COMP
.	O

TITLE	O
:	O
Investigation	O
of	O
interactions	O
between	O
two	O
monoclonal	O
antibodies	B-COMP
and	O
SARS	O
virus	O
with	O
a	O
Label	O
-	O
free	O
Protein	O
Array	O
.	O

ABSTRACT	O
:	O
The	O
investigation	O
of	O
interactions	O
between	O
two	O
kinds	O
of	O
monoclonal	O
antibodies	B-COMP
and	O
SARS	O
virus	O
with	O
a	O
label	O
-	O
free	O
protein	O
array	O
technique	O
were	O
presented	O
in	O
this	O
paper	O
.	O

The	O
model	O
reproduces	O
all	O
clinical	O
signs	O
of	O
measles	O
,	O
but	O
the	O
lack	O
of	O
ferret	O
-	O
specific	O
reagents	O
has	O
limited	O
the	O
characterization	O
of	O
the	O
cellular	B-COMP
immune	O
response	O
.	O

By	O
performing	O
a	O
forward	O
genetic	O
modifier	O
screen	O
,	O
we	O
identified	O
phosphoinositide	O
-	O
dependent	O
kinase	O
-	O
1	O
(	O
PDK	O
-	O
1	O
)	O
as	O
a	O
dominant	O
suppressor	O
of	O
M	O
-	O
induced	O
apoptotic	O
cell	B-COMP
death	O
.	O

TITLE	O
:	O
An	O
antibody	B-COMP
derivative	O
expressed	O
from	O
viral	O
vectors	O
passively	O
immunizes	O
pigs	O
against	O
transmissible	O
gastroenteritis	O
virus	O
infection	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
.	O

The	O
epsilonSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
-	O
chain	O
antibody	B-COMP
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
epsilon	O
-	O
CH4	O
domain	O
from	O
human	O
immunoglobulin	O
E	O
(	O
IgE	O
).	O

When	O
N	O
-	O
IgG	O
and	O
S	O
-	O
IgG	O
were	O
tested	O
40	O
days	O
after	O
the	O
onset	O
of	O
the	O
disease	O
at	O
three	O
different	O
times	O
,	O
the	O
positive	O
rate	O
of	O
N	O
-	O
IgG	O
(	O
92	O
.	O
5	O
%,	O
37	O
/	O
40	O
)	O
was	O
higher	O
than	O
that	O
of	O
S	O
-	O
IgG	O
(	O
67	O
.	O
5	O
%,	O
27	O
/	O
40	O
),	O
but	O
the	O
two	O
structure	O
protein	O
antibodies	B-COMP
were	O
always	O
lower	O
than	O
the	O
total	O
IgG	O
.	O

Immunized	O
sera	B-COMP
elicited	O
against	O
most	O
civet	O
S	O
glycoproteins	O
displayed	O
potent	O
neutralizing	O
activities	O
against	O
autologous	O
viruses	O
but	O
were	O
much	O
less	O
efficient	O
(	O
50	O
%	O
inhibitory	O
concentration	O
,	O
20	O
-	O
to	O
40	O
-	O
fold	O
)	O
at	O
neutralizing	O
SARS	O
-	O
CoV	O
and	O
vice	O
versa	O
.	O

Samples	O
were	O
tested	O
for	O
antibodies	B-COMP
to	O
feline	O
immunodeficiency	O
virus	O
,	O
Dirofilaria	O
immitis	O
,	O
feline	O
panleukopenia	O
virus	O
,	O
feline	O
herpesvirus	O
,	O
feline	O
coronavirus	O
,	O
canine	O
distemper	O
virus	O
,	O
and	O
Toxoplasma	O
gondii	O
and	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigen	O
.	O

A	O
major	O
factor	O
in	O
the	O
host	B-COMP
range	O
of	O
a	O
coronavirus	O
is	O
its	O
receptor	O
utilization	O
on	O
host	B-COMP
cells	B-COMP
.	O

We	O
also	O
show	O
that	O
BHK	O
-	O
21	O
cells	B-COMP
are	O
slightly	O
susceptible	O
to	O
certain	O
IBV	O
strains	O
,	O
including	O
Ark99	O
,	O
Ark_DPI	O
,	O
CA99	O
,	O
and	O
Iowa97	O
(<	O
0	O
.	O
01	O
%	O
efficiency	O
),	O
but	O
this	O
level	O
of	O
infection	O
is	O
not	O
increased	O
by	O
fAPN	O
expression	O
.	O

We	O
also	O
show	O
that	O
BHK	O
-	O
21	O
cells	B-COMP
are	O
slightly	O
susceptible	O
to	O
certain	O
IBV	O
strains	O
,	O
including	O
Ark99	O
,	O
Ark_DPI	O
,	O
CA99	O
,	O
and	O
Iowa97	O
(<	O
0	O
.	O
01	O
%	O
efficiency	O
),	O
but	O
this	O
level	O
of	O
infection	O
is	O
not	O
increased	O
by	O
fAPN	O
expression	O
.	O

TITLE	O
:	O
Importance	O
of	O
the	O
penultimate	O
positive	O
charge	O
in	O
mouse	O
hepatitis	O
coronavirus	O
A59	O
membrane	B-COMP
protein	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
efficient	O
expression	O
of	O
S	O
from	O
the	O
wild	O
-	O
type	O
spike	O
gene	O
in	O
cultured	O
cells	B-COMP
required	O
the	O
use	O
of	O
improved	O
plasmid	O
vectors	O
containing	O
donor	O
and	O
acceptor	O
splice	O
sites	O
,	O
as	O
well	O
as	O
heterologous	O
viral	O
RNA	O
export	O
elements	O
,	O
such	O
as	O
the	O
CTE	O
of	O
Mazon	O
-	O
Pfizer	O
monkey	O
virus	O
or	O
the	O
PRE	O
of	O
Woodchuck	O
hepatitis	O
virus	O
(	O
WPRE	O
).	O

Nevertheless	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
AGP	O
might	O
be	O
useful	O
in	O
monitoring	O
FCoV	O
-	O
host	B-COMP
interactions	O
in	O
FCoV	O
-	O
endemic	O
catteries	O
.	O

Cells	B-COMP
transfected	O
with	O
plasmid	O
expressing	O
the	O
6	O
protein	O
released	O
SCoV	O
6	O
protein	O
;	O
however	O
,	O
infected	O
cells	B-COMP
released	O
SCoV	O
6	O
protein	O
only	O
in	O
association	O
with	O
SCoV	O
particles	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
controversial	O
means	O
of	O
life	O
support	O
,	O
particularly	O
in	O
adults	O
.	O

Long	O
-	O
term	O
exposure	O
of	O
HIV	O
to	O
CBAs	O
in	O
cell	B-COMP
culture	O
results	O
in	O
the	O
progressive	O
deletion	O
of	O
N	O
-	O
glycans	O
of	O
HIV	O
gpl20	O
in	O
an	O
attempt	O
of	O
the	O
virus	O
to	O
escape	O
drug	O
pressure	O
.	O

Cellular	B-COMP
and	O
molecular	O
mechanisms	O
of	O
pulmonary	O
vascular	O
remodeling	O
have	O
been	O
experimentally	O
explored	O
in	O
many	O
animal	O
models	O
,	O
and	O
it	O
is	O
now	O
clear	O
that	O
microvessels	O
are	O
involved	O
.	O

Over	O
a	O
period	O
of	O
one	O
year	O
,	O
60	O
patients	O
referred	O
to	O
us	O
with	O
a	O
diagnosis	O
of	O
acute	O
pancreatitis	O
on	O
the	O
basis	O
of	O
clinical	O
findings	O
,	O
CT	O
and	O
elevated	O
serum	B-COMP
amylase	O
level	O
were	O
studied	O
prospectively	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
cyclin	O
D1	O
down	O
-	O
regulation	O
in	O
coronavirus	O
infected	O
cells	B-COMP
.	O

Among	O
antibody	B-COMP
sources	O
,	O
immunoglobulin	O
Y	O
(	O
IgY	O
)	O
is	O
the	O
major	O
antibody	B-COMP
found	O
in	O
chicken	O
eggs	O
and	O
can	O
be	O
used	O
as	O
an	O
alternative	O
to	O
mammalian	O
antibodies	B-COMP
normally	O
used	O
in	O
research	O
and	O
immunotherapy	O
.	O

After	O
purification	O
,	O
the	O
purity	O
of	O
these	O
recombinant	O
spike	O
proteins	O
was	O
examined	O
on	O
SDS	O
-	O
PAGE	O
and	O
their	O
identity	O
verified	O
with	O
Western	O
blot	O
analysis	O
using	O
anti	O
-	O
his	O
antibodies	B-COMP
and	O
sera	B-COMP
from	O
convalescent	O
stage	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

Using	O
these	O
bacteria	O
-	O
derived	O
proteins	O
to	O
immunize	O
chickens	O
,	O
it	O
was	O
found	O
that	O
polyclonal	O
IgY	O
antibodies	B-COMP
in	O
the	O
egg	O
yolk	B-COMP
and	O
sera	B-COMP
were	O
highly	O
reactive	O
to	O
the	O
immunogens	O
,	O
as	O
shown	O
by	O
Western	O
blot	O
and	O
immunocytochemical	O
staining	O
analysis	O
.	O

A	O
phage	O
displaying	O
scFv	O
library	O
was	O
also	O
established	O
from	O
spleen	O
B	O
cells	B-COMP
of	O
immunized	O
chicken	O
with	O
5	O
x	O
10	O
(	O
7	O
)	O
clones	O
.	O

In	O
sequence	O
analysis	O
with	O
chicken	O
germline	O
gene	O
,	O
five	O
phage	O
clones	O
reacted	O
,	O
with	O
large	O
dissimilarities	O
of	O
between	O
31	O
and	O
62	O
%,	O
in	O
the	O
complementarity	O
-	O
determining	O
regions	O
,	O
one	O
dominant	O
phage	O
4S1	O
had	O
strong	O
binding	O
to	O
fragment	O
Se	O
-	O
e	O
,	O
located	O
between	O
amino	O
acid	O
residues	O
456	O
-	O
650	O
of	O
the	O
spike	O
protein	O
and	O
this	O
particular	O
phage	O
had	O
significantly	O
strong	O
binding	O
to	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
molecular	O
mechanisms	O
governing	O
T	O
cell	B-COMP
activation	O
and	O
accumulation	O
within	O
the	O
CNS	O
in	O
response	O
to	O
viral	O
infection	O
,	O
MHV	O
was	O
instilled	O
into	O
the	O
CNS	O
of	O
Drak2	O
-	O
/	O
-	O
mice	O
.	O

Moreover	O
,	O
Drak2	O
-	O
deficient	O
T	O
cell	B-COMP
activation	O
,	O
expansion	O
and	O
cytokine	O
production	O
were	O
unimpaired	O
in	O
response	O
to	O
acute	O
MHV	O
infection	O
.	O

Primers	O
were	O
used	O
to	O
amplify	O
the	O
conserved	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
genome	O
,	O
and	O
the	O
nucleocapsid	B-COMP
protein	O
gene	O
of	O
TCoV	O
.	O
Histopathological	O
and	O
direct	O
immunohistochemical	O
examinations	O
were	O
performed	O
to	O
detect	O
TCoV	O
antigen	O
in	O
infected	O
intestine	O
and	O
bursa	O
slides	O
.	O

In	O
addition	O
,	O
leptodactylone	O
(	O
8	O
)	O
showed	O
potent	O
protective	O
activity	O
on	O
cells	B-COMP
infected	O
by	O
SARS	O
-	O
CoV	O
with	O
ratio	O
of	O
60	O
%	O
at	O
100	O
microg	O
/	O
ml	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
based	O
on	O
recombinant	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
generated	O
in	O
Escherichia	O
coli	O
was	O
evaluated	O
for	O
its	O
sensitivity	O
and	O
specificity	O
for	O
diagnosis	O
of	O
porcine	O
epidemic	O
diarrhea	O
(	O
PEDV	O
)	O
infection	O
.	O

The	O
molecular	O
and	O
cellular	B-COMP
basis	O
for	O
how	O
SARS	O
CoV	O
impacts	O
the	O
host	B-COMP
immune	O
system	O
resulting	O
in	O
severe	O
SARS	O
,	O
however	O
,	O
has	O
not	O
been	O
elucidated	O
.	O

TITLE	O
:	O
Computational	O
characterization	O
and	O
design	O
of	O
SARS	O
coronavirus	O
receptor	O
recognition	O
and	O
antibody	B-COMP
neutralization	O
.	O

ABSTRACT	O
:	O
The	O
sequential	O
determination	O
of	O
crystal	O
structures	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
cellular	B-COMP
receptor	O
or	O
neutralizing	O
antibody	B-COMP
opened	O
a	O
door	O
for	O
the	O
design	O
and	O
development	O
of	O
antiviral	O
competitive	O
inhibitors	O
.	O

Based	O
on	O
those	O
complex	O
structures	O
,	O
we	O
conduct	O
computational	O
characterization	O
and	O
design	O
of	O
RBD	O
-	O
mediated	O
receptor	O
recognition	O
and	O
antibody	B-COMP
neutralization	O
.	O

Our	O
previous	O
studies	O
using	O
nuclear	O
magnetic	O
resonance	O
revealed	O
the	O
domain	O
organization	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
At	O
the	O
beginning	O
of	O
the	O
20th	O
century	O
,	O
observations	O
of	O
apoplectic	O
adrenal	O
glands	O
in	O
fatal	O
meningococcemia	O
underlined	O
their	O
key	O
role	O
in	O
host	B-COMP
defence	O
against	O
infection	O
.	O

TITLE	O
:	O
Using	O
patient	O
-	O
collected	O
clinical	O
samples	O
and	O
sera	B-COMP
to	O
detect	O
and	O
quantify	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Fecal	O
samples	O
were	O
frequently	O
SARS	O
-	O
CoV	O
RT	O
-	O
PCR	O
positive	O
beyond	O
40	O
days	O
,	O
and	O
occasional	O
sera	B-COMP
still	O
had	O
SARS	O
-	O
CoV	O
detected	O
after	O
3	O
weeks	O
of	O
illness	O
.	O

The	O
latter	O
include	O
dysregulation	O
of	O
cytokines	O
/	O
chemokines	O
,	O
deficiencies	O
in	O
the	O
innate	O
immune	O
response	O
,	O
direct	O
infection	O
of	O
immune	O
cells	B-COMP
,	O
direct	O
viral	O
cytopathic	O
effects	O
,	O
down	O
-	O
regulation	O
of	O
lung	O
protective	O
angiotensin	O
converting	O
enzyme	O
2	O
,	O
autoimmunity	O
,	O
and	O
genetic	O
factors	O
.	O

Viable	O
mutant	O
nsp10	O
-	O
E2	O
was	O
compromised	O
in	O
its	O
ability	O
to	O
process	O
the	O
nascent	O
polyprotein	O
,	O
as	O
processing	O
intermediates	O
were	O
detected	O
in	O
cells	B-COMP
infected	O
with	O
this	O
virus	O
that	O
were	O
not	O
detectable	O
in	O
wild	O
-	O
type	O
infections	O
.	O

When	O
fused	O
with	O
a	O
conserved	O
neutralizing	O
epitope	O
(	O
SP1143	O
-	O
1157	O
)	O
from	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
NP111	O
and	O
NP351	O
assisted	O
in	O
the	O
production	O
of	O
high	O
-	O
titer	O
neutralizing	O
antibodies	B-COMP
in	O
vivo	O
.	O

The	O
prevalence	O
of	O
specific	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
in	O
employees	O
of	O
the	O
animal	O
market	O
were	O
somehow	O
related	O
with	O
the	O
presence	O
or	O
absence	O
of	O
palm	O
civet	O
.	O

TITLE	O
:	O
Protective	O
role	O
of	O
macrophages	O
in	O
noninflammatory	O
lung	O
injury	O
caused	O
by	O
selective	O
ablation	O
of	O
alveolar	O
epithelial	O
type	O
II	O
Cells	B-COMP
.	O

The	O
purified	O
S	O
-	O
protein	O
bound	O
to	O
Vero	O
but	O
not	O
293T	O
cells	B-COMP
and	O
was	O
itself	O
recognized	O
by	O
lung	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
),	O
a	O
collectin	O
found	O
in	O
the	O
lung	O
alveoli	O
.	O

The	O
serum	B-COMP
collectin	O
,	O
mannan	O
-	O
binding	O
lectin	O
(	O
MBL	O
),	O
exhibited	O
no	O
detectable	O
binding	O
to	O
the	O
purified	O
S	O
-	O
protein	O
.	O

Analyzing	O
the	O
cellular	B-COMP
proteins	O
involving	O
in	O
regulation	O
of	O
cell	B-COMP
cycle	O
progression	O
,	O
we	O
demonstrated	O
that	O
3a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	O
D3	O
level	O
and	O
phosphorylation	O
of	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
Ser	B-COMP
-	O
795	O
and	O
Ser	B-COMP
-	O
809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	O
D1	O
,	O
D2	O
,	O
cdk4	O
,	O
and	O
cdk6	O
in	O
293	O
cells	B-COMP
.	O

Diabetic	O
liver	O
lesions	O
include	O
glycogenic	O
hepatopathy	O
(	O
in	O
which	O
poor	O
diabetic	O
control	O
leads	O
to	O
swollen	O
,	O
glycogen	O
-	O
filled	O
hepatocytes	O
without	O
fat	O
,	O
steatohepatitis	O
or	O
fibrosis	O
)	O
and	O
diabetic	O
hepatosclerosis	O
in	O
which	O
there	O
is	O
diffuse	O
perisinusoidal	O
fibrosis	O
(	O
type	O
IV	O
collagen	B-COMP
)	O
without	O
zonal	O
predilection	O
.	O

In	O
this	O
study	O
,	O
after	O
verification	O
by	O
various	O
methods	O
that	O
the	O
golden	O
Syrian	O
hamster	O
constitutes	O
a	O
model	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
we	O
confirmed	O
that	O
the	O
antibody	B-COMP
could	O
protect	O
animals	O
completely	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
preventive	O
setting	O
.	O

More	O
importantly	O
,	O
the	O
antibody	B-COMP
could	O
reduce	O
viral	O
titers	O
or	O
copies	O
by	O
approximately	O
10	O
(	O
3	O
)-	O
to	O
10	O
(	O
4	O
)-	O
fold	O
in	O
animal	O
lung	O
after	O
virus	O
exposure	O
,	O
compared	O
with	O
negative	O
control	O
.	O

Sequence	O
analysis	O
of	O
the	O
complete	O
genomes	O
revealed	O
differences	O
at	O
123	O
and	O
149	O
nucleotides	O
(	O
nt	O
)	O
throughout	O
the	O
entire	O
genome	O
between	O
the	O
respiratory	O
and	O
enteric	O
strains	O
for	O
samples	O
AH65	O
and	O
AH187	O
,	O
respectively	O
,	O
indicating	O
the	O
presence	O
of	O
intra	O
-	O
host	B-COMP
BCoV	O
quasispecies	O
.	O

The	O
antibodies	B-COMP
against	O
MHV	O
were	O
also	O
detected	O
in	O
small	O
intestinal	O
mucosal	O
samples	O
from	O
immunized	O
mice	O
at	O
2	O
w	O
post	O
-	O
three	O
immunization	O
.	O

Endothelial	O
cells	B-COMP
are	O
capable	O
of	O
inhibiting	O
TNF	O
production	O
by	O
producing	O
prostaglandins	O
that	O
inhibit	O
TNF	O
production	O
.	O

E	O
-	O
selectin	O
,	O
an	O
endothelial	O
leukocyte	O
adhesion	O
molecule	O
,	O
is	O
released	O
from	O
the	O
endothelial	O
cell	B-COMP
membrane	I-COMP
by	O
the	O
action	O
of	O
TNF	O
and	O
exists	O
as	O
soluble	O
E	O
-	O
selectin	O
in	O
plasma	O
.	O

The	O
receptors	O
of	O
those	O
two	O
viruses	O
have	O
been	O
identified	O
and	O
their	O
cell	B-COMP
entry	O
mechanism	O
has	O
been	O
actively	O
investigated	O
.	O

TITLE	O
:	O
Identification	O
of	O
antibody	B-COMP
against	O
porcine	O
coronavirus	O
in	O
human	O
milk	O
.	O

Overall	O
,	O
114	O
TCC	B-COMP
were	O
virus	O
-	O
specific	O
,	O
31	O
were	O
specific	O
for	O
myelin	B-COMP
Ag	O
and	O
10	O
other	O
were	O
HCoV	O
/	O
myelin	B-COMP
cross	O
-	O
reactive	O
.	O

Our	O
findings	O
have	O
promising	O
implications	O
in	O
the	O
investigation	O
of	O
the	O
role	O
of	O
molecular	O
mimicry	O
between	O
coronaviruses	O
and	O
myelin	B-COMP
in	O
MS	O
as	O
a	O
mechanism	O
related	O
to	O
disease	O
initiation	O
or	O
relapses	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
emerged	O
in	O
2002	O
as	O
an	O
important	O
cause	O
of	O
severe	O
lower	O
respiratory	O
tract	O
infection	O
in	O
humans	O
and	O
in	O
vitro	O
models	O
of	O
the	O
lung	O
are	O
needed	O
to	O
elucidate	O
cellular	B-COMP
targets	O
and	O
the	O
consequences	O
of	O
viral	O
infection	O
.	O

Preincubation	O
of	O
the	O
apical	O
surface	O
of	O
cultures	O
with	O
antisera	O
directed	O
against	O
hACE2	O
reduced	O
viral	O
titers	O
by	O
two	O
logs	O
while	O
antisera	O
against	O
DC	O
-	O
SIGN	O
/	O
DC	O
-	O
SIGNR	O
did	O
not	O
reduce	O
viral	O
replication	O
levels	O
suggesting	O
that	O
hACE2	O
is	O
the	O
primary	O
receptor	O
for	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
the	O
ciliated	O
cells	B-COMP
of	O
HAE	O
cultures	O
.	O

Apoptosis	O
induced	O
by	O
SARS	O
coronavirus	O
N	O
protein	O
under	O
starvation	O
of	O
serum	B-COMP
of	O
COS	O
-	O
1	O
cells	B-COMP
was	O
monitored	O
by	O
Annexin	O
V	O
and	O
electron	O
microscopy	O
assays	O
.	O

Intracellular	B-COMP
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
mitochondrial	B-COMP
membrane	I-COMP
potential	O
(	O
DeltaPsim	O
)	O
were	O
determined	O
by	O
flow	O
cytometric	O
assay	O
.	O

In	O
conclusion	O
,	O
SARS	O
coronavirus	O
N	O
protein	O
can	O
induce	O
apoptosis	O
of	O
COS	O
-	O
1	O
cells	B-COMP
by	O
activating	O
mitochondrial	B-COMP
pathway	O
.	O

TITLE	O
:	O
Community	O
respiratory	O
virus	O
infections	O
in	O
immunocompromised	O
patients	O
:	O
hematopoietic	O
stem	O
cell	B-COMP
and	O
solid	O
organ	O
transplant	O
recipients	O
,	O
and	O
individuals	O
with	O
human	O
immunodeficiency	O
virus	O
infection	O
.	O

Respiratory	O
syncytial	O
virus	O
,	O
influenza	O
viruses	O
,	O
parainfluenza	O
viruses	O
,	O
and	O
adenoviruses	O
cause	O
the	O
most	O
serious	O
disease	O
in	O
immunocompromised	O
hosts	B-COMP
,	O
but	O
other	O
respiratory	O
viruses	O
are	O
becoming	O
increasingly	O
appreciated	O
as	O
a	O
cause	O
of	O
both	O
upper	O
and	O
lower	O
respiratory	O
tract	O
disease	O
.	O

The	O
comparison	O
of	O
serum	B-COMP
AGP	O
levels	O
in	O
the	O
different	O
groups	O
and	O
the	O
analysis	O
of	O
the	O
ROC	O
curve	O
confirmed	O
that	O
serum	B-COMP
AGP	O
is	O
a	O
powerful	O
discriminating	O
marker	O
for	O
FIP	O
.	O

The	O
Bayesian	O
approach	O
demonstrated	O
that	O
when	O
the	O
pretest	O
probability	O
of	O
FIP	O
is	O
high	O
,	O
based	O
on	O
history	O
and	O
clinical	O
signs	O
(	O
groups	O
1	O
or	O
2a	O
),	O
moderate	O
serum	B-COMP
AGP	O
levels	O
(	O
1	O
.	O
5	O
-	O
2	O
mg	O
/	O
ml	O
)	O
can	O
discriminate	O
cats	O
with	O
FIP	O
from	O
others	O
,	O
while	O
only	O
high	O
serum	B-COMP
AGP	O
levels	O
(>	O
3	O
mg	O
/	O
ml	O
)	O
can	O
support	O
a	O
diagnosis	O
of	O
FIP	O
in	O
cats	O
with	O
a	O
low	O
pretest	O
probability	O
of	O
disease	O
(	O
groups	O
2b	O
to	O
2e	O
).	O

To	O
investigate	O
whether	O
pAPN	O
is	O
a	O
receptor	O
for	O
PEDV	O
,	O
we	O
transfected	O
MDCK	O
cells	B-COMP
with	O
porcine	O
aminopeptidase	O
(	O
pAPN	O
)	O
cDNA	O
and	O
this	O
enabled	O
non	O
-	O
susceptible	O
cells	B-COMP
to	O
support	O
PEDV	O
replication	O
and	O
serial	O
viral	O
propagation	O
.	O

The	O
remaining	O
12	O
ORFs	O
encode	O
the	O
4	O
structural	O
proteins	O
:	O
spike	O
,	O
membrane	B-COMP
,	O
nucleocapsid	B-COMP
and	O
envelope	B-COMP
;	O
and	O
eight	O
accessory	O
proteins	O
.	O

TITLE	O
:	O
High	O
-	O
level	O
prokaryotic	O
expression	O
of	O
envelope	B-COMP
exterior	O
of	O
membrane	B-COMP
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

The	O
joined	O
ends	O
of	O
the	O
viral	B-COMP
genome	I-COMP
in	O
the	O
DI	O
RNA	O
create	O
a	O
single	O
continuous	O
1	O
,	O
635	O
-	O
nt	O
ORF	O
,	O
288	O
nt	O
of	O
which	O
come	O
from	O
the	O
738	O
-	O
nt	O
nsp1	O
coding	O
region	O
.	O

ABSTRACT	O
:	O
Both	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
able	O
to	O
induce	O
strong	O
humoral	O
responses	O
in	O
humans	O
following	O
an	O
infection	O
.	O

In	O
the	O
postinfection	O
period	O
,	O
however	O
,	O
a	O
number	O
of	O
patients	O
had	O
much	O
lower	O
serum	B-COMP
IgG	O
levels	O
against	O
S450	O
-	O
650	O
than	O
against	O
the	O
N	O
protein	O
.	O

TITLE	O
:	O
Lithium	O
chloride	O
inhibits	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
cell	B-COMP
culture	O
.	O

Our	O
results	O
also	O
indicate	O
that	O
it	O
should	O
be	O
possible	O
to	O
use	O
retroviral	O
pseudotypes	O
to	O
identify	O
and	O
characterize	O
the	O
cellular	B-COMP
receptor	O
for	O
type	O
I	O
feline	O
coronaviruses	O
.	O

Among	O
the	O
accessory	O
proteins	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
3a	O
protein	O
has	O
been	O
shown	O
to	O
interact	O
with	O
the	O
spike	O
,	O
envelope	B-COMP
,	O
and	O
membrane	B-COMP
glycoprotein	O
and	O
has	O
recently	O
been	O
established	O
to	O
be	O
a	O
structural	O
component	O
of	O
capsid	O
.	O

In	O
this	O
study	O
we	O
performed	O
genome	O
-	O
wide	O
microarray	O
analyses	O
of	O
the	O
expression	O
patterns	O
of	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)-	O
infected	O
cells	B-COMP
.	O

However	O
,	O
MHV	O
replication	O
per	O
se	O
does	O
not	O
appear	O
to	O
benefit	O
from	O
the	O
inhibition	O
of	O
host	B-COMP
protein	O
synthesis	O
,	O
at	O
least	O
in	O
vitro	O
,	O
since	O
viral	O
replication	O
was	O
not	O
negatively	O
affected	O
but	O
rather	O
enhanced	O
in	O
cells	B-COMP
with	O
impaired	O
translational	O
shutoff	O
.	O

In	O
cells	B-COMP
infected	O
with	O
coronaviruses	O
,	O
cell	B-COMP
cycle	O
perturbation	O
and	O
apoptosis	O
were	O
observed	O
in	O
several	O
reports	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
these	O
effects	O
are	O
brought	O
out	O
,	O
and	O
how	O
manipulation	O
of	O
the	O
functions	O
of	O
host	B-COMP
cells	B-COMP
would	O
influence	O
the	O
replication	O
cycle	O
of	O
coronavirus	O
.	O

However	O
,	O
intramuscular	O
immunization	O
evoked	O
a	O
vigorous	O
antibody	B-COMP
response	O
and	O
a	O
weak	O
T	O
-	O
cell	B-COMP
response	O
,	O
and	O
vaccination	O
by	O
electroporation	O
evoked	O
a	O
vigorous	O
response	O
with	O
a	O
predominant	O
subclass	O
IgG1	B-COMP
antibody	I-COMP
response	O
and	O
a	O
moderate	O
T	O
-	O
cell	B-COMP
response	O
.	O

The	O
rSARS	O
-	O
N	O
expressed	O
in	O
insect	O
cells	B-COMP
(	O
BrSARS	O
-	O
N	O
)	O
showed	O
remarkably	O
higher	O
specificity	O
and	O
immunoreactivity	O
than	O
rSARS	O
-	O
N	O
expressed	O
in	O
E	O
.	O
coli	O
(	O
ErSARS	O
-	O
N	O
).	O

In	O
further	O
analysis	O
to	O
determine	O
the	O
correlation	O
between	O
the	O
phosphorylation	O
and	O
the	O
antigenicity	O
of	O
SARS	O
-	O
N	O
protein	O
,	O
dephosphorylated	O
SARS	O
-	O
N	O
protein	O
treated	O
with	O
protein	O
phosphatase	O
1	O
(	O
PP1	O
)	O
remarkably	O
enhanced	O
the	O
cross	O
-	O
reactivity	O
against	O
SARS	O
negative	O
serum	B-COMP
and	O
considerably	O
reduced	O
immunoreactivity	O
with	O
SARS	O
-	O
N	O
mAb	O
.	O

ABSTRACT	O
:	O
Glycosaminoglycans	O
(	O
GAGs	O
),	O
including	O
heparan	O
sulfate	O
(	O
HS	O
),	O
are	O
expressed	O
on	O
the	O
surface	O
of	O
nearly	O
all	O
cells	B-COMP
,	O
linked	O
to	O
transmembrane	B-COMP
proteins	O
.	O

These	O
GAGs	O
are	O
sulfated	O
to	O
varying	O
extents	O
,	O
lending	O
a	O
negative	O
charge	O
,	O
and	O
are	O
used	O
by	O
a	O
large	O
number	O
of	O
viruses	O
to	O
initiate	O
infection	O
of	O
immortalized	O
cell	B-COMP
lines	O
.	O

The	O
protocols	O
presented	O
allow	O
the	O
determination	O
of	O
which	O
GAG	O
(	O
s	O
)	O
is	O
employed	O
by	O
the	O
virus	O
,	O
which	O
GAG	O
modification	O
(	O
s	O
)	O
is	O
important	O
,	O
and	O
whether	O
the	O
important	O
GAG	O
is	O
on	O
the	O
cell	B-COMP
or	O
on	O
the	O
virus	O
.	O

The	O
highly	O
immunogenic	O
D2	O
peptide	O
contains	O
both	O
neutralizing	O
and	O
Th	O
cell	B-COMP
epitopes	O
.	O

This	O
panel	O
of	O
SARS	O
-	O
CoV	O
recombinants	O
bearing	O
zoonotic	O
and	O
human	O
epidemic	O
spike	O
glycoproteins	O
will	O
provide	O
heterologous	O
challenge	O
models	O
for	O
testing	O
vaccine	O
efficacy	O
against	O
zoonotic	O
reintroductions	O
as	O
well	O
as	O
provide	O
the	O
appropriate	O
model	O
system	O
for	O
elucidating	O
the	O
complex	O
virus	O
-	O
host	B-COMP
interactions	O
that	O
contribute	O
to	O
more	O
-	O
severe	O
and	O
fatal	O
SARS	O
-	O
CoV	O
disease	O
and	O
acute	O
respiratory	O
distress	O
in	O
the	O
elderly	O
.	O

We	O
show	O
that	O
also	O
accessory	O
protein	O
ORF9b	O
does	O
not	O
play	O
a	O
pivotal	O
role	O
for	O
viral	O
replication	O
,	O
as	O
it	O
can	O
be	O
deleted	O
from	O
the	O
virus	O
displaying	O
normal	O
plaque	O
sizes	O
and	O
growth	O
characteristics	O
in	O
Vero	O
cells	B-COMP
.	O

These	O
results	O
suggest	O
that	O
when	O
SARS	O
-	O
CoV	O
binds	O
ACE2	O
it	O
is	O
internalized	O
and	O
penetrates	O
early	O
endosomes	O
in	O
a	O
clathrin	O
-	O
dependent	O
manner	O
and	O
that	O
the	O
cytoplasmic	B-COMP
tail	O
of	O
ACE2	O
is	O
not	O
required	O
for	O
the	O
penetration	O
of	O
SARS	O
-	O
CoV	O
.	O

Differential	O
inhibition	O
of	O
intracellular	B-COMP
signaling	O
steps	O
suggested	O
significant	O
contribution	O
of	O
phosphatidylcholine	O
-	O
specific	O
phospholipase	O
C	O
and	O
protein	O
kinase	O
C	O
and	O
of	O
the	O
Rho	O
/	O
Rho	O
-	O
kinase	O
pathway	O
to	O
PLY	O
-	O
induced	O
pulmonary	O
vasoconstriction	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
involved	O
in	O
virus	O
replication	O
and	O
modulation	O
of	O
cell	B-COMP
processes	I-COMP
.	O

Using	O
a	O
combination	O
of	O
live	O
-	O
cell	B-COMP
and	O
confocal	O
microscopy	O
coupled	O
to	O
mutagenesis	O
we	O
identified	O
a	O
cryptic	O
nucleolar	O
localisation	O
signal	O
in	O
the	O
central	O
part	O
of	O
the	O
N	O
protein	O
.	O

It	O
plays	O
important	O
roles	O
in	O
virion	B-COMP
assembly	O
and	O
morphogenesis	O
,	O
alteration	O
of	O
the	O
membrane	B-COMP
permeability	O
of	O
host	B-COMP
cells	B-COMP
and	O
virus	O
-	O
host	B-COMP
cell	I-COMP
interaction	O
.	O

Finally	O
,	O
colocalization	O
experiments	O
were	O
performed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
mammalian	O
cells	B-COMP
to	O
confirm	O
the	O
nsp8	O
-	O
ORF6	O
interaction	O
.	O

TITLE	O
:	O
Immune	O
response	O
induced	O
by	O
spike	O
protein	O
from	O
transmissible	O
gastroenteritis	O
coronavirus	O
expressed	O
in	O
mouse	O
mammary	O
cells	B-COMP
.	O

Endocrine	O
pancreas	O
islets	O
were	O
unremarkable	O
and	O
contained	O
insulin	O
-	O
positive	O
beta	O
cells	B-COMP
and	O
glucagon	O
-	O
positive	O
alpha	O
cells	B-COMP
.	O

13	O
patients	O
were	O
considered	O
immunocompetent	O
and	O
10	O
were	O
immunocompromised	O
when	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
started	O
.	O

The	O
S1	O
protein	O
could	O
be	O
highly	O
expressed	O
in	O
M	O
.	O
smegmatis	O
mc2	O
155	O
when	O
induced	O
by	O
heating	O
and	O
was	O
detected	O
by	O
ELISA	O
and	O
Western	O
blot	O
assays	O
using	O
monoclonal	O
antibody	B-COMP
against	O
S1	O
glycoprotein	O
of	O
IBV	O
.	O

Early	O
testing	O
for	O
anti	O
-	O
synthetase	O
antibodies	B-COMP
,	O
particularly	O
anti	O
-	O
Jo	O
-	O
1	O
,	O
and	O
creatine	O
kinase	O
determination	O
are	O
useful	O
procedures	O
in	O
patients	O
presenting	O
with	O
ILD	O
.	O

RESULTS	O
:	O
Fever	O
and	O
radiological	O
patterns	O
including	O
diffuse	O
patchy	O
ground	O
-	O
glass	O
opacities	O
,	O
basal	O
irregular	O
lines	O
and	O
consolidation	O
on	O
high	O
-	O
resolution	O
CT	O
scan	O
were	O
more	O
frequent	O
in	O
group	O
A	O
than	O
in	O
group	O
G	O
.	O
More	O
patients	O
in	O
group	O
G	O
had	O
neutrophils	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
autoantibodies	O
other	O
than	O
anti	O
-	O
Jo	O
-	O
1	O
(	O
rheumatoid	O
factor	O
,	O
anti	O
SSa	O
/	O
SSb	B-COMP
)	O
than	O
in	O
group	O
A	O
.	O
The	O
percentage	O
of	O
patients	O
in	O
whom	O
the	O
ILD	O
improved	O
at	O
3	O
months	O
was	O
significantly	O
higher	O
in	O
group	O
A	O
than	O
in	O
group	O
G	O
(	O
13	O
/	O
15	O
vs	O
9	O
/	O
17	O
;	O
p	O
=	O
0	O
.	O
006	O
).	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
carbohydrate	O
-	O
binding	O
agents	O
against	O
Nidovirales	O
in	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Cell	B-COMP
entry	O
by	O
enveloped	O
viruses	O
:	O
redox	O
considerations	O
for	O
HIV	O
and	O
SARS	O
-	O
coronavirus	O
.	O

Virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
is	O
mediated	O
by	O
the	O
virus	O
envelope	B-COMP
complex	O
,	O
and	O
its	O
fusogenicity	O
is	O
the	O
result	O
of	O
an	O
active	O
virus	O
-	O
cell	B-COMP
interaction	O
process	O
that	O
induces	O
conformation	O
changes	O
within	O
the	O
envelope	B-COMP
.	O

Oval	O
and	O
elongated	O
particles	O
,	O
approximately	O
100	O
to	O
170	O
nm	O
in	O
diameter	O
,	O
with	O
club	O
-	O
shaped	O
projections	O
were	O
seen	O
in	O
the	O
infected	O
culture	O
supernatant	O
,	O
and	O
torovirus	O
-	O
like	O
(	O
tubular	O
and	O
torus	O
nucleocapsid	B-COMP
)	O
structures	O
were	O
seen	O
in	O
the	O
infected	O
cells	B-COMP
by	O
electron	O
microscopy	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
SARS	O
-	O
CoV	O
.	O
In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
a	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
-	O
based	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
vaccine	O
could	O
induce	O
strong	O
neutralizing	O
antibody	B-COMP
(	O
Nab	O
)	O
response	O
which	O
might	O
have	O
played	O
a	O
critical	O
role	O
in	O
protecting	O
Chinese	O
rhesus	O
monkeys	O
from	O
the	O
pathogenic	O
viral	O
challenge	O
.	O

ABSTRACT	O
:	O
The	O
susceptibility	O
of	O
the	O
chicken	O
embryo	O
related	O
(	O
CER	O
)	O
cell	B-COMP
line	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
M41	O
)	O
was	O
characterized	O
after	O
five	O
consecutive	O
passages	O
in	O
CER	O
cells	B-COMP
.	O

TITLE	O
:	O
siRNAs	O
targeting	O
terminal	O
sequences	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
membrane	B-COMP
gene	O
inhibit	O
M	O
protein	O
expression	O
through	O
degradation	O
of	O
M	O
mRNA	O
.	O

These	O
findings	O
demonstrated	O
that	O
the	O
three	O
M	O
-	O
specific	O
siRNAs	O
were	O
able	O
to	O
specifically	O
and	O
effectively	O
inhibit	O
M	O
glycoprotein	O
expression	O
in	O
cultured	O
cells	B-COMP
by	O
blocking	O
the	O
accumulation	O
of	O
mRNA	O
,	O
which	O
provides	O
an	O
approach	O
for	O
studies	O
on	O
the	O
functions	O
of	O
M	O
protein	O
and	O
for	O
the	O
development	O
of	O
novel	O
prophylactic	O
or	O
therapeutic	O
agents	O
for	O
SCoV	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
host	B-COMP
innate	O
immune	O
response	O
is	O
an	O
important	O
deterrent	O
of	O
severe	O
viral	O
infection	O
in	O
humans	O
and	O
animals	O
.	O

Results	O
showed	O
that	O
the	O
intranasal	O
route	O
caused	O
the	O
highest	O
production	O
of	O
specific	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
IgG2a	B-COMP
,	O
and	O
secretory	O
IgA	O
,	O
where	O
IgG2a	B-COMP
was	O
imprinted	O
as	O
a	O
Th1	O
cell	B-COMP
bias	O
.	O

Our	O
work	O
also	O
indicates	O
that	O
the	O
type	O
IVB	O
pilus	B-COMP
operon	O
promoter	O
controlling	O
foreign	O
gene	O
expression	O
in	O
Salmonella	O
can	O
elicit	O
full	O
immune	O
responses	O
by	O
intranasal	O
vaccination	O
.	O

Western	O
-	O
blot	O
and	O
immunofluorescent	O
antibody	B-COMP
assays	O
were	O
used	O
to	O
detect	O
anti	O
-	O
ORF8a	O
antibody	B-COMP
.	O

Transgenic	O
mice	O
expressing	O
green	O
fluorescent	O
protein	O
under	O
control	O
of	O
the	O
astrocyte	O
-	O
specific	O
glial	B-COMP
fibrillary	I-COMP
acidic	I-COMP
protein	I-COMP
promoter	O
were	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
to	O
facilitate	O
phenotypic	O
characterization	O
of	O
astrocytes	O
and	O
microglia	O
using	O
flow	O
cytometry	O
.	O

Similarly	O
,	O
viral	O
clearance	O
from	O
the	O
livers	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
was	O
accelerated	O
in	O
comparison	O
to	O
MHV	O
-	O
infected	O
mice	O
,	O
yet	O
was	O
independent	O
of	O
enhanced	O
infiltration	O
of	O
T	O
lymphocytes	O
and	O
NK	O
cells	B-COMP
.	O

Pathological	O
findings	O
and	O
immunohistochemical	O
identification	O
using	O
a	O
monoclonal	O
anti	O
-	O
canine	O
Coronavirus	O
antibody	B-COMP
are	O
included	O
.	O

ABSTRACT	O
:	O
Bone	O
marrow	O
-	O
derived	O
progenitors	O
for	O
both	O
epithelial	O
and	O
endothelial	O
cells	B-COMP
have	O
been	O
observed	O
in	O
the	O
lung	O
.	O

Virtually	O
no	O
cells	B-COMP
were	O
found	O
in	O
the	O
right	O
lung	O
or	O
in	O
other	O
organs	O
.	O

We	O
showed	O
that	O
IBV	O
strains	O
M41	O
,	O
H52	O
,	O
H120	O
and	O
Gray	O
could	O
be	O
propagated	O
in	O
HeLa	O
cells	B-COMP
with	O
distinct	O
cytopathic	O
effect	O
.	O

These	O
IBV	O
strains	O
replicated	O
to	O
an	O
average	O
titre	O
of	O
10	O
(	O
3	O
.	O
4	O
+/-	O
0	O
.	O
2	O
)/	O
0	O
.	O
1	O
ml	O
median	O
tissue	O
culture	O
infectious	O
doses	O
in	O
freshly	O
dispersed	O
HeLa	O
cells	B-COMP
and	O
maintained	O
this	O
titre	O
for	O
the	O
first	O
12	O
passages	O
.	O

These	O
results	O
indicated	O
that	O
the	O
virus	O
adaptation	O
would	O
probably	O
be	O
determined	O
by	O
host	B-COMP
cell	I-COMP
modification	O
such	O
as	O
receptor	O
glycosylation	O
and	O
different	O
receptor	O
utilization	O
instead	O
of	O
viral	O
gene	O
mutation	O
.	O

Both	O
antibodies	B-COMP
competed	O
with	O
the	O
SARS	O
-	O
CoV	O
receptor	O
,	O
ACE2	O
,	O
for	O
binding	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
suggesting	O
a	O
mechanism	O
of	O
neutralization	O
that	O
involves	O
interference	O
with	O
the	O
SARS	O
-	O
CoV	O
-	O
ACE2	O
interaction	O
.	O

These	O
antibodies	B-COMP
exhibit	O
cross	O
-	O
reactivity	O
against	O
isolates	O
from	O
the	O
two	O
SARS	O
outbreaks	O
and	O
palm	O
civets	O
and	O
could	O
have	O
potential	O
applications	O
for	O
diagnosis	O
,	O
prophylaxis	O
,	O
and	O
treatment	O
of	O
SARS	O
-	O
CoV	O
infections	O
.	O

Here	O
,	O
the	O
entry	O
pathway	O
of	O
MHV	O
-	O
A59	O
into	O
murine	O
fibroblast	O
cells	B-COMP
was	O
studied	O
by	O
independent	O
approaches	O
.	O

Bright	O
labeling	O
of	O
intracellular	B-COMP
compartments	O
suggests	O
their	O
fusion	O
with	O
the	O
viral	B-COMP
envelope	I-COMP
.	O

No	O
fusion	O
with	O
the	O
plasma	B-COMP
membrane	I-COMP
was	O
observed	O
at	O
neutral	O
pH	O
conditions	O
.	O

The	O
serological	O
antibody	B-COMP
response	O
to	O
the	O
aMPV	O
vaccine	O
given	O
with	O
the	O
IBV	O
and	O
NDV	O
vaccine	O
was	O
significantly	O
lower	O
than	O
when	O
the	O
aMPV	O
vaccine	O
was	O
given	O
alone	O
.	O

Cytotoxicity	O
assay	O
clearly	O
showed	O
that	O
the	O
T	O
-	O
cells	B-COMP
obtained	O
from	O
the	O
vaccinated	O
animals	O
were	O
able	O
to	O
kill	O
the	O
N	O
-	O
protein	O
expressing	O
cells	B-COMP
with	O
a	O
cytotoxicity	O
level	O
of	O
86	O
%	O
in	O
an	O
effector	O
cells	B-COMP
/	O
target	O
cells	B-COMP
ratio	O
of	O
81	O
:	O
1	O
one	O
week	O
after	O
the	O
last	O
vaccination	O
,	O
which	O
is	O
significantly	O
higher	O
than	O
other	O
N	O
-	O
protein	O
peptides	O
previously	O
described	O
.	O

The	O
adaptation	O
of	O
animal	O
viruses	O
to	O
the	O
human	O
host	B-COMP
,	O
as	O
recently	O
exemplified	O
by	O
influenza	O
viruses	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
is	O
also	O
a	O
continuous	O
threat	O
.	O

TITLE	O
:	O
Amino	O
acid	O
substitutions	O
in	O
the	O
s2	O
region	O
enhance	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infectivity	O
in	O
rat	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
-	O
expressing	O
cells	B-COMP
.	O

Ten	O
diterpenoids	O
(	O
1	O
-	O
10	O
),	O
two	O
sesquiterpenoids	O
(	O
11	O
and	O
12	O
),	O
two	O
triterpenoids	O
(	O
13	O
and	O
14	O
),	O
five	O
lignoids	O
(	O
15	O
-	O
19	O
),	O
curcumin	O
(	O
20	O
),	O
and	O
reference	O
controls	O
niclosamide	O
(	O
21	O
)	O
and	O
valinomycin	O
(	O
22	O
)	O
were	O
potent	O
inhibitors	O
at	O
concentrations	O
between	O
3	O
.	O
3	O
and	O
10	O
microM	O
.	O
The	O
concentrations	O
of	O
the	O
22	O
compounds	O
to	O
inhibit	O
50	O
%	O
of	O
Vero	O
E6	O
cell	B-COMP
proliferation	O
(	O
CC50	O
)	O
and	O
viral	O
replication	O
(	O
EC50	O
)	O
were	O
measured	O
.	O

Collectively	O
,	O
these	O
results	O
support	O
the	O
notion	O
that	O
the	O
6	O
protein	O
interacts	O
with	O
membrane	B-COMP
-	O
bound	O
viral	O
replication	O
or	O
assembly	O
machinery	O
to	O
directly	O
enhance	O
virus	O
replication	O
and	O
virulence	O
in	O
animals	O
.	O

Use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
early	O
in	O
the	O
event	O
of	O
cardiorespiratory	O
failure	O
after	O
cardiac	O
surgery	O
may	O
be	O
of	O
benefit	O
.	O

Recombinant	O
SARS	O
-	O
CoVs	O
bearing	O
deletions	O
in	O
gene	O
7	O
were	O
used	O
to	O
assess	O
the	O
contribution	O
of	O
gene	O
7	O
to	O
virus	O
replication	O
and	O
apoptosis	O
in	O
several	O
transformed	O
cell	B-COMP
lines	O
,	O
as	O
well	O
as	O
to	O
replication	O
and	O
pathogenesis	O
in	O
golden	O
Syrian	O
hamsters	O
.	O

ABSTRACT	O
:	O
A	O
highly	O
neurovirulent	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
JHMV	O
strain	O
(	O
wt	O
)	O
with	O
receptor	O
(	O
MHVR	O
)-	O
independent	O
infection	O
activity	O
and	O
its	O
low	O
-	O
virulent	O
mutant	O
srr7	O
without	O
such	O
activity	O
were	O
found	O
to	O
attach	O
to	O
MHVR	O
-	O
negative	O
,	O
non	O
-	O
permissive	O
BHK	O
cells	B-COMP
.	O

In	O
two	O
SARS	O
patients	O
,	O
we	O
examined	O
the	O
memory	O
CD4	O
(+)	O
T	O
-	O
cell	B-COMP
responses	O
to	O
peptides	O
derived	O
from	O
SARS	O
coronavirus	O
structural	O
proteins	O
.	O

Analysis	O
of	O
gene	O
signatures	O
revealed	O
induction	O
of	O
a	O
strong	O
innate	O
immune	O
response	O
characterized	O
by	O
the	O
stimulation	O
of	O
various	O
cytokine	O
and	O
chemokine	O
genes	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IP	O
-	O
10	O
,	O
which	O
corresponds	O
to	O
the	O
host	B-COMP
response	O
seen	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
kinetics	O
of	O
attachment	O
and	O
internalization	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
serotype	O
I	O
strain	O
Black	O
and	O
serotype	O
II	O
strain	O
79	O
-	O
1146	O
were	O
determined	O
in	O
feline	O
monocytes	O
from	O
two	O
cats	O
and	O
in	O
Crandell	O
feline	O
kidney	O
(	O
CrFK	O
)	O
cells	B-COMP
.	O

Virus	B-COMP
particles	I-COMP
were	O
recorded	O
in	O
the	O
dilated	O
rough	B-COMP
endoplasmic	I-COMP
reticulum	I-COMP
and	O
Golgi	B-COMP
complex	I-COMP
of	O
the	O
isthmus	O
,	O
tubular	O
shell	O
gland	O
,	O
and	O
shell	O
gland	O
pouch	O
of	O
all	O
3	O
hens	O
that	O
had	O
stopped	O
laying	O
.	O

Furthermore	O
,	O
CBA	O
did	O
not	O
inhibit	O
virus	O
-	O
cell	B-COMP
attachment	I-COMP
,	O
but	O
rather	O
affected	O
virus	O
entry	O
at	O
a	O
post	O
-	O
binding	O
stage	O
.	O

Identification	O
of	O
functional	O
dominant	O
epitopes	O
in	O
SARS	O
CoV	O
S	O
protein	O
for	O
T	O
cells	B-COMP
is	O
crucial	O
for	O
further	O
understanding	O
of	O
cellular	B-COMP
immune	O
responses	O
elicited	O
by	O
SARS	O
CoV	O
S	O
DNA	O
vaccine	O
.	O

ABSTRACT	O
:	O
We	O
used	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	B-COMP
infected	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
an	O
indirect	O
immunofluorescent	O
assay	O
with	O
antibodies	B-COMP
against	O
TGEV	O
spike	O
and	O
nucleocapsid	B-COMP
proteins	O
to	O
screen	O
small	O
-	O
molecule	O
compounds	O
that	O
inhibit	O
TGEV	O
replication	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
infected	O
humans	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
experience	O
a	O
rapid	O
and	O
dramatic	O
loss	O
of	O
mucosal	O
CD4	O
+	O
T	O
cells	B-COMP
that	O
is	O
considered	O
to	O
be	O
a	O
key	O
determinant	O
of	O
AIDS	O
pathogenesis	O
.	O

Importantly	O
,	O
the	O
kinetics	O
of	O
the	O
loss	O
of	O
mucosal	O
CD4	O
+	O
T	O
cells	B-COMP
in	O
SMs	O
is	O
similar	O
to	O
that	O
of	O
SIVmac239	O
-	O
infected	O
rhesus	O
macaques	O
.	O

These	O
results	O
indicate	O
that	O
a	O
profound	O
depletion	O
of	O
mucosal	O
CD4	O
+	O
T	O
cells	B-COMP
is	O
not	O
sufficient	O
per	O
se	O
to	O
induce	O
loss	O
of	O
mucosal	O
immunity	O
and	O
disease	O
progression	O
during	O
a	O
primate	O
lentiviral	O
infection	O
.	O

We	O
engineered	O
an	O
attenuated	O
mutant	O
of	O
nsp1	O
in	O
SARS	O
-	O
CoV	O
through	O
reverse	O
genetics	O
,	O
and	O
the	O
resulting	O
mutant	O
virus	O
was	O
viable	O
and	O
replicated	O
as	O
efficiently	O
as	O
wild	O
-	O
type	O
virus	O
in	O
cells	B-COMP
with	O
a	O
defective	O
IFN	O
response	O
.	O

Although	O
the	O
mechanism	O
of	O
TRALI	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
it	O
has	O
been	O
associated	O
with	O
human	O
leukocyte	O
antigen	O
antibodies	B-COMP
(	O
class	O
I	O
,	O
class	O
II	O
or	O
neutrophil	O
alloantigens	O
)	O
and	O
with	O
biologically	O
active	O
mediators	O
in	O
stored	O
cellular	B-COMP
blood	O
components	O
.	O

N	O
-	O
acetylcysteine	O
((	O
NAC	B-COMP
)	O
has	O
been	O
shown	O
to	O
have	O
oxygen	O
scavenging	O
abilities	O
.	O

In	O
this	O
observational	O
study	O
peri	O
-	O
operative	O
high	O
dose	O
NAC	B-COMP
was	O
administered	O
in	O
22	O
patients	O
.	O

NAC	B-COMP
-	O
treated	O
patients	O
showed	O
significant	O
lower	O
overall	O
pulmonary	O
morbidity	O
,	O
45	O
.	O
5	O
%	O
versus	O
81	O
.	O
8	O
%	O
(	O
P	O
=	O
0	O
.	O
027	O
).	O

We	O
show	O
here	O
that	O
infection	O
of	O
SARS	O
-	O
CoV	O
triggers	O
a	O
weak	O
IFN	O
response	O
in	O
cultured	O
human	O
lung	O
/	O
bronchial	O
epithelial	O
cells	B-COMP
without	O
inducing	O
the	O
phosphorylation	O
of	O
IFN	O
-	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
),	O
a	O
latent	O
cellular	B-COMP
transcription	O
factor	O
that	O
is	O
pivotal	O
for	O
type	O
I	O
IFN	O
synthesis	O
.	O

ABSTRACT	O
:	O
Most	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
develop	O
antibodies	B-COMP
against	O
the	O
SARS	O
coronavirus	O
and	O
survive	O
the	O
infection	O
.	O

Results	O
obtained	O
from	O
single	O
or	O
double	O
mutants	O
indicate	O
that	O
the	O
organization	O
of	O
the	O
transmembrane	B-COMP
pore	B-COMP
is	O
consistent	O
with	O
our	O
previously	O
reported	O
pentameric	O
alpha	O
-	O
helical	O
bundle	O
model	O
.	O

RT	O
-	O
PCR	O
and	O
nested	O
PCR	O
using	O
the	O
primer	O
pairs	O
specific	O
to	O
the	O
nucleocapsid	B-COMP
gene	O
,	O
BCoVs	O
detected	O
the	O
BCoVs	O
in	O
56	O
(	O
15	O
.	O
6	O
%)	O
of	O
359	O
diarrhoeic	O
faecal	O
samples	O
.	O

Primary	O
rat	O
alveolar	O
type	O
II	O
cells	B-COMP
were	O
transdifferentiated	O
into	O
the	O
type	O
I	O
cell	B-COMP
phenotype	O
.	O

Virus	O
-	O
induced	O
chemokine	O
expression	O
was	O
reduced	O
by	O
the	O
IL	O
-	O
1	O
receptor	O
antagonist	O
,	O
suggesting	O
that	O
IL	O
-	O
1	O
produced	O
by	O
infected	O
cells	B-COMP
induces	O
uninfected	O
cells	B-COMP
to	O
express	O
chemokines	O
.	O

The	O
titer	O
of	O
neutralizing	O
antibodies	B-COMP
was	O
calculated	O
using	O
Reed	O
-	O
Muench	O
method	O
,	O
and	O
the	O
comparison	O
between	O
different	O
time	O
groups	O
was	O
analyzed	O
regarding	O
the	O
variance	O
of	O
data	O
on	O
repeated	O
measures	O
after	O
logarithm	O
conversion	O
.	O

Little	O
is	O
known	O
about	O
the	O
biogenesis	O
of	O
these	O
complexes	O
,	O
the	O
membrane	B-COMP
anchoring	O
of	O
which	O
is	O
probably	O
mediated	O
by	O
nsp3	O
,	O
nsp4	O
,	O
and	O
nsp6	O
,	O
as	O
they	O
contain	O
several	O
putative	O
transmembrane	B-COMP
domains	O
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
evaluate	O
the	O
efficacy	O
of	O
total	O
lymphoid	O
irradiation	O
(	O
TLI	O
)-	O
based	O
reconditioning	O
regimens	O
in	O
patients	O
with	O
graft	O
failure	O
or	O
graft	O
rejection	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
.	O

The	O
results	O
of	O
14	O
patients	O
(	O
7	O
adults	O
and	O
7	O
children	O
)	O
with	O
a	O
variety	O
of	O
hematologic	O
malignant	O
diseases	O
treated	O
with	O
a	O
TLI	O
-	O
based	O
reconditioning	O
regimen	O
with	O
7	O
-	O
Gy	O
single	O
-	O
dose	O
application	O
plus	O
anti	O
-	O
T	O
-	O
lymphocyte	O
antibody	B-COMP
OKT3	O
(	O
n	O
=	O
11	O
)	O
and	O
/	O
or	O
antithymocyte	O
globulin	O
(	O
n	O
=	O
7	O
)/	O
fludarabine	O
(	O
n	O
=	O
9	O
),	O
followed	O
by	O
an	O
infusion	O
of	O
peripheral	O
blood	O
stem	O
cells	B-COMP
(	O
n	O
=	O
13	O
)	O
or	O
bone	O
marrow	O
stem	O
cells	B-COMP
(	O
n	O
=	O
1	O
)	O
from	O
related	O
or	O
unrelated	O
donors	O
,	O
were	O
retrospectively	O
analyzed	O
.	O

ABSTRACT	O
:	O
The	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
glycoprotein	O
with	O
multiple	O
biological	O
functions	O
.	O

However	O
,	O
IgA	O
antibodies	B-COMP
remained	O
low	O
in	O
avidity	O
in	O
a	O
proportion	O
of	O
patients	O
even	O
during	O
late	O
convalescence	O
.	O

The	O
results	O
showed	O
that	O
assays	O
to	O
detect	O
low	O
-	O
avidity	O
antibody	B-COMP
may	O
be	O
useful	O
for	O
discriminating	O
early	O
from	O
late	O
antibody	B-COMP
responses	O
and	O
also	O
for	O
distinguishing	O
anamnestic	O
cross	O
-	O
reactive	O
antibody	B-COMP
responses	O
from	O
primary	O
specific	O
responses	O
.	O

HeLa	O
cells	B-COMP
infected	O
with	O
rWR	O
-	O
SARS	O
-	O
S	O
also	O
showed	O
high	O
sensitivity	O
in	O
detecting	O
specific	O
serum	B-COMP
antibody	B-COMP
by	O
indirect	O
immunofluoresence	O
assay	O
(	O
IFA	O
).	O

ABSTRACT	O
:	O
Membrane	B-COMP
(	O
M	O
)	O
protein	O
genes	O
of	O
20	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
isolated	O
in	O
China	O
between	O
1995	O
and	O
2004	O
were	O
sequenced	O
and	O
analyzed	O
.	O

TITLE	O
:	O
Cold	O
antibody	B-COMP
autoimmune	O
hemolytic	O
anemias	O
.	O

TITLE	O
:	O
Vaccination	O
of	O
mice	O
with	O
recombinant	O
baculovirus	O
expressing	O
spike	O
or	O
nucleocapsid	B-COMP
protein	O
of	O
SARS	O
-	O
like	O
coronavirus	O
generates	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
.	O

Identification	O
of	O
the	O
cross	O
-	O
reactive	O
and	O
non	O
-	O
cross	O
-	O
reactive	O
N	O
-	O
protein	O
regions	O
allows	O
development	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibody	B-COMP
assays	O
for	O
screening	O
animal	O
and	O
human	O
sera	B-COMP
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
SARS	O
-	O
infected	O
cells	B-COMP
also	O
express	O
the	O
stem	O
/	O
progenitor	O
cell	B-COMP
markers	O
CD34	O
and	O
Oct	O
-	O
4	O
,	O
and	O
do	O
not	O
express	O
cytokeratin	O
or	O
surfactant	O
.	O

It	O
was	O
found	O
to	O
contain	O
a	O
cleavable	O
signal	O
sequence	O
,	O
which	O
directs	O
the	O
precursor	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
and	O
mediates	O
its	O
translocation	O
into	O
the	O
lumen	O
.	O

The	O
8a	O
polypeptide	O
is	O
likely	O
to	O
remain	O
in	O
the	O
cytoplasm	B-COMP
,	O
as	O
it	O
is	O
too	O
small	O
for	O
its	O
signal	O
sequence	O
to	O
function	O
and	O
will	O
therefore	O
be	O
directly	O
released	O
from	O
the	O
ribosome	B-COMP
.	O

Nephropathogenic	O
strains	O
of	O
IBV	O
,	O
such	O
as	O
the	O
Australian	O
T	O
strain	O
,	O
can	O
cause	O
high	O
mortalities	O
due	O
to	O
kidney	O
failure	O
characterized	O
by	O
mononuclear	O
cell	B-COMP
infiltration	O
and	O
inflammation	O
.	O

In	O
addition	O
,	O
S	O
-	O
line	O
birds	O
also	O
showed	O
three	O
times	O
higher	O
serum	B-COMP
IL	O
-	O
6	O
levels	O
than	O
HWL	O
birds	O
after	O
IBV	O
infection	O
.	O

Herein	O
,	O
we	O
show	O
that	O
""""	O
immature	O
""""	O
F4	O
/	O
80	O
(+)	O
Ly	O
-	O
6C	O
(	O
hi	O
)	O
monocytes	O
are	O
the	O
first	O
cells	B-COMP
,	O
along	O
with	O
neutrophils	O
,	O
to	O
enter	O
the	O
MHV	O
-	O
JHM	O
-	O
infected	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

These	O
results	O
suggest	O
that	O
chronic	O
CNS	O
infection	O
results	O
in	O
the	O
appearance	O
of	O
CD11c	O
-	O
expressing	O
macrophages	O
from	O
the	O
blood	O
that	O
exhibit	O
properties	O
of	O
immature	O
APCs	O
,	O
are	O
closely	O
associated	O
with	O
areas	O
of	O
demyelination	O
,	O
and	O
may	O
act	O
as	O
final	O
effectors	O
of	O
myelin	B-COMP
destruction	O
.	O

Conventional	O
weaned	O
pigs	O
(	O
n	O
=	O
130	O
)	O
in	O
one	O
of	O
four	O
groups	O
(	O
PRCV	O
/	O
phosphate	O
-	O
buffered	O
saline	O
[	O
PBS	O
]	O
[	O
n	O
=	O
41	O
],	O
PRCV	O
/	O
DEX	O
[	O
n	O
=	O
41	O
],	O
mock	O
/	O
PBS	O
[	O
n	O
=	O
23	O
],	O
and	O
mock	O
/	O
DEX	O
[	O
n	O
=	O
25	O
])	O
were	O
inoculated	O
intranasally	O
and	O
intratracheally	O
with	O
the	O
ISU	O
-	O
1	O
strain	O
of	O
PRCV	O
(	O
1	O
x	O
10	O
(	O
7	O
)	O
PFU	O
)	O
or	O
cell	B-COMP
culture	O
medium	O
.	O

In	O
PRCV	O
/	O
DEX	O
pigs	O
,	O
significantly	O
milder	O
pneumonia	O
,	O
fewer	O
PRCV	O
-	O
positive	O
cells	B-COMP
,	O
and	O
lower	O
viral	O
RNA	O
titers	O
were	O
present	O
in	O
lungs	O
early	O
at	O
PID	O
2	O
;	O
however	O
,	O
at	O
PID	O
4	O
,	O
10	O
,	O
and	O
21	O
,	O
severe	O
bronchointerstitial	O
pneumonia	O
,	O
significantly	O
higher	O
numbers	O
of	O
PRCV	O
-	O
positive	O
cells	B-COMP
,	O
and	O
higher	O
viral	O
RNA	O
titers	O
were	O
observed	O
compared	O
to	O
results	O
for	O
PRCV	O
/	O
PBS	O
pigs	O
.	O

Here	O
we	O
describe	O
the	O
role	O
of	O
these	O
proteins	O
in	O
SARS	O
-	O
CoV	O
replication	O
and	O
potential	O
therapeutic	O
strategies	O
aimed	O
at	O
preventing	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
target	O
cells	B-COMP
.	O

Here	O
,	O
the	O
expression	O
of	O
the	O
3a	O
protein	O
in	O
various	O
in	O
vitro	O
systems	O
is	O
shown	O
,	O
it	O
has	O
been	O
localized	O
to	O
the	O
Golgi	B-COMP
region	O
and	O
its	O
membrane	B-COMP
topology	O
in	O
transfected	O
cells	B-COMP
has	O
been	O
confirmed	O
.	O

It	O
was	O
previously	O
found	O
that	O
cockerels	O
vaccinated	O
with	O
live	O
attenuated	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
AIBV	O
)	O
have	O
decreased	O
serum	B-COMP
testosterone	O
concentrations	O
,	O
epididymal	O
stones	O
and	O
reduced	O
fertility	O
.	O

Diagnosis	O
is	O
based	O
on	O
a	O
finding	O
of	O
elevated	O
serum	B-COMP
levels	O
of	O
components	O
that	O
are	O
normally	O
found	O
within	O
the	O
muscle	O
cell	B-COMP
,	O
chiefly	O
muscle	O
enzymes	O
and	O
myoglobin	O
.	O

We	O
have	O
shown	O
that	O
ACE2	O
binding	O
results	O
in	O
structural	O
changes	O
that	O
appear	O
to	O
be	O
the	O
initial	O
step	O
in	O
viral	B-COMP
membrane	I-COMP
fusion	O
,	O
and	O
precisely	O
localized	O
the	O
receptor	O
-	O
binding	O
and	O
fusion	O
core	O
domains	O
within	O
the	O
entire	O
spike	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
provides	O
an	O
ideal	O
model	O
system	O
to	O
study	O
receptor	O
binding	O
and	O
membrane	B-COMP
fusion	O
in	O
the	O
native	O
state	O
,	O
employing	O
cryo	O
-	O
electron	O
microscopy	O
and	O
single	O
-	O
particle	O
image	O
analysis	O
.	O

ABSTRACT	O
:	O
Virus	O
infection	O
in	O
vitro	O
can	O
either	O
result	O
in	O
a	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
or	O
proceed	O
without	O
visible	O
changes	O
in	O
infected	O
cells	B-COMP
(	O
noncytopathic	O
infection	O
).	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
DRAK2	O
[	O
death	O
-	O
associated	O
protein	O
kinase	O
(	O
DAPK	O
)-	O
related	O
apoptosis	O
-	O
inducing	O
kinase	O
2	O
]	O
to	O
anti	O
-	O
viral	O
memory	O
T	O
cell	B-COMP
responses	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
examined	O
.	O

A	O
vector	O
containing	O
a	O
fused	O
5	O
'	O
UTR	O
and	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
was	O
co	O
-	O
transfected	O
with	O
the	O
DNAzyme	O
into	O
E6	O
cells	B-COMP
and	O
the	O
cells	B-COMP
expressing	O
eGFP	O
were	O
visualized	O
with	O
fluorescence	O
microscopy	O
and	O
analyzed	O
by	O
fluorescence	O
-	O
activated	O
cell	B-COMP
sorting	O
(	O
FACS	O
).	O

TITLE	O
:	O
[	O
Changes	O
and	O
significance	O
of	O
peripheral	O
blood	O
fibrinogen	B-COMP
level	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

In	O
an	O
effort	O
to	O
characterize	O
molecular	O
components	O
of	O
the	O
virus	O
that	O
are	O
absent	O
in	O
other	O
coronaviruses	O
,	O
all	O
of	O
which	O
are	O
considerably	O
less	O
pathogenic	O
for	O
humans	O
,	O
we	O
recombinantly	O
produced	O
the	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
within	O
non	O
-	O
structural	O
protein	O
3	O
(	O
Nsp3	O
)	O
of	O
SARS	O
-	O
CoV	O
and	O
characterized	O
its	O
nucleic	B-COMP
-	O
acid	O
binding	O
properties	O
.	O

A	O
few	O
such	O
segments	O
are	O
present	O
in	O
the	O
SARS	O
-	O
CoV	O
genome	O
,	O
but	O
also	O
in	O
mRNAs	O
of	O
host	B-COMP
proteins	O
involved	O
in	O
the	O
regulation	O
of	O
signaling	O
pathways	O
.	O

A	O
putative	O
role	O
of	O
SUD	O
in	O
virus	O
-	O
induced	O
apoptosis	O
or	O
survival	O
of	O
host	B-COMP
cells	B-COMP
is	O
discussed	O
.	O

This	O
was	O
accompanied	O
or	O
immediately	O
followed	O
by	O
a	O
potent	O
Th1	O
adaptive	O
immunity	O
as	O
evidenced	O
by	O
the	O
activation	O
of	O
T	O
-	O
cell	B-COMP
signaling	O
molecules	O
,	O
surface	O
markers	O
,	O
and	O
effector	O
molecules	O
.	O

It	O
is	O
described	O
to	O
be	O
expressed	O
during	O
infection	O
and	O
to	O
be	O
a	O
component	O
of	O
the	O
virus	B-COMP
particle	I-COMP
surface	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
protein	O
7a	O
binds	O
directly	O
and	O
specifically	O
to	O
human	O
lymphocyte	O
function	O
-	O
associated	O
antigen	O
1	O
(	O
LFA	O
-	O
1	O
)	O
on	O
the	O
cell	B-COMP
surface	I-COMP
of	O
Jurkat	O
cells	B-COMP
.	O

The	O
binding	O
is	O
increased	O
upon	O
artificial	O
cell	B-COMP
activation	O
with	O
phorbol	O
ester	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
4	O
Chinese	O
herbal	O
polysaccharides	O
on	O
the	O
production	O
of	O
serum	B-COMP
antibodies	B-COMP
and	O
the	O
proliferation	O
of	O
peripheral	O
T	O
lymphocytes	O
,	O
including	O
subpopulations	O
in	O
vaccinated	O
chickens	O
.	O

At	O
postmortem	O
examination	O
,	O
remarkable	O
lesions	O
were	O
observed	O
in	O
the	O
internal	O
organs	O
of	O
the	O
euthanized	O
pups	O
,	O
that	O
tested	O
positive	O
for	O
CCoV	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
virus	O
isolation	O
on	O
cell	B-COMP
cultures	O
.	O

All	O
pups	O
seroconverted	O
for	O
CCoV	O
,	O
as	O
shown	O
by	O
the	O
high	O
optical	O
density	O
values	O
and	O
antibody	B-COMP
titres	O
detected	O
by	O
ELISA	O
and	O
virusneutralisation	O
tests	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
an	O
evaluation	O
with	O
18	O
SARS	O
-	O
positive	O
NPA	O
samples	O
,	O
all	O
confirmed	O
SARS	O
positive	O
by	O
quantitative	O
PCR	O
and	O
antibodies	B-COMP
to	O
SARS	O
CoV	O
,	O
revealed	O
that	O
all	O
(	O
18	O
/	O
18	O
)	O
were	O
found	O
positive	O
by	O
the	O
CLEIA	O
;	O
thus	O
,	O
the	O
sensitivity	O
of	O
detection	O
was	O
100	O
%.	O

The	O
effects	O
of	O
three	O
agents	O
:	O
alkyl	O
-	O
dimethyl	O
-	O
benzyl	O
-	O
ammonium	O
chloride	O
,	O
benzalkonium	O
chloride	O
and	O
didecyl	O
-	O
dimethyl	O
-	O
ammonium	O
chloride	O
,	O
on	O
the	O
infectivity	O
titre	O
of	O
CCoV	O
in	O
A72	O
cell	B-COMP
lines	O
,	O
were	O
studied	O
at	O
different	O
concentrations	O
.	O

The	O
phylogenic	O
differences	O
between	O
these	O
novel	O
IBVs	O
and	O
other	O
avian	O
coronaviruses	O
suggest	O
a	O
reservoir	O
host	B-COMP
distinct	O
from	O
domestic	O
poultry	O
.	O

Oral	O
and	O
intranasal	O
inoculations	O
of	O
recombinant	O
L	O
.	O
casei	O
into	O
pregnant	O
sow	O
and	O
mice	O
resulted	O
in	O
high	O
levels	O
of	O
serum	B-COMP
immunoglobuline	O
G	O
(	O
IgG	O
)	O
and	O
mucosal	O
IgA	O
,	O
as	O
demonstrated	O
by	O
rnELISA	O
(	O
recombinant	O
N	O
protein	O
ELISA	O
)	O
using	O
recombinant	O
N	O
protein	O
.	O

These	O
findings	O
provide	O
evidence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
N	O
protein	O
modulates	O
TGF	O
-	O
beta	O
signaling	O
to	O
block	O
apoptosis	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
host	B-COMP
cells	B-COMP
and	O
meanwhile	O
promote	O
tissue	O
fibrosis	O
.	O

Key	O
recommendations	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
prior	O
to	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
potential	O
source	O
of	O
infection	O
(	O
1C	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
within	O
1	O
hr	O
of	O
diagnosis	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1D	O
);	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
(	O
1C	O
);	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
(	O
1D	O
);	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
(	O
1C	O
);	O
administration	O
of	O
either	O
crystalloid	B-COMP
or	O
colloid	O
fluid	O
resuscitation	O
(	O
1B	O
);	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
(	O
1C	O
);	O
reduction	O
in	O
rate	O
of	O
fluid	O
administration	O
with	O
rising	O
filing	O
pressures	O
and	O
no	O
improvement	O
in	O
tissue	O
perfusion	O
(	O
1D	O
);	O
vasopressor	O
preference	O
for	O
norepinephrine	O
or	O
dopamine	O
to	O
maintain	O
an	O
initial	O
target	O
of	O
mean	O
arterial	O
pressure	O
>	O
or	O
=	O
65	O
mm	O
Hg	O
(	O
1C	O
);	O
dobutamine	O
inotropic	O
therapy	O
when	O
cardiac	O
output	O
remains	O
low	O
despite	O
fluid	O
resuscitation	O
and	O
combined	O
inotropic	O
/	O
vasopressor	O
therapy	O
(	O
1C	O
);	O
stress	O
-	O
dose	O
steroid	O
therapy	O
given	O
only	O
in	O
septic	O
shock	O
after	O
blood	O
pressure	O
is	O
identified	O
to	O
be	O
poorly	O
responsive	O
to	O
fluid	O
and	O
vasopressor	O
therapy	O
(	O
2C	O
);	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
clinical	O
assessment	O
of	O
high	O
risk	O
for	O
death	O
(	O
2B	O
except	O
2C	O
for	O
post	O
-	O
operative	O
patients	O
).	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
)	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
GI	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	B-COMP
pump	I-COMP
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

TITLE	O
:	O
Human	O
monoclonal	O
antibodies	B-COMP
by	O
immortalization	O
of	O
memory	O
B	O
cells	B-COMP
.	O

Here	O
we	O
compare	O
and	O
contrast	O
current	O
methods	O
to	O
generate	O
human	O
monoclonal	O
antibodies	B-COMP
and	O
highlight	O
the	O
advantages	O
of	O
exploiting	O
the	O
human	O
antibody	B-COMP
repertoire	O
using	O
a	O
novel	O
method	O
that	O
allows	O
efficient	O
immortalization	O
and	O
cloning	O
of	O
human	O
memory	O
B	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
relationship	O
between	O
antibodies	B-COMP
detected	O
in	O
patients	O
'	O
and	O
/	O
or	O
donors	O
'	O
sera	B-COMP
and	O
the	O
clinical	O
features	O
of	O
acute	O
non	O
-	O
haemolytic	O
transfusion	O
reactions	O
(	O
ANHTRs	O
),	O
and	O
to	O
determine	O
any	O
gender	O
-	O
related	O
difference	O
.	O

The	O
patients	O
were	O
also	O
screened	O
for	O
anti	O
-	O
plasma	O
protein	O
antibodies	B-COMP
.	O

Non	O
-	O
HLA	O
antibodies	B-COMP
were	O
significantly	O
associated	O
with	O
severe	O
reactions	O
in	O
females	O
.	O

FCV3	O
-	O
70	O
monoclonal	O
antibody	B-COMP
produced	O
immunolabelling	O
of	O
group	O
1	O
coronavirus	O
antigen	O
in	O
tissue	O
samples	O
from	O
eight	O
animals	O
,	O
the	O
antigen	O
being	O
present	O
in	O
the	O
cytoplasm	B-COMP
of	O
macrophages	O
in	O
the	O
different	O
types	O
of	O
granulomatous	O
lesions	O
.	O

TITLE	O
:	O
The	O
GPRLQPY	O
motif	O
located	O
at	O
the	O
carboxy	O
-	O
terminal	O
of	O
the	O
spike	O
protein	O
induces	O
antibodies	B-COMP
that	O
neutralize	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

To	O
identify	O
the	O
most	O
important	O
antigenic	O
region	O
of	O
S1	O
,	O
the	O
truncated	O
S1	O
-	O
GST	O
fusion	O
proteins	O
were	O
examined	O
for	O
their	O
ability	O
to	O
react	O
with	O
immune	O
serum	B-COMP
against	O
PEDV	O
and	O
to	O
elicit	O
the	O
formation	O
of	O
neutralization	O
antibodies	B-COMP
in	O
immunized	O
animals	O
.	O

We	O
used	O
IFN	O
-	O
gammaR1	O
(-/-)	O
mice	O
to	O
examine	O
the	O
target	O
of	O
IFN	O
-	O
gamma	O
in	O
CD8	O
T	O
cell	B-COMP
-	O
mediated	O
demyelination	O
.	O

The	O
pseudo	O
-	O
typed	O
lentiviral	O
particles	O
were	O
used	O
to	O
develop	O
an	O
in	O
vitro	O
microneutralization	O
assay	O
that	O
was	O
both	O
sensitive	O
and	O
specific	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-COMP
.	O

In	O
coexpression	O
experiments	O
,	O
the	O
S	O
protein	O
was	O
found	O
to	O
colocalize	O
with	O
a	O
Golgi	B-COMP
marker	O
.	O

To	O
examine	O
a	O
direct	O
role	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
viral	O
clearance	O
and	O
pathology	O
,	O
pathogenesis	O
was	O
compared	O
in	O
mice	O
deficient	O
in	O
both	O
perforin	O
and	O
IFN	O
-	O
gamma	O
that	O
were	O
selectively	O
reconstituted	O
for	O
these	O
functions	O
via	O
transfer	O
of	O
virus	O
-	O
specific	O
memory	O
CD4	O
(+)	O
T	O
cells	B-COMP
.	O

Management	O
included	O
placement	O
of	O
the	O
arteriovenous	O
femoral	O
transcutaneous	O
interventional	O
lung	O
-	O
assist	O
membrane	B-COMP
ventilator	O
,	O
lung	O
rest	O
at	O
minimal	O
mechanical	O
ventilator	O
settings	O
,	O
and	O
optimization	O
of	O
systemic	O
oxygen	O
consumption	O
and	O
delivery	O
.	O

The	O
interventional	O
lung	O
-	O
assist	O
membrane	B-COMP
ventilator	O
was	O
left	O
in	O
place	O
4	O
.	O
3	O
+/-	O

Moreover	O
,	O
we	O
examined	O
the	O
subcellular	O
localization	O
of	O
SARS	O
-	O
CoV	O
N	O
in	O
these	O
cell	B-COMP
lines	O
.	O

RESULTS	O
:	O
Key	O
recommendations	O
,	O
listed	O
by	O
category	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
potential	O
source	O
of	O
infection	O
(	O
1C	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
within	O
1	O
hr	O
of	O
diagnosis	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1D	O
);	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
(	O
1C	O
);	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
(	O
1D	O
);	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
(	O
1C	O
);	O
administration	O
of	O
either	O
crystalloid	B-COMP
or	O
colloid	O
fluid	O
resuscitation	O
(	O
1B	O
);	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
(	O
1C	O
);	O
reduction	O
in	O
rate	O
of	O
fluid	O
administration	O
with	O
rising	O
filing	O
pressures	O
and	O
no	O
improvement	O
in	O
tissue	O
perfusion	O
(	O
1D	O
);	O
vasopressor	O
preference	O
for	O
norepinephrine	O
or	O
dopamine	O
to	O
maintain	O
an	O
initial	O
target	O
of	O
mean	O
arterial	O
pressure	O
>	O
or	O
=	O
65	O
mm	O
Hg	O
(	O
1C	O
);	O
dobutamine	O
inotropic	O
therapy	O
when	O
cardiac	O
output	O
remains	O
low	O
despite	O
fluid	O
resuscitation	O
and	O
combined	O
inotropic	O
/	O
vasopressor	O
therapy	O
(	O
1C	O
);	O
stress	O
-	O
dose	O
steroid	O
therapy	O
given	O
only	O
in	O
septic	O
shock	O
after	O
blood	O
pressure	O
is	O
identified	O
to	O
be	O
poorly	O
responsive	O
to	O
fluid	O
and	O
vasopressor	O
therapy	O
(	O
2C	O
);	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
clinical	O
assessment	O
of	O
high	O
risk	O
for	O
death	O
(	O
2B	O
except	O
2C	O
for	O
postoperative	O
patients	O
).	O

ABSTRACT	O
:	O
Mannan	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
is	O
a	O
collectin	O
that	O
mediates	O
activation	O
of	O
the	O
complement	O
system	O
and	O
is	O
of	O
importance	O
for	O
host	B-COMP
defenses	O
.	O

Direct	O
fluorescent	O
antibody	B-COMP
(	O
FA	O
)	O
assays	O
were	O
performed	O
with	O
fresh	O
specimens	O
;	O
then	O
,	O
mRT	O
-	O
PCRs	O
for	O
the	O
detection	O
of	O
12	O
respiratory	O
viruses	O
(	O
Seeplex	O
RV	O
detection	O
kit	O
,	O
SeeGene	O
,	O
Seoul	O
,	O
Korea	O
)	O
were	O
tested	O
with	O
frozen	O
specimens	O
.	O

Differences	O
in	O
replication	O
and	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
between	O
the	O
KT2	O
-	O
L	O
and	O
KT2	O
-	O
H	O
strains	O
in	O
swine	O
testicular	O
cells	B-COMP
were	O
investigated	O
.	O

In	O
this	O
study	O
,	O
systemic	O
,	O
mucosal	O
,	O
and	O
cellular	B-COMP
immune	O
responses	O
and	O
long	O
-	O
term	O
protective	O
immunity	O
induced	O
by	O
RBD	O
-	O
rAAV	O
were	O
further	O
characterized	O
in	O
a	O
BALB	O
/	O
c	O
mouse	O
model	O
,	O
with	O
comparison	O
of	O
the	O
i	O
.	O
m	O
.	O

vaccination	O
elicited	O
stronger	O
systemic	O
and	O
local	O
specific	O
cytotoxic	O
T	O
cell	B-COMP
responses	O
than	O
the	O
i	O
.	O
m	O
.	O

vaccination	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
mice	O
;	O
4	O
)	O
higher	O
titers	O
of	O
mucosal	O
IgA	O
and	O
serum	B-COMP
-	O
neutralizing	O
Ab	O
were	O
associated	O
with	O
lower	O
viral	O
load	O
and	O
less	O
pulmonary	O
pathological	O
damage	O
,	O
while	O
no	O
Ab	O
-	O
mediated	O
disease	O
enhancement	O
effect	O
was	O
observed	O
;	O
and	O
5	O
)	O
the	O
vaccination	O
could	O
provide	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Ninety	O
-	O
six	O
sera	B-COMP
tested	O
positive	O
for	O
FCoV	O
antibodies	B-COMP
by	O
VN	O
and	O
ELISA	O
.	O

The	O
high	O
prevalence	O
of	O
antibodies	B-COMP
observed	O
indicates	O
that	O
FCoVs	O
are	O
common	O
in	O
southern	O
Italian	O
cat	O
populations	O
.	O

TITLE	O
:	O
Importance	O
of	O
conserved	O
cysteine	O
residues	O
in	O
the	O
coronavirus	O
envelope	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
envelope	B-COMP
(	O
E	O
)	O
proteins	O
play	O
an	O
important	O
,	O
not	O
fully	O
understood	O
role	O
(	O
s	O
)	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

Many	O
of	O
these	O
observations	O
were	O
corroborated	O
in	O
the	O
context	O
of	O
natural	O
MHV	O
infections	O
,	O
with	O
native	O
E	O
,	O
but	O
not	O
E	O
.	O
T	O
,	O
complementing	O
debilitated	O
recombinant	O
MHVs	O
lacking	O
E	O
.	O
Our	O
findings	O
suggest	O
that	O
palmitoylations	O
are	O
essential	O
for	O
E	O
to	O
act	O
as	O
a	O
vesicle	B-COMP
morphogenetic	O
protein	O
and	O
further	O
argue	O
that	O
palmitoylated	O
E	O
proteins	O
operate	O
by	O
allowing	O
the	O
primary	O
coronavirus	O
assembly	O
subunits	O
to	O
assume	O
configurations	O
that	O
can	O
mobilize	O
into	O
secreted	O
lipid	O
vesicles	B-COMP
and	O
virions	B-COMP
.	O

A	O
reporter	O
gene	O
encoding	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
was	O
inserted	O
into	O
one	O
segment	O
,	O
and	O
a	O
red	O
fluorescent	O
protein	O
dsRed	O
gene	O
was	O
inserted	O
into	O
the	O
other	O
segment	O
in	O
order	O
to	O
easily	O
detect	O
the	O
replication	O
and	O
transcription	O
of	O
segments	O
in	O
infected	O
cells	B-COMP
.	O

S	O
Delta19	O
proteins	O
with	O
other	O
double	O
alanine	O
substitutions	O
reduced	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
further	O
,	O
from	O
40	O
%	O
to	O
less	O
than	O
20	O
%	O
of	O
wild	O
-	O
type	O
levels	O
.	O

ABSTRACT	O
:	O
Glia	O
exhibit	O
differential	O
susceptibility	O
to	O
CD8	O
T	O
cell	B-COMP
mediated	O
effector	O
mechanisms	O
during	O
neurotropic	O
coronavirus	O
infection	O
.	O

The	O
M	O
protein	O
of	O
six	O
isolates	O
had	O
three	O
main	O
transmembrane	B-COMP
domains	O
(	O
aa20	O
-	O
38	O
,	O
aa43	O
-	O
65	O
,	O
aa75	O
-	O
97	O
).	O

Treatment	O
of	O
cells	B-COMP
with	O
either	O
SARS	O
-	O
CoV	O
spike	O
protein	O
or	O
spike	O
-	O
bearing	O
pseudoviruses	O
resulted	O
in	O
the	O
translocation	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
from	O
the	O
cell	B-COMP
surface	I-COMP
to	O
endosomes	O
.	O

Broad	O
spectrum	O
agents	O
that	O
can	O
serve	O
as	O
disrafters	O
or	O
neutralize	O
the	O
viral	O
infectivity	O
by	O
binding	O
to	O
the	O
envelope	B-COMP
lipid	O
or	O
sugar	O
moieties	O
will	O
not	O
be	O
affected	O
by	O
the	O
vagaries	O
of	O
hypermutation	O
of	O
surface	O
antigens	O
.	O

Moreover	O
,	O
as	O
is	O
commonly	O
observed	O
in	O
coronavirus	O
infection	O
in	O
other	O
animals	O
,	O
the	O
activities	O
of	O
effecter	O
caspases	O
-	O
caspase	O
-	O
3	O
/	O
7	O
-	O
and	O
initiator	O
caspases	O
-	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
-	O
that	O
are	O
representative	O
factors	O
in	O
the	O
death	O
receptor	O
-	O
mediated	O
apoptotic	O
pathway	O
and	O
mitochondrial	B-COMP
apoptotic	O
pathway	O
,	O
respectively	O
,	O
were	O
increased	O
in	O
ECoV	O
-	O
infected	O
MDBK	O
cells	B-COMP
.	O

These	O
findings	O
can	O
guide	O
interventions	O
for	O
respiratory	O
syncytial	O
virus	O
infection	O
in	O
high	O
risk	O
hosts	B-COMP
.	O

Compared	O
to	O
the	O
cell	B-COMP
culture	O
results	O
,	O
the	O
RespiFinder	O
assay	O
showed	O
specificities	O
and	O
sensitivities	O
of	O
98	O
.	O
2	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
adenovirus	O
;	O
96	O
.	O
4	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
human	O
metapneumovirus	O
;	O
98	O
.	O
2	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
influenza	O
A	O
virus	O
(	O
InfA	O
);	O
99	O
.	O
1	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
parainfluenza	O
virus	O
type	O
1	O
(	O
PIV	O
-	O
1	O
);	O
99	O
.	O
1	O
%	O
and	O
80	O
%,	O
respectively	O
,	O
for	O
PIV	O
-	O
3	O
;	O
90	O
.	O
1	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
rhinovirus	O
;	O
and	O
94	O
.	O
6	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
RSV	O
.	O

TITLE	O
:	O
Evolutionary	O
relationships	O
between	O
bat	O
coronaviruses	O
and	O
their	O
hosts	B-COMP
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	O
CoVs	O
and	O
their	O
hosts	B-COMP
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
and	O
the	O
bat	O
cytochrome	O
b	O
gene	O
.	O

They	O
are	O
nucleic	B-COMP
acid	O
-	O
binding	O
proteins	O
whose	O
main	O
recognized	O
function	O
is	O
to	O
package	O
viral	O
genomes	O
into	O
protective	O
structures	O
called	O
nucleocapsids	O
.	O

Purification	O
of	O
the	O
desired	O
bispecific	O
immunoprobe	O
with	O
high	O
specific	O
activity	O
from	O
a	O
mixture	O
of	O
bispecific	O
and	O
monospecific	O
monoclonal	O
antibodies	B-COMP
requires	O
special	O
strategies	O
.	O

Viral	O
gene	O
expression	O
and	O
viral	B-COMP
particle	I-COMP
production	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)-	O
deficient	O
and	O
G6PD	O
-	O
knockdown	O
cells	B-COMP
were	O
much	O
higher	O
than	O
their	O
counterparts	O
when	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
was	O
applied	O
at	O
0	O
.	O
1	O
multiplicity	O
of	O
infection	O
.	O

Accordingly	O
,	O
ectopic	O
expression	O
of	O
G6PD	O
in	O
G6PD	O
-	O
deficient	O
cells	B-COMP
or	O
addition	O
of	O
antioxidant	O
(	O
such	O
as	O
alpha	O
-	O
lipoic	O
acid	O
)	O
to	O
G6PD	O
-	O
knockdown	O
cells	B-COMP
attenuated	O
the	O
increased	O
susceptibility	O
to	O
HCoV	O
229E	O
infection	O
.	O

Detailed	O
analysis	O
of	O
the	O
point	O
mutants	O
of	O
these	O
two	O
amino	O
acid	O
residues	O
and	O
their	O
nearby	O
hydrogen	O
bond	O
partner	O
Ser	B-COMP
-	O
123	O
and	O
Ser	B-COMP
-	O
139	O
revealed	O
a	O
strong	O
correlation	O
between	O
the	O
enzyme	O
activity	O
loss	O
and	O
dimer	O
dissociation	O
.	O

Levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	O
-	O
6	O
in	O
BAL	O
and	O
serum	B-COMP
were	O
decreased	O
in	O
PRCV	O
/	O
DEX	O
pigs	O
early	O
but	O
increased	O
later	O
compared	O
to	O
those	O
in	O
phosphate	O
-	O
buffered	O
saline	O
-	O
treated	O
,	O
PRCV	O
-	O
infected	O
pigs	O
,	O
corresponding	O
to	O
a	O
similar	O
trend	O
for	O
lung	O
lesions	O
.	O

Antibodies	B-COMP
against	O
parvovirus	O
(	O
100	O
%),	O
parainfluenza	O
virus	O
(	O
100	O
%),	O
adenovirus	O
1	O
/	O
2	O
(	O
66	O
-	O
67	O
%),	O
and	O
distemper	O
virus	O
(	O
22	O
%)	O
were	O
present	O
in	O
dogs	O
.	O

RESULTS	O
:	O
Antibodies	B-COMP
against	O
parvovirus	O
(	O
100	O
%),	O
parainfluenza	O
virus	O
(	O
100	O
%),	O
adenovirus	O
1	O
/	O
2	O
(	O
66	O
-	O
67	O
%),	O
and	O
distemper	O
virus	O
(	O
22	O
%)	O
were	O
present	O
in	O
dogs	O
.	O

We	O
hypothesized	O
that	O
the	O
association	O
and	O
intense	O
utilization	O
of	O
the	O
ER	O
during	O
viral	O
replication	O
would	O
induce	O
the	O
cellular	B-COMP
unfolded	O
protein	O
response	O
(	O
UPR	O
),	O
a	O
signal	O
transduction	O
cascade	O
that	O
acts	O
to	O
modulate	O
translation	O
,	O
membrane	B-COMP
biosynthesis	O
,	O
and	O
the	O
levels	O
of	O
ER	O
chaperones	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	O
suppresses	O
host	B-COMP
gene	O
expression	O
,	O
including	O
that	O
of	O
type	O
I	O
interferon	O
,	O
in	O
infected	O
cells	B-COMP
.	O

According	O
to	O
the	O
""""	O
two	O
-	O
hit	O
""""	O
hypothesis	O
,	O
the	O
bacterial	O
infection	O
preceding	O
the	O
operation	O
may	O
have	O
primed	O
the	O
immune	O
cells	B-COMP
,	O
and	O
the	O
following	O
surgical	O
stress	O
may	O
have	O
then	O
triggered	O
rapid	O
progression	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Recently	O
,	O
H2S	O
(	O
hydrogen	O
sulfide	O
)	O
has	O
been	O
shown	O
to	O
decrease	O
the	O
synthesis	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
reduce	O
leucocyte	O
adherence	O
to	O
the	O
endothelium	O
and	O
subsequent	O
diapedesis	O
of	O
these	O
cells	B-COMP
from	O
the	O
microvasculature	O
in	O
in	O
vivo	O
studies	O
,	O
and	O
to	O
protect	O
cells	B-COMP
in	O
culture	O
from	O
oxidative	O
injury	O
.	O

Two	O
of	O
the	O
peptides	O
D07	O
(	O
residues	O
927	O
-	O
937	O
)	O
and	O
D08	O
(	O
residues	O
942	O
-	O
951	O
)	O
were	O
recognized	O
by	O
the	O
sera	B-COMP
of	O
SARS	O
patients	O
.	O

To	O
investigate	O
endotoxemia	O
,	O
plasma	O
TNFalpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
the	O
liberation	O
capacity	O
of	O
those	O
cytokines	O
from	O
mononuclear	O
cells	B-COMP
after	O
LPS	O
challenge	O
(	O
Delta	O
values	O
),	O
and	O
plasma	O
antibodies	B-COMP
to	O
endotoxins	O
and	O
alpha	O
-	O
hemolysin	O
of	O
Staphylococcus	O
aureus	O
in	O
ALI	O
/	O
ARDS	O
.	O

All	O
patients	O
presented	O
antibodies	B-COMP
to	O
lipopolysaccharides	O
and	O
alpha	O
-	O
hemolysin	O
,	O
but	O
the	O
level	O
did	O
not	O
correlate	O
with	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
).	O

All	O
patients	O
presented	O
antibodies	B-COMP
to	O
lipopolysaccharides	O
and	O
alpha	O
-	O
hemolysin	O
,	O
but	O
the	O
level	O
did	O
not	O
correlate	O
with	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
).	O

The	O
imbalance	O
in	O
the	O
IFN	O
response	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
establishment	O
of	O
viremia	O
early	O
in	O
infection	O
,	O
whereas	O
the	O
production	O
of	O
chemokines	O
by	O
infected	O
organs	O
may	O
be	O
responsible	O
for	O
(	O
i	O
)	O
massive	O
immune	O
cell	B-COMP
infiltrations	O
found	O
in	O
the	O
lungs	O
of	O
SARS	O
victims	O
,	O
and	O
(	O
ii	O
)	O
the	O
dysregulation	O
of	O
adaptive	O
immunity	O
.	O

To	O
define	O
more	O
precisely	O
the	O
basis	O
for	O
this	O
preferential	O
selection	O
,	O
we	O
combine	O
x	O
-	O
ray	O
crystallographic	O
studies	O
of	O
the	O
MHC	O
class	O
I	O
(	O
D	O
(	O
b	O
))/	O
S510	O
complexes	O
with	O
viral	O
reverse	O
genetics	O
to	O
identify	O
a	O
prominent	O
TCR	B-COMP
contact	O
residue	O
(	O
tryptophan	O
at	O
position	O
4	O
)	O
prone	O
to	O
escape	O
mutations	O
.	O

When	O
the	O
DNA	O
vaccines	O
were	O
administered	O
to	O
the	O
quadriceps	O
muscle	O
of	O
chickens	O
,	O
the	O
induced	O
humoral	O
and	O
cellular	B-COMP
responses	O
were	O
evaluated	O
.	O

At	O
the	O
10th	O
day	O
after	O
onset	O
,	O
the	O
serum	B-COMP
TG	O
level	O
in	O
early	O
group	O
was	O
lower	O
than	O
that	O
in	O
late	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Intrahepatic	O
endothelial	O
and	O
Kupffer	O
cells	B-COMP
involved	O
in	O
immunosuppressive	O
cytokines	O
and	O
natural	O
killer	O
(	O
NK	O
)/	O
NK	O
T	O
cell	B-COMP
disorders	O
in	O
viral	O
acute	O
hepatitis	O
.	O

ABSTRACT	O
:	O
Live	O
attenuated	O
recombinant	O
measles	O
viruses	O
(	O
rMV	O
)	O
expressing	O
a	O
codon	O
-	O
optimised	O
spike	O
glycoprotein	O
(	O
S	O
)	O
or	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
generated	O
(	O
rMV	O
-	O
S	O
and	O
rMV	O
-	O
N	O
).	O

The	O
antibodies	B-COMP
induced	O
by	O
rMV	O
-	O
S	O
had	O
a	O
high	O
neutralising	O
effect	O
on	O
SARS	O
-	O
CoV	O
as	O
well	O
as	O
on	O
MV	O
.	O

TITLE	O
:	O
Effects	O
of	O
different	O
immunization	O
protocols	O
and	O
adjuvant	O
on	O
antibody	B-COMP
responses	O
to	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

We	O
attempted	O
to	O
investigate	O
the	O
effects	O
of	O
different	O
immunization	O
protocols	O
and	O
adjuvant	O
on	O
the	O
antibody	B-COMP
responses	O
to	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

In	O
contrast	O
,	O
with	O
an	O
intranasal	O
(	O
IN	O
)	O
immunization	O
protocol	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
alone	O
failed	O
to	O
induce	O
any	O
detectable	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	B-COMP
in	O
sera	B-COMP
,	O
saliva	O
,	O
lung	O
,	O
and	O
intestine	O
,	O
except	O
for	O
a	O
small	O
quantity	O
of	O
IgA	O
antibodies	B-COMP
in	O
fecal	O
extracts	O
and	O
the	O
genital	O
tract	O
,	O
along	O
with	O
IgG	O
antibodies	B-COMP
in	O
sera	B-COMP
,	O
but	O
when	O
given	O
with	O
adjuvant	O
CpG	O
ODN	O
2006	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
induced	O
significant	O
amounts	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
antibodies	B-COMP
in	O
sera	B-COMP
,	O
and	O
a	O
detectable	O
amount	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	B-COMP
in	O
sera	B-COMP
and	O
all	O
tested	O
mucosal	O
secretions	O
and	O
tissues	O
(	O
i	O
.	O
e	O
.,	O
saliva	O
,	O
the	O
genital	O
tract	O
,	O
fecal	O
extract	O
,	O
lung	O
,	O
and	O
intestine	O
).	O

On	O
a	O
neutralization	O
assay	O
,	O
neutralizing	O
activity	O
with	O
the	O
IP	O
immunization	O
protocol	O
was	O
detected	O
in	O
sera	B-COMP
and	O
mucosal	O
secretions	O
(	O
from	O
the	O
saliva	O
and	O
genital	O
tract	O
),	O
but	O
sera	B-COMP
from	O
the	O
IN	O
protocol	O
failed	O
to	O
show	O
any	O
neutralizing	O
activity	O
.	O

We	O
investigated	O
whether	O
IBV	O
affects	O
recruitment	O
and	O
function	O
of	O
phagocytic	O
cells	B-COMP
and	O
examined	O
NO	O
production	O
,	O
phagocytic	O
and	O
bactericidal	O
activity	O
,	O
and	O
kinetics	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
(	O
PBMC	O
)	O
and	O
splenocytes	O
.	O

We	O
demonstrated	O
,	O
using	O
a	O
viral	O
-	O
like	O
particle	O
formation	O
system	O
,	O
that	O
the	O
S	O
mutations	O
were	O
involved	O
in	O
the	O
lower	O
incorporation	O
of	O
the	O
S	O
protein	O
into	O
virions	B-COMP
,	O
although	O
the	O
M	O
mutation	O
that	O
disrupts	O
the	O
glycosylation	O
was	O
not	O
present	O
in	O
this	O
phenotype	O
.	O

The	O
proximal	O
end	O
inserted	O
into	O
the	O
root	O
of	O
the	O
normal	O
twin	O
'	O
s	O
umbilical	O
cord	O
in	O
an	O
acute	O
angle	O
forming	O
a	O
""""	O
v	O
""""	O
close	O
to	O
the	O
placental	O
disc	B-COMP
.	O

Mass	O
spectrometry	O
and	O
kinase	O
profiling	O
techniques	O
identified	O
nearly	O
200	O
incorporated	O
host	B-COMP
and	O
viral	O
proteins	O
.	O

TITLE	O
:	O
Persistent	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
human	O
tubular	O
kidney	O
cells	B-COMP
selects	O
for	O
adaptive	O
mutations	O
in	O
the	O
membrane	B-COMP
protein	O
.	O

Productive	O
infection	O
,	O
however	O
,	O
occurred	O
only	O
in	O
PTEC	O
but	O
not	O
in	O
glomerular	O
cells	B-COMP
.	O

We	O
recently	O
showed	O
that	O
elastase	O
enhances	O
SARS	O
-	O
CoV	O
infection	O
in	O
cultured	O
cells	B-COMP
,	O
which	O
suggests	O
that	O
SARS	O
development	O
may	O
be	O
due	O
to	O
elastase	O
-	O
mediated	O
,	O
enhanced	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
lungs	O
.	O

ABSTRACT	O
:	O
In	O
summer	O
2003	O
,	O
a	O
respiratory	O
outbreak	O
was	O
investigated	O
in	O
British	O
Columbia	O
,	O
during	O
which	O
nucleic	B-COMP
acid	O
tests	O
and	O
serology	O
unexpectedly	O
indicated	O
reactivity	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Notably	O
,	O
sera	B-COMP
demonstrated	O
cross	O
-	O
reactivity	O
against	O
nucleocapsid	B-COMP
peptide	O
sequences	O
common	O
to	O
HCoV	O
-	O
OC43	O
and	O
SARS	O
-	O
CoV	O
.	O
These	O
findings	O
underscore	O
the	O
virulence	O
of	O
human	O
CoV	O
-	O
OC43	O
in	O
elderly	O
populations	O
and	O
confirm	O
that	O
cross	O
-	O
reactivity	O
to	O
antibody	B-COMP
against	O
nucleocapsid	B-COMP
proteins	O
from	O
these	O
viruses	O
must	O
be	O
considered	O
when	O
interpreting	O
serological	O
tests	O
for	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Ninety	O
-	O
five	O
of	O
142	O
residents	O
(	O
67	O
%)	O
and	O
53	O
of	O
160	O
staff	O
members	O
(	O
33	O
%)	O
experienced	O
symptoms	O
of	O
respiratory	O
infection	O
.	O

ABSTRACT	O
:	O
Avian	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
a	O
coronavirus	O
that	O
infects	O
chickens	O
via	O
the	O
respiratory	O
epithelium	O
as	O
primary	O
target	O
cells	B-COMP
.	O

The	O
binding	O
of	O
coronaviruses	O
to	O
the	O
cell	B-COMP
surface	I-COMP
is	O
mediated	O
by	O
the	O
viral	O
surface	O
protein	O
S	O
.	O
Recently	O
we	O
demonstrated	O
that	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	O
acid	O
serves	O
as	O
a	O
receptor	O
determinant	O
for	O
IBV	O
on	O
Vero	O
cells	B-COMP
and	O
primary	O
chicken	O
embryo	O
kidney	O
cells	B-COMP
.	O

In	O
addition	O
to	O
un	O
-	O
glycosylated	O
and	O
glycosylated	O
proteins	O
,	O
one	O
product	O
with	O
smaller	O
size	O
initiated	O
in	O
-	O
frame	O
from	O
the	O
third	O
Met	O
residues	O
probably	O
through	O
ribosomal	B-COMP
re	O
-	O
initiation	O
was	O
also	O
detected	O
.	O

46	O
-	O
68	O
and	O
78	O
-	O
100	O
)	O
are	O
predicted	O
to	O
be	O
the	O
primary	O
type	O
helices	O
,	O
which	O
will	O
be	O
able	O
to	O
penetrate	O
into	O
membrane	B-COMP
by	O
themselves	O
,	O
while	O
the	O
first	O
trans	O
-	O
membrane	B-COMP
region	O
(	O
a	O
.	O
a	O
.	O

We	O
identified	O
a	O
similar	O
cell	B-COMP
culture	O
adaptation	O
for	O
the	O
human	O
coronavirus	O
OC43	O
.	O

While	O
RA59	O
and	O
SJHM	O
/	O
RA59	O
infections	O
resulted	O
in	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
priming	O
within	O
the	O
first	O
2	O
days	O
postinfection	O
,	O
RJHM	O
infection	O
did	O
not	O
lead	O
to	O
proliferation	O
of	O
nave	O
CD8	O
(+)	O
T	O
cells	B-COMP
.	O

RJHM	O
was	O
also	O
unable	O
to	O
elicit	O
a	O
secondary	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
response	O
in	O
the	O
brain	O
following	O
peripheral	O
immunization	O
against	O
a	O
viral	O
epitope	O
.	O

Immunohistochemically	O
,	O
all	O
cases	O
were	O
positive	O
for	O
coronavirus	O
antigen	O
using	O
monoclonal	O
antibody	B-COMP
FIPV3	O
-	O
70	O
.	O

Humoral	O
(	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
ELISA	O
)	O
and	O
cellular	B-COMP
(	O
by	O
cell	B-COMP
proliferation	O
and	O
CD4	O
(+):	O
CD8	O
(+)	O
assay	O
)	O
immunity	O
was	O
detected	O
by	O
using	O
recombinant	O
N1	O
and	O
N3	O
specific	O
antigen	O
.	O

The	O
identification	O
of	O
antigenic	O
N	O
protein	O
fragments	O
has	O
implications	O
to	O
provide	O
basic	O
information	O
for	O
the	O
design	O
of	O
DNA	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
present	O
results	O
not	O
only	O
suggest	O
that	O
DNA	O
immunization	O
with	O
pVax	O
-	O
N3	O
could	O
be	O
used	O
as	O
potential	O
DNA	O
vaccination	O
approaches	O
to	O
induce	O
antibody	B-COMP
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
also	O
illustrates	O
that	O
gene	O
immunization	O
with	O
these	O
SARS	O
DNA	O
vaccines	O
can	O
generate	O
different	O
immune	O
responses	O
.	O

The	O
culprit	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
detected	O
in	O
patient	O
specimens	O
by	O
traditional	O
cell	B-COMP
culture	O
using	O
an	O
unusual	O
cell	B-COMP
line	O
for	O
respiratory	O
viruses	O
,	O
Vero	O
E6	O
,	O
and	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
polymerase	O
1	O
B	O
region	O
of	O
the	O
genome	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	B-COMP
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
a	O
Class	O
I	O
viral	O
fusion	O
protein	O
,	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	B-COMP
.	O

The	O
modulation	O
of	O
TACE	O
activity	O
by	O
SARS	O
-	O
S	O
depended	O
on	O
the	O
cytoplasmic	B-COMP
domain	O
of	O
ACE2	O
,	O
because	O
deletion	O
mutants	O
of	O
ACE2	O
lacking	O
the	O
carboxyl	O
-	O
terminal	O
region	O
did	O
not	O
induce	O
ACE2	O
shedding	O
or	O
TNF	O
-	O
alpha	O
production	O
.	O

TITLE	O
:	O
Predicting	O
linear	O
B	O
-	O
cell	B-COMP
epitopes	O
using	O
string	O
kernels	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
and	O
characterization	O
of	O
B	O
-	O
cell	B-COMP
epitopes	O
play	O
an	O
important	O
role	O
in	O
vaccine	O
design	O
,	O
immunodiagnostic	O
tests	O
,	O
and	O
antibody	B-COMP
production	O
.	O

This	O
argues	O
for	O
the	O
use	O
of	O
carefully	O
homology	O
-	O
reduced	O
data	O
sets	O
in	O
comparing	O
B	O
-	O
cell	B-COMP
epitope	O
prediction	O
methods	O
to	O
avoid	O
misleading	O
conclusions	O
about	O
how	O
different	O
methods	O
compare	O
to	O
each	O
other	O
.	O

The	O
distribution	O
of	O
aquaporin	O
-	O
4	O
(	O
AQP	O
-	O
4	O
)	O
on	O
the	O
cell	B-COMP
membrane	I-COMP
was	O
observed	O
with	O
immunohistochemistry	O
,	O
and	O
the	O
expression	O
of	O
AQP	O
-	O
4	O
mRNA	O
was	O
detected	O
with	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
an	O
simple	O
and	O
sensitive	O
method	O
for	O
detecting	O
anti	O
-	O
coronavirus	O
IgG	O
antibodies	B-COMP
in	O
bat	O
sera	B-COMP
based	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
second	O
antibody	B-COMP
in	O
the	O
kit	O
was	O
replaced	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
protein	O
-	O
A	O
(	O
HRP	O
-	O
SPA	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
binding	O
between	O
Staphylococcus	O
aureus	O
protein	O
A	O
(	O
SPA	O
)	O
and	O
mammal	O
IgG	O
Fc	O
fragment	O
.	O

Studies	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
have	O
provided	O
important	O
insights	O
into	O
how	O
the	O
immune	O
system	O
combats	O
neuroinvasive	O
viruses	O
,	O
and	O
have	O
identified	O
molecular	O
and	O
cellular	B-COMP
mechanisms	O
contributing	O
to	O
chronic	O
disease	O
in	O
persistently	O
infected	O
mice	O
.	O

The	O
frameshifting	O
signal	O
encoded	O
in	O
the	O
viral	B-COMP
genome	I-COMP
has	O
additional	O
features	O
that	O
are	O
not	O
essential	O
for	O
frameshifting	O
.	O

Here	O
we	O
summarize	O
current	O
knowledge	O
and	O
add	O
additional	O
insight	O
regarding	O
the	O
function	O
of	O
the	O
programmed	O
-	O
1	O
ribosomal	B-COMP
frameshift	O
signal	O
in	O
the	O
coronavirus	O
lifecycle	O
.	O

CSF	O
-	O
total	O
protein	O
(	O
TP	O
)	O
was	O
measured	O
and	O
albumin	O
and	O
IgG	O
concentrations	O
were	O
measured	O
in	O
paired	O
CSF	O
/	O
serum	B-COMP
samples	O
;	O
Q	O
(	O
alb	O
)	O
and	O
IgG	O
index	O
were	O
calculated	O
.	O

Twenty	O
-	O
nine	O
of	O
these	O
cats	O
were	O
FECV	O
nave	O
before	O
infection	O
and	O
followed	O
sequentially	O
for	O
fecal	O
virus	O
shedding	O
and	O
antibody	B-COMP
responses	O
over	O
a	O
period	O
of	O
8	O
-	O
48	O
months	O
.	O

The	O
peptide	O
is	O
deeply	O
anchored	O
in	O
the	O
B	O
and	O
F	O
pockets	O
,	O
but	O
with	O
the	O
Glu4	O
residue	O
pointing	O
away	O
from	O
the	O
floor	O
in	O
the	O
peptide	O
-	O
binding	O
groove	O
,	O
making	O
it	O
available	O
for	O
interactions	O
with	O
a	O
potential	O
T	O
-	O
cell	B-COMP
receptor	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-COMP
glycoproteins	O
of	O
the	O
class	O
I	O
family	O
,	O
which	O
include	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
influenza	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
mediate	O
viral	O
entry	O
by	O
first	O
binding	O
to	O
their	O
cellular	B-COMP
receptors	O
and	O
subsequently	O
inducing	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	B-COMP
membranes	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	O
)	O
are	O
a	O
family	O
of	O
viral	B-COMP
envelope	I-COMP
glycoproteins	O
that	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
(	O
RDEs	O
).	O

Not	O
much	O
is	O
known	O
about	O
the	O
formation	O
of	O
these	O
vesicles	B-COMP
,	O
although	O
recent	O
observations	O
indicate	O
an	O
important	O
role	O
for	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
in	O
the	O
formation	O
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
replication	O
complexes	O
(	O
RCs	O
).	O

The	O
inflow	O
of	O
partially	O
purified	O
cell	B-COMP
lysate	O
sample	O
containing	O
the	O
gold	O
binding	O
polypeptide	O
(	O
GBP	O
)-	O
fusion	O
protein	O
was	O
bound	O
onto	O
the	O
gold	O
micropatterns	O
by	O
means	O
of	O
its	O
metal	O
binding	O
affinity	O
.	O

Viral	O
antibody	B-COMP
titers	O
to	O
eight	O
respiratory	O
viruses	O
(	O
influenza	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
serotype	O
three	O
(	O
PIV	O
-	O
3	O
),	O
PIV	O
-	O
2	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
coronaviruses	O
229E	O
and	O
OC43	O
)	O
were	O
measured	O
using	O
enzyme	O
immunoassay	O
at	O
baseline	O
and	O
53	O
weeks	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
the	O
c	O
-	O
terminal	O
dimerization	O
domain	O
of	O
SARS	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
solved	O
by	O
the	O
SAIL	O
-	O
NMR	O
method	O
.	O

Here	O
we	O
demonstrate	O
that	O
cathepsin	O
L	O
indeed	O
activates	O
the	O
membrane	B-COMP
fusion	O
function	O
of	O
the	O
spike	O
protein	O
.	O

Moreover	O
,	O
cleavage	O
was	O
mapped	O
to	O
the	O
same	O
region	O
where	O
,	O
in	O
coronaviruses	O
carrying	O
furin	O
-	O
activated	O
spikes	O
,	O
the	O
receptor	O
binding	O
subunit	O
of	O
the	O
protein	O
is	O
separated	O
from	O
the	O
membrane	B-COMP
-	O
anchored	O
fusion	O
subunit	O
.	O

CONCLUSIONS	O
:	O
Early	O
alterations	O
in	O
serum	B-COMP
levels	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
7	O
and	O
IL	O
-	O
10	O
may	O
constitute	O
useful	O
predictive	O
markers	O
for	O
identifying	O
patients	O
those	O
who	O
have	O
sustained	O
a	O
burn	O
with	O
concomitant	O
inhalation	O
injury	O
and	O
who	O
have	O
high	O
mortality	O
.	O

APC	B-COMP
did	O
not	O
improve	O
outcomes	O
from	O
ALI	O
.	O

Antibody	B-COMP
-	O
mediated	O
blocking	O
of	O
either	O
IL	O
-	O
23	O
(	O
anti	O
-	O
IL	O
-	O
23p19	O
)	O
or	O
IL	O
-	O
12	O
and	O
IL	O
-	O
23	O
(	O
anti	O
-	O
IL	O
-	O
12	O
/	O
23p40	O
)	O
signaling	O
did	O
not	O
mute	O
T	O
-	O
cell	B-COMP
trafficking	O
into	O
the	O
CNS	O
or	O
antiviral	O
effector	O
responses	O
and	O
mice	O
were	O
able	O
to	O
control	O
viral	O
replication	O
within	O
the	O
brain	O
.	O

The	O
SZ16	O
-	O
S	O
mutant	O
viruses	O
adapted	O
to	O
human	O
airway	O
epithelial	O
cells	B-COMP
and	O
displayed	O
enhanced	O
affinity	O
for	O
hACE2	O
but	O
exhibited	O
severe	O
growth	O
defects	O
in	O
the	O
DBT	O
-	O
cACE2	O
cells	B-COMP
,	O
suggesting	O
that	O
the	O
evolutionary	O
pathway	O
that	O
promoted	O
efficient	O
hACE2	O
interactions	O
simultaneously	O
abolished	O
efficient	O
cACE2	O
interactions	O
.	O

Since	O
dual	O
species	O
tropism	O
was	O
preserved	O
in	O
Urbani	O
,	O
it	O
is	O
likely	O
that	O
the	O
virus	O
evolved	O
a	O
high	O
affinity	O
for	O
cACE2	O
/	O
hACE2	O
receptors	O
through	O
adaptation	O
via	O
repeated	O
passages	O
between	O
human	O
and	O
civet	O
hosts	B-COMP
.	O

In	O
a	O
sub	O
-	O
group	O
analysis	O
we	O
identified	O
9	O
LTRs	O
who	O
developed	O
early	O
bronchiolitis	O
obliterans	O
syndrome	O
(	O
BOS	O
)	O
in	O
the	O
absence	O
of	O
acute	O
cellular	B-COMP
rejection	O
or	O
cytomegalovirus	O
reactivation	O
,	O
but	O
they	O
had	O
significant	O
lung	O
allograft	O
C3d	O
/	O
C4d	O
deposition	O
along	O
with	O
corroborative	O
light	O
-	O
microscopic	O
features	O
suggestive	O
of	O
AMR	O
.	O

MBL	O
is	O
a	O
serum	B-COMP
lectin	O
that	O
mediates	O
phagocytosis	O
and	O
activates	O
the	O
lectin	O
pathway	O
of	O
complement	O
involving	O
MASP	O
-	O
2	O
.	O

Importantly	O
,	O
combining	O
two	O
monoclonal	O
antibodies	B-COMP
that	O
target	O
different	O
epitopes	O
effected	O
almost	O
complete	O
suppression	O
of	O
wild	O
type	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	B-COMP
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
a	O
class	O
I	O
viral	O
fusion	O
protein	O
,	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	B-COMP
.	O

-	O
1	O
PRF	O
is	O
programmed	O
by	O
a	O
bipartite	O
signal	O
embedded	O
in	O
the	O
mRNA	O
and	O
includes	O
a	O
heptanucleotide	O
""""	O
slip	O
site	O
""""	O
over	O
which	O
the	O
paused	O
ribosome	B-COMP
""""	O
backs	O
up	O
""""	O
by	O
one	O
nucleotide	O
,	O
and	O
a	O
downstream	O
stimulatory	O
element	O
,	O
either	O
an	O
RNA	O
pseudoknot	O
or	O
a	O
very	O
stable	O
RNA	O
stem	O
-	O
loop	O
.	O

Scanning	O
alanine	O
mutagenesis	O
identified	O
two	O
regions	O
in	O
the	O
carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
TMD	O
that	O
eliminated	O
the	O
Golgi	B-COMP
complex	I-COMP
localization	O
of	O
the	O
chimeric	O
CD4	O
proteins	O
or	O
ORF7b	O
protein	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
Golgi	B-COMP
complex	I-COMP
retention	O
signal	O
of	O
the	O
ORF7b	O
protein	O
resides	O
solely	O
within	O
the	O
TMD	O
.	O

This	O
study	O
showed	O
that	O
the	O
3a	O
protein	O
modulates	O
the	O
mitochondrial	B-COMP
death	O
pathway	O
in	O
two	O
possible	O
ways	O
.	O

The	O
genetic	O
evolution	O
of	O
dog	O
CoVs	O
is	O
paradigmatic	O
of	O
how	O
CoVs	O
evolve	O
through	O
accumulation	O
of	O
point	O
mutations	O
,	O
insertions	O
or	O
deletions	O
in	O
the	O
viral	B-COMP
genome	I-COMP
,	O
that	O
led	O
to	O
the	O
emergence	O
of	O
new	O
genotypes	O
(	O
CCoV	O
type	O
I	O
),	O
biotypes	O
(	O
pantropic	O
CCoV	O
)	O
and	O
host	B-COMP
variants	O
(	O
canine	O
respiratory	O
coronavirus	O
).	O

The	O
results	O
showed	O
that	O
HBs	O
DNA	O
positive	O
bands	O
were	O
detected	O
in	O
the	O
embryos	O
with	O
green	O
fluorescence	O
(	O
PCR	O
and	O
RT	O
-	O
PCR	O
)	O
and	O
positive	O
control	O
(	O
PCR	O
)	O
indicating	O
expression	O
of	O
pIRES2	O
-	O
EGFP	O
-	O
HBs	O
,	O
and	O
not	O
observed	O
in	O
the	O
embryos	O
without	O
green	O
fluorescence	O
and	O
negative	O
controls	O
(	O
PCR	O
and	O
RT	O
-	O
PCR	O
)	O
indicating	O
no	O
pIRES2	O
-	O
EGFP	O
-	O
HBs	O
in	O
the	O
cells	B-COMP
.	O

We	O
tested	O
sera	B-COMP
collected	O
from	O
12	O
ocelots	O
(	O
Leopardus	O
pardalis	O
)	O
native	O
to	O
Barro	O
Colorado	O
Island	O
,	O
Panama	O
,	O
which	O
is	O
free	O
of	O
domestic	O
animals	O
,	O
for	O
antibodies	B-COMP
to	O
feline	O
herpes	O
virus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
corona	O
virus	O
,	O
feline	O
panleukopenia	O
virus	O
,	O
canine	O
distemper	O
virus	O
,	O
and	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
typically	O
a	O
species	O
-	O
specific	O
infection	O
.	O

Because	O
cystatins	O
added	O
to	O
cell	B-COMP
cultures	O
can	O
inhibit	O
polio	O
,	O
herpes	O
simplex	O
and	O
coronavirus	O
replication	O
,	O
which	O
are	O
intracellular	B-COMP
processes	O
,	O
the	O
internalization	O
and	O
intracellular	B-COMP
regulation	O
of	O
cysteine	O
proteases	O
by	O
cystatin	O
C	O
should	O
be	O
considered	O
.	O

ABSTRACT	O
:	O
When	O
expressed	O
in	O
mammalian	O
cells	B-COMP
,	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
membrane	B-COMP
(	O
M	O
)	O
proteins	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
sufficient	O
to	O
form	O
pseudoparticles	O
.	O

This	O
study	O
showed	O
that	O
ApNPV	O
significantly	O
enhanced	O
inflammatory	O
cytokine	O
mRNA	O
expression	O
in	O
chicken	O
PBMC	O
and	O
HD	O
11	O
cells	B-COMP
through	O
the	O
clathrin	O
-	O
dependent	O
endocytic	O
and	O
endosomal	O
maturation	O
pathway	O
,	O
and	O
up	O
-	O
regulated	O
nitric	O
oxide	O
production	O
in	O
HD	O
11	O
cells	B-COMP
.	O

The	O
cellular	B-COMP
localisation	O
and	O
function	O
of	O
the	O
SARS	O
-	O
CoV	O
accessory	O
proteins	O
was	O
determined	O
.	O

We	O
have	O
generated	O
monoclonal	O
antibodies	B-COMP
against	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
X1	O
/	O
3a	O
protein	O
(	O
3a	O
),	O
which	O
are	O
suitable	O
for	O
western	O
blotting	O
,	O
immunocytochemistry	O
,	O
and	O
immunohistochemistry	O
.	O

It	O
is	O
induced	O
by	O
extracellular	B-COMP
agents	O
,	O
including	O
pathogens	O
such	O
as	O
RNA	O
viruses	O
.	O

The	O
presence	O
of	O
alpaca	O
coronavirus	O
(	O
ApCoV	O
)	O
in	O
the	O
small	O
intestine	O
was	O
demonstrated	O
by	O
immune	O
histochemistry	O
with	O
an	O
antinucleocapsid	O
monoclonal	O
antibody	B-COMP
that	O
reacts	O
with	O
group	O
2	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
complete	O
the	O
fusion	O
process	O
of	O
SARS	O
-	O
CoV	O
virus	O
,	O
several	O
regions	O
of	O
the	O
S2	O
virus	O
envelope	B-COMP
glycoprotein	O
are	O
necessary	O
.	O

TITLE	O
:	O
Development	O
of	O
human	O
single	O
-	O
chain	O
antibodies	B-COMP
against	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

We	O
screened	O
a	O
phage	O
displaying	O
library	O
of	O
human	O
single	O
-	O
chain	O
antibodies	B-COMP
(	O
ScFv	B-COMP
)	O
against	O
the	O
predicted	O
epitopes	O
and	O
obtained	O
a	O
human	O
ScFv	B-COMP
which	O
can	O
recognize	O
the	O
SARS	O
virus	O
in	O
vitro	O
.	O

Both	O
the	O
whole	O
killed	O
SARS	O
-	O
CoV	O
vaccine	O
(	O
with	O
and	O
without	O
alum	O
)	O
and	O
adenovirus	O
-	O
based	O
vectors	O
encoding	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
protein	O
induced	O
neutralizing	O
antibody	B-COMP
responses	O
and	O
reduced	O
viral	O
replication	O
and	O
shedding	O
in	O
the	O
upper	O
respiratory	O
tract	O
and	O
progression	O
of	O
virus	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
Experimental	O
studies	O
of	O
arbidol	O
and	O
arbidol	O
mesylate	O
versus	O
ribavirin	O
suggest	O
that	O
insertion	O
of	O
these	O
agents	O
into	O
the	O
nutrient	O
medium	O
of	O
the	O
cultured	O
cells	B-COMP
GMK	O
-	O
AH	O
-	O
1	O
(	O
D	O
)	O
after	O
infection	O
at	O
concentrations	O
of	O
50	O
,	O
25	O
,	O
and	O
100	O
microg	O
/	O
ml	O
,	O
respectively	O
,	O
is	O
effective	O
in	O
suppressing	O
the	O
reproduction	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
antibodies	B-COMP
against	O
feline	O
coronavirus	O
7b	O
protein	O
for	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
in	O
cats	O
.	O

The	O
resultant	O
recombinant	O
protein	O
was	O
produced	O
and	O
used	O
in	O
antibody	B-COMP
detection	O
assays	O
via	O
western	O
blot	O
analysis	O
of	O
serum	B-COMP
samples	O
.	O

Results	O
were	O
compared	O
with	O
those	O
of	O
an	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
for	O
FCoV	O
-	O
specific	O
antibody	B-COMP
and	O
correlated	O
with	O
health	O
status	O
.	O

They	O
belonged	O
to	O
space	O
group	O
P1	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
41	O
.	O
1	O
,	O
b	O
=	O
43	O
.	O
2	O
,	O
c	O
=	O
48	O
.	O
9	O
A	O
,	O
alpha	O
=	O
78	O
.	O
0	O
,	O
beta	O
=	O
80	O
.	O
0	O
,	O
gamma	O
=	O
73	O
.	O
6	O
degrees	O
.	O

Histopathological	O
examination	O
of	O
the	O
spinal	O
cord	O
revealed	O
severe	O
granulomatous	O
inflammation	O
associated	O
with	O
large	O
numbers	O
of	O
encapsulated	O
yeast	O
cells	B-COMP
.	O

In	O
addition	O
to	O
the	O
granulomatous	O
host	B-COMP
response	O
,	O
necrosis	O
,	O
digestion	O
chambers	O
,	O
Gitter	O
cells	B-COMP
,	O
spheroids	O
and	O
lymphocytic	O
perivascular	O
cuffs	O
were	O
features	O
of	O
the	O
malacic	O
areas	O
.	O

Bivalent	O
scFvFc	O
human	O
antibodies	B-COMP
were	O
fused	O
in	O
frame	O
with	O
different	O
transmembrane	B-COMP
(	O
TM	B-COMP
)	O
anchoring	O
moieties	O
to	O
allow	O
efficient	O
high	O
-	O
level	O
expression	O
on	O
human	O
cells	B-COMP
and	O
the	O
optimal	O
TM	B-COMP
was	O
identified	O
.	O

TITLE	O
:	O
Loss	O
of	O
extracellular	B-COMP
superoxide	O
dismutase	O
leads	O
to	O
acute	O
lung	O
damage	O
in	O
the	O
presence	O
of	O
ambient	O
air	O
:	O
a	O
potential	O
mechanism	O
underlying	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

However	O
,	O
SARS	O
-	O
CoV	O
M	O
protein	O
is	O
co	O
-	O
localized	O
almost	O
entirely	O
with	O
S	O
,	O
E	O
,	O
or	O
NC	O
protein	O
when	O
co	O
-	O
expressed	O
in	O
the	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
a	O
large	O
group	O
including	O
human	O
pathogens	O
such	O
as	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
of	O
infected	O
host	B-COMP
cells	B-COMP
.	O

Our	O
analysis	O
defines	O
a	O
unique	O
reticulovesicular	O
network	O
of	O
modified	O
endoplasmic	B-COMP
reticulum	I-COMP
that	O
integrates	O
convoluted	O
membranes	O
,	O
numerous	O
interconnected	O
DMVs	O
(	O
diameter	O
200	O
-	O
300	O
nm	O
),	O
and	O
""""	O
vesicle	B-COMP
packets	O
""""	O
apparently	O
arising	O
from	O
DMV	O
merger	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
receptor	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
utilizes	O
for	O
target	O
cell	B-COMP
entry	O
and	O
,	O
therefore	O
,	O
plays	O
an	O
important	O
role	O
in	O
SARS	O
pathogenesis	O
.	O

The	O
proportion	O
of	O
NK	O
cells	B-COMP
in	O
the	O
peripheral	O
blood	O
also	O
significantly	O
increased	O
and	O
reached	O
the	O
peak	O
(	O
18	O
.	O
0	O
%+/-	O
5	O
.	O
4	O
%)	O
at	O
48	O
h	O
.	O
However	O
,	O
there	O
were	O
few	O
NK	O
cells	B-COMP
in	O
the	O
peripheral	O
blood	O
at	O
70	O
h	O
after	O
infection	O
;	O
the	O
ratio	O
was	O
only	O
1	O
.	O
3	O
%+/-	O
0	O
.	O
6	O
%.	O

In	O
addition	O
,	O
an	O
increase	O
in	O
IFN	O
gamma	O
production	O
by	O
hepatic	O
NK	O
cells	B-COMP
was	O
observed	O
at	O
48	O
h	O
.	O
After	O
MHV	O
-	O
3	O
infection	O
,	O
NK	O
cells	B-COMP
were	O
recruited	O
to	O
the	O
liver	O
quickly	O
,	O
probably	O
from	O
the	O
spleen	O
and	O
bone	O
marrow	O
.	O

CONCLUSIONS	O
:	O
After	O
MHV	O
-	O
3	O
infection	O
,	O
NK	O
cells	B-COMP
were	O
recruited	O
to	O
the	O
liver	O
quickly	O
,	O
probably	O
from	O
the	O
spleen	O
and	O
bone	O
marrow	O
.	O

SARS	O
-	O
CoV	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	B-COMP
responses	O
were	O
detected	O
in	O
all	O
vaccinees	O
,	O
and	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
responses	O
in	O
approximately	O
20	O
%	O
of	O
individuals	O
.	O

Polychromatic	O
cytometry	O
analysis	O
indicated	O
that	O
the	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
from	O
the	O
severe	O
group	O
tended	O
to	O
be	O
a	O
central	O
memory	O
phenotype	O
(	O
CD27	O
(+)/	O
CD45RO	O
(+))	O
with	O
a	O
significantly	O
higher	O
frequency	O
of	O
polyfunctional	O
CD4	O
(+)	O
T	O
cells	B-COMP
producing	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IL	O
-	O
2	O
,	O
and	O
CD8	O
(+)	O
T	O
cells	B-COMP
producing	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
CD107a	O
(	O
degranulation	O
),	O
as	O
compared	O
with	O
the	O
mild	O
-	O
moderate	O
group	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
antibodies	B-COMP
to	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
infections	O
was	O
studied	O
in	O
20	O
conventional	O
and	O
20	O
organic	O
dairy	O
herds	O
.	O

The	O
antibody	B-COMP
prevalence	O
was	O
high	O
at	O
both	O
sampling	O
times	O
with	O
approximately	O
85	O
%	O
and	O
80	O
%	O
of	O
animals	O
positive	O
for	O
antibodies	B-COMP
to	O
BCV	O
and	O
to	O
BRSV	O
,	O
respectively	O
.	O

Recipients	O
of	O
GKO	O
CD4	O
(+)	O
T	O
cells	B-COMP
succumbed	O
more	O
rapidly	O
to	O
fatal	O
disease	O
than	O
untreated	O
control	O
infected	O
mice	O
.	O

DPD	O
activity	O
was	O
evaluated	O
by	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	B-COMP
(	O
PBMC	O
)	O
radioassay	O
,	O
genotyping	O
of	O
DPYD	O
gene	O
by	O
Denaturing	O
High	O
Performance	O
Liquid	O
Chromatography	O
(	O
DHPLC	O
),	O
or	O
2	O
-(	O
13	O
)	O
C	O
uracil	O
breath	O
test	O
(	O
UraBT	O
).	O

Immunofluorescence	O
analysis	O
visualized	O
S	O
along	O
the	O
secretory	O
pathway	O
from	O
endoplasmic	B-COMP
reticulum	I-COMP
to	O
plasma	B-COMP
membrane	I-COMP
.	O

The	O
therapeutic	O
ASODN	O
was	O
delivered	O
using	O
a	O
pH	O
-	O
sensitive	O
,	O
membrane	B-COMP
-	O
interactive	O
polymer	O
that	O
destabilizes	O
the	O
endosomal	O
membrane	B-COMP
to	O
enhance	O
access	O
cytoplasmic	B-COMP
delivery	O
in	O
targeted	O
cells	B-COMP
.	O

In	O
immunocompetent	O
hosts	B-COMP
,	O
antiviral	O
therapy	O
can	O
be	O
stopped	O
early	O
because	O
adaptive	O
immune	O
response	O
can	O
usually	O
be	O
mounted	O
within	O
5	O
-	O
14	O
days	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
complete	O
blood	O
count	O
and	O
measurements	O
of	O
serum	B-COMP
serotonin	O
immediately	O
before	O
and	O
at	O
10	O
,	O
20	O
,	O
and	O
35	O
min	O
after	O
challenge	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
viral	O
antigen	O
-	O
antibody	B-COMP
complexes	O
were	O
not	O
internalized	O
through	O
any	O
of	O
the	O
previously	O
described	O
pathways	O
.	O

Gastric	O
juice	O
from	O
critically	O
ill	O
patients	O
is	O
proinflammatory	O
and	O
stimulates	O
human	O
pulmonary	O
cells	B-COMP
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
an	O
excessive	O
host	B-COMP
immune	O
response	O
against	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
involved	O
in	O
severe	O
pneumonia	O
caused	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

We	O
screened	O
sera	B-COMP
from	O
10	O
children	O
and	O
196	O
adults	O
and	O
established	O
primary	O
cutoff	O
points	O
based	O
on	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibody	B-COMP
levels	O
of	O
the	O
predominantly	O
seronegative	O
children	O
.	O

ABSTRACT	O
:	O
Infections	O
by	O
coronaviruses	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
)	O
and	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
result	O
in	O
very	O
little	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
by	O
host	B-COMP
cells	B-COMP
,	O
which	O
is	O
potentially	O
responsible	O
for	O
the	O
rapid	O
viral	O
growth	O
and	O
severe	O
immunopathology	O
associated	O
with	O
SARS	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
for	O
the	O
low	O
IFN	O
production	O
in	O
cells	B-COMP
infected	O
with	O
coronaviruses	O
remain	O
unclear	O
.	O

We	O
found	O
that	O
HeLa	O
cells	B-COMP
infected	O
with	O
229E	O
via	O
APN	O
formed	O
syncytia	O
when	O
treated	O
with	O
trypsin	O
or	O
other	O
proteases	O
but	O
not	O
in	O
a	O
low	O
-	O
pH	O
environment	O
,	O
a	O
finding	O
consistent	O
with	O
syncytium	O
formation	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
phylogenetic	O
trees	O
constructed	O
using	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
Pol	O
),	O
helicase	O
,	O
spike	O
,	O
and	O
nucleocapsid	B-COMP
proteins	O
,	O
BuCoV	O
HKU11	O
,	O
ThCoV	O
HKU12	O
,	O
and	O
MuCoV	O
HKU13	O
formed	O
a	O
cluster	O
distantly	O
related	O
to	O
infectious	O
bronchitis	O
virus	O
and	O
turkey	O
CoV	O
(	O
group	O
3a	O
CoVs	O
).	O

To	O
address	O
this	O
,	O
the	O
complete	O
nucleocapsid	B-COMP
gene	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Expressed	O
nucleocapsid	B-COMP
gene	O
produced	O
two	O
distinct	O
proteins	O
(	O
52	O
and	O
43	O
kDa	O
);	O
their	O
specificity	O
was	O
confirmed	O
by	O
Western	O
blotting	O
using	O
two	O
different	O
monoclonal	O
antibodies	B-COMP
.	O

Recombinant	O
N	O
protein	O
was	O
purified	O
and	O
used	O
as	O
an	O
antigen	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
serological	O
detection	O
of	O
TCoV	O
that	O
was	O
then	O
validated	O
using	O
experimentally	O
derived	O
turkey	O
serum	B-COMP
.	O

In	O
addition	O
,	O
infection	O
of	O
RAG1	O
-/-	O
or	O
CXCL9	O
-/-	O
mice	O
with	O
a	O
recombinant	O
MHV	O
expressing	O
CXCL9	O
(	O
MHV	O
-	O
CXCL9	O
)	O
resulted	O
in	O
protection	O
from	O
disease	O
that	O
correlated	O
with	O
reduced	O
viral	O
titers	O
within	O
the	O
brain	O
and	O
NK	O
cell	B-COMP
-	O
mediated	O
protection	O
in	O
the	O
liver	O
.	O

However	O
some	O
viruses	O
,	O
including	O
the	O
group	O
2	O
coronaviruses	O
,	O
have	O
evolved	O
mechanisms	O
to	O
overcome	O
or	O
circumvent	O
the	O
host	B-COMP
antiviral	O
response	O
.	O

TITLE	O
:	O
Differential	O
activities	O
of	O
cellular	B-COMP
and	O
viral	O
macro	O
domain	O
proteins	O
in	O
binding	O
of	O
ADP	O
-	O
ribose	O
metabolites	O
.	O

We	O
have	O
here	O
characterized	O
three	O
novel	O
human	O
macro	O
domain	O
proteins	O
that	O
were	O
found	O
to	O
reside	O
either	O
in	O
the	O
cytoplasm	B-COMP
and	O
nucleus	B-COMP
[	O
macro	O
domain	O
protein	O
2	O
(	O
MDO2	O
)	O
and	O
ganglioside	O
-	O
induced	O
differentiation	O
-	O
associated	O
protein	O
2	O
]	O
or	O
in	O
mitochondria	B-COMP
[	O
macro	O
domain	O
protein	O
1	O
(	O
MDO1	O
)],	O
and	O
compared	O
them	O
with	O
viral	O
macro	O
domains	O
from	O
Semliki	O
Forest	O
virus	O
,	O
hepatitis	O
E	O
virus	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
with	O
a	O
yeast	O
macro	O
protein	O
,	O
Poa1p	O
.	O

Of	O
interest	O
,	O
the	O
frequency	O
of	O
IL	O
-	O
2	O
-	O
positive	O
cells	B-COMP
elicited	O
by	O
the	O
SARS	O
-	O
CoV	O
3a	O
DNA	O
vaccine	O
was	O
significantly	O
higher	O
than	O
that	O
elicited	O
by	O
the	O
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccine	O
.	O

We	O
have	O
developed	O
twin	O
assays	O
(	O
slide	O
agglutination	O
test	O
[	O
SAT	O
]	O
for	O
CPV	O
antigen	O
and	O
slide	O
inhibition	O
test	O
[	O
SIT	O
]	O
for	O
CPV	O
antibody	B-COMP
)	O
that	O
are	O
sensitive	O
,	O
specific	O
,	O
cost	O
-	O
effective	O
,	O
generic	O
for	O
all	O
genotypes	O
of	O
CPV	O
,	O
and	O
provide	O
instant	O
results	O
for	O
CPV	O
antigen	O
detection	O
in	O
feces	O
and	O
antibody	B-COMP
quantification	O
in	O
serum	B-COMP
.	O

To	O
study	O
this	O
,	O
we	O
established	O
highly	O
polarized	O
human	O
lung	O
epithelial	O
Calu	O
-	O
3	O
cells	B-COMP
by	O
using	O
the	O
Transwell	O
culture	O
system	O
.	O

Hitherto	O
used	O
cell	B-COMP
cultures	O
for	O
hCoV	O
-	O
NL63	O
show	O
low	O
levels	O
of	O
virus	O
replication	O
and	O
weak	O
and	O
diffuse	O
cytopathogenic	O
effects	O
.	O

Introduction	O
of	O
these	O
mutations	O
into	O
the	O
viral	B-COMP
genome	I-COMP
showed	O
only	O
mild	O
to	O
moderate	O
effects	O
on	O
the	O
growth	O
and	O
infectivity	O
of	O
the	O
rescued	O
mutant	O
viruses	O
.	O

To	O
establish	O
proof	O
-	O
of	O
-	O
principle	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
was	O
evaluated	O
,	O
and	O
the	O
first	O
visualization	O
of	O
HCoV	O
-	O
NL63	O
virus	O
by	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-COMP
)	O
is	O
reported	O
.	O

We	O
assume	O
that	O
these	O
cellular	B-COMP
deposits	O
lower	O
the	O
efficacy	O
of	O
ECMO	O
.	O

The	O
identification	O
of	O
these	O
cells	B-COMP
could	O
be	O
a	O
key	O
for	O
future	O
therapeutic	O
interventions	O
and	O
improvements	O
in	O
the	O
development	O
of	O
MO	O
.	O

TITLE	O
:	O
[	O
The	O
proteomics	O
research	O
on	O
relational	O
expressed	O
serum	B-COMP
proteins	O
among	O
the	O
recovered	O
SARS	O
patients	O
complicating	O
avascular	O
necrosis	O
of	O
femoral	O
head	O
].	O

2	O
-	O
DE	O
and	O
MALDI	O
-	O
TOF	O
MS	O
were	O
used	O
to	O
study	O
the	O
comparative	O
serum	B-COMP
proteomics	O
among	O
female	O
SARS	O
AVNFH	O
group	O
,	O
female	O
SARS	O
non	O
-	O
AVNFH	O
group	O
and	O
female	O
healthy	O
group	O
.	O

The	O
areas	O
under	O
the	O
ROC	O
curve	O
on	O
serum	B-COMP
amyloid	O
P	O
component	O
was	O
0	O
.	O
854	O
,	O
the	O
specificity	O
was	O
77	O
.	O
8	O
%	O
and	O
the	O
sensitivity	O
was	O
85	O
.	O
2	O
%.	O

Bat	O
-	O
SRBD	O
was	O
infectious	O
in	O
cell	B-COMP
culture	O
and	O
in	O
mice	O
and	O
was	O
efficiently	O
neutralized	O
by	O
antibodies	B-COMP
specific	O
for	O
both	O
bat	O
and	O
human	O
CoV	O
Spike	O
proteins	O
.	O

TITLE	O
:	O
The	O
expression	O
and	O
antigenicity	O
of	O
a	O
truncated	O
spike	O
-	O
nucleocapsid	B-COMP
fusion	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

TITLE	O
:	O
B	O
-	O
cell	B-COMP
activation	O
in	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
by	O
FIP	O
-	O
virus	O
-	O
induced	O
B	O
-	O
cell	B-COMP
differentiation	O
/	O
survival	O
factors	O
.	O

The	O
histopathological	O
findings	O
(	O
H	O
-	O
E	O
stain	O
)	O
of	O
the	O
autopsied	O
lungs	O
showed	O
hyaline	O
membrane	B-COMP
formation	O
and	O
hyperplasia	O
of	O
type	O
II	O
alveolar	O
epithelium	O
cells	B-COMP
,	O
so	O
-	O
called	O
,	O
diffuse	O
alveolar	O
damage	O
.	O

ABSTRACT	O
:	O
The	O
innate	O
immune	O
system	O
guards	O
against	O
virus	O
infection	O
through	O
a	O
variety	O
of	O
mechanisms	O
including	O
mobilization	O
of	O
the	O
host	B-COMP
interferon	O
system	O
,	O
which	O
attacks	O
viral	O
products	O
mainly	O
at	O
a	O
posttranscriptional	O
level	O
.	O

The	O
emergence	O
of	O
the	O
highly	O
pathogenic	O
coronavirus	O
severe	O
acute	O
respiratory	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
serves	O
as	O
a	O
robust	O
model	O
system	O
to	O
elucidate	O
the	O
virus	O
-	O
host	B-COMP
interactions	O
that	O
mediate	O
severe	O
end	O
-	O
stage	O
lung	O
disease	O
in	O
humans	O
and	O
animals	O
.	O

Using	O
SARS	O
-	O
CoV	O
as	O
a	O
model	O
,	O
we	O
review	O
the	O
current	O
literature	O
on	O
the	O
ability	O
of	O
coronaviruses	O
to	O
interact	O
with	O
and	O
modify	O
the	O
host	B-COMP
intracellular	I-COMP
environment	O
during	O
infection	O
.	O

Susceptible	O
cells	B-COMP
are	O
inoculated	O
with	O
serial	O
logarithmic	O
dilutions	O
of	O
samples	O
in	O
a	O
96	O
-	O
well	O
plate	O
.	O

TITLE	O
:	O
Identification	O
of	O
sugar	O
residues	O
involved	O
in	O
the	O
binding	O
of	O
TGEV	O
to	O
porcine	O
brush	B-COMP
border	I-COMP
membranes	O
.	O

Here	O
we	O
describe	O
the	O
engineering	O
of	O
CoV	O
full	O
-	O
length	O
cDNA	O
clones	O
using	O
bacterial	O
artificial	O
chromosomes	B-COMP
(	O
BACs	O
).	O

TITLE	O
:	O
Generating	O
antibodies	B-COMP
to	O
the	O
gene	O
3	O
proteins	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

This	O
chapter	O
details	O
methods	O
for	O
generating	O
and	O
screening	O
antibodies	B-COMP
to	O
these	O
gene	O
3	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
embryonated	O
egg	O
is	O
a	O
complex	O
structure	O
comprising	O
an	O
embryo	O
and	O
its	O
supporting	O
membranes	O
(	O
chorioallantoic	O
,	O
amniotic	O
,	O
yolk	B-COMP
).	O

Although	O
type	O
I	O
IFN	O
production	O
is	O
muted	O
in	O
JHMV	O
-	O
infected	O
glial	O
cultures	O
,	O
IFN	O
-	O
beta	O
is	O
produced	O
following	O
IFN	O
-	O
gamma	O
-	O
treatment	O
of	O
JHMV	O
-	O
infected	O
cells	B-COMP
.	O

These	O
data	O
indicate	O
that	O
JHMV	O
is	O
capable	O
of	O
infecting	O
glial	O
cells	B-COMP
generated	O
from	O
neural	O
progenitor	O
cells	B-COMP
and	O
that	O
IFN	O
-	O
gamma	O
-	O
mediated	O
control	O
of	O
viral	O
replication	O
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
type	O
I	O
IFN	O
secretion	O
.	O

Thus	O
,	O
an	O
important	O
application	O
of	O
the	O
SCHOOL	O
model	O
is	O
that	O
global	O
therapeutic	O
strategies	O
targeting	O
key	O
protein	O
-	O
protein	O
interactions	O
involved	O
in	O
MIRR	O
triggering	O
and	O
transmembrane	B-COMP
signal	O
transduction	O
may	O
be	O
used	O
to	O
treat	O
a	O
diverse	O
set	O
of	O
immune	O
-	O
mediated	O
diseases	O
.	O

This	O
assumes	O
that	O
clinical	O
knowledge	O
and	O
therapeutic	O
strategies	O
can	O
be	O
transferred	O
between	O
seemingly	O
disparate	O
disorders	O
,	O
such	O
as	O
T	O
-	O
cell	B-COMP
-	O
mediated	O
skin	O
diseases	O
and	O
platelet	O
disorders	O
,	O
or	O
combined	O
to	O
develop	O
novel	O
pharmacological	O
approaches	O
.	O

Intriguingly	O
,	O
the	O
SCHOOL	O
model	O
unravels	O
the	O
molecular	O
mechanisms	O
underlying	O
ability	O
of	O
different	O
human	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
,	O
cytomegalovirus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
to	O
modulate	O
and	O
/	O
or	O
escape	O
the	O
host	B-COMP
immune	O
response	O
.	O

The	O
non	O
-	O
specific	O
stimulation	O
did	O
not	O
occur	O
when	O
other	O
avian	O
viruses	O
or	O
other	O
coronaviruses	O
were	O
used	O
or	O
when	O
mammalian	O
cells	B-COMP
were	O
stimulated	O
with	O
IBV	O
.	O

Similar	O
numbers	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
were	O
retained	O
in	O
the	O
CNS	O
of	O
IL	O
-	O
15	O
(-/-)	O
and	O
wt	O
mice	O
,	O
consistent	O
with	O
loss	O
of	O
IL	O
-	O
2	O
/	O
15	O
receptor	O
(	O
CD122	O
)	O
expression	O
.	O

Furthermore	O
,	O
CD8	O
(+)	O
T	O
cell	B-COMP
division	O
in	O
the	O
CNS	O
was	O
reduced	O
compared	O
to	O
spleen	O
.	O

The	O
specific	O
reduction	O
of	O
PKR	O
protein	O
expression	O
by	O
antisense	O
peptide	O
-	O
conjugated	O
phosphorodiamidate	O
morpholino	O
oligomers	O
strongly	O
reduced	O
cleavage	O
of	O
PARP	O
in	O
infected	O
cells	B-COMP
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
assembly	O
,	O
we	O
cloned	O
the	O
genes	O
encoding	O
these	O
four	O
proteins	O
into	O
the	O
eukaryotic	O
expression	O
vector	O
pCAGGS	O
and	O
transfected	O
them	O
into	O
293T	O
cells	B-COMP
.	O

When	O
all	O
four	O
expression	O
vectors	O
were	O
co	O
-	O
transfected	O
VLP	B-COMP
formed	O
,	O
as	O
confirmed	O
using	O
electron	O
microscopy	O
.	O

Co	O
-	O
immunoprecipitation	O
analyses	O
demonstrated	O
an	O
interaction	O
between	O
the	O
N	O
and	O
M	O
proteins	O
,	O
suggesting	O
that	O
N	O
protein	O
binds	O
directly	O
to	O
M	O
protein	O
to	O
be	O
incorporated	O
into	O
VLP	B-COMP
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
major	O
target	O
cell	B-COMP
populations	O
of	O
this	O
first	O
wave	O
of	O
type	O
I	O
IFNs	O
.	O

MHV	O
particles	O
have	O
a	O
distinctly	O
spherical	O
shape	O
and	O
a	O
relatively	O
homogenous	O
size	O
(	O
approximately	O
85	O
nm	O
envelope	B-COMP
diameter	O
).	O

Focal	O
pairs	O
revealed	O
the	O
existence	O
of	O
an	O
extra	O
internal	O
layer	O
,	O
most	O
likely	O
formed	O
by	O
the	O
C	O
-	O
terminal	O
domains	O
of	O
the	O
major	O
envelope	B-COMP
protein	O
M	O
.	O
In	O
the	O
interior	O
of	O
the	O
particles	O
,	O
coiled	O
structures	O
and	O
tubular	O
shapes	O
are	O
observed	O
,	O
consistent	O
with	O
a	O
helical	O
nucleocapsid	B-COMP
model	O
.	O

TITLE	O
:	O
Role	O
of	O
regulatory	O
T	O
cells	B-COMP
in	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	O
.	O

IFN	O
-	O
gamma	O
production	O
reaches	O
a	O
maximum	O
level	O
2	O
days	O
after	O
viral	O
inoculation	O
,	O
especially	O
in	O
liver	O
immune	O
cells	B-COMP
.	O

Here	O
,	O
we	O
have	O
designed	O
and	O
produced	O
a	O
prototypic	O
SARS	O
vaccine	O
:	O
a	O
self	O
-	O
assembling	O
polypeptide	O
nanoparticle	O
that	O
repetitively	O
displays	O
a	O
SARS	O
B	O
-	O
cell	B-COMP
epitope	O
from	O
the	O
C	O
-	O
terminal	O
heptad	O
repeat	O
of	O
the	O
virus	O
'	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
2	O
is	O
a	O
homolog	O
of	O
the	O
well	O
-	O
characterized	O
plasma	B-COMP
membrane	I-COMP
-	O
bound	O
angiotensin	O
-	O
converting	O
enzyme	O
.	O

Together	O
,	O
these	O
proteins	O
comprise	O
a	O
subset	O
of	O
a	O
large	O
superfamily	O
of	O
2H	O
phosphoesterase	O
proteins	O
that	O
are	O
distinguished	O
by	O
a	O
pair	O
of	O
conserved	O
His	O
-	O
x	O
-	O
Thr	O
/	O
Ser	B-COMP
motifs	O
encompassing	O
catalytically	O
important	O
residues	O
.	O

Progress	O
is	O
being	O
made	O
with	O
respect	O
to	O
making	O
nucleic	B-COMP
acid	O
approaches	O
more	O
suitable	O
for	O
use	O
in	O
diagnostic	O
laboratories	O
.	O

Several	O
studies	O
have	O
implicated	O
that	O
APC	B-COMP
may	O
be	O
protective	O
in	O
ALI	O
.	O

However	O
,	O
APC	B-COMP
failed	O
to	O
prevent	O
the	O
decrease	O
in	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
.	O

0	O
.	O
6	O
in	O
APC	B-COMP
group	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

To	O
this	O
end	O
chicken	O
embryos	O
were	O
inoculated	O
in	O
the	O
allantoic	O
sac	B-COMP
with	O
10	O
(	O
3	O
)	O
EID	O
(	O
50	O
)	O
of	O
IBV	O
M41	O
at	O
10	O
days	O
of	O
age	O
.	O

RESULTS	O
:	O
To	O
this	O
end	O
chicken	O
embryos	O
were	O
inoculated	O
in	O
the	O
allantoic	O
sac	B-COMP
with	O
10	O
(	O
3	O
)	O
EID	O
(	O
50	O
)	O
of	O
IBV	O
M41	O
at	O
10	O
days	O
of	O
age	O
.	O

TITLE	O
:	O
Large	O
mixed	O
germ	O
cell	B-COMP
tumor	O
in	O
a	O
young	O
patient	O
presenting	O
as	O
an	O
intrapulmonary	O
mass	O
.	O

Histology	O
confirmed	O
a	O
teratoma	O
with	O
mature	O
and	O
immature	O
components	O
accompanied	O
by	O
residual	O
seminomatous	O
tumor	O
cells	B-COMP
.	O

The	O
three	O
major	O
diagnostic	O
methods	O
available	O
for	O
SARS	O
includes	O
viral	O
RNA	O
detection	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
virus	O
induced	O
antibodies	B-COMP
by	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
or	O
by	O
enzyme	O
linked	O
immunosorbant	O
assay	O
(	O
ELISA	O
)	O
of	O
nucleocapsid	B-COMP
protein	O
(	O
NP	O
).	O

The	O
secreted	O
SQ	O
protein	O
in	O
which	O
the	O
transmembrane	B-COMP
domain	O
was	O
deleted	O
,	O
as	O
well	O
as	O
the	O
full	O
-	O
length	O
spike	O
protein	O
,	O
showed	O
the	O
most	O
potential	O
to	O
induce	O
the	O
production	O
of	O
neutralizing	O
antibody	B-COMP
(	O
nAb	O
)	O
in	O
mice	O
.	O

Structural	O
,	O
functional	O
and	O
biochemical	O
analyses	O
[	O
corrected	O
]	O
have	O
provided	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
receptor	O
recognition	O
and	O
antibody	B-COMP
neutralization	O
,	O
and	O
suggested	O
that	O
these	O
antibodies	B-COMP
alone	O
or	O
in	O
combination	O
could	O
fight	O
the	O
viruses	O
'	O
heterogeneity	O
and	O
mutability	O
,	O
which	O
is	O
a	O
major	O
problem	O
in	O
the	O
development	O
of	O
effective	O
therapeutic	O
agents	O
against	O
viruses	O
,	O
including	O
therapeutic	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
To	O
reveal	O
the	O
putative	O
cellular	B-COMP
factors	O
involved	O
in	O
SARS	O
coronavirus	O
replication	O
,	O
the	O
helicase	O
(	O
Hel	O
,	O
nsp13	O
)	O
of	O
SARS	O
coronavirus	O
was	O
used	O
to	O
screen	O
the	O
cDNA	O
library	O
of	O
rat	O
pulmonary	O
epithelial	O
cells	B-COMP
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

Positively	O
interacting	O
proteins	O
were	O
further	O
tested	O
using	O
a	O
mammalian	O
cell	B-COMP
hybrid	O
system	O
and	O
co	O
-	O
immunoprecipitation	O
in	O
the	O
human	O
A549	O
cell	B-COMP
line	O
,	O
which	O
has	O
been	O
shown	O
to	O
support	O
SARS	O
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Differential	O
characteristics	O
of	O
the	O
early	O
stage	O
of	O
lung	O
inflammation	O
induced	O
by	O
SARS	O
-	O
CoV	O
Nucleocapsid	B-COMP
protein	O
related	O
to	O
age	O
in	O
the	O
mouse	O
.	O

Most	O
of	O
these	O
more	O
recently	O
developed	O
antiviral	O
mAbs	O
have	O
come	O
from	O
the	O
use	O
of	O
antibody	B-COMP
phage	O
-	O
display	O
technologies	O
and	O
the	O
implementation	O
of	O
simplified	O
,	O
inexpensive	O
yet	O
efficient	O
methods	O
,	O
for	O
expressing	O
and	O
purifying	O
the	O
initially	O
selected	O
fragment	O
antibodies	B-COMP
is	O
of	O
prime	O
importance	O
in	O
further	O
facilitating	O
this	O
area	O
of	O
research	O
.	O

Rats	O
were	O
intravenously	O
injected	O
with	O
oleic	O
acid	O
(	O
OA	O
)	O
to	O
induce	O
ALI	O
and	O
30	O
minutes	O
later	O
they	O
were	O
divided	O
into	O
five	O
groups	O
:	O
model	O
(	O
injury	O
only	O
),	O
PPS	O
aerosol	O
(	O
PPS	O
-	O
aer	B-COMP
),	O
saline	O
aerosol	O
(	O
saline	O
-	O
aer	B-COMP
),	O
PPS	O
instillation	O
(	O
PPS	O
-	O
inst	O
),	O
and	O
saline	O
instillation	O
(	O
Saline	O
-	O
Inst	O
).	O

The	O
ability	O
of	O
the	O
rAd	O
-	O
N	O
to	O
induce	O
anti	O
-	O
SARS	O
-	O
CoV	O
N	O
antibody	B-COMP
production	O
and	O
cellular	B-COMP
immune	O
responses	O
was	O
evaluated	O
in	O
an	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
Kb	O
transgenic	O
mouse	O
model	O
.	O

Infection	O
with	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
induces	O
a	O
cellular	B-COMP
stress	O
condition	O
known	O
as	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
).	O

Two	O
new	O
aspects	O
of	O
the	O
interaction	O
between	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
the	O
cell	B-COMP
have	O
been	O
defined	O
.	O

CONCLUSIONS	O
:	O
This	O
extensive	O
evolutionary	O
analysis	O
revealed	O
the	O
stepwise	O
evolution	O
of	O
different	O
functional	O
proteins	O
of	O
SARS	O
-	O
CoVs	O
at	O
different	O
epidemic	O
stages	O
and	O
different	O
hosts	B-COMP
.	O

In	O
addition	O
to	O
neuronal	O
transduction	O
,	O
a	O
significant	O
nonneuronal	O
cell	B-COMP
population	O
was	O
transduced	O
by	O
AAV1	O
vector	O
;	O
for	O
example	O
,	O
oligodendrocytes	O
in	O
corona	O
radiata	O
and	O
astrocytes	O
in	O
the	O
striatum	O
.	O

Nidovirus	O
RNA	O
synthesis	O
is	O
mediated	O
by	O
a	O
cytoplasmic	B-COMP
membrane	I-COMP
-	O
associated	O
replication	O
/	O
transcription	O
complex	O
that	O
includes	O
up	O
to	O
16	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
which	O
carry	O
common	O
enzymatic	O
activities	O
,	O
like	O
the	O
viral	O
RNA	O
polymerase	O
,	O
but	O
also	O
unusual	O
and	O
poorly	O
understood	O
RNA	O
-	O
processing	O
functions	O
.	O

Furthermore	O
,	O
a	O
marked	O
increased	O
level	O
of	O
DEV	O
-	O
specific	O
IgA	O
and	O
IgG	O
antibodies	B-COMP
in	O
bile	O
,	O
serum	B-COMP
and	O
the	O
intestinal	O
tract	O
,	O
as	O
well	O
as	O
the	O
density	O
of	O
IgA	O
(+)	O
cells	B-COMP
in	O
intestine	O
were	O
detected	O
between	O
1	O
and	O
12days	O
p	O
.	O
i	O
.,	O
followed	O
by	O
a	O
drastic	O
reduction	O
of	O
the	O
antibody	B-COMP
levels	O
and	O
the	O
density	O
of	O
IgA	O
(+)	O
cells	B-COMP
at	O
15days	O
p	O
.	O
i	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
the	O
expression	O
plasmid	O
of	O
S2	O
extracellular	B-COMP
domain	O
(	O
S2ED	O
)	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
and	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
to	O
obtain	O
the	O
fusion	O
protein	O
expressed	O
in	O
prokaryotic	O
cells	B-COMP
.	O

CONCLUSIONS	O
:	O
Surfactant	O
inactivation	O
and	O
dysfunction	O
is	O
also	O
a	O
hallmark	O
in	O
newborns	O
with	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-COMP
),	O
for	O
which	O
a	O
beneficial	O
effect	O
of	O
exogenous	O
surfactant	O
replacement	O
.	O

Both	O
of	O
the	O
transmembrane	B-COMP
regions	O
(	O
a	O
.	O
a	O
.	O

ABSTRACT	O
:	O
Clinical	O
use	O
of	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	B-COMP
(	O
BMMSCs	O
)	O
holds	O
great	O
promise	O
for	O
regenerative	O
medicine	O
in	O
intractable	O
lung	O
diseases	O
,	O
such	O
as	O
lung	O
fibrosis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Thirty	O
C3H	O
/	O
Hej	O
mice	O
received	O
10	O
Pfu	O
MHV	O
-	O
3	O
intraperitoneally	O
,	O
the	O
CD4	O
-	O
CD8	O
-	O
T	O
cells	B-COMP
were	O
isolated	O
using	O
magnetic	O
bead	O
sorting	O
on	O
0	O
,	O
4	O
,	O
15	O
,	O
30	O
,	O
40	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
.	O

Serum	B-COMP
samples	O
from	O
70	O
commercial	O
chicken	O
flocks	O
(	O
40	O
broilers	O
,	O
18	O
layers	O
,	O
and	O
12	O
broiler	O
breeders	O
)	O
free	O
from	O
respiratory	O
disease	O
were	O
collected	O
and	O
screened	O
for	O
the	O
presence	O
of	O
Massachusetts	O
-	O
41	O
(	O
M	O
-	O
41	O
),	O
D274	O
,	O
and	O
4	O
/	O
91	O
strain	O
antigens	O
of	O
IBV	O
by	O
using	O
the	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
test	O
.	O

Most	O
neonates	O
receiving	O
ECMO	O
suffer	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-COMP
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	O
),	O
sepsis	O
or	O
persistent	O
pulmonary	O
hypertension	O
(	O
PPH	O
).	O

It	O
can	O
be	O
achieved	O
with	O
full	O
-	O
thickness	O
laparostomy	O
(	O
midline	B-COMP
or	O
transverse	O
subcostal	O
)	O
or	O
through	O
a	O
subcutaneous	O
linea	O
alba	O
fasciotomy	O
.	O

Toll	O
-	O
like	O
receptor	O
-	O
3	O
(	O
TLR	O
-	O
3	O
)	O
is	O
an	O
integral	O
part	O
of	O
the	O
host	B-COMP
'	O
s	O
innate	O
immune	O
system	O
and	O
serves	O
as	O
an	O
important	O
signaling	O
pathway	O
for	O
the	O
recognition	O
of	O
dsRNA	O
for	O
the	O
triggering	O
of	O
antiviral	O
and	O
inflammatory	O
responses	O
to	O
combat	O
viral	O
infections	O
.	O

In	O
order	O
to	O
assess	O
the	O
role	O
of	O
activated	O
neutrophils	O
,	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
adhesion	O
molecules	O
at	O
the	O
onset	O
and	O
development	O
of	O
respiratory	O
complications	O
and	O
respiratory	O
failure	O
,	O
we	O
measured	O
the	O
serum	B-COMP
levels	O
of	O
pro	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
18	O
,	O
TNF	O
-	O
alpha	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
ra	O
,	O
IL	O
-	O
10	O
)	O
cytokines	O
in	O
51	O
AP	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
with	O
and	O
without	O
the	O
development	O
of	O
organ	O
dysfunction	O
.	O

This	O
selection	O
resulted	O
in	O
eight	O
independent	O
10Fn3	O
intrabodies	O
,	O
two	O
that	O
require	O
the	O
N	O
-	O
terminal	O
domain	O
for	O
binding	O
and	O
six	O
that	O
recognize	O
the	O
C	O
terminus	O
,	O
one	O
with	O
Kd	O
=	O
1	O
.	O
7	O
nM	O
.	O
10Fn3	O
intrabodies	O
are	O
well	O
expressed	O
in	O
mammalian	O
cells	B-COMP
and	O
are	O
relocalized	O
by	O
N	O
in	O
SARS	O
-	O
infected	O
cells	B-COMP
.	O

Our	O
previous	O
study	O
indicated	O
that	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	B-COMP
protein	O
forms	O
self	O
-	O
multimers	O
through	O
a	O
serine	O
-	O
arginine	O
(	O
SR	O
)-	O
rich	O
motif	O
(	O
SSRSSSRSRGNSR	O
)	O
by	O
using	O
a	O
mammalian	O
two	O
-	O
hybrid	O
system	O
.	O

Structure	O
comparison	O
has	O
been	O
carried	O
out	O
to	O
search	O
for	O
DUBs	O
with	O
a	O
similar	O
structure	O
to	O
that	O
of	O
PLpro	O
,	O
and	O
we	O
have	O
tried	O
to	O
dock	O
6MP	O
and	O
6TG	O
into	O
these	O
DUBs	O
to	O
investigate	O
the	O
potential	O
use	O
of	O
6MP	O
and	O
6TG	O
as	O
cellular	B-COMP
DUB	O
inhibitors	O
.	O

We	O
demonstrate	O
unique	O
shuttling	O
behavior	O
of	O
ORF	O
3b	O
,	O
whereby	O
the	O
protein	O
initially	O
accumulates	O
in	O
the	O
nucleus	B-COMP
and	O
subsequently	O
translocates	O
to	O
mitochondria	B-COMP
.	O

We	O
further	O
show	O
that	O
ORF	O
3b	O
inhibits	O
induction	O
of	O
type	O
I	O
interferon	O
induced	O
by	O
retinoic	O
acid	O
-	O
induced	O
gene	O
1	O
and	O
the	O
mitochondrial	B-COMP
antiviral	O
signaling	O
protein	O
.	O

The	O
mitochondrial	B-COMP
antiviral	O
signaling	O
adaptor	O
,	O
MAVS	O
(	O
IPS	O
-	O
1	O
,	O
VISA	O
or	O
Cardif	O
)	O
is	O
critical	O
for	O
host	B-COMP
defenses	O
to	O
viral	O
infection	O
by	O
inducing	O
type	O
-	O
1	O
interferons	O
(	O
IFN	O
-	O
I	O
),	O
however	O
its	O
role	O
in	O
virus	O
-	O
induced	O
apoptotic	O
responses	O
has	O
not	O
been	O
elucidated	O
.	O

Detection	O
methods	O
for	O
a	O
wide	O
range	O
of	O
CoVs	O
are	O
needed	O
,	O
to	O
understand	O
viral	O
evolution	O
,	O
host	B-COMP
range	O
,	O
transmission	O
and	O
maintenance	O
in	O
reservoirs	O
.	O

The	O
split	O
probe	O
strategy	O
allowed	O
detection	O
of	O
down	O
to	O
10	O
viral	O
nucleic	B-COMP
acid	O
equivalents	O
of	O
CoV	O
from	O
all	O
known	O
CoV	O
groups	O
.	O

TITLE	O
:	O
Use	O
of	O
recombinant	O
S1	O
spike	O
polypeptide	O
to	O
develop	O
a	O
TCoV	O
-	O
specific	O
antibody	B-COMP
ELISA	O
.	O

Effects	O
of	O
the	O
chimeric	O
ribozyme	O
on	O
expression	O
of	O
SARS	O
-	O
CoV	O
were	O
evaluated	O
in	O
cultured	O
3T3	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Antibody	B-COMP
mimic	O
proteins	O
(	O
AMPs	O
)	O
are	O
polypeptides	O
that	O
bind	O
to	O
their	O
target	O
analytes	O
with	O
high	O
affinity	O
and	O
specificity	O
,	O
just	O
like	O
conventional	O
antibodies	B-COMP
,	O
but	O
are	O
much	O
smaller	O
in	O
size	O
(	O
2	O
-	O
5	O
nm	O
,	O
less	O
than	O
10	O
kDa	O
).	O

TITLE	O
:	O
Antigenicity	O
and	O
immunogenicity	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
receptor	O
-	O
binding	O
domain	O
stably	O
expressed	O
in	O
CHO	O
cells	B-COMP
.	O

Here	O
we	O
used	O
CHO	O
-	O
K1	O
cells	B-COMP
to	O
establish	O
a	O
cell	B-COMP
line	O
for	O
stable	O
expression	O
of	O
a	O
193	O
-	O
mer	O
(	O
residues	O
318	O
-	O
510	O
)	O
RBD	O
(	O
RBD193	O
-	O
CHO	O
)	O
and	O
determined	O
its	O
antigenicity	O
and	O
immunogenicity	O
.	O

Extracts	O
from	O
roots	O
and	O
leaves	O
of	O
Isatis	O
indigotica	O
also	O
presented	O
CPE	O
inhibition	O
either	O
before	O
or	O
after	O
infection	O
of	O
PrV	O
on	O
porcine	O
kidney	O
(	O
PK	O
-	O
15	O
)	O
cells	B-COMP
.	O

The	O
method	O
employed	O
in	O
this	O
study	O
is	O
precise	O
and	O
accurate	O
at	O
TSA	O
levels	O
(	O
in	O
mg	O
/	O
L	O
)	O
commonly	O
encountered	O
in	O
feline	O
serum	B-COMP
.	O

The	O
significant	O
correlation	O
between	O
plasma	O
SP	O
-	O
D	O
and	O
anti	O
-	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	B-COMP
support	O
the	O
role	O
for	O
SP	O
-	O
D	O
in	O
interlinking	O
innate	O
and	O
adaptive	O
immune	O
pathways	O
.	O

Addition	O
of	O
this	O
adapter	O
protein	O
to	O
MHV	O
allowed	O
infection	O
of	O
otherwise	O
nonsusceptible	O
,	O
EGF	O
receptor	O
(	O
EGFR	O
)-	O
expressing	O
cell	B-COMP
cultures	O
.	O

The	O
resulting	O
recombinant	O
MHV	O
was	O
viable	O
and	O
had	O
indeed	O
acquired	O
the	O
ability	O
to	O
infect	O
all	O
glioblastoma	O
cell	B-COMP
lines	O
tested	O
in	O
vitro	O
.	O

Mutation	O
of	O
the	O
most	O
N	O
-	O
terminal	O
residue	O
(	O
S798	O
)	O
had	O
little	O
or	O
no	O
effect	O
on	O
membrane	B-COMP
fusion	O
.	O

To	O
review	O
anticoronaviral	O
therapies	O
based	O
on	O
inhibition	O
of	O
viral	O
entry	O
into	O
the	O
host	B-COMP
cell	I-COMP
and	O
to	O
cast	O
light	O
on	O
promising	O
approaches	O
and	O
future	O
developments	O
.	O

Of	O
the	O
viral	O
-	O
entry	O
inhibitors	O
,	O
monoclonal	O
antibodies	B-COMP
have	O
demonstrated	O
efficacy	O
,	O
clinical	O
application	O
in	O
other	O
viral	O
infections	O
,	O
and	O
the	O
potential	O
to	O
impact	O
a	O
future	O
epidemic	O
.	O

Several	O
other	O
clinical	O
trials	O
evaluating	O
recombinant	O
human	O
APC	B-COMP
have	O
been	O
completed	O
,	O
including	O
studies	O
in	O
children	O
and	O
less	O
severely	O
ill	O
adults	O
with	O
sepsis	O
as	O
well	O
as	O
a	O
study	O
in	O
acute	O
lung	O
injury	O
.	O

Our	O
results	O
showed	O
that	O
GD	O
had	O
a	O
direct	O
antiviral	O
activity	O
,	O
leading	O
to	O
complete	O
inhibition	O
of	O
cell	B-COMP
infection	O
.	O

Significant	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
were	O
characterized	O
by	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
51	O
)	O
Cr	O
release	O
assay	O
and	O
interferon	O
-	O
gamma	O
secretion	O
ELISPOT	O
assay	O
against	O
RMA	O
-	O
S	O
target	O
cells	B-COMP
presenting	O
predicted	O
MHC	O
class	O
I	O
H2	O
-	O
Kb	O
epitopes	O
,	O
including	O
those	O
spanning	O
residues	O
884	O
-	O
891	O
and	O
1116	O
-	O
1123	O
within	O
the	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

Engrafted	O
cells	B-COMP
did	O
not	O
survive	O
past	O
2	O
weeks	O
following	O
transplantation	O
despite	O
treatment	O
with	O
high	O
dose	O
cyclosporine	O
A	O
.	O
While	O
T	O
cell	B-COMP
infiltration	O
into	O
the	O
CNS	O
was	O
dampened	O
,	O
elevated	O
numbers	O
of	O
macrophage	O
/	O
microglia	O
and	O
endogenous	O
OPCs	O
were	O
evident	O
surrounding	O
the	O
implantation	O
site	O
and	O
this	O
was	O
associated	O
with	O
increased	O
remyelination	O
.	O

RESULTS	O
:	O
Addition	O
of	O
doxycycline	O
significantly	O
reduced	O
TNF	O
-	O
alpha	O
-	O
induced	O
PMN	O
transmigration	O
across	O
Matrigel	O
membrane	B-COMP
(	O
12	O
.	O
6	O
+/-	O
2	O
.	O
6	O
vs	O
.	O
20	O
.	O
1	O
+/-	O

ABSTRACT	O
:	O
A	O
chimeric	O
gene	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
and	O
a	O
S	B-COMP
-	I-COMP
layer	I-COMP
protein	O
from	O
Lactobacillus	O
brevis	O
KCTC3102	O
,	O
and	O
/	O
or	O
two	O
copies	O
of	O
the	O
Fc	O
-	O
binding	O
Z	O
-	O
domain	O
,	O
a	O
synthetic	O
analog	O
of	O
the	O
B	O
-	O
domain	O
of	O
protein	O
A	O
,	O
was	O
constructed	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
).	O

Owing	O
to	O
their	O
affinity	O
towards	O
intestinal	O
cells	B-COMP
and	O
immunoglobulin	O
G	O
,	O
the	O
Slayer	O
fusion	O
proteins	O
enabled	O
the	O
adhesion	O
of	O
antibodies	B-COMP
to	O
human	O
epithelial	O
cells	B-COMP
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
infectivity	O
and	O
propagation	O
of	O
HEV	O
in	O
comparison	O
with	O
those	O
of	O
pseudorabies	O
virus	O
(	O
PRV	O
),	O
another	O
neurotropic	O
virus	O
,	O
using	O
dorsal	O
root	O
ganglia	O
cells	B-COMP
of	O
newborn	O
mice	O
containing	O
nerve	O
cells	B-COMP
and	O
non	O
-	O
neuronal	O
cells	B-COMP
.	O

Nine	O
(	O
4	O
%)	O
patients	O
had	O
serum	B-COMP
bilirubin	O
>	O
3	O
mg	O
/	O
dl	O
with	O
normal	O
liver	O
enzymes	O
.	O

One	O
patient	O
went	O
into	O
acute	O
renal	O
failure	O
following	O
quinine	O
therapy	O
and	O
showed	O
red	O
cell	B-COMP
fragments	O
in	O
the	O
peripheral	O
blood	O
.	O

TITLE	O
:	O
Toll	O
-	O
like	O
receptors	O
,	O
chemokine	O
receptors	O
and	O
death	O
receptor	O
ligands	O
responses	O
in	O
SARS	O
coronavirus	O
infected	O
human	O
monocyte	O
derived	O
dendritic	B-COMP
cells	B-COMP
.	O

We	O
demonstrate	O
that	O
chloroquine	O
,	O
a	O
widely	O
used	O
drug	O
with	O
well	O
-	O
known	O
antimalarial	O
effects	O
,	O
inhibits	O
HCoV	O
-	O
OC43	O
replication	O
in	O
HRT	O
-	O
18	O
cells	B-COMP
,	O
with	O
a	O
50	O
%	O
effective	O
concentration	O
(+/-	O

Immunohistochemistry	O
was	O
employed	O
to	O
detect	O
the	O
expression	O
of	O
the	O
structural	O
proteins	O
of	O
SARS	O
-	O
CoV	O
in	O
transfected	O
cells	B-COMP
.	O

Current	O
data	O
suggest	O
that	O
cytotoxins	O
and	O
activated	O
cells	B-COMP
are	O
formed	O
in	O
the	O
airway	O
and	O
carried	O
to	O
the	O
parenchyma	O
.	O

Cytometry	O
analysis	O
indicated	O
that	O
the	O
majority	O
of	O
memory	O
CD8	O
(+)	O
T	O
cells	B-COMP
produced	O
IFN	O
-	O
gamma	O
,	O
whereas	O
memory	O
CD4	O
(+)	O
T	O
cells	B-COMP
produced	O
IFN	O
-	O
gamma	O
,	O
IL	O
-	O
2	O
or	O
TNF	O
-	O
alpha	O
.	O

The	O
5	O
-	O
Acetyl	O
-	O
2	O
-(	O
4	O
'-	O
nitrobiphenyl	O
-	O
4	O
-	O
yl	O
)-	O
1H	O
-	O
benzimidazole	O
(	O
24	O
)	O
emerged	O
as	O
potent	O
active	O
lead	O
compound	O
against	O
Yellow	O
Fever	O
Virus	O
(	O
a	O
Flavivirus	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
0	O
.	O
5	O
microM	O
)	O
and	O
CVB	O
-	O
2	O
at	O
1	O
microM	O
and	O
was	O
not	O
cytotoxic	O
,	O
whereas	O
the	O
other	O
title	O
benzimidazoles	O
showed	O
no	O
antiviral	O
activity	O
at	O
concentrations	O
not	O
cytotoxic	O
for	O
the	O
resting	O
cell	B-COMP
monolayers	O
.	O

The	O
results	O
showed	O
that	O
co	O
-	O
administration	O
of	O
pVAX	O
-	O
chGM	O
-	O
CSF	O
led	O
to	O
a	O
significant	O
enhancement	O
of	O
humoral	O
and	O
cellular	B-COMP
responses	O
over	O
that	O
of	O
vaccination	O
with	O
pVAX	O
-	O
S1	O
alone	O
.	O

The	O
serum	B-COMP
samples	O
were	O
initially	O
tested	O
with	O
the	O
virus	O
neutralisation	O
(	O
VN	O
)	O
test	O
and	O
the	O
results	O
were	O
then	O
compared	O
with	O
the	O
ELISA	O
.	O

The	O
prevalence	O
of	O
FCoV	O
II	O
antibodies	B-COMP
in	O
the	O
sampled	O
population	O
based	O
on	O
the	O
gold	O
standard	O
was	O
62	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
44	O
-	O
0	O
.	O
77	O
)	O
among	O
multi	O
-	O
cat	O
environments	O
,	O
and	O
4	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
01	O
-	O
0	O
.	O
11	O
)	O
among	O
single	O
cat	O
households	O
.	O

However	O
,	O
the	O
severity	O
of	O
MHV	O
-	O
1	O
-	O
induced	O
pulmonary	O
disease	O
varies	O
among	O
mouse	O
strains	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
differences	O
in	O
the	O
host	B-COMP
immune	O
response	O
might	O
account	O
for	O
this	O
variation	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
host	B-COMP
and	O
cell	B-COMP
specificities	O
are	O
determined	O
by	O
specific	O
interactions	O
between	O
the	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
and	O
host	B-COMP
cell	I-COMP
receptor	O
(	O
s	O
).	O

By	O
construction	O
of	O
chimeric	O
S	O
constructs	O
and	O
site	O
-	O
directed	O
mutagenesis	O
,	O
a	O
point	O
mutation	O
(	O
L857	O
-	O
F	O
)	O
at	O
amino	O
acid	O
position	O
857	O
in	O
the	O
heptad	O
repeat	O
1	O
region	O
of	O
S	O
protein	O
was	O
shown	O
to	O
be	O
responsible	O
for	O
its	O
acquisition	O
of	O
the	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
activity	O
.	O

To	O
identify	O
cellular	B-COMP
proteins	O
involved	O
in	O
coronavirus	O
RNA	O
synthesis	O
,	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
genome	O
ends	O
,	O
harboring	O
essential	O
cis	O
-	O
acting	O
signals	O
for	O
replication	O
,	O
were	O
used	O
as	O
baits	O
for	O
RNA	O
affinity	O
protein	O
purification	O
.	O

ELISA	O
and	O
Western	O
blot	O
analysis	O
showed	O
that	O
the	O
purified	O
fusion	O
proteins	O
had	O
excellent	O
immune	O
activity	O
with	O
chicken	O
anti	O
-	O
IBV	O
serum	B-COMP
.	O

Nsp4	O
is	O
localized	O
to	O
the	O
ER	B-COMP
membrane	I-COMP
when	O
expressed	O
alone	O
but	O
is	O
recruited	O
into	O
the	O
replication	O
complex	O
in	O
infected	O
cells	B-COMP
.	O

P	O
-	O
TMA	O
Cl	O
significantly	O
decreased	O
P	O
(	O
DA	O
)	O
in	O
normal	O
and	O
inflamed	O
cells	B-COMP
and	O
attenuated	O
pressure	O
-	O
induced	O
increases	O
in	O
L	O
(	O
p	O
).	O

The	O
nsps	O
assemble	O
into	O
the	O
viral	O
replication	O
-	O
transcription	O
complex	O
and	O
nsp3	O
,	O
nsp4	O
and	O
nsp6	O
are	O
believed	O
to	O
anchor	O
this	O
enzyme	O
complex	O
to	O
modified	O
intracellular	B-COMP
membranes	O
.	O

The	O
current	O
study	O
determines	O
the	O
antigen	O
-	O
specificity	O
of	O
the	O
T	O
lymphocytes	O
present	O
during	O
chronic	O
disease	O
and	O
evaluates	O
how	O
blocking	O
CXCL10	O
signaling	O
affects	O
retention	O
of	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
.	O

Significant	O
expression	O
levels	O
were	O
identified	O
for	O
ANPEP	O
(	O
a	O
receptor	O
for	O
CoV	O
),	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
STAT1	O
pathway	O
,	O
IFNs	O
production	O
and	O
CXCL10	O
(	O
a	O
T	O
-	O
cell	B-COMP
recruiter	O
).	O

ABSTRACT	O
:	O
Red	O
cell	B-COMP
exchange	O
(	O
RCE	O
)	O
is	O
part	O
of	O
the	O
management	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
)	O
in	O
patients	O
with	O
sickle	O
cell	B-COMP
disease	O
.	O

For	O
nsp2	O
,	O
we	O
identified	O
an	O
interaction	O
with	O
two	O
host	B-COMP
proteins	O
,	O
prohibitin	O
1	O
(	O
PHB1	O
)	O
and	O
PHB2	O
.	O

Using	O
an	O
enzyme	O
immunosorbent	O
assay	O
,	O
the	O
authors	O
compared	O
sera	B-COMP
from	O
95	O
turkey	O
-	O
exposed	O
individuals	O
with	O
sera	B-COMP
from	O
82	O
nonexposed	O
controls	O
for	O
serologic	O
evidence	O
of	O
infection	O
with	O
HEV	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
in	O
human	O
serum	B-COMP
using	O
a	O
localized	O
surface	O
plasmon	O
coupled	O
fluorescence	O
fiber	O
-	O
optic	O
biosensor	O
.	O

Our	O
results	O
show	O
that	O
all	O
rRBD	O
proteins	O
expressed	O
in	O
the	O
above	O
systems	O
maintained	O
intact	O
conformation	O
,	O
being	O
able	O
to	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-COMP
responses	O
and	O
complete	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
mice	O
,	O
albeit	O
the	O
rRBD	O
expressed	O
in	O
293T	O
cells	B-COMP
elicited	O
stronger	O
humoral	O
immune	O
responses	O
with	O
significantly	O
higher	O
neutralizing	O
activity	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
expressed	O
in	O
Sf9	O
and	O
E	O
.	O
coli	O
cells	B-COMP
.	O

TITLE	O
:	O
Elucidation	O
of	O
the	O
stability	O
and	O
functional	O
regions	O
of	O
the	O
human	O
coronavirus	O
OC43	O
nucleocapsid	B-COMP
protein	O
.	O

Postoperatively	O
,	O
he	O
appeared	O
increasingly	O
hyperthermic	O
,	O
showed	O
respiratory	O
exhaustion	O
,	O
and	O
was	O
neutropenic	O
(	O
lowest	O
white	O
blood	O
cell	B-COMP
count	O
was	O
0	O
.	O
8	O
Gpt	O
with	O
a	O
normal	O
granulocyte	O
count	O
).	O

In	O
CaCo	O
-	O
2	O
and	O
HUH7	O
cells	B-COMP
,	O
but	O
not	O
in	O
Vero	O
cells	B-COMP
,	O
the	O
variant	O
carrying	O
the	O
ORF	O
7b	O
deletion	O
had	O
a	O
replicative	O
advantage	O
against	O
the	O
parental	O
virus	O
(	O
4	O
-	O
and	O
6	O
-	O
fold	O
increase	O
of	O
virus	O
RNA	O
in	O
supernatant	O
,	O
respectively	O
).	O

However	O
,	O
pretreatment	O
of	O
cells	B-COMP
with	O
interferon	O
beta	O
caused	O
the	O
deleted	O
virus	O
to	O
replicate	O
to	O
higher	O
titers	O
than	O
the	O
parental	O
strain	O
(	O
3	O
.	O
4	O
-	O
fold	O
in	O
Vero	O
cells	B-COMP
,	O
7	O
.	O
9	O
-	O
fold	O
in	O
CaCo	O
-	O
2	O
cells	B-COMP
).	O

TITLE	O
:	O
Two	O
-	O
step	O
conformational	O
changes	O
in	O
a	O
coronavirus	O
envelope	B-COMP
glycoprotein	O
mediated	O
by	O
receptor	O
binding	O
and	O
proteolysis	O
.	O

In	O
contrast	O
,	O
in	O
the	O
absence	O
of	O
extracellular	B-COMP
proteases	O
,	O
these	O
viruses	O
can	O
enter	O
cells	B-COMP
via	O
an	O
endosomal	O
pathway	O
and	O
utilize	O
endosomal	O
cathepsins	O
for	O
S	O
protein	O
activation	O
.	O

Interestingly	O
,	O
consecutive	O
treatment	O
with	O
CPL	O
and	O
then	O
chlorpromazine	O
enabled	O
a	O
portion	O
of	O
the	O
virus	O
to	O
enter	O
from	O
cell	B-COMP
surface	I-COMP
.	O

TITLE	O
:	O
Population	O
context	O
determines	O
cell	B-COMP
-	O
to	O
-	O
cell	B-COMP
variability	O
in	O
endocytosis	O
and	O
virus	O
infection	O
.	O

This	O
heterogeneity	O
has	O
been	O
measured	O
for	O
gene	O
transcription	O
,	O
phosphorylation	O
,	O
cell	B-COMP
morphology	O
and	O
drug	O
perturbations	O
,	O
and	O
used	O
to	O
explain	O
various	O
aspects	O
of	O
cellular	B-COMP
physiology	O
.	O

We	O
find	O
that	O
accounting	O
for	O
population	O
-	O
determined	O
heterogeneity	O
is	O
essential	O
for	O
interpreting	O
differences	O
between	O
the	O
activity	O
levels	O
of	O
cell	B-COMP
populations	O
.	O

ABSTRACT	O
:	O
The	O
S2	O
domain	O
of	O
the	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
is	O
known	O
to	O
be	O
responsible	O
for	O
mediating	O
membrane	B-COMP
fusion	O
.	O

Based	O
on	O
available	O
predictive	O
models	O
,	O
we	O
propose	O
that	O
the	O
conserved	O
domain	O
flanked	O
by	O
cysteines	O
822	O
and	O
833	O
forms	O
a	O
loop	O
structure	O
that	O
interacts	O
with	O
components	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
trimer	O
to	O
control	O
the	O
activation	O
of	O
membrane	B-COMP
fusion	O
.	O

These	O
drugs	O
have	O
complex	O
mechanisms	O
of	O
action	O
involving	O
both	O
genomic	O
and	O
non	O
-	O
genomic	O
mechanisms	O
and	O
interfere	O
with	O
different	O
signal	O
transduction	O
pathways	O
in	O
the	O
cell	B-COMP
.	O

The	O
number	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
peripheral	O
blood	O
was	O
examined	O
.	O

In	O
the	O
period	O
of	O
45	O
-	O
72	O
day	O
after	O
renal	O
transplantation	O
,	O
36	O
cases	O
were	O
found	O
to	O
have	O
significantly	O
lower	O
number	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
than	O
that	O
before	O
operation	O
.	O

In	O
8	O
survival	O
patients	O
with	O
CMV	O
pneumonia	O
,	O
the	O
number	O
of	O
CD4	O
(+)	O
T	O
cell	B-COMP
rose	O
slowly	O
,	O
on	O
21	O
day	O
after	O
the	O
withdrawal	O
increased	O
to	O
the	O
normal	O
level	O
.	O

But	O
in	O
4	O
non	O
-	O
survival	O
patients	O
,	O
the	O
number	O
of	O
CD4	O
(+)	O
T	O
cell	B-COMP
kept	O
continuously	O
in	O
lower	O
level	O
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
as	O
a	O
bait	O
,	O
the	O
N	O
protein	O
was	O
found	O
to	O
interact	O
with	O
MAP19	O
,	O
a	O
non	O
-	O
enzymatic	O
protein	O
of	O
MASP	O
(	O
mannan	O
-	O
associated	O
serine	O
protease	O
).	O

Six	O
liposomal	O
peptides	O
effectively	O
induced	O
IFN	O
-	O
gamma	O
-	O
producing	O
CD8	O
(+)	O
T	O
cells	B-COMP
and	O
seven	O
liposomal	O
peptides	O
including	O
the	O
six	O
peptides	O
primed	O
CTLs	O
showing	O
in	O
vivo	O
killing	O
activities	O
.	O

ALI	O
-	O
EX	O
caused	O
a	O
greater	O
thickening	O
of	O
the	O
alveolar	O
walls	O
,	O
more	O
areas	O
of	O
atelectasis	O
and	O
a	O
greater	O
abundance	O
of	O
inflammatory	O
cells	B-COMP
in	O
comparison	O
to	O
ALI	O
-	O
P	O
.	O
These	O
results	O
demonstrate	O
that	O
glycogen	O
content	O
in	O
ALI	O
,	O
induced	O
by	O
an	O
herbicide	O
that	O
is	O
highly	O
toxic	O
to	O
humans	O
and	O
animals	O
,	O
is	O
altered	O
in	O
different	O
tissues	O
depending	O
on	O
the	O
location	O
of	O
the	O
injury	O
.	O

To	O
understand	O
whether	O
this	O
suppression	O
is	O
through	O
inhibition	O
of	O
protein	O
kinase	O
R	O
(	O
PKR	O
),	O
the	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
dependent	O
kinase	O
that	O
is	O
one	O
of	O
the	O
main	O
kinases	O
responsible	O
for	O
phosphorylation	O
of	O
eIF	O
-	O
2alpha	O
,	O
cells	B-COMP
infected	O
with	O
IBV	O
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

The	O
results	O
showed	O
that	O
the	O
level	O
of	O
phosphorylated	O
PKR	O
was	O
greatly	O
reduced	O
in	O
IBV	O
-	O
infected	O
cells	B-COMP
.	O

In	O
this	O
study	O
the	O
development	O
of	O
a	O
real	O
-	O
time	O
TaqMan	O
RT	O
-	O
PCR	O
targeting	O
the	O
highly	O
conserved	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
of	O
IBV	O
and	O
including	O
an	O
internal	O
PCR	O
control	O
is	O
described	O
.	O

Furthermore	O
,	O
CCoV	O
-	O
II	O
infection	O
resulted	O
in	O
truncated	O
bid	O
(	O
tbid	O
)	O
translocation	O
from	O
the	O
cytosolic	B-COMP
to	O
the	O
mitochondrial	B-COMP
fraction	O
,	O
the	O
cytochrome	O
c	O
release	O
from	O
mitochondria	B-COMP
,	O
and	O
alterations	O
in	O
the	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
of	O
bcl	O
-	O
2	O
family	O
.	O

Although	O
the	O
antibody	B-COMP
levels	O
in	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
-	O
vaccinated	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
H120	O
group	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
group	O
,	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
provided	O
the	O
strongest	O
protection	O
against	O
an	O
IBV	O
LX4	O
virus	O
challenge	O
(	O
15	O
out	O
of	O
16	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
were	O
protected	O
),	O
followed	O
by	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
(	O
13	O
/	O
16	O
protected	O
)	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
(	O
12	O
/	O
16	O
protected	O
).	O

This	O
study	O
demonstrated	O
that	O
chicken	O
type	O
II	O
interferon	O
increased	O
the	O
immunoprotective	O
efficacy	O
of	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
and	O
normal	O
weight	O
gain	O
in	O
vaccinated	O
chickens	O
although	O
it	O
inhibited	O
serum	B-COMP
antibody	B-COMP
production	O
.	O

Interestingly	O
,	O
immunocytostaining	O
revealed	O
that	O
basal	O
cells	B-COMP
are	O
resistant	O
to	O
IBV	O
infection	O
.	O

ABSTRACT	O
:	O
In	O
some	O
cases	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hypoxemia	O
occurs	O
despite	O
optimized	O
conservative	O
therapy	O
;	O
however	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
assure	O
sufficient	O
gas	O
exchange	O
.	O

To	O
increase	O
safety	O
and	O
reliability	O
of	O
devices	O
,	O
the	O
oxygenator	O
design	O
was	O
optimized	O
integrating	O
new	O
plasma	O
-	O
resistant	O
composite	O
membranes	O
and	O
new	O
blood	O
pumps	O
are	O
used	O
with	O
longer	O
durability	O
and	O
reduced	O
blood	O
cell	B-COMP
damage	O
.	O

The	O
three	O
CRCoV	O
-	O
positive	O
samples	O
were	O
found	O
to	O
be	O
competent	O
for	O
viral	O
propagation	O
and	O
isolation	O
,	O
using	O
human	O
rectal	O
tumor	O
cells	B-COMP
(	O
HRT	O
-	O
18	O
),	O
and	O
the	O
structure	O
and	O
nonstructure	O
proteins	O
encoded	O
in	O
the	O
3	O
'-	O
end	O
of	O
the	O
CRCoV	O
genome	O
were	O
sequenced	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-COMP
glycoproteins	O
S1	O
and	O
S2	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
mediate	O
viral	O
entry	O
by	O
conformational	O
change	O
from	O
a	O
prefusion	O
state	O
to	O
a	O
postfusion	O
state	O
that	O
enables	O
fusion	O
of	O
the	O
viral	O
and	O
target	O
membranes	O
.	O

The	O
dynamic	O
properties	O
of	O
the	O
different	O
states	O
,	O
which	O
are	O
stabilized	O
under	O
different	O
experimental	O
conditions	O
,	O
extend	O
the	O
current	O
model	O
of	O
viral	B-COMP
membrane	I-COMP
fusion	O
and	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	O
of	O
SARS	O
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
such	O
as	O
HIV	O
.	O

Chemical	O
shift	O
changes	O
upon	O
the	O
addition	O
of	O
single	O
-	O
stranded	O
RNAs	O
(	O
ssRNAs	O
)	O
identified	O
a	O
group	O
of	O
residues	O
that	O
form	O
a	O
positively	O
charged	O
patch	O
on	O
the	O
protein	O
surface	O
as	O
the	O
binding	O
site	O
responsible	O
for	O
the	O
previously	O
reported	O
affinity	O
for	O
nucleic	B-COMP
acids	O
.	O

A	O
22	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
was	O
admitted	O
unconscious	O
with	O
a	O
body	O
temperature	O
of	O
42	O
degrees	O
C	O
,	O
elevated	O
serum	B-COMP
creatine	O
phosphokinase	O
,	O
tachycardia	O
and	O
hypotonic	O
blood	O
pressure	O
.	O

TITLE	O
:	O
Prolonged	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
therapy	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
child	O
affected	O
by	O
rituximab	O
-	O
resistant	O
autoimmune	O
hemolytic	O
anemia	O
:	O
a	O
case	O
report	O
.	O

Nsp1	O
bound	O
to	O
the	O
40S	B-COMP
ribosomal	I-COMP
subunit	I-COMP
and	O
inactivated	O
the	O
translational	O
activity	O
of	O
the	O
40S	O
subunits	O
.	O

Nsp1	O
also	O
induced	O
RNA	O
cleavage	O
in	O
templates	O
carrying	O
the	O
internal	O
ribosome	B-COMP
entry	O
site	O
(	O
IRES	O
)	O
from	O
encephalomyocarditis	O
virus	O
,	O
but	O
not	O
in	O
those	O
carrying	O
IRES	O
elements	O
from	O
hepatitis	O
C	O
or	O
cricket	O
paralysis	O
viruses	O
,	O
demonstrating	O
that	O
the	O
nsp1	O
-	O
induced	O
RNA	O
modification	O
was	O
template	O
-	O
dependent	O
.	O

Plasma	B-COMP
membrane	I-COMP
budding	O
was	O
occasionally	O
observed	O
.	O

There	O
was	O
a	O
major	O
contribution	O
of	O
the	O
IRE1	O
/	O
XBP1	O
pathway	O
,	O
followed	O
by	O
caspase	O
-	O
3	O
activation	O
and	O
nuclear	O
fragmentation	O
,	O
with	O
no	O
significant	O
role	O
of	O
the	O
ATF6	O
and	O
eIF2	B-COMP
-	O
alpha	O
/	O
ATF4	O
pathways	O
.	O

Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp4	O
is	O
glycosylated	O
at	O
residues	O
Asn176	O
(	O
N176	O
)	O
and	O
N237	O
during	O
plasmid	O
expression	O
of	O
nsp4	O
in	O
cells	B-COMP
.	O

TITLE	O
:	O
Antibody	B-COMP
-	O
mediated	O
synergy	O
and	O
interference	O
in	O
the	O
neutralization	O
of	O
SARS	O
-	O
CoV	O
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
a	O
virus	O
escapes	O
from	O
antibody	B-COMP
-	O
mediated	O
neutralization	O
,	O
we	O
have	O
investigated	O
the	O
interactions	O
of	O
non	O
-	O
neutralizing	O
and	O
neutralizing	O
antibodies	B-COMP
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
human	O
coronaviruses	O
(	O
CoVs	O
)	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
and	O
NL63	O
employ	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
for	O
cell	B-COMP
entry	O
.	O

Finally	O
,	O
SARS	O
-	O
CoV	O
but	O
not	O
NL63	O
replicated	O
efficiently	O
in	O
ACE2	O
-	O
positive	O
Vero	O
cells	B-COMP
and	O
reduced	O
ACE2	O
expression	O
,	O
indicating	O
robust	O
receptor	O
interference	O
in	O
the	O
context	O
of	O
SARS	O
-	O
CoV	O
but	O
not	O
NL63	O
infection	O
.	O

In	O
addition	O
,	O
we	O
report	O
that	O
ORF	O
3a	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
SARS	O
-	O
CoV	O
-	O
induced	O
Golgi	B-COMP
fragmentation	O
and	O
that	O
the	O
3a	O
protein	O
accumulates	O
and	O
localizes	O
to	O
vesicles	B-COMP
containing	O
markers	O
for	O
late	O
endosomes	O
.	O

ABSTRACT	O
:	O
To	O
accommodate	O
its	O
RNA	O
synthesis	O
in	O
the	O
infected	O
cell	B-COMP
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
induces	O
a	O
cytoplasmic	B-COMP
reticulovesicular	O
network	O
(	O
RVN	O
)	O
that	O
is	O
derived	O
from	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
membranes	O
.	O

Collectively	O
,	O
these	O
findings	O
highlight	O
a	O
previously	O
unappreciated	O
role	O
for	O
ELR	O
-	O
positive	O
chemokines	O
in	O
enhancing	O
host	B-COMP
defense	O
during	O
acute	O
viral	O
infections	O
of	O
the	O
CNS	O
.	O

We	O
then	O
investigate	O
the	O
novel	O
and	O
exciting	O
possibilities	O
of	O
targeting	O
tetraspanins	O
for	O
the	O
treatment	O
of	O
infectious	O
disease	O
,	O
using	O
specific	O
antibodies	B-COMP
,	O
recombinant	O
EC2	O
domains	O
,	O
small	O
-	O
molecule	O
mimetics	O
,	O
and	O
small	O
interfering	O
RNA	O
.	O

However	O
,	O
depletion	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
resulted	O
in	O
an	O
enhanced	O
immune	O
-	O
mediated	O
interstitial	O
pneumonitis	O
and	O
delayed	O
clearance	O
of	O
SARS	O
-	O
CoV	O
from	O
the	O
lungs	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
neutralizing	O
antibody	B-COMP
and	O
cytokine	O
production	O
and	O
reduced	O
pulmonary	O
recruitment	O
of	O
lymphocytes	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
characterized	O
by	O
diffuse	O
impairment	O
of	O
alveolocapillary	O
membrane	B-COMP
in	O
the	O
settings	O
of	O
different	O
predisposing	O
conditions	O
such	O
as	O
sepsis	O
,	O
trauma	O
and	O
shock	O
.	O

Antibody	B-COMP
titers	O
against	O
CDV	O
,	O
CPV	O
and	O
CAV	O
-	O
1	O
in	O
unvaccinated	O
giant	O
pandas	O
were	O
highly	O
variable	O
,	O
especially	O
CPV	O
titer	O
.	O

TITLE	O
:	O
MicroRNome	O
analysis	O
unravels	O
the	O
molecular	O
basis	O
of	O
SARS	O
infection	O
in	O
bronchoalveolar	O
stem	O
cells	B-COMP
.	O

In	O
this	O
line	O
,	O
mechanical	O
ventilation	O
may	O
affect	O
the	O
macromolecules	O
that	O
constitute	O
the	O
extracellular	B-COMP
matrix	I-COMP
(	O
collagen	B-COMP
,	O
elastin	O
,	O
fibronectin	O
,	O
laminin	O
,	O
proteoglycan	O
and	O
glycosaminoglycans	O
),	O
suffer	O
changes	O
and	O
impact	O
the	O
biomechanical	O
behavior	O
of	O
lung	O
parenchyma	O
.	O

TITLE	O
:	O
Antibody	B-COMP
binding	O
site	O
mapping	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	O
domain	O
by	O
a	O
combination	O
of	O
yeast	O
surface	O
display	O
and	O
phage	O
peptide	O
library	O
screening	O
.	O

Using	O
these	O
monoclonal	O
antibodies	B-COMP
in	O
phage	O
peptide	O
library	O
screening	O
identified	O
10	O
distinct	O
mimotopes	O
12	O
amino	O
acids	O
in	O
length	O
.	O

Here	O
we	O
show	O
that	O
CD8	O
(+)	O
T	O
cell	B-COMP
-	O
stimulating	O
activity	O
can	O
be	O
effectively	O
augmented	O
by	O
combining	O
DNA	O
vaccination	O
with	O
protein	O
transfer	O
.	O

The	O
adjuvant	O
effect	O
of	O
4	O
-	O
1BBL	O
was	O
lipidation	O
-	O
dependent	O
,	O
indicating	O
that	O
it	O
functions	O
as	O
a	O
cell	B-COMP
membrane	I-COMP
-	O
anchored	O
co	O
-	O
stimulator	O
.	O

Results	O
of	O
our	O
study	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
muscle	O
cells	B-COMP
may	O
be	O
modified	O
in	O
situ	O
,	O
at	O
the	O
DNA	O
injection	O
site	O
,	O
into	O
APC	B-COMP
-	O
like	O
cells	B-COMP
to	O
allow	O
direct	O
priming	O
of	O
CD8	O
(+)	O
T	O
cells	B-COMP
and	O
thereby	O
improve	O
the	O
efficacy	O
of	O
DNA	O
vaccines	O
.	O

Methods	O
of	O
detection	O
and	O
the	O
role	O
for	O
cattle	O
persistently	O
infected	O
bovine	O
viral	O
diarrhea	O
virus	O
(	O
BVDV	O
)	O
were	O
identified	O
;	O
viral	O
subunits	O
,	O
cellular	B-COMP
components	O
and	O
bacterial	O
products	O
have	O
been	O
characterized	O
.	O

Primary	O
cells	B-COMP
were	O
successfully	O
cultured	O
from	O
20	O
different	O
organs	O
.	O

Furthermore	O
,	O
an	O
increased	O
surface	O
expression	O
and	O
raft	O
-	O
structure	O
distribution	O
of	O
annexin	O
A2	O
was	O
present	O
in	O
A549	O
cells	B-COMP
after	O
stimulation	O
with	O
SARS	O
-	O
induced	O
cytokines	O
interleukin	O
-	O
6	O
and	O
interferon	O
-	O
gamma	O
.	O

Cytokine	O
stimulation	O
increased	O
the	O
binding	O
capability	O
of	O
anti	O
-	O
S2	O
antibodies	B-COMP
to	O
human	O
lung	O
epithelial	O
cells	B-COMP
.	O

TITLE	O
:	O
A	O
new	O
miniaturized	O
system	O
for	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
adult	O
respiratory	O
failure	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
aromatic	O
and	O
hydrophobic	O
parts	O
of	O
S	O
in	O
the	O
entry	O
of	O
SARS	O
CoV	O
and	O
in	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
.	O

Specific	O
modalities	O
covered	O
include	O
conservative	O
fluid	O
management	O
,	O
prone	O
positioning	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
inhaled	O
vasodilatory	O
prostaglandins	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
and	O
life	O
support	O
.	O

ABSTRACT	O
:	O
A	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
required	O
for	O
viral	O
replication	O
,	O
cleaving	O
the	O
replicase	O
polyproteins	O
at	O
11	O
sites	O
with	O
the	O
conserved	O
Gln	O
[	O
downward	O
arrow	O
](	O
Ser	B-COMP
,	O
Ala	O
,	O
Gly	O
)	O
sequences	O
.	O

Immunization	O
with	O
the	O
multivalent	O
DNA	O
vaccine	O
induced	O
synergistic	O
augmentation	O
of	O
humoral	O
and	O
cellular	B-COMP
responses	O
in	O
comparison	O
with	O
the	O
individual	O
vaccines	O
,	O
and	O
provided	O
up	O
to	O
85	O
%	O
immune	O
protection	O
.	O

In	O
-	O
silico	O
analysis	O
of	O
the	O
225	O
amino	O
acid	O
sequence	O
of	O
hCoV	O
-	O
NL63	O
ORF	O
3	O
predicted	O
a	O
triple	O
membrane	B-COMP
-	O
spanning	O
protein	O
.	O

By	O
fluorescence	O
microscopy	O
of	O
differently	O
tagged	O
envelope	B-COMP
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
it	O
was	O
shown	O
that	O
ORF	O
3	O
protein	O
colocalizes	O
extensively	O
with	O
E	O
and	O
M	O
within	O
the	O
ERGIC	B-COMP
.	O

ABSTRACT	O
:	O
Due	O
to	O
the	O
complexity	O
of	O
biological	O
membrane	B-COMP
,	O
computer	O
simulation	O
of	O
transmembrane	B-COMP
protein	O
'	O
s	O
folding	O
is	O
challenging	O
.	O

It	O
was	O
found	O
that	O
the	O
coil	O
-	O
helix	O
transition	O
of	O
the	O
transmembrane	B-COMP
segment	O
occurred	O
earlier	O
than	O
the	O
coil	O
-	O
globule	O
transition	O
of	O
the	O
two	O
terminal	O
domains	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
)	O
are	O
enveloped	O
positive	O
-	O
strand	O
RNA	O
viruses	O
that	O
induce	O
different	O
membrane	B-COMP
rearrangements	O
in	O
infected	O
cells	B-COMP
in	O
order	O
to	O
efficiently	O
replicate	O
and	O
assemble	O
.	O

ABSTRACT	O
:	O
Human	O
lung	O
epithelial	O
cells	B-COMP
are	O
likely	O
among	O
the	O
first	O
targets	O
to	O
encounter	O
invading	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

We	O
also	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
lambdas	O
were	O
capable	O
of	O
exerting	O
previously	O
unrecognized	O
,	O
non	O
-	O
redundant	O
,	O
and	O
complementary	O
abilities	O
to	O
limit	O
SARS	O
-	O
CoV	O
replication	O
,	O
even	O
though	O
their	O
expression	O
could	O
not	O
be	O
detected	O
in	O
infected	O
2B4	O
bronchial	O
epithelial	O
cells	B-COMP
until	O
48	O
hrs	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
Switch	O
from	O
venoarterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
to	O
arteriovenous	O
pumpless	O
extracorporeal	O
lung	O
assist	O
.	O

To	O
this	O
end	O
,	O
LAB	O
strains	O
selected	O
on	O
the	O
basis	O
of	O
previous	O
in	O
vitro	O
trials	O
were	O
co	O
-	O
incubated	O
with	O
cell	B-COMP
line	O
monolayers	O
,	O
which	O
were	O
subsequently	O
challenged	O
with	O
rotavirus	O
(	O
RV	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

In	O
order	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
responsible	O
for	O
the	O
antiviral	O
activity	O
,	O
the	O
induction	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
release	O
as	O
well	O
as	O
the	O
attachment	O
ability	O
of	O
LAB	O
on	O
the	O
cell	B-COMP
lines	O
was	O
investigated	O
.	O

Highest	O
protection	O
effects	O
were	O
recorded	O
with	O
the	O
known	O
probiotics	O
Lactobacillus	O
rhamnosus	O
GG	O
and	O
Lactobacillus	O
casei	O
Shirota	O
against	O
both	O
RV	O
and	O
TGEV	O
,	O
while	O
notable	O
antiviral	O
activity	O
was	O
also	O
attributed	O
to	O
Enterococcus	O
faecium	O
PCK38	O
,	O
Lactobacillus	O
fermentum	O
ACA	O
-	O
DC179	O
,	O
Lactobacillus	O
pentosus	O
PCA227	O
and	O
Lactobacillus	O
plantarum	O
PCA236	O
and	O
PCS22	O
,	O
depending	O
on	O
the	O
cell	B-COMP
line	O
and	O
virus	O
combination	O
used	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
p6	O
has	O
an	O
N	O
-	O
terminal	O
region	O
-	O
cytoplasm	B-COMP
-	O
C	O
-	O
terminal	O
region	O
-	O
cytoplasm	B-COMP
configuration	O
with	O
residues	O
2	O
to	O
37	O
likely	O
membrane	B-COMP
embedded	O
.	O

We	O
have	O
tested	O
the	O
performance	O
of	O
the	O
EpiSearch	O
algorithm	O
for	O
six	O
experimental	O
data	O
sets	O
of	O
phage	O
display	O
experiments	O
,	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
-	O
2	O
(	O
HER	O
-	O
2	O
/	O
neu	O
),	O
the	O
antibody	B-COMP
mAb	O
Bo2C11	O
targeting	O
the	O
C	O
(	O
2	O
)	O
domain	O
of	O
FVIII	O
,	O
antibodies	B-COMP
mAb	O
17b	O
and	O
mAb	O
b12	O
of	O
the	O
HIV	O
envelope	B-COMP
protein	O
gp120	O
,	O
mAb	O
13b5	O
targeting	O
HIV	O
-	O
1	O
capsid	O
protein	O
and	O
80R	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
protein	O
.	O

Thus	O
,	O
ALI	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
aged	O
macaques	O
developed	O
as	O
a	O
result	O
of	O
an	O
exacerbated	O
innate	O
host	B-COMP
response	O
.	O

TITLE	O
:	O
3D	O
Telomere	B-COMP
FISH	O
defines	O
LMP1	O
-	O
expressing	O
Reed	O
-	O
Sternberg	O
cells	B-COMP
as	O
end	O
-	O
stage	O
cells	B-COMP
with	O
telomere	B-COMP
-	O
poor	O
'	O
ghost	O
'	O
nuclei	O
and	O
very	O
short	O
telomeres	B-COMP
.	O

However	O
,	O
the	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
telomere	B-COMP
organization	O
in	O
latent	O
membrane	B-COMP
protein	O
1	O
(	O
LMP1	O
)-	O
expressing	O
RS	O
cells	B-COMP
of	O
EBV	O
-	O
associated	O
HL	O
is	O
not	O
known	O
.	O

These	O
nuclei	O
and	O
their	O
telomere	B-COMP
content	O
strongly	O
contrasted	O
with	O
the	O
corona	O
of	O
surrounding	O
lymphocytes	O
showing	O
numerous	O
midsized	O
telomere	B-COMP
hybridization	O
signals	O
.	O

Both	O
H	O
cells	B-COMP
and	O
RS	O
cells	B-COMP
of	O
two	O
EBV	O
-	O
negative	O
HL	O
cases	O
analyzed	O
in	O
parallel	O
showed	O
3D	O
telomere	B-COMP
patterns	O
identical	O
to	O
those	O
of	O
LMP1	O
-	O
expressing	O
cases	O
.	O

As	O
a	O
major	O
advance	O
,	O
our	O
3D	O
nuclear	O
imaging	O
approach	O
allows	O
the	O
visualization	O
of	O
hitherto	O
unknown	O
profound	O
changes	O
in	O
the	O
3D	O
nuclear	O
telomere	B-COMP
organization	O
associated	O
with	O
the	O
transition	O
from	O
LMP1	O
-	O
positive	O
H	O
cells	B-COMP
to	O
LMP1	O
-	O
positive	O
RS	O
cells	B-COMP
.	O

We	O
conclude	O
that	O
RS	O
cells	B-COMP
irrespective	O
of	O
LMP1	O
expression	O
are	O
end	O
-	O
stage	O
tumor	O
cells	B-COMP
in	O
which	O
the	O
extent	O
of	O
their	O
inability	O
to	O
divide	O
further	O
is	O
proportional	O
to	O
the	O
increase	O
of	O
very	O
short	O
telomeres	B-COMP
,	O
telomere	B-COMP
loss	O
,	O
aggregate	O
formation	O
and	O
the	O
generation	O
of	O
'	O
ghost	O
'	O
nuclei	O
.	O

The	O
presence	O
of	O
acute	O
cellular	B-COMP
rejection	O
episodes	O
,	O
CMV	O
disease	O
,	O
and	O
GERD	O
were	O
factors	O
associated	O
with	O
chronic	O
lung	O
rejection	O
.	O

Another	O
isolate	O
demonstrated	O
the	O
incorporation	O
of	O
China	O
-	O
like	O
and	O
H120	O
-	O
like	O
genome	O
fragments	O
within	O
the	O
S2	O
gene	O
and	O
the	O
membrane	B-COMP
protein	O
(	O
M	O
)	O
gene	O
region	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Viral	O
fitness	O
is	O
determined	O
by	O
replication	O
within	O
hosts	B-COMP
and	O
transmission	O
between	O
them	O
.	O

The	O
coefficients	O
describe	O
the	O
binding	O
affinity	O
between	O
the	O
virus	O
and	O
the	O
induced	O
antibody	B-COMP
and	O
that	O
between	O
the	O
virus	O
and	O
its	O
receptor	O
.	O

Using	O
population	O
genetic	O
theory	O
,	O
we	O
evaluated	O
the	O
probability	O
that	O
a	O
mutant	O
is	O
fixed	O
in	O
a	O
host	B-COMP
population	O
.	O

The	O
clinical	O
course	O
was	O
notable	O
for	O
mild	O
hyaline	O
membrane	B-COMP
disease	O
,	O
continuous	O
ventilatory	O
support	O
,	O
and	O
symmetrically	O
distributed	O
pulmonary	O
cysts	O
by	O
imaging	O
.	O

We	O
show	O
that	O
Tregs	O
dampen	O
the	O
inflammatory	O
response	O
mediated	O
by	O
transferred	O
JHMV	O
-	O
immune	O
splenocytes	O
in	O
infected	O
RAG1	O
(-/-)	O
mice	O
by	O
decreasing	O
T	O
cell	B-COMP
proliferation	O
,	O
dendritic	B-COMP
cell	B-COMP
activation	O
,	O
and	O
proinflammatory	O
cytokine	O
/	O
chemokine	O
production	O
,	O
without	O
inducing	O
apoptosis	O
.	O

The	O
GICA	O
test	O
strip	O
is	O
a	O
reliable	O
and	O
useful	O
tool	O
for	O
the	O
on	O
-	O
site	O
surveillance	O
of	O
anti	O
-	O
IBV	O
antibodies	B-COMP
.	O

Five	O
months	O
after	O
the	O
antibody	B-COMP
examination	O
,	O
a	O
TGE	O
outbreak	O
occurred	O
at	O
one	O
of	O
these	O
seven	O
farms	O
.	O

There	O
were	O
21	O
of	O
62	O
post	O
-	O
SARS	O
osteonecrosis	O
patients	O
(	O
33	O
.	O
9	O
%)	O
who	O
showed	O
at	O
least	O
one	O
type	O
of	O
anticardiolipin	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Murine	O
Coronavirus	O
Cell	B-COMP
Type	I-COMP
Dependent	O
Interaction	O
with	O
the	O
Type	O
I	O
Interferon	O
Response	O
.	O

However	O
,	O
in	O
primary	O
cell	B-COMP
types	O
such	O
as	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
(	O
pDC	O
)	O
and	O
macrophages	O
,	O
IFN	O
is	O
induced	O
by	O
MHV	O
infection	O
and	O
an	O
antiviral	O
state	O
is	O
established	O
.	O

Thus	O
MHV	O
induction	O
of	O
IFN	O
-	O
alpha	O
/	O
beta	O
and	O
the	O
ability	O
to	O
induce	O
an	O
antiviral	O
state	O
in	O
response	O
to	O
interferon	O
is	O
extremely	O
cell	B-COMP
type	I-COMP
dependent	O
.	O

We	O
also	O
used	O
this	O
ELISA	O
system	O
to	O
evaluate	O
77	O
murine	O
serum	B-COMP
samples	O
obtained	O
from	O
15	O
conventional	O
mouse	O
rooms	O
in	O
research	O
facilities	O
in	O
Japan	O
and	O
found	O
that	O
approximately	O
half	O
of	O
the	O
serum	B-COMP
samples	O
contained	O
antibody	B-COMP
to	O
MNV	O
-	O
S7	O
.	O

We	O
found	O
that	O
some	O
serum	B-COMP
samples	O
were	O
negative	O
for	O
antibodies	B-COMP
to	O
mouse	O
hepatitis	O
virus	O
and	O
Mycoplasma	O
pulmonis	O
but	O
positive	O
for	O
antibody	B-COMP
to	O
MNV	O
-	O
S7	O
.	O

RESULTS	O
:	O
A	O
potent	O
,	O
prolonged	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
Calu	O
-	O
3	O
cells	B-COMP
with	O
IFN	O
-	O
alfacon	O
1	O
was	O
observed	O
.	O

TITLE	O
:	O
GeneReviews	O
ABSTRACT	O
:	O
Mitochondrial	B-COMP
DNA	I-COMP
(	O
mtDNA	B-COMP
)-	O
associated	O
Leigh	O
syndrome	O
and	O
NARP	O
(	O
neurogenic	O
muscle	O
weakness	O
,	O
ataxia	O
,	O
and	O
retinitis	O
pigmentosa	O
)	O
are	O
part	O
of	O
a	O
continuum	O
of	O
progressive	O
neurodegenerative	O
disorders	O
caused	O
by	O
abnormalities	O
of	O
mitochondrial	B-COMP
energy	O
generation	O
.	O

Occasionally	O
the	O
mother	O
has	O
a	O
substantial	O
proportion	O
of	O
abnormal	O
mtDNA	B-COMP
and	O
develops	O
severe	O
symptoms	O
in	O
adulthood	O
.	O

ABSTRACT	O
:	O
The	O
methods	O
of	O
repeated	O
immunization	O
with	O
inactivated	O
vaccines	O
have	O
been	O
used	O
widely	O
to	O
increase	O
antibody	B-COMP
protection	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
Cell	B-COMP
permeabilization	O
by	O
poliovirus	O
2B	O
viroporin	O
triggers	O
bystander	O
permeabilization	O
in	O
neighbouring	O
cells	B-COMP
through	O
a	O
mechanism	O
involving	O
gap	B-COMP
junctions	I-COMP
.	O

Here	O
we	O
describe	O
a	O
previously	O
unreported	O
bystander	O
effect	O
in	O
which	O
healthy	O
baby	O
hamster	O
kidney	O
(	O
BHK	O
)	O
cells	B-COMP
become	O
sensitive	O
to	O
HB	O
when	O
co	O
-	O
cultured	O
with	O
a	O
low	O
proportion	O
of	O
cells	B-COMP
expressing	O
poliovirus	O
2B	O
.	O

Viroporins	O
E	O
from	O
mouse	O
hepatitis	O
virus	O
,	O
6K	O
from	O
Sindbis	O
virus	O
and	O
NS4A	O
protein	O
from	O
hepatitis	O
C	O
virus	O
were	O
also	O
able	O
to	O
permeabilize	O
neighbouring	O
cells	B-COMP
to	O
different	O
extents	O
.	O

Finally	O
,	O
inhibition	O
of	O
HB	O
entry	O
to	O
neighbouring	O
cells	B-COMP
was	O
observed	O
with	O
18alpha	O
-	O
glycyrrhethinic	O
acid	O
,	O
an	O
inhibitor	O
of	O
gap	B-COMP
junctions	I-COMP
.	O

IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
,	O
and	O
other	O
type	O
I	O
IFN	O
molecules	O
signal	O
through	O
a	O
common	O
,	O
universally	O
expressed	O
cell	B-COMP
surface	I-COMP
receptor	O
,	O
whereas	O
type	O
III	O
IFN	O
(	O
IFN	O
-	O
lambda	O
)	O
uses	O
a	O
distinct	O
cell	B-COMP
-	O
type	O
-	O
specific	O
receptor	B-COMP
complex	I-COMP
for	O
signaling	O
.	O

There	O
was	O
also	O
a	O
significant	O
increase	O
in	O
somatic	O
cell	B-COMP
count	O
(	O
of	O
12	O
,	O
000	O
cells	B-COMP
/	O
mL	O
)	O
for	O
cows	O
located	O
in	O
herds	O
with	O
a	O
BRSV	O
outbreak	O
.	O

Viral	O
RNA	O
is	O
also	O
detectable	O
in	O
the	O
serum	B-COMP
of	O
patients	O
with	O
RSV	O
,	O
influenza	O
,	O
and	O
MPV	O
pneumonia	O
and	O
may	O
correlate	O
with	O
the	O
severity	O
of	O
disease	O
.	O

In	O
primary	O
bone	O
-	O
marrow	O
-	O
derived	O
macrophages	O
and	O
mouse	O
embryonic	O
fibroblasts	O
,	O
MHV	O
replication	O
was	O
significantly	O
reduced	O
by	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
antiviral	O
state	O
,	O
whereas	O
IFN	O
treatment	O
of	O
cell	B-COMP
lines	O
(	O
L2	O
and	O
293T	O
)	O
has	O
only	O
minor	O
effects	O
on	O
replication	O
(	O
K	O
.	O
M	O
.	O
Rose	O
and	O
S	O
.	O
R	O
.	O
Weiss	O
,	O
Viruses	O
1	O
:	O
689	O
-	O
712	O
,	O
2009	O
).	O

TITLE	O
:	O
A	O
novel	O
B	O
-	O
cell	B-COMP
epitope	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
N	O
protein	O
.	O

It	O
could	O
induce	O
strong	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
and	O
high	O
titers	O
of	O
neutralizing	O
antibodies	B-COMP
in	O
the	O
vaccinated	O
mice	O
.	O

The	O
virus	O
-	O
host	B-COMP
interactions	O
that	O
governed	O
development	O
of	O
these	O
acute	O
end	O
stage	O
lung	O
diseases	O
and	O
death	O
are	O
unknown	O
.	O

Among	O
the	O
compounds	O
tested	O
SPIII	O
-	O
5F	O
exhibits	O
the	O
45	O
%	O
maximum	O
protection	O
against	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
Vero	O
cells	B-COMP
.	O

In	O
the	O
first	O
,	O
the	O
results	O
of	O
the	O
alpha	O
-	O
IBV	O
IgM	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
on	O
post	O
-	O
vaccination	O
sera	B-COMP
were	O
compared	O
with	O
the	O
efficacy	O
of	O
the	O
IBV	O
vaccination	O
against	O
homologous	O
challenge	O
of	O
the	O
same	O
broilers	O
.	O

Our	O
study	O
suggests	O
that	O
unlike	O
PRRSV	O
which	O
induces	O
apoptosis	O
in	O
AMs	O
,	O
respiratory	O
CoVs	O
such	O
as	O
PRCV	O
that	O
infect	O
pulmonary	O
epithelial	O
cells	B-COMP
and	O
cause	O
cytolysis	O
,	O
induce	O
NO	O
production	O
in	O
the	O
respiratory	O
tract	O
.	O

Clinical	O
signs	O
,	O
lung	O
virus	O
titres	O
,	O
inflammatory	O
cells	B-COMP
and	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
compared	O
with	O
those	O
of	O
animals	O
in	O
PRCV	O
-	O
and	O
LTA	O
-	O
inoculated	O
control	O
groups	O
.	O

Furthermore	O
,	O
SJL	O
mice	O
produced	O
antiviral	O
antibodies	B-COMP
after	O
MHV	O
-	O
A59	O
inoculation	O
with	O
10	O
(	O
5	O
)	O
PFU	O
,	O
but	O
cB61ba	O
mice	O
did	O
not	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
a	O
set	O
of	O
mRNAs	O
,	O
which	O
presumably	O
are	O
capped	O
at	O
their	O
5	O
'	O
end	O
and	O
direct	O
the	O
synthesis	O
of	O
all	O
viral	O
proteins	O
in	O
the	O
infected	O
cell	B-COMP
.	O

Furthermore	O
,	O
sensitive	O
in	O
vitro	O
inhibition	O
assays	O
of	O
both	O
activities	O
show	O
that	O
aurintricarboxylic	O
acid	O
,	O
active	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	B-COMP
,	O
targets	O
both	O
MTases	O
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
the	O
micromolar	O
range	O
,	O
providing	O
a	O
validated	O
basis	O
for	O
anti	O
-	O
coronavirus	O
drug	O
design	O
.	O

Knockdown	O
of	O
another	O
cytoplasmic	B-COMP
receptor	O
,	O
the	O
melanoma	O
-	O
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
),	O
by	O
small	O
interfering	O
RNAs	O
also	O
blocked	O
IFN	O
-	O
beta	O
induction	O
.	O

In	O
our	O
study	O
,	O
serum	B-COMP
procalcitonin	O
and	O
C	O
-	O
reactive	O
protein	O
did	O
not	O
discriminate	O
virus	O
-	O
associated	O
exacerbations	O
from	O
others	O
.	O

More	O
interestingly	O
,	O
a	O
mutant	O
3CLpro	O
with	O
either	O
a	O
P166S	O
or	O
P166L	O
mutation	O
was	O
selected	O
when	O
an	O
IBV	O
infectious	O
cDNA	O
clone	O
carrying	O
the	O
Q6327N	O
mutation	O
at	O
the	O
nsp15	O
-	O
16	O
site	O
was	O
introduced	O
into	O
cells	B-COMP
.	O

The	O
compound	O
also	O
displayed	O
cathepsin	O
L	O
/	O
B	O
selectivity	O
of	O
>	O
700	O
-	O
fold	O
and	O
was	O
nontoxic	O
to	O
human	O
aortic	O
endothelial	O
cells	B-COMP
at	O
100	O
muM	O
.	O
The	O
oxocarbazate	O
and	O
a	O
related	O
thiocarbazate	O
(	O
PubChem	O
CID	O
16725315	O
)	O
were	O
tested	O
in	O
a	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
and	O
Ebola	O
virus	O
-	O
pseudotype	O
infection	O
assay	O
with	O
the	O
oxocarbazate	O
but	O
not	O
the	O
thiocarbazate	O
,	O
demonstrating	O
activity	O
in	O
blocking	O
both	O
SARS	O
-	O
CoV	O
(	O
IC	O
(	O
50	O
)	O
=	O
273	O
+/-	O

Compounds	O
were	O
tested	O
in	O
cell	B-COMP
-	O
based	O
assays	O
against	O
viruses	O
representative	O
of	O
:	O
i	O
)	O
two	O
of	O
the	O
three	O
genera	O
of	O
the	O
Flaviviridae	O
family	O
,	O
i	O
.	O
e	O
.	O
Pestiviruses	O
and	O
Flaviviruses	O
;	O
ii	O
)	O
other	O
RNA	O
virus	O
families	O
,	O
such	O
as	O
Retroviridae	O
,	O
Picornaviridae	O
,	O
Paramyxoviridae	O
,	O
Rhabdoviridae	O
and	O
Reoviridae	O
;	O
iii	O
)	O
two	O
DNA	O
virus	O
families	O
(	O
Herpesviridae	O
and	O
Poxviridae	O
)	O
as	O
well	O
as	O
for	O
cytotoxicity	O
tests	O
,	O
run	O
in	O
parallel	O
with	O
antiviral	O
assays	O
,	O
against	O
MDBK	O
,	O
BHK	O
and	O
Vero	O
76	O
cells	B-COMP
.	O

Three	O
strains	O
adapted	O
to	O
the	O
in	O
vitro	O
grow	O
on	O
human	O
rectal	O
tumour	O
cells	B-COMP
were	O
also	O
evaluated	O
for	O
their	O
ability	O
to	O
replicate	O
in	O
a	O
bovine	O
cell	B-COMP
line	O
(	O
Madin	O
Darby	O
bovine	O
kidney	O
)	O
and	O
to	O
cause	O
haemagglutination	O
of	O
chicken	O
erythrocytes	O
and	O
all	O
displayed	O
biological	O
properties	O
similar	O
to	O
those	O
already	O
described	O
for	O
the	O
prototype	O
BuCoV	O
.	O
The	O
present	O
report	O
shows	O
that	O
albeit	O
genetically	O
heterogeneous	O
,	O
the	O
different	O
BuCoV	O
strains	O
possess	O
a	O
common	O
biological	O
pattern	O
which	O
is	O
different	O
from	O
most	O
BCoV	O
and	O
BCoV	O
-	O
like	O
isolates	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
Life	O
Support	O
(	O
ECLS	O
)	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
have	O
been	O
indicated	O
as	O
treatment	O
for	O
acute	O
respiratory	O
and	O
/	O
or	O
cardiac	O
failure	O
.	O

TITLE	O
:	O
Serum	B-COMP
and	O
lung	O
endothelin	O
-	O
1	O
increased	O
in	O
a	O
canine	O
model	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

They	O
belonged	O
to	O
the	O
cubic	O
space	O
group	O
I432	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
b	O
=	O
c	O
=	O
123	O
.	O
4	O
A	O
,	O
alpha	O
=	O
beta	O
=	O
gamma	O
=	O
90	O
degrees	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
antibody	B-COMP
status	O
to	O
bovine	O
corona	O
virus	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
and	O
disease	O
incidence	O
,	O
reproduction	O
and	O
herd	O
characteristics	O
in	O
dairy	O
herds	O
.	O

Treatment	O
with	O
anti	O
-	O
CXCL12	O
[	O
stromal	O
derived	O
factor	O
-	O
1alpha	O
,	O
(	O
SDF	O
-	O
1alpha	O
)]	O
blocking	O
serum	B-COMP
resulted	O
in	O
a	O
marked	O
impairment	O
in	O
migration	O
and	O
proliferation	O
of	O
engrafted	O
stem	O
cells	B-COMP
.	O

This	O
method	O
allows	O
infection	O
of	O
bronchial	O
cells	B-COMP
within	O
their	O
natural	O
tissue	O
composition	O
under	O
in	O
vitro	O
conditions	O
.	O

We	O
demonstrate	O
that	O
IBV	O
strains	O
4	O
/	O
91	O
,	O
Italy02	O
,	O
and	O
QX	O
infect	O
ciliated	O
and	O
mucus	O
-	O
producing	O
cells	B-COMP
of	O
the	O
bronchial	O
epithelium	O
,	O
whereas	O
cells	B-COMP
of	O
the	O
parabronchial	O
tissue	O
are	O
resistant	O
to	O
infection	O
.	O

Downregulation	O
of	O
LC3	O
,	O
but	O
not	O
inactivation	O
of	O
host	B-COMP
cell	I-COMP
autophagy	O
,	O
protects	O
cells	B-COMP
from	O
CoV	O
infection	O
.	O

Infection	O
with	O
CB	O
/	O
05	O
resulted	O
in	O
a	O
profound	O
depletion	O
of	O
T	O
cells	B-COMP
and	O
a	O
slight	O
loss	O
of	O
B	O
cells	B-COMP
in	O
the	O
first	O
week	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
The	O
cellular	B-COMP
RNA	O
helicase	O
DDX1	O
interacts	O
with	O
coronavirus	O
nonstructural	O
protein	O
14	O
and	O
enhances	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
is	O
a	O
serum	B-COMP
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
host	B-COMP
defenses	O
as	O
an	O
opsonin	O
and	O
through	O
activation	O
of	O
the	O
complement	O
system	O
.	O

27	O
pg	O
/	O
mL	O
.	O
The	O
values	O
of	O
C	O
-	O
reactive	O
Protein	O
(	O
CRP	O
)	O
measured	O
after	O
48h	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
II	O
)	O
score	O
on	O
admission	O
and	O
Ranson	O
score	O
showed	O
the	O
similar	O
correlation	O
,	O
but	O
serum	B-COMP
amylase	O
level	O
did	O
not	O
correlate	O
significantly	O
with	O
Ranson	O
score	O
,	O
IL	O
-	O
6	O
concentration	O
and	O
APACHE	O
II	O
score	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
SIRS	O
score	O
on	O
admission	O
and	O
IL	O
-	O
6	O
serum	B-COMP
concentration	O
can	O
be	O
early	O
,	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
in	O
SAP	O
.	O

Furthermore	O
,	O
telbivudine	O
treatment	O
enhanced	O
the	O
ability	O
of	O
T	O
cells	B-COMP
to	O
undergo	O
proliferation	O
and	O
secrete	O
cytokines	O
but	O
did	O
not	O
affect	O
cytotoxicity	O
of	O
infected	O
hepatocytes	O
.	O

A	O
TGEV	O
derived	O
vector	O
(	O
rTGEV	O
)	O
was	O
generated	O
,	O
expressing	O
PRRSV	O
wild	O
type	O
or	O
modified	O
GP5	O
and	O
M	O
proteins	O
,	O
described	O
as	O
the	O
main	O
inducers	O
of	O
neutralizing	O
antibodies	B-COMP
and	O
cellular	B-COMP
immune	O
response	O
,	O
respectively	O
.	O

We	O
hypothesized	O
that	O
during	O
host	B-COMP
invasion	O
,	O
the	O
replicating	O
IBV	O
population	O
further	O
changes	O
as	O
it	O
confronts	O
the	O
distinct	O
environments	O
of	O
different	O
tissues	O
,	O
leading	O
to	O
selection	O
of	O
the	O
most	O
fit	O
population	O
.	O

ABSTRACT	O
:	O
The	O
nsp1	O
protein	O
of	O
the	O
highly	O
pathogenic	O
SARS	O
coronavirus	O
suppresses	O
host	B-COMP
protein	O
synthesis	O
,	O
including	O
genes	O
involved	O
in	O
the	O
innate	O
immune	O
system	O
.	O

However	O
,	O
synthesis	O
of	O
host	B-COMP
immune	O
and	O
non	O
-	O
immune	O
proteins	O
was	O
inhibited	O
by	O
nsp1	O
proteins	O
at	O
both	O
transcriptional	O
and	O
translational	O
levels	O
,	O
similar	O
to	O
SARS	O
coronavirus	O
nsp1	O
.	O

In	O
an	O
effort	O
to	O
survey	O
for	O
the	O
presence	O
of	O
other	O
infectious	O
agents	O
,	O
known	O
and	O
unknown	O
,	O
we	O
screened	O
sera	B-COMP
from	O
16	O
Pteropus	O
giganteus	O
bats	O
from	O
Faridpur	O
,	O
Bangladesh	O
,	O
using	O
high	O
-	O
throughput	O
pyrosequencing	O
.	O

Advanced	O
modes	O
of	O
respiratory	O
support	O
such	O
as	O
high	O
-	O
frequency	O
ventilation	O
,	O
airway	O
pressure	O
release	O
ventilation	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
were	O
required	O
in	O
a	O
majority	O
of	O
the	O
cohort	O
(	O
6	O
of	O
8	O
patients	O
).	O

This	O
review	O
focuses	O
on	O
recent	O
studies	O
using	O
either	O
mouse	O
neural	O
stem	O
cells	B-COMP
(	O
NSCs	O
)	O
or	O
human	O
oligodendrocyte	O
progenitor	O
cells	B-COMP
(	O
OPCs	O
)	O
derived	O
from	O
human	O
embryonic	O
stem	O
cell	B-COMP
(	O
hESC	O
)	O
to	O
promote	O
remyelination	O
in	O
mice	O
persistently	O
infected	O
with	O
MHV	O
.	O

A	O
locked	O
nucleic	B-COMP
acid	O
probe	O
-	O
based	O
reverse	O
transcription	O
real	O
-	O
time	O
PCR	O
test	O
was	O
designed	O
and	O
used	O
to	O
detect	O
the	O
IBV	O
strain	O
N1	O
/	O
88	O
from	O
the	O
oviduct	O
and	O
feces	O
of	O
unvaccinated	O
and	O
vaccinated	O
laying	O
hens	O
.	O

TITLE	O
:	O
Influenza	O
virus	O
variation	O
in	O
susceptibility	O
to	O
inactivation	O
by	O
pomegranate	O
polyphenols	O
is	O
determined	O
by	O
envelope	B-COMP
glycoproteins	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
serum	B-COMP
levels	O
of	O
prolactin	O
(	O
PRL	O
),	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
),	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
of	O
SARS	O
patients	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
control	O
groups	O
,	O
while	O
estradiol	O
(	O
E2	O
),	O
pregnancy	O
hormone	O
(	O
P	O
),	O
and	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
are	O
considerably	O
lower	O
than	O
those	O
of	O
normal	O
controls	O
.	O

However	O
,	O
up	O
to	O
now	O
there	O
has	O
been	O
no	O
direct	O
histological	O
investigation	O
on	O
the	O
endocrine	O
cells	B-COMP
of	O
patients	O
'	O
pituitary	O
.	O

The	O
immunohistochemistry	O
and	O
quantitative	O
image	O
results	O
showed	O
that	O
compared	O
with	O
control	O
cases	O
,	O
both	O
the	O
number	O
of	O
positive	O
cells	B-COMP
and	O
the	O
staining	O
intensity	O
of	O
immunoreactivity	O
for	O
growth	O
hormone	O
,	O
TSH	O
,	O
and	O
adrenocorticotrophic	O
hormone	O
in	O
these	O
cells	B-COMP
were	O
remarkably	O
decreased	O
,	O
while	O
that	O
of	O
PRL	O
,	O
FSH	O
,	O
and	O
LH	O
were	O
significantly	O
increased	O
in	O
all	O
SARS	O
cases	O
studied	O
.	O

TITLE	O
:	O
An	O
interaction	O
between	O
the	O
nucleocapsid	B-COMP
protein	O
and	O
a	O
component	O
of	O
the	O
replicase	O
-	O
transcriptase	O
complex	O
is	O
crucial	O
for	O
the	O
infectivity	O
of	O
coronavirus	O
genomic	O
RNA	O
.	O

In	O
re	O
-	O
infection	O
experiments	O
,	O
co	O
-	O
infected	O
cells	B-COMP
produced	O
fewer	O
EBs	O
than	O
monoinfected	O
cells	B-COMP
.	O

It	O
seems	O
that	O
adaptation	O
of	O
the	O
virus	O
within	O
the	O
host	B-COMP
animal	O
and	O
the	O
subsequent	O
abnormal	O
immune	O
responses	O
may	O
be	O
key	O
factors	O
in	O
the	O
pathogenesis	O
of	O
this	O
new	O
and	O
fatal	O
respiratory	O
disease	O
.	O

TITLE	O
:	O
SARS	O
spike	O
protein	O
induces	O
phenotypic	O
conversion	O
of	O
human	O
B	O
cells	B-COMP
to	O
macrophage	O
-	O
like	O
cells	B-COMP
.	O

Cell	B-COMP
surface	I-COMP
expression	O
of	O
CD19	O
or	O
Mac	B-COMP
-	O
1	O
(	O
CD11b	O
)	O
was	O
determined	O
by	O
flow	O
cytometry	O
.	O

Prolonged	O
exposure	O
to	O
hypoxia	O
could	O
also	O
induce	O
macrophage	O
-	O
like	O
conversion	O
of	O
B	O
cells	B-COMP
.	O

One	O
hundred	O
twenty	O
-	O
seven	O
people	O
diagnosed	O
with	O
OSAHS	O
by	O
polysomnography	O
(	O
PSG	B-COMP
)	O
were	O
admitted	O
into	O
the	O
OSAHS	O
group	O
,	O
and	O
52	O
subjects	O
without	O
OSAHS	O
were	O
recruited	O
for	O
the	O
control	O
group	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
examine	O
host	B-COMP
genetic	O
markers	O
that	O
may	O
predict	O
clinical	O
outcome	O
.	O

ABSTRACT	O
:	O
Bats	O
may	O
host	B-COMP
emerging	O
viruses	O
,	O
including	O
coronaviruses	O
(	O
CoV	O
).	O

This	O
is	O
the	O
first	O
report	O
describing	O
coinfection	O
of	O
different	O
coronavirus	O
genotypes	O
in	O
bats	O
and	O
coronavirus	O
genotypes	O
of	O
diverse	O
nucleotide	O
variation	O
in	O
the	O
same	O
host	B-COMP
.	O

IFN	O
-	O
	O
(+)	O
CD8	O
(+)	O
T	O
cells	B-COMP
and	O
CD107a	O
/	O
b	O
(+)	O
CD8	O
(+)	O
T	O
cells	B-COMP
distributed	O
throughout	O
the	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
tissues	O
,	O
but	O
the	O
frequency	O
of	O
peptide	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
was	O
higher	O
in	O
lungs	O
than	O
in	O
spleens	O
and	O
lymph	O
nodes	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
immunization	O
with	O
SARS	O
S	O
DNA	O
and	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
peptides	O
can	O
elicit	O
antigen	O
-	O
specific	O
CD8	O
(+)	O
T	O
cell	B-COMP
immune	O
responses	O
which	O
may	O
have	O
a	O
significant	O
implication	O
in	O
the	O
long	O
-	O
term	O
protection	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
membrane	B-COMP
(	O
M	O
)	O
proteins	O
play	O
key	O
roles	O
in	O
virus	O
assembly	O
,	O
through	O
M	O
-	O
M	O
,	O
M	O
-	O
spike	O
(	O
S	O
),	O
and	O
M	O
-	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
interactions	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
characteristics	O
,	O
clinical	O
evolution	O
and	O
outcome	O
in	O
adult	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
treated	O
with	O
or	O
without	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

ABSTRACT	O
:	O
A	O
series	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamide	O
derivatives	O
(	O
2	O
-	O
4	O
)	O
designed	O
as	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
replication	O
in	O
MT	O
-	O
4	O
cell	B-COMP
cultures	O
.	O

TITLE	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
is	O
dynamically	O
associated	O
with	O
the	O
replication	O
-	O
transcription	O
complexes	O
.	O

This	O
interference	O
with	O
nuclear	O
import	O
requires	O
interaction	O
between	O
protein	O
6	O
and	O
cellular	B-COMP
karyopherins	O
,	O
a	O
process	O
that	O
typically	O
involves	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
motifs	O
.	O

To	O
establish	O
stable	O
expressing	O
cell	B-COMP
clones	O
,	O
we	O
transfected	O
CHO	O
/	O
dhFr	O
-	O
cells	B-COMP
with	O
the	O
amplifiable	O
vectors	O
ISID	O
(	O
IRES	O
-	O
driven	O
dhfr	O
)	O
and	O
ISIZ	O
(	O
SV40	O
-	O
driven	O
dhfr	O
)	O
to	O
select	O
stepwise	O
MTX	O
,	O
and	O
observed	O
enhanced	O
	O
115	O
kDa	O
glycoform	O
generation	O
through	O
gene	O
amplification	O
.	O

The	O
S	O
(	O
TR2	O
)	O
glycoform	O
did	O
not	O
change	O
between	O
suspension	O
and	O
serum	B-COMP
-	O
free	O
cultures	O
,	O
suggesting	O
that	O
the	O
stable	O
and	O
amplified	O
cell	B-COMP
clones	O
analyzed	O
in	O
this	O
study	O
have	O
potential	O
for	O
producing	O
homologous	O
S	O
(	O
TR2	O
)	O
on	O
a	O
large	O
scale	O
.	O

Positive	O
strand	O
RNA	O
coronaviruses	O
(	O
CoVs	O
)	O
such	O
as	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
and	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
induce	O
in	O
infected	O
cells	B-COMP
the	O
formation	O
of	O
autophagosome	B-COMP
-	O
like	O
,	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
)	O
to	O
which	O
their	O
replication	O
and	O
transcription	O
complexes	O
are	O
anchored	O
.	O

PEDV	O
obtained	O
after	O
ten	O
passages	O
through	O
the	O
brains	O
(	O
MK	O
-	O
p10	O
)	O
had	O
increased	O
virulence	O
for	O
mice	O
,	O
and	O
its	O
fusion	O
activity	O
in	O
cultured	O
cells	B-COMP
exceeded	O
that	O
of	O
the	O
original	O
strain	O
.	O

These	O
demonstrated	O
that	O
specific	O
rather	O
than	O
generic	O
changes	O
occurred	O
in	O
the	O
nucleolar	O
proteome	O
in	O
infectious	O
bronchitis	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

TITLE	O
:	O
Novel	O
immunodominant	O
peptide	O
presentation	O
strategy	O
:	O
a	O
featured	O
HLA	O
-	O
A	O
*	O
2402	O
-	O
restricted	O
cytotoxic	O
T	O
-	O
lymphocyte	O
epitope	O
stabilized	O
by	O
intrachain	O
hydrogen	O
bonds	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

This	O
may	O
contribute	O
to	O
the	O
T	O
-	O
cell	B-COMP
receptor	O
(	O
TCR	B-COMP
)	O
interaction	O
,	O
showing	O
a	O
host	B-COMP
immunodominant	O
peptide	O
presentation	O
strategy	O
.	O

We	O
report	O
here	O
that	O
biosafe	O
coronavirus	O
-	O
based	O
vaccine	O
vectors	O
facilitate	O
delivery	O
of	O
multiple	O
antigens	O
and	O
immunostimulatory	O
cytokines	O
to	O
professional	O
antigen	O
-	O
presenting	O
cells	B-COMP
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Pathological	O
findings	O
revealed	O
that	O
the	O
virus	O
efficiently	O
replicated	O
in	O
alveolar	O
cells	B-COMP
and	O
caused	O
diffuse	O
alveolar	O
damage	O
as	O
well	O
as	O
bronchiolitis	O
.	O

Serum	B-COMP
amylase	O
(	O
AMY	O
)	O
levels	O
,	O
sPLA	O
(	O
2	O
)	O
and	O
lung	O
wet	O
/	O
dry	O
ratio	O
(	O
W	O
/	O
D	O
)	O
were	O
determined	O
.	O

We	O
identified	O
Neural	O
Cell	B-COMP
Adhesion	O
Molecule	O
(	O
NCAM	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
of	O
the	O
PHE	O
-	O
CoV	O
S	O
protein	O
.	O

These	O
emerging	O
sublineages	O
display	O
varying	O
levels	O
of	O
drug	O
resistance	O
and	O
in	O
some	O
cases	O
an	O
increased	O
preference	O
for	O
binding	O
to	O
human	O
2	O
,	O
6	O
-	O
linked	O
sialic	O
acid	O
cellular	B-COMP
receptors	O
.	O

In	O
silico	O
simulations	O
indicated	O
that	O
the	O
binding	O
site	O
of	O
1	O
,	O
8	O
-	O
cineole	O
was	O
located	O
at	O
the	O
N	O
terminus	O
of	O
phosphorylated	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
with	O
interaction	O
energy	O
equaling	O
-	O
40	O
.	O
33	O
kcal	O
mol	O
(-	O
1	O
).	O

ABSTRACT	O
:	O
The	O
distribution	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
,	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
does	O
not	O
strictly	O
correlate	O
with	O
SARS	O
-	O
CoV	O
cell	B-COMP
tropism	O
in	O
lungs	O
;	O
therefore	O
,	O
other	O
cellular	B-COMP
factors	O
have	O
been	O
predicted	O
to	O
be	O
required	O
for	O
activation	O
of	O
virus	O
infection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
transmembrane	B-COMP
protease	O
serine	O
2	O
(	O
TMPRSS2	O
),	O
whose	O
expression	O
does	O
correlate	O
with	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
upper	O
lobe	O
of	O
the	O
lung	O
.	O

On	O
the	O
other	O
hand	O
,	O
production	O
of	O
virus	O
in	O
TMPRSS2	O
-	O
expressing	O
cells	B-COMP
did	O
not	O
result	O
in	O
S	O
-	O
protein	O
cleavage	O
or	O
increased	O
infectivity	O
of	O
the	O
resulting	O
virus	O
.	O

ABSTRACT	O
:	O
Five	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
against	O
recombinant	O
nucleocapsid	B-COMP
protein	O
(	O
NP	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
causing	O
coronavirus	O
(	O
CoV	O
)	O
were	O
developed	O
by	O
hybridoma	O
technology	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
prevalence	O
of	O
mucosal	O
antibodies	B-COMP
induced	O
by	O
infection	O
with	O
human	O
coronaviruses	O
(	O
HCoV	O
),	O
including	O
HCoV	O
-	O
229E	O
and	O
-	O
OC43	O
and	O
recently	O
described	O
strains	O
(	O
HCoV	O
-	O
NL63	O
and	O
-	O
HKU1	O
).	O

The	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
highly	O
abundant	O
during	O
viral	O
infections	O
and	O
is	O
a	O
critical	O
element	O
for	O
viral	O
assembly	O
.	O

Nucleotide	O
substitution	O
in	O
the	O
viral	B-COMP
genome	I-COMP
occurs	O
frequently	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
recombinant	O
plasmid	O
of	O
pTRE	O
-	O
Tight	O
-	O
SARS	O
-	O
N	O
was	O
constructed	O
by	O
using	O
the	O
plasmid	O
p8S	O
as	O
the	O
PCR	O
template	O
which	O
contains	O
a	O
cDNA	O
clone	O
covering	O
the	O
nucleocapsid	B-COMP
gene	O
of	O
SARS	O
-	O
CoV	O
HKU	O
-	O
39449	O
.	O

Restriction	O
enzymes	O
digestion	O
and	O
sequence	O
analysis	O
indicated	O
the	O
recombinant	O
plasmid	O
of	O
pTRE	O
-	O
Tight	O
-	O
SARS	O
-	O
N	O
contained	O
the	O
nucleocapsid	B-COMP
gene	O
with	O
the	O
optimized	O
nucleotide	O
sequence	O
which	O
will	O
improve	O
the	O
translation	O
efficiency	O
.	O

The	O
expression	O
of	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
was	O
tightly	O
regulated	O
by	O
the	O
varying	O
concentration	O
of	O
doxcycline	O
in	O
the	O
constructed	O
double	O
-	O
stable	O
cell	B-COMP
line	O
.	O

Despite	O
SL	O
-	O
CoVs	O
and	O
SARS	O
-	O
CoV	O
share	O
identical	O
genome	O
structure	O
and	O
high	O
-	O
level	O
sequence	O
similarity	O
,	O
SL	O
-	O
CoV	O
does	O
not	O
bind	O
to	O
the	O
same	O
cellular	B-COMP
receptor	O
as	O
for	O
SARS	O
-	O
CoV	O
and	O
the	O
N	O
-	O
terminus	O
of	O
the	O
S	O
proteins	O
only	O
share	O
64	O
%	O
amino	O
acid	O
identity	O
,	O
suggesting	O
there	O
are	O
fundamental	O
differences	O
between	O
these	O
two	O
groups	O
of	O
coronaviruses	O
.	O

Further	O
,	O
our	O
results	O
also	O
show	O
that	O
BMM	O
are	O
generally	O
more	O
responsive	O
to	O
MHV	O
infection	O
,	O
since	O
MyD88	O
-	O
dependent	O
pathways	O
are	O
also	O
activated	O
to	O
a	O
greater	O
extent	O
in	O
these	O
cells	B-COMP
than	O
in	O
BMDC	O
.	O

Eleven	O
of	O
the	O
15	O
patients	O
had	O
increased	O
serum	B-COMP
lactate	O
dehydrogenase	O
levels	O
,	O
which	O
were	O
above	O
245	O
U	O
/	O
L	O
.	O
Three	O
patients	O
had	O
elevated	O
creatine	O
kinase	O
levels	O
at	O
admission	O
.	O

Finally	O
,	O
we	O
used	O
the	O
density	O
-	O
optimized	O
nanotube	O
biosensors	O
to	O
detect	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
the	O
SARS	O
virus	O
and	O
demonstrated	O
improved	O
detection	O
limits	O
under	O
physiological	O
conditions	O
.	O

Further	O
biochemical	O
and	O
electron	O
microscopic	O
analyses	O
revealed	O
that	O
virions	B-COMP
,	O
while	O
assembled	O
,	O
contained	O
little	O
spike	O
in	O
the	O
envelope	B-COMP
,	O
indicating	O
that	O
lack	O
of	O
infectivity	O
during	O
persistence	O
was	O
likely	O
due	O
to	O
deficiency	O
in	O
spike	O
incorporation	O
.	O

Moreover	O
,	O
ISG20	O
demonstrated	O
cell	B-COMP
-	O
type	O
specific	O
antiviral	O
activity	O
against	O
yellow	O
fever	O
virus	O
,	O
a	O
classical	O
flavivirus	O
.	O

TITLE	O
:	O
Potent	O
and	O
persistent	O
antibody	B-COMP
responses	O
against	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
recovered	O
patients	O
.	O

Unlike	O
the	O
nsp1	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
a	O
betacoronavirus	O
,	O
the	O
TGEV	O
nsp1	O
protein	O
was	O
unable	O
to	O
bind	O
40S	B-COMP
ribosomal	I-COMP
subunits	I-COMP
or	O
promote	O
host	B-COMP
mRNA	O
degradation	O
.	O

TGEV	O
nsp1	O
also	O
suppressed	O
protein	O
translation	O
in	O
cell	B-COMP
-	O
free	O
HeLa	O
cell	B-COMP
extract	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
translation	O
in	O
rabbit	O
reticulocyte	O
lysate	O
(	O
RRL	O
).	O

Our	O
data	O
suggested	O
that	O
HeLa	O
cell	B-COMP
extracts	O
and	O
cultured	O
host	B-COMP
cells	B-COMP
,	O
but	O
not	O
RRL	O
,	O
contain	O
a	O
host	B-COMP
factor	O
(	O
s	O
)	O
that	O
is	O
essential	O
for	O
TGEV	O
nsp1	O
-	O
induced	O
translational	O
suppression	O
.	O

The	O
mutant	O
virus	O
,	O
IBV	O
-	O
EG3	O
,	O
was	O
defective	O
in	O
release	O
of	O
infectious	O
virus	B-COMP
particles	I-COMP
.	O

The	O
amount	O
of	O
viral	O
nucleic	B-COMP
acid	O
was	O
recorded	O
semiquantitatively	O
based	O
on	O
the	O
cycle	O
threshold	O
value	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
can	O
cause	O
mild	O
to	O
severe	O
disease	O
in	O
humans	O
and	O
animals	O
,	O
their	O
host	B-COMP
range	O
and	O
environmental	O
spread	O
seem	O
to	O
have	O
been	O
largely	O
underestimated	O
,	O
and	O
they	O
are	O
currently	O
being	O
investigated	O
for	O
their	O
potential	O
medical	O
relevance	O
.	O

The	O
latter	O
membrane	B-COMP
fusion	O
requires	O
an	O
S	O
protein	O
conformational	O
flexibility	O
that	O
is	O
facilitated	O
by	O
proteolytic	O
cleavages	O
.	O

These	O
findings	O
indicate	O
that	O
a	O
cell	B-COMP
surface	I-COMP
complex	O
comprising	O
a	O
primary	O
receptor	O
and	O
a	O
separate	O
endoprotease	O
operates	O
as	O
a	O
portal	O
for	O
activation	O
of	O
SARS	O
-	O
CoV	O
cell	B-COMP
entry	O
.	O

Lung	O
injury	O
,	O
neutrophil	O
infiltration	O
,	O
cell	B-COMP
death	O
,	O
fibrin	O
deposition	O
,	O
and	O
tissue	O
factor	O
expression	O
in	O
the	O
lung	O
were	O
determined	O
.	O

TITLE	O
:	O
Nucleic	B-COMP
acid	O
amplification	O
-	O
based	O
diagnosis	O
of	O
respiratory	O
virus	O
infections	O
.	O

ABSTRACT	O
:	O
Increasing	O
the	O
intracellular	B-COMP
Zn	O
(	O
2	O
+)	O
concentration	O
with	O
zinc	O
-	O
ionophores	O
like	O
pyrithione	O
(	O
PT	O
)	O
can	O
efficiently	O
impair	O
the	O
replication	O
of	O
a	O
variety	O
of	O
RNA	O
viruses	O
,	O
including	O
poliovirus	O
and	O
influenza	O
virus	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
the	O
combination	O
of	O
Zn	O
(	O
2	O
+)	O
and	O
PT	O
at	O
low	O
concentrations	O
(	O
2	O
M	O
Zn	O
(	O
2	O
+)	O
and	O
2	O
M	O
PT	O
)	O
inhibits	O
the	O
replication	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
in	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Differentiation	O
between	O
human	O
coronaviruses	O
NL63	O
and	O
229E	O
using	O
a	O
novel	O
double	O
-	O
antibody	B-COMP
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
specific	O
monoclonal	O
antibodies	B-COMP
.	O

Subsequently	O
,	O
pGEX	O
-	O
SARS	O
-	O
S1	O
was	O
transformed	O
into	O
host	B-COMP
cells	B-COMP
BL21	O
(	O
DE3	O
)	O
pLysS	O
,	O
and	O
the	O
expression	O
of	O
the	O
S1	O
protein	O
was	O
induced	O
by	O
isopropyl	O
	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
).	O

However	O
,	O
its	O
low	O
extracellular	B-COMP
activity	O
hinders	O
the	O
precise	O
measurement	O
of	O
changes	O
that	O
take	O
place	O
during	O
ALI	O
/	O
ARDS	O
.	O

Since	O
dermatomyositis	O
(	O
DM	O
)-	O
specific	O
skin	O
alterations	O
were	O
not	O
found	O
,	O
none	O
of	O
the	O
patients	O
in	O
this	O
study	O
fulfilled	O
Bohan	O
and	O
Peter	O
'	O
s	O
criteria	O
for	O
DM	O
;	O
however	O
,	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-COMP
was	O
detected	O
in	O
case	O
number	O
1	O
.	O

Elongated	O
M	O
protein	O
is	O
associated	O
with	O
rigidity	O
,	O
clusters	O
of	O
spikes	O
and	O
a	O
relatively	O
narrow	O
range	O
of	O
membrane	B-COMP
curvature	O
.	O

Analysis	O
of	O
several	O
types	O
of	O
virus	O
-	O
like	O
particles	O
and	O
virions	B-COMP
revealed	O
that	O
S	O
protein	O
,	O
N	O
protein	O
and	O
genomic	O
RNA	O
each	O
help	O
to	O
regulate	O
virion	B-COMP
size	O
and	O
variation	O
,	O
presumably	O
through	O
interactions	O
with	O
M	O
.	O
These	O
findings	O
provide	O
insight	O
into	O
how	O
M	O
protein	O
functions	O
to	O
promote	O
virus	O
assembly	O
.	O

The	O
results	O
of	O
western	O
blot	O
analysis	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	B-COMP
showed	O
the	O
synthesis	O
and	O
assembly	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
into	O
oligomeric	O
structures	O
with	O
pentameric	O
sizing	O
.	O

In	O
a	O
recent	O
randomized	O
trial	O
,	O
centralization	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
to	O
a	O
specialized	O
center	O
able	O
to	O
provide	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
showed	O
better	O
survival	O
as	O
compared	O
to	O
conventional	O
treatment	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
change	O
of	O
special	O
antibodies	B-COMP
titer	O
IgG	O
,	O
IgM	O
and	O
nucleocapsid	B-COMP
to	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
and	O
observing	O
the	O
expression	O
of	O
stomach	O
and	O
enteric	O
involvement	O
on	O
SARS	O
-	O
CoV	O
infection	O
by	O
monoclonal	O
antibody	B-COMP
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
7	O
-	O
year	O
recovery	O
period	O
among	O
family	O
clustering	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Special	O
antibody	B-COMP
titer	O
to	O
SARS	O
-	O
CoV	O
of	O
14	O
patients	O
from	O
5	O
different	O
families	O
and	O
their	O
10	O
kinfolks	O
continuously	O
tested	O
by	O
IFA	O
and	O
antigen	O
-	O
capturing	O
ELISA	O
methods	O
.	O

When	O
testing	O
the	O
IgG	B-COMP
antibody	I-COMP
titer	O
of	O
the	O
14	O
SARS	O
patients	O
by	O
IFA	O
method	O
,	O
the	O
average	O
titer	O
was	O
1	O
/	O
71	O
(	O
95	O
%	O
CI	O
:	O
1	O
/	O
58	O
-	O
1	O
/	O
85	O
)	O
in	O
the	O
1	O
(	O
st	O
)	O
year	O
,	O
but	O
began	O
to	O
descend	O
in	O
the	O
following	O
years	O
,	O
and	O
the	O
IgG	B-COMP
antibody	I-COMP
of	O
the	O
most	O
SARS	O
patients	O
disappeared	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
.	O

ABSTRACT	O
:	O
Three	O
cats	O
were	O
evaluated	O
at	O
a	O
veterinary	O
teaching	O
hospital	O
for	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
secondary	O
to	O
hyperviscosity	O
syndrome	O
from	O
plasma	O
cell	B-COMP
neoplasia	O
.	O

Overall	O
,	O
our	O
study	O
shows	O
that	O
the	O
SILAC	O
approach	O
is	O
a	O
suitable	O
tool	O
to	O
study	O
host	B-COMP
-	O
pathogen	O
interactions	O
and	O
to	O
identify	O
host	B-COMP
proteins	O
involved	O
in	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
Although	O
enveloped	O
viruses	O
typically	O
trigger	O
the	O
prodigious	O
secretion	O
of	O
alpha	O
interferon	O
(	O
IFN	O
-	O
	O
)	O
by	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
(	O
pDC	O
),	O
porcine	O
pDC	O
remain	O
quiescent	O
when	O
exposed	O
to	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
).	O

Co	O
-	O
stimulatory	O
molecules	O
(	O
CD80	O
and	O
CD86	O
)	O
and	O
class	O
II	O
major	O
histocompatibility	O
complex	O
molecules	O
(	O
I	O
-	O
Ad	O
)	O
were	O
increased	O
on	O
CD11c	O
+	O
dendritic	B-COMP
cells	B-COMP
in	O
cervical	O
lymph	O
node	O
from	O
the	O
mice	O
after	O
PEI	O
/	O
pci	O
-	O
S	O
vaccination	O
.	O

TITLE	O
:	O
Mutation	O
of	O
neutralizing	O
/	O
antibody	B-COMP
-	O
dependent	O
enhancing	O
epitope	O
on	O
spike	O
protein	O
and	O
7b	O
gene	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
:	O
influences	O
of	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
and	O
virulence	O
in	O
cats	O
.	O

ABSTRACT	O
:	O
The	O
antibody	B-COMP
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
has	O
been	O
recognized	O
in	O
experimentally	O
infected	O
cats	O
,	O
and	O
cellular	B-COMP
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
S1	O
region	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
contains	O
four	O
antigenic	O
sites	O
(	O
C	O
,	O
B	O
,	O
D	O
and	O
A	O
,	O
from	O
the	O
N	O
-	O
to	O
the	O
C	O
-	O
terminal	O
end	O
)	O
and	O
is	O
engaged	O
in	O
host	B-COMP
-	O
cell	B-COMP
receptor	O
recognition	O
.	O

The	O
most	O
N	O
-	O
terminal	O
portion	O
of	O
the	O
S1	O
region	O
,	O
which	O
comprises	O
antigenic	O
sites	O
C	O
and	O
B	O
,	O
is	O
needed	O
for	O
the	O
enteric	O
tropism	O
of	O
TGEV	O
,	O
whereas	O
the	O
major	O
antigenic	O
site	O
A	O
at	O
the	O
C	O
-	O
terminal	O
moiety	O
is	O
required	O
for	O
both	O
respiratory	O
and	O
enteric	O
cell	B-COMP
tropism	O
,	O
and	O
is	O
engaged	O
in	O
recognition	O
of	O
the	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
receptor	O
.	O

These	O
processes	O
include	O
population	O
growth	O
and	O
movement	O
,	O
urbanisation	O
,	O
changes	O
in	O
food	O
production	O
,	O
agriculture	O
and	O
land	B-COMP
use	O
,	O
water	O
and	O
sanitation	O
,	O
and	O
the	O
effect	O
of	O
health	O
systems	O
through	O
generation	O
of	O
drug	O
resistance	O
.	O

A	O
proteomics	O
approach	O
demonstrated	O
downregulation	O
of	O
extracellular	B-COMP
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
and	O
upregulation	O
of	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
(	O
UBC	O
)	O
E2	O
-	O
25k	O
as	O
inhibitory	O
mechanism	O
of	O
PLpro	O
on	O
IFN	O
-	O
	O
-	O
induced	O
responses	O
.	O

ABSTRACT	O
:	O
To	O
express	O
the	O
nuclear	O
capsid	O
protein	O
(	O
N	O
protein	O
)	O
and	O
the	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
of	O
HCoV	O
-	O
HKU1	O
,	O
and	O
to	O
develop	O
the	O
corresponding	O
serum	B-COMP
assay	O
for	O
antibody	B-COMP
detection	O
.	O

The	O
N	O
protein	O
of	O
HCoV	O
-	O
HKU1	O
was	O
expressed	O
in	O
E	O
.	O
Coli	O
,	O
anti	O
-	O
N	O
antibody	B-COMP
assay	O
was	O
established	O
using	O
Western	O
Blotting	O
with	O
turn	O
-	O
based	O
membrane	B-COMP
.	O

Six	O
primers	O
were	O
designed	O
to	O
amplify	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
of	O
PEDV	O
.	O

Research	O
in	O
wounded	O
military	O
showed	O
that	O
a	O
high	O
ratio	O
of	O
fresh	O
frozen	O
plasma	O
to	O
packed	O
red	O
blood	O
cells	B-COMP
(	O
FFP	O
:	O
PRBC	O
)	O
seemed	O
to	O
have	O
a	O
positive	O
effect	O
on	O
survival	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
is	O
the	O
configuration	O
mode	O
an	O
important	O
predictor	O
for	O
the	O
outcome	O
?	O

We	O
show	O
that	O
these	O
siRNAs	O
could	O
effectively	O
and	O
specifically	O
block	O
the	O
isolated	O
N	O
gene	O
expression	O
in	O
mammal	O
cells	B-COMP
.	O

Furthermore	O
,	O
the	O
protein	O
levels	O
of	O
NF	O
-	O
kB	O
decreased	O
in	O
3CLpro	O
-	O
transfected	O
A549	O
cells	B-COMP
when	O
compared	O
to	O
EGFP	O
transfected	O
cells	B-COMP
.	O

Our	O
results	O
suggest	O
that	O
the	O
3CLpro	O
may	O
suppress	O
expression	O
of	O
GM	O
-	O
CSF	O
in	O
transfected	O
A549	O
cells	B-COMP
through	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kB	O
production	O
.	O

Furthermore	O
,	O
the	O
protein	O
levels	O
of	O
NF	O
-	O
kB	O
decreased	O
in	O
3CLpro	O
-	O
transfected	O
A549	O
cells	B-COMP
when	O
compared	O
to	O
EGFP	O
transfected	O
cells	B-COMP
.	O

In	O
contrast	O
,	O
it	O
is	O
largely	O
unknown	O
whether	O
host	B-COMP
cell	I-COMP
proteases	O
located	O
in	O
the	O
secretory	O
pathway	O
of	O
infected	O
cells	B-COMP
and	O
/	O
or	O
on	O
the	O
surface	O
of	O
target	O
cells	B-COMP
can	O
cleave	O
SARS	O
S	O
.	O
We	O
along	O
with	O
others	O
could	O
previously	O
show	O
that	O
the	O
type	O
II	O
transmembrane	B-COMP
protease	O
TMPRSS2	O
activates	O
the	O
influenza	O
virus	O
hemagglutinin	O
and	O
the	O
human	O
metapneumovirus	O
F	O
protein	O
by	O
cleavage	O
.	O

TITLE	O
:	O
Infection	O
with	O
human	O
coronavirus	O
NL63	O
enhances	O
streptococcal	O
adherence	O
to	O
epithelial	O
cells	B-COMP
.	O

The	O
antibody	B-COMP
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	O
has	O
been	O
recognised	O
in	O
experimentally	O
infected	O
cats	O
,	O
and	O
cellular	B-COMP
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
FIP	O
.	O

In	O
all	O
tests	O
,	O
fIFN	O
-	O
	O
production	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
(	O
PBMCs	O
)	O
obtained	O
from	O
cats	O
experimentally	O
infected	O
with	O
an	O
FIPV	O
isolate	O
that	O
did	O
not	O
develop	O
the	O
disease	O
was	O
significantly	O
increased	O
by	O
heat	O
-	O
inactivated	O
FIPV	O
stimulation	O
in	O
comparison	O
with	O
medium	O
alone	O
.	O

ABSTRACT	O
:	O
Granulocytes	O
play	O
an	O
important	O
role	O
in	O
the	O
host	B-COMP
defense	O
against	O
invading	O
microorganisms	O
such	O
as	O
bacteria	O
and	O
fungi	O
(	O
1	O
,	O
2	O
).	O

When	O
UDA	O
was	O
exposed	O
to	O
N	O
-	O
acetylglucosamine	O
and	O
then	O
UDA	O
was	O
added	O
to	O
cells	B-COMP
just	O
prior	O
to	O
adsorption	O
,	O
UDA	O
did	O
not	O
inhibit	O
the	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Green	O
fluorescent	O
protein	O
(	O
GFP	O
)-	O
tagged	O
mouse	O
hepatitis	O
coronavirus	O
nonstructural	O
protein	O
4	O
(	O
nsp4	O
)	O
was	O
shown	O
to	O
localize	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
and	O
to	O
be	O
recruited	O
to	O
the	O
coronavirus	O
replicative	O
structures	O
.	O

These	O
most	O
critically	O
ill	O
patients	O
may	O
require	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
survival	O
.	O

The	O
efficacy	O
of	O
this	O
vaccine	O
is	O
highly	O
dose	O
dependent	O
and	O
the	O
flock	O
antibody	B-COMP
response	O
is	O
weak	O
.	O

To	O
improve	O
the	O
functionality	O
of	O
the	O
vaccine	O
and	O
investigate	O
its	O
potential	O
as	O
a	O
delivery	O
vector	O
for	O
foreign	O
antigens	O
and	O
immunomodulatory	O
proteins	O
,	O
we	O
developed	O
a	O
derivative	O
of	O
ts	O
-	O
11	O
expressing	O
infectious	O
bronchitis	O
virus	O
-	O
S1	O
glycoprotein	O
(	O
IBV	O
-	O
S1	O
)	O
and	O
releasing	O
chicken	O
interleukin	O
-	O
6	O
into	O
the	O
extracellular	B-COMP
milieu	O
(	O
MG	O
ts	O
-	O
11	O
C3	O
(+	O
CS	O
))	O
using	O
a	O
transposon	O
-	O
based	O
delivery	O
vector	O
.	O

Currently	O
,	O
the	O
longitudinal	O
profiles	O
of	O
antibody	B-COMP
responses	O
in	O
recovered	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

For	O
IgG	O
antibodies	B-COMP
in	O
the	O
3rd	O
y	O
,	O
the	O
positive	O
rate	O
of	O
whole	O
-	O
virus	O
-	O
specific	O
antibodies	B-COMP
was	O
42	O
%,	O
which	O
was	O
tested	O
with	O
commercial	O
kits	O
at	O
1	O
/	O
10	O
dilution	O
of	O
the	O
sera	B-COMP
.	O

The	O
average	O
optical	O
density	O
(	O
OD	O
)	O
reading	O
of	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
-	O
specific	O
antibodies	B-COMP
fell	O
dramatically	O
between	O
month	O
3	O
and	O
month	O
12	O
,	O
and	O
it	O
decreased	O
gradually	O
at	O
low	O
levels	O
that	O
were	O
a	O
little	O
higher	O
than	O
the	O
cut	O
-	O
off	O
value	O
from	O
month	O
12	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibodies	B-COMP
and	O
their	O
neutralizing	O
activities	O
decreased	O
throughout	O
the	O
entire	O
phase	O
of	O
the	O
study	O
.	O

The	O
two	O
most	O
effective	O
siRNAs	O
,	O
targeting	O
the	O
untranslated	O
5	O
'	O
leader	O
sequence	O
(	O
L2	O
)	O
and	O
the	O
nucleocapsid	B-COMP
gene	O
(	O
N1	O
),	O
resulted	O
in	O
a	O
>	O
95	O
%	O
reduction	O
in	O
extracellular	B-COMP
viral	O
titre	O
.	O

At	O
48	O
h	O
post	O
-	O
infection	O
,	O
only	O
a	O
few	O
siRNA	O
-	O
treated	O
cells	B-COMP
were	O
positive	O
for	O
viral	O
antigen	O
staining	O
,	O
whereas	O
most	O
untreated	O
virus	O
-	O
infected	O
cells	B-COMP
were	O
positive	O
.	O

ABSTRACT	O
:	O
Interferon	O
gamma	O
(	O
IFN	O
-	O
	O
)	O
plays	O
an	O
important	O
role	O
in	O
cell	B-COMP
mediated	O
responses	O
against	O
mutated	O
feline	O
coronavirus	O
strains	O
(	O
FCoV	O
)	O
involved	O
in	O
the	O
pathogenesis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

Diagnoses	O
of	O
viral	O
infections	O
were	O
established	O
according	O
to	O
positive	O
results	O
in	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
influenza	O
rapid	O
diagnostic	O
testing	O
,	O
and	O
based	O
on	O
a	O
fourfold	O
increase	O
in	O
antibody	B-COMP
titer	O
of	O
influenza	O
virus	O
antibody	B-COMP
in	O
paired	O
sera	B-COMP
.	O

Furthermore	O
,	O
many	O
piglets	O
were	O
seropositive	O
to	O
PHEV	O
,	O
indicating	O
the	O
possible	O
transfer	O
of	O
maternal	O
antibodies	B-COMP
via	O
the	O
colostrum	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
,	O
sensitivity	O
,	O
and	O
stability	O
of	O
the	O
immunochromatographic	O
strip	O
,	O
it	O
would	O
be	O
suitable	O
for	O
on	O
-	O
site	O
detection	O
of	O
PHEV	O
antibodies	B-COMP
in	O
order	O
to	O
monitor	O
PHEV	O
infections	O
in	O
an	O
animal	O
population	O
.	O

Pulmonary	O
complications	O
represent	O
20	O
to	O
30	O
%	O
of	O
mortality	O
due	O
to	O
sickle	O
cell	B-COMP
and	O
can	O
be	O
divided	O
into	O
acute	O
and	O
chronic	O
events	O
.	O

ABSTRACT	O
:	O
Kartagener	O
syndrome	O
is	O
a	O
rare	O
,	O
ciliopathic	O
,	O
autosomal	B-COMP
recessive	O
genetic	O
disorder	O
that	O
causes	O
a	O
defect	O
in	O
the	O
action	O
of	O
the	O
cilia	B-COMP
lining	O
the	O
respiratory	O
tract	O
and	O
fallopian	O
tube	O
.	O

Diagnosis	O
can	O
be	O
made	O
by	O
tests	O
to	O
prove	O
impaired	O
cilia	B-COMP
function	O
,	O
biopsy	O
,	O
and	O
genetic	O
studies	O
.	O

The	O
contribution	O
of	O
host	B-COMP
cell	I-COMP
proteins	O
to	O
CoV	O
transcription	O
needs	O
additional	O
information	O
.	O

The	O
assay	O
was	O
carried	O
out	O
using	O
two	O
sets	O
of	O
primers	O
designed	O
to	O
amplify	O
highly	O
conserved	O
sequences	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
of	O
BCoV	O
and	O
the	O
internal	O
control	O
,	O
bovine	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
,	O
RNA	O
.	O

TITLE	O
:	O
Histopathological	O
and	O
immunohistochemical	O
study	O
of	O
air	O
sac	B-COMP
lesions	O
induced	O
by	O
two	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

Laboratory	O
data	O
revealed	O
severe	O
renal	O
insufficiency	O
and	O
positive	O
titers	O
for	O
the	O
myeloperoxidase	O
anti	O
-	O
neutrophil	O
cytoplasmic	B-COMP
and	O
anti	O
-	O
glomerular	O
basement	B-COMP
membrane	I-COMP
antibodies	B-COMP
.	O

Surprisingly	O
,	O
pleiomorphic	O
SLIV	O
structures	O
,	O
including	O
a	O
terminal	B-COMP
loop	I-COMP
deletion	O
,	O
were	O
found	O
among	O
debilitated	O
progeny	O
from	O
intra	O
-	O
SLIV	O
chimeras	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
used	O
increasingly	O
in	O
adults	O
with	O
severe	O
acute	O
reversible	O
respiratory	O
failure	O
.	O

Activation	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)-	O
protein	O
by	O
host	B-COMP
cell	I-COMP
proteases	O
is	O
essential	O
for	O
viral	O
infectivity	O
.	O

We	O
report	O
our	O
experience	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenator	O
(	O
ECMO	O
)	O
rescue	O
and	O
transportation	O
of	O
patients	O
with	O
H1N1	O
ARDS	O
within	O
an	O
insular	O
and	O
rural	O
Mediterranean	O
area	O
of	O
seven	O
million	O
inhabitants	O
.	O

In	O
contrast	O
to	O
many	O
well	O
-	O
studied	O
enveloped	O
viruses	O
that	O
assemble	O
and	O
bud	O
at	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
coronaviruses	O
assemble	O
by	O
budding	O
into	O
the	O
lumen	O
of	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
-	I-COMP
Golgi	I-COMP
intermediate	I-COMP
compartment	I-COMP
and	O
are	O
released	O
from	O
the	O
cell	B-COMP
by	O
exocytosis	O
.	O

This	O
motif	O
is	O
conserved	O
in	O
E	O
proteins	O
of	O
beta	O
and	O
gamma	O
coronaviruses	O
(	O
formerly	O
referred	O
to	O
as	O
group	O
2	O
and	O
3	O
coronaviruses	O
),	O
where	O
it	O
also	O
functions	O
as	O
a	O
Golgi	B-COMP
complex	I-COMP
-	O
targeting	O
signal	O
.	O

To	O
determine	O
whether	O
the	O
activity	O
of	O
a	O
C	O
-	O
peptide	O
could	O
be	O
improved	O
by	O
increasing	O
its	O
intracellular	B-COMP
concentration	O
,	O
we	O
prepared	O
an	O
EboV	O
C	O
-	O
peptide	O
conjugated	O
to	O
the	O
arginine	O
-	O
rich	O
sequence	O
from	O
HIV	O
-	O
1	O
Tat	O
,	O
which	O
is	O
known	O
to	O
accumulate	O
in	O
endosomes	O
.	O

Pan	B-COMP
-	O
viral	O
microarrays	O
revealed	O
additional	O
evidence	O
of	O
viral	O
infection	O
(	O
herpes	O
simplex	O
virus	O
[	O
n	O
=	O
1	O
],	O
Epstein	O
-	O
Barr	O
virus	O
[	O
n	O
=	O
2	O
],	O
and	O
torque	O
teno	O
virus	O
[	O
TTV	O
]	O
[	O
n	O
=	O
12	O
])	O
in	O
patients	O
with	O
acute	O
exacerbation	O
.	O

ABSTRACT	O
:	O
During	O
the	O
co	O
-	O
evolution	O
of	O
viruses	O
and	O
their	O
hosts	B-COMP
,	O
the	O
latter	O
have	O
equipped	O
themselves	O
with	O
an	O
elaborate	O
immune	O
system	O
to	O
defend	O
themselves	O
from	O
the	O
invading	O
viruses	O
.	O

This	O
inhibitor	O
significantly	O
decreased	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
replication	O
,	O
reducing	O
the	O
percentage	O
of	O
infected	O
cells	B-COMP
and	O
intra	O
-	O
and	O
extracellular	B-COMP
infectious	O
virus	O
titers	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
the	O
reduction	O
of	O
ASC	O
in	O
the	O
CNS	O
,	O
neither	O
virus	O
-	O
specific	O
ASC	O
trafficking	O
to	O
bone	O
marrow	O
nor	O
antiviral	O
serum	B-COMP
antibody	B-COMP
was	O
reduced	O
relative	O
to	O
levels	O
in	O
control	O
mice	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
44	O
-	O
year	O
-	O
old	O
man	O
infected	O
with	O
HIV	O
and	O
HCV	O
with	O
a	O
high	O
CD4	O
cell	B-COMP
count	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
influenza	O
virus	O
A	O
/	O
H1N1v	O
infection	O
.	O

Infection	O
of	O
transgenic	O
IL	O
-	O
10	O
/	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
reporter	O
mice	O
revealed	O
that	O
CNS	O
-	O
infiltrating	O
T	O
cells	B-COMP
were	O
the	O
major	O
source	O
of	O
IL	O
-	O
10	O
,	O
with	O
minimal	O
IL	O
-	O
10	O
production	O
by	O
macrophages	O
and	O
resident	O
microglia	O
.	O

Unlike	O
CD8	O
(+)	O
T	O
cells	B-COMP
,	O
a	O
large	O
proportion	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
retained	O
IL	O
-	O
10	O
production	O
throughout	O
persistence	O
.	O

While	O
IL	O
-	O
10	O
production	O
by	O
CD8	O
(+)	O
T	O
cells	B-COMP
was	O
limited	O
primarily	O
to	O
the	O
time	O
of	O
acute	O
effector	O
function	O
,	O
CD4	O
(+)	O
T	O
cells	B-COMP
continued	O
to	O
produce	O
IL	O
-	O
10	O
throughout	O
infection	O
.	O

In	O
addition	O
,	O
a	O
plaque	O
reduction	O
assay	O
was	O
performed	O
using	O
sera	B-COMP
from	O
groups	O
pg611	O
,	O
pg612	O
-	O
6D	O
,	O
pg11	O
-	O
6D	O
,	O
and	O
phosphate	O
-	O
buffered	O
saline	O
(	O
blank	O
control	O
)	O
to	O
analyze	O
TGEV	O
-	O
neutralizing	O
antibody	B-COMP
activity	O
in	O
vitro	O
.	O

While	O
there	O
were	O
significant	O
differences	O
in	O
the	O
number	O
of	O
host	B-COMP
genes	O
differentially	O
regulated	O
during	O
the	O
host	B-COMP
responses	O
between	O
the	O
three	O
SARS	O
-	O
CoV	O
strains	O
,	O
the	O
top	O
pathways	O
and	O
functions	O
were	O
similar	O
and	O
only	O
apparent	O
early	O
during	O
infection	O
with	O
the	O
majority	O
of	O
genes	O
associated	O
with	O
interferon	O
signaling	O
pathways	O
.	O

Protocols	O
for	O
propagating	O
MHV	O
in	O
DBT	O
and	O
17CL	O
-	O
1	O
cells	B-COMP
;	O
the	O
storage	O
and	O
titration	O
of	O
viral	O
stocks	O
;	O
purification	O
of	O
MHV	O
on	O
sucrose	O
gradients	O
;	O
and	O
the	O
generation	O
of	O
recombinant	O
viruses	O
by	O
a	O
cDNA	O
assembly	O
method	O
and	O
by	O
targeted	O
recombination	O
will	O
be	O
presented	O
.	O

The	O
results	O
suggest	O
that	O
bundles	O
are	O
likely	O
with	O
the	O
second	O
TMD	O
facing	O
the	O
putative	O
pore	B-COMP
.	O

Attempts	O
were	O
made	O
to	O
detect	O
viruses	O
by	O
inoculation	O
of	O
these	O
eluates	O
in	O
cell	B-COMP
cultures	O
(	O
Vero	O
,	O
MDCK	O
,	O
and	O
RK	O
-	O
13	O
)	O
and	O
specific	O
pathogen	O
-	O
free	O
embryonated	O
chicken	O
eggs	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
purified	O
recombinant	O
human	O
ADAM17	O
is	O
able	O
to	O
cleave	O
a	O
20	O
-	O
amino	O
acid	O
peptide	O
mimetic	O
corresponding	O
to	O
the	O
extracellular	B-COMP
juxtamembrane	B-COMP
region	O
of	O
human	O
ACE2	O
between	O
Arg	O
(	O
708	O
)	O
and	O
Ser	B-COMP
(	O
709	O
).	O

The	O
observation	O
of	O
the	O
shedding	O
profiles	O
of	O
ACE2	O
mutants	O
expressing	O
CHO	O
-	O
K1	O
and	O
CHO	O
-	O
P	O
cells	B-COMP
indicates	O
that	O
the	O
Arg	O
(	O
708	O
)	O
	O
Glu	O
(	O
708	O
)	O
mutation	O
and	O
the	O
Arg	O
(	O
708	O
)	O
Arg	O
(	O
710	O
)	O
	O
Glu	O
(	O
708	O
)	O
Glu	O
(	O
710	O
)	O
double	O
mutation	O
produced	O
increases	O
in	O
the	O
amount	O
of	O
ACE2	O
shed	O
when	O
stimulated	O
by	O
phorbol	O
ester	O
PMA	O
.	O

TITLE	O
:	O
Action	O
mechanisms	O
of	O
lithium	O
chloride	O
on	O
cell	B-COMP
infection	O
by	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

Plaque	O
assays	O
and	O
3	O
-(	O
4	O
,	O
5	O
)-	O
dimethylthiahiazo	O
(-	O
z	O
-	O
y1	O
)-	O
3	O
,	O
5	O
-	O
di	O
-	O
phenyl	O
tetrazoliumbromide	O
(	O
MTT	O
)	O
assays	O
showed	O
that	O
the	O
cell	B-COMP
infection	O
by	O
TGEV	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
when	O
LiCl	O
was	O
added	O
to	O
virus	O
-	O
infected	O
cells	B-COMP
;	O
the	O
cell	B-COMP
infection	O
was	O
not	O
affected	O
when	O
either	O
cells	B-COMP
or	O
viruses	O
were	O
pretreated	O
with	O
the	O
drug	O
.	O

Factors	O
in	O
relation	O
to	O
humoral	O
and	O
cellular	B-COMP
immunity	O
were	O
investigated	O
.	O

No	O
SARS	O
-	O
CoV	O
Ag	O
-	O
specific	O
memory	O
B	O
cell	B-COMP
response	O
was	O
detected	O
in	O
either	O
23	O
former	O
SARS	O
patients	O
or	O
22	O
close	O
contacts	O
of	O
SARS	O
patients	O
.	O

Additionally	O
,	O
IL	O
-	O
10	O
increased	O
both	O
the	O
frequency	O
and	O
number	O
of	O
Foxp3	O
(+)	O
regulatory	O
CD4	O
T	O
cells	B-COMP
in	O
the	O
infected	O
central	O
nervous	O
system	O
.	O

Following	O
oral	O
and	O
nasal	O
administration	O
to	O
chickens	O
,	O
the	O
serum	B-COMP
and	O
mucosal	O
samples	O
were	O
collected	O
and	O
antibodies	B-COMP
against	O
IBV	O
were	O
measured	O
.	O

The	O
expression	O
and	O
antigenicity	O
of	O
S	O
fragments	O
was	O
confirmed	O
by	O
immunofluorescence	O
antibody	B-COMP
(	O
IFA	O
)	O
assay	O
using	O
an	O
anti	O
-	O
histidine	O
monoclonal	O
antibody	B-COMP
or	O
anti	O
-	O
TCoV	O
serum	B-COMP
.	O

We	O
found	O
that	O
PEDV	O
infection	O
was	O
enhanced	O
,	O
and	O
viruses	O
were	O
efficiently	O
released	O
into	O
the	O
culture	O
fluid	O
,	O
from	O
Vero	O
cells	B-COMP
infected	O
in	O
the	O
presence	O
of	O
protease	O
,	O
while	O
in	O
cells	B-COMP
without	O
protease	O
,	O
the	O
virus	O
grew	O
,	O
but	O
its	O
release	O
into	O
the	O
culture	O
fluid	O
was	O
strongly	O
hampered	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
infected	O
Vero	O
/	O
TMPRSS2	O
cells	B-COMP
with	O
the	O
protease	O
inhibitor	O
leupeptin	O
strongly	O
blocked	O
the	O
release	O
of	O
virus	O
into	O
the	O
culture	O
fluid	O
.	O

With	O
this	O
method	O
,	O
we	O
could	O
characterize	O
extremely	O
low	O
populations	O
of	O
infected	O
cells	B-COMP
in	O
the	O
spleen	O
(	O
less	O
than	O
0	O
.	O
1	O
%)	O
at	O
12	O
h	O
post	O
-	O
inoculation	O
with	O
srr7	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
tuberculosis	O
and	O
severe	O
ARDS	O
(	O
PaO2	O
/	O
FiO2	O
<	O
100	O
mmHg	O
)	O
who	O
was	O
initially	O
managed	O
with	O
advanced	O
up	O
-	O
to	O
-	O
date	O
treatments	O
(	O
protective	O
ventilation	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
ECMO	O
)	O
but	O
failed	O
to	O
improve	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
B	O
virus	O
core	O
antibody	B-COMP
(	O
HBcAb	O
)-	O
positive	O
organ	O
donors	O
have	O
the	O
potential	O
to	O
transmit	O
infection	O
to	O
transplant	O
recipients	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
A59	O
)	O
induces	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
),	O
a	O
soluble	O
cytosolic	B-COMP
enzyme	O
present	O
in	O
the	O
liver	O
and	O
kidneys	O
,	O
in	O
various	O
mouse	O
strains	O
.	O

Using	O
various	O
cell	B-COMP
cycle	O
inhibitors	O
,	O
we	O
have	O
shown	O
that	O
the	O
nuclear	O
entry	O
of	O
9b	O
is	O
independent	O
of	O
the	O
cell	B-COMP
cycle	O
.	O

Macromolecular	O
synthesis	O
analysis	O
showed	O
that	O
rTGEV	O
-	O
7	O
virus	O
infection	O
led	O
to	O
host	B-COMP
translational	O
shut	O
-	O
off	O
and	O
increased	O
cellular	B-COMP
RNA	O
degradation	O
compared	O
with	O
rTGEV	O
-	O
wt	O
infection	O
.	O

These	O
results	O
suggested	O
that	O
the	O
removal	O
of	O
gene	O
7	O
promoted	O
an	O
intensified	O
dsRNA	O
-	O
activated	O
host	B-COMP
antiviral	O
response	O
.	O

We	O
postulated	O
that	O
TGEV	O
protein	O
7	O
may	O
counteract	O
host	B-COMP
antiviral	O
response	O
by	O
its	O
association	O
with	O
PP1c	O
.	O

ABSTRACT	O
:	O
The	O
binding	O
of	O
viruses	O
to	O
host	B-COMP
cells	B-COMP
is	O
the	O
first	O
step	O
in	O
determining	O
tropism	O
and	O
pathogenicity	O
.	O

Here	O
we	O
investigated	O
whether	O
the	O
interaction	O
between	O
the	O
viral	O
attachment	O
proteins	O
and	O
the	O
host	B-COMP
could	O
explain	O
these	O
differences	O
by	O
using	O
recombinant	O
spike	O
domains	O
(	O
S1	O
)	O
of	O
IBV	O
strains	O
with	O
different	O
pathogenicities	O
,	O
as	O
well	O
as	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
protein	O
of	O
IAV	O
H5N1	O
.	O

TITLE	O
:	O
Effectiveness	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
when	O
conventional	O
ventilation	O
fails	O
:	O
valuable	O
option	O
or	O
vague	O
remedy	O
?	O

Specifically	O
,	O
we	O
review	O
the	O
effects	O
of	O
hypercapnia	O
and	O
acidosis	O
on	O
the	O
attenuation	O
of	O
pulmonary	O
inflammation	O
,	O
reduction	O
of	O
apoptosis	O
in	O
alveolar	O
epithelial	O
cells	B-COMP
,	O
improvement	O
in	O
sepsis	O
-	O
induced	O
ALI	O
and	O
the	O
therapeutic	O
effects	O
on	O
other	O
organ	O
systems	O
,	O
as	O
well	O
as	O
the	O
potentially	O
harmful	O
effects	O
of	O
these	O
strategies	O
.	O

However	O
,	O
future	O
research	O
should	O
focus	O
on	O
the	O
intracellular	B-COMP
signaling	O
pathways	O
that	O
mediate	O
ALI	O
development	O
,	O
potentially	O
focusing	O
on	O
the	O
role	O
of	O
reactive	O
biological	O
species	O
in	O
ALI	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
Endothelial	O
cells	B-COMP
(	O
ECs	O
),	O
forming	O
a	O
semi	O
-	O
permeable	O
barrier	O
between	O
the	O
interior	O
space	O
of	O
blood	O
vessels	O
and	O
underlying	O
tissues	O
,	O
control	O
such	O
diverse	O
processes	O
as	O
vascular	O
tone	O
,	O
homeostasis	O
,	O
adhesion	O
of	O
platelets	O
,	O
and	O
leukocytes	O
to	O
the	O
vascular	O
wall	O
and	O
permeability	O
of	O
vascular	O
wall	O
for	O
cells	B-COMP
and	O
fluids	O
.	O

Viral	O
gene	O
signatures	O
in	O
the	O
spike	O
,	O
non	O
-	O
structural	O
protein	O
3c	O
,	O
and	O
membrane	B-COMP
of	O
the	O
coronavirus	O
genome	O
have	O
been	O
shown	O
to	O
often	O
correlate	O
with	O
disease	O
manifestation	O
.	O

If	O
their	O
'	O
fresh	O
'	O
host	B-COMP
had	O
no	O
defences	O
,	O
the	O
viruses	O
could	O
cause	O
a	O
serious	O
pandemic	O
,	O
as	O
seen	O
with	O
HIV	O
,	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
and	O
avian	O
influenza	O
virus	O
that	O
originated	O
from	O
chimpanzees	O
,	O
the	O
common	O
palm	O
civet	O
and	O
birds	O
,	O
respectively	O
.	O

Finally	O
,	O
we	O
detected	O
greatly	O
increased	O
expression	O
of	O
GRP78	O
(	O
78	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
),	O
a	O
typical	O
marker	O
of	O
ERS	O
(	O
ER	O
stress	O
)	O
and	O
found	O
that	O
the	O
formation	O
of	O
autophagosomes	O
was	O
closely	O
related	O
to	O
the	O
expanded	O
ER	B-COMP
membrane	I-COMP
.	O

ABSTRACT	O
:	O
Early	O
studies	O
that	O
explored	O
host	B-COMP
-	O
pathogen	O
interactions	O
assumed	O
that	O
infected	O
individuals	O
within	O
a	O
population	O
have	O
equal	O
chances	O
of	O
transmitting	O
the	O
infection	O
to	O
others	O
.	O

Gag	O
proteins	O
,	O
encoded	O
by	O
retroviruses	O
,	O
orchestrate	O
the	O
assembly	O
of	O
virus	B-COMP
particles	I-COMP
in	O
close	O
collaboration	O
with	O
host	B-COMP
cell	I-COMP
machinery	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
immune	O
responses	O
of	O
peptide	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
induced	O
by	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
epitopes	O
plus	O
CpG	O
oligodeoxynucleotide	O
(	O
CpG	O
ODN	O
),	O
PolyI	O
:	O
C	O
and	O
R848	O
as	O
adjuvants	O
.	O

In	O
the	O
case	O
of	O
the	O
emergence	O
of	O
SevereAcute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
several	O
studies	O
have	O
shown	O
coronavirus	O
diversity	O
in	O
bats	O
as	O
well	O
as	O
the	O
existence	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
apparently	O
healthy	O
bats	O
,	O
suggesting	O
that	O
bats	O
may	O
be	O
a	O
crucial	O
host	B-COMP
in	O
the	O
genesis	O
of	O
this	O
disease	O
.	O

This	O
is	O
due	O
in	O
part	O
to	O
the	O
extreme	O
genetic	O
variability	O
of	O
RNA	O
viruses	O
such	O
as	O
the	O
coronaviruses	O
,	O
the	O
many	O
animal	O
reservoirs	O
that	O
seem	O
to	O
be	O
able	O
host	B-COMP
the	O
SARS	O
-	O
CoV	O
in	O
which	O
reassortment	O
or	O
recombination	O
events	O
could	O
occur	O
and	O
the	O
ability	O
coronaviruses	O
have	O
to	O
transmit	O
relatively	O
rapidly	O
from	O
species	O
to	O
species	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O

TITLE	O
:	O
[	O
Expression	O
and	O
purification	O
of	O
different	O
segments	O
from	O
HCoV	O
-	O
NL63	O
nucleocapsid	B-COMP
protein	O
and	O
their	O
application	O
in	O
detection	O
of	O
antibodies	B-COMP
].	O

The	O
inhibition	O
or	O
perturbation	O
of	O
the	O
function	O
of	O
cellular	B-COMP
PDZ	O
proteins	O
appears	O
to	O
be	O
a	O
widely	O
used	O
strategy	O
for	O
viruses	O
to	O
enhance	O
their	O
replication	O
,	O
disseminate	O
in	O
the	O
host	B-COMP
,	O
and	O
transmit	O
to	O
new	O
hosts	B-COMP
.	O

Antibody	B-COMP
-	O
mediated	O
infection	O
was	O
dependent	O
on	O
Fc	O
receptor	O
II	O
but	O
did	O
not	O
use	O
the	O
endosomal	O
/	O
lysosomal	O
pathway	O
utilized	O
by	O
angiotensin	O
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
accepted	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
This	O
suggests	O
that	O
ADE	O
of	O
SARS	O
-	O
CoV	O
utilizes	O
a	O
novel	O
cell	B-COMP
entry	O
mechanism	O
into	O
immune	O
cells	B-COMP
.	O

In	O
addition	O
,	O
the	O
display	O
of	O
detection	O
data	O
on	O
remote	O
platforms	O
such	O
as	O
cell	B-COMP
phone	O
and	O
computer	O
was	O
also	O
successfully	O
demonstrated	O
with	O
a	O
wireless	O
module	O
.	O

TNF	O
and	O
IL	O
-	O
1	O
were	O
not	O
detected	O
in	O
the	O
serum	B-COMP
.	O

Compound	O
3d	O
was	O
found	O
inhibit	O
viral	O
replication	O
of	O
para	O
influenza	O
-	O
3virus	O
,	O
reovirus	O
-	O
1	O
,	O
Sindbis	O
virus	O
,	O
Coxsackie	O
virus	O
B4	O
,	O
Punta	O
Toro	O
virus	O
in	O
Vero	O
cell	B-COMP
cultures	O
.	O

The	O
vesicles	B-COMP
recruited	O
double	O
FYVE	O
-	O
domain	O
containing	O
protein	O
(	O
DFCP	O
)	O
indicating	O
localised	O
concentration	O
of	O
phosphatidylinositol	O
3	O
phosphate	O
,	O
and	O
therefore	O
shared	O
many	O
features	O
with	O
omegasomes	O
formed	O
from	O
the	O
ER	O
in	O
response	O
to	O
starvation	O
.	O

Unimpaired	O
T	O
cell	B-COMP
mediated	O
virus	O
control	O
supported	O
an	O
unexpectedly	O
redundant	O
role	O
of	O
MMP9	O
in	O
promoting	O
leukocyte	O
access	O
to	O
the	O
brain	O
parenchyma	O
.	O

Vero	O
E6	O
cells	B-COMP
were	O
transfected	O
with	O
plasmids	O
pAcGFP1	O
-	O
C1	O
/	O
N	O
and	O
pDsRed2	O
-	O
N1	O
/	O
B23	O
.	O
1	O
.	O

This	O
was	O
an	O
observational	O
cohort	O
study	O
of	O
114	O
adults	O
with	O
SCD	O
who	O
completed	O
respiratory	O
symptom	O
questionnaires	O
and	O
had	O
serum	B-COMP
IgE	O
measurements	O
.	O

TITLE	O
:	O
Identification	O
of	O
antigenic	O
peptides	O
derived	O
from	O
B	O
-	O
cell	B-COMP
epitopes	O
of	O
nucleocapsid	B-COMP
protein	O
of	O
mouse	O
hepatitis	O
virus	O
for	O
serological	O
diagnosis	O
.	O

To	O
develop	O
an	O
antigen	O
that	O
is	O
more	O
specific	O
,	O
more	O
sensitive	O
,	O
and	O
easier	O
to	O
prepare	O
for	O
serological	O
diagnosis	O
,	O
the	O
antigenic	O
sites	O
in	O
the	O
MHV	O
-	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
were	O
screened	O
in	O
this	O
study	O
.	O

Furthermore	O
,	O
ELISA	O
performed	O
using	O
these	O
peptides	O
was	O
more	O
sensitive	O
than	O
commercial	O
ELISA	O
used	O
for	O
a	O
screening	O
sera	B-COMP
from	O
mice	O
infected	O
accidentally	O
to	O
MHV	O
maintained	O
in	O
cages	O
,	O
suggesting	O
that	O
these	O
peptides	O
are	O
useful	O
for	O
serological	O
diagnosis	O
of	O
MHV	O
infection	O
.	O

These	O
engineered	O
CD8	O
+	O
T	O
cells	B-COMP
displayed	O
avidity	O
and	O
functionality	O
similar	O
to	O
that	O
of	O
natural	O
SARS	O
-	O
specific	O
memory	O
CD8	O
+	O
T	O
cells	B-COMP
.	O

A	O
second	O
,	O
unrelated	O
viral	B-COMP
envelope	I-COMP
is	O
used	O
as	O
an	O
internal	O
control	O
to	O
reduce	O
the	O
number	O
of	O
false	O
positives	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
H1381R	O
mutation	O
is	O
responsible	O
for	O
enhanced	O
fusion	O
activity	O
,	O
which	O
may	O
be	O
attributed	O
to	O
the	O
efficient	O
transfer	O
of	O
S	O
onto	O
the	O
cell	B-COMP
surface	I-COMP
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
universally	O
accepted	O
as	O
a	O
potential	O
lifesaving	O
therapy	O
for	O
neonates	O
suffering	O
severe	O
cardiorespiratory	O
failure	O
,	O
with	O
survival	O
reported	O
as	O
81	O
%	O
weaning	O
off	O
ECMO	O
and	O
69	O
%	O
to	O
hospital	O
discharge	O
in	O
this	O
population	O
.	O

The	O
balance	O
between	O
viral	O
replication	O
and	O
the	O
host	B-COMP
immune	O
responses	O
is	O
central	O
to	O
disease	O
pathogenesis	O
,	O
and	O
the	O
extent	O
of	O
lung	O
injury	O
in	O
severe	O
influenza	O
infections	O
may	O
be	O
due	O
in	O
part	O
to	O
overly	O
exuberant	O
or	O
dysregulated	O
innate	O
inflammatory	O
responses	O
or	O
sometimes	O
deficient	O
responses	O
.	O

Twenty	O
-	O
nine	O
HCoV	O
-	O
OC43	O
strains	O
from	O
nasopharyngeal	O
aspirates	O
,	O
collected	O
from	O
2004	O
to	O
2011	O
,	O
were	O
subjected	O
to	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
,	O
and	O
nucleocapsid	B-COMP
gene	O
analysis	O
.	O

They	O
were	O
evaluated	O
initially	O
on	O
RNA	O
templates	O
from	O
virus	O
-	O
infected	O
cells	B-COMP
using	O
a	O
two	O
-	O
step	O
RT	O
-	O
PCR	O
protocol	O
that	O
was	O
further	O
advanced	O
to	O
a	O
one	O
-	O
step	O
assay	O
.	O

TITLE	O
:	O
Sustained	O
high	O
-	O
efficiency	O
daily	O
diafiltration	O
using	O
a	O
mediator	O
-	O
adsorbing	O
membrane	B-COMP
(	O
SHEDD	O
-	O
fA	O
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
sepsis	O
.	O

ABSTRACT	O
:	O
Sustained	O
high	O
-	O
efficiency	O
daily	O
diafiltration	O
using	O
a	O
mediator	O
-	O
adsorbing	O
membrane	B-COMP
(	O
SHEDD	O
-	O
fA	O
)	O
is	O
an	O
effective	O
,	O
intensive	O
modality	O
for	O
sepsis	O
treatment	O
.	O

After	O
separation	O
of	O
the	O
nanoparticle	O
-	O
protein	B-COMP
complex	I-COMP
from	O
plasma	O
,	O
the	O
protein	O
mixture	O
was	O
digested	O
,	O
and	O
peptides	O
were	O
analyzed	O
by	O
nanoliquid	O
chromatography	O
-	O
Orbitrap	O
LTQ	O
-	O
XL	O
mass	O
spectrometry	O
.	O

TITLE	O
:	O
Safe	O
transport	O
of	O
critically	O
ill	O
adult	O
patients	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
to	O
a	O
regional	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
center	O
.	O

TITLE	O
:	O
Complementary	O
roles	O
of	O
Fas	O
-	O
associated	O
death	O
domain	O
(	O
FADD	O
)	O
and	O
receptor	O
interacting	O
protein	O
kinase	O
-	O
3	O
(	O
RIPK3	O
)	O
in	O
T	O
-	O
cell	B-COMP
homeostasis	O
and	O
antiviral	O
immunity	O
.	O

Here	O
we	O
demonstrate	O
that	O
RIPK3	O
and	O
FADD	O
have	O
opposing	O
and	O
complementary	O
roles	O
in	O
promoting	O
T	O
-	O
cell	B-COMP
clonal	O
expansion	O
and	O
homeostasis	O
.	O

Further	O
,	O
we	O
have	O
examined	O
if	O
the	O
structure	O
of	O
mitochondria	B-COMP
is	O
altered	O
.	O

The	O
results	O
of	O
the	O
current	O
study	O
demonstrated	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
the	O
complex	B-COMP
I	I-COMP
by	O
31	O
and	O
48	O
%	O
at	O
18	O
and	O
24	O
h	O
respectively	O
after	O
the	O
thioacetamide	O
injection	O
.	O

Our	O
results	O
also	O
suggest	O
mitochondrial	B-COMP
swelling	O
in	O
FHF	O
induced	O
rats	O
.	O

We	O
further	O
investigated	O
the	O
role	O
of	O
LF	O
in	O
the	O
entry	O
of	O
SARS	O
pseudovirus	O
into	O
HEK293E	O
/	O
ACE2	O
-	O
Myc	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
In	O
May	O
2011	O
,	O
an	O
outbreak	O
of	O
Shiga	O
toxin	O
-	O
producing	O
enterohaemorrhagic	O
E	O
coli	O
O104	O
:	O
H4	O
in	O
northern	O
Germany	O
led	O
to	O
a	O
high	O
proportion	O
of	O
patients	O
developing	O
post	O
-	O
enteritis	O
haemolytic	O
uraemic	O
syndrome	O
and	O
thrombotic	O
microangiopathy	O
that	O
were	O
unresponsive	O
to	O
therapeutic	O
plasma	O
exchange	O
or	O
complement	O
-	O
blocking	O
antibody	B-COMP
(	O
eculizumab	O
).	O

Antibodies	B-COMP
are	O
probably	O
involved	O
in	O
the	O
pathogenesis	O
of	O
severe	O
neurological	O
symptoms	O
in	O
patients	O
with	O
E	O
coli	O
O104	O
:	O
H4	O
-	O
induced	O
haemolytic	O
uraemic	O
syndrome	O
.	O

A	O
mutation	O
in	O
tRNA	O
(	O
Lys	O
)	O
that	O
causes	O
myoclonic	O
epilepsy	O
with	O
ragged	O
-	O
red	O
fibers	O
(	O
MERRF	O
)	O
is	O
also	O
reported	O
to	O
prevent	O
modification	O
of	O
the	O
wobble	O
U	O
.	O
Here	O
we	O
show	O
that	O
mitochondrial	B-COMP
translation	O
is	O
unaffected	O
in	O
fibroblasts	O
from	O
an	O
MTU1	O
patient	O
,	O
in	O
which	O
MTU1	O
is	O
undetectable	O
by	O
immunoblotting	O
,	O
despite	O
the	O
severe	O
reduction	O
in	O
the	O
2	O
-	O
thiolation	O
of	O
mitochondrial	B-COMP
tRNA	O
(	O
Lys	O
),	O
tRNA	O
(	O
Glu	O
)	O
and	O
tRNA	O
(	O
Gln	O
).	O

While	O
antibodies	B-COMP
against	O
Feline	O
parvovirus	O
and	O
Feline	O
coronavirus	O
(	O
FCoV	O
),	O
Feline	O
calicivirus	O
and	O
Bartonella	O
spp	O
.	O
were	O
frequently	O
detected	O
by	O
serologic	O
tests	O
,	O
antibodies	B-COMP
against	O
Felid	O
herpesvirus	O
1	O
or	O
infection	O
with	O
hemotropic	O
mycoplasmas	O
were	O
less	O
prevalent	O
.	O

RESULTS	O
:	O
Desialylation	O
of	O
cells	B-COMP
only	O
had	O
a	O
minor	O
effect	O
on	O
the	O
infection	O
by	O
TGEV	O
strain	O
Purdue	O
46	O
when	O
an	O
adsorption	O
period	O
of	O
60	O
min	O
was	O
allowed	O
for	O
initiation	O
of	O
infection	O
.	O

Since	O
the	O
RNA	O
pseudoknot	O
located	O
in	O
the	O
frameshifting	O
region	O
of	O
IBV	O
was	O
used	O
as	O
bait	O
for	O
cellular	B-COMP
RBPs	O
,	O
we	O
tested	O
whether	O
ANXA2	O
could	O
regulate	O
the	O
frameshfting	O
of	O
IBV	O
pseudoknot	O
RNA	O
by	O
dual	O
luciferase	O
assay	O
.	O

Inhibition	O
of	O
glutamate	O
excitotoxicity	O
using	O
a	O
2	O
-	O
amino	O
-	O
3	O
-(	O
5	O
-	O
methyl	O
-	O
3	O
-	O
oxo	O
-	O
1	O
,	O
2	O
-	O
oxazol	O
-	O
4	O
-	O
yl	O
)	O
propranoic	O
acid	O
(	O
AMPA	O
)	O
receptor	O
antagonist	O
(	O
GYKI	O
-	O
52466	O
)	O
improved	O
clinical	O
scores	O
related	O
to	O
the	O
paralysis	O
and	O
motor	O
disabilities	O
in	O
S	O
mutant	O
virus	O
-	O
infected	O
mice	O
,	O
as	O
well	O
as	O
protected	O
the	O
CNS	O
from	O
neuronal	O
dysfunctions	O
,	O
as	O
illustrated	O
by	O
restoration	O
of	O
the	O
phosphorylation	O
state	O
of	O
neurofilaments	B-COMP
.	O

The	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
by	O
controlling	O
gas	O
exchange	O
,	O
allowed	O
the	O
performing	O
of	O
a	O
successful	O
liver	O
transplantation	O
and	O
final	O
recovery	O
.	O

ABSTRACT	O
:	O
We	O
have	O
recently	O
identified	O
apurinic	O
/	O
apyrimidinic	O
endonuclease	O
1	O
(	O
APE1	O
)	O
as	O
an	O
endoribonuclease	O
that	O
cleaves	O
c	O
-	O
myc	O
mRNA	O
in	O
vitro	O
and	O
regulates	O
c	O
-	O
myc	O
mRNA	O
levels	O
and	O
half	O
-	O
life	O
in	O
cells	B-COMP
.	O

TITLE	O
:	O
Referral	O
to	O
an	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
center	O
and	O
mortality	O
among	O
patients	O
with	O
severe	O
2009	O
influenza	O
A	O
(	O
H1N1	O
).	O

We	O
found	O
that	O
HAT	O
activates	O
SARS	O
-	O
S	O
in	O
the	O
context	O
of	O
surrogate	O
systems	O
and	O
authentic	O
SARS	O
-	O
CoV	O
infection	O
and	O
is	O
coexpressed	O
with	O
the	O
viral	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
in	O
bronchial	O
epithelial	O
cells	B-COMP
and	O
pneumocytes	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
pAPN	O
-	O
C	O
recombinant	O
protein	O
and	O
its	O
polyclonal	O
antibody	B-COMP
can	O
provide	O
some	O
basis	O
for	O
further	O
receptor	O
antagonist	O
.	O

ABSTRACT	O
:	O
Immunological	O
detection	O
of	O
viruses	O
and	O
their	O
components	O
using	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
is	O
a	O
powerful	O
diagnostic	O
method	O
.	O

The	O
primary	O
IBV	O
infection	O
induced	O
changes	O
in	O
circulating	O
T	O
-	O
cell	B-COMP
populations	O
and	O
in	O
the	O
specific	O
antibody	B-COMP
responses	O
.	O

We	O
have	O
previously	O
reported	O
that	O
HCoV	O
-	O
OC43	O
infection	O
of	O
human	O
neurons	O
activates	O
the	O
unfolded	O
-	O
protein	O
response	O
and	O
caspase	O
-	O
3	O
and	O
induces	O
cell	B-COMP
death	O
and	O
that	O
the	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
involved	O
in	O
the	O
process	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
proapoptotic	O
proteins	O
BAX	O
,	O
cytochrome	O
c	O
(	O
CytC	O
),	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
were	O
relocalized	O
toward	O
the	O
mitochondria	B-COMP
,	O
cytosol	B-COMP
,	O
and	O
nucleus	B-COMP
,	O
respectively	O
,	O
after	O
infection	O
by	O
both	O
virus	O
variants	O
.	O

We	O
compared	O
this	O
with	O
white	O
blood	O
cell	B-COMP
(	O
WBC	O
)	O
counts	O
,	O
serum	B-COMP
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
serum	B-COMP
procalcitonin	O
(	O
PCT	O
),	O
urine	O
output	O
,	O
creatinine	O
clearance	O
(	O
CCr	O
),	O
serum	B-COMP
creatinine	O
(	O
SCr	O
),	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
).	O

Overall	O
,	O
the	O
activation	O
of	O
the	O
IRE	O
-	O
1	O
pathway	O
was	O
not	O
able	O
to	O
restore	O
cell	B-COMP
homeostasis	O
,	O
and	O
apoptosis	O
was	O
induced	O
probably	O
as	O
a	O
measure	O
to	O
protect	O
the	O
host	B-COMP
by	O
limiting	O
virus	O
production	O
and	O
dissemination	O
.	O

TITLE	O
:	O
Vaccination	O
against	O
pandemic	O
H1N1	O
(	O
2009	O
)	O
in	O
patients	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
:	O
a	O
retrospective	O
analysis	O
.	O

TITLE	O
:	O
Cell	B-COMP
-	O
based	O
therapies	O
for	O
lung	O
vascular	O
diseases	O
:	O
lessons	O
for	O
the	O
future	O
.	O

Finally	O
,	O
we	O
show	O
that	O
in	O
vitro	O
migration	O
of	O
CD8	O
(+)	O
T	O
lymphocytes	O
across	O
blood	O
-	O
brain	O
barrier	O
-	O
endothelial	O
cells	B-COMP
is	O
dependent	O
on	O
4	O
integrin	O
,	O
but	O
independent	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
/	O
leucocyte	O
function	O
-	O
associated	O
antigen	O
-	O
1	O
,	O
activated	O
leucocyte	O
cell	B-COMP
adhesion	O
molecule	O
/	O
CD6	O
and	O
the	O
chemokine	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
/	O
CCL2	O
.	O

Four	O
patients	O
needed	O
an	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
due	O
to	O
severe	O
respiratory	O
failure	O
with	O
global	O
respiratory	O
insufficiency	O
that	O
could	O
not	O
be	O
treated	O
by	O
conservative	O
ventilatory	O
support	O
.	O

Recombinant	O
human	O
APC	B-COMP
(	O
continuous	O
infusion	O
24	O
g	O
/	O
kg	O
per	O
hour	O
)	O
and	O
ceftazidime	O
(	O
3	O
-	O
g	O
bolus	O
at	O
1	O
and	O
13	O
h	O
)	O
were	O
intravenously	O
administered	O
.	O

However	O
,	O
a	O
human	O
bronchial	O
epithelial	O
cell	B-COMP
line	O
(	O
16HBE	O
)	O
was	O
readily	O
infected	O
.	O

ABSTRACT	O
:	O
Antibody	B-COMP
repertoires	O
for	O
library	O
construction	O
are	O
conventionally	O
harvested	O
from	O
mRNAs	O
of	O
immune	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
The	O
concentrations	O
of	O
haptoglobin	O
(	O
Hp	O
),	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
serum	B-COMP
amyloid	O
A	O
(	O
SAA	O
)	O
were	O
measured	O
in	O
wasted	O
pigs	O
,	O
first	O
to	O
evaluate	O
their	O
usefulness	O
in	O
the	O
diagnosis	O
of	O
infectious	O
,	O
wasting	O
diseases	O
in	O
pigs	O
,	O
and	O
second	O
,	O
to	O
evaluate	O
whether	O
their	O
concentrations	O
can	O
distinguish	O
the	O
lymphoid	O
depletion	O
score	O
in	O
the	O
lymph	O
tissues	O
of	O
wasted	O
affected	O
pigs	O
.	O

Serum	B-COMP
Hp	O
was	O
significantly	O
higher	O
in	O
pigs	O
with	O
PRDC	O
in	O
comparison	O
with	O
the	O
PMWS	O
affected	O
pigs	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
of	O
a	O
critically	O
ill	O
patient	O
with	O
diffuse	O
large	O
B	O
-	O
cell	B-COMP
lymphoma	O
nongerminal	O
center	O
B	O
-	O
cell	B-COMP
phenotype	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
influenza	O
B	O
virus	O
infection	O
.	O

DS	O
pathogenesis	O
is	O
not	O
completely	O
understood	O
,	O
but	O
it	O
is	O
believed	O
that	O
an	O
excessive	O
inflammatory	O
response	O
is	O
the	O
main	O
phenomenon	O
involved	O
,	O
which	O
results	O
in	O
increased	O
production	O
of	O
chemokines	O
and	O
expression	O
of	O
adhesion	O
molecules	O
on	O
APL	O
cells	B-COMP
.	O

In	O
combination	O
with	O
their	O
superior	O
isolation	O
efficiency	O
,	O
MDCK	O
cells	B-COMP
appear	O
highly	O
suitable	O
to	O
be	O
used	O
as	O
an	O
alternative	O
to	O
embryonated	O
eggs	O
to	O
isolate	O
and	O
propagate	O
influenza	O
vaccine	O
candidate	O
viruses	O
.	O

The	O
compound	O
1	O
,	O
evaluated	O
in	O
HepG	O
2	O
.	O
2	O
.	O
15	O
cells	B-COMP
expressing	O
permanently	O
HBV	O
,	O
significantly	O
reduced	O
the	O
levels	O
of	O
HBV	O
antigens	O
and	O
HBV	O
DNA	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Acute	O
chest	O
syndrome	O
is	O
a	O
severe	O
respiratory	O
complication	O
of	O
sickle	O
cell	B-COMP
disease	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
replication	O
by	O
short	O
hairpin	O
RNAs	O
targeting	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
in	O
a	O
porcine	O
kidney	O
cell	B-COMP
line	O
.	O

The	O
shRNAs	O
were	O
transiently	O
transfected	O
into	O
a	O
porcine	O
kidney	O
cell	B-COMP
line	O
,	O
PK	O
-	O
15	O
,	O
to	O
determine	O
whether	O
these	O
constructs	O
inhibited	O
PHEV	O
production	O
.	O

We	O
have	O
developed	O
VIRsiRNAdb	O
,	O
a	O
manually	O
curated	O
database	O
having	O
comprehensive	O
details	O
of	O
1358	O
siRNA	O
/	O
shRNA	O
targeting	O
viral	B-COMP
genome	I-COMP
regions	O
.	O

TITLE	O
:	O
Contemporary	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
adult	O
respiratory	O
failure	O
:	O
life	O
support	O
in	O
the	O
new	O
era	O
.	O

MAS	B-COMP
results	O
from	O
aspiration	O
of	O
meconium	O
during	O
intrauterine	O
gasping	O
or	O
during	O
the	O
first	O
few	O
breaths	O
.	O

Another	O
suppressor	O
,	O
NSC158011	O
,	O
demonstrated	O
the	O
ability	O
to	O
inhibit	O
PLP	O
protease	O
activity	O
in	O
a	O
cell	B-COMP
-	O
based	O
assay	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
the	O
BToV	O
nucleocapsid	B-COMP
,	O
spike	O
,	O
and	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
genes	O
revealed	O
a	O
close	O
relatedness	O
among	O
the	O
detected	O
BToV	O
strains	O
from	O
each	O
outbreak	O
and	O
those	O
of	O
Japanese	O
BToV	O
strain	O
Aichi	O
/	O
2004	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
interhospital	O
transfer	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
:	O
5	O
-	O
year	O
experience	O
.	O

Recently	O
,	O
these	O
issues	O
were	O
addressed	O
by	O
showing	O
a	O
very	O
good	O
response	O
to	O
inducing	O
neutralizing	O
antibodies	B-COMP
by	O
plant	O
-	O
derived	O
dengue	O
vaccine	O
antigens	O
.	O

It	O
is	O
expected	O
that	O
in	O
the	O
near	O
future	O
,	O
plant	O
-	O
derived	O
vaccine	O
antigens	O
or	O
antibodies	B-COMP
will	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
human	O
infectious	O
diseases	O
.	O

ABSTRACT	O
:	O
CD4	O
T	O
cell	B-COMP
activation	O
during	O
peripheral	O
infections	O
not	O
only	O
is	O
essential	O
in	O
inducing	O
protective	O
CD8	O
T	O
cell	B-COMP
memory	O
but	O
also	O
promotes	O
CD8	O
T	O
cell	B-COMP
function	O
and	O
survival	O
.	O

We	O
report	O
the	O
development	O
of	O
CVID	O
in	O
an	O
IgA	O
-	O
and	O
IgG2	B-COMP
-	O
deficient	O
patient	O
with	O
SLE	O
on	O
the	O
basis	O
of	O
multiple	O
episodes	O
of	O
infection	O
.	O

PK	O
deficiency	O
in	O
red	O
blood	O
cells	B-COMP
is	O
known	O
to	O
result	O
in	O
human	O
hereditary	O
non	O
-	O
spherocytic	O
hemolytic	O
anemia	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
observed	O
that	O
all	O
known	O
HIV	O
-	O
1	O
broadly	O
neutralizing	O
antibodies	B-COMP
(	O
bnAbs	O
)	O
are	O
highly	O
divergent	O
from	O
germline	O
antibodies	B-COMP
in	O
contrast	O
to	O
bnAbs	O
against	O
Hendra	O
virus	O
,	O
Nipah	O
virus	O
and	O
SARS	O
coronavirus	O
(	O
SARS	O
CoV	O
).	O

We	O
have	O
hypothesized	O
that	O
because	O
the	O
germline	O
antibodies	B-COMP
are	O
so	O
different	O
from	O
the	O
mature	O
HIV	O
-	O
1	O
-	O
specific	O
bnAbs	O
they	O
may	O
not	O
bind	O
the	O
epitopes	O
of	O
the	O
mature	O
antibodies	B-COMP
and	O
provided	O
the	O
first	O
evidence	O
to	O
support	O
this	O
hypothesis	O
by	O
using	O
individual	O
putative	O
germline	O
-	O
like	O
predecessor	O
antibodies	B-COMP
.	O

The	O
modern	O
variants	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
are	O
not	O
only	O
rescue	O
alternatives	O
but	O
also	O
therapeutic	O
options	O
for	O
patients	O
with	O
severe	O
but	O
potentially	O
reversible	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Human	O
serum	B-COMP
albumin	O
:	O
from	O
bench	O
to	O
bedside	O
.	O

Mice	O
infected	O
with	O
SD	O
/	O
09	O
virus	O
showed	O
typical	O
ARDS	O
symptoms	O
characterized	O
by	O
60	O
%	O
lethality	O
on	O
days	O
8	O
-	O
10	O
post	O
-	O
inoculation	O
,	O
highly	O
edematous	O
lungs	O
,	O
inflammatory	O
cellular	B-COMP
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
lung	O
hemorrhage	O
,	O
progressive	O
and	O
severe	O
hypoxemia	O
,	O
and	O
elevated	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
.	O

Depalmitylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	O
proteins	O
abolished	O
this	O
interaction	O
,	O
resulting	O
in	O
the	O
failure	O
of	O
S	O
incorporation	O
into	O
virions	B-COMP
.	O

Serious	O
impacts	O
on	O
susceptible	O
populations	O
most	O
frequently	O
occur	O
when	O
generalist	O
pathogens	O
are	O
maintained	O
within	O
populations	O
of	O
abundant	O
(	O
often	O
domestic	O
)	O
""""	O
reservoir	O
""""	O
hosts	B-COMP
,	O
and	O
spill	O
over	O
into	O
less	O
abundant	O
host	B-COMP
species	O
.	O

However	O
,	O
pathogen	O
transmission	O
within	O
threatened	O
host	B-COMP
populations	O
may	O
also	O
be	O
important	O
,	O
and	O
may	O
not	O
be	O
controllable	O
by	O
managing	O
another	O
host	B-COMP
species	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
a	O
rescue	O
technique	O
in	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	O
A	O
/	O
H1N1	O
infection	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
will	O
be	O
advisable	O
if	O
all	O
other	O
options	O
have	O
failed	O
to	O
improve	O
oxygenation	O
.	O

The	O
centralization	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
referral	O
hospitals	O
is	O
recommended	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
antibodies	B-COMP
to	O
selected	O
viral	O
pathogens	O
in	O
wild	O
boars	O
(	O
Sus	O
scrofa	O
)	O
in	O
Croatia	O
in	O
2005	O
-	O
06	O
and	O
2009	O
-	O
10	O
.	O

ABSTRACT	O
:	O
Wild	O
Amur	O
tigers	O
(	O
Panthera	O
tigris	O
altaica	O
,	O
n	O
=	O
44	O
)	O
from	O
the	O
Russian	O
Far	O
East	O
were	O
tested	O
for	O
antibodies	B-COMP
to	O
feline	O
leukemia	O
virus	O
,	O
feline	O
corona	O
virus	O
(	O
FCoV	O
),	O
feline	O
immunodeficiency	O
virus	O
,	O
feline	O
parvovirus	O
(	O
FPV	O
),	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
Toxoplasma	O
gondii	O
,	O
and	O
Bartonella	O
henselae	O
.	O

Antibodies	B-COMP
to	O
FCoV	O
,	O
CDV	O
,	O
FPV	O
,	O
and	O
T	O
.	O
gondii	O
were	O
detected	O
in	O
43	O
,	O
15	O
,	O
68	O
,	O
and	O
42	O
%	O
of	O
tigers	O
,	O
respectively	O
.	O

These	O
observations	O
give	O
some	O
insights	O
into	O
the	O
pathogenesis	O
of	O
coronavirus	O
infection	O
and	O
are	O
thought	O
to	O
help	O
understand	O
the	O
interactions	O
between	O
sensory	O
neurons	O
and	O
their	O
satellite	O
cells	B-COMP
.	O

TITLE	O
:	O
Phosphatidylinositol	O
4	O
-	O
kinase	O
III	O
is	O
required	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
-	O
mediated	O
cell	B-COMP
entry	O
.	O

Interestingly	O
,	O
the	O
onset	O
of	O
apoptosis	O
occurred	O
earlier	O
in	O
IBV	O
-	O
infected	O
mammalian	O
cells	B-COMP
silenced	O
with	O
short	O
interfering	O
RNA	O
targeting	O
Mcl	O
-	O
1	O
(	O
siMcl	O
-	O
1	O
),	O
and	O
was	O
delayed	O
in	O
cells	B-COMP
silenced	O
with	O
siBak	O
.	O

ABSTRACT	O
:	O
In	O
vitro	O
infection	O
of	O
Vero	O
E6	O
cells	B-COMP
by	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
blocked	O
by	O
hexapeptide	O
Tyr	O
-	O
Lys	O
-	O
Tyr	O
-	O
Arg	O
-	O
Tyr	O
-	O
Leu	O
.	O

These	O
results	O
not	O
only	O
illustrate	O
the	O
detailed	O
mechanisms	O
of	O
host	B-COMP
receptor	O
adaptation	O
by	O
SARS	O
-	O
CoV	O
but	O
also	O
provide	O
a	O
molecular	O
and	O
structural	O
basis	O
for	O
tracking	O
future	O
SARS	O
-	O
CoV	O
evolution	O
in	O
animals	O
.	O

TITLE	O
:	O
SARS	O
CoV	O
subunit	O
vaccine	O
:	O
antibody	B-COMP
-	O
mediated	O
neutralisation	O
and	O
enhancement	O
.	O

Rat	O
coronavirus	O
(	O
RCoV	O
)	O
is	O
used	O
as	O
a	O
model	O
to	O
study	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
in	O
the	O
lung	O
of	O
the	O
natural	O
host	B-COMP
.	O

Both	O
catalytically	O
active	O
and	O
inactive	O
forms	O
of	O
CoV	O
PLPs	O
co	O
-	O
immunoprecipitated	O
with	O
STING	O
,	O
and	O
viral	O
replicase	O
proteins	O
co	O
-	O
localize	O
with	O
STING	O
in	O
HCoV	O
-	O
NL63	O
-	O
infected	O
cells	B-COMP
.	O

As	O
compared	O
to	O
that	O
of	O
pre	O
-	O
treatment	O
period	O
,	O
white	O
blood	O
cells	B-COMP
[	O
WBC	O
,	O
	O
10	O
(	O
9	O
)/	O
L	O
:	O
12	O
.	O
18	O
	O
4	O
.	O
76	O
vs	O
.	O
21	O
.	O
93	O
	O
6	O
.	O
21	O
],	O
neutrophil	O
percentage	O
(	O
0	O
.	O
87	O
	O
0	O
.	O
05	O
vs	O
.	O
0	O
.	O
92	O
	O
0	O
.	O
03	O
),	O
hemoglobin	O
(	O
Hb	O
,	O
g	O
/	O
L	O
:	O
128	O
.	O
12	O
	O
25	O
.	O
65	O
vs	O
.	O
173	O
.	O
71	O
	O
23	O
.	O
53	O
),	O
blood	O
platelet	O
count	O
[	O
PLT	O
,	O
10	O
(	O
9	O
)/	O
L	O
:	O
165	O
.	O
12	O
	O
31	O
.	O
70	O
vs	O
.	O
254	O
.	O
47	O
	O
70	O
.	O
80	O
],	O
alanine	O
transaminase	O
(	O
ALT	O
,	O
U	O
/	O
L	O
:	O
70	O
.	O
71	O
	O
46	O
.	O
70	O
vs	O
.	O
212	O
.	O
71	O
	O
141	O
.	O
34	O
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
,	O
U	O
/	O
L	O
:	O
52	O
.	O
47	O
	O
34	O
.	O
68	O
vs	O
.	O
82	O
.	O
41	O
	O
34	O
.	O
60	O
),	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
,	O
mmol	O
/	O
L	O
:	O
5	O
.	O
83	O
	O
4	O
.	O
09	O
vs	O
.	O
7	O
.	O
89	O
	O
5	O
.	O
96	O
),	O
serum	B-COMP
creatinine	O
(	O
SCr	O
,	O
mol	O
/	O
L	O
:	O
48	O
.	O
13	O
	O
14	O
.	O
97	O
vs	O
.	O
67	O
.	O
25	O
	O
24	O
.	O
29	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
,	O
U	O
/	O
L	O
:	O
280	O
.	O
10	O
	O
81	O
.	O
77	O
vs	O
.	O
586	O
.	O
35	O
	O
186	O
.	O
71	O
),	O
creatine	O
kinase	O
(	O
CK	O
,	O
U	O
/	O
L	O
:	O
199	O
.	O
12	O
	O
106	O
.	O
75	O
vs	O
.	O
683	O
.	O
00	O
	O
323	O
.	O
21	O
),	O
MB	O
isoenzyme	O
of	O
creatine	O
kinase	O
(	O
CK	O
-	O
MB	O
,	O
U	O
/	O
L	O
:	O
26	O
.	O
94	O
	O
9	O
.	O
13	O
vs	O
.	O
45	O
.	O
59	O
	O
11	O
.	O
21	O
),	O
serum	B-COMP
chlorine	O
anion	O
[	O
Cl	O
(-),	O
mmol	O
/	O
L	O
:	O
95	O
.	O
88	O
	O
6	O
.	O
06	O
vs	O
.	O
102	O
.	O
29	O
	O
7	O
.	O
28	O
],	O
respiratory	O
rate	O
(	O
RR	O
,	O
beats	O
/	O
min	O
:	O
20	O
.	O
88	O
	O
4	O
.	O
30	O
vs	O
.	O
30	O
.	O
06	O
	O
5	O
.	O
78	O
),	O
heart	O
rate	O
(	O
HR	O
,	O
beats	O
/	O
min	O
:	O
82	O
.	O
76	O
	O
17	O
.	O
16	O
vs	O
.	O
113	O
.	O
35	O
	O
16	O
.	O
90	O
),	O
blood	O
pH	O
value	O
(	O
7	O
.	O
34	O
	O
0	O
.	O
44	O
vs	O
.	O
7	O
.	O
39	O
	O
0	O
.	O
03	O
)	O
were	O
all	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

This	O
study	O
describes	O
ultrasensitive	O
ELISA	O
using	O
19B6	O
monoclonal	O
antibody	B-COMP
as	O
the	O
capture	O
antibody	B-COMP
and	O
IgY	O
as	O
the	O
detecting	O
antibody	B-COMP
against	O
the	O
most	O
abundant	O
SARS	O
-	O
CoV	O
NP	O
antigens	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
was	O
the	O
use	O
of	O
inexpensive	O
polyclonal	O
IgY	O
antibody	B-COMP
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
detection	O
system	O
for	O
SARS	O
-	O
CoV	O
at	O
the	O
picogram	O
level	O
.	O

DC	O
-	O
SIGN	O
mediated	O
infection	O
was	O
inhibited	O
by	O
mannan	O
and	O
anti	O
-	O
lectin	O
antibodies	B-COMP
,	O
and	O
was	O
independent	O
of	O
sialic	O
acid	O
levels	O
on	O
the	O
cell	B-COMP
.	O

TITLE	O
:	O
Impact	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
and	O
continuous	O
venovenous	O
hemodiafiltration	O
on	O
the	O
pharmacokinetics	O
of	O
oseltamivir	O
carboxylate	O
in	O
critically	O
ill	O
patients	O
with	O
pandemic	O
(	O
H1N1	O
)	O
influenza	O
.	O

TITLE	O
:	O
Dendritic	B-COMP
cell	B-COMP
targeted	O
chitosan	O
nanoparticles	O
for	O
nasal	O
DNA	O
immunization	O
against	O
SARS	O
CoV	O
nucleocapsid	B-COMP
protein	O
.	O

TITLE	O
:	O
Treatment	O
of	O
sepsis	O
and	O
ARDS	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
and	O
interventional	O
lung	O
assist	O
membrane	B-COMP
ventilator	O
in	O
a	O
patient	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

She	O
was	O
successfully	O
treated	O
with	O
extraordinary	O
life	O
support	O
measures	O
,	O
which	O
included	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
double	O
lumen	O
lung	O
ventilation	O
for	O
management	O
of	O
hemoptysis	O
,	O
and	O
lung	O
assist	O
membrane	B-COMP
ventilation	O
.	O

We	O
present	O
here	O
a	O
computational	O
analysis	O
of	O
intraviral	O
protein	O
networks	O
(	O
EBV	O
,	O
FLUAV	O
,	O
HCV	O
,	O
HSV	O
-	O
1	O
,	O
KSHV	O
,	O
SARS	O
-	O
CoV	O
,	O
VACV	O
,	O
and	O
VZV	O
)	O
and	O
virus	O
-	O
host	B-COMP
protein	O
networks	O
(	O
DENV	O
,	O
EBV	O
,	O
FLUAV	O
,	O
HCV	O
,	O
and	O
VACV	O
)	O
from	O
up	O
-	O
to	O
-	O
date	O
interaction	O
data	O
,	O
using	O
various	O
mathematical	O
approaches	O
.	O

Overlaps	O
between	O
virus	O
-	O
host	B-COMP
data	O
sets	O
identify	O
a	O
core	O
of	O
human	O
proteins	O
involved	O
in	O
the	O
cellular	B-COMP
response	O
to	O
viral	O
infection	O
and	O
in	O
the	O
viral	O
capacity	O
to	O
hijack	O
the	O
cell	B-COMP
machinery	O
for	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Technological	O
advances	O
improved	O
the	O
practice	O
of	O
""""	O
modern	O
""""	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

TITLE	O
:	O
Ameliorative	O
effect	O
of	O
a	O
microbial	O
feed	O
additive	O
on	O
infectious	O
bronchitis	O
virus	O
antibody	B-COMP
titer	O
and	O
stress	O
index	O
in	O
broiler	O
chicks	O
fed	O
deoxynivalenol	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
severe	O
hypoxemia	O
:	O
time	O
for	O
reappraisal	O
?	O

ABSTRACT	O
:	O
A	O
conserved	O
cysteine	O
-	O
rich	O
motif	O
located	O
between	O
the	O
transmembrane	B-COMP
domain	O
and	O
the	O
endodomain	O
is	O
essential	O
for	O
membrane	B-COMP
fusion	O
and	O
assembly	O
of	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Compared	O
with	O
nonobstetric	O
rabbits	O
,	O
obstetric	O
rabbits	O
had	O
more	O
severe	O
lung	O
injury	O
as	O
indicated	O
by	O
alveolar	O
and	O
interstitial	O
fluid	O
accumulation	O
and	O
marked	O
neutrophil	O
sequestration	O
and	O
greater	O
lung	O
injury	O
score	O
,	O
myeloperoxidase	O
activity	O
,	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
serum	B-COMP
tumor	O
necrosis	O
factor	O
-	O
	O
levels	O
,	O
and	O
nuclear	O
factor	O
-	O
B	O
activation	O
,	O
and	O
lower	O
serum	B-COMP
interleukin	O
-	O
10	O
levels	O
(	O
p	O
<.	O
05	O
for	O
all	O
).	O

TITLE	O
:	O
Identification	O
of	O
common	O
biological	O
pathways	O
and	O
drug	O
targets	O
across	O
multiple	O
respiratory	O
viruses	O
based	O
on	O
human	O
host	B-COMP
gene	O
expression	O
analysis	O
.	O

Pathway	O
enrichment	O
analysis	O
also	O
identified	O
a	O
potential	O
novel	O
host	B-COMP
response	O
,	O
the	O
Parkin	O
-	O
Ubiquitin	O
Proteasomal	O
System	O
(	O
Parkin	O
-	O
UPS	O
)	O
pathway	O
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
progression	O
of	O
neurodegenerative	O
Parkinson	O
'	O
s	O
disease	O
.	O

The	O
expression	O
of	O
KCTD9	O
protein	O
was	O
mainly	O
evidenced	O
in	O
infiltrative	O
mononuclear	O
cells	B-COMP
of	O
liver	O
as	O
shown	O
by	O
immunohistochemistry	O
.	O

TITLE	O
:	O
Prolonged	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
combined	O
with	O
prone	O
positioning	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
invasive	O
Aspergillosis	O
.	O

Here	O
,	O
we	O
studied	O
coronavirus	O
RNA	O
synthesis	O
by	O
feeding	O
cells	B-COMP
with	O
a	O
uridine	O
analogue	O
,	O
after	O
which	O
nascent	O
RNAs	O
were	O
detected	O
using	O
click	O
chemistry	O
.	O

The	O
proteomic	O
alterations	O
described	O
here	O
may	O
suggest	O
that	O
these	O
changes	O
to	O
protein	O
expression	O
correlate	O
with	O
IBV	O
virus	O
'	O
virulence	O
in	O
chicken	O
,	O
hence	O
provides	O
valuable	O
insights	O
into	O
the	O
interactions	O
of	O
IBV	O
with	O
its	O
host	B-COMP
and	O
may	O
also	O
assist	O
with	O
investigations	O
of	O
the	O
pathogenesis	O
of	O
IBV	O
and	O
other	O
coronavirus	O
infections	O
.	O

ABSTRACT	O
:	O
Vitamin	O
D	O
deficiency	O
is	O
known	O
to	O
be	O
common	O
among	O
patients	O
with	O
sickle	O
cell	B-COMP
anemia	O
(	O
SCA	O
).	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	B-COMP
protease	O
TMPRSS2	O
activates	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
on	O
the	O
cell	B-COMP
surface	I-COMP
following	O
receptor	O
binding	O
during	O
viral	O
entry	O
into	O
cells	B-COMP
.	O

In	O
the	O
absence	O
of	O
TMPRSS2	O
,	O
SARS	O
-	O
CoV	O
achieves	O
cell	B-COMP
entry	O
via	O
an	O
endosomal	O
pathway	O
in	O
which	O
cathepsin	O
L	O
may	O
play	O
an	O
important	O
role	O
,	O
i	O
.	O
e	O
.,	O
the	O
activation	O
of	O
spike	O
protein	O
fusogenicity	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
immunosuppressive	O
agent	O
that	O
targets	O
the	O
nuclear	O
factor	O
pathway	O
of	O
activated	O
T	O
-	O
cells	B-COMP
(	O
NF	O
-	O
AT	O
)	O
to	O
bind	O
cellular	B-COMP
cyclophilins	O
(	O
CyP	O
),	O
dose	O
-	O
dependently	O
inhibited	O
FIPV	O
replication	O
in	O
vitro	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
vitro	O
infection	O
by	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
induces	O
massive	O
cytopathic	O
effects	O
in	O
DCs	O
,	O
including	O
the	O
formation	O
of	O
large	O
syncytia	O
and	O
cell	B-COMP
death	O
within	O
only	O
few	O
hours	O
.	O

Cell	B-COMP
death	O
induced	O
by	O
HCoV	O
-	O
229E	O
is	O
independent	O
of	O
TRAIL	O
,	O
FasL	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
caspase	O
activity	O
,	O
indicating	O
that	O
viral	O
replication	O
is	O
directly	O
responsible	O
for	O
the	O
observed	O
cytopathic	O
effects	O
.	O

The	O
infection	O
is	O
an	O
intrinsic	O
property	O
of	O
the	O
virions	B-COMP
,	O
and	O
the	O
biological	O
process	O
provides	O
a	O
good	O
model	O
for	O
studying	O
how	O
these	O
nanoparticles	O
enter	O
into	O
cells	B-COMP
.	O

During	O
the	O
infection	O
,	O
the	O
viruses	O
employ	O
different	O
strategies	O
to	O
which	O
the	O
cells	B-COMP
have	O
developed	O
respective	O
responses	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
pathogenesis	O
:	O
host	B-COMP
innate	O
immune	O
responses	O
and	O
viral	O
antagonism	O
of	O
interferon	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
myricetin	O
and	O
scutellarein	O
did	O
not	O
exhibit	O
cytotoxicity	O
against	O
normal	O
breast	O
epithelial	O
MCF10A	O
cells	B-COMP
.	O

In	O
this	O
article	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
concerning	O
some	O
cellular	B-COMP
aspects	O
of	O
NOXs	O
localization	O
and	O
function	O
in	O
the	O
lungs	O
,	O
consider	O
their	O
contribution	O
in	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	O
and	O
discuss	O
the	O
place	O
of	O
NOX	O
inhibitors	O
as	O
potential	O
therapeutical	O
target	O
.	O

Virus	O
persists	O
within	O
white	O
matter	O
tracts	O
of	O
surviving	O
mice	O
resulting	O
in	O
demyelination	O
that	O
is	O
amplified	O
by	O
inflammatory	O
T	O
cells	B-COMP
and	O
macrophages	O
.	O

During	O
chronic	O
disease	O
,	O
CXCR2	O
signaling	O
on	O
oligodendroglia	O
protects	O
these	O
cells	B-COMP
from	O
apoptosis	O
and	O
restricts	O
the	O
severity	O
of	O
demyelination	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
E	O
protein	O
is	O
a	O
small	O
membrane	B-COMP
protein	O
that	O
has	O
an	O
important	O
role	O
in	O
the	O
assembly	O
of	O
virions	B-COMP
.	O

Rapid	O
evolution	O
in	O
IBV	O
is	O
facilitated	O
by	O
strong	O
selection	O
,	O
large	O
population	O
sizes	O
and	O
high	O
genetic	O
diversity	O
within	O
hosts	B-COMP
,	O
and	O
transmission	O
bottlenecks	O
between	O
hosts	B-COMP
.	O

Rapid	O
evolution	O
of	O
avian	O
coronavirus	O
IBV	O
makes	O
this	O
virus	O
extremely	O
difficult	O
to	O
diagnose	O
and	O
control	O
,	O
but	O
also	O
makes	O
it	O
an	O
excellent	O
model	O
system	O
to	O
study	O
viral	O
genetic	O
diversity	O
and	O
the	O
mechanisms	O
behind	O
the	O
emergence	O
of	O
coronaviruses	O
in	O
their	O
natural	O
host	B-COMP
.	O

Efficient	O
replication	O
of	O
CCoV	O
-	O
A76	O
is	O
restricted	O
to	O
canine	O
cell	B-COMP
lines	O
,	O
in	O
contrast	O
to	O
the	O
prototypical	O
type	O
II	O
strain	O
CCoV	O
-	O
1	O
-	O
71	O
that	O
more	O
efficiently	O
replicates	O
in	O
feline	O
cells	B-COMP
.	O

We	O
showed	O
a	O
clear	O
unwinding	O
lag	O
with	O
increasing	O
length	O
of	O
the	O
double	O
-	O
stranded	O
region	O
of	O
the	O
nucleic	B-COMP
acid	O
,	O
suggesting	O
the	O
presence	O
of	O
intermediates	O
in	O
the	O
unwinding	O
process	O
.	O

Here	O
we	O
identify	O
the	O
complex	O
comprising	O
the	O
type	O
-	O
I	O
transmembrane	B-COMP
protein	O
SEL1L	O
and	O
the	O
cytosolic	B-COMP
protein	O
LC3	O
-	O
I	O
as	O
an	O
ERAD	O
tuning	O
receptor	O
regulating	O
the	O
COPII	O
-	O
independent	O
,	O
vesicle	B-COMP
-	O
mediated	O
removal	O
of	O
the	O
lumenal	O
ERAD	O
regulators	O
EDEM1	O
and	O
OS	O
-	O
9	O
from	O
the	O
ER	O
.	O

Immunofluorescence	O
assays	O
in	O
BHK	O
-	O
21	O
cells	B-COMP
demonstrated	O
successful	O
protein	O
expression	O
from	O
all	O
3	O
constructs	O
.	O

Animals	O
were	O
examined	O
for	O
T	O
lymphocyte	O
proliferation	O
,	O
anti	O
-	O
PEDV	O
antibodies	B-COMP
,	O
IFN	O
-	O
	O
and	O
IL	O
-	O
4	O
protein	O
levels	O
,	O
and	O
cytotoxic	O
T	O
cell	B-COMP
function	O
in	O
mouse	O
peripheral	O
blood	O
and	O
spleen	O
.	O

Incidence	O
is	O
higher	O
in	O
immunocompromised	O
hosts	B-COMP
like	O
HIV	O
-	O
infected	O
individuals	O
and	O
solid	O
organ	O
transplant	O
recipients	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
feline	O
coronavirus	O
antibodies	B-COMP
in	O
Japanese	O
domestic	O
cats	O
during	O
the	O
past	O
decade	O
.	O

Among	O
purebreds	O
,	O
the	O
American	O
shorthair	O
,	O
Himalayan	O
,	O
Oriental	O
,	O
Persian	O
,	O
and	O
Siamese	O
showed	O
low	O
seroprevalence	O
,	O
while	O
the	O
American	O
curl	B-COMP
,	O
Maine	O
coon	O
,	O
Norwegian	O
forest	O
cat	O
,	O
ragdoll	O
and	O
Scottish	O
fold	O
showed	O
high	O
seroprevalence	O
.	O

The	O
crystals	O
diffracted	O
to	O
2	O
.	O
8	O
	O
resolution	O
and	O
belonged	O
to	O
space	O
group	O
P2	O
(	O
1	O
),	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
57	O
.	O
0	O
,	O
b	O
=	O
192	O
.	O
3	O
,	O
c	O
=	O
105	O
.	O
7	O
	O
,	O
	O
=	O
90	O
.	O
8	O
.	O

Collectively	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
engineered	O
antibodies	B-COMP
with	O
picomolar	O
dissociation	O
constants	O
for	O
a	O
neutralizing	O
epitope	O
can	O
confer	O
escape	O
-	O
resistant	O
protection	O
.	O

Retrocyclin	O
-	O
1	O
inhibits	O
the	O
cellular	B-COMP
entry	O
of	O
HIV	O
-	O
1	O
,	O
HSV	O
,	O
and	O
influenza	O
A	O
virus	O
.	O

Thus	O
,	O
RNase	O
L	O
is	O
a	O
critical	O
cellular	B-COMP
factor	O
for	O
protection	O
against	O
viral	O
infection	O
of	O
the	O
liver	O
and	O
the	O
resulting	O
hepatitis	O
.	O

Susceptibility	O
to	O
vectors	O
carrying	O
SARS	O
coronavirus	O
S	O
or	O
VSV	O
-	O
G	O
glycoproteins	O
suggests	O
that	O
endocytic	O
and	O
processing	O
pathways	O
utilized	O
by	O
other	O
viruses	O
are	O
intact	O
in	O
these	O
cells	B-COMP
.	O

Conversely	O
,	O
expression	O
of	O
the	O
recently	O
described	O
ebolavirus	O
host	B-COMP
entry	O
factor	O
Niemann	O
-	O
Pick	O
Type	O
C1	O
(	O
NPC1	O
)	O
restored	O
infection	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
inhibitor	O
that	O
interferes	O
with	O
the	O
nucleic	B-COMP
acid	O
unwinding	O
of	O
the	O
viral	O
helicase	O
.	O

Moreover	O
,	O
SSYA10	O
-	O
001	O
does	O
not	O
affect	O
ATP	O
hydrolysis	O
or	O
nsp13	O
binding	O
to	O
the	O
nucleic	B-COMP
acid	O
substrate	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
neutralizing	O
epitope	O
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
:	O
M	O
cell	B-COMP
targeting	O
ligand	O
fusion	O
protein	O
expressed	O
in	O
transgenic	O
rice	O
calli	O
.	O

As	O
an	O
alternative	O
treatment	O
,	O
the	O
effect	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
was	O
evaluated	O
.	O

We	O
demonstrate	O
that	O
predominant	O
population	O
of	O
DN	O
T	O
cells	B-COMP
in	O
the	O
liver	O
of	O
healthy	O
or	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
express	O
TCR	O
(+).	O

Viral	O
recognition	O
by	O
TLRs	O
and	O
other	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
has	O
been	O
proven	O
to	O
be	O
cell	B-COMP
-	O
type	O
specific	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
triggering	O
TLR2	O
,	O
TLR3	O
,	O
TLR4	O
,	O
and	O
TLR7	O
with	O
selected	O
ligands	O
on	O
the	O
susceptibility	O
of	O
the	O
J774A	O
.	O
1	O
macrophage	O
cell	B-COMP
line	O
to	O
infection	O
with	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
,	O
[	O
MHV	O
]).	O

In	O
a	O
fibrotic	O
cell	B-COMP
model	O
with	O
transforming	O
growth	O
factor	O
beta	O
-	O
1	O
induction	O
,	O
the	O
human	O
lung	O
epithelial	O
A549	O
acquired	O
a	O
mesenchymal	O
phenotype	O
and	O
an	O
increase	O
of	O
vimentin	B-COMP
expression	O
with	O
a	O
concomitant	O
decrease	O
of	O
E	O
-	O
cadherin	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
has	O
been	O
indicated	O
in	O
patients	O
with	O
severe	O
refractory	O
respiratory	O
failure	O
from	O
various	O
causes	O
for	O
more	O
than	O
30	O
years	O
,	O
even	O
for	O
the	O
small	O
infant	O
.(	O
1	O
)	O

ABSTRACT	O
:	O
Animal	O
coronaviruses	O
,	O
such	O
as	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
and	O
arteriviruses	O
,	O
such	O
as	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
are	O
able	O
to	O
manifest	O
highly	O
contagious	O
infections	O
in	O
their	O
specific	O
native	O
hosts	B-COMP
,	O
thereby	O
arising	O
in	O
critical	O
economic	O
damage	O
to	O
animal	O
industries	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
enveloped	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
that	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
.	O

It	O
is	O
classified	O
as	O
a	O
class	O
I	O
fusion	O
protein	O
,	O
and	O
is	O
responsible	O
for	O
binding	O
to	O
the	O
receptor	O
on	O
the	O
host	B-COMP
cell	I-COMP
as	O
well	O
as	O
mediating	O
the	O
fusion	O
of	O
host	B-COMP
and	O
viral	O
membranes	O
-	O
A	O
process	O
driven	O
by	O
major	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
.	O

These	O
proteins	O
are	O
involved	O
in	O
viral	O
morphogenesis	O
and	O
tropism	O
,	O
and	O
their	O
absence	O
leads	O
in	O
some	O
cases	O
to	O
aberrant	O
virions	B-COMP
,	O
or	O
to	O
viral	O
attenuation	O
.	O

In	O
common	O
to	O
other	O
viroporins	O
,	O
coronavirus	O
envelope	B-COMP
proteins	O
increase	O
membrane	B-COMP
permeability	O
to	O
ions	O
.	O

This	O
interaction	O
has	O
been	O
reinforced	O
by	O
co	O
-	O
localization	O
of	O
both	O
proteins	O
in	O
the	O
cytoplasm	B-COMP
of	O
SARS	O
-	O
CoV	O
infected	O
cells	B-COMP
.	O

Compared	O
with	O
controls	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
positive	O
granulocytes	O
and	O
monocytes	O
was	O
higher	O
among	O
sick	O
cats	O
(	O
especially	O
cats	O
with	O
diseases	O
other	O
than	O
FIP	O
)	O
and	O
cats	O
with	O
high	O
serum	B-COMP
AGP	O
concentration	O
,	O
but	O
not	O
in	O
cats	O
with	O
leucocytosis	O
or	O
that	O
were	O
FCoV	O
-	O
seropositive	O
.	O

TITLE	O
:	O
Infectious	O
bronchitis	O
virus	O
nucleoprotein	O
specific	O
CTL	O
response	O
is	O
generated	O
prior	O
to	O
serum	B-COMP
IgG	O
.	O
ABSTRACT	O
:	O
Infectious	O
bronchitis	O
(	O
IB	O
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
viral	O
respiratory	O
disease	O
of	O
chickens	O
.	O

However	O
,	O
serum	B-COMP
IgG	O
dramatically	O
increased	O
after	O
M41	O
challenge	O
.	O

We	O
previously	O
hypothesized	O
that	O
HIV	O
-	O
1	O
could	O
have	O
evolved	O
a	O
strategy	O
to	O
evade	O
the	O
immune	O
system	O
due	O
to	O
absent	O
or	O
very	O
weak	O
binding	O
of	O
germline	O
antibodies	B-COMP
to	O
the	O
conserved	O
epitopes	O
that	O
may	O
not	O
be	O
sufficient	O
to	O
initiate	O
and	O
/	O
or	O
maintain	O
an	O
effective	O
immune	O
response	O
.	O

Moreover	O
,	O
a	O
time	O
course	O
study	O
showed	O
that	O
the	O
percentage	O
of	O
both	O
IL	O
-	O
17	O
-	O
producing	O
CD4	O
(+)	O
T	O
cells	B-COMP
and	O
IL	O
-	O
17	O
-	O
producing	O
CD8	O
(+)	O
T	O
cells	B-COMP
was	O
increased	O
remarkably	O
in	O
the	O
liver	O
starting	O
from	O
48	O
h	O
and	O
peaked	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

The	O
analysis	O
reveals	O
that	O
p7	O
and	O
2B	O
TMDs	O
align	O
with	O
the	O
pore	B-COMP
-	O
facing	O
TMD	O
of	O
MscL	O
,	O
and	O
3a	O
-	O
TMDs	O
align	O
with	O
those	O
of	O
ligand	O
-	O
gated	O
ion	O
channels	O
.	O

TITLE	O
:	O
Clara	O
cell	B-COMP
protein	O
16	O
:	O
A	O
biomarker	O
for	O
detecting	O
secondary	O
respiratory	O
complications	O
in	O
patients	O
with	O
multiple	O
injuries	O
.	O

In	O
the	O
latter	O
patients	O
,	O
median	O
CC16	O
serum	B-COMP
levels	O
were	O
significantly	O
elevated	O
(	O
14	O
.	O
5	O
ng	O
/	O
mL	O
)	O
at	O
the	O
onset	O
of	O
pneumonia	O
compared	O
with	O
their	O
levels	O
(	O
7	O
.	O
3	O
ng	O
/	O
mL	O
)	O
1	O
day	O
before	O
.	O

Analytical	O
specificity	O
was	O
confirmed	O
using	O
Canine	O
and	O
Feline	O
coronavirus	O
,	O
Giardia	O
spp	O
.,	O
and	O
noninfected	O
bovine	O
purified	O
nucleic	B-COMP
acid	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
S	O
protein	O
maturation	O
in	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
by	O
calnexin	O
is	O
important	O
for	O
the	O
infectivity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
results	O
of	O
this	O
experiment	O
indicate	O
that	O
the	O
number	O
of	O
total	O
cells	B-COMP
and	O
neutrophils	O
and	O
the	O
concentration	O
of	O
protein	O
exudation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
significantly	O
decreased	O
in	O
the	O
MCR	O
-	O
LPS	O
group	O
.	O

Observation	O
of	O
the	O
cytopathic	O
effect	O
and	O
apoptosis	O
,	O
as	O
well	O
as	O
a	O
cell	B-COMP
proliferation	O
assay	O
demonstrated	O
that	O
the	O
three	O
shRNAs	O
were	O
capable	O
of	O
protecting	O
ST	O
cells	B-COMP
against	O
TGEV	O
destruction	O
,	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

TITLE	O
:	O
WFDC1	O
/	O
ps20	O
:	O
a	O
host	B-COMP
factor	O
that	O
influences	O
the	O
neutrophil	O
response	O
to	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
1	O
infection	O
.	O

Characterization	O
of	O
the	O
immune	O
cell	B-COMP
profile	O
in	O
nave	O
ps20	O
(-/-)	O
mice	O
revealed	O
an	O
increase	O
in	O
circulating	O
neutrophils	O
compared	O
to	O
ps20	O
(+/+)	O
mice	O
.	O

We	O
revealed	O
that	O
administration	O
of	O
PGRN	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	B-COMP
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
.	O

all	O
sera	B-COMP
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
were	O
the	O
ELISA	O
positive	O
(	O
100	O
%	O
sensitivity	O
).	O

While	O
SARS	O
-	O
CoV	O
,	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
MA15	O
),	O
and	O
chimeric	O
SARS	O
-	O
CoVs	O
bearing	O
the	O
spike	O
genes	O
of	O
early	O
human	O
strains	O
replicated	O
inefficiently	O
,	O
HCoV	O
-	O
NL63	O
replicated	O
for	O
multiple	O
passages	O
in	O
the	O
immortalized	O
lung	O
cells	B-COMP
from	O
this	O
bat	O
species	O
.	O

In	O
other	O
cell	B-COMP
lines	O
,	O
the	O
virus	O
cannot	O
be	O
propagated	O
beyond	O
passage	O
5	O
.	O

To	O
test	O
this	O
,	O
we	O
created	O
bone	O
marrow	O
chimeras	O
and	O
cell	B-COMP
-	O
type	O
-	O
specific	O
knockouts	O
of	O
STAT1	O
to	O
identify	O
which	O
cell	B-COMP
type	I-COMP
(	O
s	O
)	O
is	O
critical	O
to	O
protection	O
from	O
severe	O
lung	O
disease	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

Repeated	O
lung	O
lavage	O
combined	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
was	O
performed	O
after	O
transferring	O
to	O
the	O
ICU	O
of	O
our	O
hospital	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
respiratory	O
virus	O
(	O
CARV	O
)	O
infections	O
have	O
been	O
recognized	O
as	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
leukemia	O
and	O
those	O
undergoing	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
HSCT	O
).	O

One	O
hybridoma	O
cell	B-COMP
line	O
secreting	O
anti	O
-	O
M	O
protein	O
monoclonal	O
antibody	B-COMP
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

The	O
relevance	O
of	O
the	O
selection	O
process	O
has	O
been	O
further	O
understood	O
more	O
recently	O
by	O
identifying	O
genetic	O
and	O
phenotypic	O
differences	O
between	O
IBV	O
populations	O
prior	O
to	O
,	O
and	O
during	O
,	O
replication	O
in	O
the	O
natural	O
host	B-COMP
.	O

Most	O
importantly	O
for	O
the	O
current	O
study	O
,	O
chickens	O
vaccinated	O
with	O
the	O
different	O
vaccines	O
displayed	O
significant	O
differences	O
in	O
specific	O
B	O
-	O
lymphocyte	O
responses	O
in	O
the	O
Harderian	O
gland	O
(	O
i	O
.	O
e	O
.,	O
the	O
challenge	O
virus	O
encountered	O
differing	O
immune	O
selective	O
pressure	O
during	O
invasion	O
among	O
host	B-COMP
groups	O
).	O

The	O
mean	O
level	O
of	O
anti	O
-	O
B	O
-	O
crystallin	O
antibodies	B-COMP
in	O
non	O
-	O
COPD	O
smokers	O
was	O
0	O
.	O
291	O
nm	O
.	O

Antibodies	B-COMP
to	O
FPV	O
,	O
FCV	O
,	O
FIV	O
,	O
and	O
T	O
.	O
gondii	O
were	O
found	O
in	O
domestic	O
cats	O
.	O

These	O
structural	O
features	O
enable	O
APN	O
to	O
function	O
ubiquitously	O
in	O
peptide	O
metabolism	O
,	O
interact	O
with	O
other	O
proteins	O
to	O
mediate	O
cell	B-COMP
motility	O
and	O
adhesion	O
,	O
and	O
serve	O
as	O
a	O
coronavirus	O
receptor	O
.	O

EXTRACORPOREAL	O
LUNG	O
SUPPORT	O
TECHNOLOGIES	O
:	O
ECMO	O
:	O
The	O
ECMO	O
system	O
consists	O
of	O
a	O
centrifugal	O
pump	O
,	O
a	O
membrane	B-COMP
oxygenator	O
,	O
inlet	O
and	O
outlet	O
cannulas	O
,	O
and	O
tubing	O
.	O

ABSTRACT	O
:	O
Danger	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
)	O
are	O
host	B-COMP
-	O
derived	O
molecules	O
that	O
can	O
function	O
to	O
regulate	O
the	O
activation	O
of	O
pathogen	O
recognition	O
receptors	O
(	O
PRRs	O
).	O

TITLE	O
:	O
[	O
If	O
the	O
extracorporeal	O
lung	O
assist	O
comes	O
to	O
its	O
limit	O
:	O
use	O
and	O
management	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

ABSTRACT	O
:	O
Coronavirus	O
replicase	O
nsp4	O
is	O
critical	O
for	O
virus	O
-	O
induced	O
membrane	B-COMP
modifications	O
.	O

TITLE	O
:	O
Epstein	O
-	O
Barr	O
virus	O
-	O
induced	O
gene	O
3	O
negatively	O
regulates	O
neuroinflammation	O
and	O
T	O
cell	B-COMP
activation	O
following	O
coronavirus	O
-	O
induced	O
encephalomyelitis	O
.	O

The	O
polyclonal	O
antibodies	B-COMP
also	O
potently	O
cross	O
-	O
neutralized	O
viruses	O
from	O
the	O
same	O
serogroup	O
.	O

TITLE	O
:	O
Biogenesis	O
of	O
the	O
vaccinia	O
virus	O
membrane	B-COMP
:	O
genetic	O
and	O
ultrastructural	O
analysis	O
of	O
the	O
contributions	O
of	O
the	O
A14	O
and	O
A17	O
proteins	O
.	O

ABSTRACT	O
:	O
Vaccinia	O
virus	O
membrane	B-COMP
biogenesis	O
requires	O
the	O
A14	O
and	O
A17	O
proteins	O
.	O

When	O
N	O
-	O
terminal	O
processing	O
was	O
abrogated	O
,	O
virions	B-COMP
attempted	O
to	O
undergo	O
the	O
IV	O
-	O
to	O
-	O
MV	O
transition	O
without	O
removing	O
the	O
D13	O
scaffold	O
and	O
were	O
therefore	O
noninfectious	O
and	O
structurally	O
aberrant	O
.	O

The	O
N	O
-	O
terminal	O
most	O
domain	O
of	O
nsp3	O
,	O
nsp3a	O
,	O
has	O
been	O
identified	O
by	O
reverse	O
genetics	O
as	O
a	O
likely	O
binding	O
partner	O
of	O
MHV	O
nucleocapsid	B-COMP
protein	O
.	O

After	O
3	O
days	O
of	O
hospitalization	O
,	O
the	O
APACHEII	O
,	O
score	O
SAA	O
levels	O
,	O
serum	B-COMP
CRP	O
and	O
IL	O
-	O
6	O
in	O
the	O
treatment	O
group	O
was	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Three	O
assays	O
were	O
conducted	O
:	O
inhibition	O
of	O
cancer	O
cell	B-COMP
proliferation	O
,	O
inhibition	O
of	O
TGEV	O
replication	O
for	O
anticoronavirus	O
activity	O
,	O
and	O
suppression	O
of	O
nitric	O
oxide	O
production	O
in	O
RAW264	O
.	O
7	O
cells	B-COMP
(	O
a	O
measure	O
of	O
anti	O
-	O
inflammation	O
).	O

We	O
have	O
determined	O
the	O
complete	O
genome	O
of	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
using	O
an	O
unbiased	O
virus	O
discovery	O
approach	O
involving	O
next	O
-	O
generation	O
sequencing	O
techniques	O
,	O
which	O
enabled	O
subsequent	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
bioinformatics	O
,	O
phylogenetics	O
,	O
and	O
taxonomic	O
analyses	O
.	O

Using	O
the	O
purified	O
recombinant	O
NP	O
as	O
an	O
antigen	O
,	O
a	O
polyclonal	O
antibody	B-COMP
from	O
rabbit	O
serum	B-COMP
with	O
specificity	O
for	O
HCoV	O
-	O
OC43	O
NP	O
was	O
generated	O
;	O
this	O
antibody	B-COMP
reacts	O
specifically	O
with	O
HCoV	O
-	O
OC43	O
NP	O
and	O
does	O
not	O
cross	O
-	O
react	O
with	O
other	O
human	O
CoV	O
NPs	O
(	O
including	O
those	O
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
229E	O
)	O
by	O
Western	O
blot	O
.	O

The	O
effect	O
of	O
an	O
ORF3	O
deletion	O
was	O
less	O
pronounced	O
,	O
indicating	O
only	O
a	O
supportive	O
role	O
of	O
ORF3	O
encoded	O
proteins	O
during	O
the	O
infection	O
of	O
the	O
in	O
vivo	O
target	O
cell	B-COMP
by	O
FIPVs	O
.	O

EAV	O
replication	O
could	O
be	O
fully	O
restored	O
in	O
these	O
cells	B-COMP
by	O
expression	O
of	O
a	O
nonlipidated	O
form	O
of	O
LC3	O
.	O

We	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
as	O
bait	O
the	O
carboxy	O
-	O
terminal	O
endodomain	O
of	O
S	O
,	O
which	O
faces	O
the	O
cytosol	B-COMP
during	O
and	O
after	O
opening	O
of	O
the	O
fusion	O
pore	B-COMP
at	O
early	O
stages	O
of	O
the	O
virus	O
life	O
cycle	O
.	O

Viability	O
assays	O
revealed	O
that	O
E	O
.	O
faecium	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
rescue	O
of	O
viability	O
of	O
TGEV	O
-	O
infected	O
cells	B-COMP
reaching	O
nearly	O
to	O
complete	O
protection	O
.	O

Prospective	O
studies	O
with	O
viral	O
load	O
determination	O
and	O
asymptomatic	O
controls	O
are	O
needed	O
to	O
study	O
the	O
association	O
of	O
these	O
emerging	O
respiratory	O
viruses	O
with	O
LRTI	O
in	O
children	O
with	O
cancer	O
and	O
posthematopoietic	O
stem	O
cell	B-COMP
transplant	O
.	O

A	O
current	O
focus	O
of	O
funding	O
agencies	O
,	O
and	O
hence	O
research	O
,	O
is	O
the	O
development	O
of	O
broad	O
-	O
spectrum	O
antivirals	O
,	O
and	O
in	O
particular	O
,	O
those	O
targeting	O
common	O
cellular	B-COMP
pathways	O
.	O

Renal	O
replacement	O
therapy	O
contributed	O
to	O
patient	O
survival	O
,	O
with	O
improvement	O
of	O
oxygenation	O
and	O
a	O
dramatic	O
decrease	O
in	O
serum	B-COMP
cytokine	O
levels	O
if	O
initiated	O
earlier	O
.	O

ViPR	O
provides	O
access	O
to	O
sequence	O
records	O
,	O
gene	O
and	O
protein	O
annotations	O
,	O
immune	O
epitopes	O
,	O
3D	O
structures	O
,	O
host	B-COMP
factor	O
data	O
,	O
and	O
other	O
data	O
types	O
through	O
an	O
intuitive	O
web	O
-	O
based	O
search	O
interface	O
.	O

ABSTRACT	O
:	O
Inoculation	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
susceptible	O
strains	O
of	O
mice	O
results	O
in	O
an	O
acute	O
encephalomyelitis	O
in	O
which	O
virus	O
preferentially	O
replicates	O
within	O
glial	O
cells	B-COMP
while	O
excluding	O
neurons	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
EMC	B-COMP
does	O
not	O
require	O
the	O
SARS	O
-	O
coronavirus	O
receptor	O
and	O
maintains	O
broad	O
replicative	O
capability	O
in	O
mammalian	O
cell	B-COMP
lines	O
.	O

Our	O
results	O
implicate	O
that	O
the	O
new	O
virus	O
might	O
use	O
a	O
receptor	O
that	O
is	O
conserved	O
between	O
bats	O
,	O
pigs	O
and	O
humans	O
suggesting	O
a	O
low	O
barrier	O
against	O
cross	O
-	O
host	B-COMP
transmission	O
.	O

By	O
contrast	O
,	O
the	O
absence	O
of	O
B7	O
-	O
H1	O
enhances	O
CD8	O
T	O
-	O
cell	B-COMP
function	O
and	O
accelerates	O
viral	O
control	O
,	O
but	O
increases	O
morbidity	O
.	O

A	O
total	O
of	O
288	O
samples	O
were	O
tested	O
:	O
165	O
samples	O
were	O
collected	O
from	O
patients	O
with	O
suspected	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	O
during	O
the	O
first	O
pandemic	O
wave	O
in	O
2009	O
;	O
and	O
123	O
samples	O
were	O
collected	O
from	O
patients	O
of	O
a	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
program	O
in	O
2008	O
-	O
2009	O
.	O

There	O
was	O
no	O
difference	O
in	O
virus	O
growth	O
,	O
whereas	O
clear	O
differences	O
between	O
these	O
two	O
virus	O
infections	O
existed	O
in	O
the	O
type	O
of	O
target	O
cells	B-COMP
infected	O
,	O
the	O
spread	O
of	O
virus	O
and	O
the	O
cytokine	O
levels	O
produced	O
in	O
the	O
brain	O
.	O

TITLE	O
:	O
Rapid	O
NK	O
-	O
cell	B-COMP
activation	O
in	O
chicken	O
after	O
infection	O
with	O
infectious	O
bronchitis	O
virus	O
M41	O
.	O

ABSTRACT	O
:	O
Chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	O
2	O
(	O
CCL2	O
),	O
a	O
chemoattractant	O
for	O
macrophages	O
,	O
T	O
cells	B-COMP
,	O
and	O
cells	B-COMP
expressing	O
CCR2	O
,	O
is	O
upregulated	O
during	O
acute	O
and	O
chronic	O
inflammation	O
.	O

We	O
have	O
previously	O
determined	O
the	O
minimal	O
mechanism	O
of	O
helicase	O
function	O
by	O
nsp13	O
where	O
we	O
demonstrated	O
that	O
the	O
enzyme	O
unwinds	O
nucleic	B-COMP
acid	O
in	O
discrete	O
steps	O
of	O
9	O
.	O
3	O
base	O
	O
pairs	O
each	O
with	O
a	O
catalytic	O
rate	O
of	O
30	O
steps	O
per	O
second	O
.	O

TITLE	O
:	O
RNA	O
dimerization	O
plays	O
a	O
role	O
in	O
ribosomal	B-COMP
frameshifting	O
of	O
the	O
SARS	O
coronavirus	O
.	O

Furthermore	O
,	O
the	O
inability	O
to	O
dimerize	O
caused	O
by	O
the	O
silent	O
codon	O
change	O
in	O
Stem	O
3	O
of	O
SARS	O
-	O
CoV	O
changed	O
the	O
viral	O
growth	O
kinetics	O
and	O
affected	O
the	O
levels	O
of	O
genomic	O
and	O
subgenomic	O
RNA	O
in	O
infected	O
cells	B-COMP
.	O

HLA	O
tetramers	O
with	O
redirected	O
specificity	O
could	O
detect	O
antigen	O
-	O
specific	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
responses	O
against	O
human	O
cytomegalovirus	O
,	O
hepatitis	O
B	O
(	O
HBV	O
),	O
dengue	O
virus	O
(	O
DENV	O
),	O
and	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infections	O
.	O

This	O
flow	O
cytometry	O
-	O
based	O
technology	O
therefore	O
holds	O
considerable	O
promise	O
for	O
monitoring	O
clinically	O
relevant	O
antigen	O
-	O
specific	O
T	O
-	O
cell	B-COMP
responses	O
in	O
populations	O
of	O
distinct	O
ethnicity	O
.	O

In	O
a	O
multi	O
-	O
variate	O
Cox	O
regression	O
model	O
,	O
pre	O
-	O
ECMO	O
factors	O
including	O
lower	O
PaO2	O
/	O
FiO2	O
and	O
increasing	O
white	O
blood	O
cell	B-COMP
count	O
were	O
associated	O
with	O
increased	O
risks	O
of	O
death	O
(	O
RR	O
was	O
0	O
.	O
733	O
,	O
1	O
.	O
701	O
respectively	O
,	O
both	O
P	O
values	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
study	O
of	O
11	O
cases	O
].	O

Alternatively	O
,	O
the	O
rate	O
of	O
sweep	O
gas	O
flow	O
through	O
the	O
membrane	B-COMP
lung	O
determined	O
blood	O
decarboxylation	O
,	O
while	O
PaCO2	O
(	O
arterial	O
carbon	O
dioxide	O
tension	O
)	O
was	O
unaffected	O
when	O
the	O
ECMO	O
blood	O
flow	O
and	O
FiO	O
(	O
2ECMO	O
)	O
were	O
reduced	O
to	O
<	O
2	O
.	O
5	O
L	O
/	O
min	O
and	O
40	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Microbial	O
infections	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
are	O
often	O
associated	O
with	O
local	O
accumulation	O
of	O
antibody	B-COMP
(	O
Ab	O
)-	O
secreting	O
cells	B-COMP
(	O
ASC	O
).	O

However	O
,	O
neither	O
CXCL9	O
nor	O
CXCL10	O
deficiency	O
diminished	O
neutralizing	O
serum	B-COMP
Ab	O
,	O
supporting	O
a	O
direct	O
role	O
for	O
CXCL10	O
in	O
ASC	O
migration	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
positive	O
-	O
sense	O
,	O
single	O
-	O
stranded	O
,	O
enveloped	O
RNA	O
viruses	O
that	O
infect	O
a	O
variety	O
of	O
vertebrate	O
hosts	B-COMP
.	O

The	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
contains	O
two	O
structurally	O
independent	O
RNA	O
binding	O
domains	O
,	O
designated	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
and	O
the	O
dimeric	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
joined	O
by	O
a	O
charged	O
linker	O
region	O
rich	O
in	O
serine	O
and	O
arginine	O
residues	O
(	O
SR	O
-	O
rich	O
linker	O
).	O

Three	O
bovine	O
nasal	O
samples	O
infected	O
with	O
bovine	O
coronavirus	O
were	O
used	O
to	O
infect	O
human	O
and	O
bovine	O
macrophage	O
and	O
lung	O
cell	B-COMP
lines	O
.	O

RESULTS	O
:	O
133	O
participants	O
had	O
one	O
or	O
more	O
of	O
the	O
following	O
risk	O
factors	O
:	O
body	O
mass	O
index	O
<	O
16	O
-	O
18	O
.	O
5	O
(	O
kg	O
/	O
m	O
(	O
2	O
)),	O
unintentional	O
weight	O
loss	O
>	O
15	O
%	O
in	O
the	O
preceding	O
3	O
-	O
6	O
months	O
,	O
very	O
little	O
or	O
no	O
nutritional	O
intake	O
>	O
10	O
days	O
,	O
history	O
of	O
alcohol	O
or	O
drug	O
abuse	O
and	O
low	O
baseline	O
levels	O
of	O
serum	B-COMP
potassium	O
,	O
phosphate	O
or	O
magnesium	O
prior	O
to	O
recruitment	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
EMC	B-COMP
is	O
not	O
the	O
same	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Microtubule	B-COMP
-	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
(	O
MAP1LC3	O
/	O
LC3	O
)	O
is	O
an	O
important	O
marker	O
for	O
autophagy	O
and	O
is	O
used	O
to	O
follow	O
autophagosome	B-COMP
formation	O
.	O

These	O
vectors	O
can	O
be	O
used	O
as	O
tools	O
to	O
visualize	O
autophagosome	B-COMP
formation	O
and	O
fusion	O
with	O
endosomes	O
/	O
lysosomes	B-COMP
in	O
avian	O
cells	B-COMP
and	O
provide	O
a	O
valuable	O
resource	O
for	O
studying	O
autophagy	O
in	O
avian	O
cells	B-COMP
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
E	O
protein	O
causes	O
endoplasmic	B-COMP
reticulum	I-COMP
stress	O
and	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	O
.	O

ABSTRACT	O
:	O
In	O
previous	O
studies	O
,	O
differences	O
in	O
the	O
amount	O
of	O
genomic	O
and	O
subgenomic	O
RNA	O
produced	O
by	O
coronaviruses	O
with	O
mutations	O
in	O
the	O
programmed	O
ribosomal	B-COMP
frameshift	O
signal	O
of	O
ORF1a	O
/	O
b	O
were	O
observed	O
.	O

Hantavirus	O
serology	O
(	O
immunofluorescence	O
antibody	B-COMP
assay	O
):	O
1	O
:	O
2048	O
;	O
serotype	O
Puumala	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
performed	O
to	O
characterize	O
respiratory	O
viral	O
infections	O
in	O
pediatric	O
patients	O
undergoing	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
HSCT	O
).	O

Across	O
intracellular	B-COMP
and	O
extracellular	B-COMP
GSH	O
pools	O
in	O
alveolar	O
type	O
II	O
cells	B-COMP
and	O
alveolar	O
macrophages	O
,	O
chronic	O
alcohol	O
ingestion	O
consistently	O
induced	O
a	O
40	O
-	O
60	O
mV	O
oxidation	O
of	O
GSH	O
/	O
GSSG	O
suggesting	O
that	O
the	O
redox	O
potentials	O
of	O
different	O
alveolar	O
GSH	O
pools	O
are	O
in	O
equilibrium	O
.	O

Chimera	O
experiments	O
demonstrated	O
that	O
the	O
transfer	O
of	O
WT	O
but	O
not	O
ADORA2A	O
(-/-)	O
bone	O
marrow	O
cells	B-COMP
into	O
irradiated	O
ADORA2A	O
(-/-)	O
mice	O
reduced	O
lung	O
injury	O
after	O
LPS	O
plus	O
oxygen	O
,	O
demonstrating	O
myeloid	O
ADORA2A	O
protection	O
.	O

TITLE	O
:	O
Analysis	O
of	O
a	O
QX	O
-	O
like	O
avian	O
infectious	O
bronchitis	O
virus	O
genome	O
identified	O
recombination	O
in	O
the	O
region	O
containing	O
the	O
ORF	O
5a	O
,	O
ORF	O
5b	O
,	O
and	O
nucleocapsid	B-COMP
protein	O
gene	O
sequences	O
.	O

Recombination	O
analysis	O
showed	O
that	O
Sczy3	O
is	O
a	O
chimeric	O
strain	O
derived	O
from	O
LX4	O
(	O
major	O
parental	O
sequence	O
)	O
and	O
H120	O
(	O
minor	O
parental	O
sequence	O
)	O
suggesting	O
that	O
recombination	O
occurred	O
in	O
a	O
region	O
containing	O
the	O
3	O
'	O
terminal	O
5a	O
sequence	O
(	O
83	O
nt	O
),	O
the	O
5	O
'	O
terminal	O
5b	O
sequence	O
(	O
222	O
nt	O
),	O
and	O
the	O
5	O
'	O
terminal	O
nucleocapsid	B-COMP
protein	O
gene	O
sequence	O
(	O
132	O
nt	O
).	O

TITLE	O
:	O
Release	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nuclear	O
import	O
block	O
enhances	O
host	B-COMP
transcription	O
in	O
human	O
lung	O
cells	B-COMP
.	O

Critical	O
illness	O
is	O
the	O
result	O
of	O
significant	O
tissue	O
damage	O
,	O
due	O
to	O
cellular	B-COMP
ischemia	O
,	O
trauma	O
or	O
infection	O
,	O
inducing	O
a	O
systemic	O
inflammatory	O
syndrome	O
.	O

Septic	O
PMVEC	O
hyper	O
-	O
permeability	O
was	O
also	O
attenuated	O
following	O
treatment	O
with	O
culture	O
medium	O
conditioned	O
by	O
previous	O
incubation	O
with	O
either	O
nave	O
or	O
cytomix	O
-	O
treated	O
A549	O
cells	B-COMP
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
this	O
protective	O
effect	O
of	O
A549	O
cell	B-COMP
-	O
conditioned	O
medium	O
was	O
both	O
heat	O
-	O
stable	O
and	O
transferable	O
following	O
lipid	O
extraction	O
.	O

Two	O
ArkDPI	O
-	O
derived	O
vaccines	O
that	O
contain	O
a	O
higher	O
proportion	O
of	O
viruses	O
with	O
S1	O
genes	O
that	O
become	O
selected	O
during	O
replication	O
in	O
chickens	O
exhibited	O
more	O
rapid	O
establishment	O
of	O
those	O
selected	O
subpopulations	O
in	O
chickens	O
,	O
produced	O
significantly	O
higher	O
viral	O
loads	O
in	O
tears	O
,	O
and	O
induced	O
higher	O
antibody	B-COMP
responses	O
compared	O
with	O
two	O
other	O
ArkDPI	O
vaccines	O
with	O
lower	O
proportions	O
of	O
viruses	O
that	O
become	O
selected	O
in	O
chickens	O
.	O

TITLE	O
:	O
Innate	O
immune	O
response	O
of	O
human	O
alveolar	O
type	O
II	O
cells	B-COMP
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
.	O

Viral	O
antigens	O
were	O
detected	O
in	O
the	O
cytoplasm	B-COMP
of	O
infected	O
type	O
II	O
cells	B-COMP
,	O
electron	O
micrographs	O
demonstrated	O
secretory	B-COMP
vesicles	I-COMP
filled	O
with	O
virions	B-COMP
,	O
virus	O
RNA	O
concentrations	O
increased	O
with	O
time	O
,	O
and	O
infectious	O
virions	B-COMP
were	O
released	O
by	O
exocytosis	O
from	O
the	O
apical	O
surface	O
of	O
polarized	O
type	O
II	O
cells	B-COMP
.	O

A	O
surprising	O
finding	O
involved	O
the	O
variability	O
of	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
,	O
the	O
SARS	O
-	O
CoV	O
receptor	O
,	O
in	O
type	O
II	O
cells	B-COMP
from	O
different	O
donors	O
.	O

For	O
future	O
pandemics	O
,	O
this	O
study	O
identified	O
the	O
need	O
for	O
all	O
staff	O
to	O
have	O
a	O
basic	O
understanding	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
;	O
strengthen	O
inter	O
-	O
professional	O
collaboration	O
and	O
communication	O
;	O
provision	O
for	O
more	O
support	O
and	O
recognition	O
of	O
these	O
highly	O
specialized	O
nurses	O
,	O
along	O
with	O
providing	O
regular	O
pandemic	O
updates	O
and	O
offering	O
counselling	O
services	O
.	O

ABSTRACT	O
:	O
Bovine	O
torovirus	O
(	O
BToV	O
)-	O
Aichi	O
,	O
recently	O
isolated	O
in	O
cultured	O
cells	B-COMP
,	O
showed	O
hemagglutination	O
(	O
HA	O
)	O
activity	O
,	O
although	O
the	O
virus	O
has	O
a	O
truncated	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
protein	O
,	O
judging	O
from	O
its	O
gene	O
structure	O
,	O
indicating	O
the	O
existence	O
of	O
another	O
viral	O
protein	O
with	O
HA	O
activity	O
.	O

TITLE	O
:	O
Efficient	O
replication	O
of	O
the	O
novel	O
human	O
betacoronavirus	O
EMC	B-COMP
on	O
primary	O
human	O
epithelium	O
highlights	O
its	O
zoonotic	O
potential	O
.	O

Closely	O
related	O
coronaviruses	O
replicate	O
in	O
bats	O
,	O
suggesting	O
that	O
,	O
like	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
EMC	B-COMP
is	O
of	O
zoonotic	O
origin	O
.	O

Importantly	O
,	O
type	O
I	O
and	O
type	O
III	O
interferon	O
treatment	O
can	O
efficiently	O
reduce	O
HCoV	O
-	O
EMC	B-COMP
replication	O
in	O
the	O
human	O
airway	O
epithelium	O
,	O
providing	O
a	O
possible	O
avenue	O
for	O
treatment	O
of	O
emerging	O
virus	O
infections	O
.	O

ABSTRACT	O
:	O
A	O
strong	O
cell	B-COMP
-	O
mediated	O
immunity	O
(	O
CMI	O
)	O
is	O
thought	O
to	O
be	O
indispensable	O
for	O
protection	O
against	O
infection	O
with	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
in	O
cats	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	B-COMP
and	O
regulatory	O
T	O
cells	B-COMP
(	O
Tregs	O
),	O
central	O
players	O
in	O
the	O
innate	O
and	O
adaptive	O
CMI	O
respectively	O
,	O
was	O
examined	O
during	O
natural	O
FIPV	O
infection	O
.	O

Phenotypic	O
analysis	O
of	O
blood	O
-	O
derived	O
NK	O
cells	B-COMP
in	O
FIP	O
cats	O
revealed	O
an	O
upregulation	O
of	O
activation	O
markers	O
(	O
CD16	O
and	O
CD25	O
)	O
and	O
migration	O
markers	O
(	O
CD11b	O
and	O
CD62L	O
)	O
while	O
LN	O
-	O
derived	O
NK	O
cells	B-COMP
showed	O
upregulation	O
of	O
only	O
CD16	O
and	O
CD62L	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
PS	O
is	O
pivotal	O
in	O
the	O
selection	O
of	O
viral	O
genomic	O
RNA	O
for	O
incorporation	O
into	O
virions	B-COMP
.	O

However	O
,	O
HCoV	O
-	O
EMC	B-COMP
was	O
markedly	O
more	O
sensitive	O
to	O
the	O
antiviral	O
state	O
established	O
by	O
ectopic	O
IFN	O
.	O

Thus	O
,	O
HCoV	O
-	O
EMC	B-COMP
can	O
utilize	O
a	O
broad	O
range	O
of	O
human	O
cell	B-COMP
substrates	O
and	O
suppress	O
IFN	O
induction	O
,	O
but	O
it	O
does	O
not	O
reach	O
the	O
IFN	O
resistance	O
of	O
SARS	O
-	O
CoV	O
.	O

In	O
addition	O
,	O
they	O
define	O
TMPRSS2	O
and	O
cathepsins	O
B	O
and	O
L	O
as	O
potential	O
targets	O
for	O
intervention	O
and	O
suggest	O
that	O
neutralizing	O
antibodies	B-COMP
contribute	O
to	O
the	O
control	O
of	O
hCoV	O
-	O
EMC	B-COMP
infection	O
.	O

Antibodies	B-COMP
to	O
T	O
.	O
gondii	O
were	O
found	O
in	O
26	O
.	O
5	O
%	O
(	O
18	O
/	O
68	O
)	O
Megaderma	O
lyra	O
,	O
13	O
.	O
6	O
%	O
(	O
12	O
/	O
88	O
)	O
Rousettus	O
leschenaulti	O
,	O
13	O
.	O
6	O
%	O
(	O
3	O
/	O
22	O
)	O
Cynopterus	O
sphinx	O
,	O
20	O
%	O
(	O
4	O
/	O
20	O
)	O
Vespertilio	O
superaus	O
,	O
and	O
15	O
.	O
8	O
%	O
(	O
3	O
/	O
19	O
)	O
Pipistrellus	O
javanicus	O
.	O

The	O
status	O
of	O
79	O
dairy	O
herds	O
located	O
in	O
two	O
Northern	O
and	O
two	O
Southern	O
Regions	O
of	O
Sweden	O
were	O
surveyed	O
by	O
measuring	O
antibody	B-COMP
concentrations	O
to	O
BCV	O
and	O
BRSV	O
in	O
pooled	O
milk	O
samples	O
from	O
primiparous	O
cows	O
,	O
and	O
in	O
bulk	O
-	O
tank	O
milk	O
twice	O
annually	O
.	O

A	O
myocardial	O
biopsy	O
was	O
taken	O
to	O
exclude	O
giant	O
cell	B-COMP
myocarditis	O
.	O

The	O
immediate	O
initiation	O
of	O
a	O
mechanical	O
circulatory	O
support	O
by	O
an	O
Extracorporal	O
Membrane	B-COMP
Oxygenator	O
(	O
ECMO	O
)	O
facilitated	O
rapid	O
hemodynamic	O
stabilization	O
and	O
recovery	O
of	O
organ	O
function	O
.	O

Synthetic	O
peptides	O
corresponding	O
to	O
each	O
of	O
its	O
three	O
individual	O
transmembrane	B-COMP
domains	O
(	O
TMDs	O
)	O
are	O
reconstituted	O
into	O
artificial	O
lipid	O
bilayers	O
.	O

TITLE	O
:	O
Dipeptidyl	O
peptidase	O
4	O
is	O
a	O
functional	O
receptor	O
for	O
the	O
emerging	O
human	O
coronavirus	O
-	O
EMC	B-COMP
.	O

Expression	O
of	O
human	O
and	O
bat	O
(	O
Pipistrellus	O
pipistrellus	O
)	O
DPP4	O
in	O
non	O
-	O
susceptible	O
COS	O
-	O
7	O
cells	B-COMP
enabled	O
infection	O
by	O
hCoV	O
-	O
EMC	B-COMP
.	O

TGEV	O
/	O
PEDV	O
specific	O
antibody	B-COMP
responses	O
as	O
well	O
as	O
kinetic	O
changes	O
of	O
T	O
lymphocyte	O
subgroups	O
of	O
the	O
immunized	O
mice	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
TMPRSS2	O
(	O
transmembrane	B-COMP
serine	O
proteinase	O
2	O
)	O
is	O
a	O
multidomain	O
type	O
II	O
transmembrane	B-COMP
serine	O
protease	O
that	O
cleaves	O
the	O
surface	O
glycoprotein	O
HA	O
(	O
haemagglutinin	O
)	O
of	O
influenza	O
viruses	O
with	O
a	O
monobasic	O
cleavage	O
site	O
,	O
which	O
is	O
a	O
prerequisite	O
for	O
virus	O
fusion	O
and	O
propagation	O
.	O

TITLE	O
:	O
Differential	O
cell	B-COMP
line	O
susceptibility	O
to	O
the	O
emerging	O
novel	O
human	O
betacoronavirus	O
2c	O
EMC	B-COMP
/	O
2012	O
:	O
implications	O
for	O
disease	O
pathogenesis	O
and	O
clinical	O
manifestation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
diagnosis	O
,	O
pathogenesis	O
,	O
and	O
transmission	O
of	O
HCoV	O
-	O
EMC	B-COMP
.	O

The	O
transmissibility	O
and	O
pathogenesis	O
of	O
HCoV	O
-	O
EMC	B-COMP
remain	O
poorly	O
understood	O
,	O
and	O
elucidating	O
its	O
cellular	B-COMP
tropism	O
in	O
human	O
respiratory	O
tissues	O
will	O
provide	O
mechanistic	O
insights	O
into	O
the	O
key	O
cellular	B-COMP
targets	O
for	O
virus	O
propagation	O
and	O
spread	O
.	O

Their	O
involvement	O
in	O
host	B-COMP
immune	O
response	O
against	O
bacterial	O
and	O
viral	O
infections	O
is	O
reported	O
.	O

Although	O
not	O
significant	O
(	O
P	O
>	O
.	O
05	O
),	O
MCC	B-COMP
was	O
also	O
higher	O
in	O
ECA	O
than	O
in	O
IBD	O
.	O

The	O
IEC	O
expressing	O
PEDV	O
N	O
protein	O
can	O
express	O
higher	O
levels	O
of	O
IL	O
-	O
8	O
than	O
control	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
More	O
than	O
40	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
have	O
been	O
approved	O
for	O
a	O
number	O
of	O
disease	O
indications	O
with	O
only	O
one	O
of	O
these	O
(	O
Synagis	O
)	O
-	O
for	O
a	O
viral	O
disease	O
,	O
and	O
not	O
for	O
therapy	O
but	O
for	O
prevention	O
.	O

TITLE	O
:	O
Acute	O
-	O
phase	O
concentrations	O
of	O
soluble	O
fibrinogen	B-COMP
inhibit	O
neutrophil	O
adhesion	O
under	O
flow	O
conditions	O
in	O
vitro	O
through	O
interactions	O
with	O
ICAM	O
-	O
1	O
and	O
MAC	B-COMP
-	O
1	O
(	O
CD11b	O
/	O
CD18	O
).	O

Isolated	O
leukocytes	O
and	O
soluble	O
fibrinogen	B-COMP
were	O
studied	O
in	O
various	O
in	O
vitro	O
settings	O
under	O
static	O
and	O
under	O
flow	O
conditions	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
the	O
increased	O
circulating	O
concentrations	O
of	O
soluble	O
fibrinogen	B-COMP
found	O
during	O
the	O
acute	O
-	O
phase	O
response	O
can	O
act	O
as	O
a	O
natural	O
antagonist	O
of	O
leukocyte	O
recruitment	O
,	O
and	O
therefore	O
might	O
contribute	O
to	O
the	O
resolution	O
of	O
inflammation	O
.	O

RESULTS	O
:	O
Soluble	O
fibrinogen	B-COMP
functioned	O
as	O
a	O
natural	O
antagonist	O
of	O
neutrophil	O
functions	O
that	O
are	O
dependent	O
on	O
MAC	B-COMP
-	O
1	O
,	O
such	O
as	O
the	O
respiratory	O
burst	O
induced	O
by	O
unopsonized	O
zymosan	O
and	O
adhesion	O
to	O
ICAM	O
-	O
1	O
and	O
heparin	O
.	O

ABSTRACT	O
:	O
A	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
disease	O
due	O
to	O
a	O
novel	O
betacoronavirus	O
,	O
human	O
coronavirus	O
EMC	B-COMP
(	O
HCoV	O
-	O
EMC	B-COMP
),	O
has	O
emerged	O
recently	O
.	O

RESULTS	O
:	O
Two	O
(	O
2	O
.	O
1	O
%)	O
animal	O
handlers	O
had	O
IF	O
antibody	B-COMP
titer	O
of	O
	O
1	O
:	O
20	O
against	O
both	O
HCoV	O
-	O
EMC	B-COMP
and	O
SARS	O
-	O
CoV	O
with	O
neutralizing	O
antibody	B-COMP
titer	O
of	O
<	O
1	O
:	O
10	O
.	O

However	O
,	O
the	O
alcoholic	O
lung	O
represents	O
a	O
clear	O
example	O
of	O
environment	O
-	O
host	B-COMP
interactions	O
that	O
should	O
be	O
well	O
suited	O
for	O
such	O
applications	O
.	O

Since	O
there	O
is	O
no	O
current	O
consensus	O
about	O
the	O
underlying	O
dynamics	O
of	O
alveolar	O
mechanics	O
,	O
as	O
an	O
initial	O
step	O
we	O
investigate	O
the	O
ventilatory	O
dynamics	O
of	O
an	O
alveolar	O
sac	B-COMP
(	O
AS	O
)	O
with	O
the	O
lung	O
alveolar	O
spatial	O
model	O
(	O
LASM	O
),	O
a	O
3D	O
spatial	O
biomechanical	O
representation	O
of	O
the	O
AS	O
and	O
its	O
interaction	O
with	O
airflow	O
pressure	O
and	O
the	O
surface	O
tension	O
effects	O
of	O
pulmonary	O
surfactant	O
.	O

Moreover	O
,	O
the	O
serum	B-COMP
tumor	O
necrosis	O
factor	O
-	O
	O
,	O
interleukin	O
-	O
8	O
and	O
C	O
-	O
reactive	O
protein	O
levels	O
in	O
the	O
SH	O
and	O
SHG	O
groups	O
were	O
obviously	O
lower	O
than	O
in	O
the	O
NS	O
group	O
at	O
each	O
time	O
point	O
.	O

Furthermore	O
,	O
urine	O
L	O
/	O
M	O
ratio	O
and	O
serum	B-COMP
endotoxin	O
were	O
significantly	O
lower	O
in	O
the	O
SH	O
group	O
and	O
further	O
decreased	O
in	O
the	O
SHG	O
group	O
.	O

Furthermore	O
,	O
urine	O
L	O
/	O
M	O
ratio	O
and	O
serum	B-COMP
endotoxin	O
were	O
significantly	O
lower	O
in	O
the	O
SH	O
group	O
and	O
further	O
decreased	O
in	O
the	O
SHG	O
group	O
.	O

Immunofluorescence	O
assays	O
indicated	O
that	O
MAb	O
7G7	O
was	O
capable	O
of	O
detecting	O
cell	B-COMP
infection	O
by	O
TGEV	O
.	O

Herein	O
,	O
DNA	O
plasmid	O
bearing	O
TGEV	O
S1	O
gene	O
(	O
the	O
N	O
terminal	O
half	O
of	O
TGEV	O
S	O
gene	O
)	O
was	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
followed	O
by	O
generation	O
of	O
a	O
monoclonal	O
antibody	B-COMP
(	O
MAb	O
)	O
using	O
the	O
hybridoma	O
technique	O
.	O

Immunofluorescence	O
assays	O
showed	O
that	O
MAb	O
1H4	O
was	O
able	O
to	O
detect	O
infection	O
of	O
cells	B-COMP
with	O
TGEV	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
therapy	O
that	O
has	O
been	O
used	O
in	O
severe	O
cases	O
of	O
ARDS	O
when	O
patients	O
fail	O
to	O
improve	O
with	O
traditional	O
management	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
MERS	O
-	O
CoV	O
replication	O
and	O
cytotoxicity	O
in	O
human	O
and	O
monkey	O
cell	B-COMP
lines	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
assembles	O
into	O
virions	B-COMP
via	O
its	O
carboxy	O
-	O
terminus	O
,	O
which	O
is	O
composed	O
of	O
a	O
transmembrane	B-COMP
domain	O
and	O
an	O
endodomain	O
.	O

TITLE	O
:	O
Cell	B-COMP
host	B-COMP
response	O
to	O
infection	O
with	O
novel	O
human	O
coronavirus	O
EMC	B-COMP
predicts	O
potential	O
antivirals	O
and	O
important	O
differences	O
with	O
SARS	O
coronavirus	O
.	O

In	O
the	O
process	O
,	O
they	O
can	O
pause	O
the	O
elongating	O
ribosome	B-COMP
for	O
regulation	O
.	O

Mutagenesis	O
to	O
disrupt	O
or	O
restore	O
base	O
pairs	O
in	O
the	O
potential	O
hairpin	O
stem	O
reveals	O
that	O
base	O
-	O
pair	O
formation	O
is	O
required	O
for	O
-	O
1	O
frameshifting	O
attenuation	O
in	O
vitro	O
and	O
in	O
293T	O
cells	B-COMP
.	O

Both	O
cell	B-COMP
types	O
had	O
increased	O
expression	O
of	O
IL	O
-	O
1	O
mRNA	O
upon	O
viral	O
infection	O
,	O
though	O
at	O
different	O
levels	O
.	O

Gross	O
lesions	O
,	O
white	O
exudate	O
and	O
mucous	O
membrane	B-COMP
congestion	O
in	O
the	O
trachea	O
as	O
well	O
as	O
blue	O
to	O
purple	O
color	O
changes	O
and	O
sclerosis	O
in	O
lungs	O
were	O
observed	O
.	O

Each	O
class	O
of	O
mutants	O
clustered	O
on	O
SARS	O
-	O
CoV	O
nsp1	O
surface	O
and	O
suggested	O
nsp1	O
interacts	O
with	O
distinct	O
host	B-COMP
factors	O
to	O
exert	O
its	O
inhibitory	O
activities	O
.	O

The	O
immunoreactivity	O
between	O
PEDV	O
particles	O
or	O
the	O
bacterially	O
expressed	O
N	O
protein	O
and	O
rabbit	O
anti	O
-	O
PEDV	O
serum	B-COMP
was	O
confirmed	O
by	O
immunofluorescence	O
assays	O
and	O
Western	O
blot	O
.	O

We	O
reason	O
that	O
the	O
recalcitrant	O
life	O
-	O
threatening	O
hypokalemia	O
was	O
caused	O
by	O
several	O
mechanisms	O
including	O
total	O
body	O
potassium	O
depletion	O
(	O
chronic	O
respiratory	O
acidosis	O
),	O
a	O
shift	O
of	O
potassium	O
from	O
the	O
extracellular	B-COMP
to	O
intracellular	B-COMP
space	O
(	O
rapid	O
correction	O
of	O
respiratory	O
acidosis	O
with	O
mechanical	O
ventilation	O
),	O
increased	O
sodium	O
delivery	O
to	O
the	O
distal	O
nephron	O
(	O
normal	O
saline	O
resuscitation	O
),	O
hyperaldosteronism	O
(	O
secondary	O
to	O
hypotension	O
plus	O
administration	O
of	O
hydrocortisone	O
)	O
and	O
hypomagnesemia	O
.	O

We	O
observed	O
that	O
TGEV	O
infection	O
decreased	O
p300	O
/	O
CBP	O
,	O
downregulated	O
MDM2	O
and	O
promoted	O
p53	O
phosphorylation	O
at	O
serines	O
15	O
,	O
20	O
and	O
46	O
,	O
resulting	O
in	O
accumulation	O
and	O
activation	O
of	O
p53	O
in	O
PK	O
-	O
15	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Blinatumomab	O
is	O
a	O
CD19	O
/	O
CD3	O
-	O
bispecific	O
T	O
-	O
cell	B-COMP
receptor	O
-	O
engaging	O
(	O
BiTE	O
)	O
antibody	B-COMP
with	O
efficacy	O
in	O
refractory	O
B	O
-	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
results	O
showed	O
moderate	O
induction	O
of	O
PERK	O
phosphorylation	O
in	O
IBV	O
-	O
infected	O
cells	B-COMP
.	O

Serologic	O
testing	O
of	O
broiler	O
flocks	O
found	O
<	O
3	O
%	O
(	O
2	O
of	O
69	O
)	O
tested	O
to	O
possess	O
specific	O
antibodies	B-COMP
to	O
DMV	O
/	O
1639	O
/	O
11	O
,	O
indicating	O
the	O
virus	O
had	O
not	O
become	O
established	O
in	O
the	O
region	O
.	O

ABSTRACT	O
:	O
A	O
partial	O
characterization	O
of	O
the	O
ion	O
channels	O
formed	O
by	O
the	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
was	O
previously	O
reported	O
(	O
C	O
.	O
Verdi	O
-	O
Bguena	O
et	O
al	O
.,	O
2012	O
[	O
12	O
]).	O

TITLE	O
:	O
Concentrated	O
ascites	O
reinfusion	O
therapy	O
for	O
sinusoidal	O
obstructive	O
syndrome	O
after	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
the	O
treatment	O
of	O
poisoned	O
patients	O
.	O

ABSTRACT	O
:	O
Although	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
was	O
used	O
in	O
many	O
patients	O
following	O
its	O
introduction	O
in	O
1972	O
,	O
most	O
hospitals	O
had	O
abandoned	O
this	O
experimental	O
treatment	O
for	O
adult	O
patients	O
.	O

Activation	O
of	O
RNase	O
L	O
correlated	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
and	O
the	O
consequent	O
high	O
levels	O
of	O
OAS	O
mRNA	O
induced	O
in	O
these	O
cell	B-COMP
types	O
.	O

Pretreatment	O
of	O
nonmyeloid	O
cells	B-COMP
with	O
interferon	O
restricted	O
A59	O
and	O
ns2	O
-	O
H126R	O
to	O
the	O
same	O
extent	O
and	O
failed	O
to	O
activate	O
RNase	O
L	O
following	O
infection	O
,	O
despite	O
induction	O
of	O
OAS	O
expression	O
.	O

TITLE	O
:	O
Cell	B-COMP
culture	O
and	O
electron	O
microscopy	O
for	O
identifying	O
viruses	O
in	O
diseases	O
of	O
unknown	O
cause	O
.	O

Recombinant	O
human	O
activated	O
protein	O
C	O
(	O
APC	B-COMP
)	O
reportedly	O
improves	O
circulation	O
and	O
respiration	O
in	O
severe	O
sepsis	O
,	O
but	O
is	O
contraindicated	O
after	O
head	O
injury	O
because	O
of	O
increased	O
risk	O
of	O
intracranial	O
bleeding	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
)	O
plays	O
an	O
essential	O
structural	O
role	O
in	O
virions	B-COMP
through	O
a	O
network	O
of	O
interactions	O
with	O
positive	O
-	O
strand	O
viral	O
genomic	O
RNA	O
,	O
the	O
envelope	B-COMP
membrane	B-COMP
protein	O
(	O
M	O
),	O
and	O
other	O
N	O
molecules	O
.	O

ABSTRACT	O
:	O
Bats	O
host	B-COMP
a	O
broad	O
diversity	O
of	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
close	O
relatives	O
of	O
human	O
pathogens	O
.	O

Moreover	O
,	O
the	O
tripeptide	O
pan	B-COMP
-	O
ICE	O
(	O
caspase	O
)	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
FMK	O
blocked	O
PHEV	O
-	O
induced	O
apoptosis	O
but	O
did	O
not	O
have	O
an	O
effect	O
on	O
virus	O
production	O
by	O
96h	O
post	O
-	O
infection	O
.	O

These	O
results	O
suggested	O
that	O
PHEV	O
induces	O
apoptosis	O
in	O
PK	O
-	O
15	O
cells	B-COMP
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

Apoptotic	O
death	O
of	O
infected	O
cells	B-COMP
is	O
detrimental	O
to	O
animals	O
because	O
it	O
causes	O
cell	B-COMP
and	O
tissue	O
destruction	O
.	O

Ratios	O
of	O
fresh	O
frozen	O
plasma	O
-	O
packed	O
red	O
blood	O
cell	B-COMP
(	O
PRBC	O
)	O
were	O
calculated	O
and	O
divided	O
in	O
two	O
groups	O
:	O
HRR	O
(	O
1	O
-	O
1	O
:	O
2	O
)	O
and	O
low	O
-	O
ratio	O
resuscitation	O
(	O
LRR	O
<	O
1	O
:	O
2	O
).	O

Caution	O
in	O
overzealous	O
use	O
of	O
crystalloid	B-COMP
during	O
HRR	O
is	O
warranted	O
.	O

ABSTRACT	O
:	O
The	O
C	O
-	O
type	O
lectin	O
DC	O
-	O
SIGNR	O
(	O
dendritic	B-COMP
cell	B-COMP
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
non	O
-	O
integrin	O
-	O
related	O
;	O
also	O
known	O
as	O
L	O
-	O
SIGN	O
or	O
CD299	O
)	O
is	O
a	O
promising	O
drug	O
target	O
due	O
to	O
its	O
ability	O
to	O
promote	O
infection	O
and	O
/	O
or	O
within	O
-	O
host	B-COMP
survival	O
of	O
several	O
dangerous	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
HIV	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
))	O
via	O
interactions	O
with	O
their	O
surface	O
glycans	O
.	O

TITLE	O
:	O
Isolation	O
and	O
genetic	O
characterization	O
of	O
human	O
coronavirus	O
NL63	O
in	O
primary	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	B-COMP
obtained	O
from	O
a	O
commercial	O
supplier	O
,	O
and	O
confirmation	O
of	O
its	O
replication	O
in	O
two	O
different	O
types	O
of	O
human	O
primary	O
kidney	O
cells	B-COMP
.	O

Adventitious	O
viruses	O
in	O
the	O
RPTEC	O
were	O
isolated	O
and	O
/	O
or	O
detected	O
and	O
identified	O
by	O
isolation	O
in	O
various	O
indicator	O
cell	B-COMP
lines	O
,	O
observation	O
of	O
cytopathology	O
,	O
an	O
immunoflurorescence	O
assay	O
,	O
electron	O
microscopy	O
,	O
PCR	O
,	O
and	O
sequencing	O
.	O

Human	O
coronavirus	O
NL63	O
was	O
isolated	O
and	O
identified	O
by	O
RT	O
-	O
PCR	O
and	O
sequencing	O
,	O
and	O
its	O
replication	O
in	O
a	O
fresh	O
batch	O
of	O
RPTEC	O
and	O
another	O
type	O
of	O
primary	O
human	O
kidney	O
cells	B-COMP
was	O
confirmed	O
.	O

TITLE	O
:	O
Malaria	O
,	O
clinical	O
features	O
and	O
acute	O
crisis	O
in	O
children	O
suffering	O
from	O
sickle	O
cell	B-COMP
disease	O
in	O
resource	O
-	O
limited	O
settings	O
:	O
a	O
retrospective	O
description	O
of	O
90	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
sickle	O
cell	B-COMP
disease	O
(	O
SCD	O
)	O
is	O
extremely	O
high	O
in	O
the	O
Democratic	O
Republic	O
of	O
Congo	O
(	O
DRC	O
).	O

RESULTS	O
:	O
Of	O
the	O
90	O
homozygous	O
sickle	O
cell	B-COMP
children	O
with	O
malaria	O
,	O
fever	O
,	O
pallor	O
,	O
and	O
jaundice	O
were	O
the	O
commonly	O
-	O
found	O
symptoms	O
.	O

Viruses	O
have	O
developed	O
diverse	O
strategies	O
to	O
subvert	O
host	B-COMP
defense	O
mechanisms	O
and	O
increase	O
their	O
survival	O
.	O

The	O
pattern	O
of	O
gene	O
expression	O
of	O
cells	B-COMP
infected	O
with	O
a	O
recombinant	O
mutant	O
TGEV	O
,	O
lacking	O
gene	O
7	O
expression	O
(	O
rTGEV	O
-	O
7	O
),	O
was	O
compared	O
to	O
that	O
of	O
cells	B-COMP
infected	O
with	O
the	O
parental	O
virus	O
(	O
rTGEV	O
-	O
wt	O
).	O

Here	O
we	O
showed	O
that	O
residues	O
377	O
to	O
662	O
in	O
the	O
S	O
protein	O
of	O
MERS	O
-	O
CoV	O
specifically	O
bound	O
to	O
DPP4	O
-	O
expressing	O
cells	B-COMP
and	O
soluble	O
DPP4	O
protein	O
and	O
induced	O
significant	O
neutralizing	O
antibody	B-COMP
responses	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
has	O
a	O
potential	O
to	O
be	O
developed	O
as	O
a	O
MERS	O
-	O
CoV	O
vaccine	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
encodes	O
an	O
extensively	O
phosphorylated	O
and	O
highly	O
basic	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
.	O

TITLE	O
:	O
Identification	O
of	O
cellular	B-COMP
proteome	O
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
in	O
ST	O
cells	B-COMP
infected	O
with	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
endothelial	O
progenitor	O
cell	B-COMP
mobilization	O
in	O
the	O
models	O
of	O
moderate	O
and	O
severe	O
lung	O
injury	O
,	O
we	O
hypothesized	O
that	O
there	O
were	O
differences	O
in	O
endothelial	O
progenitor	O
cell	B-COMP
levels	O
and	O
mobilizing	O
cytokines	O
between	O
moderate	O
and	O
severe	O
lung	O
injury	O
.	O

XILP	O
inhibited	O
proliferation	O
of	O
various	O
cancer	O
cell	B-COMP
lines	O
but	O
did	O
not	O
do	O
so	O
in	O
human	O
embryonic	O
liver	O
(	O
WRL	O
68	O
)	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Total	O
internal	O
reflection	O
microscopy	O
combined	O
with	O
microfluidics	O
and	O
supported	O
bilayers	O
is	O
a	O
powerful	O
,	O
single	O
particle	O
tracking	O
(	O
SPT	O
)	O
platform	O
for	O
host	B-COMP
-	O
pathogen	O
membrane	B-COMP
fusion	O
studies	O
.	O

Because	O
of	O
this	O
,	O
viruses	O
requiring	O
proteinaceous	O
receptors	O
,	O
or	O
other	O
unknown	O
cellular	B-COMP
co	O
-	O
factors	O
,	O
have	O
been	O
precluded	O
from	O
study	O
.	O

Following	O
the	O
discovery	O
of	O
novel	O
coronavirus	O
infection	O
(	O
nCoV	O
)	O
in	O
the	O
Arabian	O
peninsula	O
in	O
September	O
2012	O
,	O
stored	O
respiratory	O
and	O
serum	B-COMP
samples	O
of	O
patients	O
from	O
this	O
outbreak	O
were	O
retested	O
and	O
the	O
diagnosis	O
of	O
nCoV	O
was	O
confirmed	O
in	O
2	O
deceased	O
patients	O
.	O

We	O
were	O
not	O
able	O
to	O
infect	O
alveolar	O
type	O
I	O
-	O
like	O
cells	B-COMP
or	O
alveolar	O
macrophages	O
.	O

At	O
72	O
hours	O
post	O
inoculation	O
,	O
HCoV	O
-	O
HKU1	O
infection	O
of	O
type	O
II	O
cells	B-COMP
induced	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
IL29	O
,	O
CXCL10	O
,	O
CCL5	O
,	O
and	O
IL	O
-	O
6	O
with	O
no	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
IFN	O
.	O

Binding	O
of	O
the	O
IBV	O
spike	O
protein	O
to	O
host	B-COMP
cells	B-COMP
was	O
in	O
all	O
experiments	O
sialic	O
acid	O
dependent	O
,	O
whereas	O
the	O
soluble	O
TGEV	O
spike	O
showed	O
binding	O
to	O
APN	O
but	O
had	O
no	O
detectable	O
sialic	O
acid	O
binding	O
activity	O
.	O

Independent	O
risk	O
factors	O
associated	O
with	O
increased	O
risk	O
of	O
ARDS	O
development	O
included	O
intermediate	O
(	O
2	O
-	O
3	O
.	O
9	O
mmol	O
/	O
L	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
high	O
(	O
4	O
)	O
serum	B-COMP
lactate	O
levels	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
Lung	O
Injury	O
Prediction	O
score	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
microbiologically	O
proven	O
infection	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

The	O
expression	O
of	O
CD107a	O
and	O
NKG2D	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
TNF	O
-	O
	O
,	O
IFN	O
-	O
	O
and	O
IL	O
-	O
9	O
in	O
hepatic	O
CD69	O
+	O
NK	O
cells	B-COMP
was	O
all	O
significantly	O
up	O
-	O
regulated	O
during	O
48	O
-	O
72	O
h	O
post	O
-	O
infection	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
:	O
Viral	B-COMP
Membrane	I-COMP
Proteins	O
-	O
Channels	O
for	O
Cellular	B-COMP
Networking	O
.	O

TITLE	O
:	O
The	O
PRESERVE	O
mortality	O
risk	O
score	O
and	O
analysis	O
of	O
long	O
-	O
term	O
outcomes	O
after	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Granulocytes	O
of	O
FIP	O
cats	O
displayed	O
an	O
increased	O
expression	O
of	O
the	O
	O
chain	O
of	O
Mac	B-COMP
-	O
1	O
(	O
CD11b	O
).	O

Since	O
up	O
to	O
75	O
%	O
of	O
sepsis	O
originates	O
from	O
the	O
lung	O
,	O
aPC	B-COMP
treatment	O
may	O
not	O
have	O
added	O
enough	O
to	O
the	O
beneficial	O
effect	O
of	O
lung	O
-	O
protective	O
ventilation	O
to	O
show	O
lower	O
mortality	O
.	O

Here	O
,	O
by	O
ligating	O
head	O
-	O
to	O
-	O
tail	O
viral	O
RNAs	O
from	O
bovine	O
coronavirus	O
-	O
infected	O
cells	B-COMP
and	O
sequencing	O
across	O
the	O
ligated	O
junctions	O
,	O
it	O
was	O
learned	O
that	O
at	O
the	O
time	O
of	O
peak	O
viral	O
RNA	O
synthesis	O
[	O
6	O
hours	O
postinfection	O
(	O
hpi	O
)]	O
the	O
3	O
'	O
poly	O
(	O
A	O
)	O
tail	O
on	O
genomic	O
and	O
sgmRNAs	O
is	O
~	O
65	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
that	O
involves	O
no	O
T	O
cell	B-COMP
stimulation	O
or	O
propagation	O
in	O
vitro	O
.	O

MERS	O
-	O
CoV	O
neutralising	O
antibody	B-COMP
titres	O
varied	O
between	O
1	O
/	O
320	O
and	O
1	O
/	O
2560	O
for	O
the	O
Omani	O
camel	O
sera	B-COMP
and	O
between	O
1	O
/	O
20	O
and	O
1	O
/	O
320	O
for	O
the	O
Spanish	O
camel	O
sera	B-COMP
.	O

Polymerase	O
chain	O
reaction	O
-	O
based	O
assays	O
,	O
direct	O
fluorescent	O
antigen	O
(	O
DFA	O
)	O
assays	O
,	O
and	O
viral	O
cultures	O
can	O
detect	O
viruses	O
in	O
samples	O
from	O
the	O
human	O
respiratory	O
tract	O
,	O
but	O
the	O
presence	O
of	O
the	O
virus	O
does	O
not	O
prove	O
it	O
to	O
be	O
a	O
pathogen	O
,	O
nor	O
does	O
it	O
give	O
information	O
regarding	O
the	O
interaction	O
of	O
viruses	O
with	O
the	O
host	B-COMP
immune	O
response	O
and	O
bacterial	O
flora	O
of	O
the	O
respiratory	O
tract	O
.	O

Using	O
this	O
system	O
,	O
we	O
deleted	O
the	O
ORF3	O
gene	O
entirely	O
from	O
the	O
viral	B-COMP
genome	I-COMP
and	O
showed	O
that	O
the	O
ORF3	O
protein	O
is	O
not	O
essential	O
for	O
replication	O
of	O
the	O
virus	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
),	O
like	O
other	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
,	O
redirect	O
and	O
rearrange	O
host	O
cell	B-COMP
membranes	I-COMP
for	O
use	O
as	O
part	O
of	O
the	O
viral	B-COMP
genome	I-COMP
replication	O
and	O
transcription	O
machinery	O
.	O

Here	O
,	O
we	O
use	O
transfection	O
of	O
plasmid	O
constructs	O
encoding	O
full	O
-	O
length	O
versions	O
of	O
the	O
three	O
transmembrane	B-COMP
-	O
containing	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
to	O
examine	O
the	O
ability	O
of	O
each	O
to	O
induce	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
in	O
tissue	O
culture	O
.	O

ABSTRACT	O
:	O
Humoral	O
immunity	O
is	O
important	O
for	O
controlling	O
viral	O
diseases	O
of	O
poultry	O
,	O
but	O
recent	O
studies	O
have	O
indicated	O
that	O
cytotoxic	O
T	O
cells	B-COMP
also	O
play	O
an	O
important	O
role	O
in	O
the	O
immune	O
response	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
benefit	O
on	O
hospital	O
mortality	O
is	O
unclear	O
.	O

To	O
date	O
,	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
research	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
susceptible	O
cell	B-COMP
lines	O
for	O
the	O
propagation	O
of	O
serotype	O
I	O
FCoVs	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	B-COMP
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	O
-	O
and	O
human	O
Telomerase	O
Reverse	O
Transcriptase	O
(	O
hTERT	O
)-	O
induced	O
immortalization	O
.	O

The	O
enzyme	O
arginase	O
,	O
the	O
activity	O
of	O
which	O
can	O
be	O
regulated	O
by	O
the	O
redox	O
status	O
of	O
the	O
cell	B-COMP
,	O
exists	O
in	O
two	O
isoforms	O
-	O
arginase	O
1	O
(	O
cytosolic	B-COMP
)	O
and	O
arginase	O
2	O
(	O
mitochondrial	B-COMP
)	O
-	O
both	O
of	O
which	O
can	O
be	O
expressed	O
in	O
lung	O
microvascular	O
endothelial	O
cells	B-COMP
.	O

TITLE	O
:	O
Production	O
and	O
characterization	O
of	O
egg	O
yolk	B-COMP
antibodies	B-COMP
against	O
bovine	O
alimentary	O
tract	O
pathogens	O
.	O

Based	O
on	O
the	O
duration	O
and	O
the	O
highest	O
level	O
of	O
IgY	O
antibody	B-COMP
against	O
bovine	O
alimentary	O
tract	O
pathogens	O
C	O
vaccine	O
was	O
further	O
used	O
in	O
next	O
two	O
trials	O
for	O
vaccination	O
of	O
1000	O
hens	O
each	O
time	O
.	O

Taken	O
together	O
,	O
the	O
established	O
MERS	O
-	O
CoV	O
inhibition	O
assay	O
is	O
a	O
safe	O
and	O
convenient	O
pseudovirus	O
-	O
based	O
alternative	O
to	O
BSL	O
-	O
3	O
live	O
-	O
virus	O
restrictions	O
and	O
can	O
be	O
used	O
to	O
rapidly	O
screen	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	O
,	O
as	O
well	O
as	O
evaluate	O
vaccine	O
-	O
induced	O
neutralizing	O
antibodies	B-COMP
against	O
the	O
highly	O
pathogenic	O
MERS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Our	O
results	O
demonstrated	O
that	O
the	O
generated	O
MERS	O
-	O
CoV	O
pseudovirus	O
allows	O
for	O
single	O
-	O
cycle	O
infection	O
of	O
a	O
variety	O
of	O
cells	B-COMP
expressing	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
the	O
confirmed	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Consistent	O
with	O
the	O
results	O
from	O
a	O
live	O
MERS	O
-	O
CoV	O
-	O
based	O
inhibition	O
assay	O
,	O
the	O
antisera	O
of	O
mice	O
vaccinated	O
with	O
a	O
recombinant	O
protein	O
containing	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
,	O
residues	O
377	O
-	O
662	O
)	O
of	O
MERS	O
-	O
CoV	O
S	O
fused	O
with	O
Fc	O
of	O
human	O
IgG	O
exhibited	O
neutralizing	O
antibody	B-COMP
response	O
against	O
infection	O
of	O
MERS	O
-	O
CoV	O
pseudovirus	O
.	O

ABSTRACT	O
:	O
Microglia	O
,	O
the	O
major	O
resident	O
immune	O
cells	B-COMP
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
are	O
considered	O
as	O
the	O
key	O
cellular	B-COMP
mediators	O
of	O
neuroinflammatory	O
processes	O
.	O

Median	O
duration	O
of	O
MCS	B-COMP
was	O
4	O
days	O
(	O
0	O
-	O
18	O
days	O
),	O
12	O
patients	O
(	O
75	O
%)	O
were	O
weaned	O
successfully	O
from	O
MCS	B-COMP
,	O
4	O
of	O
these	O
children	O
(	O
25	O
%)	O
died	O
after	O
weaning	O
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
15	O
days	O
(	O
6	O
-	O
28	O
days	O
).	O

RESULTS	O
:	O
Median	O
duration	O
of	O
MCS	B-COMP
was	O
4	O
days	O
(	O
0	O
-	O
18	O
days	O
),	O
12	O
patients	O
(	O
75	O
%)	O
were	O
weaned	O
successfully	O
from	O
MCS	B-COMP
,	O
4	O
of	O
these	O
children	O
(	O
25	O
%)	O
died	O
after	O
weaning	O
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
15	O
days	O
(	O
6	O
-	O
28	O
days	O
).	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
delivered	O
by	O
modified	O
vaccinia	O
virus	O
Ankara	O
efficiently	O
induces	O
virus	O
-	O
neutralizing	O
antibodies	B-COMP
.	O

Variables	O
associated	O
with	O
mechanical	O
ventilation	O
in	O
multivariate	O
analysis	O
included	O
serum	B-COMP
bicarbonates	O
less	O
than	O
20	O
mM	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
9	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
22	O
.	O
7	O
];	O
p	O
=	O
0	O
.	O
041	O
),	O
serum	B-COMP
urea	O
greater	O
than	O
10	O
mM	O
(	O
odds	O
ratio	O
,	O
7	O
.	O
0	O
[	O
95	O
%	O
CI	O
,	O
2	O
.	O
2	O
-	O
22	O
.	O
8	O
];	O
p	O
<	O
0	O
.	O
001	O
),	O
a	O
detached	O
body	O
surface	O
area	O
between	O
10	O
%	O
and	O
29	O
%	O
(	O
odds	O
ratio	O
,	O
3	O
.	O
7	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
13	O
.	O
8	O
];	O
p	O
=	O
0	O
.	O
048	O
)	O
or	O
greater	O
than	O
or	O
equal	O
to	O
30	O
%	O
(	O
odds	O
ratio	O
,	O
19	O
.	O
7	O
[	O
95	O
%	O
CI	O
,	O
4	O
.	O
4	O
-	O
87	O
.	O
4	O
];	O
p	O
<	O
0	O
.	O
0001	O
),	O
WBCs	O
more	O
than	O
12	O
,	O
000	O
/	O
mm3	O
(	O
odds	O
ratio	O
,	O
11	O
.	O
6	O
[	O
95	O
%	O
CI	O
,	O
2	O
.	O
8	O
-	O
48	O
.	O
1	O
];	O
p	O
<	O
0	O
.	O
001	O
),	O
blood	O
hemoglobin	O
less	O
than	O
8	O
g	O
/	O
dL	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
1	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
55	O
.	O
2	O
];	O
p	O
=	O
0	O
.	O
032	O
),	O
and	O
more	O
extensive	O
pulmonary	O
infiltrates	O
(	O
odds	O
ratio	O
,	O
9	O
.	O
7	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
6	O
-	O
25	O
.	O
9	O
];	O
p	O
<	O
0	O
.	O
0001	O
).	O

Only	O
one	O
residue	O
change	O
was	O
observed	O
in	O
the	O
spike	O
glycoprotein	O
,	O
which	O
reverted	O
back	O
on	O
subsequent	O
passages	O
,	O
four	O
changes	O
were	O
observed	O
in	O
the	O
3c	O
protein	O
,	O
and	O
one	O
change	O
was	O
observed	O
in	O
each	O
3a	O
,	O
small	O
membrane	B-COMP
,	O
nucleocapsid	B-COMP
and	O
7a	O
proteins	O
.	O

The	O
study	O
by	O
de	O
Prost	O
and	O
colleagues	O
in	O
the	O
current	O
issue	O
of	O
Critical	O
Care	O
provides	O
new	O
insights	O
into	O
the	O
impact	O
of	O
ventilation	O
strategies	O
on	O
pulmonary	O
function	O
,	O
gas	O
exchange	O
,	O
and	O
regional	O
cellular	B-COMP
metabolic	O
activity	O
during	O
early	O
ALI	O
in	O
sheep	O
.	O

ABSTRACT	O
:	O
The	O
advent	O
of	O
publicly	O
available	O
databases	O
containing	O
system	O
-	O
wide	O
phenotypic	O
data	O
of	O
the	O
host	B-COMP
response	O
to	O
both	O
drugs	O
and	O
pathogens	O
,	O
in	O
conjunction	O
with	O
bioinformatics	O
and	O
computational	O
methods	O
now	O
allows	O
for	O
in	O
silico	O
predictions	O
of	O
FDA	O
-	O
approved	O
drugs	O
as	O
treatments	O
against	O
infection	O
diseases	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
viral	O
N	O
sequences	O
suggested	O
that	O
CoVs	O
in	O
domestic	O
fowls	O
have	O
diverged	O
into	O
several	O
region	O
-	O
specific	O
or	O
host	B-COMP
-	O
specific	O
clades	O
or	O
subclades	O
in	O
the	O
world	O
,	O
and	O
IBVs	O
can	O
infect	O
ducks	O
,	O
geese	O
and	O
pigeons	O
,	O
although	O
they	O
mainly	O
circulate	O
in	O
chickens	O
.	O

By	O
contrast	O
,	O
viral	O
pseudotypes	O
containing	O
the	O
surface	O
protein	O
GP	O
of	O
Marburg	O
virus	O
from	O
the	O
family	O
Filoviridae	O
infected	O
all	O
six	O
cell	B-COMP
lines	O
though	O
at	O
different	O
efficiency	O
.	O

These	O
results	O
indicate	O
that	O
bat	O
cells	B-COMP
are	O
more	O
resistant	O
to	O
infection	O
by	O
coronaviruses	O
than	O
to	O
infection	O
by	O
paramyxoviruses	O
,	O
filoviruses	O
and	O
influenza	O
viruses	O
.	O

Furthermore	O
,	O
these	O
results	O
show	O
a	O
receptor	O
-	O
dependent	O
restriction	O
of	O
the	O
infection	O
of	O
bat	O
cells	B-COMP
by	O
CoV	O
.	O
The	O
implications	O
for	O
the	O
isolation	O
of	O
coronaviruses	O
from	O
bats	O
are	O
discussed	O
.	O

Furthermore	O
,	O
the	O
susceptibility	O
of	O
Vero	O
-	O
TMPRSS2	O
cells	B-COMP
to	O
MERS	O
-	O
CoV	O
was	O
100	O
-	O
fold	O
higher	O
than	O
that	O
of	O
non	O
-	O
TMPRSS2	O
-	O
expressing	O
parental	O
Vero	O
cells	B-COMP
.	O

Importantly	O
,	O
the	O
coronavirus	O
is	O
thought	O
to	O
enter	O
cells	B-COMP
via	O
two	O
distinct	O
pathways	O
,	O
one	O
mediated	O
by	O
TMPRSS2	O
at	O
the	O
cell	B-COMP
surface	I-COMP
and	O
the	O
other	O
mediated	O
by	O
cathepsin	O
L	O
in	O
the	O
endosome	B-COMP
.	O

Surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
)	O
is	O
a	O
C	O
-	O
type	O
lectin	O
that	O
is	O
mainly	O
produced	O
in	O
alveolar	O
type	O
II	O
cells	B-COMP
.	O

However	O
,	O
the	O
natural	O
prevalence	O
of	O
antibodies	B-COMP
against	O
these	O
viruses	O
in	O
serum	B-COMP
among	O
population	O
is	O
unknown	O
.	O

Of	O
794	O
blood	O
samples	O
tested	O
,	O
only	O
29	O
(	O
3	O
.	O
65	O
%)	O
were	O
negative	O
for	O
anti	O
-	O
S	O
IgG	O
.	O
The	O
seropositivity	O
of	O
the	O
four	O
anti	O
-	O
S	O
IgG	O
antibodies	B-COMP
was	O
>	O
70	O
%	O
within	O
the	O
general	O
population	O
.	O

TITLE	O
:	O
Contributions	O
of	O
the	O
S2	O
spike	O
ectodomain	O
to	O
attachment	O
and	O
host	B-COMP
range	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

However	O
,	O
we	O
have	O
previously	O
shown	O
that	O
this	O
domain	O
of	O
the	O
embryo	O
-	O
and	O
cell	B-COMP
culture	O
adapted	O
Beaudette	O
strain	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
virulent	O
M41	O
strain	O
,	O
is	O
not	O
sufficient	O
for	O
binding	O
to	O
chicken	O
trachea	O
(	O
Wickramasinghe	O
et	O
al	O
.,	O
2011	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
lack	O
of	O
binding	O
of	O
Beaudette	O
S1	O
was	O
not	O
due	O
to	O
absence	O
of	O
virus	O
receptors	O
on	O
this	O
tissue	O
nor	O
due	O
to	O
the	O
production	O
of	O
S1	O
from	O
mammalian	O
cells	B-COMP
,	O
as	O
S1	O
proteins	O
expressed	O
from	O
chicken	O
cells	B-COMP
also	O
lacked	O
the	O
ability	O
to	O
bind	O
IBV	O
-	O
susceptible	O
embryonic	O
tissue	O
.	O

To	O
investigate	O
the	O
role	O
of	O
the	O
3C	O
protein	O
,	O
a	O
full	O
-	O
length	O
3c	O
gene	O
was	O
transiently	O
expressed	O
and	O
the	O
cytoplasmic	B-COMP
distribution	O
of	O
the	O
protein	O
was	O
found	O
to	O
be	O
primarily	O
in	O
the	O
perinuclear	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
ability	O
of	O
NetMHCpan	O
to	O
predict	O
antiviral	O
CD8	O
(+)	O
T	O
cell	B-COMP
epitopes	O
that	O
we	O
identified	O
with	O
a	O
traditional	O
approach	O
in	O
patients	O
of	O
Asian	O
ethnicity	O
infected	O
with	O
Dengue	O
virus	O
,	O
hepatitis	O
B	O
virus	O
,	O
or	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Upon	O
a	O
combination	O
of	O
intratracheal	O
,	O
ocular	O
,	O
oral	O
,	O
and	O
intranasal	O
inoculation	O
with	O
7	O
	O
10	O
(	O
6	O
)	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
of	O
the	O
MERS	O
-	O
CoV	O
isolate	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
,	O
rhesus	O
macaques	O
developed	O
a	O
transient	O
lower	O
respiratory	O
tract	O
infection	O
.	O

Notably	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
expression	O
levels	O
of	O
interleukin	O
12	O
,	O
IFN	O
-	O
	O
,	O
and	O
chemokines	O
(	O
IP	O
-	O
10	O
/	O
CXCL	O
-	O
10	O
,	O
MCP	O
-	O
1	O
/	O
CCL	O
-	O
2	O
,	O
MIP	O
-	O
1	O
/	O
CCL	O
-	O
3	O
,	O
RANTES	O
/	O
CCL	O
-	O
5	O
,	O
and	O
interleukin	O
8	O
)	O
than	O
SARS	O
-	O
CoV	O
.	O
The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
and	O
costimulatory	O
molecules	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
MDMs	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
During	O
the	O
H1N1	O
pandemic	O
of	O
2009	O
and	O
2010	O
,	O
the	O
large	O
number	O
of	O
patients	O
with	O
severe	O
respiratory	O
failure	O
due	O
to	O
H1N1	O
infection	O
strained	O
the	O
capacities	O
of	O
treatment	O
facilities	O
for	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
around	O
the	O
world	O
.	O

TITLE	O
:	O
Seroepidemiology	O
for	O
MERS	O
coronavirus	O
using	O
microneutralisation	O
and	O
pseudoparticle	O
virus	O
neutralisation	O
assays	O
reveal	O
a	O
high	O
prevalence	O
of	O
antibody	B-COMP
in	O
dromedary	O
camels	O
in	O
Egypt	O
,	O
June	O
2013	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
novel	O
spike	O
pseudoparticle	O
neutralisation	O
assay	O
(	O
ppNT	O
)	O
for	O
seroepidemiological	O
studies	O
on	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERSCoV	O
)	O
and	O
apply	O
this	O
assay	O
together	O
with	O
conventional	O
microneutralisation	O
(	O
MN	O
)	O
tests	O
to	O
investigate	O
1	O
,	O
343	O
human	O
and	O
625	O
animal	O
sera	B-COMP
.	O

MAb	O
2	O
-	O
4	O
exhibited	O
high	O
neutralizing	O
activity	O
against	O
natural	O
TNF	O
-	O
alpha	O
derived	O
from	O
FIPV	O
-	O
infected	O
macrophages	O
,	O
and	O
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
feline	O
TNF	O
-	O
alpha	O
-	O
induced	O
conditions	O
in	O
vitro	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
the	O
survival	O
rate	O
of	O
neutrophils	O
from	O
cats	O
with	O
FIP	O
,	O
(	O
ii	O
)	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
mRNA	O
expression	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
apoptosis	O
of	O
a	O
feline	O
T	O
-	O
lymphocyte	O
cell	B-COMP
line	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggested	O
that	O
TGEV	O
infection	O
induced	O
S	O
and	O
G2	O
/	O
M	O
phase	O
arrest	O
in	O
host	B-COMP
cells	B-COMP
,	O
which	O
might	O
provide	O
a	O
favorable	O
condition	O
for	O
viral	O
replication	O
.	O

The	O
serum	B-COMP
concentrations	O
achievable	O
at	O
therapeutic	O
doses	O
of	O
mycophenolic	O
acid	O
and	O
interferon	O
-	O
1b	O
were	O
60	O
-	O
300	O
and	O
3	O
-	O
4	O
times	O
higher	O
than	O
the	O
concentrations	O
at	O
which	O
in	O
-	O
vitro	O
anti	O
-	O
MERS	O
-	O
CoV	O
activities	O
were	O
demonstrated	O
,	O
whereas	O
that	O
of	O
ribavirin	O
was	O
	O
2	O
times	O
lower	O
.	O

Mortality	O
(	O
13	O
.	O
9	O
%	O
for	O
mild	O
ARDS	O
;	O
11	O
.	O
3	O
%	O
for	O
moderate	O
ARDS	O
;	O
25	O
%	O
for	O
severe	O
ARDS	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
the	O
composite	O
outcome	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)/	O
mortality	O
(	O
13	O
.	O
9	O
%	O
for	O
mild	O
ARDS	O
;	O
11	O
.	O
3	O
%	O
for	O
moderate	O
ARDS	O
;	O
28	O
.	O
4	O
%	O
for	O
severe	O
ARDS	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
different	O
across	O
the	O
BD	O
classes	O
,	O
whereas	O
they	O
were	O
similar	O
using	O
the	O
previous	O
definition	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
OC43	O
nucleocapsid	B-COMP
protein	O
binds	O
microRNA	O
9	O
and	O
potentiates	O
NF	O
-	O
B	O
activation	O
.	O

While	O
a	O
multitude	O
of	O
studies	O
have	O
examined	O
nucleocapsid	B-COMP
function	O
,	O
none	O
have	O
described	O
the	O
effects	O
of	O
OC43	O
nucleocapsid	B-COMP
on	O
the	O
transcription	O
factor	O
NF	O
-	O
B	O
.	O
We	O
report	O
that	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
OC43	O
causes	O
potentiation	O
of	O
NF	O
-	O
B	O
activation	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
monoclonal	O
antibody	B-COMP
to	O
S1	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Pioneer	O
studies	O
identified	O
cathepsins	O
and	O
type	O
II	O
transmembrane	B-COMP
serine	O
proteases	O
as	O
cellular	B-COMP
activators	O
of	O
SARS	O
-	O
CoV	O
and	O
demonstrated	O
that	O
several	O
emerging	O
viruses	O
might	O
exploit	O
these	O
enzymes	O
to	O
promote	O
their	O
spread	O
.	O

In	O
the	O
present	O
report	O
,	O
a	O
series	O
of	O
three	O
cases	O
of	O
imported	O
malaria	O
complicated	O
by	O
refractory	O
severe	O
ARDS	O
supported	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
presented	O
.	O

The	O
similarities	O
observed	O
between	O
males	O
and	O
Turner	O
syndrome	O
patients	O
using	O
an	O
endotoxin	O
stimulation	O
model	O
support	O
the	O
difference	O
in	O
gene	O
expression	O
between	O
monosomy	O
and	O
disomy	O
for	O
the	O
X	B-COMP
chromosome	I-COMP
.	O

In	O
the	O
cytoplasm	B-COMP
of	O
the	O
infected	O
cell	B-COMP
,	O
recognition	O
of	O
the	O
presence	O
of	O
viral	O
dsRNA	O
as	O
a	O
signature	O
of	O
""""	O
non	O
-	O
self	O
""""	O
nucleic	B-COMP
acid	O
is	O
carried	O
out	O
by	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
),	O
a	O
set	O
of	O
dedicated	O
helicases	O
whose	O
activation	O
leads	O
to	O
the	O
production	O
of	O
type	O
I	O
interferon	O
	O
/	O
	O
(	O
IFN	O
-	O
	O
/	O
	O
).	O

TITLE	O
:	O
Feature	O
selection	O
methods	O
for	O
identifying	O
genetic	O
determinants	O
of	O
host	B-COMP
species	O
in	O
RNA	O
viruses	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	B-COMP
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	O
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	O
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

The	O
prevalence	O
of	O
HCoVs	O
was	O
higher	O
among	O
children	O
with	O
heart	O
diseases	O
(	O
24	O
.	O
6	O
%),	O
patients	O
under	O
stem	O
cell	B-COMP
transplantation	O
program	O
(	O
24	O
.	O
3	O
%)	O
and	O
renal	O
transplanted	O
patients	O
(	O
20	O
.	O
2	O
%).	O

RESULTS	O
:	O
IBV	O
infection	O
contributed	O
to	O
differential	O
expression	O
of	O
1777	O
genes	O
,	O
of	O
which	O
876	O
were	O
up	O
-	O
regulated	O
and	O
901	O
down	O
-	O
regulated	O
in	O
the	O
kidney	O
compared	O
to	O
those	O
of	O
control	O
chickens	O
and	O
103	O
associated	O
with	O
immune	O
and	O
inflammatory	O
responses	O
may	O
play	O
important	O
roles	O
in	O
the	O
host	B-COMP
defense	O
response	O
during	O
IBV	O
infection	O
.	O

Diverse	O
SARS	O
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoVs	O
)	O
have	O
now	O
been	O
reported	O
from	O
bats	O
in	O
China	O
,	O
Europe	O
and	O
Africa	O
,	O
but	O
none	O
is	O
considered	O
a	O
direct	O
progenitor	O
of	O
SARS	O
-	O
CoV	O
because	O
of	O
their	O
phylogenetic	O
disparity	O
from	O
this	O
virus	O
and	O
the	O
inability	O
of	O
their	O
spike	O
proteins	O
to	O
use	O
the	O
SARS	O
-	O
CoV	O
cellular	B-COMP
receptor	O
molecule	O
,	O
the	O
human	O
angiotensin	O
converting	O
enzyme	O
II	O
(	O
ACE2	O
).	O

ABSTRACT	O
:	O
Plus	O
-	O
strand	O
RNA	O
virus	O
replication	O
occurs	O
in	O
tight	O
association	O
with	O
cytoplasmic	B-COMP
host	O
cell	B-COMP
membranes	I-COMP
.	O

This	O
renders	O
IFN	O
-	O
	O
a	O
better	O
choice	O
for	O
the	O
treatment	O
against	O
many	O
diseases	O
including	O
viral	O
hepatitis	O
and	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
EMC	B-COMP
).	O

The	O
two	O
isolates	O
have	O
been	O
serially	O
propagated	O
in	O
cell	B-COMP
culture	O
for	O
over	O
30	O
passages	O
and	O
were	O
characterized	O
for	O
the	O
first	O
10	O
passages	O
.	O

Virus	O
production	O
in	O
cell	B-COMP
culture	O
was	O
confirmed	O
by	O
PEDV	O
-	O
specific	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
immunofluorescence	O
assays	O
,	O
and	O
electron	O
microscopy	O
.	O

TITLE	O
:	O
Transcriptional	O
profiling	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infection	O
in	O
CRFK	O
cells	B-COMP
and	O
in	O
PBMCs	O
from	O
FIP	O
diagnosed	O
cats	O
.	O

Currently	O
,	O
the	O
viruses	O
virulence	O
determinants	O
and	O
host	B-COMP
gene	O
expressions	O
during	O
FIPV	O
infection	O
are	O
not	O
fully	O
understood	O
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
developed	O
focusing	O
on	O
2	O
up	O
-	O
regulated	O
genes	O
(	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
together	O
with	O
an	O
apoptosis	O
associated	O
gene	O
PD	O
-	O
1	O
expressions	O
in	O
FIPV	O
infected	O
CRFK	O
cells	B-COMP
and	O
in	O
PBMCs	O
from	O
healthy	O
and	O
FIP	O
diagnosed	O
cats	O
produced	O
concordant	O
results	O
with	O
transcriptome	O
data	O
.	O

TITLE	O
:	O
Role	O
of	O
CD25	O
(+)	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
acute	O
and	O
persistent	O
coronavirus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

TITLE	O
:	O
Investigation	O
of	O
anti	O
-	O
middle	O
East	O
respiratory	O
syndrome	O
antibodies	B-COMP
in	O
blood	O
donors	O
and	O
slaughterhouse	O
workers	O
in	O
Jeddah	O
and	O
Makkah	O
,	O
Saudi	O
Arabia	O
,	O
fall	O
2012	O
.	O

The	O
infected	O
monkeys	O
showed	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	O
replication	O
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-COMP
production	O
,	O
indicating	O
that	O
this	O
monkey	O
model	O
is	O
suitable	O
for	O
studies	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

However	O
,	O
E2	O
treatment	O
reduced	O
the	O
basal	O
expression	O
of	O
platelet	O
endothelial	O
cell	B-COMP
adhesion	O
molecule	O
1	O
.	O

HCoV	O
strain	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
can	O
infect	O
and	O
persist	O
in	O
human	O
neural	O
cells	B-COMP
and	O
activate	O
neuroinflammatory	O
and	O
neurodegenerative	O
mechanisms	O
,	O
suggesting	O
that	O
it	O
could	O
be	O
involved	O
in	O
neurological	O
disease	O
of	O
unknown	O
etiology	O
in	O
humans	O
.	O

ERGIC	B-COMP
-	O
53	O
is	O
required	O
for	O
arenavirus	O
,	O
coronavirus	O
,	O
and	O
filovirus	O
propagation	O
;	O
in	O
its	O
absence	O
,	O
GP	O
-	O
containing	O
virus	B-COMP
particles	I-COMP
form	O
but	O
are	O
noninfectious	O
,	O
due	O
in	O
part	O
to	O
their	O
inability	O
to	O
attach	O
to	O
host	B-COMP
cells	B-COMP
.	O

Thus	O
,	O
we	O
have	O
identified	O
a	O
class	O
of	O
pathogen	O
-	O
derived	O
ERGIC	B-COMP
-	O
53	O
ligands	O
,	O
a	O
lectin	O
-	O
independent	O
basis	O
for	O
their	O
association	O
with	O
ERGIC	B-COMP
-	O
53	O
,	O
and	O
a	O
role	O
for	O
ERGIC	B-COMP
-	O
53	O
in	O
the	O
propagation	O
of	O
several	O
highly	O
pathogenic	O
RNA	O
virus	O
families	O
.	O

An	O
important	O
regulatory	O
factor	O
in	O
the	O
pathology	O
observed	O
in	O
ALI	O
/	O
ARDS	O
is	O
a	O
disruption	O
of	O
the	O
pulmonary	O
endothelial	O
barrier	O
which	O
,	O
in	O
combination	O
with	O
epithelial	O
barrier	O
disruption	O
,	O
causes	O
leakage	O
of	O
fluid	O
,	O
protein	O
and	O
cells	B-COMP
into	O
lung	O
airspaces	O
.	O

TITLE	O
:	O
Cell	B-COMP
-	O
based	O
antiviral	O
screening	O
against	O
coronaviruses	O
:	O
developing	O
virus	O
-	O
specific	O
and	O
broad	O
-	O
spectrum	O
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
,	O
MERS	O
-	O
CoV	O
(	O
NCoV	O
,	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
),	O
originating	O
from	O
the	O
Middle	O
-	O
East	O
,	O
has	O
been	O
discovered	O
.	O

However	O
,	O
optimal	O
use	O
of	O
this	O
core	O
public	O
health	O
laboratory	O
capacity	O
requires	O
a	O
fundamental	O
understanding	O
of	O
kinetics	O
of	O
viral	O
shedding	O
and	O
antibody	B-COMP
response	O
,	O
of	O
assay	O
validation	O
and	O
of	O
interpretation	O
of	O
test	O
outcomes	O
.	O

We	O
found	O
that	O
all	O
DNA	O
vaccines	O
induced	O
IgG	O
antibodies	B-COMP
,	O
predominantly	O
of	O
the	O
IgG2a	B-COMP
class	O
and	O
S3	O
DNA	O
vaccine	O
was	O
the	O
strongest	O
inducer	O
.	O

Multivariate	O
regression	O
analysis	O
identified	O
previous	O
cardiac	O
surgery	O
,	O
complex	O
cardiac	O
surgery	O
,	O
and	O
more	O
than	O
three	O
transfusions	O
with	O
packed	O
red	O
blood	O
cells	B-COMP
(	O
PRBC	O
)	O
were	O
independent	O
predictors	O
for	O
developing	O
ARDS	O
.	O

MBL	O
has	O
earlier	O
been	O
described	O
to	O
play	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
IBV	O
infection	O
and	O
the	O
production	O
of	O
IBV	O
-	O
specific	O
antibodies	B-COMP
,	O
which	O
may	O
be	O
exploited	O
in	O
optimising	O
IBV	O
vaccine	O
strategies	O
.	O

The	O
serum	B-COMP
MMP	O
-	O
9	O
was	O
positively	O
correlated	O
with	O
the	O
APACHE	O
II	O
score	O
on	O
the	O
1st	O
day	O
(	O
r	O
=	O
0	O
.	O
430	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
The	O
serum	B-COMP
MMP	O
-	O
9	O
,	O
CRP	O
and	O
the	O
APACHE	O
II	O
scores	O
on	O
the	O
3rd	O
,	O
5th	O
and	O
7th	O
day	O
in	O
the	O
treatment	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Efficacy	O
of	O
antitumor	O
vaccination	O
depends	O
to	O
a	O
large	O
extent	O
on	O
antigen	O
targeting	O
to	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
).	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
role	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
as	O
potential	O
therapeutic	O
option	O
for	O
severe	O
cases	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Interferon	O
-	O
	O
and	O
mycophenolic	O
acid	O
are	O
potent	O
inhibitors	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
cell	B-COMP
-	O
based	O
assays	O
.	O

We	O
showed	O
that	O
Ac	O
-	O
CMV	O
-	O
S1	O
induced	O
excellent	O
cellular	B-COMP
immunity	O
,	O
but	O
did	O
not	O
confer	O
adequate	O
protection	O
in	O
chickens	O
compared	O
with	O
the	O
conventional	O
inactivated	O
vaccine	O
.	O

ABSTRACT	O
:	O
Between	O
June	O
and	O
September	O
2013	O
,	O
sera	B-COMP
from	O
11	O
dromedary	O
camels	O
,	O
150	O
goats	O
,	O
126	O
sheep	O
and	O
91	O
cows	O
were	O
collected	O
in	O
Jordan	O
,	O
where	O
the	O
first	O
human	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
cluster	O
appeared	O
in	O
2012	O
.	O

Here	O
,	O
we	O
report	O
the	O
unexpected	O
identification	O
of	O
leaderless	O
genomes	O
,	O
in	O
addition	O
to	O
leader	O
-	O
containing	O
genomes	O
,	O
in	O
a	O
cell	B-COMP
culture	O
persistently	O
infected	O
with	O
BCoV	O
.	O
The	O
discovery	O
was	O
made	O
by	O
using	O
a	O
head	O
-	O
to	O
-	O
tail	O
ligation	O
method	O
that	O
examines	O
genomic	O
5	O
'-	O
terminal	O
sequences	O
at	O
different	O
times	O
postinfection	O
.	O

TITLE	O
:	O
Effect	O
of	O
microtubule	B-COMP
disruption	O
on	O
neuronal	O
spread	O
and	O
replication	O
of	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
vitro	O
.	O

We	O
tested	O
serum	B-COMP
samples	O
from	O
the	O
camels	O
for	O
IgG	O
immunofluorescence	O
assay	O
,	O
protein	O
microarray	O
,	O
and	O
virus	O
neutralisation	O
assay	O
.	O

Histopathological	O
observations	O
confirmed	O
the	O
nephritis	O
and	O
described	O
an	O
unusual	O
erosive	O
/	O
necrotic	O
proventriculitis	O
with	O
infiltration	O
of	O
lymphocytes	O
,	O
plasma	O
cells	B-COMP
and	O
heterophils	O
,	O
as	O
well	O
as	O
fibroplasia	O
in	O
the	O
lamina	O
propria	O
.	O

Its	O
surface	O
receptor	O
glycoproteins	O
,	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
neuraminidase	O
(	O
NA	O
),	O
are	O
characterized	O
by	O
high	O
antigenic	O
variation	O
,	O
thus	O
a	O
host	B-COMP
organism	I-COMP
cannot	O
develop	O
permanent	O
resistance	O
.	O

The	O
production	O
of	O
mature	O
pro	O
-	O
inflammatory	O
cytokines	O
was	O
also	O
suppressed	O
by	O
pretreatment	O
with	O
FJU	O
-	O
C4	O
in	O
either	O
cell	B-COMP
culture	O
medium	O
or	O
mice	O
serum	B-COMP
when	O
stimulated	O
by	O
LPS	O
.	O

The	O
chimeric	O
VLPs	O
elicited	O
significantly	O
higher	O
S1	O
-	O
specific	O
antibody	B-COMP
responses	O
in	O
intramuscularly	O
immunized	O
mice	O
and	O
chickens	O
than	O
inactivated	O
IBV	O
viruses	O
.	O

ABSTRACT	O
:	O
Concomitant	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
and	O
metabolic	O
syndrome	O
exacerbates	O
mortality	O
risk	O
;	O
yet	O
,	O
few	O
studies	O
have	O
examined	O
the	O
effect	O
of	O
combining	O
(	O
AER	B-COMP
+	O
RES	O
)	O
aerobic	O
(	O
AER	B-COMP
)	O
and	O
resistance	O
(	O
RES	O
)	O
training	O
for	O
individuals	O
with	O
T2D	O
and	O
metabolic	O
syndrome	O
.	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
metabolic	O
syndrome	O
scores	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
003	O
)	O
for	O
AER	B-COMP
(-	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
-	O
0	O
.	O
21	O
)	O
and	O
AER	B-COMP
+	O
RES	O
(-	O
0	O
.	O
79	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
40	O
to	O
-	O
0	O
.	O
35	O
),	O
both	O
being	O
significant	O
(	O
P	O
	O
0	O
.	O
02	O
)	O
versus	O
control	O
(	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
58	O
to	O
0	O
.	O
40	O
)	O
and	O
RES	O
(-	O
0	O
.	O
13	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
0	O
.	O
24	O
).	O

In	O
this	O
article	O
we	O
will	O
review	O
our	O
current	O
understanding	O
of	O
the	O
N	O
protein	O
structure	O
and	O
its	O
interaction	O
with	O
nucleic	B-COMP
acid	O
.	O

The	O
model	O
highlights	O
the	O
critical	O
role	O
of	O
modular	O
organization	O
and	O
intrinsic	O
disorder	O
of	O
the	O
N	O
protein	O
in	O
the	O
formation	O
and	O
functions	O
of	O
the	O
dynamic	O
RNP	B-COMP
capsid	O
in	O
RNA	O
viruses	O
.	O

Cells	B-COMP
and	O
supernatants	O
were	O
harvested	O
separately	O
and	O
virus	O
titers	O
were	O
quantified	O
by	O
plaque	O
assay	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
antibody	B-COMP
reactors	O
among	O
camels	O
in	O
Dubai	O
,	O
United	O
Arab	O
Emirates	O
,	O
in	O
2005	O
.	O

Thus	O
,	O
induction	O
of	O
the	O
cellular	B-COMP
immune	O
response	O
is	O
essential	O
in	O
vaccines	O
against	O
FIP	O
virus	O
(	O
FIPV	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
protein	O
coded	O
by	O
the	O
open	O
-	O
reading	O
-	O
frame	O
3a	O
of	O
SARS	O
coronavirus	O
has	O
been	O
demonstrated	O
to	O
form	O
a	O
cation	O
-	O
selective	O
channel	O
that	O
may	O
become	O
expressed	O
in	O
the	O
infected	O
cell	B-COMP
.	O

Pulmonary	O
hypertension	O
has	O
rarely	O
been	O
reported	O
in	O
mitochondrial	B-COMP
disorders	O
and	O
,	O
so	O
far	O
,	O
it	O
has	O
been	O
described	O
in	O
association	O
with	O
TMEM70	O
deficiency	O
only	O
in	O
one	O
patient	O
.	O

These	O
viruses	O
depend	O
on	O
cathepsin	O
L	O
for	O
entry	O
into	O
their	O
target	O
cells	B-COMP
.	O

In	O
addition	O
,	O
the	O
Hendra	O
and	O
Nipah	O
virus	O
fusion	O
glycoproteins	O
were	O
not	O
cleaved	O
in	O
the	O
presence	O
of	O
the	O
small	O
molecule	O
in	O
a	O
cell	B-COMP
-	O
based	O
cleavage	O
assay	O
.	O

The	O
main	O
finding	O
is	O
that	O
the	O
second	O
of	O
the	O
two	O
domains	O
plays	O
an	O
essential	O
role	O
in	O
recognizing	O
the	O
RNA	O
structure	O
that	O
allows	O
the	O
selective	O
packaging	O
of	O
genomic	O
RNA	O
into	O
assembled	O
virions	B-COMP
.	O

Direct	O
florescent	O
antibody	B-COMP
technique	O
(	O
dFAT	O
)	O
and	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
to	O
confirm	O
the	O
isolated	O
virus	O
strains	O
at	O
antigenic	O
and	O
genomic	O
levels	O
,	O
respectively	O
.	O

Subsequently	O
BCoV	O
got	O
adapted	O
to	O
the	O
vero	O
cell	B-COMP
line	O
upto	O
three	O
passages	O
,	O
which	O
was	O
confirmed	O
both	O
at	O
genomic	O
and	O
antigenic	O
levels	O
by	O
dFAT	O
and	O
RT	O
-	O
PCR	O
testing	O
.	O

Further	O
studies	O
are	O
required	O
for	O
isolation	O
of	O
different	O
viral	O
strains	O
,	O
finding	O
the	O
susceptible	O
cell	B-COMP
lines	O
and	O
also	O
to	O
confirm	O
the	O
variations	O
among	O
the	O
BCoV	O
isolates	O
at	O
antigenic	O
/	O
genomic	O
levels	O
.	O

All	O
three	O
ICA	O
kits	O
were	O
capable	O
of	O
detecting	O
anti	O
-	O
FCoV	O
antibodies	B-COMP
;	O
however	O
,	O
non	O
-	O
specific	O
positive	O
reactions	O
of	O
anti	O
-	O
FCoV	O
antibody	B-COMP
-	O
negative	O
plasma	O
samples	O
with	O
the	O
test	O
line	O
were	O
observed	O
in	O
2	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
and	O
CJNP	O
/	O
TNP	O
),	O
in	O
which	O
rNP	B-COMP
was	O
used	O
as	O
the	O
test	O
line	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
which	O
kinases	O
and	O
cytoskeletal	B-COMP
proteins	O
are	O
of	O
importance	O
during	O
internalisation	O
and	O
subsequent	O
intracellular	B-COMP
transport	O
.	O

Intracellular	B-COMP
trafficking	O
over	O
microtubules	B-COMP
was	O
mediated	O
by	O
MLCK	O
,	O
myosin	O
1	O
and	O
a	O
small	O
actin	O
tail	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
belong	O
to	O
the	O
family	O
Coronaviridae	O
,	O
which	O
primarily	O
cause	O
infection	O
of	O
the	O
upper	O
respiratory	O
and	O
gastrointestinal	O
tract	O
of	O
hosts	B-COMP
.	O

Our	O
data	O
indicate	O
that	O
Ag	O
NMs	O
are	O
effective	O
in	O
prevention	O
of	O
TGEV	O
-	O
mediated	O
cell	B-COMP
infection	O
as	O
a	O
virucidal	O
agent	O
or	O
as	O
an	O
inhibitor	O
of	O
viral	O
entry	O
and	O
the	O
present	O
findings	O
may	O
provide	O
new	O
insights	O
into	O
antiviral	O
therapy	O
of	O
coronaviruses	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
T	O
helper	O
1	O
and	O
linear	O
immunodominant	O
antibody	B-COMP
-	O
binding	O
epitopes	O
in	O
spike	O
1	O
domain	O
and	O
membrane	B-COMP
protein	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
synthetic	O
peptides	O
including	O
Th1	O
and	O
a	O
linear	O
immunodominant	O
antibody	B-COMP
-	O
binding	O
epitope	O
in	O
the	O
S1	O
domain	O
and	O
M	O
protein	O
of	O
FIPV	O
.	O

TITLE	O
:	O
Cell	B-COMP
adhesion	O
as	O
a	O
novel	O
approach	O
to	O
determining	O
the	O
cellular	B-COMP
binding	O
motif	O
on	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
.	O

Eukaryotic	O
viruses	O
generally	O
modify	O
the	O
5	O
'-	O
end	O
of	O
their	O
RNAs	O
to	O
mimic	O
the	O
cellular	B-COMP
mRNA	O
structure	O
,	O
thereby	O
facilitating	O
viral	O
replication	O
in	O
host	B-COMP
cells	B-COMP
.	O

Our	O
previous	O
work	O
showed	O
that	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
non	O
-	O
structural	O
protein	O
14	O
represents	O
a	O
structurally	O
novel	O
and	O
unique	O
guanine	O
-	O
N7	O
-	O
methyltransferase	O
(	O
N7	O
-	O
MTase	O
)	O
that	O
is	O
able	O
to	O
functionally	O
complement	O
yeast	O
cellular	B-COMP
N7	O
-	O
MTase	O
.	O

The	O
structure	O
also	O
revealed	O
an	O
N	O
-	O
cyclohexyl	O
-	O
2	O
-	O
aminethanesulfonic	O
acid	O
molecule	O
near	O
the	O
catalytic	O
triad	B-COMP
,	O
and	O
kinetic	O
studies	O
suggest	O
that	O
this	O
binding	O
site	O
is	O
also	O
used	O
by	O
other	O
PLpro	O
inhibitors	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
N	O
-	O
glycosylation	O
of	O
the	O
Fc	O
-	O
portion	O
of	O
serum	B-COMP
IgG	O
was	O
investigated	O
in	O
patients	O
with	O
GBS	O
before	O
and	O
after	O
treatment	O
with	O
IVIg	O
in	O
relation	O
to	O
clinical	O
course	O
and	O
outcome	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
serum	B-COMP
IgG	O
Fc	O
glycosylation	O
in	O
GBS	O
is	O
related	O
to	O
disease	O
severity	O
and	O
clinical	O
recovery	O
after	O
IVIg	O
and	O
may	O
help	O
to	O
develop	O
new	O
measures	O
to	O
monitor	O
the	O
efficacy	O
of	O
treatment	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
TGEV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
on	O
PK	O
-	O
15	O
cells	B-COMP
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
N	O
protein	O
might	O
play	O
an	O
important	O
role	O
in	O
TGEV	O
infection	O
-	O
induced	O
p53	O
activation	O
and	O
cell	B-COMP
cycle	O
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
occurrence	O
.	O

A	O
M	O
.	O
suis	O
-	O
expression	O
library	O
was	O
screened	O
for	O
immunogens	O
using	O
sera	B-COMP
from	O
infected	O
pigs	O
.	O

Serum	B-COMP
25	O
-	O
OHD	O
measured	O
early	O
after	O
admission	O
to	O
intensive	O
care	O
is	O
not	O
associated	O
with	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
,	O
hospital	O
or	O
one	O
-	O
year	O
mortality	O
in	O
critically	O
ill	O
patients	O
with	O
sepsis	O
although	O
lower	O
25	O
-	O
OHD	O
levels	O
were	O
associated	O
with	O
higher	O
one	O
-	O
year	O
mortality	O
in	O
patients	O
with	O
severe	O
trauma	O
.	O

vaccination	O
,	O
including	O
neutralizing	O
antibodies	B-COMP
,	O
but	O
more	O
robust	O
systemic	O
cellular	B-COMP
immune	O
responses	O
and	O
significantly	O
higher	O
local	O
mucosal	O
immune	O
responses	O
in	O
mouse	O
lungs	O
.	O

CoVs	O
encode	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
a	O
major	O
structural	O
protein	O
that	O
plays	O
multiple	O
roles	O
in	O
the	O
virus	O
replication	O
cycle	O
and	O
forms	O
a	O
ribonucleoprotein	B-COMP
complex	I-COMP
with	O
the	O
viral	O
RNA	O
through	O
the	O
N	O
protein	O
'	O
s	O
N	O
-	O
terminal	O
domain	O
(	O
N	O
-	O
NTD	O
).	O

Knockdown	O
of	O
the	O
cellular	B-COMP
Cyclophilin	O
A	O
(	O
CypA	O
/	O
PPIA	O
)	O
gene	O
in	O
Caco	O
-	O
2	O
cells	B-COMP
prevents	O
replication	O
of	O
HCoV	O
-	O
NL63	O
,	O
suggesting	O
that	O
CypA	O
is	O
required	O
for	O
virus	O
replication	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
analyses	O
allow	O
sensitive	O
detection	O
of	O
viral	O
nucleic	B-COMP
acids	O
,	O
but	O
it	O
is	O
not	O
clear	O
to	O
what	O
extent	O
specific	O
viruses	O
contribute	O
to	O
disease	O
because	O
many	O
viruses	O
have	O
been	O
detected	O
in	O
asymptomatic	O
children	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
adults	O
:	O
experience	O
from	O
the	O
Middle	O
East	O
.	O

Therefore	O
,	O
we	O
examined	O
tonsils	O
for	O
the	O
presence	O
of	O
respiratory	O
viruses	O
'	O
nucleic	B-COMP
acids	O
in	O
children	O
with	O
OSA	O
,	O
and	O
in	O
children	O
without	O
OSA	O
(	O
undergoing	O
surgery	O
for	O
recurrent	O
throat	O
infections	O
(	O
RI	O
)).	O

Important	O
differences	O
are	O
the	O
presence	O
of	O
multinucleated	O
giant	O
cells	B-COMP
and	O
intra	O
-	O
alveolar	O
fibrosis	O
in	O
SARS	O
and	O
more	O
fulminant	O
necrotizing	O
and	O
haemorrhagic	O
pneumonia	O
in	O
H5N1	O
influenza	O
.	O

Mice	O
developed	O
a	O
pneumonia	O
characterized	O
by	O
extensive	O
inflammatory	O
-	O
cell	B-COMP
infiltration	O
with	O
virus	O
clearance	O
occurring	O
6	O
-	O
8	O
d	O
after	O
infection	O
.	O

This	O
process	O
is	O
mediated	O
by	O
a	O
host	B-COMP
cell	I-COMP
protease	O
(	O
s	O
)	O
in	O
vivo	O
.	O

Both	O
of	O
these	O
conditions	O
can	O
present	O
with	O
hyperthermia	O
,	O
marked	O
muscle	O
rigidity	O
,	O
altered	O
consciousness	O
,	O
autonomic	O
dysfunction	O
,	O
and	O
elevated	O
serum	B-COMP
creatine	O
-	O
kinase	O
(	O
CK	O
)	O
levels	O
.	O

Mice	O
deficient	O
in	O
the	O
C5a	O
receptor	O
(	O
C5aR	O
)	O
or	O
the	O
susceptible	O
strains	O
treated	O
with	O
C5aR	O
antagonists	O
(	O
C5aRa	O
)	O
exhibit	O
significant	O
attenuation	O
of	O
the	O
disease	O
,	O
accompanied	O
by	O
a	O
remarkable	O
reduction	O
of	O
hepatic	O
fibrinogen	B-COMP
-	O
like	O
protein	O
2	O
(	O
Fgl2	O
),	O
a	O
hallmark	O
protein	O
that	O
causes	O
necrosis	O
of	O
infected	O
livers	O
.	O

Also	O
mitochondria	B-COMP
are	O
affected	O
;	O
a	O
subunit	O
of	O
respiratory	O
complex	B-COMP
III	I-COMP
is	O
dysregulated	O
,	O
the	O
inner	B-COMP
mitochondrial	I-COMP
membrane	I-COMP
is	O
leaking	O
protons	O
,	O
and	O
brain	O
ATP	O
levels	O
seem	O
reduced	O
.	O

Adverse	O
side	O
effects	O
of	O
Trolox	O
on	O
mitochondria	B-COMP
can	O
be	O
excluded	O
,	O
but	O
clear	O
indications	O
for	O
an	O
improvement	O
of	O
mitochondrial	B-COMP
function	O
were	O
not	O
found	O
.	O

The	O
nucleocapsid	B-COMP
gene	O
(	O
N	O
)	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
was	O
cloned	O
in	O
a	O
baculovirus	O
expression	O
system	O
for	O
insect	O
cell	B-COMP
expression	O
.	O

Transduction	O
of	O
the	O
N	O
gene	O
in	O
the	O
insect	O
Sf9	O
cells	B-COMP
revealed	O
a	O
high	O
level	O
of	O
protein	O
expression	O
.	O

However	O
,	O
despite	O
similar	O
viral	O
replication	O
and	O
CD4	O
(+)	O
T	O
cell	B-COMP
depletion	O
during	O
primary	O
SIV	O
infection	O
,	O
CD4	O
(+)	O
T	O
cell	B-COMP
restoration	O
kinetics	O
in	O
the	O
lung	O
and	O
gut	O
diverged	O
during	O
acute	O
viral	O
infection	O
.	O

Metabolic	O
gene	O
expression	O
and	O
signaling	O
was	O
examined	O
3	O
h	O
after	O
a	O
novel	O
30	O
-	O
min	O
bout	O
of	O
contraction	O
(	O
10	O
Hz	O
)	O
in	O
cachectic	O
Apc	B-COMP
(	O
Min	O
/+)	O
(	O
Min	O
)	O
and	O
C57BL	O
/	O
6	O
(	O
BL	O
-	O
6	O
)	O
mice	O
.	O

Active	O
inflammatory	O
demyelinating	O
lesions	O
induced	O
by	O
CD8	O
(+)	O
T	O
cells	B-COMP
or	O
by	O
innate	O
immunity	O
showed	O
macrophage	O
and	O
microglial	O
activation	O
together	O
with	O
the	O
expression	O
of	O
p22phox	O
,	O
but	O
low	O
or	O
absent	O
iNOS	O
reactivity	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
used	O
to	O
support	O
adults	O
with	O
severe	O
forms	O
of	O
respiratory	O
failure	O
.	O

Total	O
lung	O
leukocyte	O
numbers	O
and	O
relative	O
frequency	O
of	O
CD8	O
T	O
cells	B-COMP
,	O
B	O
cells	B-COMP
,	O
macrophages	O
and	O
dendritic	B-COMP
cells	B-COMP
were	O
greatly	O
reduced	O
in	O
the	O
aged	O
host	B-COMP
during	O
SARS	O
-	O
CoV	O
infection	O
,	O
despite	O
high	O
levels	O
of	O
chemoattractants	O
for	O
many	O
of	O
these	O
cells	B-COMP
in	O
the	O
aged	O
lung	O
.	O

This	O
virus	O
(	O
in	O
its	O
many	O
forms	O
)	O
is	O
difficult	O
to	O
treat	O
,	O
in	O
part	O
because	O
it	O
is	O
very	O
good	O
at	O
finding	O
""""	O
holes	O
""""	O
in	O
the	O
way	O
that	O
the	O
host	B-COMP
(	O
the	O
infected	O
individual	O
)	O
tries	O
to	O
control	O
and	O
eliminate	O
the	O
virus	O
.	O

These	O
data	O
provide	O
insight	O
into	O
host	B-COMP
-	O
virus	O
interactions	O
during	O
coronavirus	O
infection	O
and	O
suggest	O
that	O
the	O
ISG15	O
pathway	O
is	O
a	O
reasonable	O
target	O
for	O
controlling	O
severe	O
coronavirus	O
infection	O
although	O
the	O
best	O
treatment	O
will	O
likely	O
involve	O
multiple	O
pathways	O
and	O
targets	O
.	O

We	O
present	O
a	O
case	O
where	O
an	O
ICU	O
ventilator	O
was	O
brought	O
to	O
the	O
operating	O
room	O
and	O
used	O
in	O
the	O
treatment	O
of	O
ARDS	O
post	O
-	O
cardiopulmonary	O
bypass	O
and	O
ultimately	O
allowed	O
us	O
to	O
avoid	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
.	O

TITLE	O
:	O
Serum	B-COMP
MMP	O
-	O
8	O
and	O
TIMP	O
-	O
1	O
in	O
critically	O
ill	O
patients	O
with	O
acute	O
respiratory	O
failure	O
:	O
TIMP	O
-	O
1	O
is	O
associated	O
with	O
increased	O
90	O
-	O
day	O
mortality	O
.	O

Rarer	O
still	O
is	O
the	O
transport	O
of	O
such	O
a	O
patient	O
using	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
to	O
a	O
specialized	O
ECMO	O
center	O
for	O
definitive	O
repair	O
.	O

In	O
the	O
course	O
of	O
ALI	O
/	O
ARDS	O
,	O
mediators	O
released	O
from	O
resident	O
cells	B-COMP
,	O
such	O
as	O
alveolar	O
macrophages	O
,	O
may	O
act	O
as	O
chemoattractants	O
for	O
invading	O
cells	B-COMP
and	O
stimulate	O
local	O
cells	B-COMP
to	O
build	O
up	O
a	O
proinflammatory	O
micromilieu	O
.	O

Next	O
to	O
methods	O
for	O
nucleic	B-COMP
acid	O
detection	O
,	O
validated	O
serological	O
assays	O
are	O
particularly	O
important	O
as	O
the	O
timeframe	O
for	O
antibody	B-COMP
detection	O
is	O
less	O
restricted	O
.	O

Finally	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
documented	O
an	O
earlier	O
and	O
higher	O
systemic	O
TGEV	O
-	O
specific	O
serum	B-COMP
antibody	B-COMP
response	O
.	O

JMML	O
are	O
all	O
stem	O
cell	B-COMP
diseases	O
the	O
common	O
denominator	O
of	O
which	O
is	O
RAS	O
pathway	O
dysregulation	O
,	O
due	O
to	O
mutations	O
in	O
RAS	O
(	O
NRAS	O
,	O
KRAS	O
)	O
or	O
RAS	O
regulatory	O
components	O
(	O
PTPN11	O
,	O
NF1	O
or	O
CBL	O
).	O

IMPORTANCE	O
The	O
viruses	O
that	O
cause	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
poliomyelitis	O
,	O
and	O
hepatitis	O
C	O
all	O
replicate	O
in	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
).	O

None	O
of	O
these	O
viruses	O
was	O
found	O
to	O
be	O
significantly	O
less	O
fit	O
than	O
wild	O
-	O
type	O
,	O
and	O
two	O
were	O
actually	O
fitter	O
in	O
tests	O
in	O
two	O
kinds	O
of	O
cells	B-COMP
.	O

This	O
suggests	O
that	O
viruses	O
have	O
evolved	O
to	O
have	O
tremendous	O
plasticity	O
in	O
the	O
ability	O
to	O
form	O
membrane	B-COMP
-	O
associated	O
replication	O
complexes	O
and	O
that	O
large	O
and	O
numerous	O
DMVs	O
are	O
not	O
exclusively	O
associated	O
with	O
efficient	O
coronavirus	O
replication	O
.	O

Cross	O
species	O
(	O
including	O
zoonotic	O
)	O
poxvirus	O
infections	O
can	O
have	O
drastic	O
consequences	O
for	O
the	O
recipient	O
host	B-COMP
.	O

RT	O
-	O
qPCR	O
results	O
showed	O
that	O
the	O
circular	O
TFO	O
RNAs	O
,	O
except	O
TFO2	O
,	O
inhibit	O
FIPV	O
replication	O
,	O
where	O
the	O
viral	B-COMP
genome	I-COMP
copy	O
numbers	O
decreased	O
significantly	O
by	O
5	O
-	O
fold	O
log10	O
from	O
10	O
(	O
14	O
)	O
in	O
the	O
virus	O
-	O
inoculated	O
cells	B-COMP
to	O
10	O
(	O
9	O
)	O
in	O
the	O
circular	O
TFO	O
RNAs	O
-	O
transfected	O
cells	B-COMP
.	O

Furthermore	O
,	O
the	O
binding	O
of	O
the	O
circular	O
TFO	O
RNA	O
with	O
the	O
targeted	O
viral	B-COMP
genome	I-COMP
segment	O
was	O
also	O
confirmed	O
using	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

ABSTRACT	O
:	O
Although	O
many	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronaviruses	O
(	O
SARS	O
-	O
like	O
CoVs	O
)	O
have	O
been	O
identified	O
in	O
bats	O
in	O
China	O
,	O
Europe	O
,	O
and	O
Africa	O
,	O
most	O
have	O
a	O
genetic	O
organization	O
significantly	O
distinct	O
from	O
human	O
/	O
civet	O
SARS	O
CoVs	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
mediates	O
receptor	O
binding	O
and	O
determines	O
the	O
host	B-COMP
spectrum	O
,	O
resulting	O
in	O
their	O
failure	O
to	O
cause	O
human	O
infections	O
and	O
making	O
them	O
unlikely	O
progenitors	O
of	O
human	O
/	O
civet	O
SARS	O
CoVs	O
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
used	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
can	O
damage	O
pulmonary	O
epithelial	O
cells	B-COMP
through	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
oxygen	O
radicals	O
,	O
and	O
neutrophil	O
infiltration	O
,	O
termed	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Most	O
coronaviruses	O
cause	O
respiratory	O
or	O
intestinal	O
infections	O
in	O
their	O
animal	O
or	O
human	O
host	B-COMP
.	O

These	O
observations	O
help	O
us	O
understand	O
the	O
local	O
or	O
systematic	O
spread	O
of	O
the	O
infection	O
within	O
its	O
host	B-COMP
as	O
well	O
as	O
the	O
spread	O
of	O
the	O
virus	O
within	O
the	O
host	B-COMP
population	O
.	O

Available	O
evidence	O
from	O
clinical	O
studies	O
as	O
well	O
as	O
animal	O
models	O
of	O
SCI	O
demonstrate	O
that	O
increased	O
susceptibility	O
to	O
infection	O
is	O
derived	O
from	O
disruption	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
communication	O
with	O
the	O
host	B-COMP
immune	O
system	O
that	O
ultimately	O
leads	O
to	O
immunodepression	O
.	O

On	O
an	O
evolutionary	O
scale	O
,	O
this	O
host	B-COMP
-	O
virus	O
interaction	O
might	O
have	O
resulted	O
in	O
the	O
large	O
diversity	O
of	O
zoonotic	O
viruses	O
in	O
bats	O
,	O
possibly	O
through	O
bat	O
viruses	O
adapting	O
to	O
be	O
more	O
tolerant	O
of	O
the	O
fever	O
response	O
and	O
less	O
virulent	O
to	O
their	O
natural	O
hosts	B-COMP
.	O

IFITMs	O
typically	O
exert	O
their	O
antiviral	O
function	O
by	O
inhibiting	O
the	O
entry	O
of	O
a	O
broad	O
spectrum	O
of	O
viruses	O
into	O
their	O
host	B-COMP
cells	B-COMP
,	O
presumably	O
by	O
trapping	O
and	O
degrading	O
invading	O
virions	B-COMP
within	O
the	O
endocytic	O
compartments	O
.	O

Antibodies	B-COMP
against	O
canine	O
parvovirus	O
were	O
detected	O
in	O
71	O
.	O
6	O
%	O
(	O
63	O
/	O
88	O
)	O
blood	O
samples	O
and	O
the	O
seroprevalence	O
found	O
for	O
canine	O
distemper	O
virus	O
was	O
51	O
.	O
1	O
%	O
(	O
45	O
/	O
88	O
).	O

The	O
recombinant	O
virus	O
showed	O
somewhat	O
-	O
reduced	O
pathogenicity	O
compared	O
to	O
the	O
parental	O
lentogenic	O
LaSota	O
strain	O
but	O
effectively	O
elicited	O
hemagglutination	O
inhibition	O
antibodies	B-COMP
against	O
NDV	O
and	O
protected	O
chickens	O
against	O
lethal	O
challenge	O
with	O
virulent	O
NDV	O
/	O
CA02	O
.	O

Chickens	O
vaccinated	O
with	O
vaccine	O
B	O
had	O
significantly	O
higher	O
viral	O
loads	O
in	O
tears	O
at	O
5	O
days	O
postvaccination	O
(	O
DPV	O
)	O
than	O
those	O
vaccinated	O
with	O
vaccine	O
A	O
.	O
Vaccine	O
B	O
also	O
induced	O
a	O
significantly	O
higher	O
lachrymal	O
immunoglobulin	O
M	O
response	O
at	O
11	O
DPV	O
,	O
an	O
earlier	O
peak	O
of	O
IBV	O
-	O
specific	O
lachrymal	O
immunoglobulin	O
A	O
,	O
and	O
higher	O
serum	B-COMP
antibodies	B-COMP
than	O
vaccine	O
A	O
.	O
In	O
addition	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
birds	O
vaccinated	O
with	O
vaccine	O
B	O
had	O
vaccine	O
virus	O
detected	O
in	O
the	O
trachea	O
at	O
20	O
DPV	O
than	O
those	O
vaccinated	O
with	O
vaccine	O
A	O
.	O
Furthermore	O
,	O
the	O
virus	O
detected	O
at	O
20	O
DPV	O
in	O
most	O
of	O
the	O
chickens	O
vaccinated	O
with	O
vaccine	O
B	O
was	O
a	O
single	O
specific	O
subpopulation	O
(	O
subpopulation	O
4	O
)	O
selected	O
from	O
multiple	O
vaccine	O
subpopulations	O
detected	O
earlier	O
at	O
5	O
and	O
7	O
DPV	O
in	O
the	O
same	O
chickens	O
.	O

In	O
vitro	O
transcription	O
-	O
translation	O
was	O
performed	O
to	O
estimate	O
cell	B-COMP
free	O
protein	O
synthesis	O
.	O

Because	O
of	O
the	O
physiological	O
function	O
of	O
these	O
peptidase	O
systems	O
,	O
pathogenic	O
host	B-COMP
responses	O
may	O
be	O
potentially	O
amplified	O
and	O
cause	O
acute	O
respiratory	O
distress	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
last	O
E	O
carboxyl	O
-	O
terminal	O
residue	O
markedly	O
affected	O
E	O
release	O
,	O
N	O
association	O
,	O
and	O
VLP	B-COMP
incorporation	O
,	O
but	O
did	O
not	O
significantly	O
compromise	O
the	O
contribution	O
of	O
E	O
to	O
efficient	O
VLP	B-COMP
production	O
.	O

However	O
,	O
their	O
fatal	O
outcomes	O
and	O
critically	O
severe	O
illness	O
were	O
significantly	O
associated	O
with	O
high	O
serum	B-COMP
levels	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
	O
.	O

Here	O
,	O
we	O
used	O
a	O
well	O
-	O
characterized	O
nonimmune	O
human	O
Ab	O
-	O
phage	O
library	O
and	O
a	O
panning	O
strategy	O
with	O
proteoliposomes	O
and	O
cells	B-COMP
to	O
identify	O
seven	O
human	O
nAbs	O
against	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
Spike	O
protein	O
.	O

TITLE	O
:	O
Potent	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
by	O
human	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
to	O
the	O
viral	O
spike	O
glycoprotein	O
.	O

E	O
gene	O
encodes	O
a	O
small	O
multifunctional	O
protein	O
that	O
possesses	O
ion	O
channel	O
(	O
IC	O
)	O
activity	O
,	O
an	O
important	O
function	O
in	O
virus	O
-	O
host	B-COMP
interaction	O
.	O

TITLE	O
:	O
Exceptionally	O
potent	O
neutralization	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
by	O
human	O
monoclonal	O
antibodies	B-COMP
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
human	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
from	O
a	O
large	O
nonimmune	O
antibody	B-COMP
library	O
that	O
target	O
MERS	O
-	O
CoV	O
.	O
One	O
of	O
the	O
antibodies	B-COMP
,	O
m336	O
,	O
neutralized	O
the	O
virus	O
with	O
exceptional	O
potency	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
spike	O
fusion	O
protein	O
by	O
trypsin	O
in	O
cell	B-COMP
culture	O
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	O
activity	O
on	O
infection	O
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	O
-	O
independent	O
cell	B-COMP
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

TITLE	O
:	O
Diffuse	O
alveolar	O
damage	O
in	O
a	O
patient	O
with	O
Epstein	O
Barr	O
virus	O
(	O
EBV	O
)-	O
positive	O
diffuse	O
large	O
B	O
-	O
cell	B-COMP
lymphoma	O
,	O
severely	O
low	O
serum	B-COMP
folate	O
,	O
and	O
megaloblastic	O
anemia	O
:	O
a	O
case	O
report	O
of	O
autopsy	O
.	O

ABSTRACT	O
:	O
Sickle	O
cell	B-COMP
disease	O
(	O
or	O
drepanocytosis	O
)	O
is	O
a	O
hemoglobinopathy	O
characterized	O
by	O
an	O
increase	O
in	O
viscosity	O
and	O
adhesivity	O
of	O
the	O
typically	O
sickle	O
-	O
shaped	O
erythrocytes	O
.	O

Cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
were	O
identified	O
using	O
3	O
US	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
serologic	O
tests	O
for	O
detection	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
.	O

Here	O
,	O
we	O
report	O
the	O
requirement	O
of	O
a	O
cellular	B-COMP
factor	O
,	O
importin	O
-	O
7	O
,	O
for	O
efficient	O
virus	O
replication	O
in	O
the	O
alveolar	O
epithelium	O
of	O
mice	O
.	O

There	O
was	O
a	O
correlation	O
noted	O
between	O
SIRS	O
and	O
high	O
serum	B-COMP
creatinine	O
levels	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
between	O
SIRS	O
and	O
a	O
high	O
MELD	O
score	O
(	O
p	O
=	O
0	O
.	O
00	O
).	O

What	O
are	O
the	O
interactions	O
between	O
host	B-COMP
and	O
virus	O
that	O
determine	O
both	O
disease	O
form	O
(	O
wet	O
or	O
dry	O
)	O
and	O
outcome	O
(	O
death	O
or	O
resistance	O
)?	O

ABSTRACT	O
:	O
Neural	O
precursor	O
cells	B-COMP
(	O
NPCs	O
)	O
offer	O
a	O
promising	O
approach	O
for	O
treating	O
demyelinating	O
diseases	O
.	O

NPCs	O
preferentially	O
accumulated	O
within	O
areas	O
of	O
axonal	O
damage	O
,	O
initiated	O
direct	O
contact	O
with	O
axons	B-COMP
,	O
and	O
subsequently	O
expressed	O
the	O
myelin	B-COMP
proteolipid	O
protein	O
gene	O
,	O
initiating	O
remyelination	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
vv	O
-	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
support	O
to	O
mechanical	O
ventilation	O
when	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
present	O
.	O

We	O
report	O
the	O
case	O
of	O
an	O
18	O
-	O
year	O
-	O
old	O
male	O
driver	O
who	O
strayed	O
from	O
the	O
road	O
and	O
fell	O
15	O
m	O
into	O
a	O
backyard	O
by	O
landing	O
on	O
the	O
roof	O
of	O
its	O
car	B-COMP
.	O

However	O
,	O
whole	O
inactivated	O
SARS	O
vaccine	O
that	O
includes	O
nucleocapsid	B-COMP
protein	O
is	O
reported	O
to	O
induce	O
eosinophilic	O
infiltration	O
in	O
mouse	O
lungs	O
after	O
challenge	O
with	O
live	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
an	O
ability	O
of	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
to	O
reduce	O
the	O
side	O
effects	O
of	O
UV	O
-	O
V	O
vaccination	O
in	O
a	O
6	O
-	O
month	O
-	O
old	O
adult	O
BALB	O
/	O
c	O
mouse	O
model	O
was	O
investigated	O
,	O
using	O
the	O
mouse	O
-	O
passaged	O
Frankfurt	O
1	O
isolate	O
of	O
SARS	O
-	O
CoV	O
.	O
Immunization	O
of	O
adult	O
mice	O
with	O
UV	O
-	O
V	O
,	O
with	O
or	O
without	O
alum	O
,	O
resulted	O
in	O
partial	O
protection	O
from	O
lethal	O
doses	O
of	O
SARS	O
-	O
CoV	O
challenge	O
,	O
but	O
extensive	O
eosinophil	O
infiltration	O
in	O
the	O
lungs	O
was	O
observed	O
.	O

Inactivated	O
whole	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
related	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
vaccines	O
induce	O
neutralizing	O
antibodies	B-COMP
in	O
mouse	O
models	O
;	O
however	O
,	O
they	O
also	O
cause	O
increased	O
eosinophilic	O
immunopathology	O
in	O
the	O
lungs	O
upon	O
SARS	O
-	O
CoV	O
challenge	O
.	O

With	O
this	O
in	O
mind	O
,	O
there	O
is	O
a	O
need	O
to	O
incorporate	O
better	O
and	O
more	O
suitable	O
adjuvants	O
in	O
the	O
vaccines	O
to	O
elicit	O
the	O
elevated	O
immune	O
response	O
in	O
the	O
host	B-COMP
.	O

Acute	O
and	O
chronic	O
human	O
CNS	O
infections	O
are	O
associated	O
with	O
an	O
accumulation	O
of	O
heterogeneous	O
B	O
cell	B-COMP
subsets	O
;	O
however	O
,	O
their	O
influence	O
on	O
viral	O
load	O
and	O
disease	O
is	O
unclear	O
.	O

Collectively	O
,	O
this	O
study	O
proposes	O
an	O
evolutionary	O
conserved	O
step	O
in	O
the	O
life	O
cycle	O
of	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
,	O
the	O
recruitment	O
of	O
cellular	B-COMP
membranes	O
for	O
viral	O
replication	O
,	O
as	O
vulnerable	O
and	O
,	O
most	O
importantly	O
,	O
druggable	O
target	O
for	O
antiviral	O
intervention	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
30	O
years	O
,	O
we	O
have	O
learned	O
much	O
about	O
the	O
molecular	O
,	O
cellular	B-COMP
,	O
and	O
physiological	O
mechanisms	O
that	O
regulate	O
the	O
resolution	O
of	O
pulmonary	O
edema	O
in	O
both	O
the	O
normal	O
and	O
the	O
injured	O
lung	O
.	O

To	O
gain	O
insight	O
into	O
the	O
underlying	O
molecular	O
mechanism	O
,	O
we	O
performed	O
mutational	O
analysis	O
with	O
a	O
series	O
of	O
truncated	O
and	O
chimeric	O
constructs	O
of	O
fragment	O
crystallizable	O
	O
receptors	O
(	O
FcR	O
),	O
which	O
bind	O
antibody	B-COMP
-	O
coated	O
pathogens	O
.	O

Furthermore	O
,	O
only	O
FcRII	O
with	O
intact	O
cytoplasmic	B-COMP
signaling	O
domains	O
were	O
competent	O
to	O
sustain	O
ADE	O
of	O
SARS	O
-	O
CoVpp	O
infection	O
,	O
thus	O
providing	O
additional	O
information	O
on	O
the	O
role	O
of	O
downstream	O
signaling	O
by	O
FcRII	O
.	O

Since	O
cellular	B-COMP
immunity	O
is	O
thought	O
to	O
be	O
critical	O
in	O
preventing	O
FIP	O
and	O
because	O
diseased	O
cats	O
often	O
show	O
a	O
significant	O
decrease	O
in	O
interferon	O
-	O
	O
(	O
IFN	O
-	O
	O
)	O
production	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
the	O
feline	O
IFN	O
-	O
	O
gene	O
(	O
fIFNG	O
)	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Carbohydrate	O
structures	O
,	O
including	O
Lewis	O
X	O
(	O
Le	O
(	O
x	O
)),	O
which	O
is	O
not	O
synthesized	O
in	O
mutant	O
mice	O
that	O
lack	O
1	O
,	O
3	O
-	O
fucosyltransferase	O
9	O
(	O
Fut9	O
(-/-)),	O
are	O
involved	O
in	O
cell	B-COMP
-	O
cell	B-COMP
recognition	O
and	O
inflammation	O
.	O

The	O
absence	O
of	O
IL	O
-	O
27	O
signaling	O
accelerated	O
virus	O
control	O
within	O
the	O
CNS	O
associated	O
with	O
increased	O
IFN	O
-	O
	O
secreting	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	B-COMP
.	O

However	O
,	O
IL	O
-	O
10	O
production	O
by	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	B-COMP
was	O
reduced	O
significantly	O
.	O

TITLE	O
:	O
Activating	O
receptor	O
NKG2D	O
targets	O
RAE	O
-	O
1	O
-	O
expressing	O
allogeneic	O
neural	O
precursor	O
cells	B-COMP
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

We	O
also	O
demonstrate	O
that	O
transplantation	O
of	O
allogeneic	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
mice	O
resulted	O
in	O
infection	O
of	O
the	O
transplanted	O
cells	B-COMP
suggesting	O
that	O
these	O
cells	B-COMP
may	O
be	O
targets	O
for	O
infection	O
.	O

Viral	O
infection	O
of	O
cultured	O
cells	B-COMP
increased	O
RAE	O
-	O
1	O
expression	O
,	O
resulting	O
in	O
enhanced	O
NK	O
cell	B-COMP
-	O
mediated	O
killing	O
through	O
NKG2D	O
recognition	O
.	O

Replacing	O
proline	O
939	O
with	O
the	O
corresponding	O
HCoV	O
-	O
OC43	O
residue	O
,	O
leucine	O
,	O
decreased	O
the	O
ability	O
MHV	O
to	O
induce	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
,	O
providing	O
experimental	O
support	O
for	O
an	O
earlier	O
proposal	O
that	O
residues	O
929	O
-	O
944	O
make	O
up	O
the	O
fusion	O
peptide	O
of	O
the	O
MHV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
outcome	O
of	O
respiratory	O
virus	O
infection	O
is	O
determined	O
by	O
a	O
complex	O
interplay	O
of	O
viral	O
and	O
host	B-COMP
factors	O
.	O

The	O
coronavirus	O
nonstructural	O
integral	O
membrane	B-COMP
proteins	O
(	O
nsps	O
)	O
3	O
,	O
4	O
and	O
6	O
,	O
are	O
key	O
players	O
in	O
the	O
formation	O
of	O
the	O
rearranged	O
membranes	O
.	O

Severe	O
lung	O
disease	O
in	O
newborn	O
infants	O
and	O
older	O
patients	O
is	O
caused	O
by	O
mutations	O
in	O
genes	O
regulating	O
alveolar	O
epithelial	O
cells	B-COMP
and	O
surfactant	O
homeostasis	O
.	O

TITLE	O
:	O
Genetic	O
manipulation	O
of	O
outer	B-COMP
membrane	I-COMP
permeability	O
:	O
generating	O
porous	O
heterogeneous	O
catalyst	O
analogs	O
in	O
Escherichia	O
coli	O
.	O

In	O
these	O
patients	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
used	O
as	O
rescue	O
oxygenation	O
therapy	O
.	O

ABSTRACT	O
:	O
To	O
present	O
the	O
3	O
-	O
year	O
experience	O
of	O
using	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
patients	O
with	O
severe	O
respiratory	O
failure	O
in	O
a	O
single	O
centre	O
in	O
Hong	O
Kong	O
.	O

Overall	O
,	O
31	O
patients	O
(	O
mean	O
age	O
,	O
42	O
.	O
2	O
years	O
,	O
standard	O
deviation	O
,	O
14	O
.	O
1	O
years	O
;	O
21	O
males	O
)	O
received	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
the	O
treatment	O
of	O
severe	O
respiratory	O
failure	O
.	O

The	O
median	O
Murray	O
score	O
was	O
3	O
.	O
5	O
(	O
interquartile	O
range	O
,	O
3	O
.	O
0	O
-	O
3	O
.	O
5	O
);	O
the	O
median	O
duration	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
was	O
5	O
.	O
0	O
(	O
2	O
.	O
8	O
-	O
8	O
.	O
6	O
)	O
days	O
;	O
and	O
the	O
median	O
duration	O
of	O
mechanical	O
ventilator	O
support	O
was	O
18	O
.	O
2	O
(	O
7	O
.	O
8	O
-	O
27	O
.	O
9	O
)	O
days	O
.	O

The	O
downstream	O
pseudoknot	O
in	O
the	O
mRNA	O
impairs	O
the	O
closing	O
movement	O
of	O
the	O
30S	O
subunit	O
head	O
,	O
the	O
dissociation	O
of	O
EF	O
-	O
G	O
,	O
and	O
the	O
release	O
of	O
tRNA	O
from	O
the	O
ribosome	B-COMP
.	O

ABSTRACT	O
:	O
The	O
pseudoparticle	O
virus	O
neutralisation	O
test	O
(	O
ppNT	O
)	O
and	O
a	O
conventional	O
microneutralisation	O
(	O
MN	O
)	O
assay	O
are	O
specific	O
for	O
detecting	O
antibodies	B-COMP
to	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
when	O
used	O
in	O
seroepidemiological	O
studies	O
in	O
animals	O
.	O

The	O
RIM	O
tests	O
were	O
the	O
best	O
for	O
obtaining	O
a	O
result	O
quickly	O
(	O
10	O
-	O
15	O
mins	O
);	O
of	O
these	O
,	O
the	O
Speed	O
F	O
-	O
Corona	O
was	O
the	O
most	O
sensitive	O
,	O
at	O
92	O
.	O
4	O
%,	O
followed	O
by	O
FASTest	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
;	O
84	O
.	O
6	O
%)	O
and	O
Anigen	O
Rapid	O
FCoV	O
antibody	B-COMP
test	O
(	O
64	O
.	O
1	O
%).	O

TITLE	O
:	O
EF1A	O
interacting	O
with	O
nucleocapsid	B-COMP
protein	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
and	O
plays	O
a	O
role	O
in	O
virus	O
replication	O
.	O

Viroporins	O
,	O
encoded	O
by	O
all	O
common	O
respiratory	O
viruses	O
,	O
are	O
responsible	O
for	O
the	O
changes	O
in	O
intracellular	B-COMP
ion	O
homeostasis	O
that	O
modulate	O
inflammasome	O
activation	O
.	O

ABSTRACT	O
:	O
Autophagy	O
is	O
a	O
cellular	B-COMP
response	O
to	O
starvation	O
that	O
generates	O
autophagosomes	O
to	O
carry	O
long	O
-	O
lived	O
proteins	O
and	O
cellular	B-COMP
organelles	B-COMP
to	O
lysosomes	B-COMP
for	O
degradation	O
.	O

Treatment	O
of	O
mice	O
with	O
a	O
different	O
vaccine	O
consisting	O
of	O
L	O
.	O
casei	O
expressing	O
MDP	O
and	O
tuftsin	O
stimulated	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
.	O

These	O
findings	O
suggest	O
that	O
L	O
.	O
casei	O
expressing	O
MDP	O
and	O
tuftsin	O
possesses	O
substantial	O
immunopotentiating	O
properties	O
,	O
as	O
it	O
can	O
induce	O
humoral	O
and	O
T	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
upon	O
oral	O
administration	O
,	O
and	O
it	O
may	O
be	O
useful	O
in	O
oral	O
vaccines	O
against	O
TGEV	O
challenge	O
.	O

The	O
first	O
serum	B-COMP
sample	O
taken	O
on	O
day	O
6	O
tested	O
negative	O
for	O
leptospira	O
,	O
while	O
PCR	O
showed	O
positive	O
results	O
for	O
leptospiral	O
DNA	O
.	O

TITLE	O
:	O
Sensitivity	O
of	O
SARS	O
/	O
MERS	O
CoV	O
to	O
interferons	O
and	O
other	O
drugs	O
based	O
on	O
achievable	O
serum	B-COMP
concentrations	O
in	O
humans	O
.	O

The	O
most	O
active	O
drugs	O
against	O
SARS	O
/	O
MERS	O
CoV	O
at	O
clinically	O
achievable	O
serum	B-COMP
levels	O
were	O
type	O
I	O
interferons	O
and	O
a	O
TLR3	O
agonist	O
,	O
interferon	O
inducer	O
/	O
activator	O
.	O

Here	O
we	O
describe	O
novel	O
,	O
highly	O
adaptable	O
viral	O
entry	O
assays	O
making	O
use	O
of	O
minimal	O
complementation	O
of	O
the	O
E	O
.	O
coli	O
	O
-	O
galactosidase	O
in	O
mammalian	O
cells	B-COMP
.	O

Here	O
,	O
we	O
examined	O
whether	O
the	O
regulation	O
of	O
viral	O
poly	O
(	O
A	O
)	O
tail	O
length	O
is	O
cell	B-COMP
-	O
type	O
independent	O
and	O
whether	O
it	O
is	O
a	O
common	O
feature	O
of	O
coronaviruses	O
to	O
assess	O
the	O
significance	O
of	O
the	O
regulation	O
.	O

ABSTRACT	O
:	O
If	O
we	O
use	O
the	O
analogy	O
of	O
a	O
virus	O
as	O
a	O
living	O
entity	O
,	O
then	O
the	O
replicative	O
organelle	B-COMP
is	O
the	O
part	O
of	O
the	O
body	O
where	O
its	O
metabolic	O
and	O
reproductive	O
activities	O
are	O
concentrated	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
is	O
occurring	O
in	O
a	O
region	O
that	O
is	O
a	O
major	O
global	O
transport	O
hub	O
and	O
hosts	B-COMP
significant	O
mass	O
gatherings	O
,	O
making	O
it	O
imperative	O
to	O
understand	O
the	O
source	O
and	O
means	O
of	O
the	O
yet	O
unexplained	O
and	O
puzzling	O
ongoing	O
persistence	O
of	O
the	O
virus	O
in	O
the	O
human	O
population	O
.	O

Damage	O
control	O
resuscitation	O
strategies	O
can	O
be	O
used	O
for	O
such	O
patients	O
,	O
but	O
an	O
adequate	O
fresh	O
frozen	O
plasma	O
:	O
packed	O
red	O
blood	O
cell	B-COMP
(	O
FFP	O
:	O
PRBC	O
)	O
administration	O
ratio	O
must	O
be	O
established	O
.	O

Intravenous	O
immunization	O
with	O
peptide	O
-	O
loaded	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
followed	O
by	O
intranasal	O
boosting	O
with	O
recombinant	O
vaccinia	O
virus	O
(	O
rVV	O
)	O
encoding	O
S436	O
or	O
S525	O
resulted	O
in	O
accumulation	O
of	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	B-COMP
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BAL	O
),	O
lungs	O
,	O
and	O
spleen	O
.	O

Upon	O
challenge	O
with	O
a	O
lethal	O
dose	O
of	O
SARS	O
-	O
CoV	O
,	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	B-COMP
efficiently	O
produced	O
multiple	O
effector	O
cytokines	O
(	O
gamma	O
interferon	O
[	O
IFN	O
-	O
	O
],	O
tumor	O
necrosis	O
factor	O
alpha	O
[	O
TNF	O
-	O
	O
],	O
and	O
interleukin	O
2	O
[	O
IL	O
-	O
2	O
])	O
and	O
cytolytic	O
molecules	O
(	O
granzyme	O
B	O
)	O
and	O
reduced	O
lung	O
viral	O
loads	O
.	O

Proteolytic	O
activation	O
of	O
MERS	O
-	O
S	O
during	O
viral	O
uptake	O
into	O
target	O
cells	B-COMP
has	O
been	O
demonstrated	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
in	O
adults	O
is	O
growing	O
rapidly	O
given	O
recent	O
advances	O
in	O
technology	O
,	O
even	O
though	O
there	O
is	O
controversy	O
regarding	O
the	O
evidence	O
justifying	O
its	O
use	O
.	O

Antibody	B-COMP
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
is	O
a	O
mechanism	O
through	O
which	O
dengue	O
viruses	O
,	O
feline	O
coronaviruses	O
,	O
and	O
HIV	O
viruses	O
take	O
advantage	O
of	O
anti	O
-	O
viral	O
humoral	O
immune	O
responses	O
to	O
infect	O
host	B-COMP
target	O
cells	B-COMP
.	O

Here	O
we	O
describe	O
our	O
observations	O
of	O
SARS	O
-	O
CoV	O
using	O
ADE	O
to	O
enhance	O
the	O
infectivity	O
of	O
a	O
HL	O
-	O
CZ	O
human	O
promonocyte	O
cell	B-COMP
line	O
.	O

Testing	O
for	O
circulating	O
FIV	O
antibody	B-COMP
and	O
FeLV	O
antigen	O
,	O
a	O
PCR	O
assay	O
for	O
feline	O
coronavirus	O
performed	O
on	O
a	O
sample	O
of	O
peritoneal	O
fluid	O
,	O
and	O
fecal	O
flotation	O
yielded	O
negative	O
results	O
.	O

Our	O
data	O
confirmed	O
that	O
PEDV	O
entry	O
followed	O
clathrin	O
-	O
mediated	O
endocytosis	O
independence	O
of	O
caveolae	B-COMP
-	O
coated	B-COMP
pit	I-COMP
assembly	O
.	O

These	O
results	O
demonstrate	O
that	O
recombinant	O
DEV	O
expressing	O
the	O
TE	O
and	O
pre	O
-	O
membrane	B-COMP
proteins	O
is	O
protective	O
and	O
can	O
serve	O
as	O
a	O
potential	O
candidate	O
vaccine	O
to	O
prevent	O
DTMUV	O
infection	O
in	O
ducks	O
.	O

Quantitative	O
PCR	O
studies	O
and	O
fluorescence	O
-	O
activated	O
cell	B-COMP
sorting	O
(	O
FACS	O
)	O
analyses	O
showed	O
that	O
RDS1759	O
selectively	O
inhibited	O
reverse	O
transcription	O
in	O
cell	B-COMP
-	O
based	O
assays	O
.	O

Overall	O
,	O
we	O
provide	O
the	O
first	O
demonstration	O
that	O
RNase	O
H	O
inhibition	O
by	O
DKAs	O
is	O
due	O
not	O
only	O
to	O
their	O
chelating	O
properties	O
but	O
also	O
to	O
specific	O
interactions	O
with	O
highly	O
conserved	O
amino	O
acid	O
residues	O
in	O
the	O
RNase	O
H	O
domain	O
,	O
leading	O
to	O
effective	O
targeting	O
of	O
HIV	O
retrotranscription	O
in	O
cells	B-COMP
and	O
hence	O
offering	O
important	O
insights	O
for	O
the	O
rational	O
design	O
of	O
RNase	O
H	O
inhibitors	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
plays	O
a	O
variable	O
role	O
in	O
CoV	O
morphogenesis	O
,	O
depending	O
on	O
the	O
CoV	O
genus	O
,	O
being	O
absolutely	O
essential	O
in	O
some	O
cases	O
(	O
genus	O
	O
CoVs	O
such	O
as	O
TGEV	O
,	O
and	O
genus	O
	O
CoVs	O
such	O
as	O
MERS	O
-	O
CoV	O
),	O
but	O
not	O
in	O
others	O
(	O
genus	O
	O
CoVs	O
such	O
as	O
MHV	O
or	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Host	B-COMP
genetic	O
factors	O
are	O
thought	O
to	O
modulated	O
the	O
severity	O
of	O
disease	O
caused	O
by	O
infection	O
with	O
the	O
2009	O
H1N1	O
pandemic	O
influenza	O
virus	O
(	O
H1N1pdm09	O
).	O

We	O
recruited	O
29	O
H1N1pdm09	O
infected	O
subjects	O
from	O
Southern	O
Europe	O
(	O
mostly	O
Italians	O
)	O
with	O
a	O
wide	O
clinical	O
spectrum	O
of	O
disease	O
symptoms	O
;	O
the	O
sample	O
included	O
7	O
subjects	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
requiring	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
inhibitor	O
-	O
resistant	O
viruses	O
also	O
exhibited	O
postponed	O
and	O
reduced	O
production	O
of	O
infectious	O
virus	B-COMP
particles	I-COMP
.	O

Mutation	O
of	O
the	O
catalytic	O
cysteine	O
residue	O
of	O
PLpro	O
or	O
addition	O
of	O
a	O
PLpro	O
inhibitor	O
blocked	O
deISGylation	O
in	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
highlight	O
the	O
properties	O
and	O
functions	O
of	O
the	O
N	O
protein	O
,	O
with	O
specific	O
reference	O
to	O
(	O
i	O
)	O
the	O
topology	O
;	O
(	O
ii	O
)	O
the	O
intracellular	B-COMP
localization	O
and	O
(	O
iii	O
)	O
the	O
functions	O
of	O
the	O
protein	O
.	O

ABSTRACT	O
:	O
Leukocyte	O
adhesion	O
deficiency	O
type	O
1	O
(	O
LAD	O
1	O
-	O
CD18	O
deficiency	O
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
disturbance	O
of	O
phagocyte	O
function	O
associated	O
with	O
less	O
severe	O
cellular	B-COMP
and	O
humoral	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
and	O
extracorporeal	O
CO	O
(	O
2	O
)	O
removal	O
(	O
ECCO	O
(	O
2	O
)	O
R	O
)	O
techniques	O
have	O
increasingly	O
been	O
applied	O
in	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
refractory	O
to	O
conventional	O
mechanical	O
ventilatory	O
support	O
.	O

TITLE	O
:	O
Receptor	O
usage	O
and	O
cell	B-COMP
entry	O
of	O
bat	O
coronavirus	O
HKU4	O
provide	O
insight	O
into	O
bat	O
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
coronavirus	O
.	O

Thus	O
,	O
MERS	O
-	O
CoV	O
,	O
but	O
not	O
HKU4	O
,	O
has	O
adapted	O
to	O
use	O
human	O
DPP4	O
and	O
human	O
cellular	B-COMP
proteases	O
for	O
efficient	O
human	O
cell	B-COMP
entry	O
,	O
contributing	O
to	O
the	O
enhanced	O
pathogenesis	O
of	O
MERS	O
-	O
CoV	O
in	O
humans	O
.	O

They	O
also	O
suggest	O
that	O
DPP4	O
-	O
recognizing	O
bat	O
coronaviruses	O
threaten	O
human	O
health	O
because	O
of	O
their	O
spikes	O
'	O
capability	O
to	O
adapt	O
to	O
human	O
cells	B-COMP
for	O
cross	O
-	O
species	O
transmissions	O
.	O

The	O
lung	O
wet	O
:	O
dry	O
ratio	O
indicated	O
damage	O
to	O
the	O
alveolar	O
capillary	O
membrane	B-COMP
.	O

TITLE	O
:	O
DESC1	O
and	O
MSPL	O
activate	O
influenza	O
A	O
viruses	O
and	O
emerging	O
coronaviruses	O
for	O
host	B-COMP
cell	I-COMP
entry	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
two	O
cellular	B-COMP
serine	O
proteases	O
,	O
DESC1	O
and	O
MSPL	O
,	O
activate	O
influenza	O
viruses	O
and	O
emerging	O
coronaviruses	O
in	O
cell	B-COMP
culture	O
and	O
,	O
because	O
of	O
their	O
expression	O
in	O
human	O
lung	O
tissue	O
,	O
might	O
promote	O
viral	O
spread	O
in	O
the	O
infected	O
host	B-COMP
.	O

Moreover	O
,	O
most	O
of	O
the	O
cats	O
(	O
84	O
.	O
6	O
%,	O
22	O
/	O
26	O
)	O
infected	O
with	O
a	O
genotypic	O
untypable	O
virus	O
bearing	O
a	O
type	O
I	O
FCoV	O
antibody	B-COMP
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
oxidative	O
stress	O
represents	O
a	O
mechanism	O
for	O
modulating	O
the	O
virus	O
-	O
specific	O
T	O
cell	B-COMP
response	O
.	O

These	O
results	O
correlated	O
with	O
impaired	O
ability	O
to	O
control	O
viral	O
replication	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
within	O
the	O
CNS	O
at	O
days	O
7	O
and	O
14	O
post	O
-	O
infection	O
,	O
which	O
was	O
associated	O
with	O
diminished	O
accumulation	O
of	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	B-COMP
(	O
P	O
<	O
0	O
.	O
05	O
)	O
into	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
The	O
unfolded	O
-	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
a	O
signal	O
transduction	O
cascade	O
triggered	O
by	O
perturbation	O
of	O
the	O
homeostasis	O
of	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
).	O

It	O
has	O
been	O
well	O
established	O
that	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
is	O
closely	O
associated	O
with	O
coronavirus	O
replication	O
.	O

The	O
purified	O
recombinant	O
N	O
protein	O
based	O
single	O
serum	B-COMP
dilution	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
developed	O
for	O
IBV	O
to	O
measure	O
specific	O
antibody	B-COMP
in	O
the	O
sera	B-COMP
of	O
chickens	O
.	O

Using	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
a	O
model	O
of	O
normal	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IPEC	O
-	O
J2	O
),	O
we	O
researched	O
the	O
interaction	O
between	O
tight	O
and	O
adherens	B-COMP
junctions	I-COMP
and	O
microfilaments	B-COMP
of	O
IPEC	O
-	O
J2	O
cells	B-COMP
with	O
these	O
viruses	O
.	O

In	O
addition	O
,	O
they	O
also	O
could	O
affect	O
the	O
microfilaments	B-COMP
remodelling	O
of	O
IPEC	O
-	O
J2	O
cells	B-COMP
,	O
and	O
the	O
drug	O
-	O
interfered	O
microfilaments	B-COMP
could	O
inhibit	O
viral	O
replication	O
and	O
release	O
.	O

In	O
addition	O
,	O
the	O
3	O
'-	O
terminal	O
recombination	O
sites	O
of	O
M91	O
-	O
267	O
,	O
KUK	O
-	O
H	O
/	O
L	O
and	O
Tokyo	O
/	O
cat	O
/	O
130627	O
were	O
different	O
from	O
one	O
another	O
within	O
the	O
genes	O
encoding	O
membrane	B-COMP
and	O
spike	O
proteins	O
,	O
and	O
the	O
5	O
'-	O
terminal	O
recombination	O
sites	O
were	O
also	O
located	O
at	O
different	O
regions	O
of	O
ORF1	O
.	O

However	O
,	O
memory	O
CD8	O
T	O
cells	B-COMP
primed	O
without	O
CD4	O
T	O
cells	B-COMP
and	O
transferred	O
into	O
infected	O
CD4	O
-	O
sufficient	O
recipients	O
expanded	O
less	O
efficiently	O
and	O
were	O
not	O
sustained	O
in	O
the	O
CNS	O
,	O
contrasting	O
with	O
their	O
helped	O
counterparts	O
.	O

The	O
present	O
study	O
showed	O
that	O
directed	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
on	O
cells	B-COMP
previously	O
resistant	O
to	O
HCoV	O
-	O
NL63	O
renders	O
them	O
susceptible	O
,	O
showing	O
that	O
ACE2	O
protein	O
acts	O
as	O
a	O
functional	O
receptor	O
and	O
that	O
its	O
expression	O
is	O
required	O
for	O
infection	O
.	O

The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
a	O
characteristic	O
structural	O
component	O
of	O
the	O
viral	B-COMP
envelope	I-COMP
,	O
is	O
considered	O
as	O
a	O
key	O
target	O
of	O
vaccines	O
against	O
coronavirus	O
infection	O
.	O

This	O
protein	B-COMP
complex	I-COMP
is	O
a	O
fascinating	O
example	O
of	O
the	O
functional	O
integration	O
of	O
RNA	O
polymerase	O
,	O
capping	O
,	O
and	O
proofreading	O
activities	O
.	O

The	O
concentration	O
of	O
serum	B-COMP
IL	O
-	O
8	O
showed	O
a	O
similar	O
expression	O
pattern	O
in	O
both	O
groups	O
,	O
but	O
the	O
expression	O
increased	O
more	O
significantly	O
in	O
the	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
ARDS	O
group	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
observed	O
that	O
all	O
known	O
potent	O
broadly	O
neutralizing	O
antibodies	B-COMP
(	O
bnAbs	O
)	O
against	O
HIV	O
-	O
1	O
are	O
highly	O
divergent	O
from	O
their	O
putative	O
germline	O
predecessors	O
in	O
contrast	O
to	O
bnAbs	O
against	O
viruses	O
causing	O
acute	O
infections	O
such	O
as	O
henipaviruses	O
and	O
SARS	O
CoV	O
,	O
which	O
are	O
much	O
less	O
divergent	O
from	O
their	O
germline	O
counterparts	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	B-COMP
(	O
BMSCs	O
)	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
apoptosis	O
in	O
AMs	O
using	O
transwell	O
experiments	O
,	O
and	O
examined	O
the	O
underlying	O
mechanisms	O
LPS	O
induced	O
AMs	O
apoptosis	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
fashion	O
,	O
whereas	O
BMSCs	O
reduced	O
AMs	O
apoptosis	O
when	O
co	O
-	O
cultured	O
at	O
appropriate	O
ratios	O
.	O

TITLE	O
:	O
Effects	O
of	O
human	O
anti	O
-	O
spike	O
protein	O
receptor	O
binding	O
domain	O
antibodies	B-COMP
on	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
neutralization	O
escape	O
and	O
fitness	O
.	O

In	O
addition	O
,	O
S377	O
-	O
588	O
-	O
Fc	O
elicited	O
higher	O
-	O
titer	O
neutralizing	O
antibodies	B-COMP
than	O
all	O
the	O
other	O
RBD	O
fragments	O
in	O
mice	O
,	O
and	O
also	O
induced	O
high	O
-	O
titer	O
neutralizing	O
antibodies	B-COMP
in	O
immunized	O
rabbits	O
.	O

Leucocyte	O
and	O
lymphocyte	O
subsets	O
,	O
antibody	B-COMP
titers	O
,	O
1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
),	O
globulin	O
fractions	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
12	O
and	O
IFN	O
-	O
	O
in	O
blood	O
and	O
fecal	O
FCoV	O
excretion	O
were	O
determined	O
in	O
HB	O
(	O
n	O
=	O
75	O
)	O
and	O
in	O
cats	O
from	O
other	O
breeds	O
(	O
n	O
=	O
94	O
).	O

We	O
evaluated	O
whether	O
serum	B-COMP
SP	O
-	O
A	O
levels	O
in	O
the	O
presence	O
of	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
can	O
be	O
qualitatively	O
assessed	O
for	O
diagnosis	O
of	O
SAP	O
-	O
induced	O
ARDS	O
.	O

The	O
optimal	O
serum	B-COMP
SP	O
-	O
A	O
cut	O
-	O
off	O
value	O
to	O
discriminate	O
SAP	O
-	O
induced	O
ARDS	O
and	O
other	O
groups	O
(	O
SO	O
group	O
and	O
non	O
-	O
ARDS	O
group	O
)	O
is	O
around	O
150	O
ug	O
/	O
ml	O
.	O

TITLE	O
:	O
Hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
for	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
and	O
Down	O
syndrome	O
.	O

The	O
only	O
common	O
and	O
strong	O
association	O
identified	O
between	O
the	O
various	O
GWAS	O
case	O
configurations	O
was	O
for	O
the	O
34	O
.	O
7	O
-	O
45	O
.	O
8Mb	O
region	O
of	O
chromosome	B-COMP
A3	O
.	O

Arterial	O
oxygen	O
tension	O
(	O
PaO2	O
),	O
oxygenation	O
index	O
(	O
OI	O
)	O
as	O
well	O
as	O
dynamic	O
pulmonary	O
compliance	O
were	O
all	O
elevated	O
significantly	O
,	O
whereas	O
peak	O
inspiratory	O
pressure	O
significantly	O
decreased	O
at	O
6h	O
,	O
12h	O
and	O
24h	O
after	O
CRRT	O
respectively	O
;	O
serum	B-COMP
cytokine	O
level	O
and	O
CRP	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

This	O
review	O
highlights	O
innate	O
immune	O
receptors	O
and	O
cell	B-COMP
types	O
that	O
function	O
to	O
protect	O
against	O
infectious	O
challenges	O
to	O
the	O
respiratory	O
system	O
yet	O
also	O
may	O
be	O
associated	O
with	O
exacerbations	O
in	O
chronic	O
lung	O
diseases	O
.	O

We	O
report	O
here	O
a	O
carbohydrate	O
microarray	O
analysis	O
of	O
a	O
number	O
of	O
tumor	O
-	O
associated	O
carbohydrates	O
for	O
their	O
serum	B-COMP
antibody	B-COMP
reactivities	O
and	O
potential	O
immunogenicity	O
in	O
humans	O
.	O

Overall	O
,	O
this	O
research	O
revealed	O
that	O
polysaccharide	O
could	O
inhibit	O
PEDV	O
infection	O
,	O
and	O
that	O
polysaccharide	O
may	O
be	O
involved	O
in	O
PEDV	O
-	O
Vero	O
cell	B-COMP
interactions	O
,	O
as	O
the	O
virus	O
attachment	O
and	O
entry	O
to	O
the	O
Vero	O
cells	B-COMP
was	O
hindered	O
by	O
the	O
polysaccharide	O
.	O

Moreover	O
,	O
SHXB	O
-	O
infected	O
immature	O
Mo	O
-	O
DCs	O
showed	O
low	O
expression	O
of	O
IL	O
-	O
12	O
and	O
IFN	O
-	O
	O
,	O
and	O
also	O
lost	O
the	O
ability	O
to	O
stimulate	O
T	O
cell	B-COMP
proliferation	O
.	O

Three	O
young	O
consecutive	O
patients	O
with	O
homozygous	O
sickle	O
cell	B-COMP
disease	O
were	O
admitted	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
due	O
to	O
ACS	O
.	O

The	O
plasma	O
from	O
transfused	O
and	O
nontransfused	O
patients	O
with	O
severe	O
sepsis	O
was	O
examined	O
for	O
markers	O
of	O
cellular	B-COMP
injury	O
.	O

Many	O
studies	O
have	O
focused	O
on	O
telomeric	O
G4s	O
and	O
how	O
their	O
dynamics	O
are	O
regulated	O
to	O
enable	O
telomere	B-COMP
synthesis	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
was	O
to	O
analyze	O
altered	O
cellular	B-COMP
protein	O
levels	O
in	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)-	O
infected	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	B-COMP
in	O
order	O
to	O
determine	O
potential	O
virus	O
-	O
host	B-COMP
interactions	O
.	O

A	O
proteomic	O
approach	O
using	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantitation	O
(	O
iTRAQ	O
)-	O
coupled	O
two	O
-	O
dimensional	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
identification	O
was	O
conducted	O
on	O
the	O
TGEV	O
-	O
infected	O
ST	O
cells	B-COMP
.	O

Chickens	O
with	O
high	O
MBL	O
serum	B-COMP
concentrations	O
were	O
found	O
to	O
have	O
less	O
viral	O
load	O
in	O
the	O
trachea	O
than	O
chickens	O
with	O
low	O
MBL	O
serum	B-COMP
concentrations	O
indicating	O
that	O
these	O
chickens	O
were	O
less	O
severely	O
affected	O
by	O
the	O
infection	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
MBL	O
is	O
produced	O
locally	O
and	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
cellular	B-COMP
immune	O
response	O
after	O
an	O
IBV	O
infection	O
.	O

ABSTRACT	O
:	O
Endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)-	O
resident	O
glucosidases	O
I	O
and	O
II	O
sequentially	O
trim	O
the	O
three	O
terminal	O
glucose	O
moieties	O
on	O
the	O
N	O
-	O
linked	O
glycans	O
attached	O
to	O
nascent	O
glycoproteins	O
.	O

However	O
,	O
like	O
viral	B-COMP
envelope	I-COMP
proteins	O
,	O
the	O
cellular	B-COMP
receptors	O
of	O
many	O
viruses	O
are	O
also	O
glycoproteins	O
.	O

Blood	O
samples	O
were	O
obtained	O
to	O
determine	O
white	O
cell	B-COMP
counts	O
as	O
well	O
as	O
N	O
-	O
terminal	O
pro	O
-	O
B	O
-	O
type	O
natriuretic	O
peptide	O
,	O
C	O
reactive	O
protein	O
and	O
PCT	O
levels	O
.	O

Of	O
the	O
gammacoronaviruses	O
that	O
mainly	O
infect	O
birds	O
,	O
little	O
is	O
known	O
about	O
the	O
activation	O
of	O
the	O
host	B-COMP
immune	O
response	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
have	O
evolved	O
complex	O
relationships	O
with	O
their	O
host	B-COMP
cells	B-COMP
,	O
and	O
modulate	O
their	O
lipid	O
composition	O
,	O
lipid	O
synthesis	O
and	O
signalling	O
.	O

The	O
CCoV	O
life	O
cycle	O
is	O
closely	O
connected	O
to	O
plasma	B-COMP
membrane	I-COMP
cholesterol	O
,	O
from	O
cell	B-COMP
entry	O
to	O
viral	B-COMP
particle	I-COMP
production	O
.	O

It	O
will	O
be	O
interesting	O
in	O
the	O
future	O
to	O
analyse	O
the	O
membrane	B-COMP
microdomains	O
in	O
the	O
CCoV	O
envelope	B-COMP
.	O

Potential	O
of	O
mean	O
force	O
(	O
PMF	O
)	O
profiles	O
for	O
mono	O
(	O
Na	O
(+)	O
,	O
K	O
(+)	O
,	O
Cl	O
(-)	O
)	O
and	O
divalent	O
(	O
Ca	O
(	O
2	O
+)	O
)	O
ions	O
along	O
the	O
pore	B-COMP
are	O
calculated	O
.	O

This	O
study	O
clearly	O
confirms	O
that	O
killed	O
vaccine	O
has	O
induced	O
higher	O
antibody	B-COMP
levels	O
and	O
may	O
contribute	O
to	O
the	O
design	O
of	O
future	O
research	O
and	O
vaccine	O
programs	O
.	O

Adenovirus	O
vectors	O
to	O
silence	O
or	O
overexpress	O
ATF3	O
were	O
used	O
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	B-COMP
and	O
murine	O
BM	O
-	O
derived	O
macrophages	O
from	O
wild	O
-	O
type	O
or	O
ATF3	O
-	O
deficient	O
mice	O
.	O

Results	O
suggest	O
that	O
ATF3	O
confers	O
protection	O
to	O
lung	O
injury	O
by	O
preventing	O
inflammatory	O
cell	B-COMP
recruitment	O
and	O
barrier	O
disruption	O
in	O
a	O
cell	B-COMP
-	O
specific	O
manner	O
,	O
opening	O
novel	O
opportunities	O
for	O
cell	B-COMP
specific	O
therapy	O
for	O
ALI	O
/	O
VILI	O
.	O

Interestingly	O
,	O
robust	O
RBD	O
-	O
specific	O
antibody	B-COMP
and	O
T	O
-	O
cell	B-COMP
responses	O
were	O
induced	O
in	O
mice	O
immunized	O
with	O
the	O
rRBD	O
protein	O
in	O
combination	O
with	O
IFA	O
and	O
CpG	O
ODN	O
,	O
but	O
low	O
level	O
of	O
neutralizing	O
antibodies	B-COMP
were	O
elicited	O
.	O

The	O
vaccination	O
regimen	O
used	O
in	O
this	O
study	O
is	O
promising	O
and	O
could	O
improve	O
the	O
protection	O
offered	O
by	O
the	O
MERS	O
-	O
CoV	O
subunit	O
vaccine	O
by	O
eliciting	O
effective	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
.	O

TITLE	O
:	O
CD26	O
/	O
DPP4	O
cell	B-COMP
-	O
surface	O
expression	O
in	O
bat	O
cells	B-COMP
correlates	O
with	O
bat	O
cell	B-COMP
susceptibility	O
to	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
and	O
evolution	O
of	O
persistent	O
infection	O
.	O

We	O
found	O
that	O
the	O
susceptibility	O
or	O
resistance	O
of	O
these	O
bat	O
cell	B-COMP
lines	O
directly	O
correlates	O
with	O
the	O
presence	O
or	O
absence	O
of	O
cell	B-COMP
surface	I-COMP
-	O
expressed	O
CD26	O
/	O
DPP4	O
,	O
the	O
functional	O
human	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Human	O
anti	O
-	O
CD26	O
/	O
DPP4	O
antibodies	B-COMP
inhibited	O
infection	O
of	O
susceptible	O
bat	O
cells	B-COMP
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
gene	O
completely	O
overlaps	O
with	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
(	O
orf9a	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
emerged	O
in	O
the	O
Arabian	O
Gulf	O
region	O
,	O
with	O
its	O
epicentre	O
in	O
Saudi	O
Arabia	O
,	O
the	O
host	B-COMP
of	O
the	O
'	O
Hajj	O
'	O
which	O
is	O
the	O
world	O
'	O
s	O
the	O
largest	O
mass	O
gathering	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
salvage	O
therapy	O
,	O
but	O
the	O
effectiveness	O
is	O
controversial	O
.	O

Several	O
crystal	O
structures	O
have	O
determined	O
the	O
folding	O
of	O
CoV	O
RBD	O
and	O
the	O
mode	O
by	O
which	O
they	O
recognize	O
cell	B-COMP
entry	O
receptors	O
.	O

This	O
research	O
has	O
provided	O
significant	O
new	O
insight	O
into	O
functions	O
and	O
activities	O
of	O
the	O
replication	O
/	O
transcription	O
multi	O
-	O
protein	B-COMP
complex	I-COMP
.	O

All	O
eight	O
of	O
the	O
minor	O
structural	O
proteins	O
were	O
found	O
to	O
be	O
required	O
for	O
production	O
of	O
infectious	O
extracellular	B-COMP
virus	O
.	O

SHFV	O
causes	O
a	O
fatal	O
hemorrhagic	O
fever	O
in	O
macaques	O
but	O
asymptomatic	O
,	O
persistent	O
infections	O
in	O
natural	O
hosts	B-COMP
such	O
as	O
baboons	O
.	O

In	O
contrast	O
,	O
similar	O
percentages	O
of	O
myeloid	O
dendritic	B-COMP
cells	B-COMP
were	O
infected	O
but	O
virus	O
replication	O
was	O
efficient	O
in	O
the	O
macaque	O
cells	B-COMP
but	O
inefficient	O
in	O
the	O
baboon	O
cells	B-COMP
.	O

A	O
resazurin	O
-	O
based	O
cytopathic	O
effect	O
inhibition	O
assay	O
,	O
which	O
detects	O
viable	O
cells	B-COMP
through	O
their	O
reduction	O
of	O
the	O
substrate	O
resazurin	O
to	O
fluorescent	O
resorufin	O
,	O
was	O
developed	O
for	O
screening	O
compounds	O
for	O
antiviral	O
efficacy	O
against	O
FCoV	O
.	O
Plaque	O
reduction	O
and	O
virus	O
yield	O
reduction	O
assays	O
were	O
performed	O
to	O
confirm	O
antiviral	O
effects	O
of	O
candidate	O
compounds	O
identified	O
during	O
screening	O
,	O
and	O
the	O
possible	O
antiviral	O
mechanisms	O
of	O
action	O
of	O
these	O
compounds	O
were	O
investigated	O
using	O
virucidal	O
suspension	O
assays	O
and	O
CPE	O
inhibition	O
and	O
IFA	O
-	O
based	O
time	O
of	O
addition	O
assays	O
.	O

Rapid	O
adaptions	O
to	O
its	O
new	O
host	B-COMP
include	O
recent	O
acquisition	O
of	O
higher	O
-	O
GC	O
genes	O
,	O
expression	O
of	O
out	O
-	O
of	O
-	O
frame	O
proteins	O
within	O
predicted	O
genes	O
,	O
and	O
codon	O
selection	O
among	O
highly	O
expressed	O
genes	O
toward	O
the	O
translational	O
apparatus	O
of	O
its	O
new	O
host	B-COMP
.	O

It	O
is	O
unknown	O
how	O
these	O
proteins	O
induce	O
membrane	B-COMP
modification	O
or	O
which	O
regions	O
of	O
the	O
proteins	O
are	O
involved	O
in	O
DMV	O
formation	O
and	O
stability	O
.	O

The	O
S2	O
subunit	O
of	O
the	O
S	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
carries	O
out	O
fusion	O
between	O
the	O
virus	O
and	O
the	O
host	B-COMP
cells	B-COMP
.	O

Current	O
model	O
suggests	O
that	O
a	O
conformational	O
transition	O
,	O
upon	O
receptor	O
recognition	O
,	O
of	O
the	O
two	O
heptad	O
core	O
regions	O
of	O
S2	O
may	O
expose	O
the	O
hydrophobic	O
fusogenic	O
peptide	O
or	O
fusion	O
peptide	O
for	O
membrane	B-COMP
insertion	O
.	O

The	O
N	O
-	O
terminal	O
fusion	O
peptide	O
(	O
FP	O
,	O
residues	O
770	O
-	O
788	O
),	O
an	O
internal	O
fusion	O
peptide	O
(	O
IFP	O
,	O
residues	O
873	O
-	O
888	O
)	O
and	O
the	O
pre	O
-	O
transmembrane	B-COMP
region	O
(	O
PTM	O
,	O
residues	O
1185	O
-	O
1202	O
)	O
demonstrated	O
interactions	O
with	O
model	O
lipid	O
membranes	O
and	O
potentially	O
involved	O
in	O
the	O
fusion	O
process	O
.	O

Different	O
approaches	O
of	O
several	O
researchers	O
for	O
the	O
identification	O
of	O
cellular	B-COMP
interaction	O
candidates	O
relevant	O
for	O
coronavirus	O
replication	O
are	O
summarized	O
.	O

Cells	B-COMP
were	O
stained	O
with	O
convalescent	O
serum	B-COMP
of	O
the	O
patients	O
to	O
identify	O
infected	O
cells	B-COMP
and	O
apical	O
washes	O
were	O
analyzed	O
by	O
VIDISCA	O
-	O
454	O
,	O
a	O
next	O
-	O
generation	O
sequencing	O
virus	O
discovery	O
technique	O
.	O

Sequencing	O
subsequently	O
indicated	O
that	O
the	O
cells	B-COMP
were	O
infected	O
by	O
either	O
human	O
coronavirus	O
OC43	O
,	O
influenzavirus	O
B	O
,	O
or	O
influenzavirus	O
A	O
.	O
The	O
sequence	O
reads	O
covered	O
a	O
large	O
part	O
of	O
the	O
genome	O
(	O
52	O
%,	O
82	O
%,	O
and	O
57	O
%,	O
respectively	O
).	O

As	O
is	O
usual	O
with	O
reservoir	O
hosts	B-COMP
,	O
these	O
viruses	O
apparently	O
cause	O
little	O
or	O
no	O
pathology	O
in	O
bats	O
.	O

ABSTRACT	O
:	O
Infection	O
by	O
human	O
coronaviruses	O
is	O
usually	O
characterized	O
by	O
rampant	O
viral	O
replication	O
and	O
severe	O
immunopathology	O
in	O
host	B-COMP
cells	B-COMP
.	O

ABSTRACT	O
:	O
Aspirin	O
-	O
exacerbated	O
respiratory	O
disease	O
(	O
AERD	O
),	O
also	O
known	O
as	O
Samter	O
'	O
s	O
triad	B-COMP
,	O
is	O
a	O
clinical	O
syndrome	O
which	O
consists	O
of	O
aspirin	O
(	O
ASA	O
)	O
intolerance	O
,	O
chronic	O
rhinosinusitis	O
with	O
nasal	O
polyposis	O
,	O
and	O
intrinsic	O
bronchial	O
asthma	O
(	O
Press	O
Med	O
119	O
:	O
48	O
-	O
51	O
,	O
1922	O
).	O

Protection	O
against	O
eosinophilic	O
immunopathology	O
by	O
vaccines	O
containing	O
delta	O
inulin	O
adjuvants	O
correlated	O
better	O
with	O
enhanced	O
T	O
-	O
cell	B-COMP
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
)	O
recall	O
responses	O
rather	O
than	O
reduced	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
responses	O
,	O
suggesting	O
that	O
immunopathology	O
predominantly	O
reflects	O
an	O
inadequate	O
vaccine	O
-	O
induced	O
Th1	O
response	O
.	O

The	O
level	O
of	O
antibodies	B-COMP
to	O
elastase	O
was	O
greatly	O
increased	O
in	O
all	O
56	O
(	O
100	O
%)	O
children	O
.	O

The	O
STem	O
cells	B-COMP
for	O
ARDS	O
Treatment	O
(	O
START	O
)	O
trial	O
was	O
a	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalation	O
,	O
phase	O
1	O
clinical	O
trial	O
.	O

The	O
first	O
three	O
patients	O
were	O
treated	O
with	O
low	O
dose	O
MSCs	O
(	O
1	O
million	O
cells	B-COMP
/	O
kg	O
predicted	O
bodyweight	O
[	O
PBW	O
]),	O
the	O
next	O
three	O
patients	O
received	O
intermediate	O
dose	O
MSCs	O
(	O
5	O
million	O
cells	B-COMP
/	O
kg	O
PBW	O
),	O
and	O
the	O
final	O
three	O
patients	O
received	O
high	O
dose	O
MSCs	O
(	O
10	O
million	O
cells	B-COMP
/	O
kg	O
PBW	O
).	O

TITLE	O
:	O
Identification	O
of	O
the	O
interaction	O
between	O
vimentin	B-COMP
and	O
nucleocapsid	B-COMP
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

Clinical	O
features	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
include	O
atypical	O
pneumonia	O
and	O
progressive	O
respiratory	O
failure	O
that	O
is	O
highly	O
reminiscent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
caused	O
by	O
SARS	O
-	O
CoV	O
.	O
The	O
host	B-COMP
response	O
is	O
a	O
key	O
component	O
of	O
highly	O
pathogenic	O
respiratory	O
virus	O
infection	O
.	O

Through	O
our	O
genomics	O
-	O
based	O
approach	O
,	O
we	O
found	O
topological	O
differences	O
in	O
the	O
kinetics	O
and	O
magnitude	O
of	O
the	O
host	B-COMP
response	O
to	O
MERS	O
-	O
CoV	O
SA	O
1	O
and	O
MERS	O
-	O
CoV	O
Eng	O
1	O
,	O
with	O
differential	O
expression	O
of	O
innate	O
immune	O
and	O
pro	O
-	O
inflammatory	O
responsive	O
genes	O
as	O
a	O
result	O
of	O
IFN	O
,	O
TNF	O
and	O
IL	O
-	O
1	O
signaling	O
.	O

Diagnosis	O
of	O
refractory	O
Mycoplasma	O
pneumoniae	O
pneumonia	O
was	O
made	O
,	O
which	O
was	O
accompanied	O
by	O
decreased	O
neutrophils	O
[(	O
0	O
.	O
08	O
-	O
0	O
.	O
68	O
)	O
10	O
(	O
9	O
)/	O
L	O
],	O
hemoglobin	O
[(	O
79	O
-	O
103	O
)	O
g	O
/	O
L	O
],	O
platelet	O
[(	O
64	O
-	O
157	O
)	O
10	O
(	O
9	O
)/	O
L	O
],	O
plasma	O
fibrinogen	B-COMP
[(	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
)	O
g	O
/	O
L	O
],	O
lactate	O
dehydrogenase	O
[(	O
1	O
,	O
170	O
-	O
1	O
,	O
285	O
)	O
U	O
/	O
L	O
]	O
and	O
increased	O
serum	B-COMP
ferritin	O
[(	O
936	O
.	O
7	O
-	O
39	O
789	O
.	O
0	O
)	O
g	O
/	O
L	O
]	O
in	O
the	O
third	O
week	O
of	O
course	O
.	O

Cross	O
-	O
reactivities	O
between	O
other	O
lineage	O
A	O
and	O
B	O
CoVs	O
and	O
ChRCoV	O
HKU24	O
nucleocapsid	B-COMP
but	O
not	O
spike	O
polypeptide	O
were	O
demonstrated	O
.	O

Other	O
rats	O
,	O
including	O
Norway	O
rats	O
from	O
Hong	O
Kong	O
,	O
possessed	O
antibodies	B-COMP
only	O
against	O
N	O
protein	O
and	O
not	O
against	O
the	O
spike	O
polypeptide	O
,	O
suggesting	O
infection	O
by	O
CoVs	O
different	O
from	O
ChRCoV	O
HKU24	O
.	O

MARC	O
-	O
145	O
cells	B-COMP
were	O
treated	O
with	O
LiCl	O
at	O
various	O
stages	O
of	O
PRRSV	O
life	O
cycle	O
.	O

In	O
multivariate	O
analysis	O
,	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
during	O
the	O
first	O
3	O
days	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
were	O
associated	O
with	O
lower	O
mortality	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
75	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
64	O
-	O
0	O
.	O
88	O
;	O
p	O
=	O
0	O
.	O
0006	O
).	O

Moreover	O
,	O
infected	O
mice	O
treated	O
with	O
MT	O
did	O
express	O
anti	O
-	O
FAH	O
autoAb	O
and	O
high	O
levels	O
of	O
serum	B-COMP
HMGB1	O
.	O

Bioinformatics	O
,	O
GO	O
annotation	O
and	O
pathway	O
analysis	O
indicated	O
that	O
five	O
of	O
these	O
genes	O
(	O
Plexin	O
B1	O
,	O
TRIM27	O
,	O
PDGFC	O
,	O
SETBP1	O
and	O
USP7	O
)	O
may	O
be	O
important	O
for	O
the	O
generation	O
of	O
protective	O
antibodies	B-COMP
against	O
NDV	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

This	O
paves	O
the	O
way	O
for	O
further	O
research	O
on	O
host	B-COMP
immune	O
responses	O
against	O
NDV	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
,	O
immunoblotting	O
using	O
monoclonal	O
antibodies	B-COMP
and	O
Escherichia	O
coli	O
-	O
expressed	O
recombinant	O
PEDV	O
and	O
TGEV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
,	O
and	O
sequence	O
analysis	O
suggested	O
at	O
least	O
one	O
epitope	O
on	O
the	O
N	O
-	O
terminal	O
region	O
of	O
PEDV	O
/	O
TGEV	O
N	O
protein	O
that	O
contributed	O
to	O
this	O
cross	O
-	O
reactivity	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
virus	O
-	O
host	B-COMP
interaction	O
that	O
regulates	O
coronavirus	O
pathogenesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
egg	O
-	O
laying	O
phase	O
and	O
estrogen	O
affect	O
the	O
induction	O
of	O
cytotoxic	O
cells	B-COMP
in	O
response	O
to	O
avian	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
virus	O
at	O
early	O
stage	O
of	O
infection	O
in	O
the	O
oviduct	O
.	O

To	O
this	O
end	O
,	O
mast	O
cells	B-COMP
were	O
depleted	O
using	O
compound	O
48	O
/	O
80	O
(	O
C48	O
/	O
80	O
).	O

Ambulance	O
transportation	O
and	O
support	O
using	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
were	O
necessary	O
until	O
the	O
patient	O
recovered	O
.	O

Ultimately	O
,	O
the	O
potential	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
in	O
low	O
-	O
middle	O
income	O
countries	O
to	O
manage	O
common	O
diseases	O
is	O
discussed	O
.	O

TITLE	O
:	O
High	O
secretion	O
of	O
interferons	O
by	O
human	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
upon	O
recognition	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

A	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
CoV	O
-	O
MA15	O
)	O
lacking	O
the	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
(	O
rSARS	O
-	O
CoV	O
-	O
MA15	O
-	O
E	O
)	O
is	O
attenuated	O
in	O
vivo	O
.	O

We	O
computationally	O
predicted	O
potential	O
13	O
cellular	B-COMP
miRNAs	O
from	O
11	O
potential	O
hairpin	O
sequences	O
of	O
MERS	O
-	O
CoV	O
genome	O
.	O

Vacuolar	B-COMP
degeneration	O
and	O
diffuse	O
fatty	O
change	O
were	O
observed	O
in	O
the	O
liver	O
.	O

The	O
assay	O
has	O
a	O
sample	O
to	O
answer	O
turnaround	O
time	O
of	O
less	O
than	O
an	O
hour	O
using	O
extracted	O
RNA	O
or	O
diluted	O
or	O
low	O
volume	O
of	O
neat	O
serum	B-COMP
.	O

Among	O
patients	O
with	O
severe	O
trauma	O
and	O
major	O
bleeding	O
,	O
early	O
administration	O
of	O
plasma	O
,	O
platelets	O
,	O
and	O
red	O
blood	O
cells	B-COMP
in	O
a	O
1	O
:	O
1	O
:	O
1	O
ratio	O
compared	O
with	O
a	O
1	O
:	O
1	O
:	O
2	O
ratio	O
did	O
not	O
result	O
in	O
significant	O
differences	O
in	O
mortality	O
at	O
24	O
hours	O
or	O
at	O
30	O
days	O
.	O

Using	O
gene	O
silencing	O
,	O
the	O
ATP1A1	O
protein	O
was	O
shown	O
to	O
be	O
critical	O
for	O
infection	O
of	O
cells	B-COMP
with	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
and	O
VSV	O
but	O
not	O
with	O
IAV	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
inhibition	O
of	O
PPV	O
replication	O
in	O
swine	O
testis	O
(	O
ST	O
)	O
cells	B-COMP
by	O
LiCl	O
is	O
dose	O
-	O
dependent	O
,	O
and	O
that	O
the	O
antiviral	O
effect	O
of	O
LiCl	O
occurred	O
in	O
the	O
early	O
phase	O
of	O
PPV	O
replication	O
.	O

A	O
total	O
of	O
27	O
Korean	O
strains	O
from	O
1998	O
to	O
2013	O
were	O
analyzed	O
(	O
excluding	O
the	O
noncoding	O
regions	O
)	O
and	O
divided	O
into	O
two	O
groups	O
for	O
comparison	O
of	O
the	O
spike	O
(	O
S	O
),	O
ORF3	O
,	O
envelope	B-COMP
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
genes	O
with	O
those	O
of	O
reference	O
strains	O
,	O
vaccine	O
strains	O
,	O
and	O
previously	O
identified	O
strains	O
based	O
on	O
phylogenetic	O
analysis	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
can	O
use	O
serine	O
proteases	O
localized	O
at	O
the	O
cell	B-COMP
surface	I-COMP
,	O
for	O
their	O
activation	O
.	O

The	O
significantly	O
higher	O
incidence	O
of	O
bacteremia	O
noted	O
in	O
the	O
study	O
group	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
was	O
associated	O
with	O
a	O
higher	O
number	O
of	O
patients	O
with	O
multiple	O
trauma	O
and	O
a	O
higher	O
red	O
blood	O
cell	B-COMP
transfusion	O
requirement	O
(	O
P	O
=	O
0	O
.	O
008	O
).	O

PEDV	O
entry	O
into	O
polarized	O
cells	B-COMP
and	O
pAPN	O
grown	O
on	O
membrane	B-COMP
inserts	O
occurs	O
via	O
apical	O
membrane	B-COMP
.	O

ABSTRACT	O
:	O
Ubiquitin	O
-	O
like	O
domains	O
(	O
Ubls	O
)	O
now	O
are	O
recognized	O
as	O
common	O
elements	O
adjacent	O
to	O
viral	O
and	O
cellular	B-COMP
proteases	O
;	O
however	O
,	O
their	O
function	O
is	O
unclear	O
.	O

Biochemical	O
analyses	O
revealed	O
that	O
the	O
protein	O
shares	O
characteristics	O
with	O
homologous	O
proteins	O
encoded	O
in	O
other	O
coronaviral	O
genomes	O
,	O
with	O
the	O
N	O
-	O
terminal	O
domain	O
responsible	O
for	O
nucleic	B-COMP
acid	O
binding	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
involved	O
in	O
protein	O
oligomerization	O
.	O

To	O
assess	O
the	O
association	O
between	O
BRD	O
and	O
antibody	B-COMP
titers	O
,	O
38	O
calves	O
<	O
3	O
months	O
old	O
that	O
were	O
treated	O
for	O
BRD	O
were	O
matched	O
with	O
38	O
untreated	O
calves	O
.	O

Antibody	B-COMP
rates	O
of	O
decay	O
were	O
calculated	O
.	O

Calves	O
with	O
initial	O
antibody	B-COMP
titers	O
against	O
BRSV	O
<	O
1	O
:	O
64	O
that	O
were	O
treated	O
for	O
BRD	O
had	O
a	O
slower	O
rate	O
of	O
anti	O
-	O
BRSV	O
antibody	B-COMP
decay	O
than	O
did	O
similar	O
calves	O
that	O
were	O
not	O
treated	O
for	O
BRD	O
.	O

Vaccination	O
at	O
2	O
or	O
5	O
weeks	O
of	O
age	O
had	O
no	O
effect	O
on	O
the	O
rate	O
of	O
antibody	B-COMP
decay	O
.	O

The	O
full	O
-	O
length	O
coding	O
genome	O
sequence	O
was	O
26	O
,	O
985	O
nucleotides	O
long	O
with	O
11	O
open	O
reading	O
frames	O
and	O
no	O
hemagglutinin	O
-	O
esterase	O
gene	O
:	O
a	O
genome	O
organization	O
identical	O
to	O
that	O
of	O
turkey	O
coronavirus	O
[	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)-	O
replicase	O
(	O
ORFs	O
1a	O
,	O
1ab	O
)-	O
spike	O
(	O
S	O
)	O
protein	O
-	O
ORF3	O
(	O
ORFs	O
3a	O
,	O
3b	O
)-	O
small	O
envelop	O
(	O
E	O
or	O
3c	O
)	O
protein	O
-	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
-	O
ORF5	O
(	O
ORFs	O
4b	O
,	O
4c	O
,	O
5a	O
,	O
5b	O
)-	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
(	O
ORFs	O
N	O
and	O
6b	O
)-	O
3	O
'	O
UTR	O
].	O

A	O
colloidal	O
gold	O
-	O
labeled	O
recombinant	O
FCoV	O
nucleocapsid	B-COMP
protein	O
(	O
rNP	B-COMP
)	O
is	O
used	O
as	O
a	O
conjugate	O
.	O

A	O
technique	O
for	O
the	O
preparation	O
of	O
such	O
cell	B-COMP
cultures	O
,	O
using	O
a	O
combination	O
of	O
manual	O
and	O
trypsin	O
disaggregation	O
of	O
kidneys	O
dissected	O
from	O
2	O
-	O
to	O
3	O
-	O
week	O
-	O
old	O
birds	O
is	O
described	O
.	O

This	O
technique	O
routinely	O
gives	O
high	O
cell	B-COMP
yield	O
together	O
with	O
high	O
viability	O
and	O
the	O
resultant	O
adherent	O
primary	O
cultures	O
can	O
be	O
used	O
for	O
virus	O
growth	O
and	O
plaque	O
formation	O
.	O

Recent	O
studies	O
on	O
the	O
proteome	O
of	O
coronavirus	O
virions	B-COMP
have	O
shown	O
that	O
in	O
addition	O
to	O
the	O
structural	O
proteins	O
,	O
accessory	O
and	O
non	O
-	O
structural	O
virus	O
proteins	O
and	O
a	O
wide	O
variety	O
of	O
host	B-COMP
cell	I-COMP
proteins	O
associate	O
with	O
virus	B-COMP
particles	I-COMP
.	O

Our	O
assay	O
is	O
particularly	O
convenient	O
to	O
elucidate	O
critical	O
virus	O
-	O
host	B-COMP
interactions	O
for	O
viruses	O
for	O
which	O
infection	O
models	O
are	O
limited	O
.	O

Interfering	O
with	O
receptor	O
recognition	O
is	O
an	O
attractive	O
antiviral	O
therapy	O
,	O
since	O
it	O
occurs	O
before	O
the	O
viral	B-COMP
genome	I-COMP
has	O
reached	O
the	O
relative	O
safe	O
haven	O
within	O
the	O
cell	B-COMP
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
for	O
incorporating	O
a	O
proteinaceous	O
viral	O
receptor	O
,	O
feline	O
aminopeptidase	O
N	O
(	O
fAPN	O
),	O
into	O
SLBs	O
using	O
cell	B-COMP
blebbing	O
of	O
mammalian	O
cells	B-COMP
expressing	O
fAPN	O
in	O
the	O
plasma	B-COMP
membrane	I-COMP
.	O

After	O
the	O
identification	O
of	O
specific	O
cellular	B-COMP
factors	O
interacting	O
with	O
the	O
target	O
viral	O
protein	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
screening	O
system	O
,	O
co	O
-	O
immunoprecipitation	O
and	O
confocal	O
microscopy	O
analyses	O
are	O
often	O
used	O
to	O
verify	O
the	O
virus	O
-	O
host	B-COMP
protein	O
interactions	O
in	O
cells	B-COMP
.	O

TITLE	O
:	O
Investigation	O
of	O
the	O
functional	O
roles	O
of	O
host	B-COMP
cell	I-COMP
proteins	O
involved	O
in	O
coronavirus	O
infection	O
using	O
highly	O
specific	O
and	O
scalable	O
RNA	O
interference	O
(	O
RNAi	O
)	O
approach	O
.	O

Kal	O
'	O
s	O
Z	O
test	O
statistical	O
analysis	O
is	O
used	O
to	O
analyze	O
the	O
differentially	O
expressed	O
genes	O
from	O
the	O
infected	O
CRFK	O
cells	B-COMP
.	O

TITLE	O
:	O
Quantification	O
of	O
interferon	O
signaling	O
in	O
avian	O
cells	B-COMP
.	O

To	O
successfully	O
establish	O
functional	O
membrane	B-COMP
-	O
bound	O
RTCs	O
all	O
of	O
the	O
viral	O
and	O
host	B-COMP
constituents	O
need	O
to	O
be	O
correctly	O
spatiotemporally	O
organized	O
during	O
viral	O
infection	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
hybridoma	O
cell	B-COMP
line	O
secreting	O
monoclonal	O
antibody	B-COMP
against	O
S	O
protein	O
of	O
a	O
Chinese	O
variant	O
of	O
PEDV	O
.	O

The	O
cellular	B-COMP
localization	O
and	O
dynamics	O
of	O
mouse	O
hepatitis	O
CoV	O
A59	O
(	O
MHV	O
)	O
E	O
protein	O
were	O
investigated	O
to	O
further	O
understanding	O
of	O
its	O
role	O
during	O
infection	O
.	O

MHV	O
was	O
genetically	O
engineered	O
with	O
a	O
tetracysteine	O
tag	O
at	O
the	O
carboxy	O
end	O
of	O
E	O
.	O
Fluorescence	O
recovery	O
after	O
photobleaching	O
(	O
FRAP	O
)	O
showed	O
that	O
E	O
is	O
mobile	O
in	O
ERGIC	B-COMP
/	O
Golgi	B-COMP
membranes	O
.	O

However	O
,	O
whether	O
there	O
is	O
interplay	O
between	O
nsp16	O
and	O
host	B-COMP
proteins	O
was	O
not	O
yet	O
clear	O
.	O

Cell	B-COMP
culture	O
isolation	O
and	O
propagation	O
were	O
optimized	O
,	O
and	O
the	O
isolates	O
were	O
serially	O
propagated	O
in	O
cell	B-COMP
culture	O
for	O
>	O
20	O
passages	O
.	O

Results	O
showed	O
that	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
in	O
combination	O
with	O
ionomycin	O
was	O
a	O
consistent	O
inducer	O
of	O
CD107a	O
cell	B-COMP
surface	I-COMP
mobilisation	O
on	O
chicken	O
CTL	O
in	O
a	O
4h	O
cell	B-COMP
culture	O
model	O
.	O

In	O
chickens	O
experimentally	O
infected	O
with	O
IBV	O
,	O
higher	O
frequencies	O
of	O
CTL	O
isolated	O
from	O
respiratory	O
tissues	O
were	O
positive	O
for	O
CD107a	O
on	O
the	O
cell	B-COMP
surface	I-COMP
compared	O
to	O
those	O
from	O
uninfected	O
control	O
chickens	O
indicating	O
in	O
vivo	O
activation	O
.	O

Monitoring	O
of	O
CD107a	O
cell	B-COMP
surface	I-COMP
mobilisation	O
may	O
thus	O
be	O
a	O
useful	O
tool	O
for	O
studies	O
of	O
chicken	O
CTL	O
cytolytic	O
potential	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Goat	O
anti	O
-	O
turkey	O
IgG	O
(	O
H	O
+	O
L	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-COMP
.	O

Of	O
the	O
322	O
sera	B-COMP
from	O
the	O
field	O
,	O
101	O
were	O
positive	O
for	O
TCoV	O
by	O
immunofluorescent	O
antibody	B-COMP
assay	O
(	O
IFA	O
).	O

These	O
results	O
indicated	O
that	O
the	O
established	O
antibody	B-COMP
-	O
capture	O
ELISA	O
in	O
conjunction	O
with	O
recombinant	O
TCoV	O
N	O
protein	O
as	O
the	O
coating	O
protein	O
can	O
be	O
utilized	O
for	O
detection	O
of	O
antibodies	B-COMP
to	O
TCoV	O
in	O
turkey	O
flocks	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
the	O
viral	O
RNA	O
motif	O
bound	O
the	O
GAIT	B-COMP
complex	I-COMP
and	O
inhibited	O
the	O
in	O
vitro	O
translation	O
of	O
a	O
chimeric	O
mRNA	O
containing	O
this	O
RNA	O
motif	O
.	O

Moreover	O
,	O
the	O
disruption	O
of	O
the	O
viral	O
GAIT	O
-	O
like	O
RNA	O
motif	O
led	O
to	O
an	O
exacerbated	O
innate	O
immune	O
response	O
triggered	O
by	O
MDA5	O
,	O
indicating	O
that	O
the	O
GAIT	O
-	O
like	O
RNA	O
motif	O
counteracts	O
the	O
host	B-COMP
innate	O
immune	O
response	O
.	O

Following	O
convection	O
enhanced	O
delivery	O
(	O
CED	O
),	O
conventional	O
gene	O
vectors	O
are	O
confined	O
to	O
the	O
injection	O
site	O
,	O
presumably	O
by	O
adhesive	O
interactions	O
with	O
the	O
brain	O
ECM	B-COMP
and	O
do	O
not	O
provide	O
gene	O
expression	O
beyond	O
the	O
point	O
of	O
administration	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS5B	O
RNA	O
-	O
depended	O
-	O
RNA	O
-	O
polymerase	O
(	O
RdRp	O
)	O
is	O
an	O
essential	O
enzyme	O
in	O
HCV	O
viral	O
replication	O
and	O
has	O
no	O
functional	O
equivalent	O
in	O
mammalian	O
cells	B-COMP
.	O

TITLE	O
:	O
Eucalyptol	O
suppresses	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
through	O
an	O
extracellular	B-COMP
signal	O
-	O
regulated	O
kinase	O
-	O
dependent	O
nuclear	O
factor	O
-	O
kappa	O
B	O
pathway	O
to	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
in	O
an	O
acute	O
lung	O
inflammation	O
model	O
.	O

The	O
change	O
in	O
virulence	O
was	O
highly	O
predictable	O
from	O
the	O
host	B-COMP
phylogeny	O
,	O
with	O
hosts	B-COMP
clustering	O
together	O
in	O
distinct	O
clades	O
displaying	O
high	O
or	O
low	O
virulence	O
.	O

59	O
unique	O
miRNAs	O
displayed	O
significant	O
differentially	O
expression	O
between	O
the	O
normal	O
and	O
TGEV	O
-	O
infected	O
ST	O
cell	B-COMP
samples	O
:	O
15	O
miRNAs	O
were	O
significantly	O
up	O
-	O
regulated	O
and	O
44	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
identification	O
of	O
ST	O
cell	B-COMP
miRNAs	O
and	O
the	O
comprehensive	O
analysis	O
of	O
the	O
miRNA	O
regulatory	O
mechanism	O
during	O
TGEV	O
infection	O
,	O
which	O
revealed	O
the	O
miRNA	O
molecular	O
regulatory	O
mechanisms	O
for	O
the	O
viral	O
infection	O
,	O
expression	O
of	O
viral	O
genes	O
and	O
the	O
expression	O
of	O
immune	O
-	O
related	O
genes	O
.	O

Herein	O
,	O
the	O
self	O
-	O
assembly	O
of	O
TK9	O
,	O
a	O
nine	O
-	O
residue	O
peptide	O
of	O
the	O
extra	O
membrane	B-COMP
C	O
-	O
terminal	O
tail	O
of	O
the	O
SARS	O
corona	O
virus	O
envelope	B-COMP
,	O
and	O
its	O
variants	O
were	O
characterized	O
through	O
biophysical	O
,	O
spectroscopic	O
,	O
and	O
simulated	O
studies	O
,	O
and	O
it	O
was	O
confirmed	O
that	O
the	O
structure	O
of	O
these	O
peptides	O
influences	O
their	O
aggregation	O
propensity	O
,	O
hence	O
,	O
mimicking	O
amyloid	O
proteins	O
.	O

Antivirals	O
with	O
potent	O
in	O
vitro	O
activities	O
include	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
,	O
antiviral	O
peptides	O
,	O
interferons	O
,	O
mycophenolic	O
acid	O
,	O
and	O
lopinavir	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
ubiquitin	O
-	O
like	O
domain	O
at	O
the	O
amino	O
terminus	O
of	O
nsp3	O
is	O
essential	O
and	O
participates	O
in	O
a	O
critical	O
interaction	O
with	O
the	O
viral	B-COMP
nucleocapsid	I-COMP
protein	O
early	O
in	O
infection	O
.	O

ABSTRACT	O
:	O
Plus	O
strand	O
RNA	O
viruses	O
that	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
face	O
challenges	O
in	O
supporting	O
the	O
numerous	O
biosynthetic	O
functions	O
required	O
for	O
replication	O
and	O
propagation	O
.	O

This	O
review	O
summarizes	O
recent	O
gains	O
in	O
our	O
knowledge	O
of	O
how	O
cytoplasmic	B-COMP
RNA	O
viruses	O
use	O
these	O
co	O
-	O
opted	O
host	B-COMP
nuclear	O
factors	O
in	O
new	O
functional	O
roles	O
supporting	O
virus	O
translation	O
and	O
virus	O
RNA	O
replication	O
and	O
common	O
themes	O
employed	O
between	O
different	O
virus	O
groups	O
.	O

TITLE	O
:	O
Serum	B-COMP
biomarkers	O
of	O
oxidative	O
stress	O
in	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
possible	O
presence	O
of	O
oxidative	O
stress	O
in	O
cats	O
naturally	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
by	O
investigating	O
two	O
antioxidant	O
biomarkers	O
in	O
serum	B-COMP
:	O
paraoxonase	O
-	O
1	O
(	O
PON1	O
)	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
).	O

Tetraspanin	O
antibodies	B-COMP
inhibited	O
CoV	O
and	O
LP	O
IAV	O
infections	O
,	O
but	O
their	O
virus	O
-	O
blocking	O
activities	O
were	O
overcome	O
by	O
expressing	O
excess	O
TEM	B-COMP
-	O
associated	O
proteases	O
.	O

Among	O
these	O
priming	O
components	O
are	O
proteases	O
,	O
which	O
cleave	O
viral	O
surface	O
glycoproteins	O
,	O
unleashing	O
them	O
to	O
refold	O
in	O
ways	O
that	O
catalyze	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusions	O
.	O

At	O
PIDs	O
1	O
-	O
5	O
,	O
PEDV	O
-	O
infected	O
pigs	O
exhibited	O
mildly	O
to	O
extensively	O
disorganized	O
,	O
irregular	O
distribution	O
and	O
reduced	O
expression	O
of	O
ZO	O
-	O
1	O
or	O
E	O
-	O
Cadherin	O
in	O
villous	O
,	O
but	O
not	O
crypt	O
epithelial	O
cells	B-COMP
of	O
the	O
jejunum	O
and	O
ileum	O
,	O
but	O
not	O
in	O
the	O
large	O
intestine	O
,	O
when	O
compared	O
to	O
the	O
negative	O
controls	O
.	O

This	O
patient	O
was	O
successfully	O
managed	O
by	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
high	O
frequency	O
oscillator	O
ventilation	O
,	O
proning	O
position	O
and	O
tube	O
thoracostomy	O
.	O

ABSTRACT	O
:	O
Scientific	O
evidence	O
suggests	O
that	O
dromedary	O
camels	O
are	O
the	O
intermediary	O
host	B-COMP
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

We	O
aimed	O
to	O
do	O
a	O
nationwide	O
serosurvey	O
in	O
Saudi	O
Arabia	O
to	O
establish	O
the	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
,	O
both	O
in	O
the	O
general	O
population	O
and	O
in	O
populations	O
of	O
individuals	O
who	O
have	O
maximum	O
exposure	O
to	O
camels	O
.	O

Between	O
Dec	O
1	O
,	O
2012	O
,	O
and	O
Dec	O
1	O
,	O
2013	O
,	O
we	O
obtained	O
individual	O
serum	B-COMP
samples	O
from	O
10	O
,	O
009	O
individuals	O
.	O

Compared	O
with	O
the	O
general	O
population	O
,	O
seroprevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
was	O
significantly	O
increased	O
by	O
15	O
times	O
in	O
shepherds	O
(	O
two	O
[	O
2	O
	O
3	O
%]	O
of	O
87	O
,	O
p	O
=	O
0	O
	O
0004	O
)	O
and	O
by	O
23	O
times	O
in	O
slaughterhouse	O
workers	O
(	O
five	O
[	O
3	O
	O
6	O
%]	O
of	O
140	O
;	O
p	O
<	O
0	O
	O
0001	O
).	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
a	O
diagnosis	O
of	O
GATA	O
-	O
2	O
deficiency	O
should	O
be	O
considered	O
in	O
all	O
patients	O
with	O
diffuse	O
parenchymal	O
lung	O
disease	O
presenting	O
together	O
with	O
leukocytopenia	O
,	O
namely	O
monocyto	O
-,	O
dendritic	B-COMP
cell	B-COMP
-	O
and	O
B	O
-	O
lymphopenia	O
,	O
irrespective	O
of	O
severity	O
of	O
the	O
clinical	O
phenotype	O
.	O

Pulmonary	O
edema	O
,	O
protein	O
concentration	O
in	O
BALF	O
,	O
injury	O
of	O
lung	O
tissue	O
,	O
inflammatory	O
cytokines	O
in	O
serum	B-COMP
and	O
BALF	O
,	O
inflammatory	O
cell	B-COMP
infiltration	O
,	O
inflammatory	O
cytokines	O
mRNA	O
expression	O
,	O
and	O
MAPKs	O
phosphorylation	O
were	O
analyzed	O
.	O

In	O
vivo	O
,	O
LPS	O
significantly	O
increased	O
protein	O
concentration	O
and	O
number	O
of	O
inflammatory	O
cells	B-COMP
in	O
BALF	O
,	O
pulmonary	O
edema	O
,	O
pathological	O
changes	O
of	O
lung	O
tissue	O
,	O
inflammatory	O
cytokines	O
in	O
serum	B-COMP
and	O
BALF	O
,	O
macrophage	O
infiltration	O
,	O
inflammatory	O
gene	O
expression	O
,	O
and	O
MAPKs	O
phosphorylation	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
it	O
was	O
conserved	O
in	O
the	O
5	O
'	O
and	O
3	O
'-	O
non	O
-	O
translated	O
regions	O
,	O
and	O
there	O
were	O
no	O
insertions	O
or	O
deletions	O
in	O
nonstructural	O
genes	O
,	O
such	O
as	O
ORF1a	O
,	O
ORF1b	O
,	O
ORF3a	O
,	O
ORF3b	O
,	O
and	O
ORF7	O
,	O
as	O
well	O
as	O
in	O
genes	O
encoding	O
structural	O
proteins	O
,	O
such	O
as	O
the	O
envelope	B-COMP
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
proteins	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
uses	O
cell	B-COMP
-	O
surface	O
heparan	O
sulfate	O
as	O
an	O
attachment	O
factor	O
.	O

This	O
patient	O
also	O
had	O
other	O
complications	O
like	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
kidney	O
injury	O
,	O
and	O
septic	O
shock	O
that	O
required	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
.	O

Its	O
interaction	O
with	O
P6	O
was	O
confirmed	O
within	O
cells	B-COMP
.	O

In	O
addition	O
,	O
IgG	O
antibodies	B-COMP
from	O
the	O
1	O
-	O
day	O
-	O
old	O
group	O
had	O
lower	O
avidity	O
indices	O
than	O
day	O
28	O
vaccinated	O
birds	O
.	O

Need	O
for	O
red	O
blood	O
cell	B-COMP
(	O
RBC	O
)	O
transfusion	O
was	O
highest	O
in	O
patients	O
with	O
extrapulmonary	O
sepsis	O
(	O
257	O
mL	O
/	O
day	O
),	O
and	O
was	O
significantly	O
lower	O
in	O
primary	O
pulmonary	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
102	O
mL	O
/	O
day	O
).	O

Among	O
the	O
six	O
hCoVs	O
identified	O
to	O
date	O
,	O
only	O
hCoV	O
-	O
HKU1	O
has	O
no	O
defined	O
cellular	B-COMP
receptor	O
.	O

As	O
found	O
in	O
other	O
coronaviruses	O
,	O
the	O
majority	O
of	O
the	O
positive	O
-	O
stranded	O
RNA	O
MERS	O
-	O
CoV	O
genome	O
is	O
translated	O
into	O
two	O
polyproteins	O
,	O
one	O
created	O
by	O
a	O
ribosomal	B-COMP
frameshift	O
,	O
that	O
are	O
cleaved	O
at	O
three	O
sites	O
by	O
a	O
papain	O
-	O
like	O
protease	O
and	O
at	O
11	O
sites	O
by	O
a	O
3C	O
-	O
like	O
protease	O
(	O
3	O
CL	O
(	O
pro	O
)).	O

We	O
found	O
that	O
hypertonic	O
saline	O
(	O
NaCl	O
7	O
.	O
5	O
%)	O
treatment	O
in	O
rat	O
model	O
of	O
LPS	O
-	O
induced	O
ARDS	O
avoided	O
pulmonary	O
function	O
worsening	O
and	O
inhibited	O
type	O
I	O
collagen	B-COMP
deposition	O
.	O

This	O
technique	O
enables	O
simultaneous	O
serological	O
testing	O
against	O
multiple	O
recombinant	O
HA	O
-	O
types	O
in	O
5	O
l	O
of	O
serum	B-COMP
.	O

As	O
ALI	O
developed	O
over	O
6	O
hr	O
,	O
extracellular	B-COMP
histones	O
appeared	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
).	O

When	O
purified	O
histones	O
were	O
delivered	O
to	O
lung	O
via	O
the	O
airways	O
,	O
intense	O
inflammatory	O
injury	O
ensued	O
and	O
type	O
II	O
cells	B-COMP
developed	O
large	O
blebs	O
indicating	O
cellular	B-COMP
damage	O
and	O
apoptosis	O
.	O

The	O
animal	O
hosts	B-COMP
,	O
including	O
non	O
-	O
human	O
primates	O
and	O
reservoir	O
hosts	B-COMP
(	O
fruit	O
bats	O
),	O
play	O
a	O
significant	O
role	O
in	O
transmission	O
and	O
maintenance	O
of	O
EBOV	O
in	O
nature	O
.	O

Magnetic	O
resonance	O
imaging	O
of	O
lumbosacral	O
and	O
cervical	O
spine	B-COMP
showed	O
tumor	O
-	O
like	O
masses	O
mistaken	O
for	O
neurofibromatosis	O
(	O
axial	O
diameter	O
,	O
7	O
.	O
5	O
-	O
10	O
mm	O
).	O

ABSTRACT	O
:	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
supplemental	O
genistein	O
(	O
an	O
isoflavonoid	O
)	O
on	O
performance	O
,	O
lymphoid	O
organs	O
'	O
development	O
,	O
and	O
cellular	B-COMP
and	O
humoral	O
immune	O
responses	O
in	O
broiler	O
chicks	O
.	O

Among	O
the	O
four	O
N	O
-	O
terminal	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
site	O
A	O
and	O
to	O
a	O
lesser	O
extent	O
site	O
D	O
(	O
S	O
-	O
AD	O
)	O
induce	O
key	O
neutralizing	O
antibodies	B-COMP
.	O

Our	O
findings	O
indicate	O
that	O
a	O
balanced	O
immune	O
response	O
operating	O
through	O
both	O
TRIF	O
-	O
driven	O
and	O
MyD88	O
-	O
driven	O
pathways	O
likely	O
provides	O
the	O
most	O
effective	O
host	B-COMP
cell	I-COMP
intrinsic	O
antiviral	O
defense	O
responses	O
to	O
severe	O
SARS	O
-	O
CoV	O
disease	O
,	O
while	O
removal	O
of	O
either	O
branch	O
of	O
TLR	O
signaling	O
causes	O
lethal	O
SARS	O
-	O
CoV	O
disease	O
in	O
our	O
mouse	O
model	O
.	O

Patients	O
with	O
severe	O
ARDS	O
who	O
received	O
statin	O
therapy	O
had	O
significantly	O
more	O
vasopressor	O
-	O
free	O
days	O
compared	O
with	O
those	O
without	O
statin	O
therapy	O
(	O
13	O
	O
7	O
and	O
9	O
	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0034	O
),	O
and	O
they	O
also	O
required	O
less	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
and	O
had	O
more	O
ECMO	O
-	O
free	O
days	O
(	O
18	O
	O
9	O
and	O
15	O
	O
9	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0873	O
).	O

Alveolar	O
epithelial	O
cells	B-COMP
(	O
AECs	O
)	O
are	O
the	O
first	O
cells	B-COMP
that	O
influenza	O
virus	O
encounters	O
upon	O
entering	O
the	O
alveolus	O
.	O

Infected	O
epithelial	O
cells	B-COMP
produce	O
cytokines	O
that	O
attract	O
and	O
activate	O
neutrophils	O
and	O
macrophages	O
,	O
which	O
in	O
turn	O
induce	O
damage	O
to	O
the	O
epithelial	O
-	O
endothelial	O
barrier	O
.	O

Hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)/	O
c	O
-	O
Met	O
and	O
transforming	O
growth	O
factor	O
-	O
	O
(	O
TGF	O
-	O
	O
)/	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
are	O
well	O
known	O
to	O
regulate	O
repair	O
of	O
damaged	O
alveolar	O
epithelium	O
by	O
stimulating	O
cell	B-COMP
migration	O
and	O
proliferation	O
.	O

The	O
previously	O
believed	O
chicken	O
-	O
specific	O
coronavirus	O
(	O
CoV	O
)	O
M41	O
spike	O
(	O
S1	O
)	O
protein	O
displayed	O
a	O
broad	O
attachment	O
pattern	O
to	O
respiratory	O
tissues	O
of	O
various	O
avian	O
species	O
,	O
albeit	O
with	O
lower	O
affinity	O
than	O
hemagglutinin	O
,	O
suggesting	O
that	O
other	O
avian	O
species	O
might	O
be	O
susceptible	O
for	O
chicken	O
CoV	O
.	O
When	O
comparing	O
tissue	O
-	O
specific	O
binding	O
patterns	O
of	O
various	O
avian	O
coronaviral	O
S1	O
proteins	O
on	O
the	O
single	O
-	O
species	O
TMAs	O
,	O
chicken	O
and	O
partridge	O
CoV	O
S1	O
had	O
predominant	O
affinity	O
for	O
the	O
trachea	O
,	O
while	O
pigeon	O
CoV	O
S1	O
showed	O
marked	O
preference	O
for	O
lung	O
of	O
their	O
respective	O
hosts	B-COMP
.	O

Many	O
viruses	O
that	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
of	O
eukaryotes	O
have	O
evolved	O
2	O
'-	O
O	O
-	O
methyltransferases	O
(	O
2	O
'-	O
O	O
-	O
MTase	O
)	O
to	O
autonomously	O
modify	O
their	O
mRNAs	O
and	O
carry	O
a	O
cap	O
-	O
1	O
structure	O
(	O
m7GpppNm	O
)	O
at	O
the	O
5	O
'	O
end	O
,	O
thereby	O
facilitating	O
viral	O
replication	O
and	O
escaping	O
innate	O
immune	O
recognition	O
in	O
host	B-COMP
cells	B-COMP
.	O

Recombinant	O
plasmid	O
pcDNA3	O
.	O
1	O
expressing	O
SPA	O
,	O
SPB	B-COMP
and	O
SPC	O
was	O
constructed	O
and	O
introduced	O
into	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	B-COMP
by	O
transfection	O
.	O

Histopathology	O
of	O
the	O
excised	O
mass	O
showed	O
multiple	O
meningeal	O
nodular	O
lesions	O
with	O
infiltrates	O
of	O
epithelioid	O
macrophages	O
,	O
occasionally	O
centred	O
on	O
degenerated	O
neutrophils	O
and	O
surrounded	O
by	O
a	O
broad	O
rim	O
of	O
plasma	O
cells	B-COMP
,	O
features	O
consistent	O
with	O
pyogranulomatous	O
meningitis	O
.	O

In	O
addition	O
,	O
searches	O
for	O
protein	O
-	O
protein	O
interactions	O
using	O
yeast	O
-	O
two	O
hybrid	O
techniques	O
have	O
shed	O
light	O
on	O
possible	O
functional	O
roles	O
for	O
their	O
exposed	O
cytoplasmic	B-COMP
domains	O
.	O

These	O
mutations	O
are	O
present	O
in	O
MERS	O
-	O
CoV	O
spike	O
,	O
explaining	O
why	O
MERS	O
-	O
CoV	O
infects	O
human	O
cells	B-COMP
.	O

Thus	O
,	O
receptor	O
expression	O
patterns	O
can	O
define	O
viral	O
tissue	O
tropism	O
and	O
might	O
to	O
some	O
extent	O
predict	O
the	O
susceptibility	O
of	O
a	O
host	B-COMP
to	O
a	O
particular	O
virus	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
acute	O
kidney	O
injury	O
on	O
outcome	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
under	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
and	O
to	O
analyze	O
the	O
association	O
between	O
prognosis	O
and	O
the	O
time	O
of	O
occurrence	O
of	O
acute	O
kidney	O
injury	O
and	O
renal	O
replacement	O
therapy	O
initiation	O
.	O

However	O
,	O
the	O
necessity	O
of	O
renal	O
replacement	O
therapy	O
during	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
was	O
not	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
in	O
these	O
patients	O
(	O
p	O
=	O
0	O
.	O
37	O
).	O

We	O
and	O
other	O
investigators	O
demonstrated	O
that	O
MVs	O
released	O
by	O
mesenchymal	O
stem	O
cells	B-COMP
(	O
MSCs	O
)	O
were	O
as	O
effective	O
as	O
the	O
cells	B-COMP
themselves	O
in	O
inflammatory	O
injuries	O
,	O
such	O
as	O
after	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

We	O
also	O
studied	O
the	O
interactions	O
between	O
MVs	O
and	O
human	O
monocytes	O
and	O
human	O
alveolar	O
epithelial	O
type	O
2	O
cells	B-COMP
.	O

TITLE	O
:	O
Hematologic	O
Disorders	O
:	O
Sickle	O
Cell	B-COMP
Disease	O
.	O

Increased	O
viscosity	O
and	O
cell	B-COMP
adhesion	O
result	O
in	O
vasoocclusion	O
.	O

TITLE	O
:	O
The	O
Nucleocapsid	B-COMP
Protein	O
of	O
Coronaviruses	O
Acts	O
as	O
a	O
Viral	O
Suppressor	O
of	O
RNA	O
Silencing	O
in	O
Mammalian	O
Cells	B-COMP
.	O

We	O
identified	O
a	O
novel	O
VSR	O
from	O
coronaviruses	O
,	O
a	O
group	O
of	O
medically	O
important	O
mammalian	O
viruses	O
including	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
showed	O
that	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
protein	O
)	O
of	O
coronaviruses	O
suppresses	O
RNAi	O
triggered	O
by	O
either	O
short	O
hairpin	O
RNAs	O
or	O
small	O
interfering	O
RNAs	O
in	O
mammalian	O
cells	B-COMP
.	O

The	O
replication	O
of	O
MHV	O
increased	O
when	O
the	O
N	O
proteins	O
were	O
expressed	O
in	O
trans	O
,	O
while	O
knockdown	O
of	O
Dicer1	O
or	O
Ago2	O
transcripts	O
facilitated	O
the	O
MHV	O
replication	O
in	O
mammalian	O
cells	B-COMP
.	O

Viral	O
etiology	O
was	O
determined	O
using	O
conventional	O
cell	B-COMP
culture	O
and	O
a	O
commercial	O
respiratory	O
virus	O
panel	O
fast	O
assay	O
(	O
xTAG	O
RVP	O
),	O
capable	O
of	O
detecting	O
19	O
different	O
respiratory	O
viruses	O
and	O
subtype	O
targets	O
.	O

In	O
this	O
study	O
,	O
PEDV	O
strain	O
HN1303	O
was	O
isolated	O
successfully	O
on	O
Vero	O
cells	B-COMP
with	O
supplemental	O
trypsin	O
,	O
and	O
the	O
isolate	O
has	O
been	O
serially	O
propagated	O
in	O
cell	B-COMP
culture	O
for	O
over	O
95	O
passages	O
.	O

Passive	O
immunization	O
by	O
oral	O
administration	O
of	O
egg	O
yolk	B-COMP
antibodies	B-COMP
(	O
IgY	O
)	O
obtained	O
from	O
immunized	O
chickens	O
provides	O
an	O
alternative	O
source	O
of	O
specific	O
antibodies	B-COMP
for	O
the	O
prevention	O
and	O
treatment	O
of	O
PEDV	O
in	O
newborn	O
piglets	O
.	O

TITLE	O
:	O
Functional	O
characterization	O
and	O
proteomic	O
analysis	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
porcine	O
deltacoronavirus	O
.	O

We	O
then	O
assessed	O
alterations	O
in	O
production	O
levels	O
of	O
proteins	O
in	O
the	O
N	O
-	O
expressing	O
PK	O
(	O
PK	O
-	O
PDCoV	O
-	O
N	O
)	O
cells	B-COMP
at	O
different	O
time	O
points	O
by	O
means	O
of	O
proteomic	O
analysis	O
.	O

These	O
data	O
suggest	O
that	O
serotonin	O
receptor	O
signaling	O
influences	O
cellular	B-COMP
activities	O
that	O
regulate	O
entry	O
of	O
diverse	O
virus	O
families	O
and	O
provides	O
a	O
new	O
,	O
potentially	O
broad	O
-	O
spectrum	O
target	O
for	O
antiviral	O
drug	O
development	O
.	O

In	O
conclusion	O
,	O
the	O
neutralizing	O
antigenicity	O
of	O
recombinant	O
S1	O
protein	O
expressed	O
from	O
mammalian	O
cells	B-COMP
was	O
decreased	O
,	O
and	O
was	O
not	O
sufficient	O
to	O
induce	O
neutralizing	O
antibodies	B-COMP
.	O

Antibodies	B-COMP
against	O
M	O
.	O
pneumoniae	O
were	O
detected	O
in	O
all	O
patients	O
and	O
were	O
found	O
to	O
be	O
intrathecally	O
synthesised	O
in	O
two	O
cases	O
(	O
GBS	O
and	O
BBE	O
),	O
which	O
proves	O
intrathecal	O
infection	O
.	O

Between	O
January	O
2000	O
and	O
December	O
2012	O
,	O
844	O
patients	O
underwent	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
HSCT	O
)	O
at	O
the	O
Hospital	O
for	O
Sick	O
Children	O
:	O
491	O
were	O
allogeneic	O
and	O
353	O
were	O
autologous	O
.	O

Each	O
chicken	O
in	O
the	O
control	O
and	O
infected	O
group	O
was	O
intranasally	O
inoculated	O
with	O
0	O
.	O
2	O
mL	O
sterile	O
physiological	O
saline	O
and	O
virus	O
,	O
respectively	O
,	O
after	O
which	O
serum	B-COMP
antioxidant	O
parameters	O
and	O
renal	O
XOD	O
mRNA	O
expression	O
in	O
growing	O
layers	O
were	O
evaluated	O
at	O
8	O
,	O
15	O
and	O
22	O
days	O
post	O
-	O
inoculation	O
(	O
dpi	O
).	O

The	O
results	O
indicated	O
that	O
NIBV	O
infection	O
could	O
cause	O
the	O
increases	O
of	O
renal	O
XOD	O
gene	O
transcription	O
and	O
serum	B-COMP
XOD	O
activity	O
,	O
leading	O
to	O
hyperuricemia	O
and	O
reduction	O
of	O
antioxidants	O
in	O
the	O
body	O
.	O

TITLE	O
:	O
Pre	O
-	O
and	O
postexposure	O
efficacy	O
of	O
fully	O
human	O
antibodies	B-COMP
against	O
Spike	O
protein	O
in	O
a	O
novel	O
humanized	O
mouse	O
model	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

Here	O
we	O
demonstrate	O
the	O
use	O
of	O
the	O
VelocImmune	O
technology	O
(	O
a	O
mouse	O
that	O
expresses	O
human	O
antibody	B-COMP
-	O
variable	O
heavy	O
chains	O
and	O
	O
light	O
chains	O
)	O
alongside	O
the	O
VelociGene	O
technology	O
(	O
which	O
allows	O
for	O
rapid	O
engineering	O
of	O
the	O
mouse	O
genome	O
)	O
to	O
quickly	O
develop	O
and	O
evaluate	O
antibodies	B-COMP
against	O
an	O
emerging	O
viral	O
disease	O
.	O

TITLE	O
:	O
Dynamic	O
changes	O
of	O
virus	O
load	O
in	O
supernatant	O
of	O
primary	O
CEK	O
cell	B-COMP
culture	O
infected	O
with	O
different	O
generations	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
strains	O
Sczy3	O
as	O
revealed	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

To	O
investigate	O
the	O
dynamic	O
changes	O
in	O
IBV	O
load	O
in	O
the	O
supernatant	O
of	O
primary	O
CEK	O
cells	B-COMP
,	O
we	O
developed	O
an	O
SYBR	O
Green	O
I	O
-	O
based	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assay	O
to	O
quantify	O
nucleic	B-COMP
copy	O
numbers	O
of	O
the	O
IBV	O
-	O
Sczy3	O
strain	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
assemble	O
by	O
budding	O
into	O
the	O
lumen	O
of	O
the	O
early	O
Golgi	B-COMP
complex	I-COMP
prior	O
to	O
exocytosis	O
.	O

The	O
small	O
CoV	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
plays	O
roles	O
in	O
assembly	O
,	O
virion	B-COMP
release	O
,	O
and	O
pathogenesis	O
.	O

In	O
the	O
absence	O
of	O
these	O
responses	O
,	O
functional	O
CD8	O
T	O
cells	B-COMP
are	O
insufficient	O
to	O
control	O
viral	O
spread	O
within	O
the	O
CNS	O
,	O
resulting	O
in	O
severe	O
demyelination	O
.	O

While	O
the	O
SUD	O
-	O
N	O
and	O
the	O
X	O
domains	O
were	O
found	O
to	O
be	O
dispensable	O
,	O
the	O
SUD	O
-	O
M	O
domain	O
was	O
crucial	O
for	O
viral	B-COMP
genome	I-COMP
replication	O
/	O
transcription	O
.	O

TITLE	O
:	O
Chloroquine	O
rescues	O
A549	O
cells	B-COMP
from	O
paraquat	O
-	O
induced	O
death	O
.	O

Moreover	O
,	O
our	O
data	O
demonstrated	O
that	O
CQ	O
increased	O
lysosome	B-COMP
-	O
associated	O
membrane	B-COMP
protein	O
-	O
1	O
,	O
lysosome	B-COMP
-	O
associated	O
membrane	B-COMP
protein	O
-	O
2	O
and	O
light	O
chain	O
-	O
3	O
expressions	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
CQ	O
rescues	O
PQ	O
-	O
induced	O
cytotoxicity	O
may	O
be	O
through	O
protection	O
of	O
the	O
lysosomal	B-COMP
membrane	I-COMP
or	O
up	O
-	O
regulation	O
of	O
autophagy	O
.	O

Isolation	O
success	O
correlated	O
with	O
viral	O
RNA	O
concentration	O
and	O
time	O
after	O
diagnosis	O
as	O
well	O
as	O
with	O
the	O
amount	O
of	O
IgA	O
antibodies	B-COMP
secreted	O
in	O
respiratory	O
samples	O
used	O
for	O
isolation	O
.	O

Previous	O
work	O
identified	O
a	O
peptide	O
derived	O
from	O
the	O
heptad	O
repeat	O
(	O
HR	O
)	O
2	O
domain	O
in	O
S2	O
subunit	O
,	O
HR2P	O
,	O
which	O
potently	O
blocked	O
MERS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
membrane	B-COMP
fusion	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
mucormycosis	O
is	O
commonly	O
encountered	O
in	O
patients	O
with	O
diabetic	O
ketoacidosis	O
,	O
hematologic	O
malignancies	O
,	O
neutropenia	O
,	O
organ	O
or	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
,	O
and	O
malignancy	O
,	O
but	O
it	O
rarely	O
occurs	O
in	O
high	O
-	O
risk	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
).	O

Using	O
the	O
highly	O
hepatotropic	O
mouse	O
hepatitis	O
virus	O
type	O
3	O
(	O
MHV3	O
),	O
its	O
attenuated	O
variant	O
,	O
51	O
.	O
6	O
-	O
MHV3	O
,	O
which	O
shows	O
low	O
tropism	O
for	O
endothelial	O
cells	B-COMP
,	O
and	O
the	O
weakly	O
hepatotropic	O
MHV	O
-	O
A59	O
strain	O
from	O
the	O
murine	O
coronavirus	O
group	O
,	O
we	O
investigated	O
the	O
virus	O
-	O
induced	O
dysfunctions	O
of	O
BBB	O
in	O
vivo	O
and	O
in	O
brain	O
microvascular	O
endothelial	O
cells	B-COMP
(	O
BMECs	O
)	O
in	O
vitro	O
.	O

TITLE	O
:	O
Mucosal	O
,	O
Cellular	B-COMP
,	O
and	O
Humoral	O
Immune	O
Responses	O
Induced	O
by	O
Different	O
Live	O
Infectious	O
Bronchitis	O
Virus	O
Vaccination	O
Regimes	O
and	O
Protection	O
Conferred	O
against	O
Infectious	O
Bronchitis	O
Virus	O
Q1	O
Strain	O
.	O

Overall	O
,	O
our	O
results	O
suggested	O
that	O
the	O
unusual	O
capacity	O
of	O
MERS	O
-	O
CoV	O
to	O
infect	O
T	O
cells	B-COMP
and	O
induce	O
apoptosis	O
might	O
partly	O
contribute	O
to	O
the	O
high	O
pathogenicity	O
of	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
enters	O
human	O
hepatocytes	O
through	O
a	O
multistep	O
mechanism	O
involving	O
,	O
among	O
other	O
host	B-COMP
proteins	O
,	O
the	O
virus	O
receptor	O
CD81	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
isolation	O
of	O
a	O
potent	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-COMP
from	O
memory	O
B	O
cells	B-COMP
of	O
an	O
infected	O
individual	O
.	O

A	O
recombinant	O
North	O
American	O
nucleoprotein	O
(	O
NP	O
)	O
based	O
iELISA	O
was	O
developed	O
and	O
validated	O
along	O
with	O
a	O
bELISA	O
using	O
newly	O
developed	O
PEDV	O
-	O
NP	O
specific	O
biotinylated	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
and	O
an	O
FMIA	O
using	O
magnetic	O
beads	O
coupled	O
with	O
expressed	O
NA	O
PEDV	O
-	O
NP	O
.	O

Well	O
-	O
validated	O
iELISA	O
,	O
bELISA	O
and	O
FMIA	O
assays	O
for	O
the	O
detection	O
of	O
PEDV	O
antibodies	B-COMP
were	O
developed	O
and	O
showed	O
good	O
correlation	O
with	O
IFA	O
and	O
each	O
other	O
.	O

RESULTS	O
:	O
A	O
recombinant	O
North	O
American	O
nucleoprotein	O
(	O
NP	O
)	O
based	O
iELISA	O
was	O
developed	O
and	O
validated	O
along	O
with	O
a	O
bELISA	O
using	O
newly	O
developed	O
PEDV	O
-	O
NP	O
specific	O
biotinylated	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
and	O
an	O
FMIA	O
using	O
magnetic	O
beads	O
coupled	O
with	O
expressed	O
NA	O
PEDV	O
-	O
NP	O
.	O

To	O
detect	O
PEDV	O
antibodies	B-COMP
in	O
eight	O
herds	O
,	O
382	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
sows	O
that	O
had	O
been	O
immunized	O
with	O
a	O
PED	O
vaccine	O
,	O
and	O
screened	O
using	O
the	O
developed	O
ELISA	O
in	O
parallel	O
with	O
a	O
serum	B-COMP
neutralization	O
(	O
SN	O
)	O
assay	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
children	O
].	O

Samples	O
were	O
submitted	O
to	O
RT	O
-	O
PCR	O
and	O
sequencing	O
for	O
BCoV	O
Nucleocapsid	B-COMP
gene	O
,	O
BCoV	O
Spike	O
gene	O
and	O
BToV	O
Spike	O
gene	O
.	O

ABSTRACT	O
:	O
The	O
full	O
genome	O
sequence	O
of	O
a	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
identified	O
from	O
cultured	O
and	O
isolated	O
in	O
Vero	O
cells	B-COMP
.	O

The	O
unusually	O
short	O
helical	O
hairpin	O
structure	O
of	O
the	O
protein	O
might	O
explain	O
its	O
ability	O
to	O
deform	O
bilayers	O
and	O
is	O
reminiscent	O
of	O
other	O
peptides	O
with	O
membrane	B-COMP
disrupting	O
functionalities	O
.	O

Vero	O
cell	B-COMP
,	O
an	O
African	O
green	O
monkey	O
kidney	O
cell	B-COMP
line	O
,	O
was	O
often	O
used	O
to	O
isolate	O
and	O
propagate	O
PEDV	O
.	O

In	O
vitro	O
studies	O
of	O
the	O
MSCs	O
demonstrated	O
a	O
broad	O
anti	O
-	O
inflammatory	O
capacity	O
,	O
including	O
suppression	O
of	O
T	O
-	O
cell	B-COMP
responses	O
and	O
induction	O
of	O
regulatory	O
phenotypes	O
in	O
T	O
cells	B-COMP
,	O
monocytes	O
,	O
and	O
neutrophils	O
.	O

Unlike	O
acute	O
forms	O
of	O
ARDS	O
(	O
such	O
in	O
the	O
current	O
NIH	O
-	O
sponsored	O
study	O
of	O
mesenchymal	O
stromal	O
cells	B-COMP
in	O
ARDS	O
),	O
recovery	O
does	O
not	O
generally	O
occur	O
in	O
such	O
patients	O
.	O

TITLE	O
:	O
The	O
Virus	O
-	O
Host	B-COMP
Interplay	O
:	O
Biogenesis	O
of	O
+	O
RNA	O
Replication	O
Complexes	O
.	O

Both	O
conventional	O
and	O
deep	O
-	O
sequencing	O
results	O
consistently	O
showed	O
population	O
changes	O
occurred	O
during	O
adaptation	O
to	O
CEK	O
cells	B-COMP
.	O

Recombinant	O
plasmid	O
pVAX	O
-	O
N	O
was	O
transformed	O
into	O
competent	O
cells	B-COMP
of	O
attenuated	O
S	O
.	O
typhimurium	O
SL7207	O
via	O
electroporation	O
.	O

Here	O
we	O
offer	O
a	O
multiplexed	O
assay	O
for	O
a	O
panel	O
of	O
respiratory	O
viruses	O
that	O
mitigates	O
these	O
problems	O
by	O
combining	O
several	O
nucleic	B-COMP
acid	O
analogs	O
from	O
the	O
emerging	O
field	O
of	O
synthetic	O
biology	O
:	O
(	O
i	O
)	O
self	O
-	O
avoiding	O
molecular	O
recognition	O
systems	O
(	O
SAMRSs	O
),	O
which	O
facilitate	O
multiplexing	O
,	O
and	O
(	O
ii	O
)	O
artificially	O
expanded	O
genetic	O
information	O
systems	O
(	O
AEGISs	O
),	O
which	O
enable	O
low	O
-	O
noise	O
PCR	O
.	O

Potential	O
functions	O
supported	O
by	O
NiRAN	O
may	O
include	O
nucleic	B-COMP
acid	O
ligation	O
,	O
mRNA	O
capping	O
and	O
protein	O
-	O
primed	O
RNA	O
synthesis	O
,	O
possibilities	O
that	O
remain	O
to	O
be	O
explored	O
in	O
future	O
studies	O
.	O

Similar	O
to	O
the	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
of	O
SARS	O
-	O
CoV	O
that	O
inhibits	O
host	B-COMP
gene	O
expression	O
at	O
the	O
translational	O
level	O
,	O
we	O
report	O
that	O
MERS	O
-	O
CoV	O
nsp1	O
also	O
exhibits	O
a	O
conserved	O
function	O
to	O
negatively	O
regulate	O
host	B-COMP
gene	O
expression	O
by	O
inhibiting	O
host	B-COMP
mRNA	O
translation	O
and	O
inducing	O
the	O
degradation	O
of	O
host	B-COMP
mRNAs	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
pathogenicity	O
,	O
the	O
immune	O
antibody	B-COMP
production	O
,	O
serotype	O
and	O
the	O
tissue	O
tropism	O
.	O

TITLE	O
:	O
A	O
liberal	O
strategy	O
of	O
red	O
blood	O
cell	B-COMP
transfusion	O
reduces	O
cardiogenic	O
shock	O
in	O
elderly	O
patients	O
undergoing	O
cardiac	O
surgery	O
.	O

In	O
this	O
subgroup	O
analysis	O
,	O
we	O
separated	O
patients	O
into	O
those	O
aged	O
60	O
years	O
or	O
more	O
(	O
elderly	O
)	O
and	O
those	O
aged	O
less	O
than	O
60	O
years	O
randomized	O
to	O
a	O
restrictive	O
or	O
a	O
liberal	O
strategy	O
of	O
red	O
blood	O
cell	B-COMP
transfusion	O
.	O

PEDV	O
shares	O
some	O
important	O
characteristics	O
with	O
two	O
major	O
pandemic	O
viruses	O
(	O
porcine	O
reproductive	O
and	O
respiratory	O
virus	O
;	O
porcine	O
circovirus	O
type	O
2	O
)	O
of	O
pigs	O
that	O
have	O
high	O
rates	O
of	O
mutation	O
and	O
high	O
host	B-COMP
specificity	O
,	O
and	O
appear	O
to	O
have	O
been	O
present	O
in	O
the	O
swine	O
virome	O
for	O
decades	O
prior	O
to	O
emerging	O
to	O
cause	O
severe	O
clinical	O
disease	O
.	O

In	O
addition	O
,	O
confocal	O
imaging	O
and	O
Western	O
blotting	O
assays	O
revealed	O
that	O
the	O
increases	O
in	O
STAT	O
-	O
1	O
nuclear	O
translocation	O
and	O
phosphorylation	O
occurred	O
in	O
the	O
transfected	O
cells	B-COMP
expressing	O
both	O
genes	O
of	O
ORF6	O
and	O
NPIPB3	O
,	O
but	O
not	O
in	O
the	O
ORF6	O
-	O
expressing	O
cells	B-COMP
in	O
response	O
to	O
IFN	O
-	O
	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
PEDV	O
infection	O
,	O
five	O
shRNA	O
-	O
expressing	O
plasmids	O
targeting	O
the	O
N	O
,	O
M	O
,	O
and	O
S	O
genes	O
of	O
PEDV	O
were	O
constructed	O
and	O
transfected	O
into	O
Vero	O
cells	B-COMP
.	O

Calcium	O
ions	O
together	O
with	O
pH	O
modulated	O
E	O
protein	O
pore	B-COMP
charge	O
and	O
selectivity	O
.	O

Thus	O
,	O
this	O
assay	O
could	O
be	O
particularly	O
useful	O
to	O
identify	O
the	O
main	O
respiratory	O
viruses	O
directly	O
from	O
clinical	O
samples	O
,	O
after	O
nucleic	B-COMP
acid	O
extraction	O
,	O
and	O
,	O
also	O
,	O
to	O
screen	O
a	O
large	O
number	O
of	O
patients	O
for	O
epidemiological	O
studies	O
.	O

In	O
rare	O
cases	O
,	O
ventilator	O
therapy	O
proves	O
insufficient	O
,	O
and	O
only	O
the	O
option	O
of	O
employing	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
V	O
-	O
V	O
)	O
remains	O
.	O

Compstatin	O
decreased	O
the	O
accumulation	O
of	O
myofibroblasts	O
and	O
proliferating	O
cells	B-COMP
,	O
reduced	O
the	O
production	O
of	O
fibrosis	O
mediators	O
(	O
TGF	O
-	O
	O
,	O
phospho	O
-	O
Smad	O
-	O
2	O
and	O
CTGF	O
)	O
and	O
inhibited	O
collagen	B-COMP
deposition	O
.	O

Intriguingly	O
,	O
exogenous	O
ns12	O
.	O
9	O
and	O
heterologous	O
viroporins	O
with	O
ion	O
channel	O
activity	O
could	O
compensate	O
for	O
the	O
production	O
of	O
HCoV	O
-	O
OC43	O
-	O
ns12	O
.	O
9	O
,	O
indicating	O
that	O
the	O
ion	O
channel	O
activity	O
of	O
ns12	O
.	O
9	O
plays	O
a	O
significant	O
role	O
in	O
the	O
production	O
of	O
infectious	O
virions	B-COMP
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
the	O
ns12	O
.	O
9	O
accessory	O
protein	O
functions	O
as	O
a	O
viroporin	O
and	O
is	O
involved	O
in	O
virion	B-COMP
morphogenesis	O
and	O
the	O
pathogenesis	O
of	O
HCoV	O
-	O
OC43	O
infection	O
.	O

We	O
identified	O
the	O
important	O
functions	O
of	O
the	O
ns12	O
.	O
9	O
viroporin	O
in	O
virion	B-COMP
morphogenesis	O
during	O
HCoV	O
-	O
OC43	O
infection	O
.	O

MERS	O
-	O
CoV	O
is	O
able	O
to	O
infect	O
a	O
range	O
of	O
cell	B-COMP
types	O
,	O
but	O
replicates	O
to	O
high	O
titers	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

The	O
replication	O
of	O
MVvac2	O
-	O
CoV	O
-	O
S	O
in	O
Vero	O
cells	B-COMP
turned	O
out	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
control	O
virus	O
MVvac2	O
-	O
GFP	O
(	O
encoding	O
green	O
fluorescent	O
protein	O
),	O
while	O
titers	O
of	O
MVvac2	O
-	O
CoV	O
-	O
solS	O
were	O
impaired	O
approximately	O
3	O
-	O
fold	O
.	O

In	O
vivo	O
,	O
immunization	O
of	O
type	O
I	O
interferon	O
receptor	O
-	O
deficient	O
(	O
IFNAR	O
(-/-))-	O
CD46Ge	O
mice	O
with	O
2	O
	O
10	O
(	O
5	O
)	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
of	O
MVvac2	O
-	O
CoV	O
-	O
S	O
(	O
H	O
)	O
or	O
MVvac2	O
-	O
CoV	O
-	O
solS	O
(	O
H	O
)	O
in	O
a	O
prime	O
-	O
boost	O
regimen	O
induced	O
robust	O
levels	O
of	O
both	O
MV	O
-	O
and	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
antibodies	B-COMP
.	O

Plasma	O
BNP	O
level	O
,	O
arterial	O
blood	O
gases	O
,	O
serum	B-COMP
C	O
-	O
reactive	O
protein	O
level	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	O
difference	O
and	O
oxygenation	O
index	O
were	O
measured	O
in	O
patients	O
with	O
and	O
without	O
ALI	O
/	O
ARDS	O
within	O
24	O
h	O
of	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

We	O
discuss	O
the	O
rationale	O
and	O
potential	O
of	O
using	O
Host	B-COMP
-	O
Directed	O
Therapies	O
for	O
improving	O
the	O
poor	O
treatment	O
outcomes	O
associated	O
with	O
MERS	O
.	O

In	O
adenovirus	O
infections	O
mean	O
C	O
-	O
reactive	O
protein	O
value	O
was	O
72	O
.	O
4	O
mg	O
/	O
L	O
and	O
white	O
blood	O
cell	B-COMP
count	O
19	O
.	O
000	O
/	O
l	O
,	O
both	O
significantly	O
higher	O
than	O
in	O
other	O
viruses	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
ancestral	O
origins	O
of	O
major	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
likely	O
involve	O
bat	O
hosts	B-COMP
.	O

ABSTRACT	O
:	O
The	O
cellular	B-COMP
protease	O
TMPRSS2	O
cleaves	O
and	O
activates	O
the	O
influenza	O
virus	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
TMPRSS2	O
expression	O
is	O
essential	O
for	O
viral	O
spread	O
and	O
pathogenesis	O
in	O
mice	O
.	O

TITLE	O
:	O
Apoptosis	O
transcriptional	O
mechanism	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
cells	B-COMP
.	O

Strikingly	O
,	O
infection	O
of	O
mice	O
lacking	O
PLA2G2D	O
expression	O
(	O
Pla2g2d	O
(-/-)	O
mice	O
)	O
converted	O
a	O
uniformly	O
lethal	O
infection	O
to	O
a	O
nonlethal	O
one	O
(>	O
80	O
%	O
survival	O
),	O
subsequent	O
to	O
development	O
of	O
enhanced	O
respiratory	O
DC	O
migration	O
to	O
the	O
draining	O
lymph	O
nodes	O
,	O
augmented	O
antivirus	O
T	O
cell	B-COMP
responses	O
,	O
and	O
diminished	O
lung	O
damage	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
at	O
assessing	O
NDV	O
and	O
IBV	O
prevalences	O
in	O
Ivory	O
-	O
Coast	O
by	O
molecular	O
screening	O
of	O
>	O
22	O
,	O
000	O
avian	O
swabs	O
by	O
nested	O
PCR	O
and	O
by	O
serology	O
testing	O
of	O
close	O
to	O
2000	O
avian	O
sera	B-COMP
from	O
2010	O
through	O
2012	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
those	O
proteins	O
were	O
associated	O
with	O
GO	O
terms	O
such	O
as	O
phosphate	O
metabolic	O
process	O
,	O
calcium	O
ion	O
transport	O
,	O
cell	B-COMP
division	O
and	O
regulation	O
of	O
cell	B-COMP
motion	O
.	O

TITLE	O
:	O
Plant	O
-	O
derived	O
H7	O
VLP	B-COMP
vaccine	O
elicits	O
protective	O
immune	O
response	O
against	O
H7N9	O
influenza	O
virus	O
in	O
mice	O
and	O
ferrets	O
.	O

Studies	O
are	O
currently	O
ongoing	O
to	O
better	O
characterize	O
the	O
immune	O
response	O
elicited	O
by	O
the	O
plant	O
-	O
derived	O
VLP	B-COMP
vaccines	O
.	O

PEDV	O
infected	O
suckling	O
pigs	O
had	O
significantly	O
higher	O
diarrhea	O
scores	O
,	O
earlier	O
fecal	O
PEDV	O
RNA	O
shedding	O
and	O
significantly	O
higher	O
viremia	O
(	O
viral	O
RNA	O
in	O
serum	B-COMP
)	O
compared	O
to	O
weaned	O
pigs	O
.	O

Pro	O
-	O
inflammatory	O
cytokine	O
profiles	O
of	O
PEDV	O
infected	O
suckling	O
pigs	O
differed	O
from	O
those	O
of	O
PEDV	O
infected	O
weaned	O
pigs	O
and	O
coincided	O
with	O
onset	O
of	O
fecal	O
PEDV	O
RNA	O
shedding	O
and	O
serum	B-COMP
PEDV	O
RNA	O
titers	O
.	O

TITLE	O
:	O
Sphingosine	O
-	O
1	O
-	O
phosphate	O
receptor	O
antagonism	O
enhances	O
proliferation	O
and	O
migration	O
of	O
engrafted	O
neural	O
progenitor	O
cells	B-COMP
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
demyelination	O
.	O

ABSTRACT	O
:	O
The	O
oral	O
drug	O
FTY720	O
affects	O
sphingosine	O
-	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
signaling	O
on	O
targeted	O
cells	B-COMP
that	O
bear	O
the	O
S1P	O
receptors	O
S1P1	O
,	O
S1P3	O
,	O
S1P4	O
,	O
and	O
S1P5	O
.	O

Integrating	O
phenotypic	O
and	O
genetic	O
data	O
narrowed	O
this	O
region	O
to	O
a	O
single	O
gene	O
,	O
Trim55	O
,	O
an	O
E3	O
ubiquitin	O
ligase	O
with	O
a	O
role	O
in	O
muscle	B-COMP
fiber	I-COMP
maintenance	O
.	O

RESULTS	O
:	O
Genes	O
and	O
biological	O
pathways	O
involved	O
in	O
the	O
early	O
host	B-COMP
response	O
to	O
IBV	O
infection	O
were	O
determined	O
andgene	O
expression	O
differences	O
between	O
susceptible	O
and	O
resistant	O
birds	O
were	O
identified	O
.	O

TITLE	O
:	O
Assembly	O
and	O
immunogenicity	O
of	O
baculovirus	O
-	O
derived	O
infectious	O
bronchitis	O
virus	O
-	O
like	O
particles	O
carrying	O
membrane	B-COMP
,	O
envelope	B-COMP
and	O
the	O
recombinant	O
spike	O
proteins	O
.	O

These	O
DN	O
T	O
cells	B-COMP
were	O
predominantly	O
consisted	O
of	O
a	O
TCR	O
(+)	O
subset	O
expressing	O
high	O
levels	O
of	O
CD44	O
and	O
did	O
not	O
produce	O
cytokine	O
except	O
IL	O
-	O
2	O
.	O

The	O
infection	O
of	O
target	O
cells	B-COMP
by	O
the	O
SARS	O
CoV	O
is	O
mediated	O
through	O
the	O
interaction	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
protein	O
(	O
1255	O
amino	O
acids	O
)	O
and	O
its	O
cellular	B-COMP
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

We	O
found	O
that	O
human	O
cell	B-COMP
infection	O
with	O
Ad14p1	O
results	O
in	O
markedly	O
decreased	O
expression	O
of	O
the	O
E1B	O
20	O
-	O
kilodalton	O
(	O
20K	O
)	O
protein	O
compared	O
to	O
that	O
with	O
infection	O
with	O
wild	O
-	O
type	O
(	O
wt	O
)	O
Ad14	O
.	O

This	O
reduced	O
Ad14p1	O
E1B	O
20K	O
expression	O
caused	O
a	O
loss	O
-	O
of	O
-	O
function	O
phenotype	O
of	O
Ad	O
-	O
infected	O
cell	B-COMP
corpses	O
that	O
,	O
in	O
contrast	O
to	O
cells	B-COMP
infected	O
with	O
wt	O
Ad14	O
,	O
either	O
failed	O
to	O
repress	O
or	O
increased	O
NF	O
-	O
B	O
-	O
dependent	O
,	O
proinflammatory	O
cytokine	O
responses	O
of	O
responder	O
human	O
alveolar	O
macrophages	O
.	O

Furthermore	O
,	O
all	O
of	O
the	O
three	O
MAbs	O
reacted	O
with	O
PEDV	O
in	O
the	O
fluorescent	O
antibody	B-COMP
assay	O
.	O

These	O
data	O
indicated	O
that	O
the	O
virus	O
requires	O
a	O
PBM	O
on	O
a	O
transmembrane	B-COMP
protein	O
to	O
compensate	O
for	O
removal	O
of	O
this	O
motif	O
from	O
the	O
E	O
protein	O
.	O

The	O
independent	O
determinants	O
of	O
mortality	O
were	O
associated	O
with	O
ARDS	O
renal	O
recipients	O
with	O
rESKAPE	O
pneumonia	O
were	O
serum	B-COMP
creatinine	O
level	O
>	O
1	O
.	O
5	O
mg	O
/	O
dL	O
(	O
OR	O
13	O
.	O
7	O
,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
142	O
.	O
1	O
,	O
P	O
=	O
.	O
028	O
)	O
and	O
body	O
temperature	O
less	O
than	O
38	O
	O
C	O
(	O
OR	O
5	O
.	O
5	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
26	O
.	O
6	O
)	O
at	O
ARDS	O
onset	O
,	O
P	O
=	O
.	O
035	O
).	O

However	O
,	O
the	O
presence	O
of	O
antibodies	B-COMP
in	O
the	O
camel	O
herds	O
should	O
be	O
monitored	O
.	O

Evaluation	O
of	O
available	O
SARS	O
-	O
based	O
immune	O
-	O
therapeutic	O
and	O
prophylactic	O
modalities	O
revealed	O
poor	O
efficacy	O
;	O
both	O
monoclonal	O
antibody	B-COMP
and	O
vaccine	O
approaches	O
failed	O
to	O
neutralize	O
and	O
protect	O
from	O
infection	O
with	O
CoVs	O
using	O
the	O
novel	O
spike	O
protein	O
.	O

Although	O
SR	O
T	O
cell	B-COMP
accumulation	O
peaked	O
in	O
the	O
persistently	O
infected	O
CNS	O
during	O
maximal	O
demyelination	O
,	O
they	O
were	O
not	O
preferentially	O
retained	O
.	O

TITLE	O
:	O
Viral	O
Shedding	O
and	O
Antibody	B-COMP
Response	O
in	O
37	O
Patients	O
With	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

All	O
surviving	O
patients	O
,	O
but	O
only	O
slightly	O
more	O
than	O
half	O
of	O
all	O
fatal	O
cases	O
,	O
produced	O
IgG	O
and	O
neutralizing	O
antibodies	B-COMP
.	O

Neutralizing	O
antibodies	B-COMP
do	O
not	O
suffice	O
to	O
clear	O
the	O
infection	O
.	O

Presence	O
of	O
antibodies	B-COMP
did	O
not	O
lead	O
to	O
the	O
elimination	O
of	O
virus	O
from	O
LRT	O
.	O

Brain	O
and	O
cerebellum	O
were	O
evaluated	O
by	O
light	O
microscopy	O
and	O
immunohistochemistry	O
for	O
glial	B-COMP
fibrillary	I-COMP
acidic	I-COMP
protein	I-COMP
(	O
GFAP	O
)	O
and	O
vimentin	B-COMP
to	O
assess	O
astrocytic	O
morphology	O
,	O
and	O
lectin	O
histochemistry	O
for	O
Ricinus	O
communis	O
agglutinin	O
-	O
I	O
(	O
RCA	O
-	O
I	O
)	O
to	O
detect	O
microglia	O
was	O
performed	O
to	O
evaluate	O
the	O
glial	O
response	O
in	O
the	O
CNS	O
of	O
cats	O
with	O
FIP	O
.	O

TITLE	O
:	O
Insectivorous	O
bats	O
carry	O
host	B-COMP
specific	O
astroviruses	O
and	O
coronaviruses	O
across	O
different	O
regions	O
in	O
Germany	O
.	O

Pseudotypes	O
allow	O
for	O
accurate	O
,	O
sequence	O
-	O
directed	O
,	O
sensitive	O
antibody	B-COMP
neutralisation	O
assays	O
and	O
antiviral	O
screening	O
to	O
be	O
conducted	O
within	O
a	O
low	O
biosecurity	O
facility	O
and	O
offer	O
a	O
safe	O
and	O
efficient	O
alternative	O
to	O
wildtype	O
virus	O
use	O
.	O

ABSTRACT	O
:	O
Dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
,	O
CD26	O
),	O
a	O
type	O
II	O
transmembrane	B-COMP
ectopeptidase	O
,	O
is	O
the	O
receptor	O
for	O
the	O
Middle	O
Eastern	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

In	O
the	O
future	O
also	O
new	O
approaches	O
like	O
mesenchymal	O
cell	B-COMP
therapy	O
,	O
activation	O
of	O
hypoxia	O
-	O
elicited	O
transcription	O
factors	O
or	O
targeting	O
of	O
purinergic	O
signaling	O
may	O
be	O
successful	O
outside	O
the	O
experimental	O
setting	O
.	O

We	O
performed	O
intratracheal	O
administration	O
of	O
autologous	O
peripheral	O
blood	O
-	O
derived	O
mononuclear	O
cells	B-COMP
(	O
PBMCs	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
).	O

IFN	O
-	O
	O
secretion	O
and	O
CD8	O
(+)	O
T	O
cell	B-COMP
proliferation	O
in	O
chickens	O
were	O
tested	O
by	O
ELISpot	O
array	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

Four	O
epitopes	O
(	O
P8SRIQTATDP	O
,	O
P9SRNATGSQP	O
,	O
P18GAYAVVNV	O
,	O
and	O
P19SRIQTATQP	O
)	O
were	O
identified	O
to	O
stimulate	O
CD8	O
(+)	O
T	O
cell	B-COMP
proliferation	O
and	O
IFN	O
-	O
	O
secretion	O
,	O
indicating	O
their	O
efficacy	O
as	O
CTL	O
epitopes	O
in	O
chicken	O
.	O

However	O
,	O
viral	O
clearance	O
,	O
type	O
-	O
I	O
interferon	O
production	O
,	O
and	O
the	O
development	O
of	O
anti	O
-	O
viral	O
B	O
and	O
T	O
cell	B-COMP
immunity	O
were	O
not	O
compromised	O
by	O
CARD9	O
deficiency	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
detected	O
by	O
monoclonal	O
antibody	B-COMP
-	O
based	O
nucleocapsid	B-COMP
protein	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
RNA	O
detection	O
,	O
and	O
viral	O
culture	O
from	O
the	O
nasal	O
sample	O
of	O
a	O
1	O
-	O
month	O
-	O
old	O
dromedary	O
calf	O
in	O
Dubai	O
with	O
sudden	O
death	O
.	O

Adult	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
requiring	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
therapy	O
.	O

Three	O
different	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
systems	O
:	O
the	O
Cardiohelp	O
system	O
(	O
Maquet	O
Cardiopulmonary	O
AG	O
),	O
the	O
Dideco	O
ECC	O
.	O
O5	O
(	O
Sorin	O
Group	O
),	O
and	O
the	O
Deltastream	O
system	O
with	O
Hilite	O
7000	O
LT	O
+	O
DP3	O
pumphead	O
(	O
Medos	O
Medizintechnik	O
AG	O
)	O
were	O
compared	O
.	O

Of	O
the	O
54	O
patients	O
included	O
in	O
the	O
study	O
,	O
18	O
patients	O
each	O
were	O
randomly	O
assigned	O
to	O
the	O
three	O
different	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
systems	O
.	O

The	O
median	O
time	O
on	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
was	O
13	O
.	O
5	O
days	O
(	O
4	O
-	O
70	O
d	O
).	O

TITLE	O
:	O
Spatiotemporal	O
interplay	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
respiratory	O
mucosal	O
cells	B-COMP
drives	O
viral	O
dissemination	O
in	O
rhesus	O
macaques	O
.	O

In	O
lymphoid	O
tissues	O
,	O
viral	O
RNA	O
and	O
proteins	O
were	O
detected	O
in	O
infected	O
monocytes	O
upon	O
differentiation	O
into	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
within	O
3	O
days	O
.	O

The	O
continued	O
emergence	O
and	O
reemergence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
underscore	O
the	O
importance	O
of	O
studying	O
how	O
this	O
virus	O
manipulates	O
the	O
immune	O
responses	O
of	O
its	O
hosts	B-COMP
.	O

In	O
conclusion	O
,	O
in	O
sows	O
infected	O
with	O
PEDV	O
the	O
presence	O
of	O
effector	O
/	O
memory	O
B	O
cell	B-COMP
response	O
and	O
strong	O
virus	O
neutralization	O
titers	O
in	O
plasma	O
up	O
to	O
6	O
months	O
post	O
-	O
infection	O
,	O
suggests	O
their	O
potential	O
to	O
protect	O
sows	O
from	O
reinfection	O
and	O
provide	O
maternal	O
immunity	O
to	O
neonates	O
,	O
but	O
challenge	O
studies	O
are	O
required	O
to	O
confirm	O
such	O
responses	O
.	O

CsA	O
and	O
FK506	O
are	O
targets	O
of	O
clinically	O
relevant	O
immunosuppressive	O
drugs	O
and	O
bind	O
to	O
cellular	B-COMP
cyclophilins	O
(	O
Cyps	O
)	O
or	O
FK506	O
binding	O
proteins	O
(	O
FKBPs	O
),	O
respectively	O
.	O

TITLE	O
:	O
(+)-	O
Catechin	O
inhibition	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
in	O
swine	O
testicular	O
cells	B-COMP
is	O
involved	O
its	O
antioxidation	O
.	O

Some	O
strains	O
are	O
highly	O
similar	O
to	O
SARS	O
-	O
CoV	O
even	O
in	O
the	O
spike	O
protein	O
and	O
are	O
able	O
to	O
use	O
the	O
same	O
receptor	O
as	O
SARS	O
-	O
CoV	O
for	O
cell	B-COMP
entry	O
.	O

Treatment	O
of	O
G6PD	O
-	O
knockdown	O
cells	B-COMP
with	O
siRNA	O
against	O
HSCARG	O
enhanced	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
B	O
and	O
the	O
expression	O
of	O
TNF	O
-	O
	O
and	O
MX1	O
,	O
but	O
suppressed	O
the	O
expression	O
of	O
viral	O
genes	O
;	O
however	O
,	O
the	O
overexpression	O
of	O
HSCARG	O
inhibited	O
the	O
antiviral	O
response	O
.	O

Results	O
Specificity	O
of	O
RT	O
-	O
nPCR	O
was	O
100	O
%	O
in	O
all	O
materials	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
in	O
serum	B-COMP
/	O
plasma	O
83	O
.	O
9	O
-	O
100	O
.	O
0	O
;	O
95	O
%	O
CI	O
in	O
effusion	O
93	O
.	O
0	O
-	O
100	O
.	O
0	O
).	O

Similar	O
comparative	O
assays	O
were	O
done	O
on	O
LLC	B-COMP
-	O
PK	O
and	O
ST	O
cells	B-COMP
inoculated	O
with	O
the	O
cell	B-COMP
-	O
adapted	O
PDCoV	O
strain	O
OH	O
-	O
FD22	O
-	O
P44	O
(	O
passage	O
44	O
)	O
in	O
cell	B-COMP
culture	O
medium	O
with	O
2	O
.	O
5	O
-	O
10	O
g	O
/	O
ml	O
of	O
trypsin	O
and	O
1	O
%	O
pancreatin	O
,	O
respectively	O
.	O

At	O
post	O
-	O
inoculation	O
days	O
3	O
-	O
4	O
,	O
infected	O
pigs	O
showed	O
severe	O
watery	O
diarrhea	O
and	O
/	O
or	O
vomiting	O
and	O
mainly	O
,	O
diffuse	O
,	O
severe	O
atrophic	O
enteritis	O
,	O
with	O
mild	O
to	O
moderate	O
cytoplasmic	B-COMP
vacuolation	O
of	O
the	O
enterocytes	O
lining	O
the	O
atrophied	O
villous	O
epithelium	O
.	O

In	O
contrast	O
,	O
by	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
of	O
the	O
TUNEL	O
-	O
positive	O
signals	O
(	O
apoptotic	O
nuclear	O
fragmentation	O
)	O
were	O
found	O
in	O
PDCoV	O
antigen	O
-	O
positive	O
LLC	B-COMP
-	O
PK	O
and	O
ST	O
cells	B-COMP
that	O
also	O
showed	O
cytopathic	O
effects	O
,	O
such	O
as	O
cell	B-COMP
rounding	O
,	O
detachment	O
and	O
clumping	O
in	O
clusters	O
.	O

Secondary	O
annexin	O
V	O
/	O
propidium	O
iodide	O
(	O
PI	O
)	O
staining	O
revealed	O
increased	O
numbers	O
of	O
annexin	O
V	O
-	O
or	O
PI	O
-	O
positive	O
LLC	B-COMP
-	O
PK	O
and	O
ST	O
cells	B-COMP
at	O
21h	O
after	O
inoculation	O
,	O
compared	O
to	O
the	O
negative	O
controls	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
effects	O
of	O
indirubin	O
derivatives	O
on	O
influenza	O
A	O
virus	O
-	O
infected	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	B-COMP
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
potential	O
immunomodulatory	O
effects	O
of	O
two	O
indirubin	O
derivatives	O
,	O
indirubin	O
-	O
3	O
'-(	O
2	O
,	O
3	O
-	O
dihydroxypropyl	O
)-	O
oximether	O
(	O
E804	O
)	O
and	O
indirubin	O
-	O
3	O
'-	O
oxime	O
(	O
E231	O
),	O
on	O
IAV	O
(	O
H9N2	O
)	O
infected	O
-	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	B-COMP
(	O
HPMECs	O
).	O

Our	O
data	O
further	O
suggest	O
that	O
myeloid	O
cells	B-COMP
may	O
serve	O
as	O
sentinels	O
to	O
restrict	O
viral	O
replication	O
,	O
thus	O
protecting	O
other	O
cell	B-COMP
types	O
from	O
infection	O
.	O

All	O
vaccination	O
programmes	O
were	O
able	O
to	O
induce	O
high	O
levels	O
of	O
CD4	O
+,	O
CD8	O
+	O
and	O
IgA	O
-	O
bearing	O
B	O
cells	B-COMP
in	O
the	O
trachea	O
.	O

Prone	O
position	O
ventilation	O
was	O
applied	O
in	O
20	O
,	O
4	O
%	O
and	O
rescue	O
measures	O
in	O
12	O
,	O
2	O
%	O
(	O
12	O
patients	O
with	O
nitric	O
oxide	O
and	O
1	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
).	O

Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	B-COMP
from	O
the	O
ARDS	O
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	B-COMP
from	O
the	O
ARDS	O
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

We	O
found	O
that	O
the	O
IFN	O
-	O
	O
production	O
was	O
significantly	O
suppressed	O
during	O
PEDV	O
infection	O
in	O
cells	B-COMP
.	O

TITLE	O
:	O
A	O
molecular	O
arms	O
race	O
between	O
host	B-COMP
innate	O
antiviral	O
response	O
and	O
emerging	O
human	O
coronaviruses	O
.	O

The	O
mechanisms	O
by	O
which	O
coronaviruses	O
evade	O
host	B-COMP
innate	O
antiviral	O
response	O
are	O
under	O
intense	O
investigations	O
.	O

With	O
a	O
better	O
understanding	O
of	O
the	O
dynamic	O
interaction	O
between	O
host	B-COMP
and	O
coronaviruses	O
,	O
it	O
is	O
hoped	O
that	O
insights	O
on	O
the	O
pathogenesis	O
of	O
newly	O
-	O
identified	O
highly	O
pathogenic	O
human	O
coronaviruses	O
and	O
new	O
strategies	O
in	O
antiviral	O
development	O
can	O
be	O
derived	O
.	O

Low	O
serum	B-COMP
levels	O
of	O
immunoglobulin	O
A	O
,	O
G2	O
,	O
and	O
G4	O
were	O
also	O
observed	O
before	O
HSCT	O
;	O
however	O
,	O
these	O
values	O
normalized	O
after	O
transplantation	O
.	O

However	O
,	O
ACE2	O
solely	O
is	O
not	O
sufficient	O
to	O
allow	O
host	B-COMP
cells	B-COMP
to	O
become	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
other	O
host	B-COMP
factors	O
may	O
be	O
involved	O
in	O
SARS	O
-	O
CoV	O
spike	O
protein	O
-	O
ACE2	O
complex	O
.	O

A	O
direct	O
interaction	O
between	O
vimentin	B-COMP
and	O
SARS	O
-	O
CoV	O
spike	O
protein	O
during	O
viral	O
entry	O
was	O
observed	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
developed	O
in	O
75	O
patients	O
(	O
15	O
.	O
6	O
%)	O
undergoing	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
and	O
58	O
patients	O
(	O
2	O
.	O
7	O
%)	O
undergoing	O
autologous	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
is	O
a	O
frequent	O
complication	O
following	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
,	O
dramatically	O
influencing	O
patient	O
-	O
important	O
outcomes	O
.	O

Notable	O
progress	O
in	O
care	O
includes	O
further	O
refinements	O
in	O
mechanical	O
ventilation	O
,	O
consideration	O
of	O
salutatory	O
effects	O
of	O
early	O
prone	O
positioning	O
and	O
neuromuscular	O
blockade	O
,	O
and	O
exploration	O
of	O
adjunctive	O
extrapulmonary	O
support	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Remarkably	O
,	O
in	O
the	O
other	O
cat	O
neither	O
clinical	O
signs	O
nor	O
acute	O
shedding	O
were	O
seen	O
,	O
but	O
virus	O
was	O
detected	O
in	O
blood	O
cells	B-COMP
from	O
3	O
dpi	O
,	O
and	O
shedding	O
of	O
non	O
-	O
enterotropic	O
,	O
mutated	O
viruses	O
suddenly	O
occurred	O
from	O
14	O
dpi	O
onwards	O
.	O

The	O
inflammatory	O
responses	O
indicate	O
that	O
the	O
cellular	B-COMP
immune	O
response	O
is	O
most	O
effective	O
during	O
the	O
initial	O
stage	O
,	O
while	O
the	O
humoral	O
immune	O
response	O
is	O
more	O
significant	O
in	O
later	O
stages	O
of	O
infection	O
.	O

Although	O
there	O
is	O
no	O
consensus	O
about	O
the	O
veno	O
-	O
veno	O
-	O
arterial	O
mode	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
this	O
combined	O
mode	O
can	O
be	O
helpful	O
in	O
patients	O
with	O
acute	O
refractory	O
respiratory	O
and	O
cardiac	O
failure	O
,	O
as	O
shown	O
in	O
the	O
present	O
case	O
.	O

Many	O
viruses	O
have	O
evolved	O
mechanisms	O
for	O
generating	O
their	O
own	O
cap	O
structures	O
with	O
methylation	O
at	O
the	O
N7	O
position	O
of	O
the	O
capped	O
guanine	O
and	O
the	O
ribose	O
2	O
'-	O
Oposition	O
of	O
the	O
first	O
nucleotide	O
,	O
which	O
help	O
viral	O
RNAs	O
escape	O
recognition	O
by	O
the	O
host	B-COMP
innate	O
immune	O
system	O
.	O

Here	O
,	O
we	O
have	O
used	O
a	O
herpesviral	O
amplicon	O
vector	O
carrying	O
a	O
gene	O
encoding	O
for	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
to	O
drive	O
its	O
overexpression	O
in	O
neuronal	O
cells	B-COMP
and	O
test	O
for	O
its	O
effect	O
on	O
FXN	O
-	O
deficient	O
neurons	O
both	O
in	O
culture	O
and	O
in	O
the	O
mouse	O
cerebellum	O
in	O
vivo	O
.	O

TITLE	O
:	O
Coronaviruses	O
and	O
the	O
human	O
airway	O
:	O
a	O
universal	O
system	O
for	O
virus	O
-	O
host	B-COMP
interaction	O
studies	O
.	O

Currently	O
,	O
different	O
cell	B-COMP
culture	O
systems	O
are	O
available	O
to	O
recapitulate	O
the	O
human	O
airways	O
,	O
including	O
the	O
Air	O
-	O
Liquid	O
Interface	O
(	O
ALI	O
)	O
human	O
airway	O
epithelium	O
(	O
HAE	O
)	O
model	O
.	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibodies	B-COMP
against	O
feline	O
coronavirus	O
accessory	O
protein	O
7b	O
.	O

The	O
two	O
mAbs	O
were	O
suitable	O
to	O
detect	O
a	O
24	O
-	O
kDa	O
protein	O
,	O
which	O
represents	O
the	O
nonglycosylated	O
form	O
of	O
7b	O
in	O
FCoV	O
-	O
infected	O
cells	B-COMP
.	O

These	O
viruses	O
have	O
evolved	O
diverse	O
strategies	O
to	O
evade	O
and	O
block	O
host	B-COMP
immune	O
responses	O
,	O
facilitating	O
infection	O
and	O
transmission	O
.	O

S	O
also	O
contains	O
the	O
principal	O
antigenic	O
determinants	O
and	O
is	O
the	O
target	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
Most	O
of	O
the	O
intracellular	B-COMP
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
reside	O
in	O
either	O
the	O
endolysosome	B-COMP
or	O
the	O
cytoplasm	B-COMP
to	O
sense	O
pathogen	O
-	O
derived	O
RNAs	O
,	O
DNAs	O
,	O
or	O
synthetic	O
analogs	O
of	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
),	O
such	O
as	O
poly	O
(	O
I	O
:	O
C	O
).	O

Except	O
negative	O
result	O
of	O
antibody	B-COMP
test	O
in	O
the	O
well	O
-	O
known	O
""""	O
acute	O
window	O
phase	O
""","	O
in	O
rare	O
cases	O
,	O
patients	O
do	O
not	O
develop	O
HIV	O
antibodies	B-COMP
despite	O
demonstrable	O
infection	O
.	O

The	O
possibility	O
of	O
AIDS	O
was	O
discounted	O
by	O
his	O
physicians	O
because	O
of	O
the	O
repeatedly	O
negative	O
HIV	O
antibodies	B-COMP
tests	O
despite	O
the	O
ELISA	O
tests	O
or	O
Western	O
blot	O
tests	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	B-COMP
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	O
infection	O
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

These	O
molecules	O
are	O
able	O
to	O
directly	O
inhibit	O
many	O
viruses	O
such	O
as	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
),	O
Hepatitis	O
C	O
Virus	O
(	O
HCV	O
),	O
Dengue	O
Virus	O
,	O
Ebola	O
Virus	O
or	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
through	O
binding	O
to	O
envelope	B-COMP
protein	O
N	O
-	O
glycans	O
.	O

At	O
the	O
end	O
of	O
lectin	O
exposure	O
,	O
the	O
genome	O
of	O
the	O
isolated	O
strains	O
was	O
sequenced	O
and	O
several	O
potential	O
resistance	O
mutations	O
in	O
the	O
E1E2	O
envelope	B-COMP
glycoproteins	O
were	O
identified	O
.	O

Even	O
if	O
the	O
isolate	O
was	O
not	O
secreting	O
toxin	O
in	O
vitro	O
,	O
it	O
possesses	O
the	O
tox	O
gene	O
which	O
motivated	O
the	O
use	O
of	O
specific	O
antitoxin	O
serum	B-COMP
.	O

Severe	O
falciparum	O
malaria	O
,	O
or	O
infections	O
complicated	O
by	O
a	O
relatively	O
high	O
parasite	O
count	O
(	O
more	O
than	O
2	O
%	O
of	O
red	O
blood	O
cells	B-COMP
parasitized	O
)	O
should	O
be	O
treated	O
with	O
intravenous	O
therapy	O
until	O
the	O
patient	O
is	O
well	O
enough	O
to	O
continue	O
with	O
oral	O
treatment	O
.	O

Moreover	O
,	O
virions	B-COMP
of	O
the	O
M	O
chimera	O
were	O
markedly	O
deficient	O
in	O
spike	O
(	O
S	O
)	O
protein	O
incorporation	O
.	O

ABSTRACT	O
:	O
Accumulating	O
data	O
suggest	O
that	O
tripartite	O
-	O
motif	O
-	O
containing	O
(	O
TRIM	O
)	O
proteins	O
participate	O
in	O
host	B-COMP
responses	O
to	O
viral	O
infections	O
,	O
either	O
by	O
acting	O
as	O
direct	O
antiviral	O
restriction	O
factors	O
or	O
through	O
regulating	O
innate	O
immune	O
signaling	O
of	O
the	O
host	B-COMP
.	O

Here	O
,	O
we	O
show	O
that	O
TRIM56	O
puts	O
a	O
check	O
on	O
replication	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
in	O
cell	B-COMP
culture	O
but	O
does	O
not	O
inhibit	O
Sendai	O
virus	O
or	O
human	O
metapneumovirus	O
,	O
two	O
paramyxoviruses	O
.	O

ABSTRACT	O
:	O
Type	O
II	O
alveolar	O
epithelial	O
cells	B-COMP
have	O
potential	O
for	O
lung	O
growth	O
and	O
reparation	O
.	O

ABSTRACT	O
:	O
Although	O
Lewis	O
X	O
(	O
Le	O
(	O
x	O
)),	O
a	O
carbohydrate	O
structure	O
,	O
is	O
involved	O
in	O
innate	O
immunity	O
through	O
cell	B-COMP
-	O
to	O
-	O
cell	B-COMP
and	O
pathogen	O
recognition	O
,	O
its	O
expression	O
has	O
not	O
been	O
observed	O
in	O
mouse	O
monocytes	O
/	O
macrophages	O
(	O
Mo	O
/	O
Mas	B-COMP
).	O

We	O
investigated	O
Le	O
(	O
x	O
)	O
expression	O
using	O
CD11b	O
-	O
positive	O
peritoneal	O
exudate	O
cells	B-COMP
(	O
PECs	O
)	O
and	O
found	O
that	O
Le	O
(	O
x	O
)	O
is	O
inducible	O
in	O
Mo	O
/	O
Mas	B-COMP
after	O
infection	O
with	O
srr7	O
,	O
especially	O
in	O
the	O
syncytial	O
cells	B-COMP
during	O
the	O
late	O
phase	O
of	O
infection	O
.	O

Here	O
we	O
demonstrate	O
the	O
transient	O
expression	O
in	O
Nicotiana	O
benthamiana	O
of	O
two	O
important	O
antigenic	O
determinants	O
of	O
the	O
SARS	O
-	O
CoV	O
,	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
)	O
and	O
the	O
membrane	B-COMP
protein	O
(	O
M	O
)	O
using	O
a	O
virus	O
-	O
derived	O
vector	O
or	O
agro	O
-	O
infiltration	O
,	O
respectively	O
.	O

TITLE	O
:	O
Comparison	O
of	O
lentiviruses	O
pseudotyped	O
with	O
S	O
proteins	O
from	O
coronaviruses	O
and	O
cell	B-COMP
tropisms	O
of	O
porcine	O
coronaviruses	O
.	O

They	O
received	O
weekly	O
intravenous	O
injection	O
of	O
umbilical	O
cord	O
-	O
derived	O
mesenchymal	O
stem	O
cells	B-COMP
(	O
MSC	O
)	O
at	O
a	O
dose	O
of	O
1	O
	O
10	O
(	O
6	O
)/	O
kg	O
for	O
4	O
weeks	O
.	O

For	O
the	O
first	O
EQA	O
phase	O
,	O
in	O
vitro	O
transcribed	O
upstream	O
region	O
of	O
the	O
envelope	B-COMP
gene	O
(	O
upE	O
)	O
and	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
RNAs	O
were	O
used	O
at	O
a	O
concentration	O
of	O
1	O
,	O
000	O
copies	O
/	O
L	O
.	O
The	O
test	O
panel	O
for	O
the	O
second	O
EQA	O
phase	O
consisted	O
of	O
RNA	O
extracts	O
from	O
three	O
samples	O
,	O
which	O
were	O
obtained	O
from	O
two	O
MERS	O
-	O
CoV	O
positive	O
patients	O
and	O
one	O
MERS	O
-	O
CoV	O
negative	O
patient	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
structure	O
,	O
the	O
replication	O
,	O
and	O
the	O
transcription	O
of	O
CoV	O
.	O
This	O
protein	O
,	O
which	O
has	O
a	O
helix	O
and	O
flexible	O
structure	O
,	O
and	O
capable	O
of	O
binding	O
on	O
to	O
the	O
viral	O
genomic	O
RNA	O
,	O
is	O
a	O
non	O
-	O
structural	O
protein	O
(	O
nsp3	O
).	O

Data	O
from	O
the	O
GO	O
analysis	O
indicated	O
that	O
the	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	O
-	O
	O
as	O
well	O
as	O
the	O
genes	O
from	O
the	O
microarray	O
were	O
mainly	O
enriched	O
in	O
10	O
biological	O
processes	O
,	O
including	O
cellular	B-COMP
process	I-COMP
,	O
metabolic	O
process	O
,	O
immune	O
system	O
process	O
and	O
biological	O
regulation	O
,	O
et	O
al	O
.	O
Data	O
on	O
drug	O
target	O
genes	O
,	O
first	O
and	O
second	O
cluster	O
of	O
microarray	O
would	O
involve	O
9	O
,	O
3	O
and	O
23	O
signaling	O
pathways	O
respectively	O
,	O
and	O
only	O
the	O
former	O
two	O
showed	O
7	O
common	O
pathways	O
,	O
which	O
were	O
related	O
to	O
pathogen	O
recognition	O
,	O
cytokine	O
release	O
and	O
autoimmune	O
response	O
.	O

Ribosome	B-COMP
profiling	O
is	O
a	O
technique	O
which	O
exploits	O
the	O
capacity	O
of	O
the	O
translating	O
ribosome	B-COMP
to	O
protect	O
around	O
30	O
nucleotides	O
of	O
mRNA	O
from	O
ribonuclease	O
digestion	O
.	O

Moreover	O
,	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
),	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
),	O
stimulator	O
of	O
IFN	O
genes	O
(	O
STING	O
),	O
and	O
mitochondrial	B-COMP
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
),	O
as	O
well	O
as	O
TANK	O
binding	O
kinase	O
1	O
(	O
TBK1	O
),	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
	O
,	O
IKK	O
,	O
IKK	O
,	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
7	O
,	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
B	O
),	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
various	O
interleukins	O
(	O
ILs	O
),	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
(	O
MIP	O
-	O
1	O
)	O
were	O
significantly	O
upregulated	O
in	O
the	O
trachea	O
and	O
downregulated	O
in	O
the	O
kidney	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
eligibility	O
was	O
determined	O
based	O
on	O
published	O
criteria	O
from	O
recent	O
ECMO	O
guidelines	O
and	O
clinical	O
trials	O
.	O

Inhaled	O
RBV	O
was	O
used	O
more	O
than	O
oral	O
,	O
and	O
in	O
the	O
post	O
-	O
stem	O
cell	B-COMP
transplant	O
population	O
,	O
patients	O
with	O
lower	O
respiratory	O
tract	O
infection	O
(	O
LRTI	O
),	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
,	O
and	O
more	O
recent	O
transplantation	O
were	O
treated	O
at	O
higher	O
rates	O
.	O

Bats	O
harbour	O
several	O
betacoronaviruses	O
that	O
are	O
closely	O
related	O
to	O
MERS	O
-	O
CoV	O
but	O
more	O
research	O
is	O
needed	O
to	O
establish	O
the	O
relationship	O
between	O
bats	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
seroprevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
is	O
very	O
high	O
in	O
dromedary	O
camels	O
in	O
Eastern	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	O
.	O

These	O
unexpected	O
findings	O
suggest	O
that	O
MERS	O
-	O
CoV	O
adaptation	O
in	O
humans	O
may	O
be	O
driven	O
by	O
host	B-COMP
immunological	O
pressure	O
.	O

TITLE	O
:	O
The	O
epidermal	O
growth	O
factor	O
receptor	O
regulates	O
cofilin	O
activity	O
and	O
promotes	O
transmissible	O
gastroenteritis	O
virus	O
entry	O
into	O
intestinal	O
epithelial	O
cells	B-COMP
.	O

These	O
features	O
,	O
along	O
with	O
the	O
location	O
of	O
the	O
two	O
protease	O
sites	O
known	O
to	O
be	O
important	O
for	O
coronavirus	O
entry	O
,	O
provide	O
a	O
structural	O
basis	O
to	O
support	O
a	O
model	O
of	O
membrane	B-COMP
fusion	O
mediated	O
by	O
progressive	O
S	O
protein	O
destabilization	O
through	O
receptor	O
binding	O
and	O
proteolytic	O
cleavage	O
.	O

This	O
different	O
reactivity	O
was	O
also	O
confirmed	O
by	O
immunoblot	O
analysis	O
using	O
the	O
serum	B-COMP
from	O
the	O
ferret	O
.	O

1	O
-	O
179	O
of	O
the	O
N	O
protein	O
is	O
useful	O
for	O
detection	O
of	O
antibody	B-COMP
to	O
FRCoV	O
for	O
diagnosis	O
and	O
seroepidemiology	O
of	O
FRCoV	O
infection	O
.	O

Globally	O
,	O
Anas	O
species	O
represent	O
the	O
largest	O
fraction	O
of	O
avian	O
CoV	O
sequences	O
,	O
and	O
there	O
seems	O
to	O
be	O
no	O
host	B-COMP
species	O
,	O
geographical	O
or	O
temporal	O
structure	O
.	O

The	O
typical	O
AMAN	O
-	O
associated	O
anti	O
-	O
ganglioside	O
antibodies	B-COMP
were	O
rarely	O
present	O
.	O

After	O
establishment	O
of	O
mice	O
model	O
,	O
we	O
observed	O
the	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	O
replication	O
,	O
immunopathogenesis	O
and	O
antibody	B-COMP
response	O
.	O

The	O
results	O
indicated	O
that	O
the	O
infected	O
mice	O
showed	O
typical	O
pneumonia	O
,	O
virus	O
replication	O
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-COMP
production	O
.	O

In	O
this	O
study	O
,	O
via	O
high	O
throughput	O
screening	O
of	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drugs	O
,	O
we	O
identified	O
that	O
teicoplanin	O
,	O
a	O
glycopeptide	O
antibiotic	O
,	O
potently	O
prevents	O
the	O
entry	O
of	O
Ebola	O
envelope	B-COMP
pseudotyped	O
viruses	O
into	O
the	O
cytoplasm	B-COMP
.	O

Coronavirus	O
transcription	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
the	O
extent	O
of	O
base	O
-	O
pairing	O
between	O
transcription	O
-	O
regulating	O
sequences	O
of	O
positive	O
and	O
negative	O
polarity	O
,	O
viral	O
and	O
cell	B-COMP
protein	O
-	O
RNA	O
binding	O
,	O
and	O
high	O
-	O
order	O
RNA	O
-	O
RNA	O
interactions	O
.	O

Coronavirus	O
RNA	O
synthesis	O
is	O
connected	O
with	O
the	O
formation	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
and	O
convoluted	O
membranes	O
.	O

RESULTS	O
:	O
Multiple	O
sequence	O
alignment	O
of	O
the	O
spike	O
(	O
S	O
),	O
membrane	B-COMP
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
was	O
employed	O
to	O
identify	O
the	O
sequence	O
conservation	O
among	O
MERS	O
and	O
Bat	O
(	O
HKU4	O
,	O
HKU5	O
)	O
coronaviruses	O
.	O

We	O
also	O
showed	O
that	O
pFcRn	O
mediated	O
bidirectional	O
IgG	O
transport	O
across	O
polarized	O
IPEC	O
-	O
J2	O
cells	B-COMP
and	O
bound	O
to	O
IgG	O
in	O
a	O
pH	O
-	O
dependent	O
manner	O
.	O

The	O
issue	O
was	O
addressed	O
by	O
comparing	O
the	O
effects	O
on	O
lung	O
function	O
of	O
CMV	O
and	O
HFJV	O
in	O
two	O
rabbit	O
models	O
of	O
neonatal	O
acute	O
lung	O
injury	O
:	O
repetitive	O
saline	O
lung	O
lavage	O
(	O
LAV	O
)	O
and	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-COMP
)	O
induced	O
by	O
intratracheal	O
meconium	O
instillation	O
.	O

TITLE	O
:	O
Host	B-COMP
-	O
directed	O
therapies	O
for	O
antimicrobial	O
resistant	O
respiratory	O
tract	O
infections	O
.	O

In	O
addition	O
,	O
we	O
screened	O
for	O
antibodies	B-COMP
against	O
HEV	O
and	O
PLHV	O
.	O

TITLE	O
:	O
Control	O
of	O
Respiratory	O
Drive	O
and	O
Effort	O
in	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Patients	O
Recovering	O
from	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Serum	B-COMP
Amyloid	O
P	O
Contained	O
in	O
Alveolar	O
Fluid	O
From	O
Patients	O
With	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Mediates	O
the	O
Inhibition	O
of	O
Monocyte	O
Differentiation	O
into	O
Fibrocyte	O
.	O

Plasma	O
and	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
serum	B-COMP
amyloid	O
P	O
contents	O
were	O
determined	O
by	O
western	O
blot	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Serum	B-COMP
amyloid	O
P	O
was	O
located	O
in	O
normal	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
lung	O
by	O
immunohistochemistry	O
.	O

The	O
presence	O
of	O
fibrocytes	O
in	O
the	O
lung	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
could	O
result	O
in	O
a	O
balance	O
between	O
higher	O
ability	O
of	O
monocytes	O
to	O
differentiate	O
into	O
fibrocytes	O
and	O
the	O
inhibitory	O
effect	O
of	O
the	O
alveolar	O
environment	O
,	O
mainly	O
dependent	O
on	O
serum	B-COMP
amyloid	O
P	O
.	O

Patients	O
with	O
ARDS	O
treated	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
also	O
benefit	O
from	O
prone	O
positioning	O
;	O
however	O
,	O
the	O
procedure	O
is	O
associated	O
with	O
a	O
possible	O
higher	O
risk	O
of	O
serious	O
adverse	O
events	O
.	O

nsp14	O
N7	O
-	O
MTase	O
activity	O
is	O
required	O
for	O
viral	O
mRNA	O
cap	O
synthesis	O
and	O
prevents	O
the	O
recognition	O
of	O
viral	O
mRNAs	O
as	O
""""	O
non	O
-	O
self	O
""""	O
by	O
the	O
host	B-COMP
cell	I-COMP
.	O

ABSTRACT	O
:	O
The	O
term	O
sepsis	O
-	O
associated	O
encephalopathy	O
(	O
SAE	B-COMP
)	O
has	O
been	O
applied	O
to	O
animal	O
models	O
,	O
postmortem	O
studies	O
in	O
patients	O
,	O
and	O
severe	O
cases	O
of	O
sepsis	O
.	O

Recombinant	O
L	O
.	O
casei	O
had	O
a	O
strong	O
potentiating	O
effect	O
on	O
the	O
cellular	B-COMP
immunity	O
induced	O
by	O
the	O
oral	O
L	O
.	O
casei	O
vaccine	O
.	O

TITLE	O
:	O
Fat	O
(	O
al	O
)	O
attraction	O
:	O
Picornaviruses	O
Usurp	O
Lipid	O
Transfer	O
at	O
Membrane	B-COMP
Contact	O
Sites	O
to	O
Create	O
Replication	O
Organelles	B-COMP
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
viral	B-COMP
nucleocapsid	I-COMP
protein	O
(	O
N	O
)	O
is	O
located	O
in	O
mitochondria	B-COMP
and	O
mitophagosome	O
during	O
virus	O
infection	O
or	O
be	O
expressed	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
TGEV	O
infection	O
induce	O
mitophagy	O
to	O
promote	O
cell	B-COMP
survival	O
and	O
possibly	O
viral	O
infection	O
.	O

In	O
addition	O
,	O
virus	O
replication	O
was	O
required	O
for	O
the	O
increased	O
amount	O
of	O
the	O
autophagosome	B-COMP
marker	O
protein	O
LC3	O
-	O
II	O
.	O

The	O
patient	O
received	O
an	O
apheresis	O
PLT	O
concentrate	O
(	O
APC	B-COMP
)	O
on	O
Day	O
0	O
due	O
to	O
thrombocytopenia	O
complicated	O
by	O
mucocutaneous	O
hemorrhage	O
.	O

RESULTS	O
:	O
A	O
U	O
.	O
S	O
.	O
PEDV	O
S	O
-	O
INDEL	O
-	O
variant	O
strain	O
was	O
isolated	O
in	O
cell	B-COMP
culture	O
in	O
this	O
study	O
.	O

The	O
isotope	O
dilution	O
mass	O
spectrometry	O
traceable	O
serum	B-COMP
creatinine	O
level	O
increased	O
to	O
3	O
.	O
0	O
mg	O
/	O
dL	O
.	O
We	O
performed	O
a	O
kidney	O
biopsy	O
8	O
weeks	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

TITLE	O
:	O
Interdisciplinary	O
Peripartum	O
Management	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
with	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
-	O
a	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
used	O
for	O
the	O
management	O
of	O
acute	O
severe	O
cardiac	O
and	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Antibodies	B-COMP
in	O
Humans	O
,	O
Africa	O
,	O
2013	O
-	O
2014	O
.	O

Arterivirus	O
-	O
induced	O
DMVs	O
appear	O
to	O
be	O
closed	O
compartments	O
that	O
are	O
continuous	O
with	O
endoplasmic	B-COMP
reticulum	I-COMP
membranes	O
,	O
thus	O
forming	O
an	O
extensive	O
reticulovesicular	O
network	O
(	O
RVN	O
)	O
of	O
intriguing	O
complexity	O
.	O

We	O
review	O
here	O
the	O
current	O
knowledge	O
and	O
open	O
questions	O
on	O
arterivirus	O
replication	O
organelles	B-COMP
and	O
discuss	O
them	O
in	O
the	O
light	O
of	O
the	O
latest	O
studies	O
on	O
other	O
DMV	O
-	O
inducing	O
viruses	O
,	O
particularly	O
coronaviruses	O
.	O

However	O
,	O
uncontrolled	O
inflammation	O
could	O
be	O
detrimental	O
to	O
the	O
host	B-COMP
,	O
resulting	O
in	O
inflammatory	O
disease	O
,	O
such	O
as	O
inflammatory	O
lung	O
disease	O
.	O

Cell	B-COMP
culture	O
-	O
adapted	O
US	O
PDCoV	O
(	O
TC	O
-	O
PDCoV	O
)	O
strains	O
have	O
been	O
isolated	O
and	O
propagated	O
by	O
us	O
and	O
in	O
several	O
other	O
laboratories	O
.	O

In	O
this	O
study	O
,	O
a	O
rapid	O
method	O
for	O
detecting	O
PEDV	O
was	O
developed	O
based	O
on	O
cross	O
-	O
priming	O
amplification	O
and	O
nucleic	B-COMP
acid	O
test	O
strip	O
(	O
CPA	O
-	O
NATS	O
).	O

The	O
ability	O
of	O
MERS	O
-	O
CoV	O
to	O
evade	O
the	O
host	B-COMP
innate	O
antiviral	O
response	O
may	O
contribute	O
to	O
its	O
severe	O
pathogenesis	O
.	O

M	O
proteins	O
from	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
have	O
three	O
highly	O
similar	O
conserved	O
N	O
-	O
terminal	O
transmembrane	B-COMP
domains	O
and	O
a	O
C	O
-	O
terminal	O
region	O
.	O

Cellular	B-COMP
kinases	O
phosphorylate	O
BCX4430	O
to	O
a	O
triphosphate	O
that	O
mimics	O
ATP	O
;	O
viral	O
RNA	O
polymerases	O
incorporate	O
the	O
drug	O
'	O
s	O
monophosphate	O
nucleotide	O
into	O
the	O
growing	O
RNA	O
chain	O
,	O
causing	O
premature	O
chain	O
termination	O
.	O

TITLE	O
:	O
Diminished	O
COX	O
-	O
2	O
/	O
PGE2	O
-	O
Mediated	O
Antiviral	O
Response	O
Due	O
to	O
Impaired	O
NOX	O
/	O
MAPK	O
Signaling	O
in	O
G6PD	O
-	O
Knockdown	O
Lung	O
Epithelial	O
Cells	B-COMP
.	O

The	O
immune	O
protective	O
efficiency	O
of	O
YC2014	O
were	O
determined	O
by	O
testing	O
PEDV	O
neutralizing	O
antibodies	B-COMP
in	O
sera	B-COMP
,	O
the	O
colostrum	O
and	O
the	O
milk	O
on	O
7th	O
day	O
after	O
farrowing	O
of	O
the	O
immunized	O
sows	O
.	O

The	O
cellular	B-COMP
composition	O
of	O
the	O
lesions	O
was	O
characterized	O
on	O
the	O
basis	O
of	O
cellular	B-COMP
morphology	O
and	O
immunohistochemistry	O
using	O
markers	O
for	O
T	O
and	O
B	O
-	O
lymphocytes	O
,	O
plasma	O
cells	B-COMP
,	O
macrophages	O
,	O
and	O
neutrophils	O
.	O

G	O
-	O
N	O
lesions	O
exhibited	O
a	O
necrotic	O
center	O
surrounded	O
by	O
abundant	O
macrophages	O
,	O
some	O
T	O
-	O
lymphocytes	O
,	O
plasma	O
cells	B-COMP
,	O
and	O
a	O
few	O
B	O
-	O
lymphocytes	O
.	O

FRSCV	O
was	O
expressed	O
in	O
G	O
,	O
G	O
-	O
NL	O
,	O
G	O
-	O
N	O
,	O
and	O
DG	O
,	O
with	O
decreasing	O
numbers	O
of	O
immunoreactive	O
cells	B-COMP
.	O

After	O
ECMO	O
running	O
3	O
days	O
,	O
most	O
factors	O
of	O
the	O
ECMO	O
survival	O
group	O
were	O
better	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
except	O
MAP	O
,	O
but	O
most	O
factors	O
between	O
the	O
ECMO	O
non	O
-	O
survival	O
group	O
and	O
the	O
control	O
group	O
were	O
not	O
significantly	O
different	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
),	O
while	O
the	O
serum	B-COMP
lactate	O
level	O
was	O
higher	O
(	O
t	O
=-	O
3	O
.	O
156	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
the	O
MAP	O
lower	O
(	O
t	O
=	O
3	O
.	O
578	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

The	O
clinical	O
data	O
in	O
two	O
groups	O
were	O
recorded	O
as	O
following	O
:	O
gender	O
,	O
age	O
;	O
respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
and	O
systolic	O
blood	O
pressure	O
at	O
admission	O
;	O
the	O
lowest	O
values	O
of	O
serum	B-COMP
creatinine	O
(	O
SCr	O
),	O
white	O
blood	O
cell	B-COMP
count	O
(	O
WBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
hematocrit	O
(	O
Hct	O
),	O
respectively	O
,	O
within	O
24	O
hours	O
after	O
admission	O
;	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
Glasgow	O
coma	O
scale	O
(	O
GCS	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
score	O
,	O
injury	O
severity	O
score	O
(	O
ISS	O
)	O
within	O
24	O
hours	O
of	O
final	O
diagnosis	O
;	O
the	O
performance	O
of	O
emergency	O
operation	O
or	O
intubation	O
within	O
24	O
hours	O
;	O
incidence	O
of	O
sepsis	O
,	O
and	O
clinical	O
outcomes	O
.	O

Our	O
analyses	O
show	O
:	O
1	O
)	O
28	O
potential	O
recombinant	O
sequences	O
were	O
detected	O
and	O
they	O
can	O
be	O
classified	O
into	O
seven	O
potential	O
recombinant	O
types	O
;	O
2	O
)	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MERS	O
-	O
CoV	O
was	O
under	O
strong	O
positive	O
selection	O
when	O
MERS	O
-	O
CoV	O
transmitted	O
from	O
their	O
natural	O
host	B-COMP
to	O
human	O
;	O
3	O
)	O
Six	O
out	O
of	O
nine	O
positive	O
selection	O
sites	O
detected	O
in	O
spike	O
(	O
S	O
)	O
protein	O
are	O
located	O
in	O
its	O
receptor	O
-	O
binding	O
domain	O
which	O
is	O
in	O
direct	O
contact	O
with	O
host	B-COMP
cells	B-COMP
;	O
4	O
)	O
MERS	O
-	O
CoV	O
frequently	O
transmitted	O
back	O
and	O
forth	O
between	O
human	O
and	O
camel	O
after	O
it	O
had	O
acquired	O
the	O
human	O
-	O
camel	O
infection	O
capability	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
g	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	B-COMP
IgG	O
and	O
serum	B-COMP
neutralizing	O
antibody	B-COMP
titers	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
g	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	B-COMP
IgG	O
and	O
serum	B-COMP
neutralizing	O
antibody	B-COMP
titers	O
.	O

TITLE	O
:	O
The	O
contribution	O
of	O
the	O
cytoplasmic	B-COMP
retrieval	O
signal	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
to	O
intracellular	B-COMP
accumulation	O
of	O
S	O
proteins	O
and	O
incorporation	O
of	O
S	O
protein	O
into	O
virus	O
-	O
like	O
particles	O
.	O

Molecular	O
simulation	O
study	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
confirmed	O
that	O
compound	O
8	O
stabilized	O
HA2	B-COMP
subunit	O
of	O
hemagglutinin	O
(	O
HA	O
)	O
by	O
binding	O
with	O
amino	O
acid	O
residues	O
LYS	O
-	O
26	O
,	O
ASN	O
-	O
53	O
,	O
ASN	O
-	O
27	O
and	O
ASN	O
-	O
50	O
,	O
therefore	O
may	O
prevent	O
HA	O
from	O
conformational	O
rearranging	O
,	O
which	O
is	O
a	O
critical	O
step	O
for	O
viral	O
entry	O
.	O

Western	O
blot	O
analysis	O
with	O
anti	O
-	O
Lys48	O
and	O
anti	O
-	O
Lys63	O
ubiquitin	O
antibodies	B-COMP
indicated	O
the	O
SARS	O
-	O
CoV	O
PLPro	O
removed	O
Lys63	O
-	O
linked	O
ubiquitin	O
chains	O
of	O
TRAF3	O
and	O
TRAF6	O
,	O
but	O
not	O
Lys48	O
-	O
linked	O
ubiquitin	O
chains	O
in	O
un	O
-	O
treated	O
and	O
treated	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
DcCoV	O
UAE	O
-	O
HKU23	O
was	O
successfully	O
isolated	O
in	O
two	O
of	O
the	O
14	O
dromedary	O
fecal	O
samples	O
using	O
HRT	O
-	O
18G	O
cells	B-COMP
,	O
with	O
cytopathic	O
effects	O
observed	O
five	O
days	O
after	O
inoculation	O
.	O

TITLE	O
:	O
Bat	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
-	O
Like	O
Coronavirus	O
WIV1	O
Encodes	O
an	O
Extra	O
Accessory	O
Protein	O
,	O
ORFX	O
,	O
Involved	O
in	O
Modulation	O
of	O
the	O
Host	B-COMP
Immune	O
Response	O
.	O

SARS	O
-	O
CoV	O
PLpro	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
up	O
-	O
regulates	O
TGF	O
-	O
1	O
and	O
vimentin	B-COMP
in	O
A549	O
cells	B-COMP
.	O

While	O
there	O
is	O
no	O
specific	O
therapy	O
,	O
we	O
decided	O
to	O
support	O
the	O
patient	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
V	O
-	O
V	O
ECMO	O
)	O
to	O
allow	O
the	O
ARDS	O
to	O
resolve	O
.	O

Antibody	B-COMP
longevity	O
was	O
more	O
variable	O
in	O
patients	O
who	O
had	O
experienced	O
milder	O
disease	O
.	O

Further	O
,	O
RIP3	O
depletion	O
reduced	O
the	O
necrotic	O
cells	B-COMP
in	O
the	O
lung	O
and	O
decreased	O
the	O
expression	O
of	O
MLKL	O
,	O
but	O
had	O
no	O
impact	O
on	O
cleaved	O
caspase	O
-	O
3	O
in	O
LPS	O
-	O
induced	O
ARDS	O
.	O

Prevalence	O
of	O
CCV	O
antibodies	B-COMP
suggested	O
a	O
seasonal	O
pattern	O
with	O
higher	O
prevalence	O
during	O
spring	O
(	O
43	O
%)	O
than	O
in	O
fall	O
(	O
11	O
%).	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
death	O
among	O
sickle	O
cell	B-COMP
disease	O
(	O
SCD	O
)	O
adult	O
patients	O
.	O

Senecavirus	O
A	O
(	O
SV	O
-	O
A	O
)	O
formerly	O
known	O
as	O
Seneca	O
Valley	O
virus	O
was	O
detected	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
from	O
serum	B-COMP
,	O
skin	O
and	O
faeces	O
of	O
piglets	O
and	O
from	O
serum	B-COMP
and	O
faeces	O
of	O
sows	O
.	O

ABSTRACT	O
:	O
Equine	O
coronavirus	O
(	O
EqCoV	O
)	O
infection	O
has	O
been	O
documented	O
in	O
most	O
reports	O
through	O
quantitative	O
qPCR	O
analysis	O
of	O
feces	O
and	O
viral	B-COMP
genome	I-COMP
sequencing	O
.	O

Although	O
qPCR	O
is	O
used	O
to	O
detect	O
antigen	O
during	O
the	O
acute	O
disease	O
phase	O
,	O
there	O
is	O
no	O
equine	O
-	O
specific	O
antibody	B-COMP
test	O
available	O
to	O
study	O
EqCoV	O
seroprevalence	O
in	O
various	O
horse	O
populations	O
.	O

The	O
computationally	O
designed	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
validated	O
using	O
169	O
field	O
sera	B-COMP
,	O
whose	O
statuses	O
were	O
determined	O
by	O
a	O
PEDV	O
-	O
specific	O
immunofluorescence	O
assay	O
.	O

Fifteen	O
newborn	O
piglets	O
were	O
divided	O
into	O
two	O
groups	O
of	O
7	O
-	O
8	O
piglets	O
each	O
and	O
inoculated	O
orally	O
with	O
one	O
of	O
PEDV	O
isolates	O
maintained	O
at	O
the	O
eighth	O
passage	O
in	O
Vero	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Effects	O
of	O
inactivated	O
porcine	O
epidemic	O
diarrhea	O
virus	O
on	O
porcine	O
monocyte	O
-	O
derived	O
dendritic	B-COMP
cells	B-COMP
and	O
intestinal	O
dendritic	B-COMP
cells	B-COMP
.	O

Interactions	O
between	O
Mo	O
-	O
DCs	O
and	O
UV	O
-	O
PEDV	O
significantly	O
stimulate	O
T	O
-	O
cell	B-COMP
proliferation	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
several	O
prognostic	O
scoring	O
systems	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
requiring	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
have	O
been	O
published	O
.	O

The	O
respiratory	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
survival	O
prediction	O
(	O
RESP	O
)	O
score	O
and	O
simplified	O
acute	O
physiology	O
score	O
(	O
SAPS	O
)	O
II	O
score	O
also	O
showed	O
fair	O
prediction	O
ability	O
with	O
AUC	O
of	O
0	O
.	O
79	O
(	O
95	O
%	O
CI	O
0	O
.	O
65	O
-	O
0	O
.	O
89	O
)	O
and	O
AUC	O
of	O
0	O
.	O
78	O
(	O
95	O
%	O
CI	O
0	O
.	O
64	O
-	O
0	O
.	O
88	O
),	O
respectively	O
.	O

Many	O
viruses	O
use	O
5	O
'	O
caps	O
or	O
other	O
mechanisms	O
to	O
mimic	O
a	O
cap	O
structure	O
to	O
limit	O
detection	O
of	O
viral	O
RNAs	O
by	O
intracellular	B-COMP
innate	O
sensors	O
and	O
to	O
direct	O
efficient	O
translation	O
of	O
viral	O
proteins	O
.	O

It	O
is	O
unclear	O
as	O
to	O
when	O
the	O
virus	O
was	O
introduced	O
to	O
dromedary	O
camels	O
,	O
but	O
data	O
from	O
studies	O
that	O
investigated	O
stored	O
dromedary	O
camel	O
sera	B-COMP
and	O
geographical	O
distribution	O
of	O
involved	O
dromedary	O
camel	O
populations	O
suggested	O
that	O
the	O
virus	O
was	O
present	O
in	O
dromedary	O
camels	O
several	O
decades	O
ago	O
.	O

Though	O
bats	O
and	O
alpacas	O
can	O
serve	O
as	O
potential	O
reservoirs	O
for	O
MERS	O
-	O
CoV	O
,	O
dromedary	O
camels	O
seem	O
to	O
be	O
the	O
only	O
animal	O
host	B-COMP
responsible	O
for	O
the	O
spill	O
over	O
human	O
infections	O
.	O

In	O
this	O
study	O
,	O
the	O
NTD	O
spanning	O
amino	O
acid	O
residues	O
25	O
-	O
229	O
(	O
S25	O
-	O
229	O
)	O
of	O
S1	O
domain	O
of	O
PEDV	O
variant	O
strain	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
in	O
the	O
form	O
of	O
inclusion	B-COMP
bodies	I-COMP
(	O
IBs	O
).	O

Neutralizing	O
antibody	B-COMP
was	O
induced	O
by	O
vaccine	O
with	O
and	O
without	O
adjuvant	O
and	O
lung	O
virus	O
was	O
reduced	O
in	O
vaccinated	O
mice	O
after	O
challenge	O
.	O

TITLE	O
:	O
Low	O
Blood	O
Arterial	O
Oxygenation	O
During	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
:	O
Proposal	O
for	O
a	O
Rational	O
Algorithm	O
-	O
Based	O
Management	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
a	O
therapeutic	O
option	O
in	O
the	O
management	O
of	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Viral	O
replication	O
in	O
the	O
liver	O
is	O
generally	O
detected	O
by	O
cellular	B-COMP
endosomal	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
cytosolic	B-COMP
helicase	O
sensors	O
that	O
trigger	O
antiviral	O
inflammatory	O
responses	O
.	O

Primary	O
and	O
secondary	O
bronchi	O
,	O
epithelial	O
hyperplasia	O
and	O
mononuclear	O
inflammatory	O
cell	B-COMP
infiltrate	O
of	O
the	O
lamina	O
propria	O
were	O
also	O
observed	O
.	O

Therefore	O
,	O
the	O
overall	O
objective	O
of	O
this	O
project	O
was	O
to	O
develop	O
and	O
validate	O
selected	O
diagnostic	O
reagents	O
and	O
assays	O
for	O
PDCoV	O
antigen	O
and	O
antibody	B-COMP
detection	O
.	O

The	O
same	O
antigen	O
was	O
used	O
to	O
develop	O
serological	O
tests	O
to	O
detect	O
the	O
antibody	B-COMP
response	O
to	O
PDCoV	O
in	O
pigs	O
following	O
infection	O
.	O

Serum	B-COMP
samples	O
from	O
swine	O
herds	O
with	O
recent	O
documentation	O
of	O
PDCoV	O
infection	O
and	O
samples	O
from	O
expected	O
nave	O
herds	O
were	O
used	O
for	O
initial	O
assay	O
optimization	O
.	O

At	O
least	O
629	O
known	O
negative	O
serum	B-COMP
samples	O
and	O
311	O
known	O
positive	O
samples	O
were	O
evaluated	O
for	O
each	O
assay	O
.	O

Many	O
viruses	O
inhibit	O
protein	O
synthesis	O
by	O
their	O
host	B-COMP
cell	I-COMP
to	O
enhance	O
virus	O
replication	O
and	O
to	O
antagonize	O
antiviral	O
defense	O
mechanisms	O
.	O

The	O
IBV	O
-	O
induced	O
host	B-COMP
shutoff	O
,	O
however	O
,	O
does	O
not	O
require	O
degradation	O
of	O
host	B-COMP
RNA	O
.	O

IgG	O
and	O
IgA	O
were	O
detected	O
in	O
oral	O
fluids	O
and	O
serum	B-COMP
samples	O
by	O
13	O
DPE	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
similarity	O
of	O
group	O
I	O
and	O
II	O
viruses	O
using	O
sera	B-COMP
from	O
individual	O
pigs	O
vaccinated	O
with	O
group	O
I	O
virus	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	O
-	O
induced	O
ARDS	O
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	B-COMP
pathway	O
by	O
inhibiting	O
ERK	O
/	O
NF	O
-	O
B	O
activation	O
.	O

We	O
recommend	O
the	O
use	O
of	O
""""	O
CoV	O
Genus	O
/	O
AvCov	O
/	O
host	B-COMP
/	O
country	O
/	O
specimen	O
id	O
/	O
year	O
""""	O
to	O
refer	O
to	O
AvCoV	O
strains	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
adaptation	O
of	O
an	O
embryo	O
-	O
attenuated	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
Arkansas	O
Delmarva	O
Poultry	O
Industry	O
(	O
ArkDPI	O
)-	O
derived	O
vaccine	O
to	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	B-COMP
shifted	O
the	O
virus	O
population	O
towards	O
homogeneity	O
in	O
spike	O
(	O
S	O
)	O
and	O
nonstructural	O
protein	O
genes	O
.	O

Intraspinal	O
transplantation	O
of	O
EB	O
-	O
NPCs	O
into	O
mice	O
infected	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
resulted	O
in	O
decreased	O
accumulation	O
of	O
CD4	O
+	O
T	O
cells	B-COMP
in	O
the	O
central	O
nervous	O
system	O
that	O
was	O
concomitant	O
with	O
reduced	O
demyelination	O
at	O
the	O
site	O
of	O
injection	O
.	O

Here	O
,	O
we	O
generated	O
a	O
humanized	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
),	O
designated	O
hMS	O
-	O
1	O
,	O
which	O
targeted	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
with	O
high	O
affinity	O
.	O

Since	O
the	O
airways	O
and	O
lung	O
tissues	O
are	O
constantly	O
exposed	O
to	O
gaseous	O
oxygen	O
and	O
airborne	O
toxicants	O
,	O
the	O
bronchial	O
and	O
alveolar	O
epithelial	O
cells	B-COMP
are	O
under	O
higher	O
oxidative	O
stress	O
than	O
other	O
tissues	O
.	O

TITLE	O
:	O
Outcome	O
of	O
patients	O
supported	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
aluminum	O
phosphide	O
poisoning	O
:	O
An	O
observational	O
study	O
.	O

Serological	O
results	O
from	O
archived	O
camel	O
sera	B-COMP
provide	O
evidence	O
for	O
circulation	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
among	O
dromedary	O
camels	O
in	O
the	O
Greater	O
Horn	O
of	O
Africa	O
as	O
far	O
back	O
as	O
1983	O
and	O
in	O
Saudi	O
Arabia	O
as	O
far	O
back	O
as	O
1992	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
life	O
-	O
saving	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
pregnant	O
woman	O
with	O
status	O
asthmaticus	O
.	O

TITLE	O
:	O
Hyperleptinemia	O
is	O
associated	O
with	O
impaired	O
pulmonary	O
host	B-COMP
defense	O
.	O

Using	O
the	O
SCHOOL	O
approach	O
and	O
the	O
SARS	O
-	O
CoV	O
fusion	O
peptide	O
sequence	O
,	O
we	O
rationally	O
designed	O
a	O
novel	O
immunomodulatory	O
peptide	O
that	O
targets	O
TCR	B-COMP
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
36	O
years	O
-	O
old	O
woman	O
admitted	O
to	O
our	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
severe	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
adenovirus	O
pneumonia	O
,	O
that	O
required	O
invasive	O
respiratory	O
support	O
(	O
mechanical	O
ventilation	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
).	O

Owing	O
to	O
the	O
difficulty	O
of	O
extracting	O
RNA	O
from	O
sputum	O
containing	O
mucus	O
,	O
sputum	O
homogenization	O
is	O
desirable	O
prior	O
to	O
nucleic	B-COMP
acid	O
isolation	O
.	O

ABSTRACT	O
:	O
IL	O
-	O
6	O
contributes	O
to	O
host	B-COMP
defense	O
against	O
infections	O
and	O
tissue	O
injuries	O
.	O

One	O
of	O
the	O
ER	O
stress	O
responses	O
is	O
inhibition	O
of	O
the	O
global	O
protein	O
synthesis	O
to	O
reduce	O
the	O
amount	O
of	O
unfolded	O
proteins	O
inside	O
the	O
ER	B-COMP
lumen	I-COMP
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
improves	O
survival	O
in	O
a	O
novel	O
24	O
-	O
hour	O
pig	O
model	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

B1648	O
was	O
replicating	O
somewhat	O
better	O
than	O
M41	O
in	O
the	O
epithelium	O
of	O
the	O
respiratory	O
mucosa	O
explants	O
and	O
used	O
more	O
KUL01	O
(+)	O
cells	B-COMP
to	O
penetrate	O
the	O
deeper	O
layers	O
of	O
the	O
respiratory	O
tract	O
.	O

However	O
,	O
recently	O
TRPV4	O
has	O
been	O
identified	O
as	O
an	O
ion	O
channel	O
that	O
is	O
modulated	O
by	O
,	O
and	O
opened	O
by	O
intracellular	B-COMP
signalling	O
cascades	O
from	O
other	O
receptors	O
and	O
signalling	O
pathways	O
.	O

Regulated	O
TRPV4	O
function	O
is	O
also	O
essential	O
for	O
healthy	O
cardiovascular	O
system	O
function	O
as	O
a	O
potent	O
agonist	O
compromises	O
endothelial	O
cell	B-COMP
function	O
,	O
leading	O
to	O
vascular	O
collapse	O
.	O

In	O
experiment	O
one	O
,	O
on	O
d	O
1	O
and	O
wk	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
,	O
blood	O
samples	O
were	O
collected	O
and	O
serum	B-COMP
were	O
analyzed	O
by	O
ELISA	O
for	O
total	O
IgG	O
(	O
Y	O
),	O
and	O
MDA	O
against	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
and	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
).	O

In	O
addition	O
,	O
specific	O
antibody	B-COMP
response	O
against	O
SRBC	O
and	O
BSA	O
was	O
not	O
affected	O
by	O
diets	O
.	O

ABSTRACT	O
:	O
A	O
new	O
family	O
of	O
IFNs	O
called	O
type	O
III	O
IFN	O
or	O
IFN	O
-	O
	O
has	O
been	O
described	O
,	O
and	O
shown	O
to	O
induce	O
antiviral	O
activity	O
against	O
several	O
viruses	O
in	O
the	O
cell	B-COMP
culture	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
spike	O
proteins	O
mediate	O
host	B-COMP
-	O
cell	B-COMP
-	O
attachment	O
and	O
virus	O
entry	O
.	O

Furthermore	O
,	O
drug	O
-	O
induced	O
microtubule	B-COMP
depolymerization	O
led	O
to	O
changes	O
in	O
spike	O
protein	O
distribution	O
,	O
a	O
reduction	O
in	O
the	O
release	O
of	O
infectious	O
virus	B-COMP
particles	I-COMP
and	O
less	O
amount	O
of	O
spike	O
protein	O
incorporated	O
into	O
virions	B-COMP
.	O

We	O
identified	O
the	O
following	O
risk	O
factors	O
(	O
sensitivities	O
/	O
specificities	O
)	O
for	O
mortality	O
in	O
severe	O
leptospirosis	O
:	O
age	O
	O
55	O
years	O
(	O
67	O
%/	O
91	O
%);	O
serum	B-COMP
urea	O
	O
204	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
70	O
%);	O
creatinine	O
	O
5	O
.	O
2	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
58	O
%);	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
	O
39	O
.	O
5	O
(	O
67	O
%/	O
88	O
%);	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
	O
20	O
.	O
5	O
(	O
67	O
%/	O
85	O
%);	O
and	O
inspiratory	O
pressure	O
	O
31	O
mmHg	O
(	O
84	O
%/	O
85	O
%).	O

It	O
has	O
been	O
suggested	O
that	O
a	O
balance	O
between	O
protection	O
and	O
liver	O
damage	O
mediated	O
by	O
the	O
host	B-COMP
'	O
s	O
immune	O
response	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
would	O
be	O
determinant	O
in	O
hepatitis	O
outcome	O
.	O

The	O
viral	B-COMP
genome	I-COMP
analyses	O
revealed	O
that	O
the	O
H5	O
hemmagglutinin	O
gene	O
belongs	O
to	O
2	O
.	O
3	O
.	O
4	O
.	O
4	O
clade	O
.	O

Furthermore	O
,	O
neutrophils	O
isolated	O
from	O
the	O
blood	O
or	O
BAL	O
fluid	O
differentially	O
regulated	O
the	O
cell	B-COMP
surface	I-COMP
expression	O
of	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
1	O
and	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
2	O
during	O
ARDS	O
.	O

After	O
immunization	O
,	O
animals	O
vaccinated	O
with	O
fusion	O
proteins	O
rS1	O
-	O
HA2	B-COMP
and	O
rS1	O
-	O
H3	O
(	O
TM	O
)	O
demonstrated	O
stronger	O
robust	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
than	O
that	O
of	O
rS1	O
and	O
inactivated	O
M41	O
vaccine	O
.	O

The	O
protection	O
rates	O
of	O
groups	O
immunized	O
with	O
rS1	O
-	O
HA2	B-COMP
(	O
87	O
%)	O
were	O
significantly	O
higher	O
than	O
the	O
groups	O
inoculated	O
with	O
rS1	O
(	O
47	O
%)	O
and	O
inactivated	O
M41	O
vaccine	O
(	O
53	O
%).	O

Our	O
data	O
suggest	O
that	O
S1	O
protein	O
fused	O
to	O
the	O
HA2	B-COMP
or	O
TM	O
proteins	O
from	O
hemagglutinin	O
of	O
H3N2	O
influenza	O
virus	O
may	O
provide	O
a	O
new	O
strategy	O
for	O
high	O
efficacy	O
recombinant	O
vaccine	O
development	O
against	O
IBV	O
.	O

General	O
strategies	O
to	O
design	O
specific	O
and	O
selective	O
drugs	O
targeting	O
helicase	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
could	O
act	O
via	O
one	O
or	O
more	O
of	O
the	O
following	O
mechanisms	O
:	O
inhibition	O
of	O
the	O
NTPase	O
activity	O
,	O
by	O
interferences	O
with	O
ATP	O
binding	O
and	O
therefore	O
by	O
limiting	O
the	O
energy	O
required	O
for	O
the	O
unwinding	O
and	O
translocation	O
,	O
or	O
by	O
allosteric	O
mechanism	O
and	O
therefore	O
by	O
stabilizing	O
the	O
conformation	O
of	O
the	O
enzyme	O
in	O
low	O
helicase	O
activity	O
state	O
;	O
inhibition	O
of	O
nucleic	B-COMP
acids	O
binding	O
to	O
the	O
helicase	O
;	O
inhibition	O
of	O
coupling	O
of	O
ATP	O
hydrolysis	O
to	O
unwinding	O
;	O
inhibition	O
of	O
unwinding	O
by	O
sterically	O
blocking	O
helicase	O
translocation	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
developed	O
strategies	O
to	O
inhibit	O
host	B-COMP
immune	O
recognition	O
.	O

We	O
identify	O
cellular	B-COMP
E3	O
ubiquitin	O
ligase	O
ring	O
-	O
finger	O
and	O
CHY	O
zinc	O
-	O
finger	O
domain	O
-	O
containing	O
1	O
(	O
RCHY1	O
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
viral	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
and	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
)),	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
involvement	O
of	O
cellular	B-COMP
p53	O
as	O
antagonist	O
of	O
coronaviral	O
replication	O
.	O

TITLE	O
:	O
Xanthine	O
Oxidase	O
-	O
Derived	O
ROS	O
Display	O
a	O
Biphasic	O
Effect	O
on	O
Endothelial	O
Cells	B-COMP
Adhesion	O
and	O
FAK	O
Phosphorylation	O
.	O

Alternative	O
strategies	O
to	O
identify	O
convalescent	O
plasma	O
donors	O
with	O
adequate	O
antibody	B-COMP
titers	O
should	O
be	O
explored	O
,	O
including	O
the	O
sampling	O
of	O
serum	B-COMP
from	O
patients	O
with	O
more	O
severe	O
disease	O
and	O
sampling	O
at	O
earlier	O
points	O
during	O
illness	O
.	O

TITLE	O
:	O
Passive	O
Transfer	O
of	O
A	O
Germline	O
-	O
like	O
Neutralizing	O
Human	O
Monoclonal	O
Antibody	B-COMP
Protects	O
Transgenic	O
Mice	O
Against	O
Lethal	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Immunofluorescence	O
analysis	O
revealed	O
that	O
the	O
endothelial	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
E	O
-	O
selectin	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
vascular	O
cell	B-COMP
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
was	O
elevated	O
in	O
veins	O
close	O
to	O
granulomatous	O
infiltrates	O
in	O
the	O
renal	O
cortex	O
of	O
FIP	O
patients	O
compared	O
to	O
non	O
-	O
infiltrated	O
regions	O
and	O
specimens	O
from	O
healthy	O
cats	O
.	O

In	O
addition	O
,	O
the	O
NF	O
-	O
B	O
signaling	O
pathway	O
was	O
activated	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
by	O
TGEV	O
infection	O
.	O

We	O
identified	O
four	O
NF	O
-	O
B	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
using	O
luciferase	O
reporter	O
system	O
,	O
chromatin	B-COMP
immunoprecipitation	O
,	O
electromobility	O
shift	O
assay	O
,	O
and	O
supershift	O
analysis	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
induced	O
apoptosis	O
through	O
upregulation	O
of	O
Smad7	O
and	O
fibroblast	O
growth	O
factor	O
2	O
(	O
FGF2	O
)	O
expression	O
in	O
both	O
kidney	O
and	O
lung	O
cells	B-COMP
.	O

Our	O
results	O
provide	O
insights	O
into	O
the	O
pathogenesis	O
of	O
MERS	O
-	O
CoV	O
and	O
host	B-COMP
targets	O
for	O
treatment	O
.	O

Two	O
domains	O
in	O
S1	O
from	O
different	O
coronaviruses	O
recognize	O
a	O
variety	O
of	O
host	B-COMP
receptors	O
,	O
leading	O
to	O
viral	O
attachment	O
.	O

The	O
transition	O
from	O
prefusion	O
to	O
postfusion	O
conformation	O
of	O
the	O
spike	O
protein	O
must	O
be	O
triggered	O
,	O
leading	O
to	O
membrane	B-COMP
fusion	O
.	O

I	O
further	O
discuss	O
the	O
evolution	O
of	O
these	O
two	O
critical	O
functions	O
of	O
coronavirus	O
spike	O
proteins	O
,	O
receptor	O
recognition	O
and	O
membrane	B-COMP
fusion	O
,	O
in	O
the	O
context	O
of	O
the	O
corresponding	O
functions	O
from	O
other	O
viruses	O
and	O
host	B-COMP
cells	B-COMP
.	O

Serial	O
samples	O
of	O
blood	O
,	O
serum	B-COMP
,	O
oral	O
fluids	O
,	O
nasal	O
and	O
fecal	O
swabs	O
,	O
and	O
tissues	O
from	O
sequential	O
autopsy	O
,	O
conducted	O
daily	O
on	O
days	O
1	O
-	O
8	O
and	O
regular	O
intervals	O
thereafter	O
,	O
were	O
collected	O
throughout	O
the	O
42	O
-	O
day	O
study	O
for	O
qRT	O
-	O
PCR	O
,	O
histopathology	O
,	O
and	O
immunohistochemistry	O
.	O

Biopsy	O
of	O
the	O
left	O
sural	O
nerve	O
showed	O
moderate	O
reductions	O
of	O
large	O
and	O
small	O
myelinated	B-COMP
fibers	O
with	O
no	O
inflammation	O
,	O
no	O
depositions	O
of	O
amyloid	O
,	O
IgG	O
,	O
IgA	O
,	O
or	O
IgM	O
,	O
and	O
teased	O
fiber	O
findings	O
revealed	O
neither	O
myelin	B-COMP
ovoids	O
nor	O
segmental	O
demyelination	O
.	O

Interaction	O
of	O
SN	O
with	O
FR	O
revealed	O
maximum	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
cholesterol	O
whereas	O
interaction	O
of	O
PW	O
with	O
SI	O
indicated	O
maximum	O
antibody	B-COMP
titer	O
against	O
NDV	O
.	O

Nineteen	O
mechanically	O
ventilated	O
patients	O
underwent	O
six	O
consecutive	O
ventilatory	O
conditions	O
:	O
three	O
on	O
volume	O
assist	O
-	O
control	O
(	O
VC	O
)	O
mode	O
,	O
each	O
with	O
set	O
Vt	O
of	O
6	O
,	O
7	O
.	O
5	O
,	O
and	O
9	O
ml	O
/	O
kg	O
,	O
and	O
three	O
on	O
adaptive	O
pressure	O
-	O
control	O
(	O
APC	B-COMP
)	O
mode	O
,	O
with	O
those	O
same	O
set	O
Vts	O
and	O
matching	O
inspiratory	O
times	O
.	O

Under	O
APC	B-COMP
mode	O
,	O
compared	O
with	O
VC	O
,	O
DIs	O
were	O
lower	O
at	O
set	O
Vt	O
of	O
6	O
and	O
7	O
.	O
5	O
ml	O
/	O
kg	O
(	O
P	O
=	O
0	O
.	O
004	O
for	O
both	O
).	O

TITLE	O
:	O
[	O
Predictive	O
values	O
of	O
different	O
critical	O
scoring	O
systems	O
for	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
failure	O
supported	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
predictive	O
values	O
of	O
different	O
critical	O
scoring	O
systems	O
for	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
supported	O
by	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
).	O

Our	O
study	O
investigated	O
the	O
pathogenicity	O
of	O
the	O
tissue	O
-	O
culture	O
-	O
grown	O
PDCoV	O
(	O
TC	O
-	O
PDCoV	O
)	O
OH	O
-	O
FD22	O
at	O
cell	B-COMP
passages	O
5	O
,	O
20	O
and	O
40	O
in	O
LLC	B-COMP
-	O
PK	O
cells	B-COMP
,	O
in	O
eight	O
14	O
-	O
day	O
-	O
old	O
gnotobiotic	O
(	O
Gn	O
)	O
pigs	O
.	O

These	O
findings	O
are	O
important	O
because	O
they	O
propose	O
that	O
specific	O
changes	O
in	O
S1	O
enhances	O
virus	O
fitness	O
by	O
more	O
effective	O
binding	O
to	O
host	B-COMP
tissues	O
(	O
Y43H	O
)	O
and	O
by	O
evading	O
a	O
vaccine	O
-	O
induced	O
antibody	B-COMP
response	O
(	O
344	O
).	O

TITLE	O
:	O
Cytokine	O
Release	O
Syndrome	O
After	O
Chimeric	O
Antigen	O
Receptor	O
T	O
Cell	B-COMP
Therapy	O
for	O
Acute	O
Lymphoblastic	O
Leukemia	O
.	O

Thirteen	O
subjects	O
with	O
cardiovascular	O
dysfunction	O
were	O
treated	O
with	O
the	O
interleukin	O
-	O
6	O
receptor	O
antibody	B-COMP
tocilizumab	O
.	O

The	O
addition	O
of	O
sequence	O
data	O
from	O
this	O
group	O
of	O
viruses	O
will	O
allow	O
us	O
to	O
better	O
understand	O
coronavirus	O
evolution	O
and	O
host	B-COMP
specificity	O
.	O

Using	O
the	O
purified	O
NS6	O
from	O
an	O
Escherichia	O
coli	O
expression	O
system	O
,	O
we	O
obtained	O
two	O
anti	O
-	O
NS6	O
monoclonal	O
antibodies	B-COMP
that	O
could	O
detect	O
the	O
predicted	O
NS6	O
in	O
cells	B-COMP
infected	O
with	O
PDCoV	O
or	O
transfected	O
with	O
NS6	O
-	O
expressing	O
plasmids	O
.	O

ABSTRACT	O
:	O
The	O
complex	O
interplay	O
between	O
viral	O
replication	O
and	O
host	B-COMP
immune	O
response	O
during	O
infection	O
remains	O
poorly	O
understood	O
.	O

Using	O
mAb	O
5E8	O
,	O
we	O
observed	O
that	O
the	O
N	O
protein	O
was	O
expressed	O
in	O
the	O
cytoplasm	B-COMP
during	O
TGEV	O
replication	O
and	O
that	O
the	O
protein	O
could	O
be	O
immunoprecipitated	O
from	O
TGEV	O
-	O
infected	O
PK	O
-	O
15	O
cells	B-COMP
.	O

The	O
virions	B-COMP
entered	O
porcine	O
IECs	O
by	O
membrane	B-COMP
fusion	O
and	O
the	O
mature	O
viruses	O
in	O
the	O
vacuoles	B-COMP
were	O
transported	O
to	O
the	O
cell	B-COMP
membrane	I-COMP
before	O
release	O
.	O

The	O
results	O
also	O
showed	O
that	O
from	O
0	O
to	O
12h	O
after	O
TGEV	O
infection	O
of	O
porcine	O
IECs	O
,	O
the	O
intracellular	B-COMP
viral	O
RNA	O
content	O
did	O
not	O
change	O
significantly	O
.	O

The	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
recognizes	O
host	B-COMP
receptors	O
to	O
mediate	O
virus	O
entry	O
and	O
is	O
therefore	O
a	O
key	O
factor	O
determining	O
the	O
viral	O
tropism	O
and	O
transmission	O
capacity	O
.	O

In	O
HULEC	O
,	O
human	O
influenza	O
viruses	O
were	O
capable	O
of	O
binding	O
to	O
host	B-COMP
cellular	B-COMP
receptors	O
,	O
becoming	O
internalized	O
and	O
initiating	O
hemifusion	O
but	O
failing	O
to	O
uncoat	O
the	O
viral	B-COMP
nucleocapsid	I-COMP
and	O
to	O
replicate	O
in	O
host	B-COMP
nuclei	O
.	O

IFITM3	O
knockdown	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
could	O
partially	O
rescue	O
H1N1	O
virus	O
infection	O
in	O
HULEC	O
,	O
suggesting	O
IFITM3	O
proteins	O
were	O
involved	O
in	O
blocking	O
human	O
influenza	O
virus	O
infection	O
in	O
endothelial	O
cells	B-COMP
.	O

We	O
show	O
that	O
human	O
influenza	O
virus	O
infection	O
is	O
blocked	O
during	O
the	O
early	O
stages	O
of	O
virus	O
entry	O
,	O
which	O
is	O
likely	O
due	O
to	O
the	O
relatively	O
high	O
expression	O
of	O
the	O
host	B-COMP
antiviral	O
factors	O
IFITMs	O
(	O
interferon	O
-	O
induced	O
transmembrane	B-COMP
proteins	O
)	O
located	O
in	O
membrane	B-COMP
-	O
bound	O
compartments	O
inside	O
cells	B-COMP
.	O

Our	O
data	O
shows	O
that	O
clinical	O
condition	O
may	O
suddenly	O
deteriorate	O
around	O
7	O
days	O
of	O
illness	O
and	O
the	O
serum	B-COMP
levels	O
of	O
IL	O
-	O
6	O
and	O
CXCL	O
-	O
10	O
was	O
significantly	O
elevated	O
in	O
MERS	O
-	O
CoV	O
patients	O
who	O
developed	O
severe	O
diseases	O
.	O

Lastly	O
,	O
the	O
virion	B-COMP
is	O
a	O
durable	O
vessel	O
that	O
protects	O
the	O
genome	O
on	O
its	O
journey	O
between	O
cells	B-COMP
.	O

Genome	O
replication	O
and	O
transcription	O
is	O
mediated	O
by	O
a	O
multisubunit	O
protein	B-COMP
complex	I-COMP
comprised	O
of	O
more	O
than	O
a	O
dozen	O
virus	O
-	O
encoded	O
proteins	O
.	O

TITLE	O
:	O
Viral	O
and	O
Cellular	B-COMP
mRNA	O
Translation	O
in	O
Coronavirus	O
-	O
Infected	O
Cells	B-COMP
.	O

Here	O
,	O
we	O
review	O
the	O
recent	O
progress	O
in	O
our	O
understanding	O
of	O
the	O
strategies	O
that	O
highly	O
pathogenic	O
coronaviruses	O
employ	O
to	O
escape	O
,	O
dampen	O
,	O
or	O
block	O
the	O
antiviral	O
interferon	O
response	O
in	O
human	O
cells	B-COMP
.	O

TITLE	O
:	O
Cathepsin	O
L	O
Helps	O
to	O
Defend	O
Mice	O
from	O
Infection	O
with	O
Influenza	O
A	O
.	O
ABSTRACT	O
:	O
Host	B-COMP
-	O
derived	O
proteases	O
can	O
augment	O
or	O
help	O
to	O
clear	O
infections	O
.	O

Extracellular	B-COMP
trypsin	O
activates	O
PEDV	O
entry	O
when	O
lysosomal	O
cysteine	O
proteases	O
are	O
inhibited	O
.	O

Research	O
has	O
shown	O
that	O
the	O
entry	O
into	O
these	O
cells	B-COMP
is	O
through	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
receptor	O
.	O

After	O
20	O
passages	O
in	O
HeLa	O
cells	B-COMP
,	O
the	O
ability	O
of	O
the	O
isolate	O
to	O
use	O
cathepsin	O
increased	O
so	O
that	O
it	O
was	O
equal	O
to	O
that	O
of	O
the	O
laboratory	O
strain	O
;	O
this	O
increase	O
was	O
caused	O
by	O
an	O
amino	O
acid	O
substitution	O
(	O
I577S	O
)	O
in	O
the	O
S	O
protein	O
.	O

Many	O
enveloped	O
viruses	O
enter	O
cells	B-COMP
through	O
endocytosis	O
.	O

Proteinuria	O
and	O
urinary	O
glycosaminoglycans	O
(	O
GAGs	O
),	O
serum	B-COMP
levels	O
of	O
albumin	O
,	O
urea	O
nitrogen	O
,	O
and	O
creatinine	O
,	O
secretion	O
of	O
cytokines	O
,	O
T	O
lymphocyte	O
population	O
and	O
subsets	O
,	O
and	O
dendritic	B-COMP
cell	B-COMP
(	O
DC	O
)	O
activation	O
state	O
were	O
examined	O
.	O

For	O
lower	O
respiratory	O
tract	O
infections	O
blood	O
culture	O
,	O
serum	B-COMP
procalcitonin	O
,	O
serum	B-COMP
antibodies	B-COMP
to	O
Mycoplasma	O
and	O
Chlamydia	O
and	O
urinary	O
Streptococcus	O
pneumoniae	O
antigen	O
were	O
also	O
assayed	O
.	O

Breathlessness	O
,	O
presence	O
of	O
an	O
eschar	O
,	O
platelet	O
counts	O
of	O
<	O
20	O
,	O
000	O
cells	B-COMP
/	O
cumm	O
,	O
and	O
total	O
serum	B-COMP
bilirubin	O
>	O
2	O
mg	O
/	O
dL	O
had	O
the	O
highest	O
odds	O
of	O
having	O
an	O
abnormal	O
chest	O
radiograph	O
.	O

Only	O
hyenas	O
(	O
26	O
%,	O
5	O
/	O
19	O
)	O
were	O
positive	O
for	O
CDV	O
antibody	B-COMP
.	O

Sennoside	O
A	O
affected	O
also	O
HIV	O
-	O
1	O
IN	O
activity	O
in	O
vitro	O
and	O
HIV	O
-	O
1	O
replication	O
in	O
cell	B-COMP
-	O
based	O
assays	O
.	O

LPS	O
-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
B	O
and	O
p38	O
MAPK	O
were	O
blocked	O
by	O
Nur77	O
overexpression	O
and	O
augmented	O
by	O
Nur77	O
knockdown	O
in	O
A549	O
cells	B-COMP
.	O

In	O
this	O
work	O
we	O
investigated	O
the	O
influence	O
of	O
the	O
introduction	O
of	O
a	O
methyl	O
group	O
in	O
the	O
position	O
3	O
of	O
the	O
dihydrothiazole	O
ring	O
and	O
of	O
a	O
chlorine	O
atom	O
in	O
the	O
position	O
5	O
of	O
the	O
isatin	O
nucleus	B-COMP
.	O

Infection	O
status	O
was	O
determined	O
by	O
the	O
presence	O
of	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
.	O
To	O
assess	O
risk	O
factors	O
,	O
we	O
compared	O
infected	O
and	O
uninfected	O
participants	O
.	O

For	O
the	O
aHUS	O
the	O
initial	O
management	O
is	O
supportive	O
and	O
similar	O
to	O
the	O
approach	O
for	O
STEC	O
-	O
HUS	O
;	O
currently	O
we	O
have	O
moved	O
from	O
the	O
historic	O
plasma	O
therapy	O
to	O
new	O
therapeutic	O
approaches	O
,	O
first	O
of	O
all	O
eculizumab	O
,	O
a	O
monoclonal	O
antibody	B-COMP
that	O
blocks	O
the	O
C5	O
cascade	O
.	O

In	O
this	O
study	O
,	O
the	O
immunogenicity	O
of	O
a	O
subunit	O
vaccine	O
based	O
on	O
the	O
spike	O
protein	O
of	O
PEDV	O
,	O
which	O
was	O
directly	O
targeted	O
to	O
porcine	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
expressing	O
Langerin	O
,	O
was	O
assessed	O
.	O

The	O
PEDV	O
S	O
antigen	O
was	O
delivered	O
to	O
the	O
dendritic	B-COMP
cells	B-COMP
through	O
a	O
single	O
-	O
chain	O
antibody	B-COMP
specific	O
to	O
Langerin	O
and	O
the	O
targeted	O
cells	B-COMP
were	O
stimulated	O
with	O
cholera	O
toxin	O
adjuvant	O
.	O

This	O
approach	O
,	O
known	O
as	O
""""	O
dendritic	B-COMP
cell	B-COMP
targeting	O
","""	O
greatly	O
improved	O
PEDV	O
S	O
antigen	O
-	O
specific	O
T	O
cell	B-COMP
interferon	O
-	O
	O
responses	O
in	O
the	O
CD4	O

Consistent	O
with	O
these	O
findings	O
,	O
precleaved	O
MERS	O
viruses	O
used	O
receptor	O
-	O
proximal	O
,	O
cell	B-COMP
-	O
surface	O
proteases	O
to	O
effect	O
the	O
second	O
fusion	O
-	O
activating	O
cleavages	O
during	O
cell	B-COMP
entry	O
,	O
whereas	O
the	O
more	O
rigid	O
uncleaved	O
MERS	O
viruses	O
trafficked	O
past	O
these	O
cell	B-COMP
-	O
surface	O
proteases	O
and	O
into	O
endosomes	O
.	O

TITLE	O
:	O
Antiviral	O
Compounds	O
Against	O
Nucleocapsid	B-COMP
Protein	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
.	O

WQ	O
-	O
IDL	O
and	O
MT	O
-	O
WQ	O
-	O
IDL	O
were	O
also	O
more	O
effective	O
than	O
WQ	O
in	O
blocking	O
HIV	O
-	O
1	O
Env	O
-	O
mediated	O
membrane	B-COMP
fusion	O
and	O
had	O
higher	O
levels	O
of	O
binding	O
affinity	O
with	O
NHR	O
peptide	O
N46	O
.	O

Given	O
that	O
the	O
strain	O
OC43	O
is	O
neurovirulent	O
in	O
mice	O
and	O
induces	O
neuronal	O
cell	B-COMP
death	O
,	O
we	O
explored	O
the	O
neuronal	O
response	O
to	O
infection	O
by	O
characterizing	O
the	O
activation	O
of	O
RCD	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
binds	O
to	O
cellular	B-COMP
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
via	O
the	O
spike	O
(	O
S	O
)	O
protein	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
).	O

These	O
RBD	O
-	O
based	O
vaccine	O
candidates	O
maintained	O
good	O
functionality	O
,	O
antigenicity	O
,	O
and	O
immunogenicity	O
,	O
and	O
they	O
induced	O
strong	O
cross	O
-	O
neutralizing	O
antibodies	B-COMP
against	O
infection	O
by	O
divergent	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
strains	O
,	O
as	O
well	O
as	O
antibody	B-COMP
escape	O
MERS	O
-	O
CoV	O
mutants	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
this	O
mouse	O
model	O
to	O
analyze	O
the	O
host	B-COMP
response	O
to	O
MERS	O
-	O
CoV	O
infection	O
using	O
immunological	O
assays	O
and	O
transcriptome	O
analysis	O
.	O

At	O
the	O
beginning	O
of	O
the	O
mock	O
loop	O
experiments	O
,	O
the	O
septic	O
blood	O
showed	O
significantly	O
increased	O
thrombin	O
-	O
antithrombin	O
complexes	O
(	O
76	O
.	O
9	O
vs	O
27	O
.	O
7	O
g	O
/	O
l	O
),	O
D	O
-	O
dimers	O
(	O
1	O
.	O
2	O
vs	O
0	O
.	O
3	O
mg	O
/	O
l	O
)	O
and	O
fibrinogen	B-COMP
concentration	O
(	O
1	O
.	O
8	O
vs	O
1	O
.	O
5	O
g	O
/	O
l	O
),	O
as	O
well	O
as	O
elevated	O
extrinsic	O
coagulation	O
activity	O
(	O
shorter	O
EXTEM	O
-	O
CT	O
:	O
44	O
.	O
2	O
vs	O
57	O
s	O
)	O
and	O
higher	O
lactate	O
(	O
3	O
.	O
4	O
vs	O
1	O
.	O
5	O
mmol	O
/	O
l	O
)	O
and	O
cytokine	O
levels	O
(	O
interleukin	O
-	O
6	O
:	O
827	O
vs	O
31	O
pg	O
/	O
ml	O
)	O
when	O
compared	O
with	O
the	O
blood	O
from	O
healthy	O
animals	O
.	O

The	O
present	O
time	O
-	O
series	O
analyses	O
of	O
short	O
and	O
long	O
oligonucleotide	O
compositions	O
in	O
these	O
genomes	O
showed	O
directional	O
changes	O
in	O
their	O
composition	O
after	O
invasion	O
from	O
a	O
nonhuman	O
host	B-COMP
,	O
which	O
are	O
thought	O
to	O
recur	O
after	O
future	O
invasions	O
.	O

TITLE	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
ARDS	O
:	O
outcome	O
analysis	O
of	O
a	O
Croatian	O
referral	O
center	O
for	O
respiratory	O
ECMO	O
.	O

ABSTRACT	O
:	O
The	O
first	O
imported	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
in	O
China	O
recently	O
occurred	O
,	O
allowing	O
for	O
the	O
characterization	O
of	O
antibody	B-COMP
titers	O
in	O
a	O
series	O
of	O
the	O
patient	O
'	O
s	O
sera	B-COMP
using	O
the	O
following	O
methods	O
based	O
on	O
recombinant	O
viral	O
structural	O
antigens	O
:	O
inactivated	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
recombinant	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
,	O
or	O
fragments	O
of	O
S	O
)	O
ELISA	O
,	O
nucleoprotein	O
(	O
NP	O
)	O
ELISA	O
and	O
MERS	O
S	O
pseudovirus	O
particle	O
-	O
based	O
neutralization	O
test	O
(	O
ppNT	O
).	O

Patients	O
>	O
18	O
years	O
with	O
IE	O
and	O
available	O
serum	B-COMP
sodium	O
levels	O
were	O
included	O
in	O
the	O
study	O
.	O

Moreover	O
,	O
the	O
pharmacological	O
suppression	O
and	O
targeted	O
disruption	O
of	O
Shp2	O
in	O
myeloid	O
cells	B-COMP
alleviated	O
pulmonary	O
inflammation	O
in	O
the	O
LPS	O
-	O
induced	O
ALI	O
mouse	O
model	O
.	O

BAL	O
fluid	O
from	O
mice	O
with	O
ARDS	O
dampens	O
the	O
TNF	O
-	O
	O
production	O
compared	O
to	O
cells	B-COMP
cultured	O
with	O
BAL	O
lacking	O
sPD	O
-	O
1	O
(	O
2	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
3	O
.	O
8	O
)	O
vs	O
.	O
52	O
.	O
38	O
pg	O
/	O
mL	O
(	O
SD	O
25	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
002	O
).	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
modified	O
cardiopulmonary	O
bypass	O
circuit	O
that	O
serves	O
as	O
an	O
artificial	O
membrane	B-COMP
lung	O
and	O
blood	O
pump	O
to	O
provide	O
gas	O
exchange	O
and	O
systemic	O
perfusion	O
for	O
patients	O
when	O
their	O
own	O
heart	O
and	O
lungs	O
are	O
unable	O
to	O
function	O
adequately	O
.	O

Case	O
n	O
In	O
dermatomyositis	O
,	O
anti	O
-	O
MDA5	O
antibody	B-COMP
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

CONCLUSIONS	O
:	O
In	O
dermatomyositis	O
,	O
anti	O
-	O
MDA5	O
antibody	B-COMP
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

We	O
here	O
report	O
that	O
in	O
cultured	O
cells	B-COMP
low	O
-	O
micromolar	O
concentrations	O
of	O
alisporivir	O
,	O
a	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
-	O
analog	O
,	O
inhibit	O
the	O
replication	O
of	O
four	O
different	O
coronaviruses	O
,	O
including	O
MERS	O
-	O
and	O
SARS	O
-	O
coronavirus	O
.	O

Nevertheless	O
,	O
our	O
data	O
provide	O
a	O
basis	O
to	O
further	O
explore	O
the	O
potential	O
of	O
Cyp	O
inhibitors	O
as	O
host	B-COMP
-	O
directed	O
,	O
broad	O
-	O
spectrum	O
inhibitors	O
of	O
coronavirus	O
replication	O
.	O

The	O
results	O
showed	O
that	O
antibody	B-COMP
against	O
CCoV	O
-	O
II	O
was	O
present	O
in	O
87	O
dogs	O
(	O
43	O
.	O
3	O
%).	O

TITLE	O
:	O
Inhibition	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
infection	O
in	O
porcine	O
kidney	O
cells	B-COMP
using	O
short	O
hairpin	O
RNAs	O
targeting	O
the	O
membrane	B-COMP
gene	O
.	O

ABSTRACT	O
:	O
The	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
is	O
the	O
most	O
abundant	O
component	O
of	O
the	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
particle	O
.	O

Moreover	O
,	O
inhibition	O
studies	O
showed	O
that	O
EGFR	O
modulated	O
glucose	O
uptake	O
in	O
control	O
and	O
TGEV	O
infected	O
cells	B-COMP
.	O

Isolated	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
from	O
all	O
time	O
points	O
were	O
negative	O
for	O
PCV	O
(	O
Type	O
2	O
),	O
PLHV	O
,	O
PRRSV	O
,	O
PCMV	O
,	O
and	O
PERV	O
-	O
A	O
,	O
PERV	O
-	O
B	O
,	O
and	O
PERV	O
-	O
C	O
by	O
PCR	O
analysis	O
in	O
all	O
six	O
recipient	O
animals	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
fusion	O
peptides	O
induce	O
membrane	B-COMP
surface	O
ordering	O
and	O
curvature	O
.	O

Concurrently	O
,	O
the	O
frequency	O
of	O
occurrence	O
of	O
the	O
wild	O
type	O
at	O
the	O
two	O
positions	O
was	O
only	O
6	O
.	O
5	O
%	O
	O
1	O
.	O
7	O
%	O
on	O
average	O
,	O
supporting	O
the	O
hypothesis	O
that	O
selection	O
pressure	O
exerted	O
by	O
the	O
host	B-COMP
immune	O
response	O
played	O
a	O
critical	O
role	O
in	O
shaping	O
genetic	O
variants	O
and	O
their	O
interaction	O
in	O
human	O
MERS	O
-	O
CoVs	O
during	O
the	O
outbreak	O
.	O

TITLE	O
:	O
Treatment	O
of	O
Adenoviral	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Using	O
Cidofovir	O
With	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
.	O

TITLE	O
:	O
Outcomes	O
and	O
survival	O
prediction	O
models	O
for	O
severe	O
adult	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

ABSTRACT	O
:	O
Infection	O
with	O
nidoviruses	O
like	O
corona	O
-	O
and	O
arteriviruses	O
induces	O
a	O
reticulovesicular	O
network	O
of	O
interconnected	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)-	O
derived	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
)	O
and	O
other	O
membrane	B-COMP
structures	O
.	O

Three	O
interferon	O
-	O
stimulated	O
gene	O
products	O
,	O
two	O
of	O
which	O
have	O
been	O
reported	O
to	O
target	O
the	O
hepatitis	O
C	O
virus	O
replication	O
structures	O
,	O
were	O
tested	O
for	O
their	O
possible	O
involvement	O
,	O
but	O
none	O
of	O
them	O
affected	O
membrane	B-COMP
structure	I-COMP
formation	O
.	O

ABSTRACT	O
:	O
Pompe	O
disease	O
is	O
an	O
autosomal	B-COMP
recessive	O
disorder	O
caused	O
by	O
deficiency	O
of	O
the	O
lysosomal	O
	O
-	O
1	O
,	O
4	O
-	O
glucosidase	O
leading	O
to	O
accumulation	O
of	O
glycogen	O
in	O
target	O
tissues	O
with	O
progressive	O
organ	O
failure	O
.	O

However	O
,	O
the	O
lack	O
of	O
professional	O
immune	O
cells	B-COMP
such	O
as	O
dendritic	B-COMP
cells	B-COMP
(	O
DC	O
)	O
and	O
macrophages	O
has	O
greatly	O
limited	O
the	O
significance	O
of	O
current	O
investigations	O
.	O

The	O
successful	O
generation	O
of	O
the	O
first	O
bat	O
bone	O
marrow	O
-	O
derived	O
immune	O
cells	B-COMP
paves	O
the	O
way	O
to	O
unlocking	O
the	O
immune	O
mechanisms	O
that	O
confer	O
host	B-COMP
resilience	O
to	O
pathogens	O
in	O
bats	O
.	O

TITLE	O
:	O
Quantifying	O
the	O
effect	O
of	O
lactogenic	O
antibody	B-COMP
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
in	O
neonatal	O
piglets	O
.	O

Serum	B-COMP
and	O
mammary	O
secretions	O
were	O
tested	O
for	O
PEDV	O
IgG	O
,	O
IgA	O
,	O
and	O
virus	O
-	O
neutralizing	O
antibody	B-COMP
.	O

These	O
findings	O
indicate	O
that	O
transmission	O
is	O
determined	O
by	O
host	B-COMP
infectivity	O
and	O
the	O
number	O
of	O
contacts	O
,	O
whereas	O
super	O
-	O
spreading	O
events	O
were	O
determined	O
by	O
the	O
number	O
of	O
contacts	O
and	O
hospital	O
visits	O
.	O

TITLE	O
:	O
Severe	O
Hypoxemia	O
in	O
a	O
Healthy	O
Donor	O
for	O
Allogeneic	O
Hematopoietic	O
Stem	O
Cell	B-COMP
Transplantation	O
after	O
Only	O
the	O
First	O
Administration	O
of	O
Granulocyte	O
-	O
Colony	O
Stimulating	O
Factor	O
.	O

A	O
comparison	O
of	O
predicted	O
protein	O
sequences	O
also	O
demonstrated	O
the	O
existence	O
of	O
two	O
clade	O
A	O
lineages	O
with	O
unique	O
amino	O
acid	O
substitutions	O
,	O
A1	O
(	O
EMC	B-COMP
/	O
2012	O
and	O
Jordan	O
-	O
N3	O
/	O
2012	O
)	O
and	O
A2	O
(	O
D998	O
/	O
15	O
and	O
NRCE	O
-	O
HKU205	O
),	O
circulating	O
in	O
humans	O
and	O
camels	O
,	O
respectively	O
.	O

Overall	O
,	O
the	O
introduced	O
models	O
represent	O
meaningful	O
and	O
robust	O
methods	O
to	O
investigate	O
principles	O
of	O
pathogen	O
-	O
host	B-COMP
interaction	O
in	O
original	O
human	O
lung	O
tissue	O
.	O

ABSTRACT	O
:	O
The	O
global	O
outbreak	O
of	O
SARS	O
in	O
2002	O
-	O
2003	O
was	O
caused	O
by	O
the	O
infection	O
of	O
a	O
new	O
human	O
coronavirus	O
SARS	O
-	O
CoV	O
.	O
The	O
infection	O
of	O
SARS	O
-	O
CoV	O
is	O
mediated	O
mainly	O
through	O
the	O
viral	O
surface	O
glycoproteins	O
,	O
which	O
consist	O
of	O
S1	O
and	O
S2	O
subunits	O
and	O
form	O
trimer	O
spikes	O
on	O
the	O
envelope	B-COMP
of	O
the	O
virions	B-COMP
.	O

More	O
NP	O
/	O
PAs	B-COMP
identified	O
the	O
association	O
of	O
consciousness	O
with	O
the	O
use	O
of	O
NMBAs	O
than	O
physicians	O
(	O
P	O
=.	O
047	O
).	O

We	O
report	O
here	O
the	O
efficacy	O
of	O
a	O
vaccine	O
consisting	O
of	O
chimeric	O
virus	O
-	O
like	O
particles	O
(	O
VLP	B-COMP
)	O
expressing	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
a	O
fusion	O
of	O
the	O
canine	O
parvovirus	O
(	O
CPV	O
)	O
VP2	O
structural	O
protein	O
gene	O
with	O
the	O
RBD	O
of	O
MERS	O
-	O
CoV	O
can	O
self	O
-	O
assemble	O
into	O
chimeric	O
,	O
spherical	O
VLP	B-COMP
(	O
sVLP	O
).	O

The	O
results	O
suggest	O
potential	O
linkages	O
among	O
viral	O
strategies	O
for	O
the	O
regulation	O
of	O
cell	B-COMP
survival	O
activities	O
,	O
possibly	O
through	O
an	O
interaction	O
of	O
N	O
protein	O
with	O
NPM1	O
which	O
prevents	O
its	O
proteolytic	O
cleavage	O
and	O
enhances	O
cell	B-COMP
survival	O
,	O
thus	O
ultimately	O
promoting	O
the	O
replication	O
of	O
PEDV	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
human	O
infections	O
and	O
dromedary	O
camels	O
are	O
considered	O
an	O
intermediary	O
host	B-COMP
.	O

In	O
our	O
patient	O
,	O
the	O
electrocardiographic	O
abnormalities	O
,	O
the	O
rapidly	O
reversible	O
distinctive	O
characteristics	O
of	O
echocardiography	O
,	O
and	O
the	O
modest	O
elevation	O
of	O
serum	B-COMP
cardiac	O
biomarkers	O
levels	O
,	O
in	O
combination	O
with	O
the	O
presence	O
of	O
a	O
stress	O
trigger	O
(	O
severe	O
asthma	O
attack	O
),	O
strongly	O
supported	O
the	O
diagnosis	O
of	O
broken	O
heart	O
syndrome	O
.	O

We	O
reasoned	O
that	O
small	O
particle	O
aerosols	O
of	O
virus	O
would	O
penetrate	O
the	O
lower	O
respiratory	O
tract	O
and	O
blanket	O
alveoli	O
where	O
target	O
cells	B-COMP
reside	O
.	O

However	O
,	O
our	O
recent	O
cellular	B-COMP
studies	O
reveal	O
that	O
removing	O
the	O
Ubl2	O
domain	O
from	O
MERS	O
PLpro	O
has	O
no	O
effect	O
on	O
its	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
or	O
act	O
as	O
an	O
interferon	O
antagonist	O
,	O
which	O
involves	O
deubiquitinating	O
and	O
deISGylating	O
cellular	B-COMP
proteins	O
.	O

Further	O
studies	O
revealed	O
that	O
lipid	B-COMP
rafts	I-COMP
were	O
not	O
required	O
for	O
IBV	O
genome	O
replication	O
or	O
virion	B-COMP
release	O
at	O
later	O
stages	O
.	O

However	O
,	O
the	O
drug	O
-	O
mediated	O
depletion	O
of	O
lipid	B-COMP
rafts	I-COMP
in	O
Vero	O
cells	B-COMP
before	O
IBV	O
attachment	O
significantly	O
reduced	O
the	O
expression	O
of	O
viral	O
structural	O
proteins	O
,	O
suggesting	O
that	O
drug	O
treatment	O
impaired	O
the	O
attachment	O
of	O
IBV	O
to	O
the	O
cell	B-COMP
surface	I-COMP
.	O

Our	O
results	O
indicated	O
that	O
lipid	B-COMP
rafts	I-COMP
serve	O
as	O
attachment	O
factors	O
during	O
the	O
early	O
stages	O
of	O
IBV	O
infection	O
,	O
especially	O
during	O
the	O
attachment	O
stage	O
.	O

ARMS	O
-	O
I	O
is	O
patented	O
novel	O
formulation	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
influenza	O
,	O
comprising	O
a	O
broad	O
-	O
spectrum	O
antimicrobial	O
agent	O
(	O
cetylpyridinium	O
chloride	O
,	O
CPC	B-COMP
)	O
and	O
components	O
(	O
glycerin	O
and	O
xanthan	O
gum	O
)	O
that	O
form	O
a	O
barrier	O
on	O
the	O
host	B-COMP
mucosa	O
,	O
thus	O
preventing	O
viral	O
contact	O
and	O
invasion	O
.	O

TITLE	O
:	O
Effect	O
of	O
the	O
Protein	O
Corona	O
on	O
Antibody	B-COMP
-	O
Antigen	O
Binding	O
in	O
Nanoparticle	O
Sandwich	O
Immunoassays	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
the	O
protein	O
corona	O
on	O
the	O
function	O
of	O
nanoparticle	O
(	O
NP	O
)	O
antibody	B-COMP
(	O
Ab	O
)	O
conjugates	O
in	O
dipstick	O
sandwich	O
immunoassays	O
.	O

Sixty	O
patients	O
with	O
multiple	O
injuries	O
were	O
divided	O
into	O
three	O
groups	O
according	O
to	O
the	O
Injury	O
Severity	O
Score	O
(	O
ISS	O
)	O
and	O
the	O
serum	B-COMP
levels	O
of	O
VEGF	O
,	O
soluble	O
VEGF	O
receptor	O
1	O
(	O
sVEGFR1	O
),	O
and	O
sVEGFR2	O
,	O
were	O
measured	O
.	O

ABSTRACT	O
:	O
Optimal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
is	O
unknown	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
receiving	O
mechanical	O
ventilation	O
with	O
very	O
low	O
tidal	O
volume	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
activation	O
of	O
IFN	O
responses	O
induced	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
could	O
inhibit	O
viral	O
replication	O
in	O
the	O
early	O
infection	O
stage	O
,	O
but	O
failed	O
in	O
the	O
late	O
infection	O
stage	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
.	O

MERS	O
-	O
CoV	O
infects	O
cells	B-COMP
via	O
its	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
that	O
binds	O
on	O
Dipeptidyl	O
-	O
Peptidase	O
4	O
(	O
DPP4	O
)	O
receptor	O
present	O
on	O
macrophages	O
.	O

This	O
review	O
mainly	O
focuses	O
on	O
the	O
types	O
and	O
efficacies	O
of	O
vaccines	O
,	O
briefly	O
covering	O
treatments	O
and	O
antibodies	B-COMP
against	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
survival	O
predictors	O
and	O
optimal	O
mechanical	O
ventilator	O
settings	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
undergoing	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
are	O
uncertain	O
.	O

These	O
results	O
imply	O
the	O
involvement	O
of	O
a	O
co	O
-	O
receptor	O
because	O
cells	B-COMP
expressing	O
the	O
internalization	O
-	O
deficient	O
mutants	O
could	O
still	O
be	O
infected	O
.	O

As	O
the	O
patient	O
did	O
not	O
improve	O
after	O
3	O
days	O
of	O
antibiotics	O
and	O
donor	O
-	O
specific	O
HLA	O
antibodies	B-COMP
had	O
been	O
detected	O
,	O
an	O
acute	O
antibody	B-COMP
-	O
mediated	O
graft	O
rejection	O
was	O
treated	O
with	O
high	O
-	O
dose	O
corticosteroids	O
,	O
plasma	O
exchange	O
,	O
intravenous	O
immunoglobulin	O
,	O
and	O
rituximab	O
.	O

TITLE	O
:	O
Neurovirulent	O
Murine	O
Coronavirus	O
JHM	O
.	O
SD	O
Uses	O
Cellular	B-COMP
Zinc	O
Metalloproteases	O
for	O
Virus	O
Entry	O
and	O
Cell	B-COMP
-	O
Cell	B-COMP
Fusion	O
.	O

This	O
evasion	O
strategy	O
suggests	O
an	O
evolutionary	O
conserved	O
viral	O
function	O
that	O
has	O
evolved	O
to	O
prevent	O
RNA	O
-	O
based	O
sensing	O
of	O
infection	O
in	O
vertebrate	O
hosts	B-COMP
.	O

Collectively	O
our	O
results	O
demonstrate	O
that	O
the	O
coronavirus	O
EndoU	O
efficiently	O
prevents	O
simultaneous	O
activation	O
of	O
host	B-COMP
cell	I-COMP
dsRNA	O
sensors	O
,	O
such	O
as	O
Mda5	O
,	O
OAS	O
and	O
PKR	O
.	O

We	O
'	O
ve	O
investigated	O
the	O
development	O
of	O
URT	O
and	O
systemic	O
,	O
cell	B-COMP
-	O
mediated	O
and	O
humoral	O
immunity	O
in	O
commercial	O
broiler	O
chickens	O
vaccinated	O
with	O
Ma5	O
and	O
/	O
or	O
4	O
/	O
91	O
strains	O
at	O
hatch	O
day	O
.	O

The	O
patient	O
developed	O
a	O
severe	O
acute	O
distress	O
respiratory	O
syndrome	O
which	O
was	O
successfully	O
supported	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
and	O
treated	O
with	O
antiviral	O
therapy	O
.	O

TITLE	O
:	O
Venovenous	O
Versus	O
Venoarterial	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Adult	O
Patients	O
With	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Requiring	O
Precannulation	O
Hemodynamic	O
Support	O
:	O
A	O
Review	O
of	O
the	O
ELSO	O
Registry	O
.	O

RESULTS	O
:	O
Resveratrol	O
significantly	O
inhibited	O
MERS	O
-	O
CoV	O
infection	O
and	O
prolonged	O
cellular	B-COMP
survival	O
after	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
antibody	B-COMP
-	O
based	O
assays	O
is	O
important	O
for	O
detecting	O
infected	O
animals	O
,	O
confirming	O
previous	O
virus	O
exposure	O
,	O
and	O
monitoring	O
sow	O
herd	O
immunity	O
.	O

The	O
influence	O
of	O
the	O
protein	O
content	O
,	O
number	O
of	O
added	O
cells	B-COMP
,	O
and	O
magnitude	O
of	O
dilution	O
were	O
also	O
investigated	O
.	O

Herein	O
,	O
an	O
alternative	O
indirect	O
ELISA	O
for	O
detection	O
of	O
IBV	O
antibody	B-COMP
was	O
developed	O
with	O
IBV	O
nonstructural	O
protein	O
5	O
(	O
nsp5	O
)	O
produced	O
by	O
Escherichia	O
coli	O
.	O

The	O
diagnostic	O
sensitivity	O
(	O
DSN	O
),	O
specificity	O
(	O
DSP	O
)	O
and	O
accuracy	O
of	O
the	O
nsp5	O
-	O
ELISA	O
were	O
93	O
.	O
11	O
%,	O
95	O
.	O
38	O
%	O
and	O
93	O
.	O
33	O
%,	O
respectively	O
,	O
compared	O
with	O
IFA	O
in	O
660	O
field	O
serum	B-COMP
samples	O
,	O
and	O
were	O
98	O
.	O
11	O
%,	O
95	O
.	O
00	O
%	O
and	O
97	O
.	O
62	O
%,	O
respectively	O
,	O
compared	O
with	O
the	O
commercial	O
IBV	O
ELISA	O
kit	O
(	O
IDEXX	O
)	O
in	O
126	O
field	O
sera	B-COMP
samples	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
development	O
of	O
an	O
nsp	O
-	O
based	O
ELISA	O
to	O
detect	O
an	O
antibody	B-COMP
to	O
IBV	O
.	O

CBP	O
treatment	O
cleared	O
TNF	O
-	O
	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
10	O
partially	O
from	O
serum	B-COMP
and	O
BALF	O
.	O

The	O
characteristic	O
inflammatory	O
cells	B-COMP
in	O
the	O
lungs	O
of	O
rhesus	O
macaques	O
and	O
common	O
marmosets	O
were	O
eosinophils	O
and	O
neutrophils	O
,	O
respectively	O
.	O

There	O
are	O
currently	O
no	O
approved	O
therapeutics	O
or	O
vaccinations	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
responsible	O
for	O
receptor	O
binding	O
and	O
virion	B-COMP
entry	O
to	O
cells	B-COMP
,	O
is	O
immunodominant	O
and	O
induces	O
neutralizing	O
antibodies	B-COMP
in	O
vivo	O
,	O
all	O
of	O
which	O
,	O
make	O
the	O
S	O
protein	O
an	O
ideal	O
target	O
for	O
anti	O
-	O
MERS	O
-	O
CoV	O
vaccines	O
.	O

Interestingly	O
,	O
nsp5	O
cleaved	O
STAT2	O
at	O
two	O
sites	O
,	O
glutamine	O
685	O
(	O
Q685	O
)	O
and	O
Q758	O
,	O
and	O
similar	O
cleavage	O
was	O
observed	O
in	O
PDCoV	O
-	O
infected	O
cells	B-COMP
.	O

This	O
study	O
was	O
conducted	O
with	O
the	O
PEDV	O
-	O
infected	O
neonatal	O
piglet	O
model	O
to	O
determine	O
the	O
effect	O
of	O
NAC	B-COMP
supplementation	O
on	O
intestinal	O
function	O
.	O

The	O
development	O
of	O
anti	O
-	O
FN	O
antibodies	B-COMP
in	O
FN	O
-	O
positive	O
PTA	O
patients	O
.	O

Overexpression	O
of	O
occludin	O
in	O
target	O
cells	B-COMP
makes	O
them	O
more	O
susceptible	O
to	O
PEDV	O
infection	O
,	O
whereas	O
ablation	O
of	O
occludin	O
expression	O
by	O
use	O
of	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
in	O
target	O
cells	B-COMP
significantly	O
reduces	O
their	O
susceptibility	O
to	O
virus	O
infection	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
dynamics	O
of	O
virion	B-COMP
-	O
glycan	O
interactions	O
contribute	O
to	O
host	B-COMP
tropism	O
.	O

Mechanistically	O
,	O
neuraminidase	O
inhibition	O
assay	O
and	O
hemagglutination	O
inhibition	O
assay	O
suggested	O
that	O
N30	O
did	O
not	O
directly	O
target	O
the	O
two	O
envelope	B-COMP
glycoproteins	O
required	O
for	O
viral	O
adsorption	O
or	O
release	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
recombinant	O
mature	O
pIL	O
-	O
22	O
(	O
mpIL	O
-	O
22	O
)	O
inhibited	O
the	O
infection	O
of	O
multiple	O
diarrhea	O
viruses	O
,	O
including	O
alpha	O
coronavirus	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
and	O
porcine	O
rotavirus	O
(	O
PoRV	O
),	O
in	O
the	O
intestinal	O
porcine	O
epithelial	O
cell	B-COMP
line	O
J2	O
(	O
IPEC	O
-	O
J2	O
)	O
cells	B-COMP
.	O

TITLE	O
:	O
Clinical	O
Significance	O
of	O
Human	O
Coronavirus	O
in	O
Bronchoalveolar	O
Lavage	O
Samples	O
From	O
Hematopoietic	O
Cell	B-COMP
Transplant	O
Recipients	O
and	O
Patients	O
With	O
Hematologic	O
Malignancies	O
.	O

ABSTRACT	O
:	O
The	O
possible	O
role	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
in	O
lower	O
respiratory	O
tract	O
disease	O
(	O
LRTD	O
)	O
in	O
hematopoietic	O
cell	B-COMP
transplant	O
(	O
HCT	O
)	O
recipients	O
and	O
patients	O
with	O
hematologic	O
malignancies	O
(	O
HM	O
)	O
has	O
not	O
been	O
well	O
studied	O
.	O

In	O
February	O
2014	O
,	O
an	O
assessment	O
was	O
made	O
of	O
the	O
suitability	O
and	O
sensitivity	O
of	O
different	O
types	O
of	O
sample	O
for	O
the	O
detection	O
of	O
MERSCoV	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
three	O
gene	O
targets	O
:	O
UpE	O
(	O
upstream	O
of	O
the	O
E	O
gene	O
),	O
the	O
N	O
(	O
nucleocapsid	B-COMP
)	O
gene	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
.	O

He	O
could	O
be	O
successfully	O
treated	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
and	O
therapeutic	O
plasma	O
exchange	O
.	O

To	O
obtain	O
more	O
insight	O
into	O
the	O
signals	O
and	O
molecular	O
events	O
that	O
coordinate	O
global	O
host	B-COMP
responses	O
in	O
the	O
nucleus	B-COMP
of	O
coronavirus	O
-	O
infected	O
cells	B-COMP
,	O
first	O
,	O
transcriptome	O
dynamics	O
was	O
studied	O
in	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)-	O
infected	O
A549	O
and	O
HuH7	O
cells	B-COMP
,	O
respectively	O
,	O
revealing	O
a	O
core	O
signature	O
of	O
upregulated	O
genes	O
in	O
these	O
cells	B-COMP
.	O

Second	O
,	O
we	O
characterized	O
actively	O
transcribed	O
genomic	O
regions	O
and	O
enhancers	O
in	O
HCoV	O
-	O
229E	O
-	O
infected	O
cells	B-COMP
and	O
systematically	O
correlated	O
the	O
genome	O
-	O
wide	O
gene	O
expression	O
changes	O
with	O
the	O
recruitment	O
of	O
Ser5	O
-	O
phosphorylated	O
RNA	O
polymerase	O
II	O
and	O
prototypical	O
histone	O
modifications	O
(	O
H3K9ac	O
,	O
H3K36ac	O
,	O
H4K5ac	O
,	O
H3K27ac	O
,	O
H3K4me1	O
).	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
virus	O
-	O
like	O
particles	O
produced	O
in	O
insect	O
cells	B-COMP
induce	O
specific	O
immune	O
responses	O
in	O
mice	O
.	O

To	O
definitively	O
prove	O
this	O
conclusion	O
,	O
we	O
applied	O
CRISPR	O
/	O
Cas9	O
genome	O
engineering	O
to	O
knock	O
out	O
APN	O
expression	O
in	O
PEDV	O
-	O
susceptible	O
porcine	O
(	O
ST	O
)	O
and	O
human	O
cell	B-COMP
lines	O
(	O
Huh7	O
and	O
HeLa	O
).	O

The	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
responsible	O
for	O
receptor	O
binding	O
and	O
cell	B-COMP
entry	O
,	O
is	O
the	O
major	O
target	O
for	O
neutralizing	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Multiplex	O
Paper	O
-	O
Based	O
Colorimetric	O
DNA	O
Sensor	O
Using	O
Pyrrolidinyl	O
Peptide	O
Nucleic	B-COMP
Acid	O
-	O
Induced	O
AgNPs	O
Aggregation	O
for	O
Detecting	O
MERS	O
-	O
CoV	O
,	O
MTB	B-COMP
,	O
and	O
HPV	O
Oligonucleotides	O
.	O

Here	O
,	O
a	O
paper	O
-	O
based	O
colorimetric	O
assay	O
for	O
DNA	O
detection	O
based	O
on	O
pyrrolidinyl	O
peptide	O
nucleic	B-COMP
acid	O
(	O
acpcPNA	O
)-	O
induced	O
nanoparticle	O
aggregation	O
is	O
reported	O
as	O
an	O
alternative	O
to	O
traditional	O
colorimetric	O
approaches	O
.	O

The	O
method	O
was	O
used	O
for	O
screening	O
of	O
synthetic	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
Mycobacterium	O
tuberculosis	O
(	O
MTB	B-COMP
),	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
DNA	O
based	O
on	O
a	O
colorimetric	O
paper	O
-	O
based	O
analytical	O
device	O
developed	O
using	O
the	O
aforementioned	O
principle	O
.	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
a	O
frequent	O
condition	O
following	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
.	O

Thirty	O
-	O
seven	O
patients	O
,	O
nine	O
of	O
whom	O
underwent	O
noninvasive	O
ventilation	O
at	O
the	O
time	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
initiation	O
,	O
were	O
analyzed	O
.	O

Only	O
one	O
of	O
24	O
patients	O
(	O
4	O
%)	O
initiated	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
within	O
240	O
days	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
survived	O
compared	O
to	O
six	O
of	O
13	O
(	O
46	O
%)	O
of	O
those	O
treated	O
thereafter	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

On	O
the	O
contrary	O
,	O
long	O
-	O
term	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
recipients	O
otherwise	O
eligible	O
for	O
full	O
-	O
code	O
ICU	O
management	O
may	O
be	O
potential	O
candidates	O
for	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
therapy	O
in	O
case	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
failing	O
conventional	O
measures	O
.	O

ABSTRACT	O
:	O
Venovenous	O
(	O
VV	O
)	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
lung	O
failure	O
refractory	O
to	O
conventional	O
therapy	O
.	O

Specific	O
inhibitors	O
for	O
TGF	O
-	O
RI	O
,	O
p38	O
MAPK	O
,	O
MEK	O
,	O
and	O
STAT3	O
proved	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
induced	O
TGF	O
-	O
1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Type	O
I	O
collagen	B-COMP
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Subcellular	O
localization	O
analysis	O
of	O
SMAD3	O
and	O
SMAD7	O
indicated	O
that	O
non	O
-	O
SMAD	O
pathways	O
in	O
TGF	O
-	O
1	O
signaling	O
involved	O
in	O
the	O
production	O
of	O
Type	O
I	O
collagen	B-COMP
in	O
transfected	O
cells	B-COMP
with	O
pSARS	O
-	O
PLpro	O
.	O

pentosaceus	O
77F	O
showed	O
CPE	O
reduction	O
in	O
the	O
viral	O
infected	O
cells	B-COMP
to	O
<	O
50	O
%	O
observed	O
field	O
area	O
.	O

APACHE	O
II	O
score	O
and	O
serum	B-COMP
PCT	O
in	O
non	O
-	O
survival	O
group	O
(	O
n	O
=	O
38	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
survival	O
group	O
[	O
n	O
=	O
51	O
;	O
APACHE	O
II	O
score	O
:	O
26	O
.	O
00	O
(	O
23	O
.	O
00	O
,	O
28	O
.	O
50	O
)	O
vs	O
.	O
21	O
.	O
00	O
(	O
17	O
.	O
00	O
,	O
25	O
.	O
00	O
),	O
PCT	O
(	O
g	O
/	O
L	O
):	O
6	O
.	O
38	O
(	O
2	O
.	O
82	O
,	O
9	O
.	O
49	O
)	O
vs	O
.	O
3	O
.	O
09	O
(	O
1	O
.	O
08	O
,	O
3	O
.	O
57	O
),	O
both	O
P	O
<	O
0	O
.	O
01	O
],	O
but	O
Murray	O
score	O
and	O
CRP	O
level	O
were	O
similar	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
.	O

The	O
respiratory	O
parameters	O
by	O
means	O
of	O
blood	O
gas	O
results	O
,	O
measurements	O
of	O
lung	O
injury	O
,	O
inflammatory	O
responses	O
,	O
and	O
integrity	O
of	O
the	O
alveolar	O
capillary	O
barrier	O
after	O
the	O
infusion	O
of	O
these	O
cells	B-COMP
were	O
analyzed	O
.	O

In	O
vitro	O
,	O
both	O
pharmacological	O
inhibitors	O
(	O
AG1478	O
and	O
451	O
)	O
and	O
si	O
-	O
RNA	O
silencing	O
of	O
EGFR	O
significantly	O
inhibited	O
LPS	O
-	O
induced	O
EGFR	O
signaling	O
activation	O
and	O
inflammatory	O
response	O
in	O
human	O
lung	O
epithelial	O
cells	B-COMP
or	O
macrophages	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
positive	O
-	O
sense	O
RNA	O
viruses	O
that	O
generate	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
intermediates	O
during	O
replication	O
,	O
yet	O
evade	O
detection	O
by	O
host	B-COMP
innate	O
immune	O
sensors	O
.	O

ABSTRACT	O
:	O
CNS	O
inflammation	O
resulting	O
from	O
infection	O
,	O
injury	O
,	O
or	O
neurodegeneration	O
leads	O
to	O
accumulation	O
of	O
diverse	O
B	O
cell	B-COMP
subsets	O
.	O

Although	O
antibody	B-COMP
secreting	O
cells	B-COMP
(	O
ASC	O
)	O
within	O
the	O
inflamed	O
CNS	O
have	O
been	O
extensively	O
examined	O
,	O
memory	O
B	O
cell	B-COMP
(	O
Bmem	O
)	O
characterization	O
has	O
been	O
limited	O
as	O
they	O
do	O
not	O
secrete	O
antibody	B-COMP
without	O
stimulation	O
.	O

CONCLUSIONS	O
:	O
Simultaneous	O
enumeration	O
of	O
antigen	O
-	O
specific	O
Bmem	O
and	O
ASC	O
using	O
the	O
Bmem	O
assay	O
optimized	O
for	O
CNS	O
-	O
derived	O
cells	B-COMP
enables	O
characterization	O
of	O
temporal	O
changes	O
during	O
microbial	O
or	O
auto	O
-	O
antigen	O
induced	O
neuroinflammation	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
treatment	O
strategy	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
low	O
tidal	O
volume	O
era	O
:	O
A	O
systematic	O
review	O
.	O

This	O
phenotype	O
was	O
mediated	O
by	O
miR	O
-	O
142	O
-	O
5p	O
inhibition	O
of	O
an	O
mRNA	O
encoding	O
unc	O
-	O
51	O
-	O
like	O
-	O
kinase1	O
(	O
Ulk1	O
),	O
which	O
controls	O
axon	B-COMP
outgrowth	O
and	O
dendrite	B-COMP
formation	O
.	O

In	O
this	O
randomised	O
,	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
phase	O
2	O
trial	O
,	O
29	O
academic	O
medical	O
centres	O
in	O
the	O
USA	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
anti	O
-	O
influenza	O
plasma	O
with	O
haemagglutination	O
inhibition	O
antibody	B-COMP
titres	O
of	O
1	O
:	O
80	O
or	O
more	O
to	O
the	O
infecting	O
strain	O
.	O

However	O
,	O
maximal	O
expression	O
of	O
this	O
epithelial	O
-	O
derived	O
cytokine	O
was	O
dependent	O
on	O
NF	O
-	O
B	O
RelA	O
in	O
myeloid	O
cells	B-COMP
.	O

Out	O
of	O
a	O
total	O
of	O
26	O
farms	O
,	O
14	O
tested	O
positive	O
for	O
SwIV	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
Type	O
II	O
transmembrane	B-COMP
serine	O
proteases	O
(	O
TTSPs	O
)	O
facilitate	O
the	O
spread	O
and	O
replication	O
of	O
viruses	O
such	O
as	O
influenza	O
and	O
human	O
coronaviruses	O
,	O
although	O
it	O
remains	O
unclear	O
whether	O
TTSPs	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
animal	O
coronavirus	O
infections	O
,	O
such	O
as	O
that	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

In	O
sum	O
,	O
we	O
identified	O
two	O
host	B-COMP
proteases	O
,	O
TMPRSS2	O
and	O
MSPL	O
,	O
which	O
may	O
provide	O
insights	O
and	O
a	O
novel	O
method	O
for	O
enhancing	O
viral	O
titers	O
,	O
expanding	O
virus	O
production	O
,	O
and	O
improving	O
the	O
adaptability	O
of	O
PEDV	O
isolates	O
in	O
vitro	O
.	O

Alignment	O
and	O
comparison	O
of	O
full	O
-	O
length	O
sequences	O
of	O
PEDVPT	O
-	O
P5	O
and	O
PEDVPT	O
-	O
P96	O
revealed	O
23	O
nucleotide	O
changes	O
and	O
resultant	O
19	O
amino	O
acid	O
substitutions	O
in	O
non	O
-	O
structure	O
proteins	O
2	O
,	O
3	O
,	O
4	O
,	O
9	O
,	O
14	O
,	O
15	O
,	O
spike	O
,	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
),	O
and	O
membrane	B-COMP
proteins	O
with	O
no	O
detectable	O
deletion	O
or	O
insertion	O
.	O

Moreover	O
,	O
data	O
regarding	O
viral	O
attenuation	O
and	O
potency	O
of	O
induced	O
antibodies	B-COMP
against	O
PEDVPT	O
-	O
P5	O
identified	O
PEDVPT	O
-	O
P96	O
as	O
a	O
potential	O
live	O
-	O
attenuated	O
vaccine	O
candidate	O
.	O

The	O
correlation	O
between	O
serum	B-COMP
CC16	O
levels	O
and	O
the	O
severity	O
of	O
ARDS	O
as	O
quantified	O
by	O
PaO	O
The	O
serum	B-COMP
CC16	O
levels	O
in	O
ARDS	O
patients	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
ARDS	O
patients	O
(	O
54	O
.	O
44	O
	O
19	O
.	O
62	O
vs	O
24	O
.	O
13	O
	O
12	O
.	O
32	O
ng	O
/	O
mL	O
,	O
P	O
=.	O
001	O
).	O

RESULTS	O
:	O
The	O
serum	B-COMP
CC16	O
levels	O
in	O
ARDS	O
patients	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
ARDS	O
patients	O
(	O
54	O
.	O
44	O
	O
19	O
.	O
62	O
vs	O
24	O
.	O
13	O
	O
12	O
.	O
32	O
ng	O
/	O
mL	O
,	O
P	O
=.	O
001	O
).	O

Further	O
cell	B-COMP
-	O
based	O
assays	O
indicated	O
that	O
FA	O
-	O
613	O
interfer	O
with	O
the	O
de	O
novo	O
pyrimidine	O
biosynthesis	O
pathway	O
by	O
targeting	O
the	O
dihydroorotate	O
dehydrogenase	O
.	O

Further	O
investigation	O
of	O
the	O
specific	O
connection	O
between	O
pyrimidine	O
synthesis	O
inhibition	O
and	O
the	O
induction	O
of	O
host	B-COMP
innate	O
immunity	O
might	O
aid	O
clinical	O
development	O
of	O
this	O
type	O
of	O
drug	O
in	O
antiviral	O
therapies	O
.	O

After	O
31	O
days	O
of	O
stabilization	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
and	O
lung	O
protective	O
ventilation	O
the	O
patient	O
was	O
weaned	O
of	O
ECMO	O
therapy	O
.	O

ABSTRACT	O
:	O
Intracellular	B-COMP
trafficking	O
and	O
localization	O
studies	O
of	O
spike	O
protein	O
from	O
SARS	O
and	O
OC43	O
showed	O
that	O
SARS	O
spike	O
protein	O
is	O
localized	O
in	O
the	O
ER	O
or	O
ERGIC	B-COMP
compartment	O
and	O
OC43	O
spike	O
protein	O
is	O
predominantly	O
localized	O
in	O
the	O
lysosome	B-COMP
.	O

Furthermore	O
,	O
HPS	O
was	O
strictly	O
characterized	O
by	O
the	O
upregulation	O
of	O
cytokine	O
levels	O
,	O
in	O
contrast	O
to	O
HFRS	O
where	O
cases	O
were	O
distinguished	O
by	O
a	O
dichotomy	O
in	O
serum	B-COMP
cytokine	O
levels	O
.	O

Signature	O
genes	O
were	O
identified	O
for	O
each	O
virus	O
and	O
included	O
host	B-COMP
defense	O
genes	O
for	O
PR8	O
,	O
tissue	O
remodeling	O
genes	O
for	O
RV1B	O
,	O
and	O
transcription	O
factors	O
for	O
MHV	O
-	O
1	O
.	O

The	O
multiplex	O
kindred	O
reported	O
herein	O
expands	O
the	O
genotypic	O
and	O
phenotypic	O
spectrum	O
of	O
this	O
recently	O
described	O
clinical	O
syndrome	O
due	O
to	O
autosomal	B-COMP
recessive	O
NBAS	O
deficiency	O
.	O

MVA	O
MERS	O
with	O
mH5	O
or	O
F11	O
promoter	O
induced	O
similar	O
antibody	B-COMP
levels	O
;	O
however	O
,	O
F11	O
promoter	O
enhanced	O
the	O
cellular	B-COMP
immunogenicity	O
of	O
MVA	O
MERS	O
to	O
significantly	O
higher	O
magnitudes	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Antibody	B-COMP
Responses	O
1	O
Year	O
after	O
Symptom	O
Onset	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

The	O
MERS	O
S1	O
ELISA	O
antibody	B-COMP
titers	O
correlated	O
well	O
with	O
the	O
neutralizing	O
antibody	B-COMP
response	O
.	O

A	O
retrospective	O
study	O
including	O
116	O
clinical	O
plasma	O
and	O
serum	B-COMP
samples	O
that	O
had	O
been	O
tested	O
with	O
virus	O
isolation	O
,	O
real	O
-	O
time	O
PCR	O
and	O
ELISA	O
,	O
and	O
a	O
prospective	O
study	O
including	O
150	O
clinical	O
plasma	O
and	O
serum	B-COMP
samples	O
were	O
implemented	O
to	O
evaluate	O
the	O
clinical	O
performances	O
of	O
the	O
iiPCR	O
-	O
based	O
methods	O
for	O
FeLV	O
detection	O
.	O

The	O
agreement	O
between	O
an	O
automatic	O
nucleic	B-COMP
extraction	O
/	O
RT	O
-	O
iiPCR	O
system	O
and	O
virus	O
isolation	O
to	O
detect	O
FeLV	O
in	O
plasma	O
or	O
serum	B-COMP
was	O
95	O
.	O
69	O
%	O
(	O
	O
=	O
0	O
.	O
95	O
)	O
and	O
98	O
.	O
67	O
%	O
(	O
	O
=	O
0	O
.	O
85	O
)	O
in	O
a	O
retrospective	O
(	O
n	O
=	O
116	O
)	O
and	O
a	O
prospective	O
(	O
n	O
=	O
150	O
)	O
study	O
,	O
respectively	O
.	O

TITLE	O
:	O
Allelic	O
Variation	O
in	O
the	O
Toll	O
-	O
Like	O
Receptor	O
Adaptor	O
Protein	O
ABSTRACT	O
:	O
Host	B-COMP
genetic	O
variation	O
is	O
known	O
to	O
contribute	O
to	O
differential	O
pathogenesis	O
following	O
infection	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
patients	O
experienced	O
more	O
clinically	O
significant	O
iatrogenic	O
withdrawal	O
than	O
moderate	O
/	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
managed	O
without	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

This	O
year	O
marks	O
the	O
twentieth	O
anniversary	O
of	O
the	O
identification	O
of	O
pteropid	O
bats	O
(	O
flying	O
-	O
foxes	O
)	O
as	O
the	O
natural	O
host	B-COMP
of	O
the	O
virus	O
,	O
and	O
it	O
is	O
timely	O
to	O
reflect	O
on	O
a	O
pivotal	O
meeting	O
of	O
an	O
eclectic	O
group	O
of	O
scientists	O
in	O
that	O
process	O
.	O

Within	O
weeks	O
,	O
antibodies	B-COMP
were	O
detected	O
in	O
several	O
species	O
of	O
flying	O
-	O
fox	O
,	O
and	O
the	O
virus	O
was	O
subsequently	O
isolated	O
.	O

Isolating	O
PEDV	O
neutralizing	O
antibodies	B-COMP
from	O
porcine	O
B	O
cells	B-COMP
is	O
critical	O
to	O
elucidate	O
the	O
development	O
of	O
PEDV	O
neutralizing	O
antibodies	B-COMP
and	O
the	O
protective	O
mechanism	O
of	O
PEDV	O
infection	O
.	O

We	O
surveyed	O
the	O
diversity	O
of	O
CoVs	O
in	O
multiple	O
host	B-COMP
taxa	O
from	O
twenty	O
countries	O
to	O
explore	O
the	O
factors	O
driving	O
viral	O
diversity	O
at	O
a	O
global	O
scale	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
analysis	O
of	O
oxidative	O
parameters	O
and	O
specific	O
antibody	B-COMP
titers	O
,	O
and	O
splenocytes	O
were	O
prepared	O
for	O
lymphocyte	O
proliferative	O
assay	O
.	O

We	O
then	O
show	O
that	O
phylogenetic	O
host	B-COMP
breadth	O
and	O
other	O
viral	O
traits	O
are	O
significant	O
predictors	O
of	O
zoonotic	O
potential	O
,	O
providing	O
a	O
novel	O
framework	O
to	O
assess	O
if	O
a	O
newly	O
discovered	O
mammalian	O
virus	O
could	O
infect	O
people	O
.	O

The	O
type	O
II	O
transmembrane	B-COMP
serine	O
protease	O
TMPRSS2	O
cleaves	O
and	O
activates	O
SARS	O
S	O
in	O
cell	B-COMP
culture	O
and	O
potentially	O
also	O
in	O
the	O
infected	O
host	B-COMP
.	O

For	O
example	O
,	O
by	O
interacting	O
with	O
the	O
host	B-COMP
cell	I-COMP
to	O
create	O
an	O
optimal	O
environment	O
for	O
coronavirus	O
replication	O
,	O
by	O
altering	O
host	B-COMP
gene	O
expression	O
or	O
by	O
counteracting	O
the	O
host	B-COMP
'	O
s	O
antiviral	O
defenses	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
respiratory	O
viral	O
infections	O
in	O
a	O
young	O
child	O
and	O
to	O
examine	O
the	O
duration	O
of	O
viral	B-COMP
genome	I-COMP
detection	O
in	O
clinical	O
specimens	O
.	O

TITLE	O
:	O
Kidney	O
Cell	B-COMP
-	O
Adapted	O
Infectious	O
Bronchitis	O
ArkDPI	O
Vaccine	O
is	O
Stable	O
and	O
Protective	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
adaptation	O
of	O
an	O
embryo	O
-	O
attenuated	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
Arkansas	O
(	O
Ark	O
)	O
Delmarva	O
Poultry	O
Industry	O
(	O
DPI	O
)-	O
derived	O
vaccine	O
to	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	B-COMP
(	O
CEKp7	O
)	O
shifted	O
the	O
virus	O
population	O
towards	O
homogeneity	O
in	O
spike	O
(	O
S	O
)	O
and	O
nonstructural	O
protein	O
genes	O
.	O

ABSTRACT	O
:	O
Unlike	O
for	O
serotype	O
II	O
feline	O
coronaviruses	O
(	O
FCoV	O
II	O
),	O
the	O
cellular	B-COMP
receptor	O
for	O
serotype	O
I	O
FCoV	O
(	O
FCoV	O
I	O
),	O
the	O
most	O
prevalent	O
FCoV	O
serotype	O
,	O
is	O
unknown	O
.	O

This	O
subsequently	O
blocked	O
the	O
attachment	O
of	O
S1	O
to	O
IBV	O
-	O
susceptible	O
cells	B-COMP
in	O
chicken	O
tracheal	O
tissues	O
as	O
shown	O
in	O
protein	O
histochemistry	O
.	O

Taken	O
together	O
,	O
rcMBL	O
exhibits	O
antiviral	O
activity	O
against	O
IBV	O
,	O
based	O
on	O
a	O
direct	O
interaction	O
with	O
IBV	O
virions	B-COMP
.	O

Viral	O
propagation	O
was	O
confirmed	O
in	O
Vero	O
cells	B-COMP
based	O
on	O
cytopathic	O
effect	O
,	O
immunofluorescence	O
assay	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
electron	O
microscopic	O
analyses	O
.	O

To	O
evaluate	O
performance	O
according	O
to	O
serum	B-COMP
collection	O
time	O
,	O
we	O
used	O
'	O
days	O
post	O
onset	O
of	O
illness	O
(	O
dpoi	O
)'	O
and	O
'	O
days	O
post	O
exposure	O
(	O
dpex	O
)'	O
assessing	O
neutralization	O
activity	O
and	O
infection	O
diagnosis	O
,	O
respectively	O
.	O

In	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	O
,	O
ELISA	O
IgG	O
exhibited	O
optimal	O
performance	O
using	O
sera	B-COMP
collected	O
after	O
28	O
dpex	O
,	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
OD	O
ratio	O
0	O
.	O
2	O
(	O
sensitivity	O
97	O
.	O
3	O
%	O
and	O
specificity	O
92	O
.	O
9	O
%).	O

Viral	B-COMP
genome	I-COMP
analysis	O
indicates	O
unusually	O
low	O
CpG	O
dinucleotide	O
depletion	O
in	O
KYAV	O
compared	O
to	O
other	O
ledanteviruses	O
and	O
rhabdovirus	O
groups	O
,	O
with	O
KYAV	O
displaying	O
values	O
similar	O
to	O
rhabdoviruses	O
of	O
arthropods	O
.	O

TITLE	O
:	O
SURVEILLANCE	O
FOR	O
ANTIBODIES	B-COMP
AGAINST	O
SIX	O
CANINE	O
VIRUSES	O
IN	O
WILD	O
RACCOONS	O
(	O
PROCYON	O
LOTOR	O
)	O
IN	O
JAPAN	O
.	O

In	O
2013	O
,	O
760	O
human	O
and	O
879	O
camel	O
sera	B-COMP
were	O
collected	O
from	O
275	O
and	O
85	O
households	O
respectively	O
in	O
Marsabit	O
County	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
clinical	O
characteristics	O
,	O
cytokine	O
/	O
chemokine	O
concentrations	O
,	O
viral	O
shedding	O
and	O
antibody	B-COMP
kinetics	O
in	O
30	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
including	O
6	O
non	O
-	O
survivors	O
admitted	O
to	O
3	O
MERS	O
-	O
designated	O
hospitals	O
.	O

Animal	O
inoculation	O
studies	O
revealed	O
that	O
the	O
virulence	O
of	O
both	O
S	O
DEL2	O
/	O
ORF3	O
and	O
S	O
DEL5	O
/	O
ORF3	O
viruses	O
with	O
a	O
large	O
46	O
-	O
nt	O
deletion	O
in	O
the	O
intergenic	O
portion	O
of	O
S	O
and	O
ORF3	O
was	O
remarkably	O
diminished	O
,	O
indicating	O
viral	O
attenuation	O
in	O
the	O
natural	O
host	B-COMP
.	O

Furthermore	O
,	O
the	O
S	O
proteins	O
of	O
virulent	O
mouse	O
-	O
adapted	O
MERS	O
-	O
CoVs	O
acquired	O
a	O
CD9	O
-	O
dependent	O
cell	B-COMP
entry	O
character	O
,	O
suggesting	O
that	O
CD9	O
is	O
a	O
selective	O
agent	O
in	O
the	O
evolution	O
of	O
CoV	O
virulence	O
.	O

Further	O
,	O
IBV	O
productive	O
infection	O
in	O
macrophages	O
was	O
confirmed	O
by	O
demonstrating	O
corona	O
viral	B-COMP
particles	I-COMP
in	O
macrophages	O
and	O
IBV	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
in	O
culture	O
supernatants	O
.	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	B-COMP
density	O
of	O
tryptase	O
+	O
mast	O
cells	B-COMP
and	O
dendritic	B-COMP
+	O
cells	B-COMP
and	O
an	O
increase	O
of	O
IL	O
-	O
17	O
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Here	O
,	O
we	O
outline	O
a	O
critical	O
role	O
of	O
the	O
host	B-COMP
cell	I-COMP
protease	O
TMPRSS2	O
in	O
influenza	O
virus	O
and	O
coronavirus	O
infections	O
and	O
highlight	O
an	O
antiviral	O
therapeutic	O
strategy	O
targeting	O
TMPRSS2	O
.	O

TITLE	O
:	O
Recovery	O
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
is	O
associated	O
with	O
antibody	B-COMP
and	O
T	O
-	O
cell	B-COMP
responses	O
.	O

These	O
results	O
are	O
significant	O
for	O
the	O
study	O
of	O
immune	O
responses	O
to	O
infection	O
with	O
different	O
virulent	O
IBVs	O
mediated	O
by	O
miRNAs	O
as	O
well	O
as	O
the	O
interaction	O
between	O
the	O
chicken	O
host	B-COMP
and	O
IBV	O
.	O

The	O
supernatant	O
of	O
these	O
CPE	O
positive	O
cell	B-COMP
cultures	O
were	O
grouped	O
in	O
32	O
pools	O
containing	O
2	O
-	O
26	O
supernatants	O
per	O
pool	O
.	O

The	O
results	O
illustrate	O
that	O
intramuscular	O
vaccination	O
increased	O
neutralizing	O
antibody	B-COMP
titers	O
,	O
and	O
anti	O
-	O
PEDV	O
IgA	O
and	O
IgG	O
in	O
milk	O
and	O
colostrum	O
of	O
sows	O
that	O
were	O
previously	O
infected	O
.	O

Thus	O
,	O
inactivated	O
PEDV	O
vaccines	O
may	O
provide	O
increased	O
protection	O
to	O
piglets	O
nursing	O
on	O
previously	O
infected	O
sows	O
against	O
exposure	O
to	O
PEDV	O
through	O
increased	O
delivery	O
of	O
lactogenic	O
neutralizing	O
antibodies	B-COMP
to	O
the	O
enteric	O
site	O
of	O
infection	O
.	O

TITLE	O
:	O
Persistent	O
Transmissible	O
Gastroenteritis	O
Virus	O
Infection	O
Enhances	O
Enterotoxigenic	O
Escherichia	O
coli	O
K88	O
Adhesion	O
by	O
Promoting	O
Epithelial	O
-	O
Mesenchymal	O
Transition	O
in	O
Intestinal	O
Epithelial	O
Cells	B-COMP
.	O

Here	O
we	O
use	O
structure	O
-	O
based	O
design	O
to	O
develop	O
a	O
generalizable	O
strategy	O
for	O
retaining	O
coronavirus	O
S	O
proteins	O
in	O
the	O
antigenically	O
optimal	O
prefusion	O
conformation	O
and	O
demonstrate	O
that	O
our	O
engineered	O
immunogen	O
is	O
able	O
to	O
elicit	O
high	O
neutralizing	O
antibody	B-COMP
titers	O
against	O
MERS	O
-	O
CoV	O
.	O
We	O
also	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
the	O
trimeric	O
MERS	O
-	O
CoV	O
S	O
ectodomain	O
in	O
complex	O
with	O
G4	O
,	O
a	O
stem	O
-	O
directed	O
neutralizing	O
antibody	B-COMP
.	O

TITLE	O
:	O
Enhanced	O
inflammation	O
in	O
New	O
Zealand	O
white	O
rabbits	O
when	O
MERS	O
-	O
CoV	O
reinfection	O
occurs	O
in	O
the	O
absence	O
of	O
neutralizing	O
antibody	B-COMP
.	O

Non	O
-	O
survivors	O
needed	O
significantly	O
more	O
frequent	O
renal	O
replacement	O
therapy	O
(	O
37	O
.	O
5	O
%	O
vs	O
.	O
18	O
.	O
2	O
%;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
transfusion	O
of	O
red	O
blood	O
cell	B-COMP
concentrates	O
[	O
0	O
.	O
4	O
units	O
(	O
0	O
.	O
3	O
to	O
1	O
.	O
2	O
)	O
vs	O
.	O
0	O
.	O
9	O
units	O
(	O
0	O
.	O
5	O
to	O
1	O
.	O
6	O
);	O
p	O
<	O
0	O
.	O
01	O
]	O
during	O
ECMO	O
support	O
compared	O
to	O
patients	O
who	O
survived	O
.	O

Similar	O
to	O
NPCs	O
derived	O
from	O
striatum	O
of	O
day	O
1	O
postnatal	O
GFP	O
-	O
transgenic	O
mice	O
(	O
GFP	O
-	O
NPCs	O
),	O
iPSC	O
-	O
derived	O
NPCs	O
(	O
iPSC	O
-	O
NPCs	O
)	O
are	O
able	O
to	O
differentiate	O
into	O
terminal	O
neural	O
cell	B-COMP
types	O
and	O
express	O
MHC	O
class	O
I	O
and	O
II	O
in	O
response	O
to	O
IFN	O
-	O
	O
treatment	O
.	O

At	O
most	O
time	O
points	O
,	O
the	O
titer	O
of	O
IBV	O
-	O
specific	O
antibodies	B-COMP
,	O
lymphocyte	O
proliferation	O
,	O
and	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
	O
mRNA	O
expression	O
levels	O
were	O
higher	O
in	O
three	O
APS	O
groups	O
than	O
in	O
the	O
vaccine	O
control	O
group	O
,	O
and	O
these	O
increases	O
were	O
dose	O
-	O
dependent	O
.	O

Importantly	O
,	O
attenuation	O
of	O
the	O
dORF3	O
-	O
5	O
mutant	O
is	O
primarily	O
driven	O
by	O
dysregulated	O
host	B-COMP
responses	O
,	O
including	O
disrupted	O
cell	B-COMP
processes	I-COMP
,	O
augmented	O
interferon	O
(	O
IFN	O
)	O
pathway	O
activation	O
,	O
and	O
robust	O
inflammation	O
.	O

Cerebrospinal	O
fluid	O
was	O
analysed	O
in	O
11	O
cases	O
;	O
all	O
demonstrated	O
a	O
marked	O
increase	O
in	O
total	O
protein	O
concentration	O
and	O
total	O
nucleated	O
cell	B-COMP
count	O
.	O

TITLE	O
:	O
Increased	O
serum	B-COMP
IL	O
-	O
17A	O
and	O
Th2	O
cytokine	O
levels	O
in	O
patients	O
with	O
severe	O
uncontrolled	O
asthma	O
.	O

Although	O
T	O
helper	O
cell	B-COMP
type	I-COMP
2	O
(	O
Th2	O
)	O
cytokines	O
were	O
proven	O
to	O
play	O
critical	O
roles	O
in	O
atopic	O
asthma	O
,	O
IL	O
-	O
17A	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
severe	O
refractory	O
asthma	O
.	O

Collectively	O
,	O
the	O
present	O
study	O
suggests	O
an	O
early	O
prevention	O
against	O
PEDV	O
infection	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
via	O
autophagy	O
that	O
might	O
be	O
an	O
effective	O
strategy	O
for	O
the	O
restriction	O
of	O
PEDV	O
,	O
and	O
opens	O
up	O
the	O
possibility	O
of	O
the	O
use	O
of	O
rapamycin	O
in	O
vivo	O
as	O
an	O
effective	O
prophylactic	O
and	O
prevention	O
treatment	O
.	O

We	O
then	O
induced	O
M1	O
,	O
M2a	O
and	O
M2c	O
from	O
bone	O
marrow	O
cells	B-COMP
.	O

The	O
two	O
methods	O
can	O
be	O
used	O
to	O
monitor	O
the	O
PDCoV	O
epidemiology	O
in	O
the	O
levels	O
of	O
PDCoV	O
specific	O
RNA	O
or	O
antibody	B-COMP
,	O
helping	O
better	O
prevent	O
and	O
control	O
PDCoV	O
.	O

Western	O
blot	O
and	O
indirect	O
immunofluorescence	O
assay	O
showed	O
that	O
nsp1	O
was	O
highly	O
expressed	O
in	O
transfected	O
cells	B-COMP
and	O
PEDV	O
-	O
infected	O
cells	B-COMP
.	O

According	O
to	O
the	O
whole	O
genome	O
sequence	O
comparative	O
analysis	O
,	O
we	O
identified	O
four	O
major	O
variations	O
located	O
in	O
nonstructural	O
protein	O
2	O
,	O
S	O
,	O
open	O
reading	O
frame	O
3	O
,	O
and	O
envelope	B-COMP
(	O
E	O
)	O
genes	O
,	O
respectively	O
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
a	O
recombinant	O
M	O
protein	O
-	O
based	O
indirect	O
ELISA	O
for	O
the	O
detection	O
of	O
porcine	O
deltacoronavirus	O
IgG	O
antibodies	B-COMP
.	O

Currently	O
,	O
several	O
therapeutic	O
options	O
have	O
been	O
employed	O
,	O
such	O
as	O
convalescent	O
plasma	O
(	O
CP	O
),	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
),	O
monoclonal	O
antibodies	B-COMP
and	O
repurposing	O
of	O
existing	O
clinically	O
approved	O
drugs	O
.	O

Sickle	O
-	O
cell	B-COMP
anemia	O
(	O
SCA	O
),	O
the	O
most	O
severe	O
form	O
of	O
this	O
disease	O
,	O
is	O
the	O
most	O
common	O
inherited	O
blood	O
disorder	O
in	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Ultrastructural	O
Characterization	O
of	O
Membrane	B-COMP
Rearrangements	O
Induced	O
by	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Infection	O
.	O

Two	O
testing	O
methods	O
are	O
currently	O
used	O
for	O
MERS	O
-	O
CoV	O
diagnostics	O
:	O
nucleic	B-COMP
acid	O
detection	O
(	O
the	O
gold	O
standard	O
)	O
and	O
serological	O
analysis	O
.	O

Furthermore	O
,	O
pharmacological	O
sequestration	O
of	O
cellular	B-COMP
cholesterol	O
efficiently	O
blocked	O
both	O
virus	O
attachment	O
and	O
internalization	O
and	O
,	O
accordingly	O
,	O
markedly	O
affected	O
subsequent	O
post	O
-	O
entry	O
steps	O
of	O
the	O
replication	O
cycle	O
,	O
including	O
viral	O
RNA	O
and	O
protein	O
biosynthesis	O
and	O
progeny	O
virus	O
production	O
.	O

Part	O
of	O
the	O
current	O
critical	O
care	O
knowledge	O
base	O
must	O
include	O
an	O
understanding	O
of	O
how	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
fits	O
into	O
the	O
paradigm	O
of	O
ARDS	O
management	O
without	O
using	O
it	O
as	O
a	O
""""	O
salvage	O
therapy	O
.	O

A	O
slight	O
increase	O
in	O
interferon	O
-	O
	O
protein	O
production	O
in	O
the	O
supernatants	O
of	O
PEDV	O
-	O
infected	O
cells	B-COMP
was	O
observed	O
compared	O
to	O
mock	O
infected	O
cells	B-COMP
.	O

The	O
recently	O
defined	O
receptor	O
for	O
MERS	O
-	O
CoV	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
is	O
generally	O
expressed	O
in	O
endothelial	O
and	O
epithelial	O
cells	B-COMP
and	O
has	O
been	O
shown	O
to	O
be	O
present	O
on	O
cultured	O
human	O
nonciliated	O
bronchiolar	O
epithelium	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
we	O
used	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
and	O
liver	O
to	O
assess	O
of	O
the	O
role	O
of	O
the	O
inflammasome	O
and	O
its	O
related	O
cytokines	O
on	O
pathogenesis	O
and	O
host	B-COMP
defense	O
during	O
viral	O
infection	O
.	O

Although	O
the	O
S1	O
subunit	O
is	O
the	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	B-COMP
,	O
vaccination	O
with	O
S1	O
protein	O
has	O
been	O
shown	O
to	O
confer	O
inadequate	O
protection	O
against	O
challenge	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
evolved	O
to	O
navigate	O
through	O
the	O
sophisticated	O
network	O
of	O
a	O
host	B-COMP
'	O
s	O
immune	O
system	O
.	O

Our	O
results	O
show	O
that	O
,	O
in	O
the	O
lungs	O
of	O
infected	O
mice	O
,	O
the	O
percentage	O
of	O
T	O
cells	B-COMP
,	O
but	O
not	O
the	O
percentages	O
of	O
CD4	O

Although	O
the	O
duration	O
of	O
ICU	O
stay	O
was	O
shortened	O
,	O
the	O
clinical	O
benefits	O
of	O
NAC	B-COMP
were	O
limited	O
for	O
ARDS	O
based	O
on	O
the	O
present	O
meta	O
-	O
analysis	O
.	O

A	O
novel	O
sgmRNA	O
(	O
M	O
-	O
1	O
)	O
was	O
identified	O
as	O
a	O
short	O
version	O
of	O
membrane	B-COMP
(	O
M	O
)	O
gene	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
some	O
of	O
the	O
recent	O
findings	O
of	O
host	B-COMP
cell	I-COMP
factors	O
that	O
might	O
be	O
exploited	O
by	O
HCoVs	O
to	O
facilitate	O
their	O
own	O
replication	O
cycle	O
.	O

We	O
also	O
discuss	O
various	O
cellular	B-COMP
processes	O
,	O
such	O
as	O
apoptosis	O
,	O
innate	O
immunity	O
,	O
ER	O
stress	O
response	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
pathway	O
that	O
may	O
be	O
modulated	O
by	O
HCoVs	O
.	O

In	O
this	O
study	O
,	O
chicken	O
macrophage	O
HD11	O
cells	B-COMP
were	O
established	O
as	O
a	O
cellular	B-COMP
model	O
that	O
is	O
permissive	O
to	O
IBV	O
infection	O
.	O

Then	O
,	O
IBV	O
-	O
induced	O
apoptosis	O
was	O
observed	O
through	O
a	O
cell	B-COMP
viability	O
assay	O
,	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
.	O

Additionally	O
,	O
ammonium	O
chloride	O
(	O
NHCl	O
)	O
pretreated	O
HD11	O
cells	B-COMP
blocked	O
IBV	O
from	O
entering	O
cells	B-COMP
and	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
correlation	O
between	O
the	O
serum	B-COMP
zinc	O
in	O
patients	O
with	O
HC	O
/	O
ZnCl	O
smoke	O
inhalation	O
lung	O
injury	O
and	O
disease	O
severity	O
.	O

Quantification	O
of	O
infected	O
cells	B-COMP
showed	O
that	O
PHEV	O
enters	O
cells	B-COMP
by	O
clathrin	O
-	O
mediated	O
endocytosis	O
(	O
CME	O
)	O
and	O
that	O
low	O
pH	O
,	O
dynamin	O
,	O
cholesterol	O
,	O
and	O
Eps15	O
are	O
indispensably	O
involved	O
in	O
this	O
process	O
.	O

The	O
main	O
cause	O
of	O
the	O
MS	O
is	O
yet	O
to	O
be	O
revealed	O
,	O
but	O
the	O
most	O
probable	O
theory	O
is	O
based	O
on	O
the	O
molecular	O
mimicry	O
that	O
concludes	O
some	O
infections	O
in	O
the	O
activation	O
of	O
T	O
cells	B-COMP
against	O
brain	O
auto	O
-	O
antigens	O
that	O
initiate	O
the	O
disease	O
cascade	O
.	O

The	O
Purpose	O
of	O
this	O
research	O
is	O
the	O
prediction	O
of	O
the	O
auto	O
-	O
antigen	O
potency	O
of	O
the	O
myelin	B-COMP
proteolipid	O
protein	O
(	O
PLP	O
)	O
in	O
multiple	O
sclerosis	O
.	O

TITLE	O
:	O
Host	B-COMP
-	O
Feeding	O
Patterns	O
of	O
Culex	O
stigmatosoma	O
(	O
Diptera	O
:	O
Culicidae	O
)	O
in	O
Southern	O
California	O
.	O

Currently	O
,	O
the	O
only	O
post	O
-	O
exposure	O
measure	O
that	O
is	O
effective	O
against	O
pulmonary	O
ricinosis	O
at	O
clinically	O
relevant	O
time	O
-	O
points	O
following	O
intoxication	O
in	O
pre	O
-	O
clinical	O
studies	O
is	O
passive	O
immunization	O
with	O
anti	O
-	O
ricin	O
neutralizing	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Endothelial	O
glycocalyx	B-COMP
degradation	O
is	O
more	O
severe	O
in	O
patients	O
with	O
non	O
-	O
pulmonary	O
sepsis	O
compared	O
to	O
pulmonary	O
sepsis	O
and	O
associates	O
with	O
risk	O
of	O
ARDS	O
and	O
other	O
organ	O
dysfunction	O
.	O

The	O
extent	O
of	O
endothelial	O
glycocalyx	B-COMP
degradation	O
is	O
associated	O
with	O
non	O
-	O
pulmonary	O
organ	O
dysfunction	O
in	O
subjects	O
with	O
sepsis	O
and	O
is	O
associated	O
with	O
ARDS	O
but	O
only	O
in	O
the	O
subgroup	O
with	O
non	O
-	O
pulmonary	O
sepsis	O
.	O

TITLE	O
:	O
The	O
bulky	O
and	O
the	O
sweet	O
:	O
How	O
neutralizing	O
antibodies	B-COMP
and	O
glycan	O
receptors	O
compete	O
for	O
virus	O
binding	O
.	O

The	O
N	O
-	O
terminus	O
of	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
reported	O
to	O
be	O
active	O
in	O
cell	B-COMP
fusion	O
whereby	O
FPs	O
have	O
been	O
identified	O
.	O

Anti	O
-	O
MERS	O
ELISA	O
assays	O
showed	O
that	O
70	O
.	O
9	O
%	O
of	O
camels	O
related	O
to	O
human	O
cases	O
had	O
antibodies	B-COMP
to	O
MERS	O
-	O
CoV	O
.	O
The	O
full	O
genome	O
sequences	O
of	O
the	O
ten	O
MERS	O
-	O
CoV	O
camel	O
isolates	O
were	O
identical	O
to	O
their	O
corresponding	O
patients	O
and	O
were	O
grouped	O
together	O
within	O
the	O
larger	O
MERS	O
-	O
CoV	O
sequences	O
cluster	O
for	O
human	O
and	O
camel	O
isolates	O
reported	O
form	O
the	O
Arabian	O
Peninsula	O
.	O

TITLE	O
:	O
Nanoparticulate	O
vacuolar	B-COMP
ATPase	O
blocker	O
exhibits	O
potent	O
host	B-COMP
-	O
targeted	O
antiviral	O
activity	O
against	O
feline	O
coronavirus	O
.	O

This	O
review	O
will	O
focus	O
on	O
three	O
particular	O
areas	O
:	O
the	O
origins	O
and	O
evolution	O
of	O
MERS	O
-	O
CoV	O
,	O
the	O
challenges	O
and	O
achievements	O
in	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
animal	O
models	O
,	O
and	O
our	O
understanding	O
of	O
how	O
novel	O
proteins	O
unique	O
to	O
MERS	O
-	O
CoV	O
counter	O
the	O
host	B-COMP
immune	O
response	O
.	O

ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
on	O
the	O
viral	B-COMP
envelope	I-COMP
is	O
the	O
main	O
determinant	O
of	O
infectivity	O
.	O

The	O
impact	O
on	O
S	O
protein	O
-	O
mediated	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
,	O
viral	O
recovery	O
and	O
infectivity	O
was	O
assessed	O
,	O
leading	O
to	O
the	O
identification	O
of	O
sites	O
essential	O
for	O
the	O
functions	O
of	O
IBV	O
S	O
protein	O
.	O

CoVs	O
encode	O
several	O
innate	O
immune	O
antagonists	O
that	O
counteract	O
the	O
host	B-COMP
innate	O
immune	O
response	O
to	O
facilitate	O
efficient	O
viral	O
replication	O
.	O

Our	O
results	O
indicate	O
that	O
both	O
FP1	O
and	O
the	O
region	O
immediately	O
downstream	O
(	O
amino	O
acids	O
816	O
-	O
835	O
KQYGECLGDINARDLICAQKF	O
,	O
FP2	O
)	O
induce	O
significant	O
membrane	B-COMP
ordering	O
.	O

In	O
this	O
study	O
,	O
we	O
discovered	O
that	O
CD59	O
was	O
downregulated	O
in	O
IBV	O
-	O
infected	O
cells	B-COMP
and	O
was	O
associated	O
with	O
IBV	O
virions	B-COMP
.	O

PdCoV	O
S1	O
-	O
CTD	O
binds	O
to	O
an	O
unidentified	O
receptor	O
on	O
host	B-COMP
cell	I-COMP
surfaces	O
.	O

In	O
the	O
combined	O
data	O
set	O
of	O
IBV	O
challenged	O
shell	O
gland	O
samples	O
,	O
the	O
comprehensive	O
ranking	O
showed	O
TATA	O
-	O
box	O
binding	O
protein	O
(	O
TBP	O
)	O
and	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
zeta	O
(	O
YWHAZ	O
)	O
as	O
the	O
two	O
most	O
stable	O
,	O
and	O
succinate	B-COMP
dehydrogenase	I-COMP
complex	I-COMP
flavoprotein	O
subunit	O
A	O
(	O
SDHA	O
)	O
and	O
albumin	O
(	O
ALB	O
)	O
as	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
there	O
has	O
been	O
growing	O
interest	O
in	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
cardiogenic	O
shock	O
.	O

TITLE	O
:	O
H1N1	O
Influenza	O
Induced	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Rescued	O
by	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
:	O
a	O
Case	O
Report	O
.	O

To	O
maximize	O
targeting	O
and	O
isolation	O
efficiency	O
,	O
density	O
gradient	O
centrifugation	O
and	O
nanoparticle	O
tracking	O
analysis	O
were	O
applied	O
to	O
minimize	O
the	O
presence	O
of	O
uncoated	O
particles	O
and	O
membrane	B-COMP
vesicles	B-COMP
.	O

The	O
resulting	O
nanoparticles	O
possess	O
a	O
distinctive	O
membrane	B-COMP
corona	O
,	O
a	O
sialylated	O
surface	O
,	O
and	O
form	O
colloidally	O
stable	O
clusters	O
with	O
influenza	O
viruses	O
.	O

Additionally	O
,	O
cytokine	O
levels	O
(	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
	O
)	O
in	O
coinfected	O
cells	B-COMP
are	O
lower	O
than	O
cells	B-COMP
infected	O
by	O
TGEV	O
alone	O
,	O
and	O
higher	O
than	O
cells	B-COMP
infected	O
by	O
ETEC	O
K88	O
alone	O
.	O

Moreover	O
,	O
the	O
capability	O
to	O
activate	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
of	O
this	O
isolate	O
was	O
identified	O
.	O

Electron	O
microscopy	O
observation	O
demonstrated	O
that	O
the	O
virus	B-COMP
particle	I-COMP
with	O
surface	O
projections	O
was	O
100	O
-	O
120nm	O
in	O
diameter	O
.	O

Further	O
,	O
in	O
order	O
to	O
understand	O
the	O
influence	O
of	O
quasispecies	O
of	O
these	O
viruses	O
in	O
relation	O
to	O
biology	O
,	O
techniques	O
for	O
deep	O
-	O
sequence	O
and	O
full	O
-	O
length	O
viral	B-COMP
genome	I-COMP
analysis	O
are	O
needed	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
utility	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
anti	O
-	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibody	B-COMP
test	O
for	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
the	O
antibody	B-COMP
titers	O
were	O
tested	O
in	O
CSF	O
and	O
sera	B-COMP
from	O
271	O
FIP	O
-	O
suspected	O
neurological	O
cats	O
.	O

The	O
efficient	O
delivery	O
of	O
siRNAs	O
into	O
targeted	O
cells	B-COMP
faces	O
many	O
challenges	O
like	O
enzymatic	O
degradation	O
and	O
quick	O
clearance	O
through	O
renal	O
system	O
.	O

TITLE	O
:	O
Traumatic	O
Fractures	O
of	O
the	O
Cervical	O
Spine	B-COMP
:	O
Analysis	O
of	O
Changes	O
in	O
Incidence	O
,	O
Cause	O
,	O
Concurrent	O
Injuries	O
,	O
and	O
Complications	O
Among	O
488	O
,	O
262	O
Patients	O
from	O
2005	O
to	O
2013	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	O
aggregation	O
and	O
ARDS	O
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	O
platelet	O
activation	O
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	O
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	B-COMP
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

Potential	O
targets	O
for	O
novel	O
antivirals	O
and	O
antibodies	B-COMP
are	O
discussed	O
as	O
well	O
as	O
lessons	O
learned	O
from	O
treatment	O
development	O
for	O
other	O
RNA	O
viruses	O
.	O

In	O
polarized	O
Caco	O
-	O
2	O
cells	B-COMP
cultured	O
in	O
Transwell	O
inserts	O
,	O
apical	O
MERS	O
-	O
CoV	O
inoculation	O
was	O
more	O
effective	O
in	O
establishing	O
infection	O
than	O
basolateral	O
inoculation	O
.	O

Antigen	O
-	O
specific	O
mAbs	O
have	O
been	O
isolated	O
using	O
several	O
different	O
approaches	O
,	O
including	O
hybridoma	O
,	O
transgenic	O
mice	O
,	O
phage	O
display	O
,	O
yeast	O
display	O
,	O
and	O
single	O
B	O
-	O
cell	B-COMP
isolation	O
.	O

We	O
have	O
now	O
expressed	O
MERS	O
-	O
CoV	O
replicase	O
self	O
-	O
cleaving	O
polyprotein	O
fragments	O
encompassing	O
nsp3	O
-	O
4	O
or	O
nsp3	O
-	O
6	O
,	O
as	O
well	O
as	O
coexpressed	O
nsp3	O
and	O
nsp4	O
of	O
either	O
MERS	O
-	O
CoV	O
or	O
SARS	O
-	O
CoV	O
,	O
to	O
characterize	O
the	O
membrane	B-COMP
structures	O
induced	O
.	O

Neuroimaging	O
of	O
brain	O
and	O
spine	B-COMP
and	O
NCSs	O
were	O
unremarkable	O
;	O
cerebrospinal	O
fluid	O
analysis	O
revealed	O
no	O
albuminocytologic	O
dissociation	O
.	O

These	O
findings	O
,	O
together	O
with	O
sophisticated	O
molecular	O
structure	O
analyses	O
,	O
omics	O
tools	O
and	O
computer	O
-	O
based	O
models	O
,	O
have	O
helped	O
delineate	O
the	O
interaction	O
between	O
respiratory	O
viruses	O
and	O
the	O
host	B-COMP
immune	O
system	O
,	O
which	O
will	O
facilitate	O
the	O
development	O
of	O
novel	O
treatment	O
strategies	O
and	O
vaccines	O
with	O
enhanced	O
efficacy	O
.	O

In	O
addition	O
,	O
the	O
number	O
of	O
apoptotic	O
cells	B-COMP
detected	O
experimentally	O
in	O
kidney	O
tissue	O
were	O
very	O
different	O
among	O
the	O
three	O
virus	O
inoculated	O
groups	O
and	O
were	O
positively	O
accordant	O
with	O
the	O
viral	O
titer	O
,	O
kidney	O
lesions	O
and	O
viral	O
virulence	O
of	O
each	O
group	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
develop	O
an	O
effective	O
M	O
cell	B-COMP
-	O
targeting	O
oral	O
vaccine	O
,	O
involving	O
Lactobacillus	O
casei	O
to	O
deliver	O
the	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
core	O
neutralizing	O
epitope	O
(	O
COE	O
)	O
antigen	O
conjugated	O
with	O
M	O
cell	B-COMP
-	O
targeting	O
peptide	O
Co1	O
as	O
an	O
adjuvant	O
,	O
against	O
PEDV	O
infection	O
.	O

PEDV	O
nsp1	O
blocked	O
the	O
nuclear	O
translocation	O
of	O
IRF1	O
and	O
reduced	O
the	O
number	O
of	O
peroxisomes	B-COMP
to	O
suppress	O
IRF1	O
-	O
mediated	O
type	O
III	O
IFNs	O
.	O

Cell	B-COMP
entry	O
studies	O
demonstrated	O
that	O
three	O
newly	O
identified	O
SARSr	O
-	O
CoVs	O
with	O
different	O
S	O
protein	O
sequences	O
are	O
all	O
able	O
to	O
use	O
human	O
ACE2	O
as	O
the	O
receptor	O
,	O
further	O
exhibiting	O
the	O
close	O
relationship	O
between	O
strains	O
in	O
this	O
cave	O
and	O
SARS	O
-	O
CoV	O
.	O
This	O
work	O
provides	O
new	O
insights	O
into	O
the	O
origin	O
and	O
evolution	O
of	O
SARS	O
-	O
CoV	O
and	O
highlights	O
the	O
necessity	O
of	O
preparedness	O
for	O
future	O
emergence	O
of	O
SARS	O
-	O
like	O
diseases	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
HR2P	O
peptide	O
and	O
anti	O
-	O
HR2P	O
antibody	B-COMP
can	O
serve	O
as	O
a	O
tool	O
for	O
dissecting	O
the	O
fusion	O
mechanism	O
of	O
PEDV	O
,	O
guiding	O
the	O
search	O
for	O
potent	O
inhibitors	O
with	O
therapeutic	O
value	O
against	O
PEDV	O
infection	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
a	O
valuable	O
life	O
support	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
adult	O
patients	O
.	O

The	O
primary	O
mechanisms	O
for	O
benefit	O
were	O
paracrine	O
effects	O
of	O
prostaglandin	O
E	O
ATII	O
cells	B-COMP
and	O
their	O
secreted	O
molecules	O
have	O
shown	O
an	O
ability	O
to	O
resolve	O
ALI	O
,	O
thereby	O
highlighting	O
a	O
potential	O
novel	O
therapeutic	O
target	O
.	O

Although	O
the	O
potential	O
for	O
MERS	O
-	O
CoV	O
transmission	O
through	O
blood	O
transfusion	O
is	O
not	O
clear	O
,	O
MERS	O
-	O
CoV	O
was	O
recognized	O
as	O
a	O
pathogen	O
of	O
concern	O
for	O
the	O
safety	O
of	O
the	O
blood	O
supply	O
especially	O
after	O
its	O
detection	O
in	O
whole	O
blood	O
,	O
serum	B-COMP
,	O
and	O
plasma	O
of	O
infected	O
individuals	O
.	O

TITLE	O
:	O
Retrieval	O
of	O
severe	O
acute	O
respiratory	O
failure	O
patients	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
Any	O
impact	O
on	O
their	O
outcomes	O
?	O

TITLE	O
:	O
Coronaviruses	O
and	O
arteriviruses	O
display	O
striking	O
differences	O
in	O
their	O
cyclophilin	O
A	O
-	O
dependence	O
during	O
replication	O
in	O
cell	B-COMP
culture	O
.	O

The	O
collected	O
media	O
stories	O
were	O
then	O
assessed	O
against	O
the	O
practiced	O
emergency	O
risk	O
communication	O
(	O
ERC	B-COMP
)	O
activities	O
during	O
the	O
same	O
time	O
frame	O
.	O

We	O
conditionally	O
deleted	O
the	O
Abca3	O
gene	O
in	O
AT2	O
cells	B-COMP
in	O
the	O
mature	O
mouse	O
lung	O
.	O

TITLE	O
:	O
Physiological	O
and	O
molecular	O
triggers	O
for	O
SARS	O
-	O
CoV	O
membrane	B-COMP
fusion	O
and	O
entry	O
into	O
host	B-COMP
cells	B-COMP
.	O

One	O
of	O
the	O
proposed	O
mechanisms	O
involves	O
increased	O
adhesion	O
of	O
sickle	O
red	O
cells	B-COMP
to	O
pulmonary	O
microvasculature	O
in	O
the	O
presence	O
of	O
hypoxia	O
.	O

Respiratory	O
TAC	O
detected	O
nucleic	B-COMP
acid	O
for	O
24	O
different	O
microbial	O
agents	O
,	O
including	O
12	O
viruses	O
and	O
12	O
bacteria	O
.	O

TITLE	O
:	O
The	O
OC43	O
human	O
coronavirus	O
envelope	B-COMP
protein	O
is	O
critical	O
for	O
infectious	O
virus	O
production	O
and	O
propagation	O
in	O
neuronal	O
cells	B-COMP
and	O
is	O
a	O
determinant	O
of	O
neurovirulence	O
and	O
CNS	O
pathology	O
.	O

Making	O
use	O
of	O
recombinant	O
viruses	O
either	O
devoid	O
of	O
the	O
E	O
protein	O
or	O
harboring	O
mutations	O
either	O
in	O
putative	O
transmembrane	B-COMP
domain	O
or	O
PDZ	O
-	O
binding	O
motif	O
,	O
we	O
demonstrated	O
that	O
a	O
fully	O
functional	O
HCoV	O
-	O
OC43	O
E	O
protein	O
is	O
first	O
needed	O
for	O
optimal	O
production	O
of	O
recombinant	O
infectious	O
viruses	O
.	O

RPA	B-COMP
primers	O
and	O
LF	O
probes	O
were	O
designed	O
by	O
targeting	O
the	O
specific	O
G	O
gene	O
,	O
and	O
the	O
amplification	O
product	O
can	O
be	O
visualized	O
on	O
a	O
simple	O
lateral	O
flow	O
dipstick	O
with	O
the	O
naked	O
eyes	O
.	O

ABSTRACT	O
:	O
Rhabdomyolysis	O
is	O
a	O
syndrome	O
characterized	O
by	O
the	O
breakdown	O
of	O
skeletal	O
muscle	O
and	O
leakage	O
of	O
intracellular	B-COMP
myocyte	O
contents	O
,	O
such	O
as	O
creatine	O
phosphokinase	O
(	O
CPK	O
)	O
and	O
myoglobin	O
,	O
into	O
the	O
interstitial	O
space	O
and	O
plasma	O
resulting	O
in	O
acute	O
kidney	O
injury	O
(	O
AKI	O
).	O

Positive	O
hybridoma	O
cells	B-COMP
are	O
stained	O
using	O
a	O
fluorescently	O
labeled	O
anti	O
-	O
mouse	O
IgG	O
-	O
Fc	O
antibody	B-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
instituted	O
in	O
17	O
patients	O
;	O
15	O
of	O
these	O
patients	O
required	O
CRRT	O
.	O

Through	O
the	O
construction	O
of	O
recombinant	O
IBV	O
expressing	O
proteins	O
8a	O
,	O
8b	O
and	O
8ab	O
encoded	O
by	O
SARS	O
-	O
CoV	O
ORF8	O
,	O
we	O
demonstrate	O
that	O
expression	O
of	O
8b	O
and	O
8ab	O
enables	O
the	O
corresponding	O
recombinant	O
viruses	O
to	O
partially	O
overcome	O
the	O
inhibitory	O
actions	O
of	O
IFN	O
activation	O
to	O
achieve	O
higher	O
replication	O
efficiencies	O
in	O
cells	B-COMP
.	O

Our	O
results	O
show	O
that	O
the	O
M41	O
strain	O
of	O
IBV	O
induced	O
cytopathic	O
effects	O
followed	O
by	O
the	O
release	O
of	O
new	O
viral	B-COMP
particles	I-COMP
.	O

Elevated	O
numbers	O
of	O
apoptotic	O
cells	B-COMP
were	O
observed	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
post	O
-	O
infection	O
(	O
p	O
.	O
i	O
.).	O

TITLE	O
:	O
An	O
""""	O
Old	O
""""	O
protein	O
with	O
a	O
new	O
story	O
:	O
Coronavirus	O
endoribonuclease	O
is	O
important	O
for	O
evading	O
host	B-COMP
antiviral	O
defenses	O
.	O

TITLE	O
:	O
Hemorrhage	O
under	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
:	O
a	O
retrospective	O
data	O
analysis	O
.	O

Here	O
,	O
two	O
species	O
of	O
murine	O
malaria	O
,	O
the	O
lethal	O
Plasmodium	O
berghei	O
strain	O
NK65	O
and	O
self	O
-	O
healing	O
Plasmodium	O
chabaudi	O
strain	O
AS	O
which	O
differ	O
in	O
their	O
ability	O
to	O
cause	O
hepatopathy	O
and	O
/	O
or	O
ARDS	O
were	O
used	O
to	O
investigate	O
the	O
lipid	O
alterations	O
,	O
oxidative	O
damage	O
and	O
host	B-COMP
immune	O
response	O
during	O
the	O
infection	O
in	O
relation	O
to	O
parasite	O
load	O
and	O
accumulation	O
of	O
parasite	O
products	O
,	O
such	O
as	O
haemozoin	O
.	O

Western	O
blot	O
was	O
used	O
to	O
detect	O
the	O
protein	O
expression	O
of	O
collagen	B-COMP
-	O
1	O
.	O

Ventilatory	O
and	O
mechanical	O
parameters	O
,	O
arterial	O
blood	O
gases	O
,	O
diffuse	O
alveolar	O
damage	O
score	O
,	O
epithelial	O
integrity	O
measured	O
by	O
E	O
-	O
cadherin	O
tissue	O
expression	O
,	O
and	O
biological	O
markers	O
associated	O
with	O
inflammation	O
(	O
IL	O
-	O
6	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
,	O
CINC	O
-	O
1	O
)	O
and	O
type	O
II	O
epithelial	O
cell	B-COMP
damage	O
(	O
surfactant	O
protein	O
-	O
B	O
)	O
were	O
evaluated	O
.	O

Alteration	O
of	O
glial	O
-	O
pial	O
gap	B-COMP
junction	I-COMP
intercellular	O
communication	O
(	O
GJIC	O
)	O
in	O
MHV	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
the	O
integrity	O
of	O
BBB	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
MHV	O
infection	O
on	O
Cx43	O
localization	O
and	O
function	O
in	O
mouse	O
brain	O
meningeal	O
cells	B-COMP
and	O
primary	O
meningeal	O
fibroblasts	O
.	O

We	O
employ	O
structured	O
coalescent	O
models	O
to	O
show	O
that	O
long	O
-	O
term	O
MERS	O
-	O
CoV	O
evolution	O
occurs	O
exclusively	O
in	O
camels	O
,	O
whereas	O
humans	O
act	O
as	O
a	O
transient	O
,	O
and	O
ultimately	O
terminal	O
host	B-COMP
.	O

ABSTRACT	O
:	O
Convergent	O
evolution	O
dictates	O
that	O
diverse	O
groups	O
of	O
viruses	O
will	O
target	O
both	O
similar	O
and	O
distinct	O
host	B-COMP
pathways	O
to	O
manipulate	O
the	O
immune	O
response	O
and	O
improve	O
infection	O
.	O

Pseudovirus	O
assays	O
showed	O
that	O
HKU25	O
-	O
spike	O
can	O
use	O
hDPP4	O
for	O
entry	O
to	O
hDPP4	O
-	O
expressing	O
cells	B-COMP
,	O
although	O
with	O
lower	O
efficiency	O
than	O
that	O
of	O
MERS	O
-	O
spike	O
and	O
HKU4	O
-	O
spike	O
.	O

Bat	O
CoVs	O
exhibit	O
both	O
extensive	O
genetic	O
diversity	O
and	O
a	O
broad	O
geographic	O
range	O
,	O
indicative	O
of	O
a	O
long	O
-	O
standing	O
host	B-COMP
association	O
.	O

ABSTRACT	O
:	O
Patients	O
who	O
develop	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
despite	O
full	O
medical	O
management	O
may	O
require	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
ECMO	O
)	O
to	O
support	O
respiratory	O
function	O
.	O

Galectin	O
-	O
3	O
,	O
a	O
	O
-	O
galactoside	O
-	O
binding	O
protein	O
widely	O
distributed	O
in	O
immune	O
and	O
epithelial	O
cells	B-COMP
,	O
regulates	O
various	O
immune	O
functions	O
and	O
modulates	O
microbial	O
infections	O
.	O

In	O
wild	O
-	O
type	O
virus	O
infected	O
cells	B-COMP
,	O
4b	O
localized	O
to	O
the	O
nucleus	B-COMP
,	O
while	O
NF	O
-	O
B	O
was	O
retained	O
in	O
the	O
cytoplasm	B-COMP
.	O

In	O
contrast	O
,	O
in	O
the	O
absence	O
of	O
4b	O
or	O
in	O
the	O
presence	O
of	O
cytoplasmic	B-COMP
4b	O
mutants	O
lacking	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
),	O
NF	O
-	O
B	O
was	O
translocated	O
to	O
the	O
nucleus	B-COMP
leading	O
to	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Pigs	O
inoculated	O
with	O
PEDV	O
had	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
serum	B-COMP
haptoglobin	O
and	O
increased	O
insulin	O
-	O
to	O
-	O
glucose	O
ratios	O
compared	O
with	O
Control	O
pigs	O
at	O
dpi	O
5	O
.	O

During	O
this	O
hospitalization	O
,	O
the	O
clinical	O
picture	O
of	O
fever	O
,	O
cutaneous	O
rashes	O
,	O
lymphadenitis	O
,	O
hepatitis	O
,	O
leukopenia	O
,	O
anemia	O
,	O
hyperferritinemia	O
,	O
hypertriglyceridemia	O
,	O
high	O
level	O
of	O
auto	O
-	O
antibodies	B-COMP
,	O
and	O
low	O
NK	O
activity	O
suggested	O
an	O
hemophagocytic	O
lymphohistiocytosis	O
syndrome	O
,	O
even	O
if	O
bone	O
marrow	O
biopsy	O
was	O
negative	O
for	O
hemophagocytosis	O
.	O

Genome	O
-	O
wide	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
was	O
performed	O
in	O
Vero	O
E6	O
cells	B-COMP
post	O
-	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Maladaptive	O
role	O
of	O
neutrophil	O
extracellular	B-COMP
traps	O
in	O
pathogen	O
-	O
induced	O
lung	O
injury	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
recruitment	O
of	O
macrophages	O
and	O
the	O
production	O
of	O
IL	O
-	O
1	O
originating	O
from	O
macrophages	O
,	O
as	O
well	O
as	O
other	O
sources	O
,	O
occur	O
following	O
IBV	O
infection	O
in	O
the	O
respiratory	O
tract	O
suggesting	O
potential	O
roles	O
of	O
these	O
mediators	O
in	O
the	O
host	B-COMP
responses	O
to	O
IBV	O
infection	O
.	O

He	O
presented	O
with	O
severe	O
diarrhoea	O
86	O
days	O
post	O
BMT	O
and	O
was	O
diagnosed	O
with	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
(	O
GVHD	O
)	O
based	O
on	O
skin	O
and	O
rectal	O
biopsies	O
.	O

High	O
amounts	O
of	O
RSV	O
type	O
B	O
RNA	O
was	O
detected	O
in	O
tracheal	O
aspirates	O
and	O
serum	B-COMP
sample	O
.	O

In	O
such	O
dogs	O
,	O
presence	O
of	O
peripheral	O
blood	O
nucleated	O
red	O
blood	O
cells	B-COMP
uniquely	O
occurs	O
,	O
and	O
is	O
a	O
highly	O
sensitive	O
diagnostic	O
and	O
prognostic	O
biomarker	O
.	O

The	O
resultant	O
stapled	O
peptide	O
P21S10	O
could	O
effectively	O
inhibit	O
infection	O
by	O
MERS	O
-	O
CoV	O
pseudovirus	O
and	O
its	O
spike	O
protein	O
-	O
mediated	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
;	O
additionally	O
,	O
P21S10	O
exhibits	O
improved	O
pharmacokinetic	O
properties	O
than	O
HR2P	O
-	O
M2	O
,	O
suggesting	O
strong	O
potential	O
for	O
development	O
as	O
an	O
anti	O
-	O
MERS	O
-	O
CoV	O
therapeutic	O
.	O

Human	O
postmortem	O
lung	O
tissue	O
,	O
pneumolysin	O
-	O
or	O
angiopoietin	O
-	O
2	O
-	O
stimulated	O
endothelial	O
cells	B-COMP
,	O
isolated	O
perfused	O
and	O
ventilated	O
mouse	O
lungs	O
,	O
and	O
mice	O
with	O
pneumococcal	O
pneumonia	O
were	O
investigated	O
.	O

In	O
patients	O
with	O
pneumonia	O
,	O
decreased	O
serum	B-COMP
angiopoietin	O
-	O
1	O
and	O
increased	O
angiopoietin	O
-	O
2	O
levels	O
were	O
observed	O
as	O
compared	O
with	O
healthy	O
subjects	O
.	O

Future	O
directions	O
to	O
address	O
some	O
of	O
these	O
challenges	O
to	O
better	O
understand	O
host	B-COMP
-	O
pathogen	O
interactions	O
in	O
these	O
intriguing	O
mammals	O
are	O
also	O
discussed	O
,	O
not	O
only	O
in	O
relation	O
to	O
viruses	O
but	O
also	O
other	O
pathogens	O
carried	O
by	O
bats	O
including	O
bacteria	O
and	O
fungi	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
is	O
an	O
inammatory	O
disease	O
characterized	O
by	O
dysfunction	O
of	O
pulmonary	O
epithelial	O
and	O
capillary	O
endothelial	O
cells	B-COMP
,	O
infiltration	O
of	O
alveolar	O
macrophages	O
and	O
neutrophils	O
,	O
cell	B-COMP
apoptosis	O
,	O
necroptosis	O
,	O
NETosis	O
,	O
and	O
fibrosis	O
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
labour	O
induction	O
during	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
support	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
influenza	O
and	O
review	O
of	O
the	O
literature	O
.	O

However	O
,	O
the	O
precise	O
mechanism	O
of	O
H5N1	O
infection	O
eliciting	O
the	O
unique	O
host	B-COMP
response	O
are	O
still	O
not	O
well	O
understood	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
distinct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
resident	O
cells	B-COMP
to	O
protective	O
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
	O
/	O
	O
)	O
function	O
following	O
viral	O
infections	O
is	O
poorly	O
understood	O
.	O

This	O
coronavirus	O
has	O
been	O
widely	O
distributed	O
among	O
laboratories	O
and	O
has	O
been	O
passaged	O
both	O
within	O
pigs	O
and	O
in	O
cell	B-COMP
culture	O
.	O

To	O
address	O
this	O
need	O
,	O
we	O
are	O
developing	O
a	O
subunit	O
recombinant	O
protein	O
vaccine	O
comprising	O
residues	O
377	O
-	O
588	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
,	O
when	O
formulated	O
with	O
the	O
AddaVax	O
adjuvant	O
,	O
it	O
induces	O
a	O
significant	O
neutralizing	O
antibody	B-COMP
response	O
and	O
protection	O
against	O
MERS	O
-	O
CoV	O
challenge	O
in	O
vaccinated	O
animals	O
.	O

The	O
adCHO	O
-	O
expressed	O
S377	O
-	O
588	O
-	O
Fc	O
recombinant	O
protein	O
demonstrated	O
functionality	O
and	O
binding	O
specificity	O
identical	O
to	O
those	O
of	O
the	O
protein	O
from	O
transiently	O
transfected	O
HEK293T	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Bats	O
are	O
a	O
unique	O
group	O
of	O
mammals	O
well	O
suited	O
to	O
be	O
hosts	B-COMP
for	O
emerging	O
viruses	O
.	O

We	O
found	O
that	O
nano	O
silicon	O
applied	O
with	O
inactivated	O
TGEV	O
vaccine	O
induced	O
high	O
antibody	B-COMP
titers	O
,	O
increase	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
	O
and	O
IFN	O
-	O
	O
expression	O
,	O
and	O
stimulate	O
CD3	O
+	O
T	O
cell	B-COMP
proliferation	O
with	O
a	O
high	O
CD4	O
+/	O
CD8	O
+	O
T	O
lymphocyte	O
ratio	O
.	O

SiRNA	O
-	O
knockdown	O
of	O
pAPN	O
in	O
porcine	O
jejunum	O
epithelial	O
cells	B-COMP
had	O
no	O
effects	O
on	O
PEDV	O
infection	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
we	O
developed	O
a	O
monoclonal	O
antibody	B-COMP
-	O
based	O
rapid	O
nucleocapsid	B-COMP
protein	O
detection	O
assay	O
for	O
diagnosis	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
humans	O
and	O
dromedary	O
camels	O
.	O

The	O
highest	O
antibody	B-COMP
levels	O
were	O
also	O
detected	O
in	O
the	O
group	O
infected	O
with	O
an	O
isolate	O
from	O
the	O
pigeon	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
immune	O
cells	B-COMP
present	O
in	O
different	O
forms	O
of	O
feline	O
anterior	O
uveitis	O
.	O

Heterogeneous	O
nuclear	O
ribonucleoprotein	B-COMP
A1	O
(	O
hnRNP	O
A1	O
)	O
is	O
a	O
cellular	B-COMP
protein	O
participating	O
in	O
the	O
splicing	O
of	O
pre	O
-	O
mRNA	O
in	O
the	O
nucleus	B-COMP
and	O
translation	O
regulation	O
in	O
the	O
cytoplasm	B-COMP
.	O

Two	O
reaction	O
mixtures	O
(	O
Isothermal	O
Mastermix	O
,	O
OptiGene	O
Ltd	O
.	O
and	O
PCRun	O
	O
Molecular	O
Detection	O
Mix	O
,	O
Biogal	O
)	O
were	O
tested	O
using	O
the	O
same	O
primers	O
,	O
which	O
were	O
designed	O
to	O
bind	O
to	O
a	O
conserved	O
region	O
of	O
the	O
FCoV	O
membrane	B-COMP
protein	O
gene	O
.	O

The	O
results	O
indicate	O
that	O
acute	O
CS	O
exposure	O
enhances	O
the	O
recruitment	O
of	O
immune	O
cells	B-COMP
to	O
the	O
lung	O
during	O
bacterial	O
pneumonia	O
,	O
an	O
effect	O
that	O
may	O
provide	O
microbiological	O
benefit	O
but	O
simultaneously	O
exposes	O
the	O
mice	O
to	O
more	O
severe	O
inflammatory	O
lung	O
injury	O
.	O

This	O
report	O
summarizes	O
the	O
working	O
group	O
'	O
s	O
specific	O
recommendations	O
in	O
the	O
areas	O
of	O
pneumonia	O
susceptibility	O
,	O
host	B-COMP
response	O
,	O
and	O
consequences	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
and	O
indirect	O
immunofluorescence	O
assay	O
indicated	O
that	O
LiCl	O
effectively	O
inhibited	O
the	O
entry	O
and	O
replication	O
of	O
PEDV	O
in	O
Vero	O
cells	B-COMP
.	O

The	O
assay	O
performance	O
was	O
evaluated	O
by	O
testing	O
76	O
clinical	O
samples	O
by	O
RT	O
-	O
RPA	B-COMP
and	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Fourteen	O
samples	O
were	O
TGEV	O
RNA	O
positive	O
in	O
RT	O
-	O
RPA	B-COMP
(	O
18	O
.	O
4	O
%,	O
14	O
/	O
76	O
),	O
which	O
were	O
also	O
positive	O
in	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Blood	B-COMP
serum	I-COMP
samples	O
were	O
tested	O
by	O
an	O
electrophoretic	O
method	O
for	O
the	O
assessment	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
concentration	O
,	O
whereas	O
fecal	O
samples	O
were	O
submitted	O
to	O
ELISA	O
test	O
for	O
positivity	O
to	O
Escherichia	O
coli	O
K99	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
Cryptosporidium	O
spp	O
.	O

We	O
have	O
determined	O
that	O
EV	O
-	O
D68	O
induces	O
autophagic	O
signaling	O
and	O
membrane	B-COMP
formation	O
.	O

While	O
chloroquine	O
was	O
not	O
active	O
in	O
these	O
primary	O
cells	B-COMP
,	O
chlorpromazine	O
showed	O
strong	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
,	O
but	O
it	O
was	O
associated	O
with	O
high	O
cytotoxicity	O
narrowing	O
the	O
potential	O
window	O
for	O
drug	O
utilization	O
.	O

Additionally	O
,	O
Neoromicia	O
capensis	O
have	O
previously	O
been	O
identified	O
as	O
potential	O
hosts	B-COMP
for	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
related	O
coronaviruses	O
.	O

The	O
smaller	O
size	O
of	O
the	O
medulla	O
in	O
the	O
coronavirus	O
-	O
infected	O
birds	O
may	O
lead	O
to	O
a	O
lower	O
number	O
of	O
B	O
lymphocytes	O
and	O
bursal	O
secretory	O
dendritic	B-COMP
cells	B-COMP
,	O
which	O
negatively	O
affects	O
the	O
reactivity	O
and	O
efficacy	O
of	O
the	O
immune	O
system	O
.	O

The	O
Human	O
Antiviral	O
Response	O
PCR	O
array	O
was	O
used	O
to	O
profile	O
the	O
antiviral	O
gene	O
expression	O
in	O
HEK	O
-	O
293	O
cells	B-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
applied	O
successfully	O
to	O
other	O
severe	O
fungal	O
pneumonia	O
associated	O
with	O
ARDS	O
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stem	O
cells	B-COMP
(	O
MSCs	O
)	O
have	O
attracted	O
attention	O
as	O
a	O
potential	O
therapy	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
).	O

In	O
this	O
test	O
,	O
the	O
recombinant	O
nucleocapsid	B-COMP
protein	O
of	O
PEDV	O
was	O
expressed	O
in	O
soluble	O
form	O
and	O
purified	O
by	O
using	O
Ni	O
-	O
NTA	O
resin	O
and	O
gel	O
filtration	O
chromatography	O
.	O

Staphylococcal	O
protein	O
A	O
and	O
rabbit	O
anti	O
-	O
N	O
protein	O
IgG	O
were	O
blotted	O
on	O
a	O
nitrocellulose	O
membrane	B-COMP
for	O
the	O
test	O
and	O
control	O
lines	O
,	O
respectively	O
.	O

PVP	O
-	O
I	O
7	O
%	O
gargle	O
/	O
mouthwash	O
was	O
diluted	O
1	O
:	O
30	O
with	O
water	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
(	O
the	O
recommended	O
concentration	O
for	O
""""	O
real	O
-	O
life	O
""""	O
use	O
in	O
Japan	O
)	O
and	O
tested	O
at	O
room	O
temperature	O
under	O
clean	O
conditions	O
[	O
0	O
.	O
3	O
g	O
/	O
l	O
bovine	O
serum	B-COMP
albumin	O
(	O
BSA	O
),	O
viruses	O
only	O
]	O
and	O
dirty	O
conditions	O
(	O
3	O
.	O
0	O
g	O
/	O
l	O
BSA	O
+	O
3	O
.	O
0	O
ml	O
/	O
l	O
erythrocytes	O
)	O
as	O
an	O
interfering	O
substance	O
for	O
defined	O
contact	O
times	O
(	O
minimum	O
15	O
s	O
).	O

pAPN	O
knockout	O
in	O
IPI	O
-	O
2I	O
cells	B-COMP
completely	O
blocked	O
TGEV	O
infection	O
but	O
only	O
slightly	O
decreased	O
PDCoV	O
infection	O
.	O

IBV	O
-	O
CS	O
vaccine	O
administered	O
alone	O
resulted	O
in	O
markedly	O
mucosal	O
immune	O
responses	O
,	O
characterized	O
by	O
high	O
levels	O
of	O
anti	O
-	O
IBV	O
IgA	O
isotype	O
antibodies	B-COMP
and	O
IFN	O
gene	O
expression	O
at	O
1dpi	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanism	O
of	O
deaminase	O
-	O
dependent	O
inhibition	O
of	O
coronavirus	O
replication	O
remains	O
elusive	O
,	O
our	O
results	O
further	O
our	O
understanding	O
of	O
APOBEC	B-COMP
-	O
mediated	O
restriction	O
of	O
RNA	O
virus	O
infections	O
.	O

Previously	O
reported	O
cases	O
of	O
multiple	O
mitochondrial	B-COMP
dysfunctions	O
syndrome	O
2	O
(	O
MMDS2	O
)	O
with	O
hyperglycinaemia	O
caused	O
by	O
BOLA3	O
mutations	O
have	O
leukodystrophy	O
with	O
severe	O
,	O
progressive	O
neurological	O
and	O
multisystem	O
disease	O
.	O

Dromedary	O
camels	O
are	O
considered	O
as	O
potential	O
reservoirs	O
for	O
the	O
virus	O
and	O
seem	O
to	O
be	O
the	O
only	O
animal	O
host	B-COMP
which	O
may	O
transmit	O
the	O
infection	O
to	O
human	O
.	O

The	O
conversion	O
of	O
alpha	O
-	O
linolenic	O
acid	O
(	O
ALA	O
)	O
to	O
timodonic	O
(	O
EPA	O
)	O
and	O
cervonic	O
(	O
DHA	O
)	O
acids	O
were	O
lower	O
compared	O
to	O
controls	O
,	O
and	O
together	O
with	O
high	O
levels	O
of	O
myristic	O
,	O
palmitic	O
and	O
palmitoleic	O
acids	O
was	O
associated	O
with	O
the	O
higher	O
proliferation	O
and	O
lower	O
apoptosis	O
in	O
the	O
primordial	O
,	O
primary	O
and	O
secondary	O
follicles	O
;	O
although	O
the	O
inhibition	O
of	O
the	O
cell	B-COMP
cycle	O
was	O
observed	O
in	O
relation	O
to	O
the	O
low	O
level	O
of	O
eicosadienoic	O
acid	O
.	O

Our	O
study	O
showed	O
that	O
complement	O
was	O
excessively	O
activated	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
hDPP4	O
-	O
Tg	O
mice	O
through	O
observations	O
of	O
increased	O
concentrations	O
of	O
the	O
C5a	O
and	O
C5b	O
-	O
9	O
complement	O
activation	O
products	O
in	O
sera	B-COMP
and	O
lung	O
tissues	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
have	O
a	O
wide	O
host	B-COMP
range	O
and	O
can	O
cause	O
a	O
variety	O
of	O
diseases	O
with	O
varying	O
severity	O
in	O
different	O
animals	O
.	O

ABSTRACT	O
:	O
Autophagy	O
signaling	O
pathway	O
is	O
involved	O
in	O
cellular	B-COMP
homeostasis	O
,	O
developmental	O
processes	O
,	O
cellular	B-COMP
stress	O
responses	O
,	O
and	O
immune	O
pathways	O
.	O

TITLE	O
:	O
Survival	O
of	O
Patients	O
With	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Treated	O
Without	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
.	O

We	O
found	O
that	O
the	O
virus	O
employs	O
caveolin	O
-	O
1	O
dependent	O
endocytosis	O
for	O
the	O
entry	O
and	O
the	O
scission	O
of	O
virus	O
-	O
containing	O
vesicles	B-COMP
from	O
the	O
cell	B-COMP
surface	I-COMP
is	O
dynamin	O
-	O
dependent	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
ectopic	O
expression	O
of	O
NS6	O
antagonizes	O
IFN	O
-	O
	O
production	O
by	O
interfering	O
with	O
the	O
binding	O
of	O
RIG	O
-	O
I	O
/	O
MDA5	O
to	O
double	O
-	O
stranded	O
RNA	O
,	O
revealing	O
a	O
new	O
strategy	O
employed	O
by	O
PDCoV	O
accessory	O
proteins	O
to	O
counteract	O
the	O
host	B-COMP
innate	O
antiviral	O
immune	O
response	O
.	O

We	O
applied	O
single	O
-	O
cell	B-COMP
cytometry	O
TOF	O
(	O
CyTOF	O
)	O
to	O
simultaneously	O
measure	O
36	O
cell	B-COMP
-	O
surface	O
markers	O
on	O
CD45	O
+	O
cells	B-COMP
present	O
in	O
bronchoalveolar	O
lavage	O
from	O
healthy	O
volunteers	O
,	O
as	O
well	O
as	O
mechanically	O
ventilated	O
subjects	O
with	O
and	O
without	O
ARDS	O
.	O

Visualization	O
of	O
the	O
high	O
-	O
dimensional	O
data	O
with	O
the	O
t	O
-	O
distributed	O
stochastic	O
neighbor	O
embedding	O
algorithm	O
demonstrated	O
wide	O
diversity	O
of	O
cell	B-COMP
-	O
surface	O
marker	O
profiles	O
among	O
CD33	O
+	O
CD71	O
+	O
CD163	O
+	O
AMs	O
.	O

ABSTRACT	O
:	O
The	O
primary	O
objective	O
of	O
this	O
randomized	O
controlled	O
trial	O
was	O
to	O
determine	O
whether	O
anti	O
-	O
IL	O
-	O
10	O
egg	O
yolk	B-COMP
antibodies	B-COMP
fed	O
upon	O
arrival	O
to	O
a	O
calf	O
ranch	O
would	O
lower	O
the	O
prevalence	O
of	O
Cryptosporidium	O
parvum	O
shedding	O
in	O
naturally	O
challenged	O
preweaned	O
dairy	O
calves	O
.	O

In	O
vitro	O
,	O
the	O
experiments	O
revealed	O
that	O
PFD	O
significantly	O
suppressed	O
LPS	O
/	O
ATP	O
-	O
induced	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
decreased	O
caspase	O
-	O
1	O
activation	O
and	O
the	O
level	O
of	O
IL	O
-	O
1	O
in	O
J774	O
A	O
.	O
1	O
cells	B-COMP
.	O

Additionally	O
,	O
a	O
cyclopropylquinoline	O
derivative	O
IV	O
has	O
been	O
screened	O
for	O
60	O
human	O
cancer	O
cell	B-COMP
lines	O
using	O
the	O
Development	O
Therapeutics	O
Program	O
(	O
DTP	O
)	O
of	O
NCI	O
.	O

Additionally	O
,	O
cyclopropylquinoline	O
derivative	O
IV	O
has	O
displayed	O
very	O
good	O
cytotoxicity	O
against	O
colon	O
,	O
breast	O
and	O
leukemia	O
cell	B-COMP
lines	O
in	O
vitro	O
.	O

The	O
assembly	O
of	O
the	O
viral	B-COMP
genome	I-COMP
into	O
virus	B-COMP
particles	I-COMP
involves	O
viral	O
structural	O
proteins	O
and	O
is	O
believed	O
to	O
be	O
mediated	O
through	O
recognition	O
of	O
specific	O
sequences	O
and	O
RNA	O
structures	O
of	O
the	O
viral	B-COMP
genome	I-COMP
.	O

Peptide	O
C6	O
containing	O
the	O
Cluster	O
I	O
consensus	O
sequence	O
was	O
shown	O
to	O
oligomerize	O
and	O
form	O
amyloid	O
-	O
like	O
fibrils	B-COMP
.	O

Infection	O
by	O
its	O
causative	O
agent	O
PED	O
virus	O
(	O
PEDV	O
),	O
an	O
Alpha	O
-	O
coronavirus	O
,	O
was	O
previously	O
proven	O
to	O
be	O
mediated	O
by	O
its	O
spike	O
(	O
S	O
)	O
glycoprotein	O
and	O
a	O
cellular	B-COMP
receptor	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
).	O

Although	O
this	O
study	O
cannot	O
rule	O
out	O
potential	O
antibody	B-COMP
cross	O
-	O
reactivity	O
by	O
IFA	O
,	O
the	O
presence	O
of	O
bovine	O
coronavirus	O
-	O
specific	O
antibodies	B-COMP
do	O
not	O
appear	O
to	O
impact	O
detection	O
of	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
by	O
Mnt	O
.	O

To	O
prepare	O
a	O
candidate	O
vaccine	O
against	O
the	O
prevalent	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
China	O
,	O
the	O
GI	O
-	O
19	O
/	O
QX	O
-	O
like	O
field	O
isolate	O
Sczy3	O
was	O
selected	O
as	O
the	O
progenitor	O
strain	O
and	O
attenuated	O
via	O
passaging	O
in	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	B-COMP
for	O
100	O
times	O
.	O

We	O
then	O
showed	O
that	O
Ulk1	O
forms	O
a	O
multiprotein	O
complex	O
with	O
TrkA	O
and	O
the	O
early	B-COMP
endosome	I-COMP
marker	O
Rab5	O
and	O
that	O
Ulk1	O
defects	O
lead	O
to	O
either	O
blocking	O
of	O
NGF	O
/	O
TrkA	O
endocytosis	O
or	O
premature	O
degradation	O
of	O
pTrkA	O
via	O
constitutive	O
activation	O
of	O
the	O
Rab5	O
GTPase	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
higher	O
serum	B-COMP
creatinine	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
lower	O
estimated	O
creatinine	O
clearance	O
(	O
P	O
<	O
.	O
001	O
)	O
compared	O
with	O
those	O
without	O
AKI	O
.	O

TITLE	O
:	O
Insight	O
into	O
the	O
evolution	O
of	O
nidovirus	O
endoribonuclease	O
based	O
on	O
the	O
finding	O
that	O
nsp15	O
from	O
porcine	O
ABSTRACT	O
:	O
Nidovirus	O
endoribonucleases	O
(	O
NendoUs	O
)	O
include	O
nonstructural	O
protein	O
15	O
(	O
nsp15	O
)	O
from	O
coronaviruses	O
and	O
nsp11	O
from	O
arteriviruses	O
,	O
both	O
of	O
which	O
have	O
been	O
reported	O
to	O
participate	O
in	O
the	O
viral	O
replication	O
process	O
and	O
in	O
the	O
evasion	O
of	O
the	O
host	B-COMP
immune	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
membrane	B-COMP
-	O
associated	O
78	O
-	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP78	O
)	O
as	O
an	O
additional	O
binding	O
target	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
.	O

Venous	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
has	O
been	O
implemented	O
in	O
various	O
cases	O
of	O
ARDS	O
to	O
provide	O
support	O
and	O
allow	O
for	O
protective	O
lung	O
ventilation	O
strategies	O
.	O

TITLE	O
:	O
Revisiting	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
ARDS	O
in	O
burns	O
:	O
A	O
case	O
series	O
and	O
review	O
of	O
the	O
literature	O
.	O

The	O
number	O
of	O
SIgA	O
positive	O
cells	B-COMP
,	O
CD3	O
TGEV	O
infection	O
damages	O
the	O
small	O
intestine	O
,	O
impairs	O
immune	O
functions	O
,	O
and	O
increases	O
pathogenic	O
bacterial	O
loading	O
,	O
all	O
of	O
which	O
may	O
facilitate	O
secondary	O
infections	O
by	O
other	O
pathogens	O
.	O

The	O
number	O
of	O
SIgA	O
positive	O
cells	B-COMP
,	O
CD3	O

By	O
using	O
in	O
vivo	O
studies	O
in	O
mice	O
and	O
in	O
vitro	O
studies	O
in	O
cells	B-COMP
,	O
we	O
demonstrated	O
that	O
an	O
airway	O
injection	O
of	O
TCs	O
can	O
reduce	O
the	O
pulmonary	O
inflammatory	O
response	O
and	O
improve	O
the	O
lung	O
function	O
in	O
mice	O
with	O
VILI	O
and	O
promote	O
the	O
proliferation	O
of	O
pulmonary	O
vascular	O
endothelial	O
cells	B-COMP
.	O

However	O
,	O
the	O
mechanisms	O
of	O
the	O
dimerization	O
and	O
nucleic	B-COMP
acid	O
binding	O
of	O
nsp9	O
remain	O
elusive	O
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
PDCoV	O
infection	O
stimulates	O
MOMP	O
either	O
via	O
Bax	O
recruitment	O
or	O
MPTP	O
opening	O
to	O
permit	O
the	O
release	O
of	O
apoptogenic	O
cyt	O
c	O
into	O
the	O
cytoplasm	B-COMP
,	O
thereby	O
leading	O
to	O
execution	O
of	O
the	O
caspase	O
-	O
dependent	O
intrinsic	O
apoptosis	O
pathway	O
to	O
facilitate	O
viral	O
replication	O
in	O
vitro	O
.	O

The	O
amount	O
of	O
IL	O
-	O
1	O
beta	O
,	O
in	O
supernatants	O
of	O
co	O
-	O
infected	O
cell	B-COMP
cultures	O
,	O
was	O
determined	O
using	O
an	O
ELISA	O
assay	O
.	O

Patients	O
with	O
tonsillar	O
hypertrophy	O
were	O
younger	O
,	O
smoked	O
less	O
often	O
,	O
had	O
less	O
pollen	O
allergy	O
and	O
had	O
more	O
adenovirus	O
,	O
bocavirus	O
-	O
1	O
,	O
coronavirus	O
and	O
rhinovirus	O
in	O
nasopharynx	O
(	O
all	O
Intratonsillar	O
T	O
cell	B-COMP
and	O
interferon	O
gene	O
expressions	O
appeared	O
to	O
be	O
relatively	O
stable	O
for	O
both	O
tonsillar	O
hypertrophy	O
and	O
recurrent	O
tonsillitis	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
analyze	O
the	O
Variable	O
Number	O
of	O
Tandem	O
Repeats	O
(	O
VNTRs	O
)	O
of	O
IL1RA	O
gene	O
polymorphism	O
and	O
ELISA	O
test	O
to	O
detect	O
serum	B-COMP
levels	O
of	O
IL1RA	O
.	O

At	O
day	O
10	O
,	O
17	O
,	O
24	O
,	O
31	O
,	O
38	O
,	O
and	O
45	O
,	O
the	O
serum	B-COMP
IBV	O
antibody	B-COMP
titers	O
were	O
tested	O
.	O

However	O
,	O
studies	O
reporting	O
organelle	B-COMP
dynamics	O
upon	O
viral	O
infections	O
are	O
scant	O
.	O

Our	O
results	O
also	O
showed	O
that	O
piglets	O
in	O
the	O
S	O
-	O
Bac	O
group	O
elicited	O
superior	O
PEDV	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
than	O
those	O
of	O
the	O
S1	O
-	O
Bac	O
and	O
control	O
groups	O
.	O

Three	O
hundred	O
and	O
seventy	O
-	O
five	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
132	O
Slovenian	O
small	O
,	O
one	O
-	O
site	O
pig	O
farms	O
.	O

Samples	O
were	O
tested	O
for	O
PEDV	O
antibodies	B-COMP
utilising	O
three	O
different	O
serological	O
methods	O
:	O
commercially	O
-	O
available	O
indirect	O
ELISA	O
,	O
in	O
-	O
house	O
blocking	O
ELISA	O
test	O
and	O
Immunoperoxidase	O
Monolayer	O
Assay	O
(	O
IPMA	O
)	O
test	O
.	O

TITLE	O
:	O
Canine	O
respiratory	O
coronavirus	O
employs	O
caveolin	O
-	O
1	O
-	O
mediated	O
pathway	O
for	O
internalization	O
to	O
HRT	O
-	O
18G	O
cells	B-COMP
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
Flammulina	O
velutipes	O
mushroom	O
waste	O
(	O
FVW	O
)	O
on	O
performance	O
,	O
immune	O
response	O
and	O
serum	B-COMP
immunity	O
in	O
growing	O
layer	O
hens	O
.	O

Cytopathic	O
effects	O
(	O
CPE	O
)	O
that	O
consisted	O
of	O
enlarged	O
and	O
rounded	O
cells	B-COMP
followed	O
by	O
cell	B-COMP
shrinkage	O
and	O
detachment	O
,	O
were	O
identified	O
by	O
the	O
3rd	O
viral	O
passage	O
in	O
the	O
IPEC	O
-	O
J2	O
cells	B-COMP
.	O

By	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
PDCoV	O
antigen	O
-	O
positive	O
IPEC	O
-	O
J2	O
cells	B-COMP
failed	O
to	O
show	O
TUNEL	O
-	O
positive	O
signals	O
,	O
indicating	O
that	O
PDCoV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	B-COMP
may	O
not	O
undergo	O
apoptosis	O
,	O
but	O
rather	O
necrosis	O
,	O
similar	O
to	O
necrotic	O
cell	B-COMP
death	O
of	O
infected	O
enterocytes	O
in	O
vivo	O
.	O

The	O
results	O
showed	O
that	O
the	O
swine	O
epidemic	O
diarrhea	O
virus	O
infection	O
had	O
a	O
significant	O
impact	O
on	O
the	O
level	O
of	O
miRNA	O
expression	O
in	O
PK	O
-	O
15	O
cells	B-COMP
,	O
thus	O
providing	O
a	O
new	O
idea	O
for	O
the	O
further	O
study	O
of	O
the	O
miRNA	O
preparation	O
for	O
the	O
treatment	O
of	O
PEDV	O
.	O

This	O
mechanism	O
provides	O
a	O
valuable	O
addition	O
for	O
the	O
combined	O
use	O
of	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

PEDV	O
-	O
positive	O
samples	O
were	O
inoculated	O
in	O
Vero	O
cells	B-COMP
with	O
different	O
concentrations	O
of	O
trypsin	O
.	O

TITLE	O
:	O
The	O
S2	O
Subunit	O
of	O
Infectious	O
Bronchitis	O
Virus	O
Beaudette	O
Is	O
a	O
Determinant	O
of	O
Cellular	B-COMP
Tropism	O
.	O

We	O
found	O
that	O
the	O
furin	O
inhibitor	O
dec	O
-	O
RVKR	O
-	O
CMK	O
blocked	O
entry	O
of	O
MERS	O
-	O
CoV	O
harboring	O
an	O
S	O
protein	O
lacking	O
furin	O
cleavage	O
sites	O
;	O
it	O
even	O
blocked	O
entry	O
into	O
furin	O
-	O
deficient	O
LoVo	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
specific	O
pathogen	O
-	O
free	O
chicks	O
were	O
vaccinated	O
with	O
the	O
commercial	O
live	O
vaccines	O
H120	O
,	O
4	O
/	O
91	O
and	O
LDT3	O
-	O
A	O
.	O
Blood	O
samples	O
were	O
collected	O
at	O
weekly	O
intervals	O
for	O
the	O
detection	O
of	O
IBV	O
-	O
specific	O
antibodies	B-COMP
and	O
quantification	O
of	O
CD4	O

TITLE	O
:	O
Hepatitis	O
C	O
virus	O
enters	O
liver	O
cells	B-COMP
using	O
the	O
CD81	O
receptor	B-COMP
complex	I-COMP
proteins	O
calpain	O
-	O
5	O
and	O
CBLB	O
.	O

Our	O
findings	O
reveal	O
a	O
comprehensive	O
CD81	O
network	O
in	O
human	O
liver	O
cells	B-COMP
and	O
show	O
that	O
HCV	O
and	O
Plasmodium	O
highjack	O
selective	O
CD81	O
interactions	O
,	O
including	O
CAPN5	O
and	O
CBLB	O
for	O
HCV	O
,	O
to	O
invade	O
cells	B-COMP
.	O

Surprisingly	O
,	O
combination	O
therapy	O
did	O
not	O
reduce	O
the	O
production	O
of	O
cytokines	O
and	O
chemokines	O
in	O
the	O
lungs	O
,	O
demonstrating	O
that	O
inflammatory	O
cells	B-COMP
,	O
rather	O
than	O
hypercytokinemia	O
,	O
are	O
the	O
direct	O
target	O
of	O
these	O
compounds	O
and	O
primary	O
cause	O
of	O
ARDS	O
-	O
related	O
death	O
.	O

Notably	O
,	O
tractable	O
mouse	O
genetics	O
combined	O
with	O
hCoV	O
reverse	O
genetic	O
systems	O
has	O
afforded	O
the	O
concomitant	O
manipulation	O
of	O
virus	O
and	O
host	B-COMP
genetics	O
to	O
evaluate	O
virus	O
-	O
host	B-COMP
interaction	O
networks	O
in	O
disease	O
.	O

Although	O
we	O
recognize	O
that	O
results	O
obtained	O
in	O
robust	O
mouse	O
models	O
require	O
evaluation	O
in	O
non	O
-	O
human	O
primates	O
,	O
we	O
focus	O
this	O
review	O
on	O
the	O
current	O
state	O
of	O
hCoV	O
mouse	O
models	O
,	O
their	O
use	O
as	O
tractable	O
complex	O
genetic	O
organisms	O
for	O
untangling	O
complex	O
hCoV	O
-	O
host	B-COMP
interactions	O
,	O
and	O
as	O
pathogenesis	O
models	O
for	O
preclinical	O
evaluation	O
of	O
novel	O
therapeutic	O
interventions	O
.	O

Virus	O
-	O
specific	O
T	O
cells	B-COMP
were	O
examined	O
by	O
intracellular	B-COMP
cytokine	O
staining	O
after	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
with	O
overlapping	O
peptides	O
spanning	O
whole	O
virus	O
structural	O
proteins	O
.	O

Distinctively	O
high	O
frequencies	O
of	O
MERS	O
coronavirus	O
-	O
reactive	O
CD8	O
+	O
T	O
cells	B-COMP
were	O
also	O
observed	O
in	O
patients	O
with	O
severe	O
/	O
moderate	O
illness	O
,	O
whereas	O
antibody	B-COMP
and	O
CD4	O
+	O
T	O
-	O
cell	B-COMP
responses	O
were	O
minimally	O
detected	O
at	O
this	O
stage	O
.	O

While	O
CD8	O
+	O
T	O
cells	B-COMP
responded	O
preferentially	O
to	O
the	O
viral	O
S	O
protein	O
compared	O
with	O
E	O
/	O
M	O
/	O
N	O
proteins	O
,	O
especially	O
at	O
the	O
acute	O
stage	O
,	O
slightly	O
more	O
CD4	O
+	O
T	O
cells	B-COMP
recognized	O
E	O
/	O
M	O
/	O
N	O
proteins	O
compared	O
with	O
S	O
protein	O
at	O
the	O
convalescent	O
phase	O
.	O

Our	O
findings	O
show	O
an	O
association	O
between	O
the	O
early	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
response	O
and	O
the	O
severity	O
of	O
the	O
infection	O
,	O
and	O
also	O
provide	O
basic	O
information	O
that	O
may	O
help	O
to	O
prepare	O
effective	O
control	O
strategies	O
for	O
MERS	O
in	O
humans	O
.	O

BTM	O
samples	O
were	O
collected	O
from	O
1148	O
study	O
herds	O
in	O
West	O
Norway	O
in	O
2013	O
and	O
2016	O
,	O
and	O
these	O
were	O
analyzed	O
for	O
BRSV	O
and	O
BCV	O
antibodies	B-COMP
.	O

Reverse	O
genetics	O
systems	O
established	O
previously	O
for	O
serotype	O
I	O
and	O
the	O
less	O
common	O
serotype	O
II	O
FCoVs	O
were	O
based	O
on	O
cell	B-COMP
culture	O
-	O
adapted	O
FIPV	O
strains	O
which	O
,	O
however	O
,	O
were	O
shown	O
to	O
be	O
unsuitable	O
for	O
FIP	O
pathogenesis	O
studies	O

Infiltration	O
of	O
activated	O
lymphocytes	O
and	O
myeloid	O
cells	B-COMP
are	O
thought	O
to	O
be	O
primarily	O
responsible	O
for	O
white	O
matter	O
damage	O
and	O
axonopathy	O
.	O

In	O
recent	O
years	O
,	O
there	O
has	O
been	O
increasing	O
evidence	O
that	O
some	O
kinds	O
of	O
stem	O
cells	B-COMP
and	O
their	O
derivatives	O
seem	O
to	O
be	O
able	O
to	O
mute	O
neuroinflammation	O
as	O
well	O
as	O
promote	O
remyelination	O
and	O
axonal	O
integrity	O
.	O

ABSTRACT	O
:	O
Laboratory	O
cats	O
were	O
infected	O
with	O
a	O
serotype	O
I	O
cat	O
-	O
passaged	O
field	O
strain	O
of	O
FIP	O
virus	O
(	O
FIPV	O
)	O
and	O
peritoneal	O
cells	B-COMP
harvested	O
2	O
-	O
3	O
weeks	O
later	O
at	O
onset	O
of	O
lymphopenia	O
,	O
fever	O
and	O
serositis	O
.	O

TITLE	O
:	O
A	O
mathematical	O
model	O
of	O
CO	O
ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
vv	O
-	O
ECMO	O
)	O
is	O
an	O
effective	O
treatment	O
for	O
severe	O
respiratory	O
failure	O
.	O

Our	O
results	O
suggest	O
that	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
can	O
provide	O
a	O
safe	O
and	O
effective	O
alternative	O
to	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
in	O
carefully	O
selected	O
patients	O
.	O

Interestingly	O
,	O
Ascaris	O
suum	O
,	O
a	O
large	O
roundworm	O
occurring	O
in	O
pigs	O
,	O
was	O
found	O
to	O
be	O
an	O
unusual	O
PEDV	O
host	B-COMP
,	O
providing	O
potential	O
support	O
for	O
cross	O
-	O
host	B-COMP
transmission	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
nsp1	O
suppresses	O
host	B-COMP
gene	O
expression	O
in	O
expressed	O
cells	B-COMP
by	O
inhibiting	O
translation	O
and	O
inducing	O
endonucleolytic	O
cleavage	O
of	O
host	B-COMP
mRNAs	O
,	O
the	O
latter	O
of	O
which	O
leads	O
to	O
mRNA	O
decay	O
.	O

The	O
mutant	O
viruses	O
replicated	O
less	O
efficiently	O
than	O
wild	O
-	O
type	O
virus	O
in	O
Huh	O
-	O
7	O
cells	B-COMP
,	O
HeLa	O
-	O
derived	O
cells	B-COMP
,	O
and	O
293	O
-	O
derived	O
cells	B-COMP
,	O
the	O
latter	O
two	O
of	O
which	O
stably	O
expressed	O
a	O
viral	O
receptor	O
protein	O
.	O

Accordingly	O
,	O
the	O
serological	O
detection	O
of	O
corresponding	O
antibodies	B-COMP
would	O
be	O
beneficial	O
to	O
diagnose	O
PEDV	O
indirectly	O
to	O
control	O
the	O
disease	O
.	O

Finally	O
,	O
the	O
S1	O
indirect	O
ELISA	O
was	O
applied	O
to	O
detect	O
serum	B-COMP
antibodies	B-COMP
of	O
3304	O
field	O
samples	O
collected	O
from	O
different	O
pig	O
farms	O
in	O
eastern	O
China	O
,	O
and	O
it	O
presented	O
an	O
overall	O
substantial	O
agreement	O
on	O
the	O
PEDV	O
infection	O
status	O
.	O

TITLE	O
:	O
	O
T	O
Cells	B-COMP
Contribute	O
to	O
the	O
Outcome	O
of	O
Murine	O
Fulminant	O
Viral	O
Hepatitis	O
via	O
Effector	O
Cytokines	O
TNF	O
-	O
	O
and	O
IFN	O
-	O
	O
.	O

The	O
function	O
of	O
hepatic	O
	O
T	O
cells	B-COMP
was	O
examined	O
by	O
cytotoxicity	O
assay	O
.	O

Balb	O
/	O
cJ	O
mice	O
died	O
in	O
3	O
to	O
6	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
with	O
severe	O
hepatic	O
necrosis	O
and	O
significant	O
augmentation	O
of	O
serum	B-COMP
ALT	O
and	O
AST	O
levels	O
.	O

These	O
highly	O
activated	O
liver	O
	O
T	O
cells	B-COMP
were	O
cytotoxic	O
to	O
MHV	O
-	O
3	O
-	O
infected	O
hepatocytes	O
in	O
vitro	O
and	O
this	O
effect	O
of	O
liver	O
	O
T	O
cells	B-COMP
against	O
hepatocytes	O
might	O
involve	O
the	O
TNF	O
-	O
	O
and	O
IFN	O
-	O
	O
pathway	O
.	O

These	O
results	O
demonstrated	O
that	O
	O
T	O
cells	B-COMP
might	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
MHV	O
-	O
3	O
-	O
induced	O
FVH	O
through	O
the	O
effector	O
cytokines	O
TNF	O
-	O
	O
and	O
IFN	O
-	O
	O
.	O

Treatment	O
with	O
endocytosis	O
inhibitors	O
did	O
not	O
affect	O
syncytium	O
formation	O
by	O
infected	O
cells	B-COMP
.	O

MERS	O
-	O
CoV	O
strongly	O
inhibits	O
the	O
activation	O
of	O
T	O
cells	B-COMP
with	O
downregulation	O
of	O
antigen	O
presentation	O
.	O

qPCR	O
was	O
performed	O
to	O
analyze	O
PEDV	O
binding	O
to	O
Vero	O
E6	O
cells	B-COMP
with	O
neutralizing	O
antibody	B-COMP
.	O

The	O
data	O
suggested	O
that	O
PEDV	O
neutralizing	O
antibody	B-COMP
inhibited	O
virus	O
infection	O
by	O
binding	O
to	O
infectious	O
virions	B-COMP
,	O
which	O
could	O
work	O
as	O
a	O
tool	O
to	O
find	O
the	O
receptor	O
-	O
binding	O
domains	O
.	O

While	O
previously	O
implicated	O
in	O
a	O
non	O
-	O
inflammatory	O
apoptotic	O
cell	B-COMP
death	O
pathway	O
,	O
here	O
we	O
extend	O
the	O
range	O
of	O
SARS	O
3a	O
pathophysiologic	O
targets	O
by	O
examining	O
its	O
effects	O
on	O
necrotic	O
cell	B-COMP
death	O
pathways	O
.	O

MTT	O
assay	O
was	O
performed	O
to	O
test	O
the	O
cytotoxicity	O
of	O
the	O
synthesized	O
Zr	O
QDs	O
against	O
rat	O
brain	O
glioma	O
C6	O
cells	B-COMP
.	O

Synthesized	O
QDs	O
was	O
further	O
conjugated	O
with	O
anti	O
-	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antibodies	B-COMP
of	O
coronavirus	O
to	O
form	O
an	O
immunolink	O
at	O
the	O
presence	O
of	O
the	O
target	O
analyte	O
and	O
anti	O
-	O
IBV	O
antibody	B-COMP
-	O
conjugated	O
magneto	O
-	O
plasmonic	O
nanoparticles	O
(	O
MPNPs	O
).	O

Immediately	O
after	O
the	O
first	O
cerulein	O
injection	O
,	O
phosphate	O
-	O
buffered	O
saline	O
,	O
human	O
serum	B-COMP
albumin	O
(	O
20	O
mg	O
/	O
kg	O
),	O
or	O
HRG	O
(	O
20	O
mg	O
/	O
kg	O
)	O
was	O
intravenously	O
injected	O
.	O

ArkGA	O
P60	O
accumulated	O
the	O
most	O
SNPs	O
in	O
key	O
genes	O
associated	O
with	O
pathogenicity	O
(	O
polyprotein	O
gene	O
1ab	O
)	O
and	O
cell	B-COMP
tropism	O
(	O
spike	O
gene	O
),	O
compared	O
to	O
previous	O
passages	O
,	O
which	O
likely	O
resulted	O
in	O
its	O
more	O
attenuated	O
phenotype	O
.	O

This	O
study	O
adds	O
to	O
the	O
structural	O
profiling	O
of	O
HCoVs	O
to	O
aid	O
in	O
the	O
structure	O
-	O
based	O
design	O
of	O
pan	B-COMP
-	O
coronavirus	O
small	O
molecules	O
or	O
peptides	O
to	O
inhibit	O
viral	O
fusion	O
.	O

To	O
evaluate	O
both	O
the	O
immediate	O
and	O
residual	O
effects	O
of	O
treatment	O
on	O
antibody	B-COMP
detection	O
,	O
samples	O
were	O
tested	O
immediately	O
post	O
-	O
treatment	O
,	O
then	O
stored	O
at	O
4	O
	O
C	O
and	O
retested	O
at	O
2	O
,	O
4	O
,	O
and	O
6	O
days	O
post	O
-	O
treatment	O
(	O
DPT	O
).	O

ABSTRACT	O
:	O
Investigating	O
type	O
I	O
feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
in	O
tissue	O
culture	O
is	O
critical	O
for	O
understanding	O
the	O
basic	O
virology	O
,	O
pathogenesis	O
,	O
and	O
virus	O
-	O
host	B-COMP
interactome	O
of	O
these	O
important	O
veterinary	O
pathogens	O
.	O

In	O
ex	O
vivo	O
proliferation	O
tests	O
,	O
peripheral	O
mononuclear	O
cells	B-COMP
(	O
PBMCs	O
)	O
derived	O
from	O
IBV	O
-	O
Flagellin	O
-	O
SAPN	O
immunized	O
chickens	O
had	O
a	O
significantly	O
higher	O
stimulation	O
index	O
than	O
that	O
of	O
PBMCs	O
from	O
chickens	O
receiving	O
Flagellin	O
-	O
SAPN	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
have	O
been	O
widely	O
used	O
in	O
the	O
detection	O
of	O
IBV	O
antibodies	B-COMP
in	O
the	O
early	O
infection	O
and	O
continuous	O
infection	O
of	O
IB	O
because	O
they	O
are	O
more	O
sensitive	O
and	O
quicker	O
than	O
other	O
diagnostic	O
methods	O
.	O

Two	O
microarray	O
assays	O
,	O
which	O
were	O
rapid	O
,	O
specific	O
,	O
sensitive	O
,	O
and	O
relatively	O
simple	O
,	O
were	O
developed	O
for	O
the	O
detection	O
of	O
an	O
antibody	B-COMP
against	O
IBV	O
.	O

TITLE	O
:	O
The	O
Immunological	O
Functions	O
of	O
Muramyl	O
Dipeptide	O
Compound	O
Adjuvant	O
on	O
Humoral	O
,	O
Cellular	B-COMP
-	O
mediated	O
and	O
Mucosal	O
Immune	O
Responses	O
to	O
PEDV	O
Inactivated	O
Vaccine	O
in	O
Mice	O
.	O

Extracellular	B-COMP
vesicles	B-COMP
(	O
EVs	O
)	O
have	O
been	O
shown	O
to	O
mediate	O
cellular	B-COMP
crosstalk	O
in	O
inflammation	O
by	O
transfer	O
of	O
microRNAs	O
(	O
miRNAs	O
).	O

Weaned	O
piglets	O
orally	O
immunized	O
with	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
developed	O
higher	O
levels	O
of	O
PEDV	O
-	O
specific	O
antibodies	B-COMP
(	O
IgG	O
and	O
IgA	O
)	O
in	O
their	O
sera	B-COMP
and	O
saliva	O
than	O
those	O
negative	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
or	O
p	O
<	O
0	O
.	O
01	O
).	O

Furthermore	O
,	O
neutralization	O
assays	O
demonstrated	O
that	O
serum	B-COMP
antibodies	B-COMP
in	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
groups	O
could	O
significantly	O
inhibit	O
virus	O
infection	O
in	O
Vero	O
cells	B-COMP
,	O
compared	O
to	O
PEDV	O
only	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

All	O
broilers	O
tested	O
negative	O
to	O
MG	O
antibodies	B-COMP
.	O

However	O
,	O
apoptosis	O
was	O
not	O
completely	O
prevented	O
by	O
caspases	O
inhibitors	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
a	O
caspase	O
-	O
independent	O
pathway	O
involved	O
in	O
TGEV	O
-	O
induced	O
cell	B-COMP
apoptosis	O
.	O

Moreover	O
,	O
the	O
protein	O
levels	O
in	O
nucleus	B-COMP
and	O
the	O
mRNA	O
levels	O
of	O
AIF	O
were	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
p53	O
inhibitor	O
,	O
pithrin	O
-	O
	O
(	O
PFT	O
-	O
	O
)	O
or	O
in	O
TGEV	O
-	O
infected	O
p53	O
-/-	O
cells	B-COMP
.	O

Our	O
studies	O
suggest	O
that	O
the	O
serum	B-COMP
shDPP4	O
levels	O
play	O
a	O
role	O
in	O
MERS	O
pathogenesis	O
and	O
demonstrate	O
a	O
potential	O
of	O
rshDPP4	O
as	O
a	O
treatment	O
option	O
for	O
MERS	O
.	O

ABSTRACT	O
:	O
Cell	B-COMP
entry	O
by	O
coronaviruses	O
involves	O
two	O
principal	O
steps	O
,	O
receptor	O
binding	O
and	O
membrane	B-COMP
fusion	O
;	O
the	O
latter	O
requires	O
activation	O
by	O
host	B-COMP
proteases	O
,	O
particularly	O
lysosomal	O
proteases	O
.	O

Moreover	O
,	O
purified	O
lysosomal	O
extracts	O
from	O
bat	O
cells	B-COMP
cleave	O
cell	B-COMP
surface	I-COMP
-	O
expressed	O
coronavirus	O
spikes	O
more	O
efficiently	O
than	O
their	O
counterparts	O
from	O
human	O
cells	B-COMP
.	O

PEDV	O
damages	O
pig	O
intestinal	O
epithelial	O
tissue	O
,	O
causing	O
intestinal	O
hyperemia	O
and	O
atrophy	O
of	O
intestinal	O
villi	O
,	O
with	O
formation	O
of	O
intestinal	O
epithelial	O
cell	B-COMP
cytoplasmic	B-COMP
vacuoles	B-COMP
.	O

We	O
previously	O
generated	O
a	O
genogroup	O
2b	O
(	O
G2b	O
)	O
PEDV	O
Taiwan	O
Pintung	O
52	O
(	O
PEDVPT	O
)	O
strain	O
,	O
PEDVPT	O
-	O
P96	O
,	O
and	O
determined	O
its	O
promising	O
host	B-COMP
immune	O
response	O
against	O
the	O
virulent	O
PEDVPT	O
-	O
P5	O
strain	O
.	O

Comparing	O
to	O
the	O
parental	O
PEDVPT	O
-	O
P96	O
virus	O
,	O
the	O
iPEDVPT	O
-	O
P96	O
virus	O
showed	O
efficient	O
replication	O
kinetics	O
with	O
a	O
delayed	O
decline	O
of	O
viral	O
load	O
and	O
similar	O
but	O
much	O
more	O
uniform	O
plaque	O
sizes	O
in	O
Vero	O
cells	B-COMP
.	O

Despite	O
our	O
pursuit	O
of	O
understanding	O
the	O
complexity	O
of	O
the	O
vector	O
-	O
host	B-COMP
-	O
pathogen	O
mediating	O
disease	O
transmission	O
,	O
it	O
is	O
not	O
possible	O
to	O
make	O
generalized	O
predictions	O
concerning	O
the	O
degree	O
of	O
impact	O
of	O
disease	O
emergence	O
.	O

We	O
used	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
to	O
hepatitis	O
E	O
virus	O
,	O
bluetongue	O
virus	O
,	O
West	O
Nile	O
virus	O
(	O
WNV	O
),	O
and	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
).	O

We	O
detected	O
antibodies	B-COMP
to	O
CDV	O
,	O
CHV	O
-	O
1	O
,	O
CPV	O
-	O
2	O
,	O
CPIV	O
-	O
2	O
,	O
CCV	O
,	O
WNV	O
,	O
and	O
ADV	O
in	O
seven	O
(	O
29	O
%),	O
three	O
(	O
12	O
%),	O
two	O
(	O
8	O
%),	O
two	O
(	O
8	O
%),	O
one	O
(	O
4	O
%),	O
one	O
(	O
4	O
%),	O
and	O
one	O
(	O
4	O
%)	O
bear	O
,	O
respectively	O
.	O

Sera	B-COMP
were	O
evaluated	O
by	O
nucleocapsid	B-COMP
and	O
spike	O
protein	O
enzyme	O
immunoassays	O
and	O
microneutralization	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
the	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
technology	O
was	O
used	O
to	O
analyze	O
the	O
profiles	O
of	O
mRNAs	O
,	O
miRNAs	O
,	O
and	O
circRNAs	O
in	O
Mock	O
-	O
and	O
TGEV	O
-	O
infected	O
intestinal	O
porcine	O
epithelial	O
cell	B-COMP
-	O
jejunum	O
2	O
(	O
IPEC	O
-	O
J2	O
)	O
cell	B-COMP
line	O
.	O

However	O
,	O
a	O
role	O
for	O
virus	O
-	O
specific	O
memory	O
B	O
cells	B-COMP
(	O
Bmem	O
)	O
within	O
the	O
CNS	O
is	O
poorly	O
explored	O
due	O
to	O
lack	O
of	O
robust	O
phenotypic	O
or	O
functional	O
identification	O
in	O
mice	O
.	O

Individualized	O
vancomycin	O
dosing	O
regimens	O
and	O
therapeutic	O
drug	O
monitoring	O
are	O
necessary	O
for	O
critically	O
ill	O
patients	O
receiving	O
CVVH	O
and	O
ECMO	O
to	O
ensure	O
that	O
the	O
target	O
serum	B-COMP
vancomycin	O
levels	O
are	O
reached	O
to	O
adequately	O
treat	O
the	O
infection	O
and	O
avoid	O
nephrotoxicity	O
.	O

ABSTRACT	O
:	O
Previous	O
research	O
has	O
suggested	O
that	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
vvECMO	O
)	O
is	O
useful	O
for	O
patients	O
refractory	O
to	O
conventional	O
therapy	O
.	O

On	O
lipopolysaccharide	O
challenge	O
,	O
PHD2	O
depletion	O
in	O
ECs	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
increases	O
of	O
lung	O
vascular	O
permeability	O
,	O
edema	O
,	O
and	O
inflammatory	O
cell	B-COMP
infiltration	O
.	O

Moreover	O
,	O
EC	O
-	O
specific	O
PHD2	O
inducible	O
knockout	O
mice	O
exhibit	O
improved	O
adherens	B-COMP
junction	I-COMP
integrity	O
and	O
endothelial	O
barrier	O
function	O
.	O

Post	O
hoc	O
Bayesian	O
analysis	O
of	O
data	O
from	O
a	O
randomized	O
clinical	O
trial	O
of	O
early	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
compared	O
with	O
conventional	O
lung	O
-	O
protective	O
ventilation	O
with	O
the	O
option	O
for	O
rescue	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
among	O
patients	O
with	O
very	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
provides	O
information	O
about	O
the	O
posterior	O
probability	O
of	O
mortality	O
benefit	O
under	O
a	O
broad	O
set	O
of	O
assumptions	O
that	O
may	O
help	O
inform	O
interpretation	O
of	O
the	O
study	O
findings	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
the	O
S2	O
subunit	O
of	O
the	O
avirulent	O
Beau	O
-	O
R	O
strain	O
is	O
responsible	O
for	O
its	O
extended	O
cellular	B-COMP
tropism	O
for	O
Vero	O
cells	B-COMP
.	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
a	O
monoclonal	O
antibody	B-COMP
against	O
MERS	O
-	O
CoV	O
targeting	O
the	O
spike	O
protein	O
using	O
a	O
synthetic	O
peptide	O
epitope	O
-	O
CpG	O
-	O
DNA	O
-	O
liposome	O
complex	O
.	O

Our	O
results	O
highlighted	O
the	O
importance	O
of	O
nucleic	B-COMP
acid	O
extraction	O
kit	O
selection	O
,	O
which	O
has	O
a	O
major	O
impact	O
on	O
the	O
yield	O
and	O
number	O
of	O
viral	O
reads	O
by	O
NGS	O
analysis	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
in	O
a	O
29	O
-	O
Year	O
-	O
Old	O
Man	O
with	O
ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
patients	O
who	O
have	O
acute	O
respiratory	O
distress	O
syndrome	O
has	O
been	O
generally	O
beneficial	O
.	O

Totals	O
of	O
16	O
/	O
30	O
CWs	O
and	O
0	O
/	O
30	O
healthy	O
control	O
donors	O
were	O
seropositive	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
ELISA	O
and	O
/	O
or	O
neutralizing	O
antibody	B-COMP
titer	O
,	O
and	O
an	O
additional	O
four	O
CWs	O
were	O
seronegative	O
but	O
contained	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
in	O
their	O
blood	O
.	O

These	O
results	O
demonstrated	O
the	O
ability	O
of	O
miR	O
-	O
221	O
-	O
5p	O
to	O
inhibit	O
PEDV	O
replication	O
by	O
targeting	O
the	O
3	O
'	O
UTR	O
of	O
the	O
viral	B-COMP
genome	I-COMP
and	O
activating	O
the	O
NF	O
-	O
B	O
-	O
signaling	O
pathway	O
.	O

TITLE	O
:	O
Stochastic	O
two	O
-	O
group	O
models	O
with	O
transmission	O
dependent	O
on	O
host	B-COMP
infectivity	O
or	O
susceptibility	O
.	O

We	O
apply	O
a	O
continuous	O
-	O
time	O
Markov	O
chain	O
(	O
CTMC	O
)	O
model	O
to	O
study	O
disease	O
emergence	O
or	O
re	O
-	O
emergence	O
from	O
different	O
groups	O
,	O
where	O
the	O
transmission	O
rates	O
depend	O
on	O
either	O
the	O
infectious	O
host	B-COMP
or	O
the	O
susceptible	O
host	B-COMP
.	O

Our	O
focus	O
is	O
on	O
platelet	O
-	O
endothelial	O
cell	B-COMP
adhesion	O
molecule	O
-	O
1	O
,	O
which	O
contributes	O
to	O
the	O
maintenance	O
and	O
restoration	O
of	O
vascular	O
integrity	O
following	O
barrier	O
disruption	O
.	O

In	O
infected	O
cells	B-COMP
,	O
PEDV	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
nuclear	O
concentration	O
and	O
fragmentation	O
as	O
a	O
result	O
of	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
8	O
activation	O
and	O
AIFM1	O
and	O
PARP	O
cleavage	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
S1	O
proteins	O
from	O
various	O
coronavirus	O
family	O
members	O
such	O
as	O
TGEV	O
,	O
IBV	O
,	O
CCoV	O
,	O
SARS	O
and	O
MERS	O
could	O
also	O
induce	O
Vero	O
-	O
E6	O
cells	B-COMP
apoptosis	O
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
Spike	O
Protein	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Transmitted	O
in	O
Korea	O
Increase	O
Resistance	O
to	O
Antibody	B-COMP
-	O
Mediated	O
Neutralization	O
.	O

These	O
findings	O
indicate	O
that	O
MERS	O
-	O
CoV	O
variants	O
with	O
reduced	O
neutralization	O
sensitivity	O
were	O
transmitted	O
during	O
the	O
Korean	O
outbreak	O
and	O
that	O
the	O
responsible	O
mutations	O
were	O
compatible	O
with	O
robust	O
infection	O
of	O
cells	B-COMP
expressing	O
high	O
levels	O
of	O
DPP4	O
.	O

These	O
findings	O
suggest	O
that	O
cleavage	O
at	O
S2	O
'	O
is	O
carried	O
out	O
by	O
proteases	O
recognizing	O
a	O
single	O
arginine	O
,	O
most	O
likely	O
TMPRSS2	O
and	O
cathepsin	O
L	O
.	O
Finally	O
,	O
mutation	O
of	O
the	O
proposed	O
cathepsin	O
L	O
site	O
did	O
not	O
impact	O
viral	O
entry	O
and	O
double	O
mutation	O
of	O
S1	O
/	O
S2	O
and	O
S2	O
'	O
site	O
was	O
compatible	O
with	O
cathepsin	O
L	O
-	O
but	O
not	O
TMPRSS2	O
-	O
dependent	O
host	B-COMP
cell	I-COMP
entry	O
,	O
indicating	O
that	O
cathepsin	O
L	O
can	O
process	O
the	O
S	O
protein	O
at	O
auxiliary	O
sites	O
.	O

However	O
,	O
in	O
recent	O
years	O
,	O
cell	B-COMP
therapy	O
has	O
shown	O
great	O
promise	O
in	O
preclinical	O
ARDS	O
studies	O
.	O

A	O
wide	O
range	O
of	O
cells	B-COMP
have	O
been	O
identified	O
as	O
potential	O
candidates	O
for	O
use	O
,	O
among	O
these	O
are	O
mesenchymal	O
stromal	O
cells	B-COMP
(	O
MSCs	O
),	O
which	O
are	O
adult	O
multi	O
-	O
lineage	O
cells	B-COMP
that	O
can	O
modulate	O
the	O
immune	O
response	O
and	O
enhance	O
repair	O
of	O
damaged	O
tissue	O
.	O

Cells	B-COMP
were	O
exposed	O
to	O
4	O
%	O
of	O
sevoflurane	O
and	O
1	O
%	O
of	O
isoflurane	O
for	O
24	O
hours	O
.	O

TITLE	O
:	O
Hormonal	O
Regulation	O
of	O
Physiology	O
,	O
Innate	O
Immunity	O
and	O
Antibody	B-COMP
Response	O
to	O
H1N1	O
Influenza	O
Virus	O
Infection	O
During	O
Pregnancy	O
.	O

RNA	O
was	O
extracted	O
from	O
serum	B-COMP
and	O
two	O
nasal	O
swabs	O
,	O
and	O
tested	O
with	O
conventional	O
PCR	O
at	O
the	O
family	O
level	O
for	O
viruses	O
including	O
enterovirus	O
,	O
dengue	O
,	O
chikungunya	O
,	O
influenza	O
,	O
herpesvirus	O
,	O
paramyxovirus	O
and	O
coronavirus	O
.	O

TITLE	O
:	O
Treatment	O
with	O
allogeneic	O
mesenchymal	O
stromal	O
cells	B-COMP
for	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
START	O
study	O
):	O
a	O
randomised	O
phase	O
2a	O
safety	O
trial	O
.	O

BP	O
-	O
caKII	O
shared	O
several	O
mutations	O
with	O
K2	O
(	O
nsp13	O
,	O
14	O
,	O
15	O
and	O
16	O
)	O
following	O
embryo	O
adaptation	O
but	O
acquired	O
multiple	O
additional	O
mutations	O
in	O
nonstructural	O
proteins	O
(	O
nsp3	O
,	O
4	O
and	O
12	O
),	O
spike	O
proteins	O
and	O
nucleocapsid	B-COMP
proteins	O
following	O
cold	O
adaptation	O
.	O

During	O
the	O
late	O
phase	O
(	O
day	O
10	O
),	O
both	O
lung	O
mechanics	O
and	O
the	O
cell	B-COMP
/	O
cytokine	O
homeostasis	O
recovered	O
in	O
LPS	O
-	O
treated	O
wt	O
mice	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
summarize	O
the	O
importance	O
of	O
VP35	O
and	O
VP24	O
proteins	O
in	O
counteracting	O
the	O
host	B-COMP
IFN	O
cellular	B-COMP
response	O
and	O
discuss	O
their	O
potential	O
as	O
druggable	O
viral	O
targets	O
as	O
a	O
promising	O
approach	O
toward	O
attenuation	O
of	O
EBOV	O
virulence	O
.	O

The	O
ability	O
to	O
rapidly	O
determine	O
direct	O
antibody	B-COMP
binding	O
to	O
host	B-COMP
cells	B-COMP
in	O
a	O
high	O
-	O
throughput	O
manner	O
can	O
be	O
applied	O
to	O
study	O
other	O
pathogen	O
-	O
antibody	B-COMP
interactions	O
and	O
thus	O
can	O
impact	O
future	O
research	O
on	O
viral	O
pathogens	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
lncRNA	O
expression	O
profiles	O
during	O
PEDV	O
infection	O
in	O
intestinal	O
porcine	O
epithelial	O
cell	B-COMP
-	O
jejunum	O
2	O
(	O
IPEC	O
-	O
J2	O
)	O
cell	B-COMP
lines	O
by	O
next	O
-	O
generation	O
sequencing	O
and	O
identified	O
6188	O
novel	O
lncRNAs	O
.	O

We	O
next	O
selected	O
candidate	O
lncRNAs	O
related	O
to	O
immune	O
response	O
pathways	O
and	O
further	O
identified	O
their	O
differential	O
expression	O
in	O
PEDV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	B-COMP
and	O
newborn	O
piglets	O
.	O

In	O
addition	O
,	O
TGEV	O
-	O
induced	O
the	O
changes	O
in	O
mRNA	O
levels	O
of	O
TRIF	O
,	O
TRAM	O
,	O
MDA5	O
,	O
RIG	O
-	O
I	O
,	O
IPS	O
-	O
1	O
,	O
IRF9	O
,	O
IRF3	O
,	O
ISG15	O
and	O
ISG20	O
were	O
notably	O
hindered	O
in	O
p53	O
-/-	O
PK	O
-	O
15	O
cells	B-COMP
before	O
36	O
h	O
post	O
infection	O
(	O
p	O
.	O
i	O
.).	O

TITLE	O
:	O
Muse	O
Cells	B-COMP
and	O
Ischemia	O
-	O
Reperfusion	O
Lung	O
Injury	O
.	O

On	O
the	O
outer	O
surface	O
,	O
virus	O
has	O
spike	O
like	O
glycoprotein	O
which	O
is	O
responsible	O
for	O
the	O
attachment	O
and	O
entrance	O
inside	O
host	B-COMP
cells	B-COMP
.	O

ABSTRACT	O
:	O
Technological	O
improvement	O
has	O
contributed	O
to	O
making	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
safer	O
and	O
easier	O
,	O
spreading	O
its	O
use	O
in	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
).	O

In	O
the	O
BIOLINE	O
group	O
,	O
a	O
lower	O
amount	O
of	O
packed	O
red	O
blood	O
cells	B-COMP
(	O
pRBC	O
)	O
was	O
transfused	O
considering	O
both	O
total	O
number	O
[	O
4	O
units	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
1	O
-	O
9	O
More	O
biocompatible	O
and	O
shorter	O
drainage	O
cannula	O
may	O
represent	O
one	O
of	O
the	O
contributing	O
factors	O
to	O
a	O
reduction	O
in	O
transfusions	O
and	O
costs	O
of	O
VV	O
-	O
ECMO	O
in	O
the	O
current	O
ongoing	O
technological	O
improvement	O
in	O
ECMO	O
.	O

TITLE	O
:	O
Neutralizing	O
Monoclonal	O
Antibodies	B-COMP
as	O
Promising	O
Therapeutics	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

ABSTRACT	O
:	O
In	O
an	O
initial	O
study	O
in	O
specified	O
pathogen	O
free	O
(	O
SPF	O
)	O
chickens	O
,	O
a	O
heterologous	O
virus	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-COMP
response	O
to	O
IBV	O
variants	O
Q1	O
,	O
Variant	O
2	O
(	O
Var	O
2	O
),	O
D388	O
/	O
QX	O
(	O
D388	O
),	O
D274	O
and	O
Arkansas	O
(	O
DPI	O
)	O
was	O
observed	O
using	O
a	O
vaccination	O
programme	O
incorporating	O
two	O
different	O
live	O
-	O
attenuated	O
IBV	O
vaccines	O
,	O
followed	O
by	O
boosting	O
with	O
an	O
inactivated	O
vaccine	O
containing	O
IBV	O
Massachusetts	O
(	O
Mass	O
)	O
antigen	O
.	O

Circulating	O
mitochondrial	B-COMP
DNA	I-COMP
levels	O
were	O
reduced	O
in	O
iCO	O
-	O
treated	O
participants	O
compared	O
with	O
placebo	O
-	O
treated	O
subjects	O
.	O

Nevertheless	O
,	O
both	O
IBV	O
isolates	O
elicited	O
host	B-COMP
responses	O
characterized	O
by	O
significant	O
macrophage	O
recruitment	O
to	O
the	O
respiratory	O
tract	O
and	O
there	O
was	O
evidence	O
that	O
both	O
IBV	O
isolates	O
replicated	O
within	O
tracheal	O
and	O
lung	O
macrophages	O
.	O

Further	O
analysis	O
verified	O
the	O
existence	O
of	O
eight	O
selected	O
circRNAs	O
and	O
confirmed	O
that	O
PEDV	O
infection	O
alerted	O
the	O
expression	O
patterns	O
of	O
circRNAs	O
and	O
their	O
linear	O
parent	O
genes	O
in	O
IPEC	O
-	O
J2	O
cell	B-COMP
line	O
.	O

Our	O
results	O
provided	O
not	O
only	O
the	O
first	O
large	O
-	O
scale	O
profile	O
analysis	O
of	O
circRNAs	O
associated	O
with	O
PEDV	O
infection	O
but	O
also	O
a	O
novel	O
direction	O
to	O
elucidate	O
host	B-COMP
-	O
PEDV	O
interactions	O
.	O

Constructed	O
recombinant	O
pAE	O
/	O
n	O
expression	O
vectors	O
were	O
used	O
to	O
transform	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
Star	O
competent	O
cells	B-COMP
(	O
Invitrogen	O
).	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
PHEV	O
utilizes	O
the	O
integrin	O
51	O
-	O
FAK	O
-	O
Rac1	O
/	O
Cdc42	O
-	O
PAK	O
-	O
LIMK	O
-	O
cofilin	O
pathway	O
to	O
cause	O
an	O
actin	O
cytoskeletal	B-COMP
rearrangement	O
to	O
promote	O
its	O
own	O
invasion	O
,	O
providing	O
theoretical	O
support	O
for	O
the	O
development	O
of	O
PHEV	O
pathogenic	O
mechanisms	O
and	O
new	O
antiviral	O
targets	O
.	O

TITLE	O
:	O
CD8	O
+	O
T	O
Cells	B-COMP
Responding	O
to	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Nucleocapsid	B-COMP
Protein	O
Delivered	O
by	O
Vaccinia	O
Virus	O
MVA	O
in	O
Mice	O
.	O

Antibodies	B-COMP
directed	O
against	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
controlling	O
MERS	O
-	O
CoV	O
infection	O
and	O
in	O
mediating	O
vaccine	O
-	O
induced	O
protective	O
immunity	O
.	O

One	O
family	O
of	O
susceptibility	O
factors	O
,	O
the	O
tetraspanin	O
proteins	O
,	O
facilitate	O
enveloped	O
virus	O
entry	O
by	O
promoting	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
.	O

In	O
this	O
Gem	O
,	O
we	O
discuss	O
recent	O
insights	O
into	O
how	O
tetraspanins	O
assemble	O
viral	O
entry	O
and	O
exit	O
platforms	O
on	O
cell	B-COMP
membranes	I-COMP
,	O
and	O
we	O
speculate	O
that	O
tetraspanins	O
contribute	O
to	O
nonviral	O
membrane	B-COMP
fusions	O
by	O
similar	O
mechanisms	O
.	O

However	O
,	O
aberrant	O
or	O
unrestricted	O
cytokine	O
responses	O
can	O
damage	O
host	B-COMP
tissues	O
,	O
leading	O
to	O
organ	O
dysfunction	O
,	O
and	O
even	O
death	O
.	O

For	O
example	O
,	O
human	O
-	O
like	O
symptomology	O
and	O
acute	O
respiratory	O
syndrome	O
is	O
found	O
in	O
cynomolgus	O
macaques	O
infected	O
with	O
highly	O
pathogenic	O
avian	O
influenza	O
virus	O
,	O
antibody	B-COMP
enhanced	O
dengue	O
disease	O
is	O
common	O
in	O
neotropical	O
primates	O
,	O
and	O
in	O
NHP	O
models	O
of	O
viral	O
hepatitis	O
cytokine	O
-	O
induced	O
inflammation	O
induces	O
severe	O
liver	O
damage	O
,	O
fibrosis	O
,	O
and	O
hepatocellular	O
carcinoma	O
recapitulates	O
human	O
disease	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Failure	O
in	O
a	O
Liver	O
Transplant	O
Patient	O
:	O
A	O
Case	O
Report	O
.	O

A	O
total	O
of	O
19	O
.	O
7	O
L	O
of	O
washed	O
red	O
blood	O
cells	B-COMP
were	O
returned	O
to	O
the	O
patient	O
from	O
the	O
cell	B-COMP
saver	O
.	O

MK2	O
regulates	O
the	O
expression	O
of	O
ICAM	O
-	O
1	O
in	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	B-COMP
.	O

Although	O
neutralizing	O
antibodies	B-COMP
protect	O
newborn	O
mice	O
from	O
lethal	O
EV	O
-	O
D68	O
inoculation	O
via	O
nonphysiologic	O
routes	O
,	O
cotton	O
rats	O
have	O
a	O
mixed	O
phenotype	O
of	O
both	O
benefit	O
and	O
possible	O
exacerbation	O
when	O
inoculated	O
intranasally	O
.	O

Moreover	O
,	O
The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
CT	O
severity	O
index	O
(	O
CTSI	O
),	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
incidence	O
,	O
mortality	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
white	O
blood	O
cell	B-COMP
count	O
(	O
WBC	O
),	O
procalcitonin	O
(	O
PCT	O
)	O
and	O
immature	O
granulocytes	O
in	O
persistent	O
SIRS	O
group	O
were	O
further	O
higher	O
than	O
those	O
in	O
the	O
temporary	O
SIRS	O
group	O
[	O
APACHE	O
II	O
:	O
9	O
(	O
6	O
,	O
12	O
)	O
vs	O
.	O
5	O
(	O
3	O
,	O
7	O
),	O
CTSI	O
:	O
6	O
(	O
4	O
,	O
6	O
)	O
vs	O
.	O
4	O
(	O
3	O
,	O
6	O
),	O
MOF	O
incidence	O
:	O
92	O
.	O
0	O
%	O
vs	O
.	O
32	O
.	O
8	O
%,	O
ARDS	O
incidence	O
:	O
39	O
.	O
9	O
%	O
vs	O
.	O
10	O
.	O
1	O
%,	O
morbidity	O
:	O
11	O
.	O
1	O
%	O
vs	O
.	O
4	O
.	O
2	O
%,	O
CRP	O
(	O
mg	O
/	O
L	O
):	O
25	O
.	O
00	O
(	O
0	O
.	O
80	O
,	O
212	O
.	O
25	O
)	O
vs	O
.	O
0	O
.	O
80	O
(	O
0	O
.	O
80	O
,	O
123	O
.	O
50	O
),	O
WBC	O
(	O
10	O

Oral	O
inoculation	O
led	O
to	O
higher	O
levels	O
of	O
PEDV	O
-	O
specific	O
IgA	O
antibodies	B-COMP
in	O
both	O
serum	B-COMP
and	O
gut	O
mucosal	O
sites	O
than	O
did	O
other	O
routes	O
of	O
inoculation	O
.	O

No	O
specific	O
drug	O
treatment	O
exists	O
for	O
MERS	O
;	O
however	O
,	O
the	O
neutralizing	O
antibodies	B-COMP
,	O
ribavirin	O
and	O
interferon	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
useful	O
anti	O
-	O
MERS	O
-	O
CoV	O
drugs	O
.	O

It	O
is	O
known	O
that	O
IL	O
-	O
6	O
,	O
via	O
its	O
soluble	O
receptor	O
(	O
sIL	O
-	O
6R	O
),	O
initiates	O
a	O
pro	O
-	O
inflammatory	O
response	O
while	O
an	O
anti	O
-	O
inflammatory	O
response	O
is	O
triggered	O
by	O
the	O
membrane	B-COMP
-	O
bound	O
IL	O
-	O
6	O
receptor	O
(	O
IL	O
-	O
6R	O
).	O

Therefore	O
,	O
ADAM	O
-	O
17	O
should	O
be	O
considered	O
as	O
a	O
potential	O
target	O
molecule	O
for	O
novel	O
antiviral	O
drug	O
discovery	O
that	O
would	O
regulate	O
host	B-COMP
reactivity	O
to	O
infection	O
and	O
thereby	O
limit	O
or	O
prevent	O
fatal	O
outcomes	O
.	O

The	O
median	O
platelet	O
count	O
24	O
h	O
previous	O
to	O
delivery	O
was	O
94	O
,	O
000	O
cells	B-COMP
/	O
ml	O
and	O
after	O
tocolysis	O
was	O
132	O
,	O
500	O
cells	B-COMP
/	O
ml	O
.	O

However	O
,	O
few	O
options	O
remain	O
in	O
cases	O
of	O
refractory	O
hypoxemia	O
on	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

These	O
observations	O
have	O
allowed	O
researchers	O
to	O
speculate	O
that	O
bats	O
are	O
the	O
likely	O
reservoirs	O
or	O
ancestral	O
hosts	B-COMP
for	O
several	O
CoVs	O
.	O

The	O
intermediate	O
hosts	B-COMP
of	O
most	O
of	O
the	O
human	O
coronaviruses	O
are	O
known	O
,	O
but	O
not	O
for	O
HCoV	O
-	O
NL63	O
.	O

The	O
VP7	O
protein	O
is	O
the	O
main	O
coat	O
protein	O
of	O
PoRV	O
,	O
and	O
the	O
S	O
protein	O
is	O
the	O
main	O
structural	O
protein	O
of	O
PEDV	O
,	O
which	O
are	O
capable	O
of	O
inducing	O
neutralizing	O
antibodies	B-COMP
in	O
vivo	O
.	O

Pretreatment	O
(	O
exclusion	O
assay	O
),	O
coincubation	O
(	O
competition	O
assay	O
),	O
and	O
post	O
-	O
treatment	O
(	O
displacement	O
assay	O
)	O
of	O
PEDV	O
-	O
infected	O
Vero	O
cells	B-COMP
with	O
the	O
S	B-COMP
-	I-COMP
layer	I-COMP
protein	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
findings	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	B-COMP
-	I-COMP
layer	I-COMP
protein	O
protects	O
against	O
PEDV	O
-	O
induced	O
apoptosis	O
through	O
reduced	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
activation	O
in	O
the	O
later	O
stages	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
adults	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
has	O
increased	O
in	O
the	O
past	O
10	O
years	O
.	O

TITLE	O
:	O
Two	O
critical	O
N	O
-	O
terminal	O
epitopes	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
contribute	O
to	O
the	O
cross	O
-	O
reactivity	O
between	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
.	O

Interestingly	O
,	O
exogenous	O
supplement	O
of	O
LA	O
or	O
AA	O
in	O
HCoV	O
-	O
229E	O
-	O
infected	O
cells	B-COMP
significantly	O
suppressed	O
HCoV	O
-	O
229E	O
virus	O
replication	O
.	O

CONCLUSIONS	O
:	O
Shedding	O
of	O
sVE	O
-	O
cadherin	O
is	O
associated	O
with	O
severe	O
acute	O
kidney	O
injury	O
and	O
with	O
more	O
severe	O
organ	O
dysfunction	O
in	O
patients	O
with	O
sepsis	O
,	O
suggesting	O
that	O
breakdown	O
of	O
endothelial	O
adherens	B-COMP
junctions	I-COMP
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
organ	O
dysfunction	O
in	O
sepsis	O
.	O

Here	O
,	O
we	O
developed	O
,	O
compared	O
and	O
evaluated	O
three	O
different	O
indirect	O
ELISAs	O
based	O
on	O
MERS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
),	O
spike	O
(	O
S	O
)	O
ectodomain	O
(	O
amino	O
acids	O
1	O
-	O
1297	O
)	O
and	O
S1	O
subunit	O
(	O
amino	O
acids	O
1	O
-	O
725	O
)	O
and	O
compared	O
them	O
with	O
MN	O
assay	O
.	O

Our	O
previous	O
work	O
revealed	O
that	O
extracellular	B-COMP
vesicle	B-COMP
(	O
EV	O
)-	O
mediated	O
inflammasome	O
signaling	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)-	O
induced	O
lung	O
injury	O
.	O

Here	O
,	O
serum	B-COMP
-	O
derived	O
EVs	O
from	O
severe	O
TBI	O
patients	O
were	O
analyzed	O
for	O
particle	O
size	O
,	O
concentration	O
,	O
origin	O
,	O
and	O
levels	O
of	O
the	O
inflammasome	O
component	O
,	O
an	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
caspase	O
-	O
recruiting	O
domain	O
(	O
ASC	O
).	O

The	O
program	O
can	O
handle	O
individual	O
or	O
batch	O
submissions	O
of	O
different	O
viruses	O
to	O
GenBank	O
and	O
correctly	O
annotates	O
multiple	O
viruses	O
,	O
including	O
those	O
that	O
contain	O
ribosomal	B-COMP
slippage	O
or	O
RNA	O
editing	O
without	O
prior	O
knowledge	O
of	O
the	O
virus	O
to	O
be	O
annotated	O
.	O

Neutrophil	O
extracellular	B-COMP
trap	O
concentrations	O
were	O
significantly	O
higher	O
in	O
bronchoalveolar	O
lavage	O
than	O
in	O
blood	O
of	O
ARDS	O
patients	O
(	O
median	O
[	O
first	O
to	O
third	O
quartiles	O
]:	O
154	O
[	O
74	O
to	O
1	O
,	O
000	O
]	O
vs	O
.	O
26	O
[	O
4	O
to	O
68	O
]	O
arbitrary	O
units	O
,	O
difference	O
:	O
-	O
94	O
;	O
95	O
%	O
CI	O
,	O
-	O
341	O
to	O
-	O
57	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Intensive	O
care	O
unit	O
mortality	O
(	O
12	O
%,	O
n	O
=	O
2	O
of	O
17	O
vs	O
.	O
17	O
%,	O
n	O
=	O
3	O
of	O
18	O
;	O
P	O
>	O
0	O
.	O
99	O
)	O
and	O
the	O
number	O
of	O
ventilator	O
-	O
free	O
days	O
at	O
day	O
28	O
(	O
22	O
[	O
14	O
to	O
25	O
]	O
vs	O
.	O
14	O
[	O
0	O
to	O
21	O
]	O
days	O
;	O
difference	O
:	O
-	O
5	O
;	O
95	O
%	O
CI	O
,	O
-	O
15	O
to	O
0	O
;	O
P	O
=	O
0	O
.	O
066	O
)	O
did	O
not	O
significantly	O
differ	O
between	O
patients	O
with	O
higher	O
(	O
n	O
=	O
17	O
)	O
versus	O
lower	O
(	O
n	O
=	O
18	O
)	O
bronchoalveolar	O
neutrophil	O
extracellular	B-COMP
trap	O
concentrations	O
.	O

A	O
blood	O
sample	O
was	O
taken	O
at	O
admission	O
and	O
CBC	B-COMP
parameters	O
were	O
examined	O
.	O

ABSTRACT	O
:	O
Enabled	O
by	O
new	O
approaches	O
for	O
rapid	O
identification	O
and	O
selection	O
of	O
human	O
monoclonal	O
antibodies	B-COMP
,	O
atomic	O
-	O
level	O
structural	O
information	O
for	O
viral	O
surface	O
proteins	O
,	O
and	O
capacity	O
for	O
precision	O
engineering	O
of	O
protein	O
immunogens	O
and	O
self	O
-	O
assembling	O
nanoparticles	O
,	O
a	O
new	O
era	O
of	O
antigen	O
design	O
and	O
display	O
options	O
has	O
evolved	O
.	O

To	O
determine	O
the	O
evolutionary	O
history	O
of	O
rodent	O
CoVs	O
in	O
more	O
detail	O
,	O
particularly	O
the	O
relative	O
frequencies	O
of	O
virus	O
-	O
host	B-COMP
co	O
-	O
divergence	O
and	O
cross	O
-	O
species	O
transmission	O
,	O
we	O
recovered	O
longer	O
fragments	O
of	O
CoV	O
genomes	O
from	O
previously	O
discovered	O
European	O
rodent	O
alpha	O
-	O
CoVs	O
using	O
a	O
combination	O
of	O
PCR	O
and	O
high	O
-	O
throughput	O
sequencing	O
.	O

An	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
rS1	O
(	O
rS1	O
-	O
ELISA	O
)	O
was	O
then	O
developed	O
and	O
optimized	O
by	O
checkerboard	O
assays	O
with	O
serial	O
dilutions	O
of	O
antigen	O
and	O
serum	B-COMP
.	O

Serum	B-COMP
samples	O
from	O
453	O
domestic	O
pigs	O
and	O
42	O
vaccinated	O
pigs	O
were	O
analyzed	O
by	O
the	O
indirect	O
fluorescent	O
antibody	B-COMP
(	O
IFA	O
)	O
test	O
and	O
rS1	O
-	O
ELISA	O
.	O

This	O
rS1	O
-	O
ELISA	O
was	O
then	O
applied	O
to	O
antibody	B-COMP
detection	O
in	O
inactivated	O
PEDV	O
vaccinated	O
pigs	O
.	O

Five	O
days	O
post	O
-	O
challenge	O
,	O
viral	O
load	O
,	O
clinical	O
signs	O
,	O
ciliostasis	O
,	O
tracheal	O
histopathology	O
,	O
and	O
antibody	B-COMP
titers	O
in	O
serum	B-COMP
and	O
tears	O
were	O
evaluated	O
.	O

Only	O
isolates	O
(	O
30	O
%-	O
9	O
/	O
30	O
)	O
from	O
diarrheic	O
calves	O
were	O
also	O
positive	O
for	O
fimbriae	B-COMP
,	O
specifically	O
16	O
.	O
7	O
%	O
(	O
5	O
/	O
30	O
)	O
for	O
F5	O
and	O
13	O
.	O
3	O
%	O
(	O
4	O
/	O
30	O
)	O
for	O
F18	O
.	O

TITLE	O
:	O
Mechanical	O
Ventilation	O
and	O
Extracorporeal	O
Membrane	B-COMP
Oxygena	O
tion	O
in	O
Acute	O
Respiratory	O
Insufficiency	O
.	O

In	O
this	O
study	O
,	O
a	O
recombinant	O
scFv	O
antibody	B-COMP
phage	O
display	O
library	O
was	O
constructed	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
piglets	O
infected	O
with	O
TGEV	O
.	O

Extracorporeal	O
membrane	B-COMP
pulmonary	O
oxygenation	O
(	O
ECMO	O
),	O
as	O
an	O
artificial	O
heart	O
-	O
lung	O
supporting	O
system	O
,	O
can	O
be	O
applied	O
to	O
support	O
lung	O
that	O
is	O
expected	O
to	O
recover	O
from	O
reversible	O
pathological	O
damage	O
.	O

TITLE	O
:	O
Potential	O
Intermediate	O
Hosts	B-COMP
for	O
Coronavirus	O
Transmission	O
:	O
No	O
Evidence	O
of	O
Clade	O
2c	O
Coronaviruses	O
in	O
Domestic	O
Livestock	O
from	O
Ghana	O
.	O

Rectal	O
swabs	O
and	O
serum	B-COMP
from	O
cattle	O
,	O
sheep	O
,	O
goats	O
,	O
donkeys	O
,	O
and	O
swine	O
from	O
commercial	O
and	O
household	O
farms	O
were	O
tested	O
for	O
MERS	O
-	O
CoV	O
and	O
a	O

Three	O
-	O
fold	O
diluted	O
serum	B-COMP
of	O
subjects	O
showed	O
only	O
9	O
.	O
7	O
%,	O
10	O
.	O
3	O
%,	O
and	O
2	O
.	O
2	O
%	O
reductions	O
in	O
relative	O
light	O
units	O
.	O

TITLE	O
:	O
Interferon	O
Regulatory	O
Factor	O
3	O
-	O
Mediated	O
Signaling	O
Limits	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
Coronavirus	O
Propagation	O
in	O
Cells	B-COMP
from	O
an	O
Insectivorous	O
Bat	O
.	O

Moderate	O
cytostatic	O
activity	O
against	O
cervix	O
carcinoma	O
(	O
HeLa	O
),	O
murine	O
leukemia	O
(	O
L1210	O
)	O
and	O
human	O
lymphocyte	O
(	O
CEM	O
)	O
tumor	O
cell	B-COMP
lines	O
was	O
displayed	O
by	O
the	O
protected	O
3	O
-	O
deoxy	O
derivatives	O
12b	O
,	O
12c	O
,	O
12d	O
,	O
and	O
the	O
3	O
-	O
deoxy	O
-	O
3	O
-	O
methyl	O
18a	O
,	O
18b	O
,	O
18c	O
.	O

Here	O
,	O
we	O
report	O
significantly	O
dampened	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
in	O
bat	O
primary	O
immune	O
cells	B-COMP
compared	O
to	O
human	O
or	O
mouse	O
counterparts	O
.	O

The	O
second	O
outcomes	O
were	O
to	O
determine	O
the	O
risk	O
factors	O
of	O
mortality	O
of	O
ARDS	O
in	O
leptospirosis	O
and	O
to	O
describe	O
the	O
cases	O
requiring	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
(	O
ECMO	O
).	O

Through	O
different	O
inoculation	O
routes	O
,	O
MHV	O
-	O
A59	O
can	O
provide	O
animal	O
models	O
for	O
encephalitis	O
,	O
hepatitis	O
and	O
pneumonia	O
to	O
explore	O
viral	O
life	O
machinery	O
and	O
virus	O
-	O
host	B-COMP
interactions	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
ability	O
of	O
PEDV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
in	O
improving	O
viral	O
yields	O
in	O
cell	B-COMP
culture	O
systems	O
.	O

In	O
addition	O
,	O
numerous	O
pathogens	O
have	O
been	O
found	O
to	O
encode	O
Ub	O
(	O
l	O
)-	O
ligases	O
and	O
deconjugating	O
enzymes	O
in	O
order	O
to	O
facilitate	O
infection	O
and	O
fight	O
the	O
host	B-COMP
immune	O
response	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
incidence	O
of	O
cannula	O
-	O
related	O
thrombosis	O
and	O
its	O
risk	O
factors	O
after	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

We	O
analyzed	O
consecutive	O
patients	O
with	O
severe	O
respiratory	O
failure	O
(	O
PaO2	O
/	O
FIO2	O
<	O
85	O
mm	O
Hg	O
and	O
/	O
or	O
respiratory	O
acidosis	O
with	O
pH	O
<	O
7	O
.	O
25	O
)	O
who	O
were	O
successfully	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
a	O
medical	O
ICU	O
between	O
2010	O
and	O
2017	O
.	O

After	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
weaning	O
,	O
duplex	O
sonography	O
or	O
CT	O
was	O
conducted	O
to	O
detect	O
cannula	O
-	O
related	O
thrombosis	O
.	O

Patients	O
should	O
undergo	O
routine	O
duplex	O
sonography	O
after	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
to	O
detect	O
thrombosis	O
formation	O
in	O
the	O
cannulated	O
vessel	O
.	O

Its	O
use	O
has	O
increased	O
markedly	O
in	O
the	O
last	O
decade	O
,	O
initially	O
in	O
response	O
to	O
severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
in	O
adults	O
during	O
the	O
2009	O
H1N1	O
influenza	O
epidemic	O
and	O
continuing	O
with	O
the	O
increasing	O
acceptance	O
of	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
(	O
ECMO	O
)	O
for	O
the	O
treatment	O
of	O
severe	O
respiratory	O
failure	O
in	O
adults	O
from	O
other	O
causes	O
.	O
1	O
We	O
highlight	O
the	O
use	O
of	O
ECMO	O
,	O
particularly	O
at	O
our	O
institution	O
.	O

Additionally	O
,	O
vaccinated	O
and	O
challenged	O
chickens	O
showed	O
reduced	O
viral	O
loads	O
and	O
microscopic	O
lesion	O
counts	O
in	O
tracheal	O
and	O
kidney	O
tissues	O
,	O
and	O
their	O
antibody	B-COMP
and	O
CMI	O
responses	O
were	O
negatively	O
correlated	O
with	O
viral	O
loads	O
in	O
the	O
trachea	O
and	O
kidney	O
.	O

In	O
conclusion	O
,	O
the	O
combination	O
of	O
live	O
attenuated	O
vaccine	O
containing	O
the	O
Massachusetts	O
strain	O
with	O
a	O
booster	O
dose	O
of	O
an	O
inactivated	O
vaccine	O
,	O
containing	O
a	O
BR	O
-	O
I	O
IBV	O
strain	O
,	O
confers	O
effective	O
protection	O
against	O
infection	O
with	O
nephropathogenic	O
homologous	O
IBV	O
strain	O
because	O
of	O
the	O
induction	O
of	O
consistent	O
memory	O
immune	O
responses	O
mediated	O
by	O
IgG	O
antibodies	B-COMP
and	O
TCD8	O
cells	B-COMP
in	O
the	O
mucosal	O
and	O
systemic	O
compartments	O
of	O
chickens	O
submitted	O
to	O
this	O
vaccination	O
regime	O
.	O

Their	O
relatively	O
high	O
rates	O
of	O
mutation	O
and	O
recombination	O
frequencies	O
allow	O
them	O
to	O
adapt	O
to	O
new	O
hosts	B-COMP
and	O
ecological	O
niches	O
.	O

Moreover	O
,	O
CMV	O
re	O
-	O
activation	O
was	O
confirmed	O
by	O
CMV	O
antibody	B-COMP
detection	O
,	O
and	O
we	O
administered	O
gancyclovir	O
and	O
thymosin	O
1	O
but	O
reduced	O
the	O
strength	O
of	O
the	O
immunosuppressive	O
drugs	O
.	O

TITLE	O
:	O
Mouse	O
NC	O
/	O
Jic	O
strain	O
provides	O
novel	O
insights	O
into	O
host	B-COMP
genetic	O
factors	O
for	O
malaria	O
research	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
shedding	O
and	O
antibody	B-COMP
responses	O
are	O
not	O
fully	O
understood	O
,	O
particularly	O
in	O
relation	O
to	O
underlying	O
medical	O
conditions	O
,	O
clinical	O
manifestations	O
,	O
and	O
mortality	O
.	O

Examples	O
of	O
the	O
many	O
applications	O
these	O
pseudotype	O
particles	O
can	O
be	O
used	O
in	O
include	O
investigation	O
of	O
host	B-COMP
cell	I-COMP
susceptibility	O
and	O
tropism	O
and	O
testing	O
the	O
effects	O
of	O
virus	O
entry	O
inhibitors	O
to	O
dissect	O
viral	O
entry	O
pathways	O
used	O
.	O

Cells	B-COMP
infected	O
with	O
most	O
cell	B-COMP
-	O
adapted	O
PEDVs	O
usually	O
displayed	O
large	O
syncytia	O
,	O
a	O
process	O
triggered	O
by	O
the	O
spike	O
protein	O
(	O
S	O
).	O

As	O
during	O
infection	O
by	O
other	O
viruses	O
,	O
host	B-COMP
sensing	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
induces	O
several	O
antiviral	O
pathways	O
.	O

Coronaviruses	O
,	O
including	O
MERS	O
-	O
CoV	O
,	O
potently	O
suppress	O
the	O
activation	O
of	O
these	O
pathways	O
,	O
inducing	O
only	O
modest	O
host	B-COMP
responses	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
act	O
as	O
cross	O
-	O
species	O
viruses	O
and	O
have	O
the	O
potential	O
to	O
spread	O
rapidly	O
into	O
new	O
host	B-COMP
species	O
and	O
cause	O
epidemic	O
diseases	O
.	O

The	O
patient	O
developed	O
severe	O
refractory	O
hypercapnic	O
respiratory	O
failure	O
necessitating	O
additional	O
respiratory	O
support	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
.	O

Collectively	O
,	O
these	O
antibodies	B-COMP
offer	O
new	O
ways	O
to	O
gain	O
humoral	O
protection	O
in	O
humans	O
against	O
the	O
emerging	O
MERS	O
-	O
CoV	O
by	O
targeting	O
different	O
spike	O
protein	O
epitopes	O
and	O
functions	O
.	O

ABSTRACT	O
:	O
Respiratory	O
virus	O
infections	O
in	O
hematologic	O
stem	O
cell	B-COMP
transplant	O
recipients	O
and	O
patients	O
with	O
hematologic	O
malignancies	O
are	O
increasingly	O
recognized	O
as	O
a	O
cause	O
of	O
significant	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
the	O
generation	O
of	O
the	O
attenuated	O
KNU	O
-	O
141112	O
-	O
S	O
DEL5	O
/	O
ORF3	O
virus	O
by	O
continuous	O
propagation	O
of	O
highly	O
virulent	O
G2b	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
cells	B-COMP
.	O

Thus	O
,	O
the	O
present	O
review	O
comprehensively	O
and	O
critically	O
illustrates	O
the	O
recent	O
aspects	O
on	O
the	O
epidemiology	O
of	O
the	O
virus	O
,	O
the	O
structural	O
and	O
functional	O
features	O
of	O
the	O
viral	B-COMP
genome	I-COMP
,	O
viral	O
entry	O
and	O
transmission	O
,	O
major	O
mechanisms	O
of	O
pathogenesis	O
and	O
associated	O
virulent	O
factors	O
,	O
current	O
animal	O
models	O
,	O
detection	O
methods	O
and	O
novel	O
strategies	O
for	O
the	O
development	O
of	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
review	O
further	O
illustrates	O
the	O
molecular	O
and	O
computational	O
virtual	O
screening	O
platforms	O
which	O
provide	O
insights	O
for	O
the	O
identification	O
of	O
putative	O
drug	O
targets	O
and	O
novel	O
lead	O
molecules	O
toward	O
the	O
development	O
of	O
therapeutic	O
remedies	O
.	O

TITLE	O
:	O
Rhinovirus	O
-	O
induced	O
Rapidly	O
Progressing	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
an	O
Immunocompetent	O
Host	B-COMP
.	O

Crystal	O
structures	O
indicated	O
that	O
EK1	O
can	O
form	O
a	O
stable	O
six	O
-	O
helix	O
bundle	O
structure	O
with	O
both	O
short	O
	O
-	O
HCoV	O
and	O
long	O
	O
-	O
HCoV	O
HR1s	O
,	O
further	O
supporting	O
the	O
role	O
of	O
HR1	O
region	O
as	O
a	O
viable	O
pan	B-COMP
-	O
CoV	O
target	O
site	O
.	O

The	O
host	B-COMP
differentially	O
expressed	O
genes	O
were	O
associated	O
with	O
infection	O
response	O
,	O
metabolism	O
signaling	O
and	O
organismal	O
systems	O
signaling	O
pathways	O
.	O

To	O
address	O
this	O
,	O
""""	O
unconventional	O
T	O
-	O
cells	B-COMP
(	O
UTC	O
")"""	O
-	O
T	O
,	O
NKT	O
and	O
MAIT	O
cells	B-COMP
-	O
appear	O
to	O
be	O
relevant	O
targets	O
due	O
to	O
their	O
key	O
role	O
in	O
orchestrating	O
anti	O
-	O
microbial	O
immune	O
response	O
in	O
the	O
lung	O
.	O

As	O
a	O
result	O
of	O
VPS36	O
-	O
ORF3	O
interaction	O
,	O
PEDV	O
replication	O
was	O
substantially	O
suppressed	O
in	O
cells	B-COMP
overexpressing	O
VPS36	O
.	O

The	O
current	O
study	O
employs	O
human	O
and	O
bovine	O
lung	O
microvascular	O
cells	B-COMP
,	O
as	O
well	O
as	O
pharmacologic	O
and	O
genetic	O
P53	O
modulators	O
to	O
demonstrate	O
the	O
negative	O
regulation	O
of	O
APE1	O
/	O
Ref1	O
by	O
P53	O
.	O

Although	O
there	O
has	O
been	O
extensive	O
research	O
on	O
the	O
S1	O
protein	O
of	O
TGEV	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	B-COMP
role	O
of	O
TGEV	O
-	O
S1	O
.	O

Here	O
,	O
we	O
observed	O
that	O
TGEV	O
infection	O
led	O
to	O
increased	O
UBXN1	O
expression	O
levels	O
during	O
the	O
late	O
phase	O
of	O
infection	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
.	O

ROS	O
and	O
p53	O
play	O
key	O
roles	O
in	O
regulating	O
many	O
kinds	O
of	O
cell	B-COMP
process	I-COMP
during	O
viral	O
infection	O
,	O
however	O
,	O
the	O
exact	O
function	O
in	O
PEDV	O
-	O
induced	O
apoptosis	O
remains	O
unclear	O
.	O

Treatment	O
with	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	B-COMP
),	O
significantly	O
inhibited	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
function	O
of	O
p53	O
and	O
ROS	O
in	O
the	O
interaction	O
of	O
PEDV	O
with	O
Vero	O
cells	B-COMP
.	O

In	O
the	O
quest	O
of	O
new	O
RSV	O
inhibitors	O
,	O
in	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
activity	O
of	O
a	O
series	O
of	O
variously	O
substituted	O
5	O
,	O
6	O
-	O
dichloro	O
-	O
1	O
-	O
phenyl	O
-	O
1	O
(	O
2	O
)	O
H	O
-	O
benzo	O
[	O
d	O
][	O
1	O
,	O
2	O
,	O
3	O
]	O
triazole	O
derivatives	O
in	O
cell	B-COMP
-	O
based	O
assays	O
.	O

However	O
,	O
many	O
conditions	O
,	O
including	O
cardiomyopathy	O
,	O
pulmonary	O
embolism	O
,	O
or	O
myocarditis	O
,	O
can	O
cause	O
an	O
elevation	O
in	O
serum	B-COMP
troponin	O
.	O

TITLE	O
:	O
Extension	O
of	O
the	O
known	O
distribution	O
of	O
a	O
novel	O
clade	O
C	O
betacoronavirus	O
in	O
a	O
wildlife	O
host	B-COMP
.	O

These	O
findings	O
indicate	O
that	O
the	O
Western	O
European	O
hedgehog	O
is	O
a	O
reservoir	O
host	B-COMP
of	O
EriCoV	O
in	O
the	O
absence	O
of	O
apparent	O
disease	O
.	O

OA	O
increased	O
MDA	O
level	O
in	O
lung	O
tissue	O
and	O
TNF	O
-	O
	O
and	O
IL	O
-	O
1	O
cytokine	O
levels	O
in	O
serum	B-COMP
.	O

TITLE	O
:	O
Oxygen	O
delivery	O
,	O
carbon	O
dioxide	O
removal	O
,	O
energy	O
transfer	O
to	O
lungs	O
and	O
pulmonary	O
hypertension	O
behavior	O
during	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
:	O
a	O
mathematical	O
modeling	O
approach	O
.	O

To	O
ward	O
off	O
a	O
wide	O
variety	O
of	O
pathogens	O
,	O
the	O
human	O
adaptive	O
immune	O
system	O
harbors	O
a	O
vast	O
array	O
of	O
TCRs	O
,	O
which	O
are	O
collectively	O
referred	O
to	O
as	O
the	O
TCR	B-COMP
repertoire	O
.	O

TITLE	O
:	O
Effect	O
of	O
cat	O
litters	O
on	O
feline	O
coronavirus	O
infection	O
of	O
cell	B-COMP
culture	O
and	O
cats	O
.	O

Four	O
litters	O
abrogated	O
FCoV	O
infection	O
of	O
cell	B-COMP
culture	O
,	O
nine	O
reduced	O
it	O
to	O
a	O
greater	O
or	O
lesser	O
extent	O
and	O
two	O
had	O
no	O
effect	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
in	O
a	O
Gravid	O
Patient	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
A	O
Case	O
Report	O
.	O

Any	O
damage	O
to	O
the	O
cell	B-COMP
membranes	I-COMP
under	O
conditions	O
of	O
traumatic	O
injury	O
,	O
shock	O
,	O
acute	O
respiratory	O
failure	O
,	O
destruction	O
of	O
the	O
blood	O
cells	B-COMP
against	O
the	O
background	O
of	O
hemorrhages	O
,	O
blood	O
transfusions	O
,	O
and	O
blood	O
reinfusions	O
can	O
contribute	O
to	O
the	O
enhancement	O
of	O
products	O
.	O

As	O
epidemiologic	O
and	O
etiopathologic	O
data	O
for	O
canine	O
myocarditis	O
are	O
lacking	O
,	O
we	O
performed	O
a	O
retrospective	O
study	O
using	O
nucleic	B-COMP
acid	O
extracted	O
from	O
archived	O
(	O
2007	O
to	O
2015	O
)	O
tissues	O
from	O
myocarditis	O
cases	O
and	O
control	O
dogs	O
without	O
myocardial	O
lesions	O
.	O

Serial	O
blood	O
samples	O
for	O
measurement	O
of	O
serum	B-COMP
anti	O
-	O
BCV	O
antibody	B-COMP
titers	O
and	O
nasal	O
swabs	O
for	O
detection	O
of	O
BCV	O
and	O
other	O
common	O
viral	O
and	O
bacterial	O
BRD	O
pathogens	O
were	O
collected	O
from	O
all	O
calves	O
or	O
subsets	O
of	O
calves	O
at	O
predetermined	O
times	O
from	O
birth	O
through	O
weaning	O
.	O

Previous	O
experimental	O
FIPV	O
infection	O
studies	O
suggested	O
a	O
role	O
for	O
cell	B-COMP
-	O
mediated	O
immunity	O
in	O
resistance	O
to	O
development	O
of	O
FIP	O
.	O

Nine	O
of	O
ten	O
rechallenged	O
cats	O
did	O
not	O
develop	O
FIP	O
or	O
T	O
cell	B-COMP
depletion	O
and	O
all	O
cats	O
demonstrated	O
antiviral	O
T	O
cell	B-COMP
responses	O
at	O
multiple	O
time	O
points	O
after	O
rechallenge	O
.	O

In	O
summary	O
,	O
definitive	O
adaptive	O
T	O
cell	B-COMP
responses	O
predictive	O
of	O
disease	O
outcome	O
were	O
not	O
detected	O
during	O
the	O
early	O
phase	O
of	O
primary	O
FIPV	O
infection	O
.	O

ABSTRACT	O
:	O
Eukaryotic	O
cells	B-COMP
have	O
evolved	O
a	O
number	O
of	O
survival	O
tactics	O
and	O
quality	O
control	O
pathways	O
that	O
are	O
able	O
to	O
counter	O
intrinsic	O
error	O
-	O
prone	O
mechanisms	O
and	O
allow	O
for	O
maintenance	O
of	O
cellular	B-COMP
homeostasis	O
in	O
the	O
face	O
of	O
external	O
stresses	O
.	O

As	O
obligate	O
parasites	O
,	O
viruses	O
exploit	O
host	B-COMP
-	O
cell	B-COMP
machinery	O
to	O
glycosylate	O
their	O
own	O
proteins	O
during	O
replication	O
.	O

We	O
analyzed	O
the	O
mechanisms	O
by	O
which	O
HBD	O
2	O
primes	O
innate	O
antiviral	O
immunity	O
and	O
polarized	O
activation	O
of	O
macrophage	O
-	O
like	O
THP	O
-	O
1	O
cells	B-COMP
using	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	O
.	O

Single	O
intranasal	O
immunization	O
with	O
AdC68	O
-	O
S	O
induced	O
robust	O
and	O
sustained	O
neutralizing	O
antibody	B-COMP
and	O
T	O
cell	B-COMP
responses	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
corona	O
pre	O
-	O
coating	O
differentially	O
affects	O
viral	O
infectivity	O
and	O
immune	O
cell	B-COMP
activation	O
.	O

Herein	O
,	O
we	O
generated	O
a	O
bacterial	O
outer	B-COMP
membrane	I-COMP
vesicles	B-COMP
(	O
OMVs	B-COMP
)-	O
based	O
vaccine	O
presenting	O
the	O
antigenic	O
stable	O
chimeric	O
fusion	O
protein	O
of	O
the	O
H1	O
-	O
type	O
haemagglutinin	O
(	O
HA	O
)	O
of	O
the	O
pandemic	O
influenza	O
A	O
virus	O
(	O
H1N1	O
)	O
strain	O
from	O
2009	O
(	O
H1N1pdm09	O
)	O
and	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
(	O
OMVs	B-COMP
-	O
H1	O
/	O
RBD	O
).	O

The	O
interferon	O
(	O
IFN	O
)-	O
mediated	O
antiviral	O
response	O
is	O
an	O
important	O
component	O
of	O
virus	O
-	O
host	B-COMP
interactions	O
and	O
plays	O
an	O
essential	O
role	O
in	O
inhibiting	O
virus	O
infection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
PDCoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
antagonizes	O
porcine	O
IFN	O
-	O
	O
production	O
after	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
infection	O
or	O
poly	O
(	O
I	O
:	O
C	O
)	O
stimulation	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
nsP12	O
genomic	O
region	O
suggests	O
that	O
the	O
sequences	O
group	O
according	O
to	O
host	B-COMP
family	O
and	O
sampling	O
location	O
.	O

Cell	B-COMP
tropism	O
experiments	O
suggested	O
that	O
HLJ	O
-	O
073	O
could	O
effectively	O
replicate	O
in	O
canine	O
macrophages	O
/	O
monocytes	O
and	O
human	O
THP	O
-	O
1	O
cells	B-COMP
.	O

TITLE	O
:	O
Antibodies	B-COMP
and	O
vaccines	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Through	O
a	O
histological	O
analysis	O
,	O
we	O
found	O
that	O
ATN	O
-	O
161	O
-	O
treated	O
mice	O
only	O
showed	O
pathological	O
changes	O
in	O
neuronal	O
cytoplasmic	B-COMP
swelling	O
at	O
5	O
day	O
post	O
-	O
infection	O
.	O

A	O
homogeneous	O
cell	B-COMP
line	O
,	O
designated	O
IPI	O
-	O
FX	O
,	O
obtained	O
from	O
IPI	O
-	O
2I	O
cells	B-COMP
by	O
sub	O
-	O
cloning	O
with	O
limited	O
serial	O
dilutions	O
,	O
was	O
found	O
to	O
be	O
highly	O
susceptible	O
to	O
PEDV	O
.	O

The	O
spleen	O
is	O
the	O
largest	O
peripheral	O
immune	O
organ	O
of	O
the	O
body	O
,	O
containing	O
a	O
large	O
number	O
of	O
immune	O
cells	B-COMP
and	O
secreting	O
inflammatory	O
factors	O
.	O

ABSTRACT	O
:	O
Thiazole	O
is	O
a	O
good	O
nucleus	B-COMP
owing	O
to	O
its	O
various	O
pharmaceutical	O
applications	O
.	O

More	O
importantly	O
GSLS	O
-	O
Se	O
was	O
found	O
to	O
promote	O
early	O
production	O
and	O
prolong	O
the	O
duration	O
of	O
the	O
antibody	B-COMP
responses	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
of	O
host	B-COMP
factors	O
co	O
-	O
opted	O
and	O
signaling	O
pathways	O
activated	O
during	O
HCoV	O
infection	O
,	O
with	O
an	O
emphasis	O
on	O
HCoV	O
-	O
infection	O
-	O
induced	O
stress	O
response	O
,	O
autophagy	O
,	O
apoptosis	O
,	O
and	O
innate	O
immunity	O
.	O

Experimental	O
work	O
carried	O
on	O
to	O
determine	O
the	O
mode	O
of	O
action	O
of	O
the	O
most	O
potent	O
IIa	O
,	O
containing	O
tetravalent	O
branched	O
arms	O
,	O
demonstrated	O
that	O
it	O
interacts	O
with	O
the	O
viral	O
envelopes	O
of	O
HIV	O
,	O
EV71	O
and	O
HSV	O
-	O
2	O
and	O
thus	O
may	O
prevent	O
virus	O
attachment	O
to	O
the	O
host	B-COMP
cell	I-COMP
.	O

Laboratory	O
tests	O
revealed	O
leukopenia	O
,	O
thrombocytopenia	O
and	O
increased	O
serum	B-COMP
levels	O
of	O
symmetric	O
dimethylarginine	O
(	O
SDMA	O
)	O
and	O
bilirubin	O
.	O

TITLE	O
:	O
SARS	O
-	O
Coronavirus	O
Open	O
Reading	O
Frame	O
-	O
8b	O
triggers	O
intracellular	B-COMP
stress	O
pathways	O
and	O
activates	O
NLRP3	O
inflammasomes	O
.	O

Mechanistically	O
,	O
ORF8b	O
interacts	O
directly	O
with	O
the	O
Leucine	O
Rich	O
Repeat	O
domain	O
of	O
NLRP3	O
and	O
localizes	O
with	O
NLRP3	O
and	O
ASC	O
in	O
cytosolic	B-COMP
dot	O
-	O
like	O
structures	O
.	O

The	O
apoptosis	O
of	O
ST	O
cells	B-COMP
induced	O
by	O
PDCoV	O
infection	O
was	O
studied	O
in	O
this	O
research	O
.	O

In	O
ST	O
cells	B-COMP
,	O
caspase	O
activity	O
assay	O
showed	O
that	O
the	O
activity	O
of	O
caspase	O
3	O
,	O
caspase	O
8	O
and	O
caspase	O
9	O
increased	O
significantly	O
with	O
the	O
infection	O
of	O
PDCoV	O
,	O
but	O
not	O
observed	O
in	O
UV	O
irradiated	O
PDCoV	O
-	O
infected	O
cells	B-COMP
,	O
indicating	O
that	O
PDCoV	O
infection	O
activated	O
both	O
endogenous	O
and	O
exogenous	O
apoptotic	O
pathways	O
in	O
ST	O
cells	B-COMP
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
depended	O
on	O
viral	O
replication	O
.	O

To	O
further	O
investigate	O
the	O
endogenous	O
apoptosis	O
induced	O
by	O
PDCoV	O
,	O
cytochrome	O
C	O
and	O
apoptosis	O
-	O
inducing	O
factors	O
in	O
cytoplasm	B-COMP
and	O
mitochondria	B-COMP
were	O
detected	O
.	O

In	O
both	O
organs	O
,	O
the	O
MBL	O
-	O
positive	O
cells	B-COMP
occupy	O
antigen	O
-	O
exposed	O
areas	O
,	O
indicating	O
that	O
GC	O
formation	O
depends	O
on	O
resident	O
precursors	O
of	O
dendritic	B-COMP
cells	B-COMP
.	O

ABSTRACT	O
:	O
Models	O
of	O
host	B-COMP
-	O
microbe	O
dynamics	O
typically	O
assume	O
a	O
single	O
-	O
host	B-COMP
population	O
infected	O
by	O
a	O
single	O
pathogen	O
.	O

RESULTS	O
:	O
We	O
found	O
286	O
CA	O
-	O
RVI	O
cases	O
,	O
including	O
85	O
solid	O
organ	O
transplantation	O
recipients	O
(	O
G1	O
),	O
61	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
recipients	O
(	O
G2	O
),	O
and	O
140	O
non	O
-	O
transplant	O
critically	O
ill	O
patients	O
in	O
ICU	O
(	O
G3	O
),	O
excluding	O
those	O
with	O
repeated	O
isolation	O
within	O
30	O
days	O
.	O

TITLE	O
:	O
Effects	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
on	O
tight	B-COMP
junction	I-COMP
protein	O
gene	O
expression	O
and	O
morphology	O
of	O
the	O
intestinal	O
mucosa	O
in	O
pigs	O
.	O

ABSTRACT	O
:	O
Tight	B-COMP
junction	I-COMP
proteins	O
are	O
important	O
for	O
the	O
maintenance	O
and	O
repair	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
.	O

TITLE	O
:	O
Virus	O
Envelope	B-COMP
-	O
Like	O
Self	O
-	O
Assembled	O
Nanoparticles	O
Based	O
on	O
ABSTRACT	O
:	O
Pathogen	O
-	O
sized	O
particles	O
exhibit	O
better	O
performance	O
in	O
inducing	O
immune	O
responses	O
than	O
soluble	O
protein	O
antigens	O
.	O

After	O
multivariable	O
analysis	O
was	O
performed	O
,	O
factors	O
significantly	O
associated	O
with	O
moderate	O
to	O
severe	O
disease	O
at	O
the	O
initial	O
diagnosis	O
were	O
Pediatric	O
Risk	O
of	O
Mortality	O
III	O
score	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
1	O
.	O
15	O
;	O
p	O
=	O
0	O
.	O
004	O
),	O
underlying	O
oncologic	O
/	O
hematologic	O
disorder	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
32	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
12	O
-	O
0	O
.	O
77	O
;	O
p	O
=	O
0	O
.	O
012	O
),	O
and	O
serum	B-COMP
albumin	O
level	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
46	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
80	O
;	O
p	O
=	O
0	O
.	O
006	O
),	O
whereas	O
underlying	O
oncologic	O
/	O
hematologic	O
disorder	O
(	O
odds	O
ratio	O
,	O
5	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
33	O
-	O
21	O
.	O
4	O
)	O
and	O
hemoglobin	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
44	O
-	O
0	O
.	O
89	O
)	O
predicted	O
the	O
progression	O
of	O
this	O
syndrome	O
within	O
7	O
days	O
.	O

Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
in	O
Dromedaries	O
in	O
Ethiopia	O
Is	O
Antigenically	O
Different	O
From	O
the	O
Middle	O
East	O
Isolate	O
EMC	B-COMP
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
47	O
year	O
old	O
male	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
bariatric	O
surgery	O
,	O
requiring	O
a	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
U937	O
cell	B-COMP
model	O
was	O
validated	O
by	O
testing	O
a	O
panel	O
of	O
known	O
antiviral	O
and	O
immunomodulatory	O
agents	O
and	O
screening	O
a	O
drug	O
library	O
consisting	O
of	O
1280	O
compounds	O
comprised	O
mostly	O
of	O
FDA	O
-	O
approved	O
drugs	O
.	O

TITLE	O
:	O
Microarray	O
analysis	O
of	O
infectious	O
bronchitis	O
virus	O
infection	O
of	O
chicken	O
primary	O
dendritic	B-COMP
cells	B-COMP
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
serum	B-COMP
SP	O
-	O
D	O
levels	O
were	O
analyzed	O
in	O
37	O
CDH	O
infants	O
and	O
5	O
control	O
infants	O
using	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	O
.	O

Additionally	O
,	O
anti	O
-	O
canine	O
respiratory	O
coronavirus	O
antibody	B-COMP
concentrations	O
were	O
measured	O
in	O
paired	O
blood	O
samples	O
from	O
30	O
acutely	O
diseased	O
dogs	O
.	O

In	O
addition	O
,	O
CXCL5	O
neutralizing	O
antibody	B-COMP
effectively	O
alleviated	O
inflammatory	O
response	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
pulmonary	O
edema	O
,	O
and	O
decreased	O
the	O
expression	O
levels	O
of	O
MMP2	O
and	O
MMP9	O
compared	O
to	O
LPS	O
-	O
induced	O
ARDS	O
.	O

TITLE	O
:	O
Biochemical	O
Analysis	O
of	O
Coronavirus	O
Spike	O
Glycoprotein	O
Conformational	O
Intermediates	O
during	O
Membrane	B-COMP
Fusion	O
.	O

TITLE	O
:	O
Patchy	O
Amphiphilic	O
Dendrimers	O
Bind	O
Adenovirus	O
and	O
Control	O
Its	O
Host	B-COMP
Interactions	O
and	O
in	O
Vivo	O
Distribution	O
.	O

Patchy	O
dendrimers	O
bound	O
to	O
the	O
surface	O
of	O
Ad5	O
formed	O
a	O
synthetic	O
polymer	O
corona	O
that	O
greatly	O
altered	O
various	O
host	B-COMP
interactions	O
of	O
Ad5	O
as	O
well	O
as	O

We	O
found	O
that	O
immunization	O
with	O
candidate	O
vaccines	O
via	O
intranasal	O
route	O
induced	O
S1	O
-	O
specific	O
IgG	O
antibodies	B-COMP
and	O
neutralizing	O
antibodies	B-COMP
against	O
MERS	O
spike	O
pseudotyped	O
virus	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
white	O
blood	O
cell	B-COMP
counts	O
and	O
haptoglobin	O
(	O
Hp	O
)	O
and	O
serum	B-COMP
amyloid	O
A	O
(	O
SAA	O
)	O
levels	O
in	O
post	O
-	O
weaned	O
calves	O
with	O
diarrhea	O
caused	O
by	O
BCoV	O
and	O
those	O
that	O
recovered	O
from	O
diarrhea	O
.	O

Here	O
,	O
using	O
TGEV	O
nsp1	O
as	O
a	O
model	O
to	O
explore	O
the	O
function	O
of	O
this	O
protein	O
in	O
alphacoronaviruses	O
,	O
we	O
demonstrate	O
that	O
alphacoronavirus	O
nsp1	O
inhibits	O
host	B-COMP
gene	O
expression	O
.	O

T	O
-	O
cell	B-COMP
responses	O
were	O
detected	O
in	O
47	O
(	O
71	O
%)	O
of	O
66	O
participants	O
after	O
two	O
vaccinations	O
and	O
in	O
44	O
(	O
76	O
%)	O
of	O
58	O
participants	O
after	O
three	O
vaccinations	O
.	O

Thrombocytopenia	O
,	O
anemia	O
and	O
elevated	O
serum	B-COMP
transaminases	O
were	O
noted	O
in	O
91	O
%,	O
41	O
%	O
and	O
30	O
%	O
respectively	O
;	O
coagulopathy	O
and	O
hypoalbuminemia	O
were	O
seen	O
in	O
36	O
%	O
each	O
.	O

Blocking	O
IFN	O
-	O
I	O
signaling	O
resulted	O
in	O
delayed	O
virus	O
clearance	O
,	O
enhanced	O
neutrophil	O
infiltration	O
,	O
and	O
impaired	O
MERS	O
-	O
CoV	O
-	O
specific	O
T	O
cell	B-COMP
responses	O
.	O

TITLE	O
:	O
Spike	O
proteins	O
of	O
novel	O
MERS	O
-	O
coronavirus	O
isolates	O
from	O
North	O
-	O
and	O
West	O
-	O
African	O
dromedary	O
camels	O
mediate	O
robust	O
viral	O
entry	O
into	O
human	O
target	O
cells	B-COMP
.	O

This	O
network	O
meta	O
-	O
analysis	O
supports	O
the	O
use	O
of	O
prone	O
positioning	O
and	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
addition	O
to	O
lung	O
protective	O
ventilation	O
in	O
patients	O
with	O
ARDS	O
.	O

The	O
present	O
case	O
report	O
offers	O
the	O
first	O
video	O
imaging	O
evidence	O
of	O
intraoperative	O
visible	O
air	O
bubbling	O
as	O
a	O
sign	O
of	O
a	O
massive	O
VAE	O
during	O
prone	O
-	O
position	O
spine	B-COMP
surgery	O
.	O

The	O
reported	O
isolate	O
was	O
identified	O
by	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	O
PCR	O
assay	O
targeting	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
and	O
,	O
further	O
characterized	O
by	O
full	O
-	O
length	O
spike	O
(	O
S1	O
)	O
gene	O
sequencing	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
a	O
bacterial	O
artificial	O
chromosome	B-COMP
-	O
based	O
reverse	O
genetics	O
system	O
to	O
gain	O
more	O
insights	O
into	O
FIP	O
caused	O
by	O
the	O
C3633	O
strain	O
.	O

Recent	O
crucial	O
advances	O
in	O
determining	O
genetic	O
susceptibility	O
and	O
understanding	O
how	O
T	O
cells	B-COMP
recognise	O
certain	O
medications	O
or	O
their	O
metabolites	O
via	O
the	O
major	O
histocompatibility	O
complex	O
and	O
the	O
effects	O
of	O
cofactors	O
,	O
have	O
led	O
to	O
the	O
implementation	O
of	O
cost	O
-	O
effective	O
screening	O
programs	O
enabling	O
prevention	O
in	O
a	O
number	O
of	O
countries	O
,	O
and	O
to	O
further	O
understanding	O
of	O
the	O
patho	O
-	O
mechanisms	O
involved	O
in	O
SCARs	O
and	O
their	O
significance	O
.	O

ABSTRACT	O
:	O
Interferon	O
gamma	O
(	O
IFN	O
-	O
	O
)	O
is	O
best	O
known	O
for	O
its	O
ability	O
to	O
regulate	O
host	B-COMP
immune	O
responses	O
;	O
however	O
,	O
its	O
direct	O
antiviral	O
activity	O
is	O
less	O
well	O
studied	O
.	O

After	O
starting	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
patients	O
were	O
switched	O
to	O
the	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
mode	O
with	O
1	O
second	O
of	O
24	O
cm	O
H2O	O
high	O
pressure	O
and	O
2	O
seconds	O
of	O
12	O
cm	O
H2O	O
low	O
pressure	O
for	O
24	O
hours	O
.	O

Swabs	O
were	O
taken	O
during	O
stable	O
periods	O
(	O
n	O
=	O
1909	O
),	O
at	O
URTI	O
onset	O
(	O
n	O
=	O
391	O
),	O
10	O
days	O
after	O
the	O
URTI	O
(	O
n	O
=	O
356	O
)	O
and	O
during	O
an	O
AECOPD	O
(	O
n	O
=	O
177	O
)	O
and	O
tested	O
using	O
a	O
multiplex	O
nucleic	B-COMP
acid	O
amplification	O
test	O
.	O

Coronaviruses	O
bud	O
into	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	B-COMP
)-	O
Golgi	B-COMP
intermediate	O
compartment	O
(	O
ERGIC	B-COMP
),	O
but	O
the	O
mechanisms	O
by	O
which	O
M	O
proteins	O
are	O
transported	O
from	O
their	O
site	O
of	O
synthesis	O
,	O
the	O
ER	B-COMP
,	O
to	O
the	O
budding	O
site	O
remain	O
poorly	O
understood	O
.	O

To	O
investigate	O
the	O
inhibition	O
effect	O
of	O
HY	O
on	O
IBV	O
infection	O
in	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	B-COMP
,	O
3	O
different	O
experimental	O
designs	O
:	O
pre	O
-	O
treatment	O
of	O
cells	B-COMP
prior	O
to	O
IBV	O
infection	O
,	O
direct	O
treatment	O
of	O
IBV	O
-	O
infected	O
cells	B-COMP
,	O
and	O
pre	O
-	O
treatment	O
of	O
IBV	O
prior	O
to	O
cell	B-COMP
infection	O
were	O
used	O
.	O

Furthermore	O
,	O
HY	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	O
in	O
CEK	O
cells	B-COMP
,	O
and	O
significantly	O
reduced	O
the	O
mRNA	O
expression	O
levels	O
of	O
Fas	O
,	O
FasL	O
,	O
JNK	O
,	O
Bax	O
,	O
Caspase	O
3	O
,	O
and	O
Caspase	O
8	O
,	O
and	O
significantly	O
increased	O
Bcl	O
-	O
2	O
mRNA	O
expression	O
level	O
in	O
CEK	O
cells	B-COMP
.	O

Domain	O
mapping	O
of	O
antibody	B-COMP
epitopes	O
indicated	O
the	O
presence	O
of	O
conserved	O
epitope	O
(	O
s	O
)	O
particularly	O
in	O
the	O
CD	O
domains	O
of	O
S1	O
.	O

As	O
a	O
proof	O
-	O
of	O
-	O
principle	O
,	O
we	O
demonstrate	O
that	O
host	B-COMP
gene	O
expression	O
can	O
be	O
modulated	O
post	O
-	O
differentiation	O
via	O
inducible	O
short	O
hairpin	O
(	O
sh	O
)	O
RNA	O
-	O
mediated	O
knockdown	O
.	O

Combined	O
,	O
these	O
results	O
validate	O
our	O
newly	O
established	O
protocol	O
for	O
the	O
genetic	O
modification	O
of	O
hAEC	O
cultures	O
,	O
thereby	O
unlocking	O
a	O
unique	O
potential	O
for	O
detailed	O
molecular	O
characterization	O
of	O
virus	O
-	O
host	B-COMP
interactions	O
in	O
human	O
respiratory	O
epithelium	O
.	O

We	O
observed	O
significant	O
variability	O
in	O
potential	O
for	O
lung	O
recruitment	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
requiring	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Six	O
subgenomic	O
mRNAs	O
containing	O
the	O
leader	O
-	O
body	O
junction	O
sites	O
,	O
including	O
a	O
bicistronic	O
mRNA	O
encoding	O
the	O
accessory	O
NS7a	O
and	O
NS7b	O
genes	O
,	O
were	O
experimentally	O
identified	O
in	O
SeACoV	O
-	O
infected	O
cells	B-COMP
.	O

Cellular	B-COMP
ultrastructural	O
changes	O
induced	O
by	O
SeACoV	O
infection	O
were	O
visualized	O
by	O
electron	O
microscopy	O
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barre	O
syndrome	O
(	O
GBS	O
)	O
is	O
an	O
autoimmune	O
disease	O
on	O
the	O
injury	O
of	O
peripheral	O
nerve	O
myelin	B-COMP
proteins	O
or	O
axon	B-COMP
,	O
of	O
which	O
the	O
acute	O
motor	O
axonal	O
neuropathy	O
(	O
AMAN	O
)	O
as	O
a	O
subtype	O
is	O
of	O
infrequence	O
and	O
an	O
extremely	O
low	O
incidence	O
of	O
post	O
-	O
operation	O
.	O

In	O
the	O
2008	O
-	O
2012	O
cohort	O
,	O
the	O
non	O
-	O
survivors	O
developed	O
AKI	O
earlier	O
(	O
day	O
0	O
admission	O
vs	O
.	O
day	O
3	O
admission	O
,	O
p	O
=	O
0	O
.	O
039	O
),	O
and	O
were	O
initiated	O
on	O
RRT	O
at	O
lower	O
serum	B-COMP
creatinine	O
level	O
(	O
173	O
.	O
5	O
mol	O
/	O
L	O
vs	O
.	O
254	O
.	O
0	O
mol	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
042	O
),	O
when	O
compared	O
to	O
the	O
survivors	O
in	O
this	O
same	O
cohort	O
.	O

However	O
,	O
most	O
human	O
pathogens	O
target	O
other	O
cell	B-COMP
types	O
,	O
including	O
epithelial	O
,	O
endothelial	O
and	O
mesenchymal	O
cells	B-COMP
.	O

MERS	O
-	O
CoV	O
encodes	O
5	O
accessory	O
proteins	O
and	O
generally	O
,	O
they	O
do	O
not	O
participate	O
in	O
the	O
genome	O
transcription	O
and	O
replication	O
but	O
rather	O
are	O
involved	O
in	O
viral	O
evasion	O
of	O
the	O
host	B-COMP
innate	O
immune	O
responses	O
.	O

The	O
cytopathogenicity	O
assays	O
demonstrated	O
that	O
pGenesil	O
-	O
M	O
and	O
pGenesil	O
-	O
N	O
protected	O
ST	O
cells	B-COMP
against	O
pathological	O
changes	O
with	O
high	O
specificity	O
and	O
efficacy	O
.	O

TITLE	O
:	O
Serum	B-COMP
Exosomal	O
MicroRNAs	O
Predict	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Events	O
in	O
Patients	O
with	O
Severe	O
Community	O
-	O
Acquired	O
Pneumonia	O
.	O

Exosomes	O
in	O
serum	B-COMP
were	O
isolated	O
by	O
ultracentrifugation	O
method	O
and	O
identified	O
by	O
Transmission	O
Electron	O
Microscopy	O
.	O

A	O
key	O
step	O
in	O
the	O
MERS	O
-	O
CoV	O
replication	O
cycle	O
is	O
the	O
fusion	O
of	O
the	O
virus	O
and	O
host	O
cell	B-COMP
membranes	I-COMP
mediated	O
by	O
the	O
virus	O
spike	O
protein	O
,	O
S	O
.	O
The	O
location	O
of	O
the	O
fusion	O
peptide	O
within	O
the	O
MERS	O
S	O
protein	O
has	O
not	O
been	O
precisely	O
mapped	O
.	O

Mutations	O
preventing	O
membrane	B-COMP
binding	O
in	O
vitro	O
also	O
abolished	O
S	O
-	O
mediated	O
syncytium	O
formation	O
consistent	O
with	O
the	O
identified	O
peptide	O
acting	O
as	O
the	O
fusion	O
peptide	O
for	O
the	O
S	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O

Notably	O
,	O
a	O
commercial	O
ELISA	O
kit	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
IBV	O
did	O
not	O
react	O
with	O
sera	B-COMP
against	O
all	O
types	O
of	O
IBVs	O
.	O

ABSTRACT	O
:	O
Sickle	O
cell	B-COMP
disease	O
(	O
SCD	O
)	O
is	O
a	O
hereditary	O
hemoglobinopathy	O
resulting	O
in	O
sickling	O
hemoglobin	O
.	O

In	O
the	O
present	O
work	O
,	O
a	O
novel	O
biotinylated	O
nanobody	O
-	O
based	O
blocking	O
ELISA	O
(	O
bELISA	O
)	O
was	O
developed	O
to	O
detect	O
anti	O
-	O
PEDV	O
antibodies	B-COMP
in	O
clinical	O
pig	O
serum	B-COMP
.	O

One	O
hundred	O
and	O
fifty	O
clinical	O
serum	B-COMP
samples	O
were	O
tested	O
by	O
both	O
newly	O
developed	O
bELISA	O
and	O
commercial	O
kits	O
.	O

TITLE	O
:	O
Detection	O
of	O
MERS	O
-	O
CoV	O
antigen	O
on	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
nasal	O
tissue	O
of	O
alpacas	O
by	O
immunohistochemistry	O
using	O
human	O
monoclonal	O
antibodies	B-COMP
directed	O
against	O
different	O
epitopes	O
of	O
the	O
spike	O
protein	O
.	O

In	O
the	O
current	O
study	O
,	O
eight	O
human	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
with	O
neutralizing	O
and	O
non	O
-	O
neutralizing	O
capabilities	O
,	O
directed	O
against	O
different	O
epitopes	O
of	O
the	O
MERS	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
(	O
MERS	O
-	O
S	O
)	O
protein	O
,	O
were	O
investigated	O
with	O
regard	O
to	O
their	O
ability	O
to	O
immunohistochemically	O
detect	O
respective	O
epitopes	O
on	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
nasal	O
tissue	O
sections	O
of	O
MERS	O
-	O
CoV	O
experimentally	O
infected	O
alpacas	O
.	O

Like	O
other	O
coronaviruses	O
,	O
PEDV	O
makes	O
use	O
of	O
a	O
large	O
,	O
trimeric	O
spike	O
(	O
S	O
)	O
glycoprotein	O
to	O
mediate	O
membrane	B-COMP
fusion	O
and	O
gain	O
entry	O
into	O
host	B-COMP
cells	B-COMP
.	O

TITLE	O
:	O
Lung	O
endothelial	O
cell	B-COMP
antigen	O
cross	O
-	O
presentation	O
to	O
CD8	O
ABSTRACT	O
:	O
Malaria	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
are	O
life	O
-	O
threatening	O
manifestations	O
of	O
severe	O
malaria	O
infections	O
.	O

TITLE	O
:	O
Screening	O
pulmonary	O
angiogram	O
and	O
the	O
effect	O
on	O
anticoagulation	O
strategies	O
in	O
severe	O
respiratory	O
failure	O
patients	O
on	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
the	O
treatment	O
of	O
severe	O
respiratory	O
failure	O
in	O
adults	O
continues	O
to	O
increase	O
with	O
survival	O
improving	O
;	O
however	O
,	O
it	O
remains	O
associated	O
with	O
serious	O
complications	O
.	O

We	O
report	O
that	O
polyclonal	O
cell	B-COMP
populations	O
and	O
a	O
clonal	O
isolate	O
,	O
termed	O
Fcwf	O
-	O
4	O
IRN	O
,	O
exhibited	O
significantly	O
diminished	O
IFN	O
-	O
responsiveness	O
and	O
allowed	O
FIPV	O
replication	O
kinetics	O
comparable	O
to	O
parental	O
cells	B-COMP
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
replication	O
of	O
FIPV	O
is	O
enhanced	O
by	O
ectopic	O
expression	O
of	O
a	O
host	B-COMP
serine	O
protease	O
,	O
TMPRSS2	O
,	O
in	O
these	O
cells	B-COMP
.	O

These	O
proteomic	O
data	O
will	O
provide	O
insights	O
into	O
the	O
understanding	O
of	O
specific	O
cellular	B-COMP
responses	O
to	O
the	O
accessory	O
protein	O
during	O
PDCoV	O
infection	O
.	O

Potently	O
neutralizing	O
antibodies	B-COMP
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
have	O
been	O
characterized	O
,	O
but	O
much	O
less	O
is	O
known	O
about	O
antibodies	B-COMP
targeting	O
non	O
-	O
RBD	O
epitopes	O
.	O

These	O
results	O
advance	O
our	O
understanding	O
of	O
antibody	B-COMP
-	O
mediated	O
neutralization	O
of	O
coronaviruses	O
and	O
should	O
facilitate	O
the	O
development	O
of	O
immunotherapeutics	O
and	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O

Additionally	O
,	O
16	O
of	O
the	O
host	B-COMP
cell	I-COMP
endogenous	O
miRNAs	O
were	O
predicted	O
as	O
potential	O
contributors	O
to	O
the	O
modulation	O
of	O
innate	O
immune	O
response	O
affected	O
by	O
PDCoV	O
.	O
Our	O
research	O
findings	O
indicated	O
that	O
the	O
innate	O
immune	O
-	O
associated	O
genes	O
and	O
signaling	O
pathways	O
in	O
PK	O
-	O
15	O
cells	B-COMP
could	O
be	O
modified	O
by	O
the	O
infection	O
of	O
PDCoV	O
,	O
which	O
provides	O
a	O
fundamental	O
foundation	O
for	O
further	O
studies	O
to	O
better	O
understand	O
the	O
mechanism	O
of	O
PDCoV	O
infections	O
,	O
so	O
as	O
to	O
effectively	O
control	O
and	O
prevent	O
PDCoV	O
-	O
induced	O
swine	O
diarrheal	O
disease	O
outbreaks	O
.	O

These	O
results	O
demonstrate	O
that	O
integrin	O
v3	O
enhances	O
PEDV	O
replication	O
in	O
Vero	O
E6	O
cells	B-COMP
and	O
IECs	O
.	O

Following	O
generation	O
of	O
RVP	O
-	O
MERS	O
/	O
S1	O
and	O
RVP	O
,	O
our	O
analysis	O
revealed	O
that	O
they	O
shared	O
similar	O
growth	O
properties	O
,	O
with	O
the	O
expression	O
of	O
S1	O
in	O
RVP	O
-	O
MERS	O
/	O
S1	O
-	O
infected	O
cells	B-COMP
confirmed	O
by	O
immunofluorescence	O
and	O
western	O
blot	O
,	O
and	O
the	O
immunogenicity	O
and	O
pathogenicity	O
evaluated	O
using	O
mouse	O
infection	O
experiments	O
.	O

TGEV	O
infection	O
provokes	O
mitochondrial	B-COMP
damage	O
of	O
porcine	O
intestinal	O
epthelial	O
cell	B-COMP
(	O
IPEC	O
),	O
which	O
is	O
responsible	O
for	O
inflammation	O
and	O
cell	B-COMP
death	O
.	O

TITLE	O
:	O
An	O
in	O
vivo	O
cell	B-COMP
-	O
based	O
assay	O
for	O
investigating	O
the	O
specific	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
N	O
-	O
protein	O
and	O
its	O
viral	O
RNA	O
packaging	O
sequence	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
serves	O
multiple	O
functions	O
in	O
viral	O
replication	O
,	O
transcription	O
,	O
and	O
assembly	O
of	O
the	O
viral	B-COMP
genome	I-COMP
complex	O
.	O

While	O
recent	O
studies	O
have	O
uncovered	O
the	O
sequence	O
of	O
this	O
packaging	O
signal	O
,	O
little	O
is	O
known	O
about	O
the	O
specific	O
interaction	O
between	O
the	O
N	O
-	O
protein	O
and	O
the	O
packaging	O
signal	O
sequence	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
this	O
interaction	O
drives	O
viral	B-COMP
genome	I-COMP
packaging	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
Group	O
A	O
streptococcus	O
induced	O
toxic	O
shock	O
syndrome	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
-	O
effectiveness	O
of	O
venoarterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
A	O
case	O
report	O
.	O

IFI204	O
and	O
other	O
p200	O
family	O
proteins	O
are	O
highly	O
expressed	O
in	O
mouse	O
hepatitis	O
coronavirus	O
-	O
infected	O
bone	O
marrow	O
-	O
derived	O
dendritic	B-COMP
cells	B-COMP
.	O

RESULTS	O
:	O
We	O
compared	O
vaccination	O
status	O
of	O
2880	O
people	O
with	O
non	O
-	O
influenza	O
respiratory	O
viruses	O
to	O
3240	O
people	O
with	O
pan	B-COMP
-	O
negative	O
results	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
virus	O
-	O
host	B-COMP
interactions	O
during	O
these	O
respiratory	O
infections	O
will	O
most	O
probably	O
be	O
pivotal	O
to	O
ultimately	O
meet	O
these	O
challenges	O
.	O

This	O
review	O
attempts	O
to	O
provide	O
a	O
comparative	O
overview	O
of	O
the	O
knowledge	O
about	O
an	O
important	O
part	O
of	O
the	O
interaction	O
between	O
respiratory	O
viruses	O
and	O
their	O
host	B-COMP
:	O
the	O
arms	O
race	O
between	O
host	B-COMP
innate	O
immunity	O
and	O
viral	O
innate	O
immune	O
evasion	O
.	O

ABSTRACT	O
:	O
Despite	O
high	O
sequence	O
similarity	O
between	O
pandemic	O
and	O
seasonal	O
influenza	O
viruses	O
,	O
there	O
is	O
extreme	O
variation	O
in	O
host	B-COMP
pathogenicity	O
from	O
one	O
viral	O
strain	O
to	O
the	O
next	O
.	O

Qualitative	O
polymerase	O
chain	O
reaction	O
showed	O
viral	B-COMP
genome	I-COMP
in	O
the	O
nasal	O
swabs	O
of	O
10	O
(	O
20	O
.	O
8	O
%)	O
patients	O
,	O
including	O
coronavirus	O
229E	O
(	O
three	O
cases	O
),	O
coronavirus	O
HKU1	O
(	O
two	O
cases	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
two	O
cases	O
),	O
coronavirus	O
OC43	O
(	O
one	O
case	O
),	O
coronavirus	O
NL63	O
(	O
one	O
case	O
),	O
and	O
adenovirus	O
(	O
one	O
case	O
).	O

Upon	O
infection	O
,	O
cyclophilin	O
A	O
stays	O
evenly	O
distributed	O
throughout	O
the	O
cell	B-COMP
,	O
whereas	O
cyclophilin	O
B	O
concentrates	O
at	O
ER	O
-	O
bleb	B-COMP
-	O
like	O
structures	O
.	O

Overall	O
,	O
the	O
long	O
-	O
term	O
prognosis	O
was	O
satisfactory	O
,	O
suggesting	O
that	O
this	O
procedure	O
is	O
less	O
invasive	O
and	O
effective	O
for	O
treatment	O
of	O
MAS	B-COMP
due	O
to	O
TA	O
,	O
in	O
emergencies	O
.	O

The	O
major	O
effect	O
of	O
these	O
pathways	O
is	O
reduction	O
in	O
cell	B-COMP
excitability	O
and	O
neurotransmission	O
.	O

However	O
,	O
overdoses	O
of	O
the	O
more	O
potent	O
opioids	O
have	O
been	O
linked	O
to	O
cases	O
of	O
acute	O
liver	O
injury	O
,	O
usually	O
with	O
a	O
precipitous	O
onset	O
and	O
pattern	O
of	O
acute	O
toxicity	O
with	O
marked	O
elevations	O
in	O
serum	B-COMP
aminotransferase	O
levels	O
and	O
early	O
onset	O
of	O
signs	O
of	O
hepatic	O
failure	O
.	O

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
only	O
a	O
small	O
proportion	O
of	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
positive	O
(	O
RBD	O
)	O
of	O
spike	O
protein	O
positive	O
camel	O
sera	B-COMP
in	O
Kenya	O
were	O
also	O
seropositive	O
to	O
MERS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
NP	O
).	O

Furthermore	O
,	O
we	O
found	O
bat	O
HKU8r	O
-	O
CoV	O
NP	O
antibody	B-COMP
in	O
73	O
(	O
12	O
.	O
5	O
%)	O
of	O
the	O
MERS	O
-	O
CoV	O
RBD	O
positive	O
and	O
NP	O
negative	O
samples	O
,	O
yet	O
found	O
only	O
3	O
(	O
0	O
.	O
43	O
%)	O
of	O
the	O
HKU8r	O
-	O
CoV	O
S1	O
antibody	B-COMP
in	O
the	O
same	O
samples	O
.	O

In	O
this	O
study	O
,	O
the	O
highly	O
virulent	O
epidemic	O
virus	O
strain	O
CT	O
was	O
serially	O
passaged	O
in	O
Vero	O
cells	B-COMP
for	O
up	O
to	O
120	O
generations	O
(	O
P120	O
).	O

Thus	O
,	O
an	O
attenuated	O
strain	O
was	O
obtained	O
via	O
cell	B-COMP
passaging	O
and	O
that	O
this	O
strain	O
could	O
be	O
used	O
in	O
preparing	O
attenuated	O
vaccines	O
.	O

In	O
this	O
study	O
,	O
the	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
technology	O
was	O
used	O
to	O
analyze	O
the	O
profiles	O
of	O
lncRNAs	O
in	O
Mock	O
and	O
TGEV	O
-	O
infected	O
porcine	O
intestinal	O
epithelial	O
cell	B-COMP
-	O
jejunum	O
2	O
(	O
IPEC	O
-	O
J2	O
)	O
cell	B-COMP
line	O
.	O

The	O
most	O
common	O
pathogens	O
in	O
dogs	O
with	O
UMRD	O
were	O
canine	O
distemper	O
virus	O
,	O
canine	O
coronavirus	O
,	O
canine	O
parvovirus	O
2	O
,	O
and	O
Detection	O
of	O
nucleic	B-COMP
acids	O
from	O
selected	O
cardiotropic	O
pathogens	O
in	O
myocardial	O
tissue	O
from	O
dogs	O
with	O
UMRD	O
suggested	O
a	O
possible	O
association	O
between	O
the	O
2	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
coronavirus	O
,	O
which	O
binds	O
to	O
cellular	B-COMP
receptors	O
and	O
mediates	O
membrane	B-COMP
fusion	O
for	O
cell	B-COMP
entry	O
,	O
is	O
a	O
candidate	O
vaccine	O
target	O
for	O
blocking	O
coronavirus	O
infection	O
.	O

Following	O
the	O
development	O
of	O
tissue	O
culture	O
adapted	O
strains	O
of	O
PDCoV	O
,	O
it	O
is	O
now	O
possible	O
to	O
address	O
questions	O
regarding	O
virus	O
-	O
host	B-COMP
cell	I-COMP
interactions	O
for	O
this	O
genera	O
of	O
coronavirus	O
.	O

Initial	O
laboratory	O
testing	O
was	O
significant	O
for	O
a	O
serum	B-COMP
creatinine	O
concentration	O
of	O
4	O
.	O
1	O
mg	O
/	O
dl	O
,	O
a	O
mixed	O
metabolic	O
and	O
respiratory	O
acidosis	O
,	O
thrombocytopenia	O
,	O
abnormal	O
hepatic	O
transaminases	O
,	O
and	O
coagulation	O
tests	O
.	O

We	O
also	O
show	O
that	O
MHV	O
replication	O
induced	O
the	O
expression	O
of	O
other	O
genes	O
known	O
to	O
be	O
downstream	O
of	O
AhR	O
in	O
macrophages	O
and	O
dendritic	B-COMP
cells	B-COMP
and	O
in	O
livers	O
of	O
infected	O
mice	O
.	O

Rate	O
of	O
mortality	O
was	O
higher	O
in	O
the	O
reopening	O
sternum	O
group	O
when	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
needed	O
.	O

This	O
infectious	O
single	O
-	O
stranded	O
,	O
positive	O
(+)	O
sense	O
RNA	O
virus	O
enters	O
the	O
host	B-COMP
by	O
binding	O
to	O
dipeptidyl	O
-	O
peptide	O
receptors	O
.	O

Antibody	B-COMP
responses	O
in	O
seropositive	O
camels	O
were	O
enhancedby	O
the	O
vaccine	O
;	O
these	O
camels	O
had	O
a	O
higher	O
average	O
age	O
than	O
seronegative	O
.	O

In	O
cases	O
where	O
patients	O
are	O
refractory	O
to	O
conventional	O
therapy	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
should	O
be	O
considered	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
emerges	O
when	O
feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
mutate	O
within	O
their	O
host	B-COMP
to	O
a	O
highly	O
virulent	O
biotype	O
and	O
the	O
immune	O
response	O
is	O
not	O
able	O
to	O
control	O
the	O
infection	O
.	O

MERS	O
-	O
CoV	O
antibodies	B-COMP
were	O
abundant	O
in	O
Sudan	O
camels	O
,	O
but	O
we	O
found	O
no	O
evidence	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
camel	O
workers	O
,	O
other	O
livestock	O
,	O
or	O
bats	O
.	O

Our	O
results	O
clearly	O
demonstrate	O
that	O
the	O
membrane	B-COMP
cholesterol	O
alters	O
the	O
oligomeric	O
status	O
of	O
the	O
membrane	B-COMP
-	O
bound	O
peptide	O
and	O
the	O
effect	O
of	O
peptide	O
binding	O
on	O
the	O
depth	O
-	O
dependent	O
membrane	B-COMP
organization	O
and	O
dynamics	O
.	O

Mortalin	O
protein	O
is	O
involved	O
in	O
a	O
variety	O
of	O
cellular	B-COMP
functions	O
and	O
plays	O
a	O
role	O
in	O
viral	O
infection	O
.	O

The	O
target	O
molecules	O
5a	O
-	O
q	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
activities	O
and	O
cytotoxicities	O
in	O
MT	O
-	O
4	O
cells	B-COMP
.	O

If	O
complement	O
regulatory	O
protein	O
such	O
as	O
endothelial	O
CD59	O
is	O
underexpressed	O
,	O
MAC	B-COMP
may	O
also	O
cause	O
pulmonary	O
vascular	O
injury	O
to	O
the	O
innocent	O
bystander	O
endothelial	O
cell	B-COMP
of	O
host	B-COMP
and	O
provokes	O
endotheliopathy	O
that	O
causes	O
inflammation	O
and	O
pulmonary	O
vascular	O
microthrombosis	O
,	O
leading	O
to	O
ARDS	O
.	O

Inflammatory	O
pathway	O
initiates	O
inflammation	O
,	O
but	O
microthrombotic	O
pathway	O
more	O
seriously	O
produces	O
""""	O
microthrombi	O
strings	O
""""	O
composed	O
of	O
platelet	O
-	O
ULVWF	O
complexes	O
,	O
which	O
become	O
anchored	O
on	O
the	O
injured	O
endothelial	O
cells	B-COMP
,	O
and	O
causes	O
disseminated	O
intravascular	O
microthrombosis	O
(	O
DIT	O
).	O

In	O
infected	O
cells	B-COMP
,	O
N	O
proteins	O
are	O
present	O
at	O
the	O
replication	O
-	O
transcription	O
complexes	O
(	O
RTCs	O
),	O
the	O
sites	O
of	O
CoV	O
RNA	O
synthesis	O
.	O

The	O
current	O
vaccine	O
portfolio	O
contains	O
a	O
wide	O
variety	O
of	O
technologies	O
,	O
ranging	O
across	O
recombinant	O
viral	O
vectors	O
,	O
nucleic	B-COMP
acids	O
,	O
and	O
recombinant	O
proteins	O
.	O

These	O
results	O
suggested	O
that	O
additional	O
barriers	O
limit	O
the	O
emergence	O
of	O
zoonotic	O
CoV	O
.	O
In	O
this	O
work	O
,	O
we	O
describe	O
overcoming	O
host	B-COMP
restriction	O
of	O
two	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
like	O
bat	O
CoVs	O
using	O
exogenous	O
protease	O
treatment	O
.	O

We	O
subsequently	O
show	O
that	O
the	O
bat	O
virus	O
spike	O
can	O
mediate	O
the	O
infection	O
of	O
human	O
gut	O
cells	B-COMP
but	O
is	O
unable	O
to	O
infect	O
human	O
lung	O
cells	B-COMP
.	O

TITLE	O
:	O
Molecular	O
Mechanism	O
for	O
Antibody	B-COMP
-	O
Dependent	O
Enhancement	O
of	O
Coronavirus	O
Entry	O
.	O

Coronavirus	O
spike	O
protein	O
mediates	O
viral	O
entry	O
into	O
cells	B-COMP
by	O
first	O
binding	O
to	O
a	O
receptor	O
on	O
the	O
host	B-COMP
cell	I-COMP
surface	I-COMP
and	O
then	O
fusing	O
viral	O
and	O
host	B-COMP
membranes	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
antibody	B-COMP
/	O
Fc	B-COMP
-	I-COMP
receptor	I-COMP
complex	I-COMP
functionally	O
mimics	O
viral	O
receptor	O
in	O
mediating	O
viral	O
entry	O
.	O

A	O
combination	O
of	O
as	O
yet	O
poorly	O
understood	O
host	B-COMP
and	O
viral	O
factors	O
combine	O
to	O
cause	O
a	O
minority	O
of	O
FCoV	O
-	O
infected	O
cats	O
to	O
develop	O
FIP	O
.	O

TITLE	O
:	O
Surface	O
-	O
displayed	O
porcine	O
IFN	O
-	O
3	O
in	O
ABSTRACT	O
:	O
Interferon	O
(	O
IFN	O
)-	O
	O
plays	O
an	O
essential	O
role	O
in	O
mucosal	O
cells	B-COMP
which	O
exhibit	O
strong	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
Autophagy	O
is	O
an	O
essential	O
cellular	B-COMP
process	I-COMP
affecting	O
virus	O
infections	O
and	O
other	O
diseases	O
and	O
Beclin1	O
(	O
BECN1	O
)	O
is	O
one	O
of	O
its	O
key	O
regulators	O
.	O

Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
multiplication	O
results	O
in	O
reduced	O
BECN1	O
levels	O
and	O
blocks	O
the	O
fusion	O
of	O
autophagosomes	O
and	O
lysosomes	B-COMP
.	O

Like	O
other	O
well	O
-	O
recognized	O
neuroinvasive	O
human	O
viruses	O
,	O
respiratory	O
viruses	O
may	O
damage	O
the	O
CNS	O
as	O
a	O
result	O
of	O
misdirected	O
host	B-COMP
immune	O
responses	O
that	O
could	O
be	O
associated	O
with	O
autoimmunity	O
in	O
susceptible	O
individuals	O
(	O
virus	O
-	O
induced	O
neuro	O
-	O
immunopathology	O
)	O
and	O
/	O
or	O
viral	O
replication	O
,	O
which	O
directly	O
causes	O
damage	O
to	O
CNS	O
cells	B-COMP
(	O
virus	O
-	O
induced	O
neuropathology	O
).	O

In	O
this	O
study	O
,	O
IL	O
-	O
11	O
expression	O
at	O
mRNA	O
and	O
protein	O
levels	O
were	O
found	O
to	O
be	O
high	O
in	O
Vero	O
cells	B-COMP
and	O
the	O
jejunum	O
of	O
piglets	O
during	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
,	O
while	O
IL	O
-	O
11	O
expression	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
viral	O
infection	O
.	O

Pretreatment	O
with	O
recombinant	O
porcine	O
IL	O
-	O
11	O
(	O
pIL	O
-	O
11	O
)	O
was	O
found	O
to	O
suppress	O
PEDV	O
replication	O
in	O
Vero	O
E6	O
cells	B-COMP
,	O
while	O
IL	O
-	O
11	O
knockdown	O
promoted	O
viral	O
infection	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
plasma	O
,	O
plasma	O
exosome	O
,	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
(	O
PBMCs	O
)	O
from	O
65	O
ARDS	O
patients	O
and	O
36	O
healthy	O
controls	O
.	O

Other	O
measures	O
to	O
improve	O
survival	O
are	O
prone	O
position	O
ventilation	O
(	O
PPV	O
)	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
extent	O
of	O
MERS	O
-	O
CoV	O
in	O
nature	O
can	O
be	O
traced	O
to	O
its	O
adaptable	O
cell	B-COMP
entry	O
steps	O
.	O

Here	O
we	O
describe	O
these	O
methods	O
,	O
highlighting	O
virus	O
-	O
cell	B-COMP
entry	O
factors	O
,	O
entry	O
inhibitors	O
,	O
and	O
viral	O
determinants	O
that	O
specify	O
the	O
cell	B-COMP
entry	O
routes	O
.	O

TITLE	O
:	O
Generation	O
of	O
MERS	O
-	O
CoV	O
Pseudotyped	O
Viral	B-COMP
Particles	I-COMP
for	O
the	O
Evaluation	O
of	O
Neutralizing	O
Antibodies	B-COMP
in	O
Mammalian	O
Sera	B-COMP
.	O

TITLE	O
:	O
Qualitative	O
and	O
Quantitative	O
Determination	O
of	O
MERS	O
-	O
CoV	O
S1	O
-	O
Specific	O
Antibodies	B-COMP
Using	O
ELISA	O
.	O

In	O
the	O
lung	O
,	O
lesions	O
and	O
immunostaining	O
can	O
be	O
qualitatively	O
described	O
to	O
define	O
the	O
cell	B-COMP
types	O
,	O
microanatomic	O
location	O
,	O
and	O
type	O
of	O
changes	O
seen	O
.	O

She	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
was	O
strongly	O
considered	O
for	O
being	O
placed	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

TITLE	O
:	O
Host	B-COMP
AAA	O
+	O
ATPase	O
TER94	O
Plays	O
Critical	O
Roles	O
in	O
Building	O
the	O
Baculovirus	O
Viral	O
Replication	O
Factory	O
and	O
Virion	B-COMP
Morphogenesis	O
.	O

TITLE	O
:	O
Leptospirosis	O
manifested	O
with	O
severe	O
pulmonary	O
haemorrhagic	O
syndrome	O
successfully	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

We	O
developed	O
77	O
hybridomas	O
and	O
selected	O
five	O
neutralizing	O
mAbs	O
by	O
immunization	O
with	O
STM	O
against	O
MERS	O
-	O
CoV	O
EMC	B-COMP
/	O
2012	O
strain	O
S	O
-	O
pseudotyped	O
lentivirus	O
.	O

A	O
(	O
H7N9	O
)	O
virus	O
-	O
specific	O
antibody	B-COMP
responses	O
were	O
assessed	O
by	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
and	O
neutralization	O
(	O
NT	O
)	O
assays	O
.	O

Among	O
others	O
it	O
summarizes	O
the	O
current	O
progress	O
made	O
in	O
evidence	O
-	O
based	O
recommendations	O
of	O
mechanical	O
ventilation	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

TITLE	O
:	O
Identification	O
of	O
a	O
Novel	O
Linear	O
B	O
-	O
Cell	B-COMP
Epitope	O
on	O
the	O
Nucleocapsid	B-COMP
Protein	O
of	O
Porcine	O
Deltacoronavirus	O
.	O

For	O
this	O
,	O
MERS	O
-	O
CoV	O
S	O
engages	O
the	O
host	B-COMP
cell	I-COMP
protein	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
,	O
CD26	O
)	O
and	O
the	O
interface	O
between	O
MERS	O
-	O
CoV	O
S	O
and	O
DPP4	O
has	O
been	O
resolved	O
on	O
the	O
atomic	O
level	O
.	O

Collectively	O
,	O
we	O
identified	O
naturally	O
-	O
occurring	O
polymorphisms	O
in	O
DPP4	O
that	O
negatively	O
impact	O
cellular	B-COMP
entry	O
of	O
MERS	O
-	O
CoV	O
and	O
might	O
thus	O
modulate	O
MERS	O
development	O
in	O
infected	O
patients	O
.	O

Orthohantaviruses	O
are	O
transmitted	O
by	O
aerosolized	O
excreta	O
(	O
urine	O
,	O
saliva	O
and	O
feces	O
)	O
of	O
their	O
reservoir	O
hosts	B-COMP
.	O

The	O
results	O
show	O
that	O
the	O
rabies	O
virus	O
vector	O
-	O
based	O
vaccine	O
can	O
induce	O
remarkably	O
earlier	O
antibody	B-COMP
response	O
and	O
higher	O
levels	O
of	O
cellular	B-COMP
immunity	O
than	O
the	O
GEM	O
particles	O
vector	O
.	O

However	O
,	O
the	O
GEM	O
particles	O
vector	O
-	O
based	O
vaccine	O
candidate	O
can	O
induce	O
remarkably	O
higher	O
antibody	B-COMP
response	O
,	O
even	O
at	O
a	O
very	O
low	O
dose	O
of	O
1	O
g	O
.	O

Previous	O
published	O
serological	O
studies	O
showed	O
that	O
sera	B-COMP
of	O
Bactrian	O
camels	O
were	O
all	O
negative	O
for	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
.	O

All	O
the	O
6	O
serum	B-COMP
samples	O
that	O
were	O
positive	O
for	O
the	O
S	O
-	O
ELISA	O
were	O
also	O
positive	O
with	O
the	O
neutralization	O
antibody	B-COMP
test	O
.	O

Human	O
airway	O
epithelial	O
cells	B-COMP
were	O
used	O
to	O
isolate	O
a	O
novel	O
coronavirus	O
,	O
named	O
2019	O
-	O
nCoV	O
,	O
which	O
formed	O
a	O
clade	O
within	O
the	O
subgenus	O
sarbecovirus	O
,	O
Orthocoronavirinae	O
subfamily	O
.	O

In	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
gga	O
-	O
miR	O
-	O
30d	O
in	O
the	O
process	O
of	O
IBV	O
infection	O
of	O
HD11	O
cell	B-COMP
line	O
in	O
vitro	O
.	O

Results	O
indicated	O
that	O
degree	O
of	O
intestinal	O
epithelial	O
damage	O
differed	O
among	O
calves	O
grouped	O
by	O
the	O
etiologic	O
agent	O
of	O
diarrhea	O
and	O
that	O
such	O
damage	O
might	O
have	O
been	O
more	O
severe	O
in	O
calves	O
with	O
diarrhea	O
caused	O
by	O
K99	O
RESULTS	O
:	O
Across	O
the	O
3	O
time	O
points	O
at	O
which	O
blood	O
samples	O
were	O
obtained	O
and	O
evaluated	O
,	O
the	O
groups	O
of	O
calves	O
with	O
diarrhea	O
generally	O
had	O
markedly	O
higher	O
mean	O
serum	B-COMP
concentrations	O
of	O
L	O
-	O
FABP	O
,	O
TFF	O
-	O
3	O
,	O
IAP	O
,	O
IL	O
-	O
8	O
,	O
and	O
LP	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

During	O
ECMO	O
,	O
VEGF	O
and	O
Ang2	O
serum	B-COMP
levels	O
remained	O
unchanged	O
compared	O
to	O
the	O
non	O
-	O
ECMO	O
group	O
(	O
p	O
=	O
0	O
.	O
16	O
),	O
but	O
Ang2	O
serum	B-COMP
levels	O
in	O
non	O
-	O
survivors	O
of	O
ARDS	O
were	O
significantly	O
increased	O
by	O
100	O
%	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
compared	O
to	O
survivors	O
.	O

During	O
ECMO	O
,	O
VEGF	O
and	O
Ang2	O
serum	B-COMP
levels	O
remained	O
unchanged	O
compared	O
to	O
the	O
non	O
-	O
ECMO	O
group	O
(	O
p	O
=	O
0	O
.	O
16	O
),	O
but	O
Ang2	O
serum	B-COMP
levels	O
in	O
non	O
-	O
survivors	O
of	O
ARDS	O
were	O
significantly	O
increased	O
by	O
100	O
%	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
compared	O
to	O
survivors	O
.	O

The	O
phylogenetic	O
tree	O
showed	O
that	O
2019	O
-	O
nCoV	O
significantly	O
clustered	O
with	O
bat	O
SARS	O
-	O
like	O
coronavirus	O
sequence	O
isolated	O
in	O
2015	O
,	O
whereas	O
structural	O
analysis	O
revealed	O
mutation	O
in	O
Spike	O
Glycoprotein	O
and	O
nucleocapsid	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
multiple	O
trauma	O
patients	O
with	O
post	O
-	O
traumatic	O
respiratory	O
failure	O
can	O
be	O
quite	O
challenging	O
because	O
of	O
the	O
need	O
for	O
systemic	O
anticoagulation	O
,	O
which	O
may	O
lead	O
to	O
excessive	O
bleeding	O
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
avian	O
coronavirus	O
from	O
healthy	O
Eclectus	O
parrots	O
(	O
ABSTRACT	O
:	O
Avian	O
coronavirus	O
has	O
a	O
wide	O
range	O
of	O
hosts	B-COMP
,	O
from	O
chickens	O
and	O
turkeys	O
to	O
wild	O
birds	O
.	O

Now	O
,	O
Brook	O
et	O
al	O
.	O
have	O
studied	O
this	O
exact	O
question	O
using	O
bat	O
cells	B-COMP
grown	O
in	O
the	O
laboratory	O
.	O

The	O
experiments	O
made	O
use	O
of	O
cells	B-COMP
from	O
one	O
bat	O
species	O
	O
the	O
black	O
flying	O
fox	O
	O
in	O
which	O
the	O
interferon	O
pathway	O
is	O
always	O
on	O
,	O
and	O
another	O
	O
the	O
Egyptian	O
fruit	O
bat	O
	O
in	O
which	O
this	O
pathway	O
is	O
only	O
activated	O
during	O
an	O
infection	O
.	O

Recombinant	O
IFN	O
-	O
1	O
protein	O
was	O
produced	O
in	O
E	O
.	O
coli	O
and	O
purified	O
from	O
inclusion	B-COMP
bodies	I-COMP
.	O

These	O
results	O
demonstrate	O
that	O
TGEVs	O
enter	O
ST	O
cells	B-COMP
via	O
clathrin	O
-	O
and	O
caveolae	B-COMP
-	O
mediated	O
endocytic	O
,	O
actin	O
-	O
dependent	O
,	O
and	O
dynamin	O
2	O
-	O
dependent	O
pathways	O
.	O

However	O
,	O
pre	O
-	O
existing	O
pulmonary	O
disease	O
and	O
immunosuppression	O
were	O
associated	O
with	O
severe	O
PARDS	O
(	O
12	O
/	O
20	O
[	O
60	O
.	O
0	O
%]	O
vs	O
19	O
/	O
65	O
[	O
29	O
.	O
2	O
%];	O
P	O
=	O
.	O
017	O
),	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
use	O
(	O
5	O
/	O
20	O
[	O
25	O
.	O
0	O
%]	O
vs	O
3	O
/	O
65	O
[	O
4	O
.	O
6	O
%];	O
P	O
=	O
.	O
016	O
)	O
and	O
reduced	O
ventilator	O
free	O
days	O
(	O
VFD	O
)	O
(	O
15	O
[	O
0	O
,	O
19	O
]	O
vs	O
21	O
[	O
6	O
,	O
23	O
];	O
P	O
=	O
.	O
039	O
),	O
compared	O
with	O
those	O
without	O
them	O
.	O

Although	O
little	O
is	O
known	O
about	O
the	O
virus	O
,	O
an	O
examination	O
of	O
the	O
genome	O
sequence	O
shows	O
strong	O
homology	O
with	O
its	O
better	O
-	O
studied	O
cousin	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
spike	O
protein	O
used	O
for	O
host	B-COMP
cell	I-COMP
infection	O
shows	O
key	O
nonsynonymous	O
mutations	O
that	O
might	O
hamper	O
the	O
efficacy	O
of	O
previously	O
developed	O
therapeutics	O
but	O
remains	O
a	O
viable	O
target	O
for	O
the	O
development	O
of	O
biologics	O
and	O
macrocyclic	O
peptides	O
.	O

A	O
66	O
-	O
year	O
-	O
old	O
man	O
was	O
diagnosed	O
with	O
ES	O
after	O
autologous	O
stem	O
cell	B-COMP
transplantation	O
for	O
malignant	O
lymphoma	O
.	O

He	O
required	O
the	O
red	O
blood	O
cell	B-COMP
transfusion	O
due	O
to	O
the	O
progression	O
of	O
hemolytic	O
anemia	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
technique	O
in	O
patients	O
with	O
acute	O
respiratory	O
failure	O
caused	O
by	O
ammonia	O
poisoning	O
].	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
technology	O
is	O
increasingly	O
used	O
in	O
treating	O
patients	O
with	O
ARDS	O
caused	O
by	O
infection	O
,	O
cardiogenic	O
shock	O
,	O
trauma	O
,	O
and	O
drowning	O
with	O
achieved	O
certain	O
effects	O
,	O
but	O
its	O
usage	O
for	O
ARDS	O
caused	O
by	O
ammonia	O
is	O
rarely	O
reported	O
.	O

Of	O
the	O
36	O
cases	O
in	O
the	O
ICU	O
,	O
4	O
(	O
11	O
.	O
1	O
%)	O
received	O
high	O
-	O
flow	O
oxygen	O
therapy	O
,	O
15	O
(	O
41	O
.	O
7	O
%)	O
received	O
noninvasive	O
ventilation	O
,	O
and	O
17	O
(	O
47	O
.	O
2	O
%)	O
received	O
invasive	O
ventilation	O
(	O
4	O
were	O
switched	O
to	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
).	O

RESULTS	O
:	O
Using	O
RNA	O
extracted	O
from	O
cells	B-COMP
infected	O
by	O
SARS	O
coronavirus	O
as	O
a	O
positive	O
control	O
,	O
these	O
assays	O
were	O
shown	O
to	O
have	O
a	O
dynamic	O
range	O
of	O
at	O
least	O
seven	O
orders	O
of	O
magnitude	O
(	O
2x10	O
-	O
4	O
-	O
2000	O
TCID50	O
/	O
reaction	O
).	O

Circulating	O
exosomes	O
isolated	O
from	O
lung	O
transplant	O
recipients	O
diagnosed	O
with	O
respiratory	O
viral	O
infections	O
contained	O
lung	O
self	O
-	O
antigens	O
,	O
viral	O
antigens	O
,	O
and	O
20S	B-COMP
proteasome	I-COMP
and	O
elicited	O
immune	O
responses	O
to	O
lung	O
self	O
-	O
antigens	O
that	O
resulted	O
in	O
development	O
of	O
chronic	O
lung	O
allograft	O
dysfunction	O
in	O
immunized	O
mice	O
.	O

RESULTS	O
:	O
Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	B-COMP
proteasome	I-COMP
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	B-COMP
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

Mice	O
immunized	O
with	O
exosomes	O
from	O
recipients	O
with	O
respiratory	O
viral	O
infections	O
developed	O
immune	O
responses	O
to	O
self	O
-	O
antigens	O
,	O
fibrosis	O
,	O
small	O
airway	O
occlusion	O
,	O
and	O
significant	O
cellular	B-COMP
infiltration	O
;	O
mice	O
immunized	O
with	O
exosomes	O
from	O
controls	O
did	O
not	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
structural	O
protein	O
critical	O
for	O
virion	B-COMP
morphogenesis	O
and	O
release	O
.	O

Significantly	O
,	O
all	O
these	O
defective	O
phenotypes	O
were	O
restored	O
in	O
cells	B-COMP
infected	O
with	O
the	O
putative	O
EIC	O
revertants	O
.	O

Nearly	O
80	O
%	O
of	O
the	O
patients	O
had	O
normal	O
or	O
decreased	O
white	O
blood	O
cell	B-COMP
counts	O
,	O
and	O
72	O
.	O
3	O
%	O
(	O
99	O
/	O
137	O
)	O
had	O
lymphocytopenia	O
.	O

These	O
results	O
favored	O
a	O
two	O
-	O
step	O
process	O
in	O
which	O
viruses	O
first	O
adhere	O
to	O
sialic	O
acids	O
and	O
then	O
require	O
subsequent	O
engagement	O
with	O
protein	O
receptors	O
during	O
infectious	O
cell	B-COMP
entry	O
.	O

Anti	O
-	O
PDCoV	O
IgA	O
antibodies	B-COMP
in	O
152	O
serum	B-COMP
samples	O
and	O
65	O
milk	O
samples	O
collected	O
from	O
six	O
farms	O
that	O
had	O
experienced	O
diarrhea	O
outbreaks	O
within	O
previous	O
last	O
two	O
years	O
were	O
detected	O
by	O
this	O
assay	O
,	O
and	O
62	O
.	O
5	O
%	O
of	O
the	O
serum	B-COMP
samples	O
and	O
100	O
%	O
of	O
the	O
milk	O
samples	O
were	O
positive	O
for	O
PDCoV	O
.	O
The	O
indirect	O
ELISA	O
method	O
established	O
in	O
this	O
study	O
will	O
provide	O
a	O
convenient	O
tool	O
for	O
measurement	O
of	O
serum	B-COMP
and	O
milk	O
IgA	O
levels	O
against	O
PDCoV	O
in	O
pig	O
herds	O
,	O
rapid	O
detection	O
of	O
PDCoV	O
infection	O
in	O
pigs	O
,	O
and	O
evaluation	O
of	O
the	O
immunogenicity	O
of	O
vaccines	O
.	O

ACE2	O
plays	O
an	O
important	O
role	O
in	O
the	O
RAS	O
,	O
and	O
the	O
imbalance	O
between	O
ACE	O
/	O
Ang	O
II	O
/	O
AT1R	O
pathway	O
and	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	B-COMP
receptor	O
pathway	O
in	O
the	O
RAS	O
system	O
will	O
lead	O
to	O
multi	O
-	O
system	O
inflammation	O
.	O

TITLE	O
:	O
A	O
cytosolic	B-COMP
heat	O
shock	O
protein	O
90	O
and	O
co	O
-	O
chaperone	O
p23	O
complex	O
activates	O
RIPK3	O
/	O
MLKL	O
during	O
necroptosis	O
of	O
endothelial	O
cells	B-COMP
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Sera	B-COMP
were	O
obtained	O
near	O
the	O
onset	O
of	O
RI	O
and	O
3	O
to	O
4	O
weeks	O
later	O
as	O
part	O
of	O
a	O
prospective	O
study	O
of	O
200	O
subjects	O
evaluated	O
for	O
RI	O
from	O
2009	O
to	O
2013	O
.	O

Therefore	O
,	O
a	O
successful	O
PEDV	O
vaccine	O
must	O
induce	O
protective	O
maternal	O
IgA	O
antibodies	B-COMP
that	O
passively	O
transfer	O
into	O
colostrum	O
and	O
milk	O
.	O

One	O
possible	O
answer	O
is	O
antibody	B-COMP
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
due	O
to	O
prior	O
exposure	O
to	O
other	O
coronaviruses	O
.	O

RESULTS	O
:	O
Pretreatment	O
of	O
HNE	O
and	O
HTE	O
cells	B-COMP
with	O
glycopyrronium	O
or	O
formoterol	O
decreased	O
viral	O
RNA	O
levels	O
and	O
/	O
or	O
titers	O
,	O
the	O
expression	O
of	O
the	O
HCoV	O
-	O
229E	O
receptor	O
CD13	O
,	O
the	O
number	O
and	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
where	O
HCoV	O
-	O
229E	O
RNA	O
enters	O
the	O
cytoplasm	B-COMP
,	O
and	O
the	O
infection	O
-	O
induced	O
production	O
of	O
cytokines	O
,	O
including	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IFN	O
-	O
	O
.	O

Together	O
,	O
these	O
results	O
help	O
to	O
explain	O
the	O
high	O
potency	O
of	O
RDV	O
against	O
RNA	O
viruses	O
in	O
cell	B-COMP
-	O
based	O
assays	O
.	O

Viral	O
nucleic	B-COMP
acids	O
could	O
be	O
detected	O
in10	O
%	O
patients	O
'	O
blood	O
samples	O
at	O
acute	O
periodand	O
50	O
%	O
of	O
patients	O
had	O
positive	O
RT	O
-	O
PCR	O
results	O
in	O
their	O
feces	O
.	O

The	O
interaction	O
between	O
the	O
key	O
amino	O
acids	O
of	O
S	O
protein	O
RBD	O
and	O
ACE2	O
indicated	O
that	O
,	O
other	O
than	O
pangolins	O
and	O
snakes	O
,	O
as	O
previously	O
suggested	O
,	O
turtles	O
(	O
Chrysemys	O
picta	O
bellii	O
,	O
Chelonia	O
mydas	O
,	O
and	O
Pelodiscus	O
sinensis	O
)	O
may	O
act	O
as	O
the	O
potential	O
intermediate	O
hosts	B-COMP
transmitting	O
SARS	O
-	O
CoV	O
-	O
2	O
to	O
humans	O
.	O

TITLE	O
:	O
Structure	O
-	O
Based	O
Stabilization	O
of	O
Non	O
-	O
native	O
Protein	O
-	O
Protein	O
Interactions	O
of	O
Coronavirus	O
Nucleocapsid	B-COMP
Proteins	O
in	O
Antiviral	O
Drug	O
Design	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
Bats	O
-	O
Hosts	B-COMP
-	O
Reservoir	O
-	O
People	O
transmission	O
network	O
model	O
for	O
simulating	O
the	O
potential	O
transmission	O
from	O
the	O
infection	O
source	O
(	O
probably	O
be	O
bats	O
)	O
to	O
the	O
human	O
infection	O
.	O

This	O
supports	O
the	O
hypothesis	O
of	O
the	O
role	O
of	O
an	O
asymptomatic	O
human	O
carrier	O
or	O
,	O
less	O
likely	O
,	O
an	O
unknown	O
animal	O
host	B-COMP
that	O
has	O
direct	O
contact	O
with	O
both	O
infected	O
camels	O
and	O
humans	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
infected	O
patients	O
have	O
been	O
missed	O
by	O
using	O
nucleic	B-COMP
acid	O
detection	O
only	O
.	O

The	O
differential	O
counts	O
of	O
white	O
blood	O
cells	B-COMP
were	O
analyzed	O
.	O

Patients	O
in	O
COVID	O
-	O
19	O
group	O
showed	O
relatively	O
lower	O
absolute	O
white	O
blood	O
cell	B-COMP
(	O
WBC	O
)	O
count	O
4	O
.	O
95	O
(	O
3	O
.	O
90	O
,	O
6	O
.	O
03	O
)	O
10	O
(	O
9	O
)/	O
L	O
,	O
lymphocyte	O
absolute	O
count	O
1	O
.	O
20	O
(	O
0	O
.	O
98	O
,	O
1	O
.	O
50	O
)	O
10	O
(	O
9	O
)/	O
L	O
and	O
eosinophil	O
absolute	O
count	O
0	O
.	O
01	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
)	O
10	O
(	O
9	O
)/	O
L	O
.	O
Leukopenia	O
developed	O
in	O
two	O
patients	O
(	O
2	O
/	O
10	O
),	O
lymphocytopenia	O
also	O
in	O
two	O
patients	O
(	O
2	O
/	O
10	O
).	O

I	O
consider	O
the	O
options	O
of	O
drug	O
repurposing	O
,	O
developing	O
neutralizing	O
monoclonal	O
antibody	B-COMP
therapy	O
,	O
and	O
an	O
oligonucleotide	O
strategy	O
targeting	O
the	O
viral	O
RNA	O
genome	O
,	O
emphasizing	O
the	O
promise	O
and	O
pitfalls	O
of	O
these	O
approaches	O
.	O

Blood	O
was	O
sampled	O
before	O
,	O
and	O
1	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
implantation	O
.	O

Fibrinogen	B-COMP
levels	O
,	O
fibrin	O
polymerization	O
,	O
platelet	O
activation	O
,	O
and	O
microparticle	O
release	O
were	O
increased	O
in	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
compared	O
to	O
venoarterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
patients	O
.	O

TITLE	O
:	O
[	O
Expert	O
recommendations	O
on	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
non	O
-	O
small	O
cell	B-COMP
lung	O
cancer	O
during	O
epidemic	O
of	O
COVID	O
-	O
19	O
(	O
Trial	O
version	O
)].	O

Although	O
how	O
the	O
intra	O
-	O
host	B-COMP
variant	O
spreads	O
in	O
the	O
population	O
is	O
still	O
elusive	O
,	O
it	O
is	O
necessary	O
to	O
strengthen	O
the	O
surveillance	O
of	O
the	O
viral	O
evolution	O
in	O
the	O
population	O
and	O
associated	O
clinical	O
changes	O
.	O

Monoclonal	O
antibodies	B-COMP
represent	O
the	O
major	O
class	O
of	O
biotherapeutics	O
for	O
passive	O
immunotherapy	O
to	O
fight	O
against	O
viral	O
infection	O
.	O

The	O
therapeutic	O
potential	O
of	O
monoclonal	O
antibodies	B-COMP
has	O
been	O
well	O
recognized	O
in	O
the	O
treatment	O
of	O
many	O
diseases	O
.	O

Cell	B-COMP
entry	O
of	O
coronaviruses	O
depends	O
on	O
binding	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
to	O
cellular	B-COMP
receptors	O
and	O
on	O
S	O
protein	O
priming	O
by	O
host	B-COMP
cell	I-COMP
proteases	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
structure	O
,	O
genome	O
organization	O
,	O
entry	O
of	O
CoVs	O
into	O
target	O
cells	B-COMP
,	O
and	O
provide	O
insights	O
into	O
past	O
and	O
present	O
outbreaks	O
.	O

Bats	O
,	O
snakes	O
and	O
pangolins	O
have	O
been	O
cited	O
as	O
potential	O
carriers	O
based	O
on	O
the	O
sequence	O
homology	O
of	O
CoV	O
isolated	O
from	O
these	O
animals	O
and	O
the	O
viral	O
nucleic	B-COMP
acids	O
of	O
the	O
virus	O
isolated	O
from	O
SARS	O
-	O
CoV	O
-	O
2	O
infected	O
patients	O
.	O

Asymptomatic	O
carriers	O
were	O
laboratory	O
-	O
confirmed	O
positive	O
for	O
the	O
COVID	O
-	O
19	O
virus	O
by	O
testing	O
the	O
nucleic	B-COMP
acid	O
of	O
the	O
pharyngeal	O
swab	O
samples	O
.	O

The	O
median	O
communicable	O
period	O
,	O
defined	O
as	O
the	O
interval	O
from	O
the	O
first	O
day	O
of	O
positive	O
nucleic	B-COMP
acid	O
tests	O
to	O
the	O
first	O
day	O
of	O
continuous	O
negative	O
tests	O
,	O
was	O
9	O
.	O
5	O
days	O
(	O
up	O
to	O
21	O
days	O
among	O
the	O
24	O
asymptomatic	O
cases	O
).	O

These	O
results	O
highlighted	O
the	O
importance	O
of	O
close	O
contact	O
tracing	O
and	O
longitudinally	O
surveillance	O
via	O
virus	O
nucleic	B-COMP
acid	O
tests	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
CEP	O
is	O
a	O
wide	O
-	O
spectrum	O
inhibitor	O
of	O
pan	B-COMP
-	O
betacoronavirus	O
,	O
and	O
clinical	O
trial	O
of	O
CEP	O
for	O
treatment	O
of	O
2019	O
-	O
nCoV	O
infection	O
is	O
warranted	O
.	O

Pharyngeal	O
swab	O
specimens	O
were	O
collected	O
from	O
9	O
of	O
the	O
10	O
neonates	O
1	O
to	O
9	O
days	O
after	O
birth	O
for	O
nucleic	B-COMP
acid	O
amplification	O
tests	O
for	O
2019	O
-	O
nCoV	O
,	O
all	O
of	O
which	O
showed	O
negative	O
results	O
.	O

Coronavirus	O
spike	O
(	O
S	O
)	O
glycoproteins	O
promote	O
entry	O
into	O
cells	B-COMP
and	O
are	O
the	O
main	O
target	O
of	O
antibodies	B-COMP
.	O

The	O
RT	O
-	O
PCR	O
detection	O
of	O
viral	O
nucleic	B-COMP
acid	O
test	O
(	O
NAT	O
)	O
was	O
one	O
of	O
the	O
most	O
quickly	O
established	O
laboratory	O
diagnosis	O
method	O
in	O
a	O
novel	O
viral	O
pandemic	O
,	O
just	O
as	O
in	O
this	O
COVID	O
-	O
19	O
outbreak	O
.	O

We	O
isolated	O
virus	O
from	O
nasopharyngeal	O
and	O
oropharyngeal	O
specimens	O
from	O
this	O
patient	O
and	O
characterized	O
the	O
viral	O
sequence	O
,	O
replication	O
properties	O
,	O
and	O
cell	B-COMP
culture	O
tropism	O
.	O

The	O
number	O
of	O
T	O
cells	B-COMP
significantly	O
decreased	O
,	O
and	O
more	O
hampered	O
in	O
severe	O
cases	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
use	O
IEDB	O
software	O
to	O
predict	O
the	O
suitable	O
MERS	O
-	O
CoV	O
epitope	O
vaccine	O
against	O
the	O
most	O
known	O
world	O
population	O
alleles	O
through	O
four	O
selecting	O
proteins	O
such	O
as	O
S	O
glycoprotein	O
and	O
envelope	B-COMP
protein	O
and	O
their	O
modification	O
sequences	O
after	O
the	O
pandemic	O
spread	O
of	O
MERS	O
-	O
CoV	O
in	O
2012	O
.	O

IEDB	O
services	O
is	O
one	O
of	O
the	O
computational	O
methods	O
;	O
the	O
output	O
of	O
this	O
study	O
showed	O
that	O
S	O
glycoprotein	O
,	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
,	O
and	O
S	O
and	O
E	O
protein	O
modified	O
sequences	O
of	O
MERS	O
-	O
CoV	O
might	O
be	O
considered	O
as	O
a	O
protective	O
immunogenic	O
with	O
high	O
conservancy	O
because	O
they	O
can	O
elect	O
both	O
neutralizing	O
antibodies	B-COMP
and	O
T	O
-	O
cell	B-COMP
responses	O
when	O
reacting	O
with	O
B	O
-	O
cell	B-COMP
,	O
T	O
-	O
helper	O
cell	B-COMP
,	O
and	O
cytotoxic	O
T	O
lymphocyte	O
.	O

TITLE	O
:	O
Multimodal	O
Therapeutic	O
Approach	O
of	O
Cytokine	O
Release	O
Syndrome	O
Developing	O
in	O
a	O
Child	O
Given	O
Chimeric	O
Antigen	O
Receptor	O
-	O
Modified	O
T	O
Cell	B-COMP
Infusion	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
2003	O
SARS	O
epidemic	O
that	O
the	O
receptor	O
critical	O
for	O
SARS	O
-	O
CoV	O
entry	O
into	O
host	B-COMP
cells	B-COMP
is	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

In	O
a	O
short	O
time	O
following	O
the	O
outbreak	O
,	O
it	O
has	O
been	O
shown	O
that	O
,	O
similar	O
to	O
SARS	O
-	O
CoV	O
,	O
COVID	O
-	O
19	O
virus	O
exploits	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
to	O
gain	O
entry	O
inside	O
the	O
cells	B-COMP
.	O

However	O
,	O
so	O
far	O
,	O
there	O
are	O
still	O
controversies	O
about	O
the	O
source	O
of	O
the	O
virus	O
and	O
its	O
intermediate	O
host	B-COMP
.	O

TITLE	O
:	O
Single	O
-	O
cell	B-COMP
RNA	O
-	O
seq	O
data	O
analysis	O
on	O
the	O
receptor	O
ACE2	O
expression	O
reveals	O
the	O
potential	O
risk	O
of	O
different	O
human	O
organs	O
vulnerable	O
to	O
2019	O
-	O
nCoV	O
infection	O
.	O

Moreover	O
,	O
lung	O
cells	B-COMP
that	O
have	O
ACE2	O
expression	O
may	O
be	O
the	O
main	O
target	O
cells	B-COMP
during	O
2019	O
-	O
nCoV	O
infection	O
.	O

TITLE	O
:	O
Human	O
Umbilical	O
Cord	O
-	O
Derived	O
Mesenchymal	O
Stem	O
Cells	B-COMP
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Serial	O
flow	O
-	O
cytometric	O
analyses	O
of	O
circulating	O
inflammatory	O
biomarkers	O
(	O
CD14CD33	O
/	O
CD11b	O
+	O
CD16	O
+/	O
CD16	O
+	O
MPO	O
+/	O
CD11b	O
+	O
MPO	O
+/	O
CD14CD33	O
+)	O
and	O
mesenchymal	O
stem	O
cell	B-COMP
markers	O
(	O
CD26	O
+	O
CD45	O
-/	O
CD29	O
+	O
CD45	O
-/	O
CD34	O
+	O
CD45	O
-/	O
CD44	O
+	O
CD45	O
-/	O
CD73	O
+	O
CD45	O
-/	O
CD90	O
+	O
CD45	O
-/	O
CD105	O
+	O
CD45	O
-/	O
CD26	O
+	O
CD45	O
-)	O
were	O
notably	O
progressively	O
reduced	O
(	O
p	O
for	O
trend	O
<	O
0	O
.	O
001	O
),	O
whereas	O
the	O
immune	O
cell	B-COMP
markers	O
(	O
Helper	O
-	O
T	O
-	O
cell	B-COMP
/	O
Cytotoxity	O
-	O
T	O
-	O
cell	B-COMP
/	O
Regulatory	O
-	O
T	O
-	O
cell	B-COMP
)	O
were	O
notably	O
increased	O
(	O
p	O
for	O
trend	O
<	O
0	O
.	O
001	O
)	O
after	O
cell	B-COMP
infusion	O
.	O

The	O
host	B-COMP
humoral	O
response	O
against	O
SARS	O
-	O
CoV	O
-	O
2	O
including	O
IgA	O
,	O
IgM	O
and	O
IgG	O
response	O
were	O
examined	O
by	O
using	O
an	O
ELISA	O
based	O
assay	O
on	O
the	O
recombinant	O
viral	B-COMP
nucleocapsid	I-COMP
protein	O
.	O

RESULTS	O
:	O
The	O
median	O
duration	O
of	O
IgM	O
and	O
IgA	B-COMP
antibody	I-COMP
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	O
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

Angiotensin	O
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
is	O
the	O
host	B-COMP
receptor	O
by	O
SARS	O
-	O
CoV	O
-	O
2	O
to	O
infect	O
human	O
cells	B-COMP
.	O

This	O
prediction	O
may	O
help	O
to	O
screen	O
the	O
intermediate	O
hosts	B-COMP
of	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Spike	O
protein	O
recognition	O
of	O
mammalian	O
ACE2	O
predicts	O
the	O
host	B-COMP
range	O
and	O
an	O
optimized	O
ACE2	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
.	O

Finally	O
,	O
the	O
provision	O
of	O
cardiovascular	O
care	O
may	O
place	O
health	O
care	O
workers	O
in	O
a	O
position	O
of	O
vulnerability	O
as	O
they	O
become	O
host	B-COMP
or	O
vectors	O
of	O
virus	O
transmission	O
.	O

Membranes	O
represent	O
both	O
an	O
obstacle	O
and	O
aid	O
to	O
CoV	O
replication	O
-	O
and	O
in	O
consequence	O
-	O
virus	O
-	O
encoded	O
structural	O
and	O
nonstructural	O
proteins	O
have	O
membrane	B-COMP
-	O
binding	O
properties	O
.	O

HCoVs	O
need	O
host	B-COMP
cell	I-COMP
proteins	O
to	O
successively	O
establish	O
infections	O
.	O

The	O
effect	O
of	O
LH	O
on	O
virion	B-COMP
morphology	O
was	O
visualized	O
under	O
transmission	O
electron	O
microscope	O
.	O

Furthermore	O
,	O
LH	O
treatment	O
resulted	O
in	O
abnormal	O
particle	O
morphology	O
of	O
virion	B-COMP
in	O
cells	B-COMP
.	O

Higher	O
rate	O
of	O
fever	O
,	O
cough	O
,	O
expectoration	O
,	O
and	O
headache	O
,	O
lower	O
lymphocytes	O
,	O
albumin	O
,	O
serum	B-COMP
sodium	O
levels	O
and	O
higher	O
total	O
bilirubin	O
,	O
creatine	O
kinase	O
,	O
lactate	O
dehydrogenase	O
and	O
C	O
-	O
reactive	O
protein	O
levels	O
and	O
lower	O
oxygenation	O
index	O
were	O
observed	O
in	O
pneumonia	O
patients	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Muscle	O
ache	O
,	O
shortness	O
of	O
breath	O
,	O
nausea	O
and	O
vomiting	O
,	O
lower	O
lymphocytes	O
levels	O
and	O
higher	O
serum	B-COMP
creatinine	O
and	O
radiograph	O
score	O
at	O
admission	O
were	O
predictive	O
factors	O
for	O
severe	O
/	O
critical	O
subtype	O
.	O

Neutralising	O
antibody	B-COMP
response	O
appeared	O
within	O
9	O
days	O
along	O
with	O
specific	O
IgM	O
and	O
IgG	O
response	O
,	O
targeting	O
particularly	O
nucleocapsid	B-COMP
and	O
spike	O
proteins	O
.	O

ABSTRACT	O
:	O
Age	O
and	O
inhalation	O
injury	O
are	O
important	O
risk	O
factors	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
burned	O
patient	O
;	O
however	O
,	O
the	O
impact	O
of	O
interventions	O
such	O
as	O
mechanical	O
ventilation	O
,	O
fluid	O
balance	O
(	O
FB	O
),	O
and	O
packed	O
red	O
blood	O
cell	B-COMP
transfusion	O
remains	O
unclear	O
.	O

